<SEC-DOCUMENT>0001493152-25-010978.txt : 20250320
<SEC-HEADER>0001493152-25-010978.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320073047
ACCESSION NUMBER:		0001493152-25-010978
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		25754504

	BUSINESS ADDRESS:	
		STREET 1:		6555 CARNEGIE AVE, 4TH FLOOR
		CITY:			CLEVELAND
		STATE:			OH
		ZIP:			44103
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		6555 CARNEGIE AVE, 4TH FLOOR
		CITY:			CLEVELAND
		STATE:			OH
		ZIP:			44103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ABEO="http://abeonatherapeutics.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_037_ABEO_abeonatherapeutics.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000318306 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Grantees_0_Grantees -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_064_Integer_5_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0000318306</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLoansPayableCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:GainLossOnRightofuseLeaseAssets" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:GainLossOfRightofuseLeaseAssets" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:ReclassificationOfDerivativeLiabilityToEquity" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember" id="xdx2ixbrl0629" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0701" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-012024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-012024-12-31_us-gaap_CertificatesOfDepositMember" id="xdx2ixbrl0719" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0733" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2023-01-012023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="xdx2ixbrl0741" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0749" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="xdx2ixbrl0772" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_ConstructionInProgressMember" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0805" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0807" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember" id="xdx2ixbrl0813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember" id="xdx2ixbrl0815" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0821" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0823" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="xdx2ixbrl0827" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="xdx2ixbrl0831" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember" id="xdx2ixbrl0835" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember" id="xdx2ixbrl0839" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0847" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember" id="xdx2ixbrl0850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember" id="xdx2ixbrl0852" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0857" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0864" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0865" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0868" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0869" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="xdx2ixbrl0871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="xdx2ixbrl0873" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0877" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember" id="xdx2ixbrl0879" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember" id="xdx2ixbrl0880" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember" id="xdx2ixbrl0883" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember" id="xdx2ixbrl0884" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0887" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0888" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_TwentyTwentyFourLoanAgreementMember" id="xdx2ixbrl0908" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:FairValueAdjustmentOfWarrantsIssued" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0935" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0978" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:FairValueOfDerivativesIssued" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0981" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0985" name="us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0986" name="us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric>
  <ix:nonFraction name="ABEO:ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0989" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0991" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0992" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:AccretedFinalPaymentFee" contextRef="AsOf2023-12-31" id="xdx2ixbrl1104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-12-31" id="xdx2ixbrl1110" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl1333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1335" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1337" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1343" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1345" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1355" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1357" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1363" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1365" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_SublicenseAgreementRelatingToRettSyndromeMember_us-gaap_LicenseMember" id="xdx2ixbrl1539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ABEO:IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1680" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abeo-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31_custom_DonWuchterlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ABEO:DonWuchterlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:TwentyTwentyFourLoanAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_TwentyTwentyFourLoanAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:TwentyTwentyFourLoanAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-07_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-07_custom_PreFundedWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-24_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-02_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-08_us-gaap_CommonStockMember_custom_LoanAgreementWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:LoanAgreementWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_us-gaap_CommonStockMember_custom_LoanAgreementWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:LoanAgreementWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_LoanAgreementWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:LoanAgreementWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-06_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-06_custom_PreFundedWarrants2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-09_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ABEO:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ABEO:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:FurnitureSoftwareAndOfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:FurnitureSoftwareAndOfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:FurnitureSoftwareAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:FurnitureSoftwareAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:TwentyTwentyFourLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_TwentyTwentyThreeLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:TwentyTwentyThreeLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:MoneyMarketDepositAccountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:MoneyMarketDepositAccountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:MoneyMarketDepositAccountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:MoneyMarketDepositAccountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:PayableToLicensorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:PayableToLicensorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:PayableToLicensorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:PayableToLicensorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyOnePublicOfferingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyOnePublicOfferingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyTwoPrivatePlacementOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyTwoPrivatePlacementOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwentyTwentyFourLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyFourLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwentyTwentyFourLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyFourLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyOnePublicOfferingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyTwoPrivatePlacementOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwentyTwentyFourLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyFourLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-12_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ABEO:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-112021-11-12_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ABEO:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-11</xbrli:startDate>
        <xbrli:endDate>2021-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ABEO:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ABEO:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OfficeSpaceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:OfficeSpaceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OfficeSpaceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:OfficeSpaceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeptemberTwoThouandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ABEO:SeptemberTwoThouandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SubLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SubLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SubLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SubLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:TrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_DiscretionaryTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:DiscretionaryTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-01_custom_LoanAndSecurityAgreementMember_srt_MinimumMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-01_custom_LoanAndSecurityAgreementMember_srt_MaximumMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-302024-09-30_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-30</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember_us-gaap_WarrantMember_custom_AvenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:TrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:AvenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember_us-gaap_WarrantMember_custom_AvenueTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:TrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:AvenueTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-202021-12-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-20</xbrli:startDate>
        <xbrli:endDate>2021-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-072024-05-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-07</xbrli:startDate>
        <xbrli:endDate>2024-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-072024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-07</xbrli:startDate>
        <xbrli:endDate>2024-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-242024-06-24_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-24</xbrli:startDate>
        <xbrli:endDate>2024-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-02_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-162018-08-17_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:OpenMarketSaleAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:JefferiesLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-16</xbrli:startDate>
        <xbrli:endDate>2018-08-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:OpenMarketSaleAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:JefferiesLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:OpenMarketSaleAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:JefferiesLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:ATMAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-02</xbrli:startDate>
        <xbrli:endDate>2022-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-02</xbrli:startDate>
        <xbrli:endDate>2022-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_CommonStockAndAccompanyingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:CommonStockAndAccompanyingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantAndAccompanyingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantAndAccompanyingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrivatePlacementOfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-062023-07-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-06</xbrli:startDate>
        <xbrli:endDate>2023-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-062023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-06</xbrli:startDate>
        <xbrli:endDate>2023-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-092024-05-09_custom_TwoThousandTwentyThreePreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-09</xbrli:startDate>
        <xbrli:endDate>2024-05-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember_custom_AvenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:AvenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember_custom_AvenueTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:AvenueTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-08</xbrli:startDate>
        <xbrli:endDate>2024-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-072024-05-07_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-07</xbrli:startDate>
        <xbrli:endDate>2024-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-07_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-24_srt_MinimumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-24_srt_MaximumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-20_srt_MinimumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-20_srt_MaximumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_InducementPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:InducementPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember31393828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ABEO:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-012020-08-31_custom_SublicenseAndInventoryPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-01</xbrli:startDate>
        <xbrli:endDate>2020-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-012020-08-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ABEO:EventBasedMilestonePaymentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-01</xbrli:startDate>
        <xbrli:endDate>2020-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-012020-08-31_custom_SalesBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ABEO:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-01</xbrli:startDate>
        <xbrli:endDate>2020-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-31_custom_SublicenseAgreementRelatingToRettSyndromeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ABEO:EventBasedMilestonePaymentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-31_custom_SalesBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ABEO:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SublicenseAgreementRelatingToRettSyndromeMember_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SublicenseAgreementRelatingToRettSyndromeMember_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-152022-05-16_us-gaap_LicenseAgreementTermsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-15</xbrli:startDate>
        <xbrli:endDate>2022-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_UnderAgeFifftyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">ABEO:UnderAgeFifftyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_UnderAgeFifftyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">ABEO:UnderAgeFifftyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentySixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentyEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentyNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ThereafterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:ThereafterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_us-gaap_CommonStockMember_srt_DirectorMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember_custom_ThreeEqualAnnualInstallmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:ThreeEqualAnnualInstallmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember_custom_OneAnnualInstallmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:OneAnnualInstallmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Grantees">
      <xbrli:measure>ABEO:Grantees</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>ABEO:Integer</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001692" toRefs="Footnote001721"/>
  <ix:relationship fromRefs="Fact001693" toRefs="Footnote001721"/>
  <ix:relationship fromRefs="Fact001710" toRefs="Footnote001722"/>
  <ix:relationship fromRefs="Fact001711" toRefs="Footnote001722"/>
  <ix:relationship fromRefs="Fact001716" toRefs="Footnote001723"/>
  <ix:relationship fromRefs="Fact001717" toRefs="Footnote001723"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_903_edei--DocumentType_c20240101__20241231_zHbvKWwKvoke"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000015" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
    One)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--DocumentAnnualReport_c20240101__20241231_zrM7VoeblZLl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000016" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the fiscal year ended <span id="xdx_904_edei--DocumentPeriodEndDate_c20240101__20241231_zVfRIUT1MX4b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate"><span id="xdx_90E_edei--CurrentFiscalYearEndDate_c20240101__20241231_zBaWfAdmbDHh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000018" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90A_edei--DocumentFiscalYearFocus_c20240101__20241231_zB9Asp0HS0V9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--DocumentTransitionReport_c20240101__20241231_zzpSQ0iKabG"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000020" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the transition period from _______ to _______</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number <b><span id="xdx_909_edei--EntityFileNumber_c20240101__20241231_zfAVoRg5TGk7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityFileNumber">001-15771</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityRegistrantName_c20240101__20241231_zrFpJsvFNQR9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityRegistrantName">ABEONA
THERAPEUTICS INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zs8reu5LVDs8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000023" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20240101__20241231_zx9RSHQFLx3a"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityTaxIdentificationNumber">83-0221517</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or Other Jurisdiction of <br/>
incorporation or Organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer <br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_904_edei--EntityAddressAddressLine1_c20240101__20241231_zvhd22bD7Qh5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressAddressLine1">6555
Carnegie Avenue</ix:nonNumeric></span></b></span><b><span style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_900_edei--EntityAddressAddressLine2_c20240101__20241231_zbqiLXKrgL63"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressAddressLine2">4<sup>th
</sup>Floor</ix:nonNumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityAddressCityOrTown_c20240101__20241231_zhZovM4Qtlo3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:EntityAddressCityOrTown">Cleveland</ix:nonNumeric></span>,
<span id="xdx_90A_edei--EntityAddressStateOrProvince_c20240101__20241231_z51C9HVqaqa1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:EntityAddressStateOrProvince">OH</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20240101__20241231_zaZBdUbkU8ff"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:EntityAddressPostalZipCode">44103</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices, zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_908_edei--CityAreaCode_c20240101__20241231_zvG7cizv0x4a"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:CityAreaCode">(646)</ix:nonNumeric></span>
<span id="xdx_908_edei--LocalPhoneNumber_c20240101__20241231_zRgp4KeTQjzg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000031" name="dei:LocalPhoneNumber">813-4701</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20240101__20241231_zXJeWfBGf5eg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20240101__20241231_z9i9KTfl9fxc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:TradingSymbol">ABEO</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--SecurityExchangeName_c20240101__20241231_zLOPEOqDjHa7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_908_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zOL7Gfqsr9Ag"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000035" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_90E_edei--EntityVoluntaryFilers_c20240101__20241231_zdfNR4gfXTZd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000036" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20240101__20241231_zIULEZj0XHZk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000037" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20240101__20241231_zDgAJh4rhljg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000038" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFilerCategory_c20240101__20241231_zmVlvCRZJvS3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000039" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_905_edei--EntitySmallBusiness_c20240101__20241231_zahAq0rzyxfi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000040" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20240101__20241231_zDY8Haj9fb0b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. Yes &#9744; No <span id="xdx_90E_edei--IcfrAuditorAttestationFlag_dbF_c20240101__20241231_zSCwOHMmdoS7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:IcfrAuditorAttestationFlag">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. Yes &#9744; No <span id="xdx_903_edei--DocumentFinStmtErrorCorrectionFlag_dbF_c20240101__20241231_z9MPp4lNSTpl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). Yes
&#9744; No &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_908_edei--EntityShellCompany_dbF_c20240101__20241231_zIkPAiv8ePZ6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the average bid and
asked price of such common equity, as of June 30, 2024, was approximately $<span id="xdx_900_edei--EntityPublicFloat_iI_c20240630_zVQNzOefOhOd"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,904,508</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares outstanding of the registrant&#8217;s common stock as of March 11, 2025 was <span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_c20250311_z3eAxxf5L3Af"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-11" id="Fact000046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,533,798</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABEONA
THERAPEUTICS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual
Report on Form 10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">Part I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_009">Part II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_001">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_002">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_003">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_004">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_005">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_006">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#me_007">Part III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_008">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_009">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_010">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_011">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_012">Principal Accounting Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#me_013">Part IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#me_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_015">Form 10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#me_016">Signatures</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Form 10-K (including information incorporated by reference) contains statements that express management&#8217;s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed
to be, &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221;
&#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221;
and variations of such words and similar expressions, and the negatives thereof, are intended to identify such forward-looking statements.
Such &#8220;forward-looking statements&#8221; speak only as of the date made and are not guarantees of future performance and involve
certain risks, uncertainties, estimates, and assumptions by management that are difficult to predict. Various factors, some of which
are beyond the Company&#8217;s control, could cause actual results to differ materially from those expressed in, or implied by, such
forward-looking statements. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances
after the date of this report, except as may otherwise be required by the federal securities laws.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Forward-looking
statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in forward-looking
statements due to a number of factors. These statements include statements about: the outcome and timing of the U.S. Food and Drug Administration&#8217;s
(&#8220;FDA&#8221;) review of the resubmission of our Biologics License Application for pz-cel; our plans to continue development of
AAV-based gene therapies designed to treat ophthalmic diseases; the FDA&#8217;s potential grant of a pediatric priority voucher (&#8220;PRV&#8221;)
in connection with the pz-cel BLA; the achievement of or expected timing, progress and results
of clinical development, clinical trials and potential regulatory approvals; our pipeline of product candidates; our belief that pz-cel
could potentially benefit patients with RDEB; our belief in the adequacy of the clinical trial data from our VIITAL&#8482; clinical trial,
together with the data generated in the pz-cel program to date, to support pz-cel&#8217;s regulatory approval; our dependence upon our
third-party customers and vendors and their compliance with regulatory bodies; our estimates regarding expenses, future revenues, capital
requirements, and needs for additional financing; our intellectual property position and our ability to obtain, maintain and enforce
intellectual property protection and exclusivity for our proprietary assets; our estimates regarding the size of the potential markets
for our product candidates, the strength of our commercialization strategies and our ability to serve and supply those markets; and future
economic conditions or performance.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Important
factors that could affect performance and cause results to differ materially from management&#8217;s expectations are described in the
sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; in this Form 10-K. These factors include: the timing and outcome of the FDA&#8217;s review of our resubmission of
the Biologics License Application for pz-cel; our ability to access our existing at-the-market sale agreement; our ability to access
additional financial resources and/or our financial flexibility to reduce operating expenses if required; our ability to obtain additional
equity funding from current or new stockholders; the potential impacts of global healthcare emergencies, such as pandemics, on our business,
operations, and financial condition; the potential impact of unpredicted changes in the structure and/or administration of the United
States government or its agencies; our ability to out-license technology and/or other assets, deferring and/or eliminating planned expenditures,
restructuring operations and/or reducing headcount, and sales of assets; the dilutive effect that raising additional funds by selling
additional equity securities would have on the relative equity ownership of our existing investors, including under our existing at-the-market
sale agreement; the outcome of any interactions with the FDA or other regulatory agencies relating to any of our products or product
candidates; our ability to continue to secure and maintain regulatory designations for our product candidates; our ability to develop
manufacturing capabilities compliant with current good manufacturing practices for our product candidates; our ability to manufacture
cell and gene therapy products and produce an adequate product supply to support clinical trials and potentially future commercialization;
the rate and degree of market acceptance of our product candidates for any indication once approved; and our ability to meet our obligations
contained in license agreements to which we are party.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc., a Delaware corporation (together with our subsidiaries, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;Abeona&#8221;
or the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening
diseases. Our lead clinical program is for prademagene zamikeracel (&#8220;pz-cel&#8221;), an autologous, cell-based gene therapy currently
in development for recessive dystrophic epidermolysis bullosa (&#8220;RDEB&#8221;). Pz-cel has been granted Orphan Drug and Rare Pediatric
Disease (&#8220;RPD&#8221;) designations by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and Orphan Drug Designation by
the European Medicines Agency (&#8220;EMA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to continue development of adeno-associated virus (&#8220;AAV&#8221;) based gene therapies designed to treat ophthalmic diseases
with high unmet need using the novel AIM&#8482; capsids exclusively licensed from the University of North Carolina at Chapel Hill (&#8220;UNC&#8221;)
and developed internally through our AAV vector research programs. Abeona&#8217;s novel, next-generation AAV capsids are being evaluated
to improve tropism profiles for a variety of devastating diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Mission and Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Our lead clinical
program is pz-cel, autologous, COL7A1 gene-corrected epidermal sheets, an investigational product currently in development for RDEB.
In November 2022, we announced positive top-line data from the VIITAL&#8482; study evaluating the efficacy, safety and tolerability
of pz-cel. The VIITAL&#8482; study met both its co-primary efficacy endpoints demonstrating statistically significant,
clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds. In September 2023, we
submitted a Biologics License Application (&#8220;BLA&#8221;) for pz-cel to the FDA. In November 2023, the FDA accepted and granted
priority review for our BLA for pz-cel, and subsequently, under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the FDA
set a target action date of May 25, 2024. In April 2024, the FDA issued a Complete Response Letter (&#8220;CRL&#8221;) in response
to the BLA. The CRL noted that certain additional information needed to satisfy the Chemistry Manufacturing and Controls
(&#8220;CMC&#8221;) requirements of the pz-cel BLA must be satisfactorily resolved before the application can be approved. The CRL
did not identify any deficiencies related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request
any new clinical trials or clinical data to support the approval of pz-cel. In August 2024, we completed a Type A Meeting with
the FDA to discuss the forthcoming resubmission of our BLA and in October 2024, we resubmitted our BLA. The FDA notified the
Company in November 2024 that the BLA was accepted for review, with an assigned PDUFA target action date of April 29,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
partner with leading academic researchers, patient advocacy organizations, caregivers and other biotechnology companies to develop therapies
that address the underlying cause of a broad spectrum of rare genetic diseases for which no effective treatment options exist today.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advancing
and Commercializing our Late-Stage Clinical Cell and Gene Therapy Programs with a Focus on Life-Threatening Diseases.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our cell and gene therapy expertise in research and development, we believe we are positioned to introduce efficacious and safe therapeutics
to transform the standard of care in devastating diseases and establish our leadership position in the field. We intend to commercialize
our assets either by ourselves or through strategic partnerships, subject to FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
Novel In-Vivo Gene Therapies Using AIM&#8482; Capsid Technology.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are researching and developing AAV-based gene therapies using novel AAV capsids both derived from the licensed AIM&#8482; Capsid Technology
Platform and invented by the Company. We plan to continue to develop chimeric AAV capsids capable of improved tissue targeting for various
indications and that can potentially evade immunity to wild-type AAV vectors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leveraging
our Leadership Position in Commercial-Scale Cell and Gene Therapy Manufacturing.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
established current Good Manufacturing Practice (&#8220;cGMP&#8221;), clinical-scale manufacturing capabilities for engineered cell therapies
and AAV-based gene therapies in our state-of-the-art Cleveland, Ohio facility. We believe that our manufacturing platform provides us
with distinct advantages, including flexibility, scale, reliability, and the potential for reduced development risk, reduced cost, and
faster times to market. We have focused on establishing internal CMC capabilities that drive value for our organization through process
development, assay development and manufacturing. We have also deployed robust quality systems governing all aspects of product lifecycle
from preclinical through commercial stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Establishing
Additional Cell and Gene Therapy Franchises and Adjacencies through In-Licensing and Strategic Partnerships.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to be the partner of choice in cell and gene therapy treatments and have closely collaborated with leading academic institutions,
key opinion leaders, patient foundations, and industry partners to accelerate research and development, understand the needs of patients
and their families, and generate novel intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Maintaining
and Growing our IP Portfolio.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek patent rights for various aspects of our programs, including vector engineering and construct design, our production process, and
all features of our clinical products including compositions of matter and methods of manufacture, administration, and delivery. We expect
to continue to expand our intellectual property portfolio by aggressively seeking patent rights for promising aspects of our product
engine and product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Developing
Next-Generation Cell and Gene Therapy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pz-cel
for the Treatment of RDEB</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Disease
Overview</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RDEB
belongs to a broad group of genetic skin disorders known as epidermolysis bullosa. Patients with RDEB have a defect in the COL7A1 gene,
resulting in the inability to produce Type VII collagen, which plays a vital role in skin functioning by anchoring the skin&#8217;s dermal
and epidermal layers to one another.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the genetic defect, RDEB patients have fragile skin, which can easily damage to produce open and blistering wounds, disfiguring
scars throughout the body, fused fingers and toes, limits in range of motion at joints (e.g., arms and legs), corneal abrasions, and
an abnormal narrowing of the esophagus. Long-term RDEB patients can suffer from anemia, are at high risk of developing aggressive squamous
cell carcinomas, infections, and premature death. The most severe patients are approximately 20 times more likely to die by 30 years
of age than the general population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to other rare diseases, the incidence and prevalence of RDEB are not well defined. Incidence of 0.2 to 3.05 per million births and
prevalence of 0.14 to 1.35 per million people have been observed across different geographies, primarily estimated by limited
population analyses of clinical databases or registries (Eichstadt et al.; Clinical, Cosmetic and Investigational Dermatology,
2019). Using genetic modeling of COL7A1 variants, Stanford University estimated the incidence of RDEB to be approximately 63 per
million births, and prevalence could be up to 3,850 patients in the U.S., whose wounds may benefit from COL7A1-mediated treatments
such as pz-cel. Based on claims analysis, we estimate that approximately 750 moderate to severe RDEB patients in the U.S. would be
pz-cel eligible patients at the time of a potential pz-cel launch (Clearview Claims Analysis, 2024).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RDEB
patients have active disease, with the majority of their wounds typically greater than 20 cm<sup>2</sup> in size (Stanford University;
Solis, D., et al., 2017). In 2020, a survey of RDEB patients reported that approximately 60% have active wounds covering greater than
30% of their bodies (Bruckner et al.; Orphanet Journal of Rare Diseases, 2020). Wounds covering up to approximately 80% of body surface
area have been recorded in some EB patients (Hirsch et al.; Nature Research, 2017).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our VIITAL<sup>TM</sup> phase 3 and phase 1/2a clinical trials, pz-cel was applied as a one-time surgical procedure onto RDEB wounds
and has shown up to 8 years of durable wound healing and associated pain reduction even in the tough large, chronic RDEB wounds.
Patients evaluated in the VIITAL<sup>TM</sup> phase 3 trial had large wounds (&gt; 20cm<sup>2</sup>) and, on average, had wounds
that remained open for 6.2 years, and in some cases up to 21 years, prior to pz-cel treatment. Most RDEB patients have large and
chronic wounds that carry the highest burden, including the need for frequent lengthy dressing changes, pain, pruritus (itch), risk of
infection, and developing skin cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Current
Management of RDEB</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standard
of care in RDEB wound management currently consists of lengthy and labor-intensive supportive care to limit contamination and infection,
and reduction in mechanical forces that produce new blisters. Care usually includes treatment of new blisters by lancing and draining.
Wounds are then dressed with non-adherent material, covered with padding for stability and protection, and secured with an elastic
wrap for integrity. In a cost analysis conducted by Debra of America, based on 3,274 patient health insurance claims from private
insurance, the annual cost of care for dystrophic epidermolysis bullosa (DEB) was found to be 465% greater than the annual cost to the
healthcare system from all people. The cost of wound care supplies could be as high as $996,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RDEB
patients also have periodic surgeries to relieve disease related issues such as narrowing of their esophagus, fusing of fingers, and
corneal abrasions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, Vyjuvek<sup>&#174;</sup> and Filsuvez<sup>&#174;</sup> were approved by the FDA for treatment of wounds associated with DEB and wounds
associated with Junctional (JEB) and DEB, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RDEB patients continue to seek durable treatments for addressing their
wounds in the current treatment landscape.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Program
Status</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pz-cel
is an investigational product comprised of autologous epidermal sheets in which a functioning COL7A1 gene is inserted into a patient&#8217;s
own skin cells (keratinocytes) using a retrovirus. The keratinocytes are then grown into credit card-sized sheets and surgically applied
to the patient to restore Type VII collagen expression and skin function.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
from a completed Phase 1/2a study that enrolled seven patients with large and chronic RDEB wounds at Stanford University showed that
pz-cel was well-tolerated and resulted in significant and durable wound healing (Siprashvili, Z., et al., 2016), with up to eight years
of follow-up (So. Y, Nazaraoff, et al., Orphanet Journal Rare Disease 2022). To date, there have been no reported serious adverse events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, we announced positive topline data from our VIITAL&#8482; study. The pivotal phase 3 VIITAL&#8482; study evaluated
the efficacy, safety, and tolerability of pz-cel in 43 large chronic wound pairs in 11 subjects with RDEB. The large chronic wounds
randomized and treated in VIITAL&#8482; measured greater than 20 cm<sup>2</sup> of surface area and had remained open for a minimum
of six months and a maximum of 21 years (mean 6.2 years). The co-primary endpoints of the study were assessed at the six-month timepoint for: (1) the proportion of RDEB
wound sites with greater than or equal to 50% healing from baseline, comparing randomized treated with matched untreated (control)
wound sites, as determined by direct investigator assessment; and (2) pain reduction associated with
wound dressing change assessed by the mean differences in scores of the Wong-Baker FACES<sup>&#174;</sup> Pain Rating Scale between
randomized treated and matched untreated (control) wounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
VIITAL&#8482; study met both co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful
improvements in wound healing and pain reduction in large chronic RDEB wounds. Pz-cel was shown to be well-tolerated with no serious
treatment-related adverse events observed, consistent with past clinical experience. There were no deaths or instances of positive
replication-competent retrovirus results, and no systemic immunologic responses were reported during the study, as well as no
squamous cell carcinoma at treatment sites after application of pz-cel. Two subjects reported at least one serious adverse event
unrelated to pz-cel. Four subjects reported related treatment emergent adverse events, including procedural pain, muscle spasms and
pruritis. Infections unrelated to pz-cel were observed in eight patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, we submitted a BLA for pz-cel to the FDA. In November 2023, the FDA accepted and granted priority review for our BLA
for pz-cel, and subsequently, under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the FDA set a target action date of May
25, 2024. In April 2024, the FDA issued a Complete Response Letter (&#8220;CRL&#8221;) in response to the BLA. The CRL noted that certain
additional information needed to satisfy the Chemistry Manufacturing and Controls (&#8220;CMC&#8221;) requirements of the pz-cel BLA
must be satisfactorily resolved before the application can be approved. The CRL did not identify any deficiencies related to the clinical
efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical data to support the approval
of pz-cel. In August 2024, we completed a Type A Meeting with the FDA to discuss our forthcoming resubmission of our BLA and in October 2024, we resubmitted our BLA. The FDA notified the Company in November 2024 that the BLA was accepted for review, with an assigned
PDUFA target action date of April 29, 2025. Pz-cel has been granted Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;), Breakthrough
Therapy, Orphan Drug and RPD designations by the by the FDA as well as Orphan Drug designation by the EMA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the potential benefits of Orphan Drug designation are a potential seven years of market exclusivity following FDA approval, potentially
preventing FDA approval of another product deemed to be the same as the approved product for the same indication, waiver of application
fees, and tax credits for qualified clinical testing expenses conducted after orphan designation is received. A sponsor who receives
an approval for a BLA with RPD designation may qualify for a Priority Review Voucher (&#8220;PRV&#8221;), subject to final determination
by the FDA. A PRV may be used to receive an expedited review of a subsequent marketing application for a different product or sold to another
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have continued to prepare our current Good Manufacturing Practices (&#8220;cGMP&#8221;) facility in Cleveland, Ohio for
manufacturing commercial grade pz-cel drug product to support our planned commercial launch of pz-cel, if approved. Pz-cel study
drug product for all our VIITAL&#8482; study participants has been manufactured at our Cleveland facility. As part of our commercial
planning, we continue to engage with stakeholders across the healthcare system, including private payors that cover the majority of
RDEB lives, and healthcare providers to better understand market access and potential pricing for pz-cel. We are also in discussions
with 5 to 7 epidermolysis bullosa centers of excellence to onboard them as pz-cel Qualified Treatment Centers (&#8220;QTC&#8221;)
following potential FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABO-503
for the treatment of X-linked Retinoschisis (&#8220;XLRS&#8221;)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Disease
Overview and Program Overview</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XLRS
is a rare, monogenic retinal disease that results in the irreversible loss of photoreceptor cells and severe visual impairment. XLRS
is caused by mutations in the RS1 protein, which is normally secreted by retinal photoreceptors and bipolar neurons and functions to
mediate cell-cell adhesion. XLRS is characterized by abnormal splitting of the layers of the retina, resulting in poor visual acuity,
which can progress to legal blindness. The incidence of XLRS is estimated to be between 1 in 5,000 and 1 in 20,000 in males, with an
estimated prevalence of 35,000 in the United States and Europe combined. There are currently no disease modifying therapies approved
for XLRS, but because the genetics of the disease are well understood, early intervention via gene therapy has significant potential
to reverse or stabilize disease progression at early stages and prevent vision loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABO-503,
composed of a functional human RS1 packaged in the novel AIM&#8482; capsid AAV204, has shown preclinical efficacy following delivery
to the retina in a mouse model of XLRS. Preclinical studies have demonstrated robust RS1 expression in the retina, improved cone
photoreceptor density and overall photoreceptor cell survival, as well as a restoration of outer retina architecture. Results of
these studies were presented at the American Society of Gene and Cell Therapy (&#8220;ASGCT&#8221;) Annual Meeting in May 2023. A
pre-IND meeting for ABO-503 was conducted with the FDA in April 2023 and provided Abeona with comprehensive feedback to support a
future IND submission. IND-enabling efficacy and toxicology animal studies are scheduled to be completed by the end of 2025. Additionally,
cGMP manufacturing of clinical grade material has been initiated at a third-party vendor in anticipation of first in human trials being
initiated in 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABO-504
for the Treatment of Stargardt Disease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Disease
Overview and Program Overview</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Autosomal
recessive Stargardt disease, the most common form of juvenile macular degeneration with estimated incidence of 1 in 8,000 to 10,000 people,
causes vision loss in children and young adults. The most common form of Stargardt disease is caused by mutations in the ABCA4 gene,
which prevent removal of toxic compounds from photoreceptor cells that results in photoreceptor cell death and progressive vision loss.
There are currently no FDA approved treatments available, and to date, development of investigational gene modifying therapies has remained
challenging in part due to the large size of the ABCA4 gene, which exceeds the encapsidation capacity of a single AAV capsid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona&#8217;s
internal research and development team developed ABO-504, which is designed to efficiently reconstitute the full-length ABCA4 gene by
implementing a dual AAV vector strategy using the Cre-LoxP recombinase system. Abeona previously reported preclinical data demonstrating
the ability of the dual AAV vector system to produce full length ABCA4 protein in cell culture. Recent proof-of-concept studies, presented
at the 2023 ASGCT Annual Meeting, have extended these findings by showing expression of ABCA4 mRNA and full-length ABCA4 protein in the
retina of subretinally dosed abca4-/- knockout mice, at levels similar to endogenous ABCA4 in wild-type animals. A pre-IND meeting for
ABO-504 was conducted with the FDA in June 2023 and provided Abeona with comprehensive feedback to support a future IND submission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABO-505
for the Treatment of Autosomal Dominant Optic Atrophy (&#8220;ADOA&#8221;)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Disease
Overview and Program Overview</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADOA,
a form of hereditary vision loss associated with retinal ganglion cell (&#8220;RGC&#8221;) death, is predominantly caused by mutations
in the Opa1 gene. Opa1, a dynamin-related GTPase, acts to stabilize the inner mitochondrial membrane and acts in mitochondrial fusion
and inner membrane remodeling. Mutant phenotypes present with a progressive loss of RGCs that results in optic nerve degeneration and
legal blindness with a loss of visual acuity, optic disc pallor, and color vision deficits. ADOA affects approximately 1 in 30,000 people
worldwide. Currently, there is no approved treatment for people living with ADOA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABO-505
is designed to express a functional copy of human Opa1 in the retina following para-retinal injection. ABO-505 aims to take advantage
of the robust optic nerve and RGC transduction ability of AAV204 to deliver its genetic payload to the cells most affected by ADOA. Preclinical
studies have confirmed expression of Opa1 in both cell culture and the retinas of dosed wild-type and disease model animals. Initial
efficacy results suggest an improvement in retinal signaling to the brain and improved visual acuity in treated mutant mice. These studies
were presented at the ASGCT Annual Meeting in May 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gene
Therapy Treatments anchored in AIM&#8482; Vector Platform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, we licensed a library of novel AAV capsids from UNC. The AIM&#8482; vector system is a platform of AAV capsids capable of widespread
central nervous system gene transfer and can be used to confer high transduction efficiency for various therapeutic indications. In partnership
with academic institutions, our own scientific research teams have identified capsids within the AIM&#8482; capsid library showing strong
potential to successfully target and reach the central nervous system (including the retina) as well, lung, muscle, liver, and other
tissues. Based on continuing research by Abeona and our research partners, we have observed improvements in gene delivery to specific
tissues compared to currently available AAV technology. We believe AIM&#8482; vectors also have the potential for redosing subjects who
previously received certain AAV gene therapy or subjects who have pre-existing antibodies to naturally occurring AAV serotypes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2024, we entered into a non-exclusive agreement
with Beacon Therapeutics (&#8220;Beacon&#8221;) under which Beacon will evaluate Abeona&#8217;s patented AAV204 capsid for the development
and commercialization of potential gene therapies for select ophthalmology indications. Following a 12-month evaluation period, Beacon
will have the option to take a worldwide, non-exclusive license to use AAV204 in connection with up to five gene or disease targets. Beacon
will also have the right to use AAV204 for up to four additional nominated gene or disease targets subject to certain conditions. We will
receive an upfront payment upon Beacon&#8217;s exercise of its option to license AAV204, with additional payments upon the achievement
of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating
AAV204.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Strategic
Licensing Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have out-licensed certain clinical and research programs, including for the treatment of Sanfilippo syndrome type A (MPS IIIA) to
Ultragenyx Pharmaceutical Inc. (&#8220;Ultragenyx&#8221;), and for CLN1 disease (infantile Batten disease) and Rett syndrome to
Taysha Gene Therapies, Inc. (&#8220;Taysha&#8221;). Under the terms of our agreement with Ultragenyx, we are eligible to receive
payments based on the achievement of certain sales milestones and royalties on net sales. On February 18, 2025, Ultragenyx reported
that its BLA for its MPS IIIA product, UX111 (ABO-102), had been accepted for review by the FDA, with a PDUFA date of August 18, 2025. Under
our agreements with Taysha, we are eligible to receive payments based on certain clinical, regulatory, and sales milestones and
royalties on net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leveraging
Leadership Position in Commercial-Scale Cell and Gene-Therapy Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a cGMP manufacturing facility, the Elisa Linton Center located in Cleveland, Ohio at 6555 Carnegie Avenue, which enables
us to enhance supply chain control, establish tighter quality control testing, increase supply capacity, reduce production costs and
gain manufacturing efficiency for clinical trials related to our product candidates and ensure commercial demand is met in the event
our therapies receive marketing approval. Our facility is led by a team of highly skilled production, process/assay development and quality
control scientists with expertise in cell and gene therapy, particularly in cell culture, upstream manufacturing, downstream purification,
assay development and wet lab techniques.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have over 16,000+ square foot manufacturing space in Cleveland, Ohio. The first phase, completed in 2018, was a 6,000 square foot state-of-the-art
cGMP production facility for the manufacturing of cell and gene therapies. The facility is designed to initially manufacture clinical
drug products with intent of manufacturing commercial grade cGMP drug product. The second phase, completed in 2019, was the completion
of an additional 8,000 square feet of state-of-the-art laboratory space to support our expanding quality control, process development,
and assay development teams. The second phase also included nearly 2,000 square feet of cGMP Inventory Control space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 18, 2024, we signed a lease for 16,566 square feet of office space at 6700 Euclid Avenue, Cleveland, Ohio. The lease commenced
on January 1, 2025 and the lease term matches the term for our existing 6555 Carnegie Avenue facility. The additional space at the 6700
Euclid Avenue facility will allow us to convert office space at the 6555 Carnegie Avenue facility into additional manufacturing space
to increase pz-cel manufacturing capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have advanced our in-house manufacturing capabilities for pz-cel. The product is manufactured as multilayer cellular sheets containing
gene-corrected keratinocytes that is fastened to a petrolatum gauze backing with surgical titanium ligating clips. Engineered keratinocyte
sheets expressing functional Type VII collagen are applied over wound areas, providing immediate wound coverage and allowing for long-term
wound healing. A key component to the pz-cel drug product manufacturing process is the retroviral vector, which delivers the functional
copy of the Collagen VII Alpha 1 cDNA to the patient&#8217;s own cells. We manufacture the LZRSE-Col7A1 retroviral vector at our Cleveland
facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
AAV vector manufacturing process uses the triple plasmid transient transfection method. We insert (&#8220;transfect&#8221;) many copies
of three DNA plasmids encoding the specific therapeutic gene sequence, or transgene, the capsid coding sequence, and helper sequences
into AAV-293 cells using a serum-free, suspension-based bioreactor vector production technology. During an incubation period following
transfection, each cell produces AAV vectors through biosynthesis using the cells&#8217; natural machinery. At the end of the incubation
period, the newly generated AAV vectors are harvested, filtered, and purified in a multi-step process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established and maintained strong and collaborative relationships with third-party companies specializing in the testing of cell
and gene therapy material to complement our process and assay development needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have made significant investments in developing optimized manufacturing processes and believe that our processes and methods developed
to date provide a comprehensive manufacturing process for pz-cel and AAV-based vector therapies, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficient
    scale to support commercial manufacturing requirements for pz-cel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">processes
    related to biopsy, cell collection, storage and transportation as part of manufacturing for pz-cel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">processes
    related to product release testing for pz-cel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">processes
    related to the manufacture and release testing of retroviral vector</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    transportation and packaging processes and materials for finished pz-cel product</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proprietary
    AAV vector manufacturing processes and techniques that produce a highly purified product candidate</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AAV
    serum-free suspension technology that is readily scalable</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple
    assays to accurately characterize our process and the AAV vectors we produce</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    series of purification processes, which may be adapted and customized for multiple different AAV capsids, with a goal of higher concentrations
    of active vectors, and that are essentially free of empty capsids.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that these investments will enable us to develop best-in-class, next-generation cell and gene therapy products. As we look to
commercialize pz-cel (subject to FDA approval), we have filed our BLA to support commercial manufacturing of pz-cel from our Cleveland
facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maintain
Strong Intellectual Property Protection</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect our commercially important proprietary technology, inventions, and know-how, including by seeking, maintaining, and
defending patent rights, both for inventions developed internally and for inventions licensed from third parties. We also rely on trade
secrets and know-how relating to our proprietary technology platforms, continuing technological innovation, and in-licensing opportunities
to develop, strengthen and maintain our position in the field of cell and gene therapy. We may also rely on the additional protections
afforded by data exclusivity (currently 12 years for biologics), other market exclusivities such as orphan drug exclusivity, and patent
term extensions, where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success may depend in part on our ability to obtain and maintain patents and other protections for commercially important technology,
inventions, and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets;
and operate without infringing the valid enforceable patents and other intellectual property rights of third parties. Our ability to
stop third parties from making, having made, using, selling, offering to sell, or importing our products may depend on the extent to
which we have rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, these
rights may need to be enforced by third-party licensors. With respect to both licensed and company-owned intellectual property, we may
not be granted patents with respect to any of our pending patent applications or with respect to any patent applications filed by us
in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially
useful in protecting our commercial products and methods of manufacturing the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are actively seeking U.S. and international patent protection, together with our licensors, for a variety of technologies, including
AAV capsids, AAV-based biological products, methods of designing novel AAV constructs, compositions and methods for treating diseases
of interest, including RDEB, and methods for manufacturing, packaging, and transporting our product candidates. We also intend to seek
patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and
that may be used to identify and develop novel biological products. We seek protection, in part, through confidentiality and proprietary
information agreements. We are a party to various license agreements that give us rights to use specific technologies in our research
and development, and future commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensed
Technologies and Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recessive
    Dystrophic Epidermolysis Bullosa</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
support our EB franchise, we licensed a patent family from Stanford University covering pz-cel and its use in the treatment of RDEB.
Patents covering our investigational pz-cel product have been granted in the United States (U.S. Patent Nos. 12,110,504 and 12,173,314),
by the European Patent Office (EP3400287B1) and in other geographical regions and are expected to expire in early 2037. Patent applications
remain pending in the United States which, if granted, would be expected to expire in 2037. A patent covering the packaging and transport
system for pz-cel has been granted in the United States (U.S. Patent No. 12,144,340) and is expected to expire in mid-2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also rely on the additional protection afforded by data exclusivity (currently 12 years for biologics like pz-cel), other market
exclusivity such as orphan drug exclusivity (currently seven years), and patent term extensions, where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AIM&#8482;
    Capsids</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an exclusive license to an international patent family from The University of North Carolina at Chapel Hill (&#8220;UNC&#8221;)
covering novel AAV capsids (&#8220;AIM&#8482; capsids&#8221;) that may potentially be used to deliver a wide variety of therapeutic transgenes
to human cells to treat genetic diseases. National stage applications directed to the AIM&#8482; capsids have been filed in the United
States, Europe, and other geographical regions. The first U.S. patent in this patent family, U.S. Patent No. 10,532,110 (the &#8220;&#8216;110
Patent&#8221;), was issued to UNC on January 14, 2020. The &#8216;110 Patent is entitled to 352 days of patent term adjustment, making
its projected expiration date November 6, 2036. The second U.S. patent in this patent family, U.S. Patent No. 10,561,743 (the &#8220;&#8216;743
Patent&#8221;), was issued to UNC on February 18, 2020. The &#8216;743 Patent is expected to expire on November 20, 2035. A third U.S.
patent in this patent family, U.S. Patent No. 11,491,242 (the &#8220;&#8216;242 Patent&#8221;) issued on November 8, 2022. The &#8216;242
Patent is entitled to 429 days of patent term adjustment and will not expire before January 22, 2037. Patents have also been granted
in Australia (AU2015349759B2), Israel (IL252072), and Russia (RU2727015). We have exclusive rights to these patents under our license
with UNC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also own a second patent family directed to certain AAV capsids and have filed national stage applications in the United States, Europe
and other geographical regions. Patents issuing from these applications would not be expected to expire before 2039.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>3.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CLN1
    Disease (Infantile Batten Disease)</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also licensed from UNC rights to two patent families directed to treating CLN1 disease (also known as infantile Batten disease).
The first patent family is directed to optimized CLN1 genes and expression cassettes for use in treating CLN1 disease, which has applications
pending in the United States, Europe, and other geographical regions. One U.S. patent in the first patent family, U.S. Patent No. 11,504,435
(the &#8220;&#8216;435 Patent&#8221;), was issued to UNC on November 22, 2022. The &#8216;435 Patent is entitled to 578 days of patent
term adjustment, making its projected expiration date January 12, 2039. The second patent family is directed to treating CLN1 disease
using a combination of intrathecal and intravenous administrations, and has applications pending in the United States, Europe and other
geographical regions. Patents issuing from applications in the second patent family would have a 20-year expiration date of no earlier
than 2040. We have entered into agreements exclusively sublicensing these two CLN1 patent families to Taysha Gene Therapies, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>4.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rett
    Syndrome</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have licensed rights to one patent family from UNC and two patent families from The University Court of the University of Edinburgh (&#8220;U.
Edinburgh&#8221;) and The University Court of the University of Glasgow (&#8220;U. Glasgow&#8221;) relating to gene therapy for the treatment
of Rett Syndrome. The patent family licensed from UNC at Chapel Hill is directed to viral genomes designed to regulate expression of
the MeCP2 gene, which is mutated in patients with Rett Syndrome. This patent family has pending applications in the United States, Europe
and other geographical regions. Patents issuing from these applications would have a 20-year expiration date of no earlier than 2039.
The patent families licensed from U. Edinburgh and U. Glasgow are directed to expression cassettes for MeCP2 polypeptides and to synthetic
MeCP2 polypeptides. The patent family directed to MeCP2 expression cassettes has pending applications in the United States, Europe and
other geographical regions. The patent family directed to synthetic MeCP2 polypeptides has pending applications in the United States
and other geographical regions. Patents issuing from applications in the Edinburgh patent families would have a 20-year expiration date
of no earlier than 2038. In October 2020, we entered into an agreement exclusively sublicensing these UNC and University of Edinburgh
patent rights to Taysha Gene Therapies, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>5.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Multipartite
    AAV Delivery of Large Transgenes</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own a patent family directed to multipartite delivery of large transgenes using AAV vectors and have filed national stage applications
in the United States, Europe and other geographical regions. Patents issuing from these applications would not be expected to expire
before 2041.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also own a pending U.S. application (U.S. Patent Publ. No. 2022/0090129 A1) directed to multipartite AAV delivery and its use for treating
Stargardt disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>6.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
    AAV Capsids and Ophthalmic Disease Treatment via Para-retinal AAV Administration</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own a patent family directed to (i) novel AAV capsid proteins and (ii) treating ophthalmic diseases via para-retinal administration of
AAV vectors and have filed national stage applications in the United States, Europe, and other geographical regions. Patents issuing
from these applications would not be expected to expire before 2042.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>7.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Treatment
    of Dominant Optic Atrophy and X-linked Retinoschisis</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own a pending PCT application (PCT/US2023/065877) directed to compositions and methods for treating dominant optic atrophy and X-linked
retinoschisis. Patents issuing from future national stage applications of this PCT application would not be expected to expire before
2043.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to explore in due course strategies to support patent term extensions for all of our patent portfolios.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Biologic Products Development Process</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates biologic products including gene therapy products under the Federal Food, Drug, and Cosmetic Act
(&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;), and regulations implementing these laws. The FDCA, PHSA and
their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage,
record keeping, distribution, advertising, and promotion of biologic products. Applications to the FDA are required before conducting
human clinical testing of biologic products. FDA approval also must be obtained before marketing of biologic products. Gene therapy studies
may also need to comply with the National Institutes of Health (&#8220;NIH&#8221;) Guidelines for Research Involving Recombinant or Synthetic
Nucleic Acid Molecules (&#8220;NIH Guidelines&#8221;), which includes additional requirements, such as the review and approval of the
study by an Institutional Biosafety Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
the FDA, the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) regulates gene therapy products. Within CBER, the review
of gene therapy and related products is consolidated in the Office of Tissues and Advanced Therapies (&#8220;OTAT&#8221;) and the FDA
has established the Cellular, Tissue and Gene Therapies Advisory Committee (&#8220;CTGTAC&#8221;), a panel of medical and scientific
experts and consumer representatives, to advise CBER on its reviews. The FDA has issued a growing body of guidance documents on CMC,
clinical investigations and other areas of gene therapy development, all of which are intended to facilitate the industry&#8217;s development
of gene therapy products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a biologic product candidate may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory tests and in vivo studies in accordance with the FDA&#8217;s current Good Laboratory Practice (&#8220;GLP&#8221;)
    regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an application for an IND, which allows human clinical trials to begin unless the FDA objects within 30 days;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent institutional review board (&#8220;IRB&#8221;), reviewing each clinical site before each clinical trial may be
    initiated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials according to the FDA&#8217;s Good Clinical Practice (&#8220;GCP&#8221;) regulations,
    and any additional requirements for the protection of human research subjects and their health information, to establish the safety
    and efficacy of the proposed biologic product candidate for its intended use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
    of manufacturing processes to ensure the product candidate&#8217;s identity, strength, quality, purity, and potency;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
    and submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity and potency from results
    of nonclinical testing and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the biologic product candidate is
    produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biologic
    product candidate&#8217;s identity, safety, strength, quality, potency and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    of user fees and the FDA review and approval, or licensure, of the BLA. BLA application fees for products designated as orphan drugs
    by the FDA are waived.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
testing any biologic product candidate on humans, including a gene therapy product candidate, the product candidate must undergo preclinical
testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity, and
formulation, as well as in vivo studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical
tests must comply with federal regulations and requirements including GLPs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a gene therapy trial is conducted at, or sponsored by, institutions receiving NIH funding for recombinant DNA research, the study must
also comply with the NIH Guidelines. Compliance with the NIH Guidelines is mandatory for investigators at institutions receiving NIH
funds for research involving recombinant DNA. However, many companies and other institutions, not otherwise subject to the NIH Guidelines,
voluntarily follow them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any
available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue
even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the
clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical
trial can begin. The FDA also may impose clinical holds on a biologic product candidate at any time before or during clinical trials
due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not commence or recommence without FDA authorization
and then only under terms authorized by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Human
clinical trials under an IND</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the biologic product candidate to healthy volunteers or patients under the supervision of qualified
investigators, which generally are physicians not employed by, or under the control of, the trial sponsor. Investigators must also provide
certain information to the clinical trial sponsors to allow the sponsors to make certain financial disclosures to the FDA. Clinical trials
are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection
and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial
will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA
as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP
requirements, including the requirement that all research subjects provide informed consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted.
An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves communications
to study subjects before a study commences at that site and the form and content of the informed consent that must be signed by each
clinical trial subject, or his or her legal representative, and must monitor the clinical trial until completed. Clinical trials involving
recombinant DNA also must be reviewed by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that
reviews and oversees basic and clinical research that utilizes recombinant DNA at that institution. The IBC assesses the safety of the
research and identifies any potential risk to public health or the environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
about certain clinical trials, including a description of the study and study results, must be submitted within specific timeframes to
NIH for public dissemination on their clinicaltrials.gov website. Sponsors or distributors of investigational products for the diagnosis,
monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and responding
to requests for expanded access requests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigational
biologics and therapeutic substances imported into the United States are also subject to regulation by the FDA. Further, the export of
investigational products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S.
export requirements under the FDCA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials typically are conducted in three sequential phases that may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1: The biologic product candidate initially is introduced into healthy human subjects and tested for safety, dosage tolerance, absorption,
    metabolism, distribution, excretion and, if possible, to gain an early understanding of its effectiveness. In the case of some product
    candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically
    administer to healthy volunteers, the initial human testing is often conducted in patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2: The biologic product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks,
    to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance,
    optimal dosage and dosing schedule.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3: The biologic product candidate is administered to an expanded patient population at geographically dispersed clinical trial sites
    in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the efficacy and safety of the
    product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and
    provide an adequate basis for product labeling. Typically, two phase 3 trials are required by the FDA for product approval. Under
    some limited circumstances, however, the FDA may approve a BLA based upon a single phase 3 clinical study plus confirmatory evidence
    or a single large multicenter trial without confirmatory evidence.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
kinds of data may also help to support a BLA, such as patient experience data. Real world evidence may also support a BLA, and, for appropriate
indications sought through supplemental BLAs, data summaries may provide marketing application support. For genetically targeted products
and variant protein targeted products intended to address an unmet medical need in one or more patient subgroups with a serious or life
threatening rare disease or condition, the FDA may allow a sponsor to rely upon data and information previously developed by the sponsor
or for which the sponsor has a right of reference, that was submitted previously to support an approved application for a product that
incorporates or utilizes the same or similar genetically targeted technology or a product that is the same or utilizes the same variant
protein targeted drug as the product that is the subject of the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
clinical trials, sometimes referred to as phase IV clinical trials, may be conducted or may be required by FDA after initial approval.
These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly
for long-term safety follow-up.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical
data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the
FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
IND safety reports must be promptly submitted to the FDA, IRBs, IBCs, and the investigators for serious and unexpected adverse events;
any findings from other trials, in vivo laboratory tests or in vitro testing that suggest a significant risk for human subjects; any
clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure,
or other safety information. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the
information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse
reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, the sponsor or its data safety monitoring board, may suspend a clinical trial at any time on various grounds, including a finding
that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or
if the biologic product candidate has been associated with unexpected serious harm to patients. The FDA or an IRB may also impose conditions
on the conduct of a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
regulation for gene therapy clinical trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use
of gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA
will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene
therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product efficacy
in support of an IND or BLA application; and long term patient and clinical study subject follow up and reporting requirements. The FDA
has also issued draft guidance specific to the development of gene therapy products for neurodegenerative diseases as such products may
face special challenges related to CMCs and clinical and preclinical development, due to the nature of the products and potential patient
population (e.g., children), the heterogeneity of neurodegenerative disorders, the route of administration, the volume of the product
that can be administered, the delivery device, and the study population size.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compliance
with cGMP requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
of biologics must comply with applicable cGMP regulations for both clinical and commercial supply. Manufacturers and others involved
in the manufacture and distribution of such products at the commercial stage also must register their establishments with the FDA and
certain state agencies and list the manufactured products. Recently, the information that must be submitted to FDA regarding manufactured
products was expanded through the Coronavirus Aid, Relief, and Economic Security, or CARES, Act to include the volume of drugs produced
during the prior year. Both domestic and foreign manufacturing establishments must register and provide additional information to the
FDA upon their initial participation in the manufacturing process. Establishments may be subject to periodic, unannounced inspections
by government authorities to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government
entity placing restrictions on a product, manufacturer, or holder of an approved BLA, and may extend to requiring withdrawal of the product
from the market. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply
with cGMP requirements and are adequate to assure consistent production of the product within required specification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the
physical characteristics of the biologic product candidate as well as finalize a process for manufacturing the product candidate in commercial
quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or of causing other
adverse events with the use of biologic products, the PHSA emphasizes the importance of manufacturing control for products whose attributes
cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the
final biologic product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate
that the biologic product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
review and approval processes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of the preclinical tests and clinical trials, together with detailed information relating to the product&#8217;s CMC and proposed
labeling, among other things, are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
gene therapies, selecting patients with applicable genetic defects is a necessary condition for effective treatment. For the therapies
we are currently developing, we believe that diagnoses based on symptoms, in conjunction with existing genetic tests developed and administered
by laboratories certified under the Clinical Laboratory Improvement Amendments, are sufficient to select appropriate patients and will
be permitted by the FDA. For future therapies, however, it may be necessary to use FDA-cleared or FDA-approved diagnostic tests to select
patients or to assure the safe and effective use of therapies in appropriate patients. The FDA refers to such tests as in vitro companion
diagnostic devices and the combination of the in vitro companion diagnostic device and the therapeutic would be considered to be a combination
product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of the two products together must be shown to be safe and effective for the proposed intended use and the labeling of the two products
must reflect their combined use. In some cases, the device component may require a separate premarket submission; for example, when the
device component is intended for use with multiple drug products. Sponsors of clinical studies using investigational devices are required
to comply with FDA&#8217;s investigational device exemption regulations. Once approved or cleared, the sponsor of the device component
submission (or the combination product submission, if both components are covered by one premarket submission) would need to comply with
FDA&#8217;s post-market device requirements, including establishment registration, device listing, device labeling, unique device identifier,
quality system regulation, medical device reporting, and reporting of corrections and removals requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has a policy position that, when safe and effective use of a therapeutic product depends on a diagnostic device, the FDA generally
will require approval or clearance of the diagnostic device at the same time that the FDA approves the therapeutic product. The type
of premarket submission required for a companion diagnostic device will depend on the FDA classification of the device. A premarket approval,
or PMA, application is required for high-risk devices classified as Class III; a 510(k) premarket notification is required for moderate
risk devices classified as Class II; and a <i>de novo </i>request may be used for novel devices not previously classified by the FDA
that are low or moderate risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may, however, approve a therapeutic product without the concurrent approval or clearance of a diagnostic device when the therapeutic
product is intended to treat serious and life-threatening conditions for which no alternative exists and the FDA determines that the
benefits from the use of the drug/biologic outweigh the risks from the lack of an approved/cleared companion diagnostic. The FDA would
also consider whether additional protections, such as risk evaluation and mitigation strategies, or REMS, or post-approval requirements,
are necessary. At this point, it is unclear how the FDA will apply this policy to our gene therapy candidates. Should the FDA deem genetic
tests used for selecting appropriate patients for our therapies to be in vitro companion diagnostics requiring FDA clearance or approval,
we may face significant delays or obstacles in obtaining approval for a BLA. In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;),
a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biologic product candidate for the claimed
indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which
the product candidate is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise
required by regulation, PREA does not apply to any biologic product candidate for an indication for which orphan designation has been
granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the PDUFA, each BLA must be accompanied by a substantial user fee that must be paid at the time of the first submission of the application,
even if the application is being submitted on a rolling basis. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or
reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small
business. Additionally, no user fees are assessed on BLAs for product candidates designated as orphan drugs, unless the product candidate
also includes a non-orphan indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews a BLA within 60 days of submission to determine if it is substantially complete before the agency accepts it for filing.
The FDA may refuse to accept for filing any BLA that it deems incomplete or not properly reviewable at the time of submission and may
request additional information. In that event, the BLA must be resubmitted with the additional information. The resubmitted application
also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth,
substantive review of the BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and potent, or effective, for its
intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with cGMP to assure
and preserve the product candidate&#8217;s identity, safety, strength, quality, potency, and purity. The FDA may refer applications for
novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions. During the product approval process, the FDA also will determine whether a REMS is necessary to assure
the safe use of the product candidate. A REMS could include medication guides, physician communication plans and elements to assure safe
use, such as restricted distribution methods, patient registries, and other risk minimization tools. If the FDA concludes a REMS is needed,
the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product
candidate unless it determines that the manufacturing processes and facilities comply with cGMP requirements and are adequate to assure
consistent production of the product candidate within required specifications. Additionally, before approving a BLA, the FDA typically
will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and
GCP requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may
issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the biologic product with
specific prescribing information for specific indications. A CRL generally outlines the deficiencies in the submission and may require
substantial additional testing or information for the FDA to reconsider the application. If a CRL is issued, the applicant may either:
resubmit the marketing application, addressing all of the deficiencies identified in the letter; withdraw the application; or request
an opportunity for a hearing. If those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA,
the FDA will issue an approval letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases, patient populations,
and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings,
or precautions be included in the product labeling. The FDA also may not approve label statements that are necessary for successful commercialization
and marketing. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS,
or otherwise limit the scope of any approval. In addition, the FDA may require post-marketing clinical trials, sometimes referred to
as phase IV clinical trials, designed to further assess a biologic product&#8217;s safety and effectiveness, and testing and surveillance
programs to monitor the safety of approved products that have been commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has agreed to specified performance goals in the review of BLAs under the PDUFA. One such goal is to review 90% of standard BLAs
in 10 months after the FDA accepts the BLA for filing, and 90% of priority BLAs in six months, whereupon a review decision is to be made.
The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time
to time. The review process and the PDUFA goal date may also be extended if new information is submitted to the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
drug designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may designate a biologic product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease
or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there
is no reasonable expectation that the cost of developing and making a biologic product available in the United States for treatment of
the disease or condition will be recovered from sales of the product). Additionally, sponsors must present a plausible hypothesis for
clinical superiority to obtain orphan drug designation if there is a product already approved by the FDA that is considered by the FDA
to be the same as the already approved product and is intended for the same indication. This hypothesis must be demonstrated to obtain
orphan exclusivity. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation,
the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If granted, prior to product approval,
orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs,
tax advantages, and certain user-fee waivers. The tax advantages, however, were limited in the 2017 Tax Cuts and Jobs Act. Orphan product
designation does not shorten the duration of the regulatory review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product
is entitled to orphan product exclusivity, meaning that the FDA may not approve any other applications to market the same drug or biologic
product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan exclusivity or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug
to meet the needs of patients with the disease or condition for which the drug was designated. Orphan product sameness decisions are
an evolving space. FDA has issued a final guidance document on how the agency will determine the &#8220;sameness&#8221; of gene therapy
products. Pursuant to the guidance, &#8220;sameness&#8221; will depend on the product&#8217;s transgene expression, viral vectors groups
and variants, and other product features that may have a therapeutic effect. Generally, minor differences between gene therapy products
will not result in a finding that two products are different. Any FDA sameness determinations could impact our ability to receive approval
for our product candidates and to obtain or retain orphan drug exclusivity. Competitors additionally may receive approval of different
products for the same indication for which the orphan product has exclusivity or obtain approval for the same product but for a different
indication for which the orphan product has exclusivity. Orphan medicinal product status in the European Union has similar, but not identical,
benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
development and review programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to expedite the review of BLAs in several ways. Under the Fast Track program, the sponsor of a biologic product candidate
may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of
the IND. Biologic products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition
and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of
the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to
have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track BLA before the application is complete,
a process known as rolling review. This &#8220;rolling review&#8221; is available if the applicant provides and the FDA approves a schedule
for the remaining information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended
to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Breakthrough
    therapy designation: </i>To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious
    or life-threatening disease or condition, and preliminary clinical evidence must indicate that such product candidates may demonstrate
    substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the
    sponsor of a breakthrough therapy product candidate receives the following: intensive guidance on an efficient drug development program;
    intensive involvement of senior managers and experienced staff on a proactive, collaborative, and cross-disciplinary review; and
    rolling review.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Priority
    review:</i> A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a
    significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition compared
    to marketed products. The FDA aims to complete its review of priority review applications within six months as opposed to 10 months
    for standard review.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accelerated
    approval: </i>Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses
    and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means
    that a product candidate may be approved on the basis of adequate and well-controlled clinical trials establishing that the product
    candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect
    on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account
    the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval,
    the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well-controlled
    post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional
    materials. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow
    the FDA to withdraw the drug or biologic from the market on an expedited basis.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
Track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval
but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later
decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will
not be shortened.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
with passage of the 21<sup>st</sup> Century Cures Act (the &#8220;Cures Act&#8221;) in December 2016, Congress authorized the FDA to
accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation
if it is a regenerative medicine therapy (which may include a cell or gene therapy) that is intended to treat, modify, reverse, or cure
a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug has the potential to address
unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions
with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review
and accelerated approval based on surrogate or intermediate endpoints.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-approval
requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rigorous
and extensive FDA regulation of biologic products continues after approval, particularly with respect to cGMP requirements. Manufacturers
are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance
of records and documentation. Other post-approval requirements applicable to biologic products include reporting of cGMP deviations that
may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse
events, reporting updated safety and efficacy information, and complying with electronic record and signature requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls
for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses
in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public
health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases
in the United States and between states. After a BLA is approved, the product also may be subject to official lot release. If the product
is subject to official lot release by the FDA, the manufacturer submits samples of each lot of product to the FDA, together with a release
protocol, showing a summary of the history of manufacture of the lot and the results of all tests performed on the lot. The FDA also
may perform certain confirmatory tests on lots of some products before releasing the lots for distribution. In addition, the FDA conducts
laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biologic products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
also are continuing annual program user fee requirements for approved products, excluding orphan products. In addition, manufacturers
and other entities involved in the manufacture and distribution of approved therapeutics are subject to periodic announced and unannounced
inspections by the FDA and these state agencies for compliance with cGMP and other requirements, which impose certain procedural and
documentation requirements upon the company and third-party manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor also must comply with the FDA&#8217;s marketing, advertising, and promotion requirements, such as those related to direct-to-consumer
advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved
labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities and promotional activities
involving the Internet. A company can make only those claims relating to a product that are approved by the FDA. Physicians, in their
independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described
in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Biopharmaceutical companies, however, are
required to promote their products only for the approved indications and in accordance with the provisions of the approved label. The
FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found
to have improperly promoted off-label uses may be subject to significant liability, including, but not limited to, criminal and civil
penalties under the FDCA and False Claims Act, exclusion from participation in federal healthcare programs, mandatory compliance programs
under corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the distribution of prescription biopharmaceutical samples is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;),
which regulates the distribution of samples at the federal level. Both the PDMA and state laws limit the distribution of prescription
biopharmaceutical product. Certain reporting related to samples is also required. Free trial or starter prescriptions provided through
pharmacies are also subject to regulations under the Medicaid Drug Rebate Program and potential liability under anti-kickback and false
claims laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the enacted Drug Quality and Security Act (&#8220;DQSA&#8221;), imposed obligations on sponsors of biopharmaceutical products related
to product tracking and tracing. Among the requirements of this legislation, sponsors are required to provide certain information regarding
the products to individuals and entities to which product ownership is transferred, are required to label products with a product identifier,
and are required to keep certain records regarding the product. The transfer of information to subsequent product owners by sponsors
is also required to be done electronically. Sponsors must also verify that purchasers of the sponsors&#8217; products are appropriately
licensed. Further, under this legislation manufacturers have product investigation, quarantine, disposition, and notification responsibilities
related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences
or death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution
such that they would be reasonably likely to result in serious health consequences or death. Similar requirements additionally are and
will be imposed through this legislation on other companies within the biopharmaceutical product supply chain, such as distributors and
dispensers, as well as certain sponsor licensees and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discovery
of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the
marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Further, should
new safety information arise, additional testing or FDA notification may be required. In addition, changes to the manufacturing process
or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as
adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval,
may subject an applicant or manufacturer to administrative or judicial civil or criminal actions and adverse publicity. These actions
could include refusal to approve pending applications or supplemental applications, withdrawal of an approval, clinical hold, suspension
or termination of clinical trial by an IRB, warning or untitled letters, product recalls, adverse publicity, product seizures, total
or partial suspension of production or distribution, injunctions, fines or other monetary penalties, refusals of government contracts,
mandated corrective advertising or communications to healthcare professionals or patients, exclusion from participation in federal and
state healthcare programs, debarment, restitution, disgorgement of profits or other civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
patent term restoration and marketing exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration, and specifics of FDA approval of product candidates, some of a sponsor&#8217;s U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984. The Hatch-Waxman Amendments
permit a patent restoration term of up to five years to account for patent term lost during the FDA regulatory review process. However,
patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date.
The patent term restoration period generally is one-half the time between the effective date of an IND and the submission date of a BLA
plus the time between the submission date of a BLA and the approval of that application. This period may also be reduced by any time
that the applicant did not act with due diligence. Only one patent applicable to an approved biologic product is eligible for the extension
and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark
Office (&#8220;USPTO&#8221;), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
exclusivity is a type of non-patent marketing exclusivity in the United States that, if granted, provides for the attachment of an additional
six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity.
This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly responds to a written request from the
FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical
trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric
studies are submitted to, and accepted by, the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity
or patent protection that cover the product are extended by six months. This is not a patent term extension, but it effectively extends
the regulatory period during which the FDA cannot accept or approve a biosimilar application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Biosimilars
and exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (&#8220;PPACA&#8221;), created
an abbreviated approval pathway for biologic products shown to be similar to, or interchangeable with, an FDA-licensed reference biologic
product, referred to as biosimilars. For the FDA to approve a biosimilar product, it must find that the biosimilar product is highly
similar to the reference product notwithstanding minor differences in clinically inactive components, and that there are no clinically
meaningful differences between the reference product and proposed biosimilar product. Interchangeability requires that a product is biosimilar
to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference
product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously
administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product. An application for a
biosimilar product may not be submitted to the FDA until four years following approval of the reference product, and it may not be approved
until 12 years thereafter. These exclusivity provisions only apply to biosimilars&#8212;companies that rely on their own data and file
a full BLA may be approved earlier than 12 years. Moreover, certain changes and supplements to an approved BLA, and subsequent applications
filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the twelve-year
exclusivity period. The PHSA also includes provisions to protect reference products that have patent protection. The biosimilar product
sponsor and reference product sponsor may exchange certain patent and product information for the purpose of determining whether there
should be a legal patent challenge. Based on the outcome of negotiations surrounding the exchanged information, the reference product
sponsor may bring a patent infringement suit and injunction proceedings against the biosimilar product sponsor. The biosimilar applicant
may also be able to bring an action for declaratory judgment concerning the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an effort to increase competition in the biologic product marketplace, Congress, the executive branch, and the FDA have taken certain
legislative and regulatory steps. For example, in 2020 the FDA finalized a guidance to facilitate product importation. Moreover, the
2020 Further Consolidated Appropriations Act included provisions requiring that sponsors of approved biologic products, including those
subject to REMS, provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient
quantities, and on commercially reasonable market-based terms. Failure to do so can subject the approved product sponsor to civil actions,
penalties, and responsibility for attorney&#8217;s fees and costs of the civil action. This same bill also includes provisions with respect
to shared and separate REMS programs for reference and generic drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rare
Pediatric Disease Priority Review Voucher Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Rare Pediatric Disease Priority Review Voucher Program, the FDA can award priority review vouchers to sponsors of rare pediatric
disease products where the product is intended to treat serious or life-threatening diseases that primarily affect individuals up to
age 18. To qualify, the product must contain no active ingredient (including any ester or salt of the active ingredient) that has been
previously approved by the FDA. The application must also meet other qualifying criteria, including eligibility for FDA priority review.
If the necessary qualifying criteria are met, upon a sponsor&#8217;s request and product approval, the FDA may award a priority review
voucher. This voucher may be transferred and may be redeemed to receive priority review of a subsequent marketing application for a different
product. Use of a priority review voucher is subject to an FDA user fee. As these vouchers are transferable, sponsors may sell these
vouchers for substantial sums of money. Vouchers may, however, be revoked by the FDA under certain circumstances and sponsors of approved
rare pediatric disease products must submit certain reports to the FDA. To take advantage of the benefits of this program, the product
must be designated by the FDA for a rare pediatric disease no later than December 20, 2024 (extended from September 30, 2024 under the
Continuing Appropriations and Extensions Act, 2025, signed into law by President Biden on September 26, 2024), and approved no later
than September 30, 2026, unless the law is reauthorized by Congress.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
regulation outside of the United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, sponsors are subject to a variety of regulations in other jurisdictions governing, among
other things, clinical trials and any commercial sales and distribution of biologic products. Because biologically-sourced raw materials
are subject to unique contamination risks, their use may be restricted in some countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not a sponsor obtains FDA approval for a product, a sponsor must obtain the requisite approvals from regulatory authorities in foreign
countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the
United States have a similar process that requires the submission of a clinical trial application, much like the IND, prior to the commencement
of human clinical trials. Save where the Clinical Trial Regulation applies (see below) in relation to cross-border trials, in the European
Union, for example, a request for a Clinical Trial Authorization (&#8220;CTA&#8221;) must be submitted to the competent regulatory authorities
and the competent Ethics Committees in the European Union Member States in which the clinical trial takes place, much like the FDA and
the IRB, respectively. Once the CTA request is approved in accordance with the European Union and the European Union Member State&#8217;s
requirements, clinical trial development may proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements and processes governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to
country. In all cases, the clinical trials are conducted in accordance with GCPs and the applicable regulatory requirements and the ethical
principles that have their origin in the Declaration of Helsinki.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with applicable foreign regulatory requirements may result in, among other things, fines, suspension, variation or withdrawal
of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
Union regulation and exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain regulatory approval of an investigational biologic product under European Union regulatory systems, applicants must submit a marketing
authorization application (&#8220;MAA&#8221;). The grant of marketing authorization in the European Union for products containing viable
human tissues or cells such as gene therapy medicinal products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products,
read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on
medicinal products and Regulation (EC) 726/2004 of the European Parliament and of the Council laying down Union procedures for the authorization
and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Regulation 1394/2007/EC
lays down specific rules concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products, somatic
cell therapy medicinal products and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate
the quality, safety and efficacy of their products to the EMA which provides an opinion regarding the application for marketing authorization.
The European Commission grants or refuses marketing authorization in light of the opinion delivered by EMA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovative
medicinal products are authorized in the European Union based on a full marketing authorization application (as opposed to an application
for marketing authorization that relies on data in the marketing authorization dossier for another, previously approved medicinal product).
Applications for marketing authorization for innovative medicinal products must contain the results of pharmaceutical tests, preclinical
tests and clinical trials conducted with the medicinal product for which marketing authorization is sought. Innovative medicinal products
for which marketing authorization is granted are entitled to eight years of data exclusivity. During this period, applicants for approval
of generics or biosimilars of these innovative products cannot make an MMA relying on data contained in the marketing authorization dossier
submitted for the innovative medicinal product to support their application and such generics or biosimilars cannot be placed on the
market until 10 years after the first EU marketing of the reference product. The overall 10-year period will be extended to a maximum
of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or
more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant
clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the innovator
is able to gain the period of data exclusivity, another company, nevertheless, could also market another competing medicinal product
for the same therapeutic indication if such company obtained marketing authorization based on an MAA with a complete independent data
package of pharmaceutical tests, preclinical tests and clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
receiving orphan designation in the European Union can receive 10 years of market exclusivity. During this 10-year period, the competent
authorities of the European Union Member States and European Commission may not accept applications or grant marketing authorization
for other similar medicinal product for the same orphan indication. There are, however, three exceptions to this principle. Marketing
authorization may be granted to a similar medicinal product for the same orphan indication if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already
    authorized, is safer, more effective or otherwise clinically superior;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application;
    or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal
    product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
orphan product can also obtain an additional two years of market exclusivity in the European Union for the conduct of pediatric trials.
The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer
meets the criteria for orphan designation; for example, if the product is sufficiently profitable and no longer justifies the maintenance
of market exclusivity or if the manufacturer cannot produce sufficient quantities to supply the orphan population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
criteria for designating an &#8220;orphan medicinal product&#8221; in the European Union are similar, in principle, to those in the United
States. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers. The application for
orphan medicinal product designation must be submitted before the application for marketing authorization. Orphan medicinal product designation
does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014 (the &#8220;Clinical Trials Regulation&#8221;), which replaced
the current Clinical Trials Directive 2001/20/EC (the &#8220;Clinical Trials Directive&#8221;) on January 31, 2022. The Clinical Trial
Regulation has overhauled the previous system of approvals for clinical trials in the EU whereby all clinical trial approvals were granted
purely on a national basis. Specifically, the legislation, which is directly applicable in all member states, aims at simplifying and
streamlining the approval of clinical trials in the EU, whereby there is a streamlined application procedure via a single-entry point
and strictly defined deadlines for the assessment of clinical trial applications. However, the Clinical Trial Regulation does increase
public disclosure requirements in relation to clinical trial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union there are also broadly equivalent regimes for the other issues addressed in relation to US regulation including cGMP
requirements, accelerated access (generally through so-called Conditional Marketing Authorizations), pediatric requirements and incentives
and patent term restoration (supplementary protection certificates).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Healthcare Laws and Regulations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and third-party payors play a primary role in the recommendation and use of pharmaceutical products that are granted
marketing approval. Arrangements with third-party payors, existing or potential customers and referral sources are subject to broadly
applicable fraud and abuse and other healthcare laws and regulations, and these laws and regulations may constrain the business or financial
arrangements and relationships through which manufacturers market, sell and distribute the products for which they obtain marketing approval.
Such restrictions under applicable federal and state healthcare laws and regulations include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons, and entities from knowingly and willfully soliciting,
    receiving, offering or paying remuneration, directly or indirectly, in cash or kind, in exchange for, or to induce, either the referral
    of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal
    healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between
    pharmaceutical manufacturers, on the one hand, and prescribers, purchasers, and formulary managers on the other. Although a number
    of statutory exemptions and regulatory safe harbors exist to protect certain common activities from falling under the Anti-Kickback
    Statute, these are narrow, and practices may not fall under the applicable safe harbors and exemptions. For example, the United States
    Department of Health and Human Services recently promulgated a regulation that is effective in two phases. First, the regulation
    excludes from the definition of &#8220;remuneration&#8221; limited categories of (a) PBM rebates or other reductions in price to
    a plan sponsor under Medicare Part D or a Medicaid Managed Care Organization plan reflected in point-of sale reductions in price
    and (b) PBM service fees. Second, effective January 1, 2023, the regulation expressly provides that rebates to plan sponsors under
    Medicare Part D either directly to the plan sponsor under Medicare Part D, or indirectly through a pharmacy benefit manager will
    not be protected under the anti-kickback discount safe harbor. The PPACA amended the intent requirement of the federal Anti-Kickback
    Statute. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to
    commit a violation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal false claims and civil monetary penalties laws, including the civil False Claims Act (the &#8220;FCA&#8221;), which prohibit,
    among other things, individuals, or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare,
    Medicaid or other third-party payors that are false or fraudulent, or making a false statement to avoid, decrease, or conceal an
    obligation to pay money to the federal government. Certain marketing practices, including off-label promotion, also may implicate
    the FCA. FCA claims may be pursued by whistleblowers through qui tam actions, even if the government declines to intervene and civil
    liability may be predicated on reckless disregard for the truth. The PPACA also codified case law that a claim including items or
    services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of
    the FCA. Separately, the criminal federal False Claims Act imposes criminal fines or imprisonment against individuals or entities
    who make or present a claim to the government knowing such claim to be false, fictitious, or fraudulent;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for
    which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions,
    to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), information related to payments and other
    transfers of value made to or at the request of covered recipients, such as, but not limited to, physicians, physician assistants,
    nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and teaching hospitals, as well as ownership
    and investment interests held by physicians and their immediate family. Payments made to physicians and certain research institutions
    for clinical trials are included within the ambit of this law. Reported information is made publicly available in searchable formats
    by CMS;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    federal false statements and fraud and abuse statutes prohibit knowingly and willfully executing, or attempting to execute, a scheme
    to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned
    by, or under the custody or control of, a healthcare benefit program, regardless of whether the payor is public or private, in connection
    with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit
    program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing,
    or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of,
    or payment for, healthcare benefits, items, or services relating to healthcare matters. PPACA amended the intent requirement of certain
    of these criminal statutes under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) so that a
    person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed
    a violation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items
    or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies
    to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
    by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;
    state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and
    other healthcare providers or marketing expenditures; and European Union and state laws governing the privacy and security of health
    information in certain circumstances, many of which differ from each other in significant ways, may be stricter than those applicable
    in the US and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violation
of the laws described above or any other governmental laws and regulations may result in penalties, including civil and criminal penalties,
damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare programs,
debarment from government contracting or refusal of orders under existing contracts, corporate integrity agreements or consent decrees,
disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and imprisonment. Furthermore, efforts
to ensure that business activities and business arrangements comply with applicable healthcare laws and regulations can be costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Privacy and Security</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, &#8220;HITECH Act&#8221;), and similar
    state laws impose obligations on certain entities with respect to safeguarding the privacy, security and transmission of protected
    health information. HIPAA&#8217;s security and certain privacy standards are directly applicable to persons or organizations of covered
    entities, other than members of the covered entity&#8217;s workforce, that create, receive, maintain or transmit protected health
    information on behalf of a covered entity for a function or activity regulated by HIPAA. The HITECH Act strengthened the civil and
    criminal penalties that may be imposed against covered entities, business associates and individuals, and gave state attorneys general
    new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;
    fees and costs associated with pursuing federal civil actions. In addition, other federal and state laws, such as the California
    Consumer Privacy Act, may regulate the privacy and security of information that we maintain, many of which may differ from each other
    in significant ways and may not be preempted by HIPAA; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    General European Data Protection Regulation (&#8220;GDPR&#8221;), which became applicable May 25, 2018, harmonizes data privacy laws
    across Europe. The GDPR sets forth rules relating to the protection with regard to the processing and transfer of personal data as
    well as an individual&#8217;s right to the protection of personal data, including medical information and clinical trial related
    data. In addition, there are rules relating to the export of personal data outside the European Union and in particular there are
    certain challenges in relation to export to the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the
United States, sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part on
the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities
and health programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other
organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. The process for
determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement
rate that the payor will pay for the drug product and/or application procedure. Third-party payors may limit coverage to specific drug products on an approved
list, or formulary, which might not include all FDA-approved drugs for a particular indication. Additionally, the containment of
healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort.
The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment
programs, including price controls, required disclosures of pricing and sensitive cost data, requirement for payment of manufacturer
rebates and negotiation of supplemental rebates, restrictions on reimbursement and requirements for substitution of generic
products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement
status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and
reimbursement rates may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only
after a reimbursement price has been agreed. Some countries may require the completion of additional studies as part of health technology
assessment that compare the cost-effectiveness of a particular product candidate to currently available therapies. EU member states may
approve a specific price for a product, or it may instead adopt a system of direct or indirect controls on the profitability of the company
placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control company
profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to
the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that
may reduce pricing within a country. Any country that has price controls or reimbursement limitations may not allow favorable reimbursement
and pricing arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Health
Reform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system.
There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving
quality, or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts. For example,
healthcare reform measures under the Affordable Care Act included increased Medicaid rebates, expanded the 340B drug discount program,
and changes requiring manufacturer discounts currently set at 70 percent on Part D utilization in the Part D coverage gap or &#8220;donut
hole&#8221; and multiple provisions that could affect the profitability of our drug products. There is continuing development of value-based
pricing and reimbursement models. Moreover, on November 27, 2020, CMS issued an interim final rule implementing a Most Favored Nation
payment model under which reimbursement for certain Medicare Part B drugs and biologicals will be based on a price that reflects the
lowest per capita Gross Domestic Product-adjusted (GDP-adjusted) price of any non-U.S. member country of the Organization for Economic
Co-operation and Development (OECD) with a GDP per capita that is at least sixty percent of the U.S. GDP per capita. Current and future
healthcare reform measures may significantly affect our sale of any products, and we continue to face major uncertainty due to the status
of major legislative initiatives surrounding healthcare reform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and
other laws govern the use, handling and disposal of various biologic and chemical substances used in, and wastes generated by, operations.
If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages
and governmental fines. Equivalent laws have been adopted in other countries that impose similar obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Foreign Corrupt Practices Act</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), prohibits U.S. corporations and individuals from engaging in certain activities
to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize
the payment of anything of value to any foreign government official, government staff member, political party, or political candidate
in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA
includes interactions with certain healthcare professionals in many countries. Equivalent laws have been adopted in other foreign countries
that impose similar obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
that are currently engaged in gene therapy or companies not yet focused on developing cell and gene therapies could at any time decide
to develop therapies relevant to our business. Many of our competitors, either alone or with their strategic partners, may have substantially
greater financial, technical, and human resources than we do and may have significantly greater experience in the discovery and development
of product candidates, obtaining FDA and other regulatory approvals of product candidates and commercializing those product candidates.
Accordingly, our competitors may be more successful than us in obtaining approval for product candidates and achieving widespread market
acceptance. Our competitors&#8217; product candidates may be more effective, or more effectively marketed and sold, than any product
candidate we may commercialize and may render our treatments obsolete or non-competitive before we can recover the expenses of developing
and commercializing any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mergers
and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller
number of our competitors. These competitors also may compete with us in recruiting and retaining qualified scientific and management
personnel and establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate facing intense and increasing competition as new product candidates enter the market and advanced technologies become available.
We expect any product candidates that we develop and commercialize to compete on the basis of, among other things, efficacy, safety,
convenience of administration and delivery, price, and the availability of reimbursement from government and other third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors
also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which
could result in our competitors establishing a strong market position before we are able to enter the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office as well as our manufacturing and laboratory facilities are located at 6555 Carnegie Ave, 4<sup>th</sup> Floor,
Cleveland, OH 44103. Our telephone number is (646) 813-4701.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Wyoming in 1974 as Chemex Corporation, and in 1983 we changed our name to Chemex Pharmaceuticals, Inc. We changed
our state of incorporation from Wyoming to Delaware on June 30, 1989. In 1996 we merged with Access Pharmaceuticals, Inc., a private
Texas corporation, and changed our name to Access Pharmaceuticals, Inc. On October 24, 2014, we changed our name to PlasmaTech Biopharmaceuticals,
Inc. On May 15, 2015, we acquired Abeona Therapeutics LLC and on June 19, 2015, we changed our name to Abeona Therapeutics Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Suppliers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the materials we use are specialized. We obtain materials from several suppliers based in different countries around the world. If
materials are unavailable from one supplier, we generally have alternate suppliers available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases, we seek to attract, hire,
develop and retain qualified and highly skilled personnel with experience in areas such as research and development and manufacturing
operations. We compete for such personnel with numerous pharmaceutical and chemical companies, specialized biotechnology firms and universities.
We strive to support our employees&#8217; well-being through a transparent, inclusive, and collaborative culture and by providing them
with the training, support, and resources to help them succeed professionally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had 136 full-time employees. We have never experienced employment-related work stoppages and believe that we
maintain good relations with our personnel. In addition, to complement our internal expertise, we have contracts with scientific consultants,
contract research organizations and university research laboratories that specialize in various aspects of drug development including
clinical development, regulatory affairs, toxicology, process scale-up and preclinical testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Web
Availability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make available free of charge through our website, <span style="text-decoration: underline">www.abeonatherapeutics.com</span>, including our annual reports on Form 10-K and other
reports that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) as well as certain of our corporate governance policies,
including the charters for the audit, compensation and nominating and corporate governance committees of the Board of Directors (the
&#8220;Board&#8221;) and our code of ethics, corporate governance guidelines and whistleblower policy. We will also provide to any person
without charge, upon request, a copy of any of the foregoing materials. Any such request must be made in writing to us at: Abeona Therapeutics
Inc. c/o Investor Relations, 6555 Carnegie Ave, 4<sup>th</sup> Floor, Cleveland, OH 44103. The SEC&#8217;s website, www.sec.gov, contains
reports, proxy statements, and other information that we file electronically with the SEC. The content on any website referred to in
this Form 10-K is not incorporated by reference in this Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business, financial condition, financial results, and future growth prospects are subject to a number of risks and uncertainties, including
those set forth below. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition,
financial results, and future growth prospects.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTOR SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks and uncertainties, including those described in Item 1A &#8220;Risk Factors.&#8221; These risks
include, but are not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    cell and gene therapy product candidates are based on proprietary methodologies, which makes it difficult to predict the time and
    cost of product candidate development and regulatory approval. Additionally, regulatory requirements governing cell and gene therapy
    products have evolved and may continue to change in the future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not obtain the necessary U.S. or worldwide regulatory approvals to commercialize pz-cel, we will not be able to sell pz-cel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we receive regulatory approval for pz-cel, our lead drug candidate, we may not be able to successfully manufacture or commercialize
    the product and the revenue that we generate from its sales, if any, may be limited.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of
    applicable regulatory authorities. Additionally, we may find it difficult to enroll patients in our clinical studies, which could
    delay or prevent clinical studies of our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have received and may apply for additional designations such as breakthrough therapy designation, RMAT designation, fast track designation,
    and rare pediatric disease designation from the FDA intended to facilitate or encourage product candidate development. We may not
    receive any such designations or be able to maintain them. Moreover, any such designations may not lead to faster development or
    regulatory review or approval and it does not increase the likelihood that our product candidates will receive marketing approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
    certain of our product candidates have received orphan drug designation from the FDA, there is no guarantee that we will be able
    to maintain this designation, receive this designation for any of our other product candidates, or receive or maintain any corresponding
    benefits, including periods of exclusivity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    could experience production problems in our manufacturing facility that result in delays in our development or commercialization
    programs. We might also experience delays in manufacturing if any of our vendors, contract laboratories or suppliers are found to
    be out of compliance with current Good Manufacturing Practice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with applicable regulations, the relevant regulatory authority may require remedial measures that may be costly
    or time-consuming to implement and that may include the suspension of a clinical trial or commercial sales or the closure of a manufacturing
    facility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    widespread outbreak of an illness, communicable disease, or any other public health crisis could adversely affect our business, results
    of operations and financial condition.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to rely on third parties, and these third parties may not perform satisfactorily. Additionally, our reliance on third parties
    requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets
    will be misappropriated.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    drug candidates are subject to the risks of failure inherent in the development of pharmaceutical products based on new technologies,
    and our failure to develop safe and commercially viable drugs would severely limit our ability to become profitable or to achieve
    significant revenues.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to successfully develop, market, or commercialize our products or our product candidates without establishing new relationships
    and maintaining current relationships and our ability to successfully commercialize, and market our product candidates could be limited
    if a number of these existing relationships are terminated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may incur substantial product liability expenses due to the use or misuse of our products for which we may be unable to obtain insurance
    coverage.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to successfully develop and commercialize our drug candidates will substantially depend upon the availability of reimbursement
    funds for the costs of the resulting drugs and related treatments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market may not accept any pharmaceutical products that we develop, and adverse public perception of gene therapy products may negatively
    affect demand for, or regulatory approval of, our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to federal, state, and foreign healthcare laws and regulations, including fraud and abuse laws, false claims laws,
    health information privacy and security laws and data privacy laws. If we are unable to comply, or have not fully complied, with
    such laws, we could face substantial penalties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trends
    toward managed health care and downward price pressures on medical products and services may limit our ability to profitably sell
    any drugs that we may develop.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    rights to develop and commercialize our product candidates are subject to, in part, the terms and conditions of licenses granted
    to us by others.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection
    obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical
    to ours.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property licenses with third parties may be subject to disagreements over contract interpretation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be successful in obtaining necessary rights to our product candidates through acquisitions and in-licenses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect
    our trade secrets in court, and intellectual property litigation could cause us to spend substantial resources.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-parties
    may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be
    uncertain and could harm our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets
    of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not obtain patent term extension and data exclusivity for our product candidates, our business may be harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have experienced a history of losses; we expect to incur future losses and we may be unable to obtain necessary additional capital
    to fund operations in the future. We do not have significant operating revenue and may never achieve profitability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to continue to need to raise additional capital to operate our business, and our failure to obtain funding when needed or
    on terms that are favorable to us may force us to delay, reduce or eliminate our development programs or aspects thereof.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to achieve and maintain effective internal controls could have a material adverse effect on our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our common stock may be volatile and adversely affected by several factors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
    additional funds by issuing securities or through licensing or lending arrangements or through our at-the-market sale agreement may
    cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breaches
    of data security or unauthorized disclosures of personal information could effect our business or make us subject to liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to the discovery and development of our product candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
cell and gene therapy product candidates are based on proprietary methodologies, which makes it difficult to predict the time and cost
of product candidate development and subsequently obtaining regulatory approval. Only a few gene therapy products have been approved
in the U.S. and the EU.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have concentrated our therapeutic product research and development efforts on our cell and gene therapy platform, and our future success
depends on the successful development of this therapeutic approach. There can be no assurance that any development problems we experience
in the future related to our cell and gene therapy platform will not cause significant delays or unanticipated costs, or that such development
problems can be solved. We may also experience delays in developing a sustainable, reproducible and commercial-scale manufacturing process
or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our
products on a timely or profitable basis, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the clinical study requirements of the FDA, the EMA, and other regulatory agencies and the criteria these regulators use to
determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use
and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive
and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Given that only
a few gene therapy products have been approved in the Western world, it is not possible to predict how long it will take or how much
it will cost to obtain regulatory approvals for our product candidates in the United States, the EU or other jurisdictions. Approvals
by the EMA and the European Commission may not be indicative of what the FDA may require for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
requirements governing cell and gene therapy products have evolved and may continue to change in the future. For example, the FDA has
established the Office Tissues and Advanced Therapies within CBER to consolidate the review of gene therapy and related products, and
the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
requirements in the United States and in other jurisdictions governing gene therapy products have changed frequently and will continue
to change in the future as scientific knowledge is acquired. The FDA and EMA have each expressed interest in further regulating gene
therapy. For example, the FDA has established the Office Tissues and Advanced Therapies within CBER to consolidate the review of gene
therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Over the last
few years, FDA, through CBER, has provided significant guidance regarding the development of gene therapies. Additionally, the EMA advocates
a risk-based approach to the development of a gene therapy product. Agencies at both the federal and state level in the United States,
as well as the U.S. congressional committees and other governments or governing agencies, have also expressed interest in further regulating
the biotechnology industry. Such action may delay or prevent commercialization of some, or all, of our product candidates. These regulatory
review agencies, committees and advisory groups and the new requirements and guidelines they promulgate may lengthen the regulatory review
process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions
and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval
studies, limitations, or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and
advisory groups and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue
development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary
to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter substantial delays in our clinical studies, such as clinical holds, or we may fail to demonstrate safety and efficacy to
the satisfaction of applicable regulatory authorities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies
to demonstrate the safety, purity and potency, and efficacy, of the product candidates in humans. Clinical testing is expensive, time-consuming,
and uncertain as to outcome. This is especially true for rare and/or complicated diseases. We cannot guarantee that any clinical studies
will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of
testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical studies, preliminary study results, and early clinical trials of our product candidates may not be predictive
of the results of later-stage clinical trials or the ultimately completed trial. Product candidates in later stages of clinical trials
may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials.
Preclinical and early clinical studies may also reveal unfavorable product candidate characteristics, including safety concerns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to
receive marketing approval or commercialize our product candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    or IRBs may not authorize us or our investigators to commence or continue a clinical trial, conduct a clinical trial at a prospective
    trial site, or amend trial protocols, or regulators or IRBs may require that we modify or amend our clinical trial protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols
    with prospective trial sites and our contract research organizations (&#8220;CROs&#8217;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing
    testing, surveillance, or REMS requirements to maintain regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">flaws
    in a clinical trial may not become apparent until the trial is well advanced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level
    of statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product
    development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials of our product candidates may require us to provide follow-up patient visits for safety for a minimum of five years even if
    we were to terminate and/or abandon a product development program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or fail to meet their contractual
    obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    the regulators, or IRBs may require the suspension or termination of clinical research for various reasons, including noncompliance
    with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side
    effects, or other unexpected characteristics (alone or in combination with other products) of the product candidate, or due to findings
    of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in marketing approval and regulatory review policies or changes in or the enactment of additional statutes or regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials of and marketing applications for our product candidates may be greater than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may decide, or regulators may require us, to conduct or gather, as applicable, additional clinical trials, analyses, reports, data,
    or preclinical trials, or we may abandon product development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials. For
    instance, the FDA or comparable foreign regulatory authorities may require changes to our study design that make further study impractical
    or not financially prudent;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be regulatory questions or disagreements regarding interpretations of data and results, or new information may emerge regarding
    our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may make changes to our product candidates or their manufacturing process that necessitate additional studies or that result in our
    product candidates not performing as expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our study design, including endpoints, or our interpretation of
    data from preclinical studies and clinical trials or find that a product candidate&#8217;s benefits do not outweigh its safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable regulatory authorities may disagree with our intended indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes
    or our contract manufacturer&#8217;s manufacturing facility for clinical and future commercial supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable
    foreign regulatory authorities to support the submission of a marketing application, or other comparable submission in foreign jurisdictions
    or to obtain regulatory approval in the United States or elsewhere;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    one of our product candidates does not receive marketing approval in one country, it may impact our ability to receive marketing
    approval in other countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable regulatory authorities may take longer than we anticipate to make a decision on our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future
    competitive therapies in development.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
in launching clinical trials resulting from FDA or other regulatory actions, such as a clinical hold letter, would delay the commercialization
of our product candidates and our ability to generate revenue, which would have an adverse effect on our business. For example, in September
2019, we received a clinical hold letter in connection with our phase 3 clinical trial for pz-cel stating that the FDA would not provide
approval for us to begin our planned phase 3 clinical trial for pz-cel until we submitted additional data points on transport stability
of pz-cel to clinical sites. Although the FDA removed the clinical hold in December 2019 and provided clearance for us to proceed with
our planned phase 3 clinical trial, we may encounter similar delays in our clinical studies in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
delays relating to any preclinical or clinical trials also could shorten any periods during which we may have the exclusive right to
commercialize our product candidates or allow our competitors to bring products to market before we do. This may prevent us from receiving
marketing approvals and impair our ability to successfully commercialize our product candidates. If any of the foregoing were to occur,
our business, financial condition, results of operations, and prospects will be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical studies of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical
studies depends on the speed at which we can recruit eligible patients to participate in testing our product candidates. We have experienced
delays in some of our clinical studies due to the ultra-rare nature of the diseases we aim to treat, and we may experience similar delays
in the future. If patients are unwilling to participate in our cell and gene therapy studies because of negative publicity from adverse
events in the biotechnology or gene therapy industries or for other reasons, including competitive clinical studies for similar patient
populations, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of potential products may be
delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness
of our technology or termination of the clinical studies altogether.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to identify, recruit or enroll a sufficient number of patients, or those with required or desired characteristics to
achieve diversity in a study, to complete our clinical studies in a timely manner. Patient enrollment is affected by factors including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">design
    of the study protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligibility
    criteria for and design of the study in question;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of the product candidate under study, including as a result of adverse effects observed in similar or competing
    therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    and availability of clinical study sites for prospective patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of competing therapies and clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efforts
    to facilitate timely enrollment in clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to compensate patients for their time and effort;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risk
    that enrolled patients will drop out before completion or not return for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to obtain or maintain patient informed consents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness
    of publicity created by clinical trial sites regarding the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to monitor patients adequately during and after treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also plan to seek initial marketing approval in the European Union in addition to the U.S. Our ability to successfully initiate, enroll
and complete a clinical study in any foreign country is subject to additional risks unique to conducting business in foreign countries,
such as different standards for the conduct of clinical studies; different laws, medical standards, and regulatory requirements; and
the ability to establish or manage relationships with treatment centers, contract research organizations and physicians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we have difficulty enrolling a sufficient number of patients to conduct our clinical studies as planned our development costs may increase,
the time for completion of clinical trials may increase, we may need to delay, limit or terminate ongoing or planned clinical studies,
any of which would have an adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory
approval or commercialization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our products or product candidates, including adverse events associated with our product candidates, could interrupt,
delay, or halt clinical trials and could result in the denial of regulatory approval or more limited approvals by the FDA, EMA or other
regulatory authorities for any or all targeted indications, or the inclusion of unfavorable information in our product labeling, such
as limitations on the indicated uses or populations for which the products may be marketed or distributed, a label with significant safety
warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful
commercialization, or may result in requirements for costly post-marketing testing and surveillance, or other requirements, including
REMS, to monitor the safety or efficacy of the products. These could in turn prevent us from commercializing our products or product
candidates and generating revenues from their sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we or others identify undesirable side effects caused by our product candidates after receipt of marketing approval, the
regulatory authorities may require the addition of restrictive labeling statements. Regulatory authorities may withdraw their approval
of the product. We also may be required to change the way the product is administered or conduct additional clinical trials. Any of these
events could prevent us from achieving or maintaining market acceptance of the affected products or product candidate or could substantially
increase the costs and expenses of commercializing the products or product candidate, which in turn could delay or prevent us from generating
significant revenues from its sale or adversely affect our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we complete the necessary preclinical and clinical studies, we cannot predict when or if we will obtain regulatory approval to commercialize
a product candidate or the approval may be for a narrower indication than we expect.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if
our product candidates demonstrate safety and efficacy in clinical studies, the regulatory agencies may not complete their review processes
in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or
other regulatory advisory group or authority recommends non-approval or restrictions on approval. In addition, we may experience delays
or rejections based on additional government regulation from future legislation or administrative action, or changes in regulatory agency
policy during the period of product development, clinical studies, and the review process. Regulatory agencies also may approve a treatment
candidate for fewer or more limited indications, populations, or uses than requested or may grant approval subject to the performance
of post-marketing studies, surveillance, or other requirements. In addition, regulatory agencies may not approve the labeling claims
that are necessary or desirable for the successful commercialization of our treatment candidates, or may require significant safety warnings,
including black box warnings, contraindications, and precautions. For example, the development of our product candidates for pediatric
use is an important part of our current business strategy, and if we are unable to obtain regulatory approval for the desired age ranges,
our business may suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have received and may apply for additional designations intended to facilitate or encourage product candidate development. We may not
receive any such designations or be able to maintain them. Moreover, any such designations may not lead to faster development or regulatory
review or approval and it does not increase the likelihood that our product candidates will receive marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates have received regulatory designations including breakthrough therapy designation, RMAT designation, fast track designation,
and rare pediatric disease designation from the FDA. In the future and as appropriate, we may seek additional product designations. Receipt
of such a designation is within the discretion of the FDA. Even if we believe one of our product candidates meets the criteria for a
designation, the FDA may disagree. In any event, the receipt of such a designation for a product candidate may not result in a faster
development process, review, or approval compared to product candidates considered for approval under conventional FDA procedures and
does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the product candidates no longer meet
the designation conditions, in which case any granted designations may be revoked. Finally, specifically with respect to our rare pediatric
disease designations, if we are not able to obtain FDA approval of our designated product candidates before the statute sunsets, we would
not be eligible to receive priority review vouchers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
of our product candidates have received orphan drug designation from the FDA, there is no guarantee that we will be able to maintain
this designation, receive this designation for any of our other product candidates, or receive or maintain any corresponding benefits,
including periods of exclusivity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
orphan drug designation provides certain advantages, it neither shortens the development time or regulatory review time of a product
candidate nor gives the product candidate any advantage in the regulatory review or approval process. Generally, if a product candidate
with orphan drug designation subsequently receives marketing approval before another product considered by the FDA or comparable foreign
regulatory authorities to be the same, for the same orphan indication, the product is entitled to a period of marketing exclusivity,
which precludes the FDA or comparable foreign regulatory authorities from approving another marketing application for the same drug or
biologic for the same indication for seven years. We may not be able to obtain any future orphan drug designations that we apply for,
orphan drug designations do not guarantee that we will be able to successfully develop our product candidates, and there is no guarantee
that we will be able to maintain any orphan drug designations that we receive. For instance, orphan drug designation may be revoked if
the FDA finds that the request for designation contained an untrue statement of material fact or omitted material information, or if
the FDA finds that the product candidate was not eligible for designation at the time of the submission of the request. Moreover, we
may ultimately not receive any period of regulatory exclusivity if our product candidates are approved. For instance, we may not receive
orphan product regulatory exclusivity if the indication for which we receive FDA approval is broader than the designation. Orphan exclusivity
may also be lost for the same reasons that the designation may be lost. Orphan exclusivity may further be lost if we are unable to assure
a sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain orphan exclusivity for any of our current or future product candidates, that exclusivity may not effectively protect the
product from competition as different products can be approved for the same condition or products that are the same as ours can be approved
for different conditions. Even after an orphan product is approved, the FDA or comparable foreign regulatory authorities can also subsequently
approve a product containing the same principal molecular features for the same condition if the FDA concludes that the later product
is clinically superior. The FDA may further grant orphan drug designation to multiple sponsors for the same compound or active molecule
and for the same indication. If another sponsor receives FDA or comparable foreign regulatory authority approval for such product before
we do, we would be prevented from launching our product for the orphan indication for a period of at least seven years unless we can
demonstrate clinical superiority. FDA&#8217;s thinking around sameness with respect to gene therapies, and thus the circumstances when
clinical superiority would need to be shown, is evolving. While the agency has issued guidance on the topic, certain decisions may need
to be made on a case by case basis, given the novelty of the technology. Moreover, third-party payors may reimburse for products off-label
even if not indicated for the orphan condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval in a jurisdiction, regulatory authorities may still impose significant restrictions on the indicated
uses or marketing of our product candidates or impose ongoing requirements for potentially costly post-approval studies, post-market
surveillance or patient or drug restrictions. Moreover, the FDA and comparable foreign regulatory authorities will continue to closely
monitor the safety profile of any product even after approval, including gene therapy specific requirements for long term follow up.
Additionally, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the
specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for
certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply
with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with cGMP and adherence to commitments made in the BLA. If we or a regulatory
agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or that the
product is less effective than previously thought, or problems with the facility where the product is manufactured, a regulatory agency
may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product
from the market or suspension of manufacturing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable regulatory requirements following approval of any of our product candidates or during product development,
or if we later discovery previously unknown safety, efficacy, or manufacturing issues, the following may result:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on manufacturing, distribution, marketing, or labeling of such products, including restrictions on the indication or approved patient
    population, and required additional warnings, such as black box warnings, contraindications, and precautions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to conduct post-marketing studies or clinical trials, or to institute risk mitigation strategies, such as REMS;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
    of corrective information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive, we may face reputational harm, or we may face liability for any harm caused to patients or subjects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">modifications
    on the way the product is administered;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">modifications
    on promotional pieces;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
    of warning, untitled, or cyber letters asserting that we are in violation of the law, or of safety alerts, Dear Healthcare Provider
    letters, press releases, or other communications containing warnings or other safety information about the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunction
    or imposition civil or criminal penalties or monetary fines, restitution, or disgorgement of profits or revenues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or termination of any ongoing clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve a pending marketing application, such as a BLA or supplements to a BLA submitted by us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seizure,
    detention, or recall of product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our products; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to allow us to enter into supply contracts, including government contracts, exclusion from federal healthcare programs, FDA debarment,
    consent decrees, or corporate integrity agreements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s policies may change, and additional government regulations may be enacted, that could prevent, limit or delay regulatory
approval of our product candidates, that could limit the marketability of our product candidates, or that could impose additional regulatory
obligations on us. For example, a change in administration in the U.S. may result in new, revised, postponed or frozen regulatory requirements
and associated compliance obligations. Changes in medical practice and standard of care may also impact the marketability of our product
candidates. If we are slow or unable to adapt to changes in existing requirements, standards of care, or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and
be subject to regulatory enforcement action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of the above actions take place, they could adversely affect our ability to achieve or sustain profitability. Further, the cost of
compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Complete Response Letter related to our Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic
epidermolysis bullosa may impair our ability to successfully commercialize pz-cel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, we received a CRL related to our BLA for pz-cel for the treatment of patients with RDEB. In the CRL, the FDA noted that
certain additional information needed to satisfy CMC requirements must be satisfactorily resolved before the application can be approved.
In August 2024, we completed a Type A Meeting with the FDA to discuss our forthcoming resubmission of our BLA and in October 2024,
we resubmitted our BLA. The FDA notified the Company in November 2024 that the BLA was accepted for review, with an assigned PDUFA
target action date of April 29, 2025. A delay in receiving approval of the BLA could shorten any periods during which we may have the
exclusive right to commercialize our pz-cel or allow our competitors to bring products to market before we do. This may impair our ability
to successfully commercialize pz-cel. If any of the foregoing were to occur, our business, financial condition, results of operations,
and prospects will be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could experience production problems in our manufacturing facilities that result in delays in our development or commercialization programs
or otherwise adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are susceptible to production interruptions that may impede our ability to manufacture cell and gene therapy products and produce an
adequate product supply to support clinical trials and potentially future commercialization. Several factors could cause production interruptions,
including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, public health emergencies
such as the COVID-19 pandemic, disruption in utility services, human error, or disruptions in the operations of our suppliers. Our products
and product candidates are biologic drugs requiring processing steps that are more complex than those required for most chemical pharmaceuticals.
We characterize our processes and products, and perform testing to ensure the safety, quality and efficacy of each product produced.
While we take significant measures to fully understand and characterize each product, the steps we take may not be sufficient to ensure
that a given lot will perform in the intended manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several risks specific to the manufacturing process for pz-cel which require close attention. As an autologous product there are
challenges associated with viability of biopsies as an incoming material. Due to variables such as the fragility of RDEB skin and site
of the biopsy, initiation of autologous keratinocyte growth and expansion can be challenging or may be extended beyond the scheduled
timing. Another concern during manufacturing is the slowing of cell proliferation, resulting in extended manufacturing time. If pre-release
criteria are not met, the production process must be stopped, and a new biopsy must be obtained. If release criteria are out of range,
epidermal sheets must be discarded and the manufacturing process must be repeated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a backup manufacturer to supply clinical trial material for pz-cel. An alternative manufacturer would need to be
qualified, through regulatory filings, which could result in delays to our clinical trial timeline. The regulatory authorities also may
require additional clinical trials if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve
substantial costs and could result in a delay in our desired clinical and commercial timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we employ multiple steps to control our manufacturing process to assure that the products or product candidate is made strictly and consistently
in compliance with the process. Problems with the manufacturing process, including even minor deviations from the normal process, could
result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims, or insufficient
inventory. We may encounter problems achieving adequate quantities and quality of clinical grade materials that meet FDA, EU or other
applicable standards or specifications with consistent and acceptable production yields and costs. In addition, the FDA, EMA and other
foreign regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing
the results of applicable tests at any time. Under some circumstances, the FDA, EMA or other foreign regulatory authorities may require
that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those
affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product
recalls for approved and marketed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lot
failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm
our business, financial condition, results of operations and prospects. We also may encounter problems hiring and retaining the experienced
scientific, quality control and manufacturing personnel needed to operate our manufacturing process, which could result in delays in
our production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process
or facilities could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic
research institutions, which could limit our access to additional attractive development programs. Problems in our manufacturing process
including in internal and external facilities providing supply necessary for manufacturing or challenges with procuring supplies, such
as due to global trade policies, also could restrict our ability to meet clinical trial supply demand, and eventually market demand for
any product candidates for which we may receive marketing approval. Disruptions in our manufacturing process may delay or disrupt our
commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or any of our vendors, contract laboratories or suppliers are found to be out of compliance with cGMP, we may experience delays or
disruptions in manufacturing while we implement corrective actions or work with these third parties to remedy the violation or while
we work to identify suitable replacement vendors, contract laboratories or suppliers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain regulatory approval for commercial manufacturing, we will need to continue to ensure that all of our processes, methods and equipment
are compliant with cGMP and perform extensive audits of vendors, contract laboratories and suppliers. The cGMP requirements govern quality
control of the manufacturing process and documentation policies and procedures. Complying with cGMP requires us to expend time, money
and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements.
If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any
products that we may develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may rely on third parties to conduct aspects of our product manufacturing, and these third parties may not perform satisfactorily. We
may rely on third parties to produce certain materials for our product candidates and, therefore, we can control only certain aspects
of their activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our third-party suppliers, laboratories, and manufacturers may be unable to comply with our specifications, cGMP requirements and
with other FDA, state, and foreign regulatory requirements. Poor control of production processes can lead to the introduction of adventitious
agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable
in final product testing. If we or our contract manufacturers cannot successfully manufacture material that conforms to our specifications
and the strict regulatory requirements of the FDA or other regulatory authorities, we or our contract manufacturers will not be able
to secure or maintain regulatory approval for their manufacturing facilities. Any such deviations may also require remedial measures
that may be costly and/or time-consuming for us or a third party to implement and may include the temporary or permanent suspension of
a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon or
by us or third parties with whom we contract could materially harm our business. Any delays in obtaining products or product candidates
that comply with the applicable regulatory requirements may result in delays to clinical trials, product approvals, and commercialization.
It may also require that we conduct additional studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have manufacturing agreements with third parties that provide for, among other things, production of product candidates for our current
and future early-stage clinical trials. Under certain circumstances, the other party is entitled to terminate its arrangement with us.
If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on third parties for
certain manufacturing activities will reduce our control over these activities but will not relieve us of our responsibility to ensure
compliance with all required regulations. If a third party does not successfully carry out its contractual duties, meet expected deadlines
or manufacture our product candidates in accordance with regulatory requirements, or if there are disagreements between us and any such
third party, we will not be able to complete, or may be delayed in completing, the preclinical studies required to support future IND
submissions and the clinical trials required for approval of our product candidates. In such instances, we may need to enter into an
appropriate replacement third-party relationship, which may not be readily available or on acceptable terms, which would cause additional
delay or increased expense prior to the approval of our product candidates and would thereby have a material adverse effect on our business,
financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the FDA or a comparable foreign regulatory authority does not approve our or a third party&#8217;s facilities for the manufacture
of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities,
which would significantly impact our ability to develop, obtain and maintain regulatory approval for or market our product candidates,
if approved. Any new manufacturers would need to either obtain or develop the necessary manufacturing know-how, and obtain the necessary
equipment and materials, which may take substantial time and investment. We must also receive FDA approval for the use of any new manufacturers
for commercial supply. We may not succeed in our efforts to establish manufacturing relationships or other alternative arrangements for
any of our product candidates, components, and programs. For example, our product candidates may compete with other products and product
candidates for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and
that are both capable of manufacturing for us and willing to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of biologic products requires significant expertise and capital investment, including the development of advanced manufacturing
techniques and process controls. Manufacturers of therapeutics often encounter difficulties in production, particularly in scaling up
initial production. These problems include difficulties with production costs and yields, quality control, including stability of the
product candidate and quality assurance testing, shortages of qualified personnel, and compliance with strictly enforced federal, state,
and foreign regulations. If we or our manufacturers were to encounter any of these difficulties and were unable to perform as agreed,
our ability to provide product candidates to patients in our clinical trials and for commercial use, if approved, would be jeopardized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these third parties entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    control for certain aspects of manufacturing activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    control over the protection of our trade secrets and know-how from misappropriation or inadvertent disclosure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to negotiate manufacturing agreements with third parties under commercially reasonable terms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
    on the third party for regulatory compliance and quality assurance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
    to the operations of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations,
    including the bankruptcy of the manufacturer or service provider.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize
future product candidates. Some of these events could be the basis for FDA action or action of equivalent competent authorities in foreign
jurisdictions, including injunction, recall, seizure or total or partial suspension of product manufacturing. Failure to comply with
ongoing regulatory requirements could cause us to suspend production or put in place costly or time-consuming remedial measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any inspection or audit by regulatory authorities identifies a failure to comply with applicable regulations, or if a violation of product
specifications or applicable regulations occurs independent of such an inspection or audit, the relevant regulatory authority may require
remedial measures that may be costly or time-consuming to implement and that may include the temporary or permanent suspension of a clinical
trial or commercial sales or the temporary or permanent closure of a manufacturing facility.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities may inspect or audit the manufacturing facilities for our products and product candidates at any time. Any such remedial
measures imposed upon us could materially harm our business, financial condition, results of operations and prospects. If we fail to
comply with applicable cGMP regulations, FDA and foreign regulatory authorities could impose regulatory sanctions including, among other
things, refusal to approve a pending application for a new product candidate or suspension or revocation of a pre-existing approval.
Such an occurrence may cause our business, financial condition, results of operations and prospects to be materially harmed. Additionally,
if supply from our facility is interrupted, there could be a significant disruption in commercial supply of any of our product candidates
for which we obtain marketing approval, and in clinical supply for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we, our collaborators, or any third-party manufacturers we engage fail to comply with environmental, health and safety laws and regulations,
we could become subject to fines or penalties or incur costs that could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
our collaborators, and any third-party manufacturers we engage are subject to numerous environmental, health and safety laws and regulations,
including those governing laboratory procedures and the generation, handling, use, storage, treatment, manufacture, transportation and
disposal of, and exposure to, hazardous materials and wastes, as well as laws and regulations relating to occupational health and safety.
Our operations involve the use of hazardous and flammable materials, including chemicals and biologic materials. Our operations also
produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot
eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of
hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur
significant costs associated with civil or criminal fines and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain general liability insurance and workers&#8217; compensation insurance for certain costs and expenses that we may incur due
to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide
adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may
be asserted against us in connection with our storage or disposal of biologic and hazardous materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations,
which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development,
or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions
or liabilities, which could harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
widespread outbreak of an illness, communicable disease, or any other public health crisis could adversely affect our business, results
of operations and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be negatively impacted by the widespread outbreak of an illness, communicable disease, or any other public health crisis that results
in economic or trade disruptions, including the disruption of global supply chains. The COVID-19 pandemic negatively impacted the economy
on a global, national, and local level, disrupted global supply chains, and created volatility and disruption of financial markets. Responses
from governmental authorities and companies to reduce the spread of COVID-19 affected economic activity through various containment measures
including, among others, business closures, work stoppages, quarantine and work-from-home guidelines, limiting capacity at public spaces
and events, vaccination requirements, or restrictions of global and regional travel. Another outbreak of an illness, a communicable disease,
or any other public health crisis, and any resulting impacts, such as an extended period of global supply chain and/or economic disruption,
labor shortages, or government-mandated actions in response to such public health crisis could materially affect our business, results
of operations, access to sources of liquidity, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our reliance on third-parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to rely on third parties to conduct some or all aspects of our viral vector production, drug product manufacturing, research and
preclinical, and clinical testing, and these third parties may not perform satisfactorily.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to independently conduct all aspects of our viral vector production, drug product manufacturing and distribution, research
and preclinical, and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to these matters.
In some cases, these third parties are academic, research or similar institutions that may not apply the same quality control protocols
utilized in certain commercial settings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these third parties for research and development activities reduces our control over these activities but does not relieve
us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for product candidates
that we develop and commercialize on our own, we remain responsible for ensuring that each of our IND-enabling studies and clinical studies
are conducted in accordance with the study plan and protocols, and that our viral vectors and drug products are manufactured in accordance
with GMP as applied in the relevant jurisdictions. We must also ensure that our preclinical trials are conducted in accordance with GLPs,
as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with GCPs for conducting, recording,
and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights,
integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic
inspections. If we or any of our third-party service providers fail to comply with applicable regulatory requirements, we or they may
be subject to enforcement or other legal actions, the data generated in our trials or manufacturing development may be deemed unreliable,
and the FDA or comparable foreign regulatory authorities may require us to perform additional studies and manufacturing development.
If these third parties do not successfully carry out their contractual duties, meet expected deadlines, conduct our studies in accordance
with regulatory requirements or our stated study plans and protocols, or manufacture our viral vectors and drug products in accordance
with cGMP, or if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to
adhere to our protocols, regulatory requirements or for other reasons, we will not be able to complete, or may be delayed in completing,
the preclinical and clinical studies and manufacturing process validation activities required to support future IND, MAA and BLA submissions
and approval of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could
delay our product development activities. Any of these events could lead to clinical study delays or failure to obtain regulatory approval
or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including
injunction, recall, seizure or total or partial suspension of production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we rely on third parties to manufacture our vectors and our product candidates, and because we collaborate with various organizations
and academic institutions on the advancement of our cell and gene therapy platform, we must, at times, share trade secrets with them.
We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer
agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees,
and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the
third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when
working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery
of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect
on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, these agreements typically restrict the ability of our collaborators, advisors, employees, and consultants to publish data
potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified
in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration.
In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties.
We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and
development partnerships or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade
secrets, either through breach of these agreements, independent development or publication of information including our trade secrets
in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor&#8217;s discovery of
our trade secrets would impair our competitive position and have an adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to commercializing our product candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain the necessary U.S. or worldwide regulatory approvals to commercialize pz-cel, we will not be able to sell pz-cel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot obtain regulatory approval for pz-cel, we will not be able to generate revenue from this product candidate. As a result, our
ability to generate revenue from product commercialization may be further delayed. We cannot assure you that we will receive the approvals
necessary to commercialize pz-cel or any other product candidate we may develop in the future. In order to obtain FDA approval of pz-cel
or any other product candidate requiring FDA approval, we must successfully complete an FDA BLA review. Obtaining FDA approval of any
other product candidate generally requires significant research and testing, referred to as preclinical studies, as well as human tests,
referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the
type, complexity and novelty of the product candidate and requires substantial resources for research, development and testing. We cannot
predict whether our research and clinical approaches will result in products that the FDA considers safe for humans and effective for
indicated uses. The FDA has substantial discretion in the product approval process and may require us to conduct additional preclinical
and clinical testing or to perform post-marketing studies. The approval process may also be delayed by changes in government regulation,
future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
in obtaining regulatory approvals may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    commercialization of, and our ability to derive product revenues from, pz-cel or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    costly procedures on us; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminish
    any competitive advantages that we may otherwise enjoy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we comply with all FDA requests, the FDA may ultimately reject our BLA. In addition, the FDA could determine that we must test additional
subjects or require that we conduct further studies with more subjects. We may never obtain regulatory approval for pz-cel, or any other
future potential product candidate. Failure to obtain FDA approval of any of our product candidates will severely undermine our business
by leaving us without the ability to generate additional accretive revenues. There is no guarantee that we will ever be able to develop
or acquire other product candidates. In foreign jurisdictions, we must receive approval from the appropriate regulatory authorities before
we can commercialize any products or product candidates outside the U.S. Foreign regulatory approval processes generally include all
of the risks and uncertainties associated with the FDA approval procedures described above. We cannot assure you that we will receive
the approvals necessary to commercialize any product candidate for sale outside the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive regulatory approval for pz-cel, our lead drug candidate, we may not be able to successfully commercialize the product and
the revenue that we generate from its sales, if any, may be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved for marketing, the commercial success of pz-cel will depend upon the product&#8217;s acceptance by the medical community, including
physicians, patients and healthcare payors. The degree of market acceptance for our drug candidate will depend on a number of factors,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    and perceived efficacy and safety of pz-cel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience, dosing burden and ease of administration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    or perceived advantages or disadvantages over alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    post-marketing commitments imposed by regulatory authorities, such as patient registries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strength
    of sales, marketing and distribution support;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
    of our future products, both in absolute terms and relative to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of current and future healthcare laws on pz-cel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of coverage and reimbursement from government and other third party payers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our drug candidate is approved but does not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we
may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community
and third-party payors on the benefits of our drug candidates may require significant resources and may never be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
drug candidates are subject to the risks of failure inherent in the development of pharmaceutical products based on new technologies,
and our failure to develop safe and commercially viable drugs would severely limit our ability to become profitable or to achieve significant
revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to successfully commercialize our product candidates if some or all of our product candidates are found to be unsafe or
ineffective or otherwise fail to meet applicable regulatory standards or receive necessary regulatory clearances. Additionally, our product
candidates may be deemed too difficult to develop into commercially viable drugs. We may encounter difficulty in manufacturing or marketing
our product candidates on a large scale, and proprietary rights of third parties may preclude us from marketing our drug candidates.
Moreover, competitors may be able to market superior or equivalent drugs successfully. Failure to successfully commercialize our product
candidates would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to successfully develop, market, or commercialize our products or our product candidates without establishing new relationships
and maintaining current relationships and our ability to successfully commercialize, and market our product candidates could be limited
if a number of these existing relationships are terminated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy for the research, development and commercialization of our potential pharmaceutical products may require us to enter into various
arrangements with corporate and academic collaborators, licensors, licensees and others, in addition to our existing relationships with
other parties. Specifically, we may seek to joint venture, sublicense or enter into other marketing arrangements with parties that have
an established marketing capability, or we may choose to pursue the commercialization of such products on our own. We may, however, be
unable to establish such additional collaborative arrangements, license agreements, or marketing agreements as we may deem necessary
to develop, commercialize and market our potential pharmaceutical products on acceptable terms. Furthermore, since we maintain and establish
arrangements or relationships with third parties, our business may depend upon the successful performance by these third parties of their
responsibilities under those arrangements and relationships. If we are unwilling or unable to perform our obligations under any license
or collaboration arrangement, a third party may have the right to terminate such arrangement with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to extensive governmental regulation, which increases our cost of doing business and may affect our ability to commercialize
any new products that we may develop.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable agencies in foreign countries impose substantial requirements upon the introduction of pharmaceutical products through
lengthy and detailed laboratory, preclinical and clinical testing procedures and other costly and time-consuming procedures to establish
safety and efficacy. All of our drugs and drug candidates require receipt and maintenance of governmental approvals for commercialization.
Preclinical and clinical trials and manufacturing of our drug candidates will be subject to the rigorous testing and approval processes
of the FDA and corresponding foreign regulatory authorities. Satisfaction of these requirements typically takes a significant number
of years and can vary substantially based upon the type, complexity, and novelty of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the time-consuming and uncertain nature of the drug candidate development process and the governmental approval process described
above, we cannot be certain when we, independently or with our collaborative partners, might submit a BLA for FDA or other regulatory
review. Further, our ability to commence and/or complete development projects will be subject to our ability to raise enough funds to
pay for the development costs of these projects. Government regulation also affects the manufacturing and marketing of pharmaceutical
products. Government regulations may delay marketing of our potential drugs for a considerable or indefinite period of time, impose costly
procedural requirements upon our activities and furnish a competitive advantage to larger companies or companies more experienced in
regulatory affairs. Delays in obtaining governmental regulatory approval could adversely affect our marketing as well as our ability
to generate significant revenues from commercial sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates may not receive FDA or other regulatory approvals on a timely basis or at all. Moreover, if regulatory approval of a
drug candidate is granted, such approval may impose limitations on the indicated use for which such drug may be marketed. Even if we
obtain initial regulatory approvals for our drug candidates, our drugs and our manufacturing facilities would be subject to continual
review and periodic inspection, and later discovery of previously unknown problems with a drug, manufacturer or facility may result in
restrictions on the marketing or manufacture of such drug, including withdrawal of the drug from the market. The FDA and other regulatory
authorities stringently apply regulatory standards and failure to comply with regulatory standards can, among other things, result in
fines, denial or withdrawal of regulatory approvals, product recalls or seizures, operating restrictions, and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may incur substantial product liability expenses due to the use or misuse of our products for which we may be unable to obtain insurance
coverage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to potential liability risks that are inherent in the testing, manufacturing, and marketing of pharmaceutical products.
These risks will expand with respect to our drug candidates, if any, that receive regulatory approval for commercial sale and we may
face substantial liability for damages in the event of adverse side effects, including injury or death, or product defects identified
with any of our products that are used in clinical tests or marketed to the public. Product liability actions can also have regulatory
consequences, including the withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical
programs, and the initiation of investigations, and enforcement actions by regulators, product recalls, withdrawals, revocation of approvals,
or labeling, marketing, or promotional restrictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
liability insurance for the biotechnology industry is generally expensive, if available at all, and as a result, we may be unable to
obtain insurance coverage at acceptable costs or in a sufficient amount in the future, if at all. We may be unable to satisfy any claims
for which we may be held liable as a result of the use or misuse of products which we developed, manufactured, or sold and any such product
liability claim could adversely affect our business, operating results, or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intense
competition may limit our ability to successfully develop and market commercial products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our
competitors in the U.S. and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies,
specialized biotechnology firms and universities and other research institutions. Many of our competitors have and employ greater financial
and other resources, including larger research and development, marketing, and manufacturing organizations. As a result, our competitors
may successfully develop technologies and drugs that are more effective or less costly than any that we are developing, which could render
our technology and future products obsolete and noncompetitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, some of our competitors have greater experience than we do in conducting preclinical and clinical trials and obtaining FDA
and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals for drug candidates
more rapidly than we can. Companies that complete clinical trials, obtain required regulatory agency approvals, and commence commercial
sale of their drugs before their competitors may achieve a significant competitive advantage. Drugs resulting from our research and development
efforts or from our joint efforts with collaborative partners therefore may not be commercially competitive with our competitors&#8217;
existing products or products under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products and product candidates may face competition sooner than anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and product candidates may face competition from other products that are the same as or similar to ours. If the FDA or comparable
foreign regulatory authorities approve biosimilar versions of our products or product candidates, or such authorities do not grant our
products appropriate or anticipated periods of regulatory exclusivity, the sales of our products could be adversely affected. Moreover,
even if we receive periods of regulatory exclusivity, that exclusivity may not adequately protect us from biosimilar or other product
competition. There may also be changes in regulatory exclusivity policies. For example, there have been efforts to decrease the biologic
period of exclusivity to a shorter timeframe. Future proposed budgets, international trade agreements and other arrangements or proposals
may affect periods of exclusivity. If another company pursues approval of a product that is biosimilar to any biologic product for which
we receive FDA approval, we may need to pursue costly and time-consuming patent infringement actions, which may include certain statutorily
specified regulatory steps before an infringement action may be brought. Biosimilar applicants may also be able to bring an action for
declaratory judgment concerning our patents, requiring that we spend time and money defending the action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to successfully develop and commercialize our drug candidates will substantially depend upon the availability of reimbursement
funds for the costs of the resulting drugs and related treatments.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
acceptance and sales of our product candidates may depend on coverage and reimbursement policies and health care reform measures. Decisions
about formulary coverage as well as levels at which government authorities and third-party payors, such as private health insurers and
health maintenance organizations, reimburse patients for the price they pay for our products as well as levels at which these payors
pay directly for our products, where applicable, could affect whether we are able to commercialize these products. We cannot be sure
that reimbursement will be available for any of these products. Also, we cannot be sure that coverage or reimbursement amounts will not
reduce the demand for, or the price of, our products. We have not commenced efforts to have our product candidates reimbursed by the
government or third-party payors. If coverage and reimbursement are not available or are available only at limited levels, we may not
be able to commercialize our products. In recent years, officials have made numerous proposals to change the health care system in the
U.S. These proposals include measures that would limit or prohibit payments for certain medical treatments or subject the pricing of
drugs to government control. In addition, in many foreign countries, particularly the countries of the European Union, the pricing of
prescription drugs is subject to government control. If our products are or become subject to government regulation that limits or prohibits
payment for our products, or that subjects the price of our products to governmental control, we may not be able to generate revenue,
attain profitability or commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of legislative proposals and the trend towards managed health care in the U.S., third-party payors are increasingly attempting
to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. They may also impose strict prior
authorization requirements and/or refuse to provide any coverage of uses of approved products for medical indications other than those
for which the FDA has granted market approvals. As a result, significant uncertainty exists as to whether and how much third-party payors
will reimburse patients for their use of newly approved drugs, which in turn will put pressure on the pricing of drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market may not accept any pharmaceutical products that we develop, thereby materially impairing our ability to generate revenue from
such products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
products that we are attempting to develop may compete with drugs manufactured and marketed by other pharmaceutical companies. The degree
of market acceptance of any drugs developed by us will depend on a number of factors, including the establishment and demonstration of
the clinical efficacy and safety of our drug candidates, the potential advantage of our drug candidates over existing therapies and the
reimbursement policies of government and third-party payors. Physicians, patients, or the medical community in general may not accept
or use any drugs that we may develop independently or with our collaborative partners and if they do not, our business could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
public perception of gene therapy products may negatively affect demand for, or regulatory approval of, our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates involve altering genes, and the clinical and commercial success of our product candidates will depend in part on public
acceptance of the use of gene altering therapies for the treatment of genetic diseases. Public attitude may be influenced by claims that
gene therapy is unsafe, unethical, or immoral, and, as a result, our product candidates may not gain the acceptance of the public or
the medical community. Negative public reaction to gene therapy in general could result in greater government regulation and stricter
labeling requirements of gene therapy products, including any of our product candidates, and could cause a decrease in the demand for
any products we may develop. Adverse public opinion also may adversely affect our ability to enroll patients in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
reform measures could hinder or prevent our product candidates&#8217; commercial success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government-adopted reform measures could adversely affect the pricing of healthcare products and services in the U.S. or internationally
and the amount of reimbursement available from governmental agencies or other third-party payors. The continuing efforts of the U.S.
and foreign governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce
health care costs may adversely affect our ability to set prices for our products which we believe are fair, restrict coverage and reimbursement,
or require payment of increased rebates and our ability to generate revenues and achieve and maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
laws, regulations and judicial decisions, or new interpretations of existing laws, regulations, and decisions, which relate to healthcare
availability, methods of delivery or payment for products and services, or sales, marketing, or pricing, may limit our potential revenue,
and we may need to revise our research and development programs. The pricing and reimbursement environment may change in the future and
become more challenging due to several reasons including new healthcare legislation or regulation and fiscal challenges faced by government
health administration authorities. Specifically, in both the U.S. and some foreign jurisdictions, there have been a number of legislative
and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
or executive action, either in the United States or abroad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject, directly or indirectly, to federal, state, and foreign healthcare laws and regulations, including fraud and abuse laws,
false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such
laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
will be directly, or indirectly through our prescribers, customers, and purchasers, subject to various federal and state laws and regulations,
including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims act, the civil monetary
penalties statute, HIPAA, and the Physician Payments Sunshine Act and regulations. These laws are further described in the U.S. Biologic
Products Development Process section of this annual report. These laws will impact, among other things, our proposed sales, marketing,
and educational programs. In addition, we may be subject to data privacy laws by both the federal government and the states in which
we conduct our business. Failure to comply with these laws could result in penalties, including civil and criminal penalties, damages,
fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare programs, debarment
from government contracting or refusal of orders under existing contracts, corporate integrity agreements or consent decrees, disgorgement,
contractual damages, reputational harm, diminished profits and future earnings, and imprisonment. Furthermore, efforts to ensure that
business activities and business arrangements comply with applicable healthcare laws and regulations can be costly. Comparable laws and
regulations apply internationally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to extensive laws and regulations related to data privacy, and our failure to comply with these laws and regulations could
harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
foreign, federal, and state laws and regulations govern collection, dissemination, use and confidentiality of personally identifiable
health information, including state privacy and confidentiality laws (including state laws requiring disclosure of breaches), HIPAA and
the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;). These laws and regulations are increasing in complexity
and number and may change frequently and sometimes conflict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
establishes a set of national privacy and security standards for the protection of individually identifiable health information, including
protected health information (&#8220;PHI&#8221;), by health plans, certain healthcare clearinghouses and healthcare providers that submit
certain covered transactions electronically, or covered entities, and their &#8220;business associates,&#8221; which are persons or entities
that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting PHI.
While we are not currently a covered entity or business associate under HIPAA, we may receive identifiable information from these entities.
Failure to protect this information properly could subject us to HIPAA&#8217;s criminal penalties, which may include fines up to $250,000
per violation and/or imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GDPR
imposes numerous requirements on entities that process personal data in the context of an establishment in the European Economic Area
(&#8220;EEA&#8221;) or that process the personal data of data subjects who are located in the EEA. These requirements include, for example,
establishing a basis for processing, providing notice to data subjects, developing procedures to vindicate expanded data subject rights,
implementing appropriate technical and organizational measures to safeguard personal data, and complying with restrictions on the cross-border
transfer of personal data from the EEA to countries that the European Union does not consider to have in place adequate data protection
legislation, such as the United States. GDPR additionally establishes heightened obligations for entities that process &#8220;special
categories&#8221; of personal data, such as health data. Nearly all clinical trials involve the processing of these &#8220;special categories&#8221;
of personal data, and thus processing of personal data collected during the course of clinical trials is subject to heightened protections
under GDPR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
California adopted the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), which went into effect in January 2020. The CCPA
has been characterized as the first &#8220;GDPR-like&#8221; privacy statute to be enacted in the United States because it mirrors a number
of the key provisions of the GDPR. The CCPA establishes a new privacy framework for covered businesses in the State of California, by
creating an expanded definition of personal information, establishing new data privacy rights for consumers imposing special rules on
the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of
the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legislative and regulatory landscape for privacy and data security continues to evolve, and there has been an increasing focus on privacy
and data security issues which may affect our business. Failure to comply with current and future laws and regulations could result in
government enforcement actions (including the imposition of significant penalties), criminal and/or civil liability for us and our officers
and directors, private litigation and/or adverse publicity that negatively affects our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trends
toward managed health care, health technology assessment, and downward price pressures on medical products and services may limit our
ability to profitably sell any drugs that we may develop.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
prices for pharmaceutical products or reduced profitability may result from:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party-payors&#8217;
    increasing challenges to the prices charged for medical products and services, including by limiting coverage and reimbursement and
    requiring payment of increased manufacturer rebates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    trend toward managed health care in the U.S. and the concurrent growth of Health Maintenance Organizations (&#8220;HMOs&#8221;) and
    similar organizations that can control or significantly influence the purchase of healthcare services and products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state,
    federal, and foreign legislative proposals to control drug prices, reform healthcare or reduce government insurance programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost containment measures that healthcare providers are instituting, including practice protocols and guidelines and clinical pathways,
and the effect of any healthcare reform, could limit our ability to profitably sell any drugs that we may successfully develop. Moreover,
any future legislation or regulation, if any, relating to the healthcare industry or third-party coverage and reimbursement, may cause
our business to suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our intellectual property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
rights to develop and commercialize our product candidates are subject to, in part, the terms and conditions of licenses granted to us
by others.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development
of our technology and products, including technology related to our manufacturing process and our product candidates. These and other
licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories
in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent
competitors from developing and commercializing competitive products in territories included in all of our licenses. These licenses may
also require us to grant back certain rights to licensors and to pay certain amounts relating to sublicensing patent and other rights
under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some circumstances, particularly in-licenses with academic institutions, we may not have the right to control the preparation, filing
and prosecution of patent applications, or to maintain the patents, covering in-licensed technologies. Therefore, in those cases we cannot
be certain that these patents and applications will be prosecuted, maintained and enforced in a manner consistent with the best interests
of our business. If our licensors fail to maintain such patents, or lose rights to those patents or patent applications, the rights we
have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such
licensed rights could be adversely affected. In certain circumstances, we have or may license technology from third parties on a non-exclusive
basis. In such instances, other licensees may have the right to enforce our licensed patents in their respective fields, without our
oversight or control. Those other licensees may choose to enforce our licensed patents in a way that harms our interest, for example,
by advocating for claim interpretations or agreeing on invalidity positions that conflict with our positions or our interest. In addition
to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may
own in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in many of our license agreements we are responsible for bringing any actions against any third party for infringing the patents we have
licensed. Certain of our license agreements also require us to meet development milestones to maintain the license, including establishing
a set timeline for developing and commercializing products and minimum yearly diligence obligations in developing and commercializing
the product. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our technology and processes infringe intellectual property rights of the licensor that are not subject to the licensing
    agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any dispute over in-licensed intellectual property prevents or impairs our ability to maintain our current licensing arrangements on
acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with our obligations under these license agreements, or we are subject to a bankruptcy, the licensor may have the right
to terminate the license, in which event we would not be able to develop, manufacture, or market products covered by the license or may
face other penalties under the agreements. Termination of these agreements or reduction or elimination of our rights under these agreements
may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these
agreements, including our rights to important intellectual property or technology. It is possible that such termination may occur even
if we believe that we have complied with our obligations under a license agreement, if a dispute arises between us and a licensor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
to the extent that the research resulting in certain of our licensed patent rights and technology was funded by the U.S. government,
the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed
with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive,
royalty-free license authorizing the U.S. government, or a third party on its behalf, to use the invention for non-commercial purposes.
These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use
or allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines that action
is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate
health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in
such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise
by the government, or a third party on its behalf, of such rights could harm our competitive position, business, financial condition,
results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection
obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours,
and our ability to successfully commercialize our products and technology may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in large part, on our and our licensors&#8217; ability to obtain and maintain patent protection in the United States
and other countries with respect to our proprietary product candidates and manufacturing technology. We and our licensors have sought,
and we intend to seek in the future, to protect our proprietary positions by filing patent applications in the United States and abroad
related to many of our novel technologies and product candidates that are important to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive, time-consuming and complex, and we may not have and may not in the future be able to file, prosecute,
maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. For example,
in some cases, the work of certain academic researchers in the gene therapy field has entered the public domain, which may compromise
our ability to obtain patent protection for certain inventions related to or building upon such prior work. Consequently, we will not
be able to obtain any such patents to prevent others from using our technology for, and developing and marketing competing products to
treat, these indications. It is also possible that we will fail to identify patentable aspects of our research and development output
before it is too late to obtain patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability, and commercial
value of our and our licensors&#8217; patent rights are highly uncertain. Our pending and future patent applications may not result in
patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive
technologies and product candidates. In particular, during prosecution of any patent application, the issuance of any patents based on
the application may depend upon our ability to generate additional preclinical or clinical data that support the patentability of our
proposed claims. We may not be able to generate sufficient additional data on a timely basis, or at all. Changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the
scope of our and our licensors&#8217; patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be aware of all third-party intellectual property rights potentially relating to our product candidates. Publications of discoveries
in the scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are
typically not published until 18 months after filing or, in some cases, not at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore,
we cannot be certain that we were the first to make the inventions claimed in any owned or any licensed patents or pending patent applications,
or that we were the first to file for patent protection of such inventions. Databases for patents and publications, and methods for searching
them, are inherently limited, so it is not practical to review and know the full scope of all issued and pending patent applications.
As a result, the issuance, scope, validity, enforceability, and commercial value of our and our licensed patent rights are uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the patent applications we license or may own in the future do issue as patents, they may not issue in a form that will provide us
with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive
advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies
or products in a non-infringing manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in
the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being
narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical
technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of
time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient
rights to exclude others from commercializing products similar or identical to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the
scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what
we believe to be our financial or other obligations under the relevant agreement, either of which could harm our business, financial
condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in obtaining necessary rights to our product candidates through acquisitions and in-licenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have rights to certain intellectual property, through licenses from third parties, to develop our product candidates. Because
our programs may require the use of proprietary rights held by third parties, the growth of our business likely will depend, in part,
on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license any compositions, methods
of use, processes, or other intellectual property rights from third parties that we identify as necessary for our product candidates.
The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies
may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established
companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization
capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also
may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return
on our investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
sometimes collaborate with non-profit and academic institutions to accelerate our preclinical research or development under written agreements
with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s
rights in technology resulting from the collaboration. Regardless of such an option, we may be unable to negotiate a license within the
specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property
rights to other parties, potentially blocking our ability to develop our program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual
property rights we have, we may be required to expend significant time and resources to redesign our product candidates or the methods
for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial
basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our
business significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issued
patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect
our trade secrets in court.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product
candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation
in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description
or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent
withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also
may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms
include re-examination, post grant review, <i>inter partes</i> review and equivalent proceedings in foreign jurisdictions. Such proceedings
could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates.
The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for
example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners
were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose
at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could
harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements
of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents. However, trade secrets can be difficult to protect. Some courts inside and outside the United States are less willing
or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality
agreements with our employees, consultants, scientific advisors, collaborators, contractors, and other third-parties. We cannot guarantee
that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology
and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security
of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals,
organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In
addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third-parties
may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
and could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product
candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties.
The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual
property rights. We may become party to, or threatened with, infringement litigation claims regarding our product candidates and technology,
including claims from competitors or from non-practicing entities that have no relevant product revenue and against whom our own patent
portfolio may have no deterrent effect. Moreover, we may become party to, or be threatened with, adversarial proceedings or litigation
regarding intellectual property rights with respect to our product candidates and technology, including interference or derivation proceedings,
post grant review and <i>inter partes</i> review before the USPTO or foreign patent offices. Third parties may assert infringement claims
against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third
parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe
such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and
infringed, which could adversely affect our ability to commercialize our product candidates or any other of our product candidates or
technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in
federal court, we would need to overcome a statutory presumption of validity. As this burden is a high one requiring us to prove by clear
and convincing evidence the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would
invalidate the claims of any such U.S. patent. Similar challenges exist in other jurisdictions. If we are found to infringe a third-party&#8217;s
valid and enforceable intellectual property rights, we could be required to obtain a license from such third-party to continue developing,
manufacturing, and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially
reasonable terms, or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and
other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty
payments. We could be forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology
or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees,
if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us
from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could harm
our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals, and indemnify third parties
pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business, reputation, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets
of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical
companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors
do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals
or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s
current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property
rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties,
or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial
costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain patent term extension and data exclusivity for our product candidates, our business may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of any FDA marketing approval of our product candidates, one or more of our U.S. patents may
be eligible for limited patent term extension (&#8220;PTE&#8221;) under the Drug Price Competition and Patent Term Restoration Act of
1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a PTE of up to five years as compensation for patent
term lost during the FDA regulatory review process. PTE cannot extend the remaining term of a patent beyond a total of 14 years from
the date of product approval, only one patent may be extended per FDA-approved product, and only those claims covering the approved drug,
a method for using it or a method for manufacturing it may be extended. Further, certain of our licenses currently or in the future may
not provide us with the right to control decisions of the licensor or its other licensees with respect to PTE under the Hatch-Waxman
Act. Thus, if one of our important licensed patents is eligible for PTE, and it covers a product of another licensee in addition to our
own product candidate, we may not be able to obtain that extension if the other licensee seeks and obtains that extension first. Moreover,
we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory
review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing
to satisfy applicable requirements, or the applicable time-period or the scope of patent protection afforded during any such extension
could be less than we request. If we are unable to obtain PTE or the duration of any such extension is less than we request, the period
during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing
products following our patent expiration, and our revenue could be materially reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our financial condition and capital requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have experienced a history of losses; we expect to incur future losses and we may be unable to obtain necessary additional capital to
fund operations in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have recorded minimal revenue to date and have incurred an accumulated deficit of $813.3 million through December 31, 2024. The net loss
for the year ended December 31, 2024, was $63.7 million. Our losses have resulted principally from costs incurred in research and development
activities related to our efforts to develop clinical drug candidates and from the associated administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
require substantial capital for our development programs and operating expenses, to pursue regulatory clearances and to prosecute and
defend our intellectual property rights. We expect to continue to incur significant expenses and increasing operating losses for the
foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory and marketing approvals for our product candidates that successfully complete clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    our research and preclinical and clinical development of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">further
    develop the manufacturing process for our vectors or our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    the scope of our current clinical studies for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
    or add additional manufacturers or suppliers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to identify and validate additional product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
    or in-license other product candidates and technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    milestone or other payments under any license agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    protect and expand our intellectual property portfolio;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing and distribution infrastructure in the United States and Europe to commercialize any products for which we may
    obtain marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    and retain skilled personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">build
    additional infrastructure to support our operations as a larger public company and our product development and planned future commercialization
    efforts, including manufacturing capacity; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
    any delays or encounter issues with any of the above.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of
our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating
results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, our cash, cash equivalents, restricted cash and short-term investments were $98.1 million. Based upon our
existing cash resources and the $4.8 million in net proceeds from our subsequent sales of common stock under stock under the ATM
Agreement, we believe that we have sufficient resources to fund operations through at least the next 12 months from the date of the
issuance of our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than
planned, through public or private equity, government or other third-party funding, marketing and distribution arrangements and other
collaborations, strategic alliances and licensing arrangements or a combination of these approaches. In any event, we may require additional
capital to obtain potential regulatory approval for, and to potentially commercialize, our product candidates. Even if we believe we
have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or
if we have specific strategic objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights
of our stockholders and the issuance of additional securities, whether common stock, preferred stock or debt, by us, or the possibility
of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would
dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations, and we may be required
to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to
acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage
than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay, or discontinue one or more of
our research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise
capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, and results of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not have significant operating revenue and may never achieve profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have funded our operations primarily through public offerings of our common stock. Our ability to achieve significant revenue
or profitability depends upon our ability to complete the development of our drug candidates, to develop and obtain patent protection
and regulatory approvals for our drug candidates and to manufacture and commercialize the resulting drugs. We are not expecting any significant
revenues in the short-term from our products or product candidates. Furthermore, we may not be able to ever successfully identify, develop,
commercialize, patent, manufacture, obtain required regulatory approvals or market any products. Moreover, even if we do identify, develop,
commercialize, patent, manufacture, or obtain required regulatory approvals to market additional products, we may not generate revenues
or royalties from commercial sales of these products for a significant number of years, if at all. Therefore, our operations are subject
to all the risks inherent in the establishment of a new business enterprise. In the next couple of years, we expect limited revenues
from product sales, if any, and any amounts that we receive under strategic partnerships and research or drug development collaborations
that we may establish and, as a result, we may be unable to achieve or maintain profitability in the future or to achieve significant
revenues in order to fund our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to achieve and maintain effective internal controls could have a material adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal controls are necessary for us to provide reliable financial reports. If we cannot provide reliable financial reports, our operating
results could be harmed. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those
systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our operating
results, or cause us to fail to meet our reporting obligations. Failure to achieve and maintain an effective internal control environment
could cause investors to lose confidence in our reported financial information, which could have a material adverse effect on our stock
price. Failure to comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to actions or investigations by
the SEC or other regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may need to raise additional capital to operate our business, and our failure to obtain funding when needed or on terms that are favorable
to us may force us to delay, reduce or eliminate our development programs or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to raise additional capital to fund our future operations and we cannot be certain that funding will be available to us on acceptable
terms on a timely basis, or at all. We expect to continue to spend substantial amounts on regulatory approval efforts, product development
(including commercialization activities), and conducting potential future pre-clinical or clinical trials for our product candidates.
Our ability to raise capital through the sale of securities may be limited by our number of authorized shares of common stock and various
rules of the SEC and the Nasdaq that place limits on the number and dollar amount of securities that we may sell. If we fail to raise
additional funds on acceptable terms or at all, we may be unable to complete planned preclinical and clinical trials, obtain approval
of our product candidates from the FDA and other regulatory authorities, or successfully commercialize any of our product candidates.
In addition, we could be forced to delay, discontinue, or curtail product development, or forego licensing in attractive business opportunities.
Any additional sources of financing will likely involve the issuance of our equity or debt securities, which will have a dilutive effect
on our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our common stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock may be volatile and adversely affected by several factors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock could fluctuate significantly in response to various factors and events, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to integrate operations, technology, products, and services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to execute our business plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    results below expectations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    concerning product development results, including clinical trial results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments in the U.S. or EU, including decisions from regulatory agencies relating to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    or public concern about the safety of our potential products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    issuance of additional securities, including debt or equity or a combination thereof, which will be necessary to fund our operating
    expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of technological innovations or new products by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of any strategic relationship;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">industry
    developments, including, without limitation, changes in healthcare policies or practices or third-party reimbursement policies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    and other external factors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">period-to-period
    fluctuations in our financial results; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    an active trading market in our common stock develops and is maintained.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the
operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of
our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional funds by issuing securities or through licensing or lending arrangements or through our at-the-market sale agreement may cause
dilution to our existing stockholders, restrict our operations, or require us to relinquish proprietary rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt
financing may involve covenants that, among other restrictions, limit our ability to incur liens or additional debt, pay dividends, redeem,
or repurchase our common stock, make certain investments or engage in certain merger, consolidation, or asset sale transactions. In addition,
if we raise additional funds through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish
potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities,
whether equity or debt, or the possibility of such issuance, may cause the market price of our shares to decline. We may sell shares
or other securities in other offerings, including under our open market sale agreement, at a price per share that is less than the prices
per share paid by other investors, and investors purchasing shares of our common stock, preferred stock or other securities in the future
could have rights superior to existing stockholders. The sale of additional equity or convertible securities would dilute all of our
stockholders and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to use our net operating loss carry forwards may be subject to limitation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
a change of more than 50% in the ownership of a company&#8217;s stock, by value, over a three-year period constitutes an ownership change
for U.S. federal income tax purposes or applicable state tax law. An ownership change may limit our ability to use our net operating
loss carryforwards attributable to the period prior to the change. As a result, if we earn net taxable income, our ability to use our
pre-change net operating loss carryforwards to offset U.S. federal and state taxable income may become subject to limitations, which
could potentially result in increased future tax liability for us. As of December 31, 2024, we had net operating loss carryforwards aggregating
$429.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
disruptions of information technology (&#8220;IT&#8221;) systems, breaches of data security, or unauthorized disclosures of personal
information (including sensitive personal information) could adversely affect our business and could subject us to liability or reputational
damage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate information systems that contain limited amounts of client data. As a routine element of our business, we collect, analyze, and
retain data pertaining to the clinical trials we conduct for our products. Unauthorized third parties could attempt to gain entry to
such information systems to steal data or disrupt the systems or for financial gain. Like other companies we may experience threats and
incursions to our data and systems, including malicious software and viruses, phishing, business email compromise and social engineering
attacks or other cyber-attacks. The number and complexity of these threats continue to increase over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have implemented and maintain security systems measures and safeguards, which we believe to be reasonable, to protect our information
systems and confidential information, including personal information, and that of our customers, clients and suppliers that is held or
processed by us, against unauthorized access or disclosure and to prevent, detect, contain, respond to, and mitigate security-related
threats and potential incidents. We undertake ongoing improvements to the security of our systems, connected devices, and information-sharing
products in order to minimize potential vulnerabilities, in accordance with industry and regulatory standards. Despite such efforts,
our safeguards may fail, or we may be subject to breaches of our security resulting in unauthorized access to our facilities or information
systems and the information we are trying to protect. Moreover, our business or operations may be affected in the event our customers,
clients and suppliers experience data security incidents, cyber-attacks or extended interruptions of their services or systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are continuously evaluating and, where appropriate, enhancing our IT systems to address our planned growth, including to support our
planned manufacturing operations. There are inherent costs and risks associated with implementing the enhancements to our IT systems,
including potential delays in access to, or errors in, critical business and financial information, substantial capital expenditures,
additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced
systems, demands on management time, and costs of delays or difficulties in transitioning to the enhanced systems, any of which could
harm our business and results of operations. In addition, the implementation of enhancements to our IT systems may not result in productivity
improvements at a level that outweighs the costs of implementation, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we do not believe cybersecurity incidents have resulted in any material impact on our business, operations or financial results or our
ability to service our customers or run our business, past and future incidents resulting in unauthorized access to our facilities or
information systems, or those of our suppliers, or accidental loss or disclosure of proprietary or confidential information about us,
our clients or our customers could result in, among other things, a total shutdown of our systems that would disrupt our ability to conduct
business or pay vendors and employees, violations of applicable privacy and other laws, significant legal and financial exposure, damage
to our reputation, and a loss of investor confidence in our security measures. Additional impacts from cybersecurity incidents could
include remediation costs to our customers or business partners, such as liability for stolen assets or information, repairs of system
damage, and incentives for continued business; increased cybersecurity protection costs, which may include the costs of making organizational
changes, deploying additional personnel, resources and security technologies, training employees, and engaging third-party experts and
consultants; lost revenue resulting from the unauthorized use of proprietary information or the failure to retain or attract business
partners following an incident; increased insurance premiums; and damage to the Company&#8217;s competitiveness, stock price, and long-term
shareholder value. In addition, cybersecurity risks and data security incidents could lead to unfavorable publicity, governmental inquiry
and oversight, regulatory actions by federal, state and non-U.S. governmental authorities, litigation by affected parties and possible
financial obligations for damages related to the theft or misuse of such information, any of which could have a material adverse effect
on our profitability and cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information regarding our processes and practices related to information and cybersecurity, please see Item 1C of this report, &#8220;Cybersecurity&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
1C, Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_986_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-KXTTUC_zZ80K3nH8Gve" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000053-01" escape="true" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cybersecurity
Management and Strategy</i></b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gBFCRMPFAIAMT-KXTTUC_zX0fU7jjr9pd"><ix:continuation continuedAt="ConU000053-02" id="ConU000053-01"><span id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zjSoFmBb4S05" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">In
the ordinary course of our business, we collect, use, store, and transmit confidential, financial, sensitive, proprietary, personal,
and health-related information.</ix:nonNumeric></span> <span id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zwWQTVgehmp8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">The secure maintenance of this information and our information technology systems is important to our
operations and business strategy. To this end, we consider cybersecurity, along with other significant risks that we face, within our
overall enterprise risk management framework, and have implemented processes designed to assess, identify, and manage risks from potential
unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality,
integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by a dedicated
Director of Information Technology and an Information Technology Security and Risk Manager. We have developed a cybersecurity program
following the National Institute of Standards and Technology (&#8220;NIST&#8221;) cybersecurity framework that include mechanisms, controls,
technologies, and systems designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting
the data and maintain a stable information technology environment. For example, we conduct penetration and vulnerability testing, and
data recovery testing on a periodic basis. In addition, we consult with outside advisors and experts, when appropriate, to assist with
assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the
Company&#8217;s risk environment.</ix:nonNumeric></span></ix:continuation></span></span></p>

<div id="xdx_C0F_gBFCRMPFAIAMT-KXTTUC_z8VUrsUI2zOj"><ix:continuation continuedAt="ConU000053-03" id="ConU000053-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span>Third-Party
Risk Management</span></i></b></span></p>

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have processes to evaluate <span id="xdx_904_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_z7yDrIKIiRN" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party service</ix:nonNumeric></span> providers and vendors that have access to sensitive systems and company data, which may
include due diligence procedures such as assessments of that service provider&#8217;s cybersecurity posture or a recommendation of specific
mitigation controls. <span id="xdx_90B_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zykUN2Pwg5F1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000057" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">Following an assessment, we determine and prioritize service provider risk based on potential threat impact and
likelihood, and such risk determinations drive the level of due diligence and ongoing compliance monitoring required for each service
provider.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Education
and Awareness</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We
also provide cybersecurity training to our employees and are formalizing an ongoing information security training program for active
employees and relevant consultants to address matters such as phishing, email security, social engineering and training on data privacy.</span></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C07_gBFCRMPFAIAMT-KXTTUC_zfKsbBE6gxZe"><ix:continuation continuedAt="ConU000053-04" id="ConU000053-03">&#160;</ix:continuation></span></span></p>

<p id="xdx_980_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_gBFCRBODOTB-LQU_z2eKuo4I3qEl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000061-01" escape="true" id="Fact000061" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Governance</i></b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_C0E_gBFCRBODOTB-LQU_zIKnZ1YdYhje"><ix:continuation continuedAt="ConU000061-02" id="ConU000061-01">&#160;</ix:continuation></span></i></b></span></p>

<div id="xdx_C08_gBFCRBODOTB-LQU_zQOVOVePErrc"><ix:continuation continuedAt="ConU000061-03" id="ConU000061-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Our
Director of Information Technology, who reports to our CFO, and the Information Technology Security and Risk Manager are responsible
for assessing and managing cybersecurity risks. Our Director of Information Technology has over 25 years of experience managing information
technology and cybersecurity. He has a bachelor&#8217;s degree in electrical engineering from Wright State University as well as a master&#8217;s
degree in business administration from Ashland University. He has certifications from various information technology vendors as well
as experience in implementing security frameworks such as International Organization for Standardization (&#8220;ISO&#8221;) 27001 and
NIST. Our Information Technology Security and Risk Manager has a PhD in a scientific field and various information security certifications
such as Certified Ethical Hacker (&#8220;CEH&#8221;) and Holistic Information Security Practitioner (&#8220;HISP&#8221;). She also has
decades of experience in managing information technology environments and information security such as security architecture, security
operations and governance risk and compliance.</span></span></p>

</ix:continuation></div><div><div id="xdx_C05_gBFCRBODOTB-LQU_zzwPOTHj59R3"><ix:continuation id="ConU000061-03"><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We
report on our information security program, including the results of periodic testing, to the Audit Committee of the Board of Directors
on a quarterly basis. Our Board&#8217;s <span id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zGKX8OoiDgM4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000062" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">Audit Committee is responsible for overseeing our cybersecurity</ix:nonNumeric></span> and information security procedures.
<span id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zFK8TWbLhJe9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000063" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">The Audit Committee reviews management presentations concerning cybersecurity-related issues, including information security, technology
risks, policies, and risk mitigation programs.</ix:nonNumeric></span> <span id="xdx_90C_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zsQAzKxj5pkj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000064" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">The Audit Committee reports matters to the Board of Directors as needed.</ix:nonNumeric></span> Our CFO, with
the support of our Director of Information Technology, Information Technology Security and Risk Manager and third-party consultants,
assesses and manages cybersecurity risk, including preventing, mitigating, detecting, and addressing cybersecurity incidents, if any.
Our CFO also works closely with other management positions and external legal counsel to ensure that we understand our cybersecurity
risk management responsibilities. In case of a cybersecurity incident or breach, our incident response plan defines in detail reporting
and escalation processes to management and the Board of Directors.</span></span></p>

</div></ix:continuation></div><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_C06_gBFCRMPFAIAMT-KXTTUC_zyn3mwLi5O62"><ix:continuation continuedAt="ConU000053-05" id="ConU000053-04">Current
Cybersecurity Risk Posture</ix:continuation></span></i></b></span></p>

<div id="xdx_C09_gBFCRMPFAIAMT-KXTTUC_z8zcgxn9cRG6"><ix:continuation continuedAt="ConU000053-06" id="ConU000053-05"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:continuation></div></div></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span><span id="xdx_C06_gBFCRMPFAIAMT-KXTTUC_zx57BJos3jDl"><ix:continuation id="ConU000053-06"><span id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zoteuryuGIDa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000065" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">We
have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect
us.</ix:nonNumeric></span> However, like other companies in our industry, we and our third-party vendors have from time-to-time experienced threats to and security
incidents relating to information systems. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk
Factors,&#8221; under the heading &#8220;Risks related to cybersecurity.&#8221;</ix:continuation></span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in Cleveland, Ohio, where we currently lease approximately 62,000 square feet of manufacturing, laboratory
and office space. That lease expires in December 2030. We also lease 10,400 square feet of office space located in New York, New York.
That lease expires in September 2025 and has been sublet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have signed a lease for approximately 16,566 square feet of office space with a commencement date of January 1, 2025. That
lease expires in December 2030. This additional space will allow the Company to convert office space at the existing lease into additional
manufacturing space to increase pz-cel manufacturing capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our facilities are sufficient to meet our current needs and that suitable space will be available as and when needed for
potential commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently subject to any material pending legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has traded on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;ABEO&#8221; since June 22, 2015.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common
stock in the foreseeable future. The payment of dividends, if any, in the future is within the discretion of our Board of Directors and
will depend on our earnings, capital requirements and financial condition and other relevant facts. We currently intend to retain all
future earnings, if any, to finance the development and growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of record holders of our common stock as of March 11, 2025 was 310.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of December 31, 2024, information about shares of common stock outstanding and available for issuance
under our existing equity compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Plan Category</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>be issued upon exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of outstanding options,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrants and rights</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>outstanding options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrants and rights</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>remaining available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for future issuance</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>under equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>compensation plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(excluding securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>reflected in column (a))</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(a)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(b)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(c)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation plans approved by security holders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-left: 10pt">2015 Equity Incentive Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">176,587</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">38.64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total equity compensation plans</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">176,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38.64</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Repurchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information about purchases of equity securities that are registered pursuant to Section 12 of the Exchange
Act for the three months ended December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of securities to Total number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shared (our units)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>purchased</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>paid per share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(or unit)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(a)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Shares delivered or withheld pursuant to restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; padding-left: 10pt">October 1, 2024 - October 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6.53</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">November 1, 2024 - November 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">December 1, 2024 - December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">251</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6.53</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Reflects shares of common stock surrendered to the Company for payment of tax withholding obligations in connection with the vesting
of restricted stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
6. [RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis together with our consolidated financial statements and related notes included in this
Form 10-K. This discussion and analysis contains forward-looking statements, which involve risks and uncertainties. As a result of many
factors, such as those described under &#8220;Forward-Looking Statements,&#8221; &#8220;Risk Factors&#8221; and elsewhere in this Form
10-K, our actual results may differ materially from those anticipated in these forward-looking statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OVERVIEW</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Our lead clinical program
is pz-cel, investigational autologous, COL7A1 gene-corrected epidermal sheets, currently in development for recessive dystrophic epidermolysis
bullosa (&#8220;RDEB&#8221;). In 2022, we announced positive data from the VIITAL&#8482; study evaluating the efficacy, safety and tolerability
of pz-cel. The VIITAL&#8482; study met both its co-primary efficacy endpoints demonstrating statistically significant, clinically
meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds. In September 2023, we submitted a Biologics
License Application (&#8220;BLA&#8221;) for pz-cel to the U.S. Food and Drug Administration (&#8220;FDA&#8221;). In November 2023, the
FDA accepted and granted priority review for our BLA for pz-cel, and subsequently, under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;),
the FDA set a target action date of May 25, 2024. In April 2024, the FDA issued a Complete Response Letter (&#8220;CRL&#8221;) in response
to the BLA. The CRL noted that certain additional information needed to satisfy the Chemistry Manufacturing and Controls (&#8220;CMC&#8221;)
requirements of the pz-cel BLA must be satisfactorily resolved before the application can be approved. The CRL did not identify any deficiencies
related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical
data to support the approval of pz-cel. In August 2024, we completed a Type A Meeting with the FDA to discuss our forthcoming resubmission
of our BLA and in October 2024, we resubmitted our BLA. The FDA notified the Company in November 2024 that the BLA was accepted
for review, with an assigned PDUFA target action date of April 29, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have continued to prepare our current Good Manufacturing Practices (&#8220;cGMP&#8221;) facility in Cleveland, Ohio for
manufacturing commercial grade pz-cel drug product to support our planned commercial launch of pz-cel, if approved. Pz-cel study
drug product for all our VIITAL&#8482; study participants has been manufactured at our Cleveland facility. As part of our commercial
planning, we continue to engage with stakeholders across the healthcare system, including public and private payors, and healthcare
providers to better understand market access and potential pricing for pz-cel. We have also begun discussions with high volume
treatment centers of excellence to onboard them for pz-cel application upon potential FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development portfolio also features adeno-associated virus (&#8220;AAV&#8221;) based gene therapies designed to treat ophthalmic diseases
using the novel AIM&#8482; capsids that we have exclusively licensed from the University of North Carolina at Chapel Hill and developed
internally through our AAV vector research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preclinical
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
preclinical programs are investigating the use of novel AAV capsids in AAV-based therapies for serious genetic eye diseases, including
ABO-504 for Stargardt disease, ABO-503 for X-linked retinoschisis (&#8220;XLRS&#8221;) and ABO-505 for autosomal dominant optic atrophy
(&#8220;ADOA&#8221;). We completed pre-Investigational New Drug Application (&#8220;pre-IND&#8221;) meetings with the FDA regarding the
preclinical development plans and regulatory requirements to support first-in-human trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 18, 2024, we signed a lease for 16,566 square feet of office space at 6700 Euclid Avenue, Cleveland, Ohio. The lease commences
on January 1, 2025 and the lease term matches the term for our existing 6555 Carnegie Avenue facility. The additional space at the 6700
Euclid Avenue facility will allow us to convert office space at the 6555 Carnegie Avenue facility into additional manufacturing space
to increase pz-cel manufacturing capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESULTS
OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of Years Ended December 31, 2024 and December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">($ in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 34%; text-align: left">License and other revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,500</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(100</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,605</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,847</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Gain on operating lease right-of-use assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,065</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,065</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(100</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">64,211</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">50,635</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,576</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(64,211</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,135</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,076</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,246</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,208</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(418</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,790</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">907</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant and derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(755</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,695</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,940</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(94</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,194</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,943</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,749</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(59</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(63,734</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(54,188</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,546</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>N/A
- not applicable or not meaningful</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">License
and other revenues</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
and other revenues for the year ended December 31, 2024 was nil, as compared to $3.5 million for the same period of 2023. There was no
license or other revenue in 2024 as no clinical development milestones were met in 2024. The revenue in 2023 consists of revenue resulting
from achieving clinical development milestones achieved under a sublicense agreement we entered into with Taysha Gene Therapies in October
2020 relating to an investigational AAV-based gene therapy for Rett syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Royalties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
royalty expenses were nil for the year ended December 31, 2024, as compared to $1.6 million for the same period of 2023. The royalty
expense in 2023 was due to royalties owed to our licensors resulting from the milestones due from Taysha related to Rett syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include, but are not limited to, payroll and personnel expense, lab supplies, preclinical and development costs,
clinical trial costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab
supplies and manufacturing facilities, and consultant-related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
research and development spending for the year ended December 31, 2024 was $34.4 million, as compared to $31.1 million for the same period
of 2023, an increase of $3.3 million. The increase in expenses was primarily due to a $4.0 million increase in salaries and $0.5 million
in non-cash stock-based compensation costs due to increased headcount related to manufacturing capacity expansion preparing for the potential
launch of pz-cel, partially offset by a decrease in clinical and development work costs of $1.3 million due to reduced spending on clinical
trials as the majority of our clinical trials have finalized except for our long-term follow up trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development activities to continue as we work towards advancing our product candidates towards potential regulatory
approval, reflecting costs associated with the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee
    and consultant-related expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    and developmental costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of acquiring and manufacturing clinical trial materials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    associated with regulatory approvals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and administrative</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses primarily consist of payroll and personnel costs, office facility costs, public reporting company related
costs, professional fees (e.g., legal expenses), pre-commercial launch activity costs and other general operating expenses not otherwise
included in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
general and administrative expenses were $29.9 million for the year ended December 31, 2024, as compared to $19.0 million for the same
period of 2023, an increase of $10.9 million. The increase in expenses was primarily due to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    salary and related costs of $3.8 million; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    pre-commercial preparation costs of $3.6 million;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    non-cash stock-based compensation of $1.4 million; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    other costs such as recruiting and professional fees of $2.1 million.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Gain
on operating lease right-of-use assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gain on operating lease right-of-use assets was $1.1 million for the year ended December 31, 2023. The gain on operating lease right-of-use
assets for 2023 was related to the termination of our operating leases for office space that we no longer use, resulting in a gain from
the difference between the carrying value of the right-of-use lease assets and the related lease liabilities. There was no such gain
during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income was $4.2 million for the year ended December 31, 2024, as compared to $2.1 million in the same period of 2023. The increase resulted
from higher earnings on short-term investments driven by higher interest rates and increased average short-term investment balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense was $4.2 million for the year ended December 31, 2024, as compared to $0.4 million in the same period of 2023. The increase was
primarily due to the Avenue credit facility entered into by the Company in January 2024, resulting in recognized interest expense of
$3.8 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Change
in fair value of warrant and derivative liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of warrant and derivative liabilities was a loss of $0.8 million for the year ended December 31, 2024, as compared
to a loss of $11.7 million in the same period of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
issued stock purchase warrants that are required to be classified as a liability and valued at fair market value at each reporting period.
In addition, the conversion feature in our loan agreement is required to be classified as a liability and valued at fair market value
at each reporting period. The change in the fair value of warrant and derivative liabilities was primarily due to the increase in our
stock price year over the year offset by a reduced term of each of the warrants and derivative liabilities. At September 30, 2024, the
conversion feature in our loan agreement no longer met the criteria of a derivative liability, and the derivative liability was reclassified
to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income was $1.2 million for the year ended December 31, 2024, as compared to $2.9 million in the same period of 2023. The change was
primarily a result of $2.1 million in other income related to the impact of the employee retention credit that was recorded in 2023,
partially offset by a refundable job creation tax credit of $0.5 million received in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIQUIDITY
AND CAPITAL RESOURCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows for the Years Ended December 31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">($ in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total cash, cash equivalents and restricted cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(56,015</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(37,009</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,240</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">104,139</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37,057</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net increase in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,884</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">256</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Operating
activities</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $56.0 million for the year ended December 31, 2024, primarily comprised of our net loss of
$63.7 million and decreases in operating assets and liabilities of $4.4 million, partially offset by net non-cash charges of $12.1
million. Non-cash charges consisted primarily of $0.8 million of the change in fair value of warrant and derivative liabilities,
$6.6 million of stock-based compensation, $1.5 million of non-cash interest expense and $2.0 million of depreciation and
amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $37.0 million for the year ended December 31, 2023, primarily comprised of our net loss of $54.2
million and increases in operating assets and liabilities of $1.8 million partially offset by net non-cash charges of $19.0 million.
Non-cash charges consisted primarily of $11.7 million of the change in fair value of warrant liabilities, $4.8 million of stock-based
compensation and $2.2 million of depreciation and amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Investing
activities</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $39.2 million for the year ended December 31, 2024, primarily comprised of purchases of short-term
investments of $157.0 million and capital expenditures of $2.4 million, partially offset by proceeds from maturities of short-term investments
of $120.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities was $0.2 million for the year ended December 31, 2023, primarily comprised of proceeds from maturities
of short-term investments of $51.9 million and proceeds from the disposal of property and equipment of $0.2 million, partially offset
by purchases of short-term investments of $51.6 million and capital expenditures of $0.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Financing
activities</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $104.1 million for the year ended December 31, 2024, primarily comprised of proceeds of $70.2
million in net proceeds from our May 2024 underwritten offering, $15.5 million from open market sales of common stock pursuant to the
ATM Agreement (as defined below) and net proceeds of $19.0 million from our credit facility entered into in January 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $37.1 million for the year ended December 31, 2023, primarily comprised of proceeds of $14.4
million from open market sales of common stock pursuant to the ATM Agreement (as defined below) and net proceeds of $23.0 million from
our July 2023 direct placement offering of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have historically funded our operations primarily through sales of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal source of liquidity is cash, cash equivalents, restricted cash and short-term investments, collectively referred to as our
cash resources. As of December 31, 2024, our cash resources were $98.1 million. We believe that our current cash and cash equivalents,
restricted cash and short-term investments are sufficient to fund operations through at least the next 12 months from the date of this
report on Form 10-K. We may need to secure additional funding to carry out all of our planned research and development and potential
commercialization activities. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity
and sufficient capital resources could have a material adverse effect on our future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an open market sale agreement with Jefferies LLC (as amended, the &#8220;ATM Agreement&#8221;) pursuant to which, we may sell from
time to time, through Jefferies LLC, shares of our common stock for an aggregate sales price of up to $75.0 million. Any sales of shares
pursuant to this agreement are made under our effective &#8220;shelf&#8221; registration statement on Form S-3 that is on file with and
has been declared effective by the SEC. We sold 2,825,954 shares of our common stock under the ATM Agreement and received $15.5 million
of net proceeds during the year ended December 31, 2024. We sold 3,659,882 shares of our common stock under the ATM Agreement and received
$14.6 million of net proceeds during the year ended December 31, 2023. Subsequent to December 31, 2024 and through March 11, 2025, we
sold 915,925 shares of our common stock under the ATM Agreement resulting in $4.8 million in net proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have incurred negative cash flows from operations and have expended, and expect to continue to expend, substantial
funds to complete our planned product development and potential commercialization efforts. We have not been profitable since inception
and to date have received limited revenues from the sale of products or licenses. We expect to incur losses for the next several years
as we continue to invest in commercialization, product research and development, preclinical studies, clinical trials, and regulatory
compliance and cannot provide assurance that we will ever be able to generate sufficient product sales or royalty revenue to achieve
profitability on a sustained basis, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional funds by selling additional equity securities, the relative equity ownership of our existing investors will be diluted,
and the new investors could obtain terms more favorable than previous investors. If we raise additional funds through collaborations,
strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable
to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, or terminate our product
development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties
that we would otherwise prefer to develop and market ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements and adequacy of available funds depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful development, regulatory approval and commercialization of our cell and gene therapy and other product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to establish and maintain collaborative arrangements with corporate partners for the research, development, and commercialization
    of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued
    scientific progress in our research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    magnitude, scope and results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in filing, prosecuting, and enforcing patent claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in conducting clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    technological developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing and scale-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to establish and maintain effective commercialization arrangements and activities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful outcome of our regulatory filings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to uncertainties and certain of the risks described above, our ability to successfully commercialize our product candidates, our ability
to obtain applicable regulatory approval to market our product candidates, our ability to obtain necessary additional capital to fund
operations in the future, our ability to successfully manufacture our products and our product candidates in clinical quantities or for
commercial purposes, government regulation to which we are subject, the uncertainty associated with preclinical and clinical testing,
intense competition that we face, the potential necessity of licensing technology from third parties and protection of our intellectual
property, it is not possible to reliably predict future spending or time to completion by project or product category or the period in
which material net cash inflows from significant projects are expected to commence. If we are unable to timely complete a particular
project, our research and development efforts could be delayed or reduced, our business could suffer depending on the significance of
the project and we might need to raise additional capital to fund operations, as discussed in the risks above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to continue our policy of investing any available funds in suitable certificates of deposit, money market funds, government securities
and investment-grade, interest-bearing securities. We do not invest in derivative financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into agreements in the normal course of business with clinical research organizations for clinical trials and clinical manufacturing
organizations for supply manufacturing and with vendors for preclinical research studies and other services and products for operating
purposes. These contractual obligations are cancelable at any time by us, generally upon prior written notice to the vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease amounts represent future minimum lease payments under our non-cancelable operating lease agreements. The minimum lease payments
above do not include any related common area maintenance charges or real estate taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2021, we entered into a Settlement Agreement with REGENXBIO to resolve all current disputes between the parties including
the aforementioned AAA arbitration and New York State Supreme Court action. In accordance with the Settlement Agreement, we agreed to
pay REGENXBIO a total of $30 million, payable as follows: (1) $20 million payable that was paid in 2021 after execution of the Settlement
Agreement, (2) $5 million on the first anniversary of the effective date of the Settlement Agreement that was paid in 2022, and (3) $5
million upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic
Transaction, as defined in the Settlement Agreement. As of December 31, 2024, we have paid all amounts due under the Settlement Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are also party to other license agreements, which include contingent payments. However, contingent payments related to these
license agreements are not disclosed as the satisfaction of these contingent payments is uncertain as of December 31, 2024 and, if satisfied,
the timing of payment for these amounts was not reasonably estimable as of December 31, 2024. Commitments related to the license agreements
include contingent payments that will become payable if and when certain development, regulatory and commercial milestones are achieved.
During the next 12 months, certain contingent payments could become due upon potential BLA approval and sales of pz-cel or any other
developmental milestones for sub-licensed products related to such license agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts and related disclosures in the financial statements. Management
considers an accounting estimate to be critical if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    requires assumptions to be made that were uncertain at the time the estimate was made, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the estimate or different estimates that could have been selected could have a material impact in our results of operations or
    financial condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances,
actual results could differ from those estimates and the differences could be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in greater detail in Note 2 to our consolidated financial statements appearing elsewhere
in this Annual Report, we believe that the following accounting policies are the most critical to the judgements and estimates used in
the preparation of our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Derivative
Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for the fair value of the conversion right embedded within the loan agreement in accordance with the guidance in ASC 815, which
requires us to bifurcate and separately account for the conversion feature as an embedded derivative contained in our loan agreement.
Accordingly, we account for the conversion feature as a derivative liability in our condensed consolidated balance sheet. Derivatives
are measured at their fair value on the balance sheet. In determining the appropriate fair value, we use a Monte Carlo simulation model,
which incorporated assumptions and estimates to value the derivatives. The derivative liability is remeasured at each reporting period
with the change in fair value recorded to change in fair value of warrant and derivative liabilities in the consolidated statement of
operations until the derivative is exercised, expired, reclassified, or otherwise settled. At September 30, 2024, the conversion feature
in the Company&#8217;s loan agreement no longer met the criteria of a derivative liability, and the $1.1 million derivative liability
was reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for leases pursuant to ASC 842, <i>Leases </i>(&#8220;ASC 842&#8221;). ASC 842 requires the recognition of lease assets and lease
liabilities by lessees for those leases classified as operating leases<i>. </i>We determine if an arrangement is a lease at inception
or when amended. Right-of-use lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent
our obligation to make lease payments arising from the lease. The classification of our leases as operating or finance leases along with
the initial measurement and recognition of the associated right-of-use assets and lease liabilities is performed at the lease commencement
date or when amended. The measurement of lease liabilities is based on the present value of future lease payments over the lease term.
As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease
commencement date in determining the present value of future lease payments. As we have no external borrowings, the incremental borrowing
rates are determined using information on indicative borrowing rates that would be available to us based on the value, currency and borrowing
terms provided by financial institutions, adjusted for company and market specific factors. Although we do not expect our estimates of
the incremental borrowing rates to generate material differences within a reasonable range of sensitivities, judgement is involved in
selecting an appropriate rate, and the rate selected for each lease will have an impact on the value of the lease liability and corresponding
right-of-use lease asset in the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
right-of-use asset is based on the measurement of the lease liability and includes any lease payments made prior to or on lease commencement
or lease amendment and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for our operating leases
is recognized on a straight-line basis over the lease term. We do not have any leases classified as finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants
or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease
components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the
practical expedient to group lease and non-lease components for all leases. We have elected the practical expedient to exclude short-term
leases from our right-of-use assets and lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the
majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably
certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal
period in our lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2024, we signed a lease for 16,566 square feet of office space at 6700 Euclid Avenue, Cleveland, Ohio. Pursuant to the lease
agreement, the lease commences on January 1, 2025 with an initial term through December 30, 2030. Annual lease payments during the term
of the lease are approximately $0.3 million. The total lease payments over the duration of the lease term are approximately $1.5 million.
The additional space at the 6700 Euclid Avenue facility will allow us to convert office space at the 6555 Carnegie Avenue facility into
additional manufacturing space to increase pz-cel manufacturing capacity. As the lease does not commence and we do not have access to
the leased space until January 1, 2025, the impact of this lease agreement is not reflected in our consolidated financial statements
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, we terminated one of our operating leases for office space. The termination resulted in a gain of $1.1 million for the year
ended December 31, 2023, representing the difference between the carry value of the right-of-use assets and the related lease liabilities.
This gain is included in gain on right-of-use lease assets in the consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June of 2023, we modified one of our operating leases for office space to add up to 14,032 square feet to our existing facility in Cleveland,
Ohio. The lease modification resulted in the recognition of $0.4 million of additional right-of-use assets and related lease liabilities
in our consolidated balance sheet during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-Lived Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-Lived
Assets consist of property and equipment, licensed technology, and right-of-use (&#8220;ROU&#8221;) assets. We test our long-lived assets
for impairment on an annual basis, or when events and circumstances indicate that the carrying value of an asset or group of assets may
not be fully recoverable. If indicators are present or changes in circumstance suggest that impairment may exist. We assess the recoverability
of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future
operating cash flows. If the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value
of the asset to the present value of the expected future cash flows associated with the use of the asset. The undiscounted future operating
cash flows require considerable judgement and are sensitive to changes in underlying assumptions such as operating costs related to our
current facilities, headcount requirements and our clinical costs. As a result, there can be no assurance that the estimates and assumptions
made for purpose of our impairment determinations would prove to be an accurate prediction of the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for revenue under ASC 606, <i>Revenue from Contracts with Customers</i>, (&#8220;ASC 606&#8221;). We recognize revenue when our
customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange
for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we
perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract;
(iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize
revenue when (or as) we satisfy a performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exclusive
Licenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
licenses that are combined with other performance obligations, we utilize judgment to assess the nature of the combined performance obligation
to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate
method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary,
adjust the measure of performance and related revenue recognition. The measure of progress, and therefore periods over which revenue
should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing
agreement. Such a change could have a material impact on the amount of revenue we record in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Milestone
Payments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the inception of each arrangement that includes research or development milestone payments, we evaluate whether the milestones are considered
probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction
price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone payments that are
not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals
are received. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to
achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable
that a significant cumulative revenue reversal would not occur. At the end of each subsequent reporting period, we re-evaluate the probability
of achievement of all milestones subject to constraint and, if necessary, adjust our estimate of the overall transaction price. Any such
adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Sublicense
and Inventory Purchase Agreements Relating to CLN1 Disease:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, we entered into sublicense and inventory purchase agreements with Taysha Gene Therapies (&#8220;Taysha&#8221;) relating
to a potential gene therapy for CLN1 disease. Under the sublicense agreement, Taysha received worldwide exclusive rights to intellectual
property and know-how relating to the research, development, and manufacture of the potential gene therapy, which we had referred to
as ABO-202. Under the inventory purchase agreement, we sold to Taysha certain inventory and other items related to ABO-202. We assessed
the nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated whether such
functionality can be retained without ongoing activities by us and determined that the license has significant stand-alone functionality.
Furthermore, we have no ongoing activities associated with the license to support or maintain the license&#8217;s utility. Based on this,
we determined that the pattern of transfer of control of the license to Taysha was at a point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price of the contract includes (i) $7.0 million of fixed consideration, (ii) up to $26.0 million of variable consideration
in the form of event-based milestone payments, (iii) up to $30.0 million of variable consideration in the form of sales-based milestone
payments, and (iv) other royalty-based payments based on net sales. The event-based milestone payments are based on certain development
and regulatory events occurring. At inception, we evaluated whether the milestone conditions had been achieved and if it was probable
that a significant cumulative revenue reversal would not occur before recognizing the associated revenue and determined that these milestone
payments were not within our control or the licensee&#8217;s control, such as regulatory approvals, and were not considered probable
of being achieved until those approvals were received. Accordingly, at inception, we fully constrained the $26.0 million of event-based
milestone payments until such time that it is probable that significant cumulative revenue reversal would not occur. The sales-based
milestone payments and other royalty-based payments are based on a level of sales for which the license is deemed to be the predominant
item to which the royalties relate. We will recognize revenue for these payments at the later of (i) when the related sales occur, or
(ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.
To date, we have not recognized any sales-based or royalty revenue resulting from this licensing arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no revenue recognized under this agreement during the years ended December 31, 2024 and 2023. As of December 31, 2024 and 2023, we
have no contract assets or contract liabilities as a result of this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Sublicense
Agreement Relating to Rett Syndrome:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, we entered into a sublicense agreement with Taysha for a gene therapy for Rett syndrome and MECP2 gene constructs and regulation
of their expression. The agreement grants Taysha worldwide exclusive rights to intellectual property developed by scientists at the University
of North Carolina at Chapel Hill, the University of Edinburgh and us, and our know-how relating to the research, development, and manufacture
of the gene therapy for Rett syndrome and MECP2 gene constructs and regulation of their expression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
assessed the nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated
whether such functionality can be retained without ongoing activities by us and determined that the license has significant stand-alone
functionality. Furthermore, we have no ongoing activities associated with the license to support or maintain the license&#8217;s utility.
Based on this, we determined that the pattern of transfer of control of the license to Taysha was at a point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price of the contract includes (i) $3.0 million of fixed consideration, (ii) up to $26.5 million of variable consideration
in the form of event-based milestone payments, (iii) up to $30.0 million of variable consideration in the form of sales-based milestone
payments, and (iv) other royalty-based payments based on net sales. The event-based milestone payments are based on certain development
and regulatory events occurring. We evaluated whether the milestone conditions have been achieved and if it is probable that a significant
cumulative revenue reversal would not occur before recognizing the associated revenue. We determined that these milestone payments are
not within our control or the licensee&#8217;s control, such as regulatory approvals, and are not considered probable of being achieved
until those approvals are received. Accordingly, we have fully constrained the $26.5 million of event-based milestone payments until
such time that it is probable that a significant cumulative revenue reversal would not occur. The sales-based milestone payments and
other royalty-based payments are based on a level of sales for which the license is deemed to be the predominant item to which the royalties
relate. We will recognize revenue for these payments at the later of (i) when the related sales occur, or (ii) when the performance obligation
to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any
sales-based or royalty revenue resulting from this licensing arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this arrangement, we recognized nil and $3.5 million of revenue during the years ended December 31, 2024 and 2023, respectively, which
amount related solely to variable consideration. As of December 31, 2024 and 2023, we do not have any contract assets or contract liabilities
as a result of this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accrued
Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. This process
involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed
on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been
invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed
on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our
accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us
at that time. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a
prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level
of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate,
we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from
amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date,
we have not made any material adjustments to our prior estimates of accrued expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share-Based
Compensation Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for share-based compensation expense in accordance with ASC 718, <i>Stock Based Compensation</i>. We have share-based compensation
plans under which incentive and qualified stock options and restricted shares may be granted to employees, directors, and consultants.
We measure the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the
fair value for employees and directors and vesting date fair value of the award for consultants. We use the Black-Scholes option pricing
model to determine the fair value of options as of the grant date and the Hull White I lattice model as of any option repricing dates.
The model used to determine the fair value of options includes assumptions for expected volatility, risk-free interest rate, dividend
yield and estimated expected term. Expected volatility is estimated considering the Company&#8217;s own historical volatility. The risk-free
interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend
yield is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock. Expected
term is estimated using the &#8220;simplified&#8221; method, as outlined in SEC Staff Accounting Bulletin No. 107, &#8220;Share-Based
Payment.&#8221; We use the closing price of our common stock as quoted on Nasdaq to determine the fair value of restricted stock. We
account for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures
arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option-based compensation expense recognized for the years ended December 31, 2024 and 2023 was $1.1 million and $1.4 million, respectively.
Restricted stock-based compensation expense recognized for the years ended December 31, 2024 and 2023 was $5.6 million and $3.4 million,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued warrants associated with capital raises from time to time. We determine the accounting and value of any issued warrants in
accordance with ASC 480<i>, Distinguishing Liabilities from Equity</i> and ASC 815, <i>Derivatives and Hedging</i>. The first step is
to determine if the warrants are to be classified as either a liability or equity depending on the warrant terms. The second step is
to then determine the value of the warrants. We measure the value of any liability classified warrants on their issuance date based on
their fair value using the Black-Scholes pricing model. The model used to determine the fair value of these warrants utilizes certain
unobservable inputs and this therefore considered a Level 3 fair value measurement. Inputs used in the model include assumptions for
expected volatility, risk-free interest rate, dividend yield and estimated expected term. The liability classified warrants are revalued
on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting
periods recorded in the consolidated statements of operations and comprehensive loss. Certain inputs used in this Black-Scholes pricing
model may fluctuate in future periods based upon factors that are outside of our control, including a potential change in control. A
significant change in one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair
value of our warrant liabilities, which could also result in material non-cash gains or losses being reported in the Company&#8217;s
statement of operations. In addition, the inputs we utilized to value our warrant liabilities are highly subjective. The assumptions
used in calculating the fair value of our warrant liabilities represent our best estimates, but these estimates involve inherent uncertainties
and the application of management judgment. As a result, if factors change and we use different assumptions, the fair value of the warrant
liabilities may be materially different in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of warrant liability recognized for the year ended December 31, 2024 and 2023 resulted in a loss of $0.8 million
and $11.7 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_001"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_002"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
statements required by this Item are incorporated in this Annual Report on Form 10-K starting on page F-1 hereto. Reference is made to
Item 15 of this Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_003"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_004"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness
of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Securities Exchange Act of 1934, as
amended (the &#8220;Exchange Act&#8221;)), as of the end of the period covered by this Annual Report on Form 10-K. Based on such evaluation,
our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures
were effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under
the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other
personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations
    of our management and directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that
    could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of management, including our principal executive and financial officers, we assessed our internal
control over financial reporting as of December 31, 2024, based on criteria for effective internal control over financial reporting established
in Internal Control &#8212; Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO). Our management&#8217;s assessment of the effectiveness of our internal control over financial reporting included testing and
evaluating the design and operating effectiveness of our internal controls. In our management&#8217;s opinion, we have maintained effective
internal control over financial reporting as of December 31, 2024, based on criteria established in the COSO 2013 framework.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are a non-accelerated filer and smaller reporting company, Deloitte &amp; Touche LLP, our independent registered public accounting
firm, is not required to attest to or issue a report on the effectiveness of our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inherent
Limitations of Internal Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and
procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations
in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any,
within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty,
and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts
of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also
is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed
in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in
conditions, or the degree of compliance with the policies or procedures may deteriorate. Projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements
due to error or fraud may occur and not be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated
under the Exchange Act, during the fourth quarter of 2024 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_005"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal quarter ended December 31, 2024, the following officers, as defined in Rule 16a-1(f) under the Exchange Act, as amended, adopted
a &#8220;Rule 10b5-1 trading arrangement&#8221; as defined in Regulation S-K Item 408, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            <span id="xdx_903_eecd--TrdArrAdoptionDate_c20241001__20241231__ecd--IndividualAxis__custom--DonWuchterlMember_zpTN4rsqvjA2" title="Adoption Date" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember" id="Fact000067" name="ecd:TrdArrAdoptionDate">November 23, 2024</ix:nonNumeric></span>, <span id="xdx_904_eecd--TrdArrIndName_c20241001__20241231__ecd--IndividualAxis__custom--DonWuchterlMember_zZwi7s43yxH5" title="Name" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember" id="Fact000069" name="ecd:TrdArrIndName">Don Wuchterl</ix:nonNumeric></span>, a <span id="xdx_90E_eecd--TrdArrIndTitle_c20241001__20241231__ecd--IndividualAxis__custom--DonWuchterlMember_zYMXzLXETdU9" title="Title" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember" id="Fact000071" name="ecd:TrdArrIndTitle">member</ix:nonNumeric></span> of the Company&#8217;s board of directors, <span id="xdx_900_eecd--Rule10b51ArrAdoptedFlag_dbT_c20241001__20241231__ecd--IndividualAxis__custom--DonWuchterlMember_zroE5COmaxh2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_905_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20241001__20241231__ecd--IndividualAxis__custom--DonWuchterlMember_zJGWQks7TYN2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember" format="ixt:booleantrue" id="Fact000072" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember" format="ixt:booleantrue" id="Fact000073" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>
                                            a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate
                                            of up to 40,176 shares of our common stock. The duration of the trading arrangement is until
                                            February 24, 2026, or earlier if all transactions under the trading arrangement are completed.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_006"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_007"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_008"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Reports of Beneficial Ownership</b>. The information required by this Item is incorporated herein by reference from the information
to be contained in our 2025 Proxy Statement to be filed with the SEC within 120 days after December 31, 2024, in connection with the
solicitation of proxies for our 2025 Annual Meeting of Stockholders (the &#8220;2025 Proxy Statement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b>. We have adopted a Code of Business Conduct and Ethics (the &#8220;Code&#8221;) that applies to all of our employees (including
executive officers) and directors. The Code is available on our website at <span style="text-decoration: underline">www.abeonatherapeutics.com</span> under the heading &#8220;Investors
&amp; Media&#8212;Corporate Governance&#8212;Governance&#8212;Governance Documents.&#8221; We intend to satisfy the disclosure requirement
regarding any waiver of a provision of the Code applicable to any executive officer or director, by posting such information on such
website. We shall provide to any person without charge, upon request, a copy of the Code. Any such request must be made in writing to
Abeona Therapeutics Inc., c/o Investor Relations, 6555 Carnegie Ave, 4th Floor, Cleveland, OH 44103.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate governance guidelines and the charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance
Committee of the Board of Directors are available on our website at <span style="text-decoration: underline">www.abeonatherapeutics.com</span> under the heading &#8220;Investors
&amp; Media&#8212;Corporate Governance&#8212;Governance&#8212;Governance Documents.&#8221; We shall provide to any person without charge,
upon request, a copy of any of the foregoing materials. Any such request must be made in writing to Abeona Therapeutics Inc., c/o Investor
Relations, 6555 Carnegie Ave, 4th Floor, Cleveland, OH 44103.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_009"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is contained in the 2025 Proxy Statement and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_010"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is contained in the 2025 Proxy Statement and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_011"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is contained in the 2025 Proxy Statement and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_012"></span>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is contained in the 2025 Proxy Statement and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_013"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_014"></span>ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements.</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following financial statements are submitted as part of this report:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_017">Report of Independent Registered Public Accounting Firm</a> (PCAOB 0<span id="xdx_90D_edei--AuditorFirmId_c20240101__20241231_zkWRwkLcVW1f"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000074" name="dei:AuditorFirmId">34</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_018">Consolidated Balance Sheets at December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_019">Consolidated Statements of Operations and Comprehensive Loss for 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_020">Consolidated Statements of Stockholders&#8217; Equity for 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_021">Consolidated Statements of Cash Flows for 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_022">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exhibits</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Exhibit
Index</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits:</span></td>
    <td style="padding-bottom: 1pt; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000114420419025271/tv520699_ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restated Certificate of Incorporation of Abeona Therapeutics Inc. (incorporated by reference to Exhibit 3.1 of our Form 10-Q for the quarter ended March 31, 2019)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222018257/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Restated Certificate of Incorporation of Abeona Therapeutics Inc. (incorporated by reference to Exhibit 3.1 of our Form 8-K filed on June 30, 2022)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315224026640/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of Abeona Therapeutics Inc. (incorporated by reference to Exhibit 3.1 of our Form 8-K filed on July 9, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222011829/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Redeemable Preferred Stock (incorporated by reference to Exhibit 3.1 of our Form 8-K filed on May 2, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222011829/ex3-2.htm" style="-sec-extract: exhibit">Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Redeemable Preferred Stock (incorporated by reference to Exhibit 3.2 of our Form 8-K filed on May 2, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000114420415029230/v410265_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015 Equity Incentive Plan (incorporated by reference to Exhibit 4.1 to our Form S-8 filed May 11, 2015)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000114420416093059/v435577_def14a.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015 Equity Incentive Plan Amendment (incorporated by reference to our Definitive Proxy Statement on Schedule 14A filed on April 4, 2016)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315220004015/ex4-4.htm" style="-sec-extract: exhibit">Description of Capital Stock of Abeona Therapeutics Inc. (incorporated by reference to Exhibit 4.4 of our Form 10-K for the year ended December 31, 2019)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of our Form 8-K filed on May 3, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant to Purchase Common Stock, by and between Abeona Therapeutics, Inc. and Avenue Venture Opportunities Fund, L.P., dated as of January 8, 2024 (incorporated by reference to Exhibit 4.1 of our Form 8-K filed on January 8, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant to Purchase Common Stock, by and between Abeona Therapeutics, Inc. and Avenue Venture Opportunities Fund II, L.P., dated as of January 8, 2024 (incorporated by reference to Exhibit 4.2 of our Form 8-K filed on January 8, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000031830600000003/0000318306-00-000003.txt" style="-sec-extract: exhibit">401(k) Plan (incorporated by reference to Exhibit 10.20 of our Form 10-K for the year ended December 31, 1999)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000031830605000006/d05-def14a2.txt" style="-sec-extract: exhibit">2005 Equity Incentive Plan (incorporated by reference to Exhibit 1 of our Proxy Statement filed on April 18, 2005)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000114036108006400/ex10-26.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Designation Agreement dated November 15, 2007, between the Company and SCO Capital Partners LLC (incorporated by reference to Exhibit 10.26 of our Form S-1 filed on March 11, 2008)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000114420415049282/v418191_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger, dated May 5, 2015, by and among the Company, PlasmaTech Merger Sub Inc., Abeona Therapeutics LLC and Paul A. Hawkins, in his capacity as Member Representative (incorporated by reference to Exhibit 10.1 to our Form 10-Q for the quarter ended June 30, 2015)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315220019566/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement, between the Company and directors and officers of the Company (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on October 16, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222008259/ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, dated October 6, 2021, between the Company and Vishwas Seshadri (incorporated by reference to Exhibit 10.6 of our Form 10-K for the year ended December 31, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222008259/ex10-11.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, dated September 16, 2021, between the Company and Brendan O&#8217;Malley (incorporated by reference to Exhibit 10.11 of our Form 10-K for the year ended December 31, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222013174/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, dated February 28, 2022, between the Company and Joseph Vazzano (incorporated by reference to Exhibit 10.1 of our Form 10-Q for the quarter ended March 31, 2022)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000114420418045421/tv500697_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Open Market Sale Agreement, dated August 17, 2018, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 of Form 8-K filed on August 20, 2018)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315221029401/ex1-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Open Market Sale Agreement, dated November 19, 2021, amending the Open Market Agreement, by and between the Company and Jefferies LLC, dated August 17, 2018 (incorporated by reference to Exhibit 1.2 of Form 8-K filed on November 19, 2021)</span></a></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11+</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222008259/ex10-14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement Agreement and Mutual Release, dated November 12, 2021, between the Company and REGENXBIO Inc. (incorporated by reference to Exhibit 10.14 of our Form 10-K for the year ended December 31, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222011829/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement between Abeona Therapeutics Inc. and the investors thereto, dated April 29, 2022 (incorporated by reference to Exhibit 10.1 of our Form 8-K filed on May 2, 2022)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222011829/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement by and among Abeona Therapeutics Inc. and the investors named therein, dated April 29, 2022 (incorporated by reference to Exhibit 10.2 of our Form 8-K filed on May 2, 2022)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14+</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315222021969/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement by and between Abeona Therapeutics Inc. and Ultragenyx Pharmaceutical Inc., dated May 16, 2022 (incorporated by reference to Exhibit 10.3 of our Form 10-Q for the quarter ended June 30, 2022)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315223027104/ex10-3.htm" style="-sec-extract: exhibit">Retention Bonus Letter, dated June 15, 2023, to Vishwas Seschadri, Ph.D. (incorporated by reference to Exhibit 10.5 of our Form 10-Q for the quarter ended June 30, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315223027104/ex10-4.htm" style="-sec-extract: exhibit">Retention Bonus Letter, dated June 15, 2023, to Joseph Vazzano, Ph.D. (incorporated by reference to Exhibit 10.5 of our Form 10-Q for the quarter ended June 30, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315223027104/ex10-5.htm" style="-sec-extract: exhibit">Retention Bonus Letter, dated June 15, 2023, to Brendan O&#8217;Malley, Ph.D. (incorporated by reference to Exhibit 10.5 of our Form 10-Q for the quarter ended June 30, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315223023235/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated July 3, 2023 (incorporated by reference to Exhibit 10.1 of our Form 8-K filed on July 3, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan and Security Agreement, by and among Abeona Therapeutics, Inc., MacroChem Corporation, Abeona Therapeutics LLC, Avenue Venture Opportunities Fund, L.P., as Agent, and Avenue Venture Opportunities Fund II, L.P., dated as of January 8, 2024 (incorporated by reference to Exhibit 10.1 of our Form 8-K filed on January 8, 2024</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplement to the Loan and Security Agreement, by and among Abeona Therapeutics, Inc., MacroChem Corporation, Abeona Therapeutics LLC, Avenue Venture Opportunities Fund, L.P., as Agent, and Avenue Venture Opportunities Fund II, L.P., dated as of January 8, 2024 (incorporated by reference to Exhibit 10.2 of our Form 8-K filed on January 8, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.21</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/ex1-1.htm" style="-sec-extract: exhibit">Underwriting Agreement, dated May 3, 2024 (incorporated by reference to Exhibit 1.1 of our Form 8-K filed on May 3, 2024)</a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/318306/000149315223037561/ex16-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter from Whitley Penn addressed to the United States Securities and Exchange Commission, dated October 17, 2023 (incorporated by reference to Exhibit 16.1 of our Form 8-K filed on October 18, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex19.htm">Policy on Insider Trading and Confidentiality</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21.htm">Subsidiaries of the registrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Deloitte &amp; Touche LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Principal Executive Officer Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Principal Financial Officer Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32.htm">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex97.htm">Policy Relating to Recovery of Erroneously Awarded Compensation</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Management contract or compensatory plan required to be filed as an exhibit to this report pursuant to Item 15(a)(3) of Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_015"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="me_016"></span>SIGNATURES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABEONA
    THERAPEUTICS INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Vishwas Seshadri </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishwas
    Seshadri</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Vishwas Seshadri </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishwas
    Seshadri</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Vazzano</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Vazzano</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Leila Alland</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leila
    Alland, Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Mark J. Alvino</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    J. Alvino, Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Amoroso</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Amoroso, Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Faith L. Charles</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Faith
    L. Charles, Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eric Crombez, MD</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Crombez, MD, Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christine Silverstein</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christine
    Silverstein, Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Donald A. Wuchterl</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
    A. Wuchterl, Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bernhardt G. Zeiher, MD, FCCP, FACP</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernhardt
    G. Zeiher, MD, FCCP, FACP, Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_017"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the stockholders and the Board of Directors of Abeona Therapeutics Inc</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Abeona Therapeutics Inc (the &#8220;Company&#8221;) as of December 31,
2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each
of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the
&#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of
the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United
States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Loan
and Security Agreement and Common Stock Warrants &#8212; Refer to Notes 9 and 10 to the financial statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical
Audit Matter Description</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As more fully described in Notes 9 and 10 to the financial statements, on January 8, 2024, the Company entered into a Loan and Security
Agreement, as supplemented by a Supplement, with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.
The Loan Agreement provides for senior secured term loans in an aggregate principal amount up to $50 million. Pursuant to the Supplement
to the Loan and Security Agreement, Avenue also has the right to convert up to $3 million of the outstanding principal of the Loans into
shares of Company common stock (the &#8220;Conversion Right&#8221;) at a price per share equal to 120% of the exercise price of the Warrants
at any time while the Loans are outstanding, subject to certain terms and conditions, including ownership limitations. On January 8, 2024,
in connection with entering into the Loan and Security Agreement, the Company issued to each of Avenue and Avenue II warrants to purchase
up to $480,000 and $1,920,000 worth of shares, respectively, of Company common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the assessment of the accounting for the Loan and Security Agreement and related Common Stock Warrants as a critical
audit matter because of the complexity in applying the accounting framework and the significant judgments made by management in the
determination of the existence of embedded derivative liabilities and classification of the Common Stock Warrants related to the
Loan and Security Agreement. Auditing these conclusions required a high
degree of auditor judgment and an increased extent of effort.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
the Critical Audit Matter Was Addressed in the Audit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Our audit procedures related to accounting for the Loan and Security Agreement and Common Stock Warrants included the following, among
others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We obtained and read the agreements associated with the Loan and Security Agreements, including the related Common Stock Warrant agreement,
and tested the accuracy and completeness of the significant terms identified by management for purposes identifying embedded derivative
liabilities and classification of the common stock warrants.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">With the assistance of professionals in our firm having expertise in the accounting treatment for debt and equity instruments, including
warrants, we evaluated the Company&#8217;s conclusions regarding the accounting treatment applied to the Loan and Security Agreement and
Common Stock Warrants, including the identification and recognition of embedded derivatives, initial classification of embedded derivatives
as a liability, and classification of Common Stock Warrants as a liability. We also evaluated the Company&#8217;s subsequent reclassification
of the derivative liability associated with the Conversion Right to equity on September 30, 2024 as it was considered indexed to the Company&#8217;s
own stock.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluated the completeness and accuracy of the disclosures related to the Loan and Security Agreement and Common Stock Warrants.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_904_edei--AuditorName_c20240101__20241231_zNhPsWEYNPs"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000075" name="dei:AuditorName">Deloitte &amp; Touche LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--AuditorLocation_c20240101__20241231_zKKxqb5p5Rm5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000076" name="dei:AuditorLocation">Morristown,
New Jersey</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
19, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_018"></span>ABEONA
THERAPEUTICS INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except share and per share amounts)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Consolidated Balance Sheets" id="xdx_300_111_pn3n3_zG9SYVmmcvO4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zIzYYu1qsMhc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_z1HTDSu8Kk8h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zmzAbrdMedj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrentAbstract_i01B_zYl2QmlHSuP3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzG9x_zlMNrAJdj4nb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,357</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,473</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShortTermInvestments_i02I_maCzG9x_zFOsnbKqxqxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74,363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,753</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RestrictedCash_i02I_maCzG9x_zjSRiEBZCee4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherReceivablesNetCurrent_i02I_maCzG9x_zGWqGwSsef4i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,652</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,444</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzG9x_zfRy2V4iY8md" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,143</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">729</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrent_i02TI_mtCzG9x_maCzwZM_zN66W3aNJB87" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,853</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzwZM_zhDvh52BUCpg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,430</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzwZM_z1YGOwJTYYk7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsNoncurrent_i01I_maCzwZM_zxhVQBRwIKHf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">277</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_i01TI_mtCzwZM_zdHU6XxspKhl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108,931</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,002</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zp8tgpSm2ZQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_z5KFCwvJ9MAc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_i02I_maCzILP_zqDVuut5UFoi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzILP_zDgK4k9UnThj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,985</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_i02I_maCzILP_zNjwL4AIXR6l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current portion of long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2024-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,926</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0127">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzILP_zp65O7yLXSB2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current portion of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherLoansPayableCurrent_i02I_maCzILP_zDkc6VUyzB68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current portion payable to licensor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0132">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLoansPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,580</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzILP_zmex01m1DsRg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_mtCzILP_maCzCew_zPnZFvHtjRpb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,587</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzCew_z29u5WA0LXuj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,262</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtNoncurrent_i01I_maCzCew_zoBowhlnhGKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,037</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WarrantLiabilities_i01I_maCzCew_zJBNT4ZqSy3h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ABEO:WarrantLiabilities" contextRef="AsOf2024-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,014</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ABEO:WarrantLiabilities" contextRef="AsOf2023-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,352</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_i01TI_mtCzCew_maLASEzxj2_z9AtipMAGvWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzxj2_zp7BOro9S9W8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0153">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0154">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_i01B_zjVao8eWsJ7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_maSEzxt8_zM8V0UWndN37" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred stock - $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zz4gIrVlzAL2" title="Preferred stock, par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zK5NsCS8RCAe" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; authorized <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zquBBq4FSAd2" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zyc5drtSlhV1" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20241231_zXkU0WyaRbBj" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_zZorlvPLagCj" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20231231_zLaiaQXXuIr3" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zCiOjCECQwHg" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000172" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000174" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000176" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0159">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0160">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maSEzxt8_z7ncLl1czwN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock - $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zjqdC84R1zJb" title="Common stock, par value"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zpoMMQ5x5SVa" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; authorized <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zMZYmGotsw2" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zVXrLJPvdZd4" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zr4FuTNeG3z" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zfaYSf6vSWrl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,644,091</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_z2LrGVm3bMml" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_z116TyeoXI1g" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,523,878</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdditionalPaidInCapital_i02I_maSEzxt8_zt22JEB7Z5w5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">856,824</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">764,151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzxt8_zWn7xFGK00v" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">813,258</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">749,524</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzxt8_z3hk0JimkbSi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_i02TI_mtSEzxt8_maLASEzxj2_zRiSGzZZoz99" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,031</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,826</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzxj2_zu1OFAtc9gOd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108,931</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,002</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_019"></span>ABEONA
THERAPEUTICS INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Operations and Comprehensive Loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except share and per share amounts)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" id="xdx_307_113_pn3n3_zn0CXNfBUFfk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231_zhzkO62AVzk7" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_zDPLOSUdWQw7" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">For the years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerAbstract_iB_zw4NoDRW8z0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_maCzFKN_z5uBs1MrKGv7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">License and other revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0215">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_zVcr8wy2iwd4" style="vertical-align: bottom; background-color: White">
    <td>Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RoyaltyExpense_i01_maCzux2_zbfxk9cZfqBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0221">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2023-01-012023-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,605</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzux2_z6BqLaQ6ngn6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,091</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzux2_zk6pxllqdkY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,851</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainLossOnRightofuseLeaseAssets_i01N_di_msCzux2_zn0bfKaHbrI8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Gain on operating lease right-of-use assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ABEO:GainLossOnRightofuseLeaseAssets" contextRef="From2023-01-012023-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,065</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpenses_i01T_mtCzux2_msCzFKN_zs1e58BtbgJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left">Total expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,635</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iT_mtCzFKN_maCzpUJ_zJG7hKh2pEM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">64,211</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,135</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestIncomeOperating_maCzpUJ_z3eVUYR6EPV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2024-01-01to2024-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,246</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2023-01-012023-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpense_iN_di_msCzpUJ_zGANCtVSGrv7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,208</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_msCzpUJ_zdckzXgkSM2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant and derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">755</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,695</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_maCzpUJ_zn6QDmGDXUsj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,943</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_iT_maCINOTzP5Y_mtCzpUJ_zD4iNnmSZH76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">63,734</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Basic and diluted loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_ztglue1Uoayb" title="Basic loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zOHUDVcAq0u9" title="Dilutive loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.55</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zgmIbUGzXcci" title="Basic loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zV7xgBPloycb" title="Dilutive loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.53</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Weighted average number of common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_zEozETlzAjJe" title="Weighted average number of common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_za8zIplHjxj4" title="Weighted average number of common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,048,206</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zXnPgByKnmB5" title="Weighted average number of common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zHtLW9EQRpYd" title="Weighted average number of common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,380,476</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB_zrqT3FREQhyi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive income (loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_i01_maCINOTzP5Y_zheNQq4qkQPi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in unrealized gains related to available-for-sale debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000273" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maCINOTzP5Y_zv8SOjMVo9jh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCINOTzP5Y_zhZAU9Dy4px8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">63,660</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,125</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_020"></span>ABEONA
THERAPEUTICS INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except share amounts)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_pn3n3_zALDOXQGlCI1" summary="xdx: Statement - Consolidated Statements of Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zsj5pmnypczl">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zAO0caLZR5kh">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_ztkD6v3xR4Yk">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zHxXZsh6cGx8" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B8_ze2VEP8RpTGg">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Paid-in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Comprehensive</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43B_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zXJ62oYOn493" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNTpnDag3Du8" title="Balance, shares" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000288" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,719,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">177</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000283" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">722,049</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000284" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">695,336</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">129</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,761</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zCi18uKel05j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,768</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zJRdxnbTYAKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmULYH0pEU81" title="Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,859,869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">200</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">182</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zdXZIu1aSxFa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock, net of offering costs under open market sale agreement (ATM)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpmGgofB5u5i" title="Issuance of common stock, net of offering costs under open market sale agreement (ATM), shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,659,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,623</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering_z4D6yPgfXk0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock, net of offering costs under direct placement offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zepOcBaHH3jh" title="Issuance of common stock, net of offering costs under direct placement offering, shares" style="text-align: right"><ix:nonFraction name="ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,284,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,948</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" contextRef="From2023-01-012023-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,981</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_z4DJAWses1Qj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000322" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,188</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,188</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zG6butcO0y47" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other comprehensive income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000329" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zqowAJQMupfe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQWVL57msjlb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,523,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">764,151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000334" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">749,524</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,826</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20240101__20241231_eus-gaap--StockholdersEquity_iS_z2ToUkOmodi5" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPYMx12oK2E8" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,523,878</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">265</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">764,151</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000342" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">749,524</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000343" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,826</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zZ6ghCHE5lz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,628</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-12-31" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,628</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zJi6iJ81aVAk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zasodOKjUU36" title="Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,780,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000355" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">545</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-01to2024-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">526</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zgvr4HqSxNJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock, net of offering costs under open market sale agreement (ATM)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwkeUCGPMVAa" title="Issuance of common stock, net of offering costs under open market sale agreement (ATM), shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,825,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000366" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IssuanceOfCommonStockInConnectionWithPublicOffering_zbXwvXggRx27" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock in connection with public offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--IssuanceOfCommonStockSharesInConnectionWithPublicOffering_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt30t83euojk" title="Issuance of common stock in connection with public offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="ABEO:IssuanceOfCommonStockSharesInConnectionWithPublicOffering" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000376" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,285,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering" contextRef="From2024-01-01to2024-12-31" id="Fact000374" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,153</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_ziZ2rRkkoKYi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock upon exercise of pre-funded warrants, net of shares settled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9c0ow63LnT" title="Issuance of common stock upon exercise of pre-funded warrants, net of shares settled, shares" style="text-align: right"><ix:nonFraction name="ABEO:StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000384" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,228,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000379" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zszl7yIENmMl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Reclassification of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000387" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-01to2024-12-31" id="Fact000390" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zAJcjd6aCdQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000394" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">63,734</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">63,734</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_ztDTioLd6ez3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other comprehensive income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zybcsVmZF2j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFbp1s8diJg6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000410" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,644,091</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">856,824</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">813,258</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000407" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,031</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zrwEJWb4wRIl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2YMCk3zcMo2" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,644,091</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000413" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">856,824</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000414" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">813,258</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,031</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_021"></span>ABEONA
THERAPEUTICS INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Consolidated Statements of Cash Flows" id="xdx_301_112_pn3n3_zQlU9g8gEt5j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_znFKOmjjiVGk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20230101__20231231_z7qXl5l6h3K6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_ztQU984UEss5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_maCzODz_zzMw7qxKZKbk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">63,734</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,188</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zC2Vv7F2VdSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzODz_zW0FRB8MFKQ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maCzODz_zxRyOC3INmf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,628</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i02_maCzODz_zM3z7JSrootf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant and derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">755</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GainLossOfRightofuseLeaseAssets_i02N_di_msCzODz_zUBcBObJl2Z1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ABEO:GainLossOfRightofuseLeaseAssets" contextRef="From2023-01-012023-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,065</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--AccretionAmortizationOfDiscountsAndPremiumsInvestments_i02N_di_msCzODz_zWAbBcWrEzFj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accretion and interest on short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="From2023-01-012023-12-31" id="Fact000442" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maCzODz_zyYIN5ZEGjXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of right-of-use lease assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-01-012023-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NoncashContributionExpense_i02_maCzODz_zN6hAf2bOJeb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NoncashContributionExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NoncashContributionExpense" contextRef="From2023-01-012023-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">417</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_di_msCzODz_zs3Kl92oCJd3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">(Gain) loss on disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000450" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-012023-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zOOCpFeoVNv6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOtherReceivables_i03N_di_msCzODz_zyg61Jw6Rp3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2024-01-01to2024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">792</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2023-01-012023-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,041</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzODz_zf8l1NXxjZNl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">564</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOtherNoncurrentAssets_i03N_di_msCzODz_ztidahGYu3yc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="From2023-01-012023-12-31" id="Fact000463" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maCzODz_z8B7C7rPWQh4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maCzODz_zTqAgxGEOohd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,315</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,196</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInDueToRelatedParties_i03_maCzODz_zcdQarSn7r68" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Change in payable to licensor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2024-01-01to2024-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_maCzODz_zhh2ugtXSmJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">203</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzODz_maCzcFT_zqKSsG7XQOK5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 40pt; text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">56,015</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">37,009</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zGXOwjC8h3m6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzmWv_z3ifjiReIm01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,446</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000484" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">331</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maCzmWv_zvvSCcQSXXal" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquireShortTermInvestments_i01N_di_msCzmWv_zzUSfkLDOBBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchases of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">157,010</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="From2023-01-012023-12-31" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,636</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_i01_maCzmWv_zitGlUzoSjc5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from maturities of short-term investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="From2023-01-012023-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,971</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzmWv_maCzcFT_zT9MjK5PMEob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 40pt; text-align: left">Net cash (used in) provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39,240</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000496" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zrPTbSI7mz5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzbhe_zjbT1V8qdy6g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from ATM sales of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,475</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,408</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maCzbhe_z6tfzDQK57Ja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sales of common stock under direct placement offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-01-012023-12-31" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,981</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ProceedsFromRepaymentSettlementOfRestrictedShareAwards_i01_maCzbhe_z0W62RVnb6j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payments related to net settlement of restricted share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ABEO:ProceedsFromRepaymentSettlementOfRestrictedShareAwards" contextRef="From2024-01-01to2024-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">526</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ABEO:ProceedsFromRepaymentSettlementOfRestrictedShareAwards" contextRef="From2023-01-012023-12-31" id="Fact000508" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">182</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts_i01_maCzbhe_z8iAMRS6Zyag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sales of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_i01_maCzbhe_ztD0lv8jsbmh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msCzbhe_zRsJx63gjoqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payment of debt issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">963</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzbhe_maCzcFT_zBrD0tk2d7Jd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 40pt; text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">104,139</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000520" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,057</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzcFT_z0n8LpMuYdbg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,884</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000523" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">256</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zXlDLcEvbN16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cash, cash equivalents and restricted cash at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,811</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000526" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zFmnkhro5j3j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,695</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000529" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,811</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zOCS2FKXh6r3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01E_zbYaKjc89qC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCashAndCashEquivalents_i01E_zqEVIaXcfw5i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_zVrlT3Gajn4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,695</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,811</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zS723zmD6nee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental non-cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_zN2HJbtJEJvf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use asset obtained in exchange for new operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement_i01_zDXspxq15mO6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Derivative and warrant additions associated with loan and security agreement</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ABEO:DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" contextRef="From2024-01-01to2024-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,042</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ReclassificationOfDerivativeLiabilityToEquity_i01_zUBpDyFr2URi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Reclassification of derivative liability to equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ABEO:ReclassificationOfDerivativeLiabilityToEquity" contextRef="From2024-01-01to2024-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,135</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CapitalExpendituresIncurredButNotYetPaid_i01_zmWQ5WUqWqU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Changes in accrued property and equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="From2024-01-01to2024-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">471</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPaidNet_i01_zwqDnm7sMNhj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,670</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_zP3RUaD1gWpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000562" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_022"></span>ABEONA
THERAPEUTICS INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000564" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zUrjk3OEqezc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_828_zoWHYO4E0r3h">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. (together with the Company&#8217;s subsidiaries, &#8220;Abeona&#8221; or the &#8220;Company&#8221;), a Delaware corporation,
is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. The Company&#8217;s lead
clinical program is for pz-cel, an autologous, cell-based gene therapy currently in development for recessive dystrophic epidermolysis
bullosa (&#8220;RDEB&#8221;). The Company&#8217;s development portfolio also features adeno-associated virus (&#8220;AAV&#8221;)-based
gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM&#8482; capsids that the Company has exclusively
licensed from the University of North Carolina at Chapel Hill and developed internally through its AAV vector research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, <i>Going Concern</i>, the Company has evaluated whether
there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date the accompanying consolidated financial statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a biopharmaceutical organization, the Company has devoted substantially all of its resources since inception to research and development
activities for pz-cel and other product candidates, business planning, raising capital, establishing its intellectual property portfolio,
acquiring or discovering product candidates, and providing general and administrative support for these operations. As a result, the
Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses
and negative cash flows will continue for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its inception, the Company has funded its operations primarily with proceeds from sales of shares of its stock. The Company has incurred
recurring losses since its inception, including net losses of $<span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_pn5n6_di_c20240101__20241231_zYnOSQex5FYa" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">63.7</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_pn5n6_di_c20230101__20231231_zRf0cdkw4Y0a" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000568" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">54.2</ix:nonFraction></span> million for the years ended December 31, 2024 and
2023, respectively. As of December 31, 2024, the Company had an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zbTiRKSAkb6g" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">813.3</ix:nonFraction></span> million. To date, the Company has not generated
any significant revenues and expects to continue to generate operating losses for the foreseeable future. As of the issuance date of
these consolidated financial statements, the Company expects that its existing cash, cash equivalents, restricted cash and short-term
investments of $<span id="xdx_90C_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20241231_z0quEixtTTUf" title="Cash, cash equivalents, restricted cash and short-term investments"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000572" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">98.1</ix:nonFraction></span> million as of December 31, 2024, in addition to the $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240101__20241231_zDInrsE969Qg"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-01to2024-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million in net proceeds from the Company&#8217;s subsequent
sale of common stock under the ATM Agreement, will be sufficient to fund its operating expenses and capital expenditure requirements
for at least the next 12 months from the issuance date of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes its capital resources are sufficient to fund the Company&#8217;s on-going operations for the next 12 months from
the issuance date of these consolidated financial statements, the Company&#8217;s liquidity could be materially affected over this period
by: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding;
(2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events
or unanticipated costs related to pz-cel; (4) any other unanticipated material negative events or costs. One or more of these events
or costs could materially affect the Company&#8217;s liquidity. If the Company is unable to meet its obligations when they become due,
the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to
its operating plan. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000575" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zR5OhxzNNCQ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_828_zdaTPeDcLxib">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000577" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhb68uFtp0X4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zwwaF8VVP8qh">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and the Company&#8217;s wholly-owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000579" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zEWGU3YCyry" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zwmC79jj3cqc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of
America (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amount of assets and
disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue
and expenses during the reported period. The Company&#8217;s significant estimates include, but are not limited to, fair value of warrant
and derivative liabilities, the incremental borrowing rate related to the Company&#8217;s operating leases and stock-based compensation.
Due to the uncertainty inherent in such estimates, actual results could differ from these estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000581" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeRlmtmAHMCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zjvDL2Gawxqa">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company
maintains deposits primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses related to amounts in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000583" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zQKeiPUgGIH7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zue9oDqMmvnk">Restricted
Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash serves as collateral for leased office space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000585" name="us-gaap:EquityMethodInvestmentsPolicy"><p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zDPax6UfLVp7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zq2DsxgbxVYf">Short-term
Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
investments consist of investments in U.S. treasury securities, U.S. federal agency securities and certificates of deposit. The Company
determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications
at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to Accounting Standards
Codification (&#8220;ASC&#8221;) 320, <i>Investments &#8211; Debt and Equity Securities</i>. Investments classified as current have maturities
of less than one year. The Company reviews its short-term investments for other-than-temporary impairment whenever the fair value of
a marketable security is less than the amortized cost and evidence indicates that a short-term investment&#8217;s carrying amount is
not recoverable within a reasonable period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000587" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zN8OoRi4Xeq1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zYY5txwNVgY7">Other
Receivables</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
receivables include employee retention credits (&#8220;ERC&#8221;), sublease rent receivables and other miscellaneous receivables that
are expected to be collected within the next twelve months. As of December 31, 2024 and 2023, the Company had ERC receivables of $<span id="xdx_905_eus-gaap--OtherReceivables_iI_pn5n6_c20241231_zwUUmza4kJLe" title="Other receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span>
million and $<span id="xdx_906_eus-gaap--OtherReceivables_iI_pn5n6_c20231231_zULDFuyN0IGi" title="Other receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-12-31" id="Fact000591" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million, respectively which was recorded in other receivables and as a component of other income in the consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000593" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt3fea5spP2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zObdGPOOnok">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from
three to five years. Leasehold improvements are amortized over the shorter of the asset&#8217;s useful life or the life of the lease
term ranging from five to ten years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures
for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation
are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of
the respective period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000595" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zwbJyEb7mn8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zImOb0v3alFk">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, <i>Leases</i>. Right-of-use lease assets represent the Company&#8217;s right
to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising
from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the
Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available
at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement
of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial
direct costs incurred, as applicable. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over
the lease term. The Company does not have any leases classified as finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive
covenants or contingent rent provisions. The Company&#8217;s leases include both lease (e.g., fixed payments including rent, taxes, and
insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component
as the Company has elected the practical expedient to group lease and non-lease components for all leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
leases include one or more options to renew. The exercise of lease renewal options is typically at the Company&#8217;s sole discretion;
therefore, the majority of renewals to extend the lease terms are not included in the Company&#8217;s right-of-use assets and lease liabilities
as they are not reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain
of exercise, the Company includes the renewal period in its lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000597" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"><p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zKSi7YDFYYl6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zruRFsxsTbni">Licensed
Technology</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into agreements to license the rights to certain technologies. The Company records the purchase price paid for the
license, which represents fair value, on its consolidated balance sheet. Licensed technology is amortized over the life of the patent
or the agreement. The Company maintains licensed technology on its consolidated balance sheet until either the licensed technology agreement
underlying it is completed or the asset becomes impaired. When the Company determines that an asset has become impaired, as discussed
below, or the Company abandons a project, the Company writes down the carrying value of the related intangible asset to its fair value
and recognizes an impairment charge in the period in which the impairment occurs. The Company has fully written off the licensed technology
as of December 31, 2024 and December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000599" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zAZKlmt0JUr4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zrGAQVqoD054">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets consist of property and equipment, licensed technology, and right-of-use assets. The Company tests its long-lived assets for impairment
when events and circumstances indicate that the carrying value of an asset or group of assets may not be fully recoverable. If indicators
are present or changes in circumstance suggest that impairment may exist, the Company assesses the recoverability of the affected long-lived
assets or group of assets by determining whether the carrying value of such assets or group of assets can be recovered through undiscounted
future operating cash flows. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing
the carrying value of the asset or group of assets to its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000601" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock"><p id="xdx_842_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_za4zh3mVui76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z6qyQQmeLqX6">Credit
Losses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its available-for-sale investments for credit losses on a collective basis by major security type and in line with the
Company&#8217;s investment policy. As of December 31, 2024, the Company&#8217;s available-for-sale investments were in securities that
are issued by the U.S. treasury, U.S. federal agencies and certificates of deposits, are highly rated, and have a history of zero credit
losses. The Company reviews the credit quality of its accounts receivables by monitoring the aging of its accounts receivable, the history
of write offs for uncollectible accounts, and the credit quality of its significant customers, the current economic environment/macroeconomic
trends, supportable forecasts, and other relevant factors. The Company&#8217;s accounts receivable are with customers that do not have
a history of uncollectibility nor a history of significantly aged accounts receivables. As of December 31, 2024, the Company did not
recognize a credit loss allowance for its investments or accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000603" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zdbON1eJvcA" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_ziOHC35w8WEf">Segments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines and presents operating segments based on the information that is internally provided to the Company&#8217;s chief
operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, in accordance with ASC 280, <i>Segment Reporting</i>. The
Company has determined that it operates in a single business segment, which is a clinical-stage biopharmaceutical company developing
cell and gene therapies for life-threatening diseases. Refer to Note 16 &#8211; Segment Information for further information related to
the Company&#8217;s segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000605" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgstkCMHlPc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zrTLMG0ABlf2">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for contracts with customers in accordance with ASC 606, <i>Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;).
ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an
entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an
entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a
customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance
obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research,
develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment
to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option
exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance
obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone
selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.
The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in
the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone
selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.
Amounts received prior to revenue recognition are recorded as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exclusive
Licenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred
to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct
from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the
Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt
of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance
obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable
from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment
to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over
time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company
evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may
change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount
of revenue the Company records in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Milestone
Payments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones
are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount
method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included
in the transaction price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone
payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of
being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant cumulative revenue reversal would not occur. At the end of each subsequent reporting
period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue
and earnings in the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Collaborative
Arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success
of such activities and therefore within the scope of ASC 808, <i>Collaborative Arrangements</i> (&#8220;ASC 808&#8221;). This assessment
is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration
arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration
are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship
and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an
appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration
partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements
of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000607" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zltyzeFQFeIe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z6j2XrlRwzw3">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel
expense, lab supplies, preclinical and development cost, clinical trial expense, manufacturing, regulatory, and consulting. The cost
of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses
are capitalized when acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000609" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_848_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zjAqwrMqszEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zw5h4m72fPEb">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses primarily consist of personnel, contract personnel, personnel-related expenses to support the Company&#8217;s
administrative and operating activities, facility costs, professional expenses (i.e., legal, audit, advisory expenses) and commercial
readiness costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000611" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zZug4jDZs1Jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zqr6FBR5Ln9">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain income tax positions in accordance with ASC 740, <i>Income Taxes</i>. Interest costs and penalties related
to income taxes are classified as interest expense and general and administrative costs, respectively, in the consolidated financial
statements. For the years ended December 31, 2024 and 2023, the Company did not recognize any uncertain tax positions, interest or penalty
expense related to income taxes. It is not reasonably likely for the amounts of unrecognized tax benefits to significantly increase or
decrease within the next 12 months. The Company files U.S. federal and state income tax returns as necessary. The federal return generally
has a three-year statute of limitations and most states have a four-year statute of limitations; however, the taxing authorities are
allowed to review the tax year in which the net operating loss was generated when the loss is utilized on a tax return. The Company currently
does not have any open income tax audits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000613" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zatUCAilBHGh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zfYJ7JF0PyTc">Net
Loss Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted-average number of
shares of common stock outstanding during the period. The weighted average number of shares of common stock includes the weighted average
effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price
is $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231_ztgEF9S494tl" title="Unfounded exercise price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> or less per share (Note 10). The Company does not include the potential impact of dilutive securities in diluted net loss
per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding restricted stock, stock
options, conversion features of loan agreements, and stock purchase warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the potential securities that could potentially dilute basic loss per share in the future that were not included
in the computation of diluted net loss per share because to do so would have been anti-dilutive for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000617" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSul6Rq5xdpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zabuy2wRZd61" style="display: none">SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Shares of common stock issuable upon exercise of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zmWm1k1bSY37" title="Shares of common stock issuable upon exercise of stock options"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">176,587</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z96GWyhJCia9" title="Shares of common stock issuable upon exercise of stock options"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,001</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Shares of common stock underlying restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHNOxrGn4DHb" title="Shares of common stock underlying restricted stock"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,320,811</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zBQvJ3d3JXK3" title="Shares of common stock underlying restricted stock"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,448,169</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Shares of common stock issuable upon exercise of conversion feature of loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zrovK2zgkxX3" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">614,251</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zSOzvZv3c1R8" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Shares of common stock issuable upon exercise of warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zttbklb0nqE9" title="Shares of common stock issuable upon exercise of warrants"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,987,560</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmqEepOoFY76" title="Shares of common stock issuable upon exercise of warrants"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,397,879</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zIfMwJ4Xqds7" title="Total"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,099,209</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zgs6K3Hy0yV3" title="Total"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,025,049</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_za32erE5OrRg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2024 as part of the Loan and Security Agreement, see Note 9, the Company issued warrants to purchase $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zeUUkMmdhi28" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-01-31_custom_LoanAndSecurityAgreementMember" id="Fact000639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,400,000</ix:nonFraction></span> worth of shares
of the Company&#8217;s stock which have an exercise price equal to the lesser of (i) $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zoejlqdS0Pld" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-31_custom_LoanAndSecurityAgreementMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.75</ix:nonFraction></span> and (ii) the price per share of the Company&#8217;s
net bona fide round of equity financing before September 30, 2024 (the &#8220;2024 Loan Agreement Warrants&#8221;). In connection with
the underwritten common stock offering consummated on May 7, 2024, pursuant to the terms of the 2024 Loan Agreement Warrants, the exercise
price was reduced to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zsDGYMKom5zk" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementWarrantsMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share and the shares issuable was calculated at <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zMWEeVNWdeR1" title="Shares of common stock issuable upon exercise of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementWarrantsMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,681</ix:nonFraction></span> shares. On September 30, 2024, per the terms of
the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zf2998vCfSC1" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-30_custom_TwentyTwentyFourLoanAgreementWarrantsMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share and <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zuuh8KDxTpAl" title="Shares of common stock issuable upon exercise of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-09-30_custom_TwentyTwentyFourLoanAgreementWarrantsMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,681</ix:nonFraction></span> shares, respectively.
The Company included these shares for the year ended December 31, 2024 as shares of common stock issuable upon exercise of warrants in
the table above and no shares for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000651" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zwfEFjAJz5n1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_ztD0jaU13w4f">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation expense in accordance with ASC 718, <i>Stock Based Compensation</i>. The Company measures
the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date
fair value for the employees and directors and vesting date fair value for consultants of the award. The Company uses the Black-Scholes
option pricing model to determine the fair value of options on the grant date which includes assumptions for expected volatility, risk-free
interest rate, dividend yield and estimated expected term. The Company uses the closing price of its common stock as quoted on the Nasdaq
to determine the fair value of restricted stock. The Company accounts for forfeitures as they occur, which may result in the reversal
of compensation costs in subsequent periods as the forfeitures arise. The Company estimates the expected term using the &#8220;simplified&#8221;
method, as outlined in SEC Staff Accounting Bulletin No. 107, &#8220;Share-Based Payment.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000653" name="ABEO:DerivativeLiabiltyPolicyTextBlock"><p id="xdx_84E_ecustom--DerivativeLiabiltyPolicyTextBlock_z6N5adY9gzV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zYnJzhu0QFWj">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the fair value of the conversion right embedded within the Loan and Security Agreement in accordance with the guidance
in ASC 815, which requires the Company to bifurcate and separately account for the conversion feature as an embedded derivative contained
in the Company&#8217;s Loan and Security Agreement. Accordingly, the Company accounts for the conversion feature as a derivative liability
in the consolidated balance sheet. Derivatives are measured at their fair value on the balance sheet. In determining the appropriate
fair value, the Company uses a Monte Carlo simulation model, which incorporated assumptions and estimates to value the derivatives. The
derivative liability is remeasured at each reporting period with the change in fair value recorded to change in fair value of warrant
and derivative liabilities in the consolidated statement of operations until the derivative is exercised, expired, reclassified, or otherwise
settled. At September 30, 2024, the conversion feature no longer met the criteria of a derivative liability, and the derivative liability
was reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000655" name="ABEO:WarrantsPolicyTextBlock"><p id="xdx_842_ecustom--WarrantsPolicyTextBlock_zoQGfsgsfiHj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zHFumLbJliQ9">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2024, the Company issued pre-funded warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zMVnB4QVGsG7" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-07_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,142,656</ix:nonFraction></span> shares of common stock, with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240507__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zlA8quO4olP8" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-07_custom_PreFundedWarrants2024Member" id="Fact000659" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.0699</ix:nonFraction></span> per
share (&#8220;2024 Pre-Funded Warrants&#8221;). The prefunded warrants are classified as equity in accordance with ASC 815, <i>Derivatives
and Hedging</i>, given the prefunded warrants are indexed to the Company&#8217;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#8217;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On June 24, 2024 and December 2, 2024, <span id="xdx_90D_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zFGwr8FAY0Ek" title="Exercise of warrants"><ix:nonFraction name="ABEO:NumberOfWarrantsOrRightsExercised" contextRef="AsOf2024-06-24_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member" id="Fact000661" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">700,000</ix:nonFraction></span> and <span id="xdx_90C_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20241202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zyLHJ2IPrvLd" title="Exercise of warrants"><ix:nonFraction name="ABEO:NumberOfWarrantsOrRightsExercised" contextRef="AsOf2024-12-02_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,228,511</ix:nonFraction></span>, respectively of the
2024 Pre-Funded Warrants were exercised, leaving <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zAw1cDtUxtqg" title="Exercise of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,214,125</ix:nonFraction></span> of 2024 Pre-Funded Warrants outstanding as of December 31, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, the Company issued warrants to purchase up to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zQYCyZpIteB5" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-08_us-gaap_CommonStockMember_custom_LoanAgreementWarrants2024Member" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></span> worth of shares of the Company&#8217;s common stock. On January
8, 2024, the January Warrants did not include an explicit share limit and the number of shares issuable under the warrant agreements
were variable based on the exercise price and therefore the warrants were liability classified based on a Black-Scholes valuation in
accordance with ASC 815 and were recorded at the closing date fair value of $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_z60DybBTAuGk" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-082024-01-08_us-gaap_CommonStockMember_custom_LoanAgreementWarrants2024Member" id="Fact000669" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million which was based on a Black-Scholes option pricing
model. The warrants are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes
in the fair value between reporting periods recorded in the consolidated statements of operations and comprehensive loss. On September
30, 2024, per the terms of the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zjH43fPgA0Kc" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-30_custom_LoanAgreementWarrants2024Member" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share
and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zoa6IG21xxc3" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-09-30_custom_LoanAgreementWarrants2024Member" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,681</ix:nonFraction></span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2023, the Company issued pre-funded warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_z49HJKFza3Mh" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-07-06_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,919,140</ix:nonFraction></span> shares of common stock, with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240706__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zJMeVqFRqfQ8" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-07-06_custom_PreFundedWarrants2023Member" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.0299</ix:nonFraction></span>
per share (&#8220;2023 Pre-Funded Warrants&#8221;. The prefunded warrants are classified as equity in accordance with ASC 815, <i>Derivatives
and Hedging</i>, given the prefunded warrants are indexed to the Company&#8217;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#8217;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On May 9, 2024, <span id="xdx_903_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240509__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zc9lnxMnlpF2" title="Exercise of warrants"><ix:nonFraction name="ABEO:NumberOfWarrantsOrRightsExercised" contextRef="AsOf2024-05-09_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> of the 2023 Pre-Funded Warrants were exercised, leaving
<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zwDD2RDpicle" title="Exercise of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,619,140</ix:nonFraction></span> 2023 Pre-Funded Warrants outstanding as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2022, the Company issued warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221103_zXGfklcxIXq4" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-11-03" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,609,879</ix:nonFraction></span> shares of common stock, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221103_zauKxlMXp0P6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-11-03" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.75</ix:nonFraction></span> per share,
subject to customary adjustments thereunder. On December 17, 2021, the Company issued warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211217_zCFgs9L0UKG3" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-17" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,788,000</ix:nonFraction></span> shares of common
stock, with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211217_z0EzyAiq2LFl" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-17" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.75</ix:nonFraction></span> per share, subject to customary adjustments thereunder. The warrants issued in 2022 and 2021 were
determined to be freestanding instruments as they are legally detachable and separately exercisable from each other and from the common
stock issued. The common stock warrants are accounted for as liabilities in the consolidated balance sheets at their estimated fair value
because they are not indexed to the Company&#8217;s own stock. The warrants are revalued on each subsequent balance sheet date until
such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded in the consolidated statements
of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000691" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRa96MeMTpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zbFG3tIfIBL1">Recently
Adopted Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standard Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Segment Reporting (Topic 280): <i>Improvements to Reportable Segment Disclosures</i>&#8221; (&#8220;ASU 2023-07&#8221;). ASU 2023-07
requires additional disclosures for segment reporting, including disclosure of the title and position of the Chief Operating Decision
Maker and requires a public entity that has a single reportable segment to provide all the disclosures required by the amendments in
ASU 2023-07, and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal periods beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 effective for its
Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent interim periods. Since ASU 2023-07 addresses only disclosures,
the adoption of ASU 2023-07 did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000693" name="ABEO:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"><p id="xdx_843_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zPHaeJkS5ZBb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zGcXIvinM2ze">Recently
Issued Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): <i>Disaggregation of Income Statement Expenses</i>. The amendments in ASU 2024-03 address investor requests for more
detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories
of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating this guidance to determine the impact it may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): <i>Improvements to Income Tax Disclosures</i>. ASU 2023-09 is intended
to enhance the transparency and decision usefulness of income tax information through improvements to income tax disclosures primarily
related to the rate reconciliation and income taxes paid information. The standard is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The requirements of this ASU are disclosure related and will not have an impact
on the Company&#8217;s financial condition, results of operations, or cash flows. The Company is currently evaluating the impact of adopting
this ASU on its income tax disclosures.</span></p>

</ix:nonNumeric><p id="xdx_859_zMJjXJUx4oAa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000695" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_806_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zGObbkJx31vh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_821_zhUnedacw0M3">SHORT-TERM INVESTMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000697" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock"><p id="xdx_897_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zwNNuCZofCsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the short-term investments (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zMj2EW0vkLLc" style="display: none">SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortized Cost</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Gain</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Loss</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Available-for-sale, short-term investments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">U.S. treasury securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zRlOOSqfwPgd" title="Amortized cost" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,990</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLbc29LuSFCh" title="Gross Unrealized Gain" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_ztnCRWa2fUK2" title="Gross Unrealized Loss" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zuHhOyXkVYag" title="Fair Value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000705" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,968</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">U.S. federal agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zlu9Qo9DHkw5" title="Amortized cost" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000707" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zqmu3Cv8iaH6" title="Gross Unrealized Gain" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2024-01-012024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000709" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zjRupTkeAZP3" title="Gross Unrealized Loss" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zmx6l6NAbQC8" title="Fair Value" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Certificates of deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zf7NvHz2a7ql" title="Amortized cost" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-12-31_us-gaap_CertificatesOfDepositMember" id="Fact000715" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z5vVFpxiMux4" title="Gross Unrealized Gain" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2024-01-012024-12-31_us-gaap_CertificatesOfDepositMember" id="Fact000717" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z083lbHIR0r2" title="Gross Unrealized Loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zGliwiQPj297" title="Fair Value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2024-12-31_us-gaap_CertificatesOfDepositMember" id="Fact000721" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,020</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total available-for-sale, short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zmmdnYd2SZZj" title="Amortized cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-12-31" id="Fact000723" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74,355</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zyLr3YVS25Ob" title="Gross Unrealized Gain" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2024-01-01to2024-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zfmFTJPwYvuh" title="Gross Unrealized Loss" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zFWt8v2nZ742" title="Fair Value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2024-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74,363</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortized Cost</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Gain</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Loss</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Available-for-sale, short-term investments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">U.S. treasury securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zXcaNzGOo624" title="Amortized cost" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000731" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,406</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgT8qB6kIb34" title="Gross Unrealized Gain" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zjiTfCXntg3g" title="Gross Unrealized Loss" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000735" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zROimDBYKWVb" title="Fair Value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000737" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,393</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">U.S. federal agency securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_z7CBoHFwFu7d" title="Amortized cost" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000739" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zzOqtHoBUgy" title="Gross Unrealized Gain" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zYUjnYLo9vH" title="Gross Unrealized Loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000743" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zyzsGl2pa3S2" title="Fair Value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000745" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,360</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total available-for-sale, short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zGdqgrqcp1B" title="Amortized cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31" id="Fact000747" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zx4c9m33Eq87" title="Gross Unrealized Gain" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zsvhUjgGGRw" title="Gross Unrealized Loss" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31" id="Fact000751" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zt4sJkdsAiT3" title="Fair Value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2023-12-31" id="Fact000753" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,753</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zcIEF0M6ilba" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the available-for-sale securities classified as short-term investments mature in one year or less. The Company
carries its available-for-sale securities at fair value in the consolidated balance sheets. Unrealized losses on available-for-sale securities
as of December 31, 2024, were not significant and were primarily due to changes in interest rates, including market credit spreads, and
not due to increased credit risks associated with specific securities. None of the short-term investments have been in a continuous unrealized
loss position for more than 12 months. Accordingly, no other-than-temporary impairment was recorded for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20240101__20241231_zthi3VgtNzx4" title="Available-for-sale securities realized gain loss"><span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20230101__20231231_zgEDMqpGReec" title="Available-for-sale securities realized gain loss"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000755" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2023-01-012023-12-31" id="Fact000757" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> significant realized gains or losses recognized on the sale or maturity of available-for-sale investments during the years ended
December 31, 2024 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000759" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zOqRscL1t5ma" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82A_zCd5veDxCTja">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000761" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_z3zpII5mkwEk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost and depreciated or amortized using the straight-line method based on useful lives as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zdJsbegO5u6g" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Useful
    lives (years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231_zVk9x1UGLBhi" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_zKDdVIgVTAQh" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful lives (years)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 35%; text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zcMuPkhN31Bj" title="Useful lives (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_LaboratoryEquipmentMember" format="ixt-sec:duryear" id="Fact000763" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_z3xNLAKXuDN2" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_LaboratoryEquipmentMember" id="Fact000764" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,868</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zRwQhlueoQT3" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_LaboratoryEquipmentMember" id="Fact000765" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,935</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture, software and office equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z9EQjlFyEREl" title="Useful lives (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000767" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zzMa4GmEDpi8" title="Useful lives (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000769" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_zOWoiR7cR2Ll" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember" id="Fact000770" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_z7xhfJLN8Lsb" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember" id="Fact000771" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">986</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9ss9QtDYD28" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0772">Shorter of remaining lease term or useful life</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVWATQYDPzn8" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000773" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9E0AHx7P5G5" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000774" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Construction-in-progress</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zHCVSHfZ7Wr1" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_ConstructionInProgressMember" id="Fact000775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">624</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z23Y7teNExGb" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maCzvcX_zktQhF5p3132" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000779" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msCzvcX_zUCEnoMEnzw" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,980</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,991</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtCzvcX_z78B58J3xhb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,430</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,533</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zeoVlOzy9Bhf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization on property and equipment was $<span id="xdx_90E_eus-gaap--DepreciationAndAmortization_pn5n6_c20240101__20241231_zxj8N1R0cRw6" title="Depreciation expense"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000787" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--DepreciationAndAmortization_pn5n6_c20230101__20231231_z2vXRwMHBT49" title="Depreciation expense"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000789" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million for the years ended December 31, 2024 and 2023, respectively.
The Company incurred a gain on disposal of equipment of $<span id="xdx_909_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_c20240101__20241231_zNXYFIZne613" title="Gain (loss) on disposal of equipment"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000791" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> and a loss on disposal of $<span id="xdx_90D_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn3d_di_c20230101__20231231_zjFkFDlMT9Ke" title="Gain (loss) on disposal of equipment"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-012023-12-31" id="Fact000793" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">47,000</ix:nonFraction></span> during the years ended December 31,
2024 and 2023, respectively, which is reflected in other income in the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000795" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_801_eus-gaap--FairValueDisclosuresTextBlock_zfRPP4kX3Yxi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_825_zA7nKOKVqx8j">FAIR VALUE MEASUREMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates the fair value of the Company&#8217;s assets and liabilities that qualify as financial instruments and includes additional
information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial
instruments. The estimated fair value of other receivables, prepaid expenses and other current assets, other assets, accounts payable,
accrued expenses, and payables to licensor approximate their carrying amounts due to the relatively short maturity of these instruments.
The estimated fair value of the Loan Agreement as of December 31, 2024, was $<span id="xdx_90D_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241231_zJ8gJMnukw45" title="Estimated fair value of loan agreement"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2024-12-31" id="Fact000797" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">24.7</ix:nonFraction></span> million. Both observable and unobservable inputs were
used to determine the fair value of long-term debt, which was classified within the Level 3 category.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement
date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used
to measure fair value are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active
    markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
    and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use
    significant unobservable inputs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually)
into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement
date in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000799" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zipXxzDqIJZ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of financial assets measured at fair value on a recurring and non-recurring basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zb8vLDZeZlh9" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Description</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value at<br/>
 December 31,<br/>
 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Recurring Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zr4qQKTfUFxh" title="Cash equivalents fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember" id="Fact000801" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,627</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoU7BWvsLvdj" title="Cash equivalents fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember" id="Fact000803" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,627</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoe8909E2723" title="Cash equivalents fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zf0zgOyrWeZg" title="Cash equivalents fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Money market deposit account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zQHAjJEDYsif" title="Cash equivalents fair value" style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember" id="Fact000809" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zXMBELUrecei" title="Cash equivalents fair value" style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember" id="Fact000811" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zKQvGmeek3Ci" title="Cash equivalents fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_z13aXFb8YUU3" title="Cash equivalents fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0815">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z9rkQS1WfENd" title="Short-term investments fair value" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="Fact000817" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,968</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z28ai9lBLzpg" title="Short-term investments fair value" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="Fact000819" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,968</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zsPxZ8lc6gYa" title="Short-term investments fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zSVBi1CQsure" title="Short-term investments fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">U.S. federal agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zTREwELdc2X4" title="Short-term investments fair value" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000825" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zxaUO2jH9d0g" title="Short-term investments fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zdFB5KWMuU4i" title="Short-term investments fair value" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000829" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zRbgQjl5fUg6" title="Short-term investments fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; padding-bottom: 1pt">Certificates of deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zubR8RtOnT06" title="Short-term investments fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember" id="Fact000833" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,020</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zsuCLigAJfzj" title="Short-term investments fair value" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zjbWgTF9Twx5" title="Short-term investments fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember" id="Fact000837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,020</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zdxoBDGubLc" title="Short-term investments fair value" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zA3Uzn1yrPff" title="Total assets measured at fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97,099</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkAgvzzcD9X9" title="Total assets measured at fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000843" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,704</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGlEpab97I9i" title="Total assets measured at fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQylC3rqse7i" title="Total assets measured at fair value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_z0DNPX8IHBii" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember" id="Fact000848" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,014</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zufP1eiWhOH5" title="Fair value, liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zcAP8OhzYiVj" title="Fair value, liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zlnzwh1yztLe" title="Fair value, liabilities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember" id="Fact000854" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,014</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzbS8g42I3T8" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000855" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zY6FNtSidbc4" title="Total liabilities measured at fair value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGCujSBBfiNg" title="Total liabilities measured at fair value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC4R6ZeMhQog" title="Total liabilities measured at fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000861" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value at<br/> December 31,<br/>

    2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Recurring Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 36%">Money market fund</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z5MGhwssVxC1" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember" id="Fact000862" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zcheNgrtHx4g" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember" id="Fact000863" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zBjDh39isri" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ziutopJ1uSPa" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zGjt5pcE5o97" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="Fact000866" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zs1pZH54yzXk" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="Fact000867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zgnDZ6HrS7Te" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zqH9RDjyWiy2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">U.S. federal agency securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zeImKI3jS6Vd" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000870" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,360</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zvYZOOLA1Mx3" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zpsy8MZtA2Mj" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" id="Fact000872" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,360</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zuBwpnkmg5vi" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRfh7q4IQ7sk" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000874" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,787</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQDEH1VRFQEd" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000875" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,427</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGYYJkQTK9K2" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000876" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,360</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWyylU5yoqgi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payable to licensor</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_z0wHJNRP9JZ" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember" id="Fact000878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,580</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zyn6DeUyfWj7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0879">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_ztz5ds9e83Z2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zYVb9hclTaF4" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember" id="Fact000881" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,580</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zZ29UGiWdUQ5" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember" id="Fact000882" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,352</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zJQBGntILD9b" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zj7a1Qc104kg" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0884">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zVjrMjFFAtb6" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember" id="Fact000885" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,352</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT8eW20JRiN3" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000886" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJlwZzUmA6cg" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwEYU8pbUZQ3" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUHK8JzoUS7a" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000889" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z8bJis2UhRRk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant
Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000891" name="ABEO:ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_zLtp3yxAShJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had the following outstanding warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zTEGzuH7ylNc" style="display: none">SCHEDULE OF OUTSTANDING WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zVGrSMiVrbOl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_z30RTI2vUCn9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zI8eLCm3Xrsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants issued as part of the 2021 public offering, expiration date <span id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zXq2Wwadqni6" title="Warrants, expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember" id="Fact000896" name="ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable">December 2026</ix:nonNumeric></span>, exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zfjX8HJRQEig" title="Warrants, exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.75</ix:nonFraction></span> per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,788,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,788,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zf3tzd0ffCYh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants issued as part of the 2022 Private Placement Offering, expiration date <span id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zSWZlag3Xbi9" title="Warrants, expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember" id="Fact000903" name="ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable">November 2027</ix:nonNumeric></span>, exercise price $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_z475wsbrTNUa" title="Warrants, exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember" id="Fact000905" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.75</ix:nonFraction></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,609,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember" id="Fact000901" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,609,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zgwOkqHcJMw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued as part of the 2024 Loan Agreement, expiration date <span id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zdoapL79LLR7" title="Warrants, expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwentyTwentyFourLoanAgreementMember" id="Fact000910" name="ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable">January 2029</ix:nonNumeric></span>, exercise price $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zJ5BPgaz46Vh" title="Warrants, exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_TwentyTwentyFourLoanAgreementMember" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwentyTwentyFourLoanAgreementMember" id="Fact000907" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,681</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zYoS9AsvVNr6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding warrant liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,609,879</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember" id="Fact000915" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,609,879</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_z74iCmQvhRId" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock warrants related to the 2021 Public Offering and the 2022 Private Placement are not indexed to the Company&#8217;s own stock
and therefore have been classified as liabilities at their estimated fair value. The common stock warrants issued in connection with
the Loan Agreement issuance were determined to be liability classified under ASC 815 as the common stock warrants were not considered
indexed to the Company&#8217;s stock. Changes in the estimated fair value of the warrant liabilities is recorded as changes in fair value
of warrant liabilities in the consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2024, as part of the Loan and Security Agreement, see Note 9, the Company issued warrants to purchase $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zz8pyafuZUOk" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-01-31_custom_LoanAndSecurityAgreementMember" id="Fact000917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,400,000</ix:nonFraction></span> worth of shares
of the Company&#8217;s stock which have an exercise price equal to the lesser of (i) $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zBNO2XSoqBud" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-31_custom_LoanAndSecurityAgreementMember" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.75</ix:nonFraction></span> and (ii) the price per share of the Company&#8217;s
next bona fide round of equity financing before September 30, 2024 (the &#8220;2024 Loan Agreement Warrants&#8221;). In connection with
the underwritten common stock offering consummated on May 7, 2024, pursuant to the terms of the 2024 Loan Agreement Warrants, the exercise
price was reduced to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementMember_zQqDbp7tTJ5f" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementMember" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share and the shares issuable was calculated at <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementMember_z7DJjC0HyD93" title="Shares of common stock issuable upon exercise of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementMember" id="Fact000923" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,681</ix:nonFraction></span> shares. On September 30, 2024, per the terms of
the 2023 Loan Agreement Warrants, the exercise price and the number of shares became set at $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyThreeLoanAgreementMember_zEJ18XkUsCL" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-30_custom_TwentyTwentyThreeLoanAgreementMember" id="Fact000925" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyThreeLoanAgreementMember_zNVwEminFSme" title="Shares of common stock issuable upon exercise of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-09-30_custom_TwentyTwentyThreeLoanAgreementMember" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,681</ix:nonFraction></span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000929" name="ABEO:ScheduleOfActivityWarrantyLiabilityTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfActivityWarrantyLiabilityTableTextBlock_zKvlDGvHSJrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the activity on the warrant liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zZfNqip5VEV2" style="display: none">SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zAbCkqAeriP3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zk9vNzGrMyFl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilities_iS_pn3n3_zkLpCfSAfuEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ABEO:WarrantLiabilities" contextRef="AsOf2023-12-31" id="Fact000931" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,352</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ABEO:WarrantLiabilities" contextRef="AsOf2022-12-31" id="Fact000932" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,657</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FairValueAdjustmentOfWarrantsIssued_pn3n3_zax4nmVrFkja" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fair value of warrants issued in connection with the Loan Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:FairValueAdjustmentOfWarrantsIssued" contextRef="From2024-01-01to2024-12-31" id="Fact000934" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainLossRecognizedInEarningsFromChangeInFairValue_iN_pn3n3_di_zb74aMD7CPha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Loss recognized in earnings from change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ABEO:GainLossRecognizedInEarningsFromChangeInFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact000937" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">442</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ABEO:GainLossRecognizedInEarningsFromChangeInFairValue" contextRef="From2023-01-012023-12-31" id="Fact000938" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,695</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WarrantLiabilities_iE_pn3n3_z7QIL8mstCR5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending warrant liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ABEO:WarrantLiabilities" contextRef="AsOf2024-12-31" id="Fact000940" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ABEO:WarrantLiabilities" contextRef="AsOf2023-12-31" id="Fact000941" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,352</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zFzpP8LHoEG5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities are valued using significant inputs not observable in the market. Accordingly, the warrant liability is measured
at fair value on a recurring basis using unobservable inputs and are classified as Level 3 inputs within the fair value hierarchy. Fair
value measurements categorized within Level 3 are sensitive to changes in the assumptions or methodology used to determine fair value
and such changes could result in a significant increase or decrease in the fair value. The Company&#8217;s valuation of the common stock
warrants utilized the Black-Scholes option-pricing model, which incorporated assumptions and estimates to value the common stock warrants.
The Company assessed these assumptions and estimates at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000943" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z29rlvcuTmU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the key inputs for the Black-Scholes option-pricing model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zzfRD4nJtovk" style="display: none">SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Common share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"/><td style="width: 16%; text-align: center">$<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z7AlKWJUrUw5" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact000944" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.57</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"/><td style="width: 16%; text-align: center">$<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDiCi34HRqae" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.01</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zcVhk02hsKdl" title="Expected term (years)" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000947" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.96</ix:nonNumeric></span>
&#8211; <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zEa5d86fCkKc" title="Expected term (years)" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000949" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.02</ix:nonNumeric></span> </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zMC9dmNs2Fna" title="Expected term (years)" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000951" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.96</ix:nonNumeric></span>
&#8211; <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zS3QwkJb5q1d" title="Expected term (years)" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000953" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.84</ix:nonNumeric></span> </span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zwxA83DjHxne" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.16</ix:nonFraction></span>% &#8211; <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zKrkBTFhT4Xh" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.24</ix:nonFraction></span></span>%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRAegRZo0w9h" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.84</ix:nonFraction></span>% &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zgensBV8qG76" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.92</ix:nonFraction></span>%</span></td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zhl1fCHSRzK1" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">92.64</ix:nonFraction></span>% - <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoraCYRSkFh4" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100.00</ix:nonFraction></span>%</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcsgRdfr7tOh" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100.00</ix:nonFraction></span>%</td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmv4kcxZolB" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGQhwfkSThG4" title="Warrants measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</td><td style="text-align: left"/></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zdsWkbpAnAxj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative
Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Conversion Right embedded within the Loan Agreement (see Note 9 below) required bifurcation as certain adjustments to the conversion
price were not indexed to the Company&#8217;s own stock and therefore the Conversion Right was recorded as a derivative liability. The
derivative liability is remeasured at each reporting period with the change in fair value recorded to changes in fair value of warrants
and derivative liabilities in the condensed consolidated statement of operations until the derivative is exercised, expired, reclassified,
or otherwise settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, pursuant to the Loan Agreement, the conversion price was fixed at $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zgBp5ZbjjBYf" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-09-30_custom_LoanAgreementMember" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.88</ix:nonFraction></span> and is considered indexed to the Company&#8217;s
own stock. At September 30, 2024, the Conversion Right no longer met the criteria of a derivative liability, and the derivative liability
was reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000975" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zpMU7P2RYzP5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the activity on the derivative liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8B9_z7J5r0VD8j8d" style="display: none">SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zcWsM91NpHgk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_zSJEn2Jm4WQ6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_zgKQWzylEaC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Beginning derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FairValueOfDerivativesIssued_zgOuKkKYcNna" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Fair value of derivatives issued in connection with Loan Agreement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ABEO:FairValueOfDerivativesIssued" contextRef="From2024-01-01to2024-12-31" id="Fact000980" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">822</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLossOnDerivative_zfFbfwKv7rXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span id="xdx_903_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20240101__20241231_z5JWqb45Gh44" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"><span id="xdx_90B_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20230101__20231231_zun9QKFotl4f" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"><span style="-sec-ix-hidden: xdx2ixbrl0985"><span style="-sec-ix-hidden: xdx2ixbrl0986">Loss recognized in earnings from change in fair value</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="From2024-01-01to2024-12-31" id="Fact000983" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_iN_zOvJ03xsAm81" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of derivative liability in connection with the Loan Agreement</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ABEO:ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" contextRef="From2024-01-01to2024-12-31" id="Fact000988" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,135</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_zHXFxmIpvlzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending derivative liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zPCBaxmGtRZj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000994" name="us-gaap:LossContingencyDisclosures"><p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zZSAZaApmfzj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82F_zfFw9jdS1Jfi">SETTLEMENT LIABILITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2021, the Company entered into a settlement agreement (&#8220;Settlement Agreement&#8221;) with the Company&#8217;s prior
licensor REGENXBIO Inc. (&#8220;REGENXBIO&#8221;) to resolve all existing disputes between the parties. In accordance with the Settlement
Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_905_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zEwu1gvduwK8" title="Settlement liabilities, current"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_custom_REGENXBIOMember" id="Fact000996" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zz8ou7zWJNTi" title="Loss contingency settlement agreement terms"><ix:nonNumeric contextRef="From2021-11-112021-11-12_custom_REGENXBIOMember" id="Fact000998" name="us-gaap:LossContingencySettlementAgreementTerms">(1) $20.0 million paid in November 2021
after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement
(paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement
or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement (paid in November 2024).</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the payable due to REGENXBIO in the consolidated balance sheet based on the present value of the remaining payments
due to REGENXBIO under the Settlement Agreement using an effective interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_znVsSSoGPVrj"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-12-31_custom_REGENXBIOMember" id="Fact000999" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.6</ix:nonFraction></span>%. The Company paid all amounts due in November
2024 and therefore there were no amounts outstanding as of December 31, 2024. The present value of the amount due as of December 31,
2023 was $<span id="xdx_906_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_z41pAKc5Haq8"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-12-31_custom_REGENXBIOMember" id="Fact001000" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.6</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001002" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zCF2pdtOPzbi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_82E_z8swC3D3KsM6">ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001004" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0klTybGiMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the components of accrued expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhHL2yHiwIrf" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zgf4LoVT2Kc3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231_zvLG8hnRct3b" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz9Ql_zyVyMa7TPaHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued employee compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2024-12-31" id="Fact001006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2023-12-31" id="Fact001007" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,688</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCz9Ql_ze73B163aD3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued contracted services and other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-12-31" id="Fact001009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,941</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact001010" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,297</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz9Ql_zPeVdkGjBeY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001012" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001013" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,985</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_z5zrktVjewKc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001015" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zujyXqb0Dln3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_822_zWlQ7cfA1YGa">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases space under operating leases for administrative, manufacturing and laboratory facilities in Cleveland, Ohio. The Company
also leases office space in New York, New York, that the Company sublets. The Company also leases certain office equipment under operating
leases, which have a non-cancelable lease term of less than one year and the Company has elected the practical expedient to exclude these
short-term leases from the Company&#8217;s right-of-use assets and lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, the Company signed a lease for <span id="xdx_900_eus-gaap--AreaOfLand_iI_usqft_c20241231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zCwLK6jtSFIc" title="Lease cost"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2024-12-31_custom_LeaseAgreementMember" id="Fact001017" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">16,566</ix:nonFraction></span> square feet of office space at 6700 Euclid Avenue, Cleveland, Ohio. Pursuant to the lease
agreement, the lease term commences on January 1, 2025 with an initial term through December 30, 2030. Annual lease payments during the
term of the lease are approximately $<span id="xdx_90F_eus-gaap--OperatingLeasePaymentsUse_pn5n6_c20240101__20241231_za46fa05eibg" title="Annual lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2024-01-01to2024-12-31" id="Fact001019" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million. The total lease payments over the duration of the lease term are approximately $<span id="xdx_90E_eus-gaap--OperatingLeasePayments_pn5n6_c20240101__20241231_zPtGr1jSwOWd" title="Total lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact001021" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>
million. The additional space at the 6700 Euclid Avenue facility will allow the Company to convert office space at the 6555 Carnegie
Avenue facility into additional manufacturing space to increase pz-cel manufacturing capacity. As the lease does not commence and the
Company does not have access to the leased space until January 1, 2025, the impact of this lease agreement is not reflected in the consolidated
financial statements of the Company as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company terminated one of its operating leases for office space. The termination resulted in a gain of $<span id="xdx_905_eus-gaap--GainLossOnTerminationOfLease_pn5n6_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceOneMember_zJBI1L0xa0Y8" title="Gain (loss) on termination of lease"><ix:nonFraction name="us-gaap:GainLossOnTerminationOfLease" contextRef="From2023-01-012023-12-31_custom_OfficeSpaceOneMember" id="Fact001023" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million representing
the difference between the carry value of the right-of-use assets and the related lease liabilities. This gain was recorded in the year
ended December 31, 2023, and is included in gain on operating lease right-of-use assets in the consolidated statement of operations and
comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company modified one of its operating leases for office space to add up to <span id="xdx_906_eus-gaap--AreaOfLand_iI_usqft_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zvtL4x96Rfjf" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2023-12-31_custom_OfficeSpaceTwoMember" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">14,032</ix:nonFraction></span> square feet to the Company&#8217;s existing
facility in Cleveland, Ohio. The lease modification resulted in the recognition of $<span id="xdx_90B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zPpxYS5Tdx5k" title="Right-of-use assets"><span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_pn5n6_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_z5J77HKxd5d1" title="Lease liabilities"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31_custom_OfficeSpaceTwoMember" id="Fact001027" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31_custom_OfficeSpaceTwoMember" id="Fact001029" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></ix:nonFraction></span></span> million of additional right-of-use assets and
related lease liabilities in the Company&#8217;s consolidated balance sheet during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022 and 2023, the Company entered into two sublease agreements with unrelated third parties to occupy the Company&#8217;s administrative
offices in New York, New York. The Company expects to receive $<span id="xdx_90D_eus-gaap--SubleaseIncome_pn5n6_c20240101__20241231__us-gaap--AwardDateAxis__custom--SeptemberTwoThouandTwentyFiveMember_znBZUuU9JCN1" title="Sublease income"><ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2024-01-012024-12-31_custom_SeptemberTwoThouandTwentyFiveMember" id="Fact001031" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million in future sublease income through September 2025 from the
two subleases noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001033" name="ABEO:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock"><p id="xdx_896_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zHqncXgOgfI8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s operating lease liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zSXKYa6qpv1a" style="display: none">SUMMARY OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zywhxeVoY6Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zExrjeakqDU7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzJ5e_zzftb7jKYr4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Current operating lease liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact001035" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact001036" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzJ5e_z3ptF5BnuDR1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Non-current operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact001038" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact001039" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,402</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzJ5e_zbEYM6NwI84k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001041" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001042" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,400</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z1NMcCerDdFb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs and rent are reflected in general and administrative expenses and research and development expenses in the consolidated statements
of operations and comprehensive loss, as determined by the underlying activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001044" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zLO5vmxyZoff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the components of lease costs and rent (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAqOuKsMyG1i" style="display: none">SCHEDULE OF COMPONENTS OF LEASE COST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zPbyK4BgezUg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zEe20696qzHk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_maLCzRlC_zexGgZSlOph4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001046" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,288</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,389</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--VariableLeaseCost_pn3n3_maLCzRlC_zOknanic4gh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001049" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzRlC_zWFA1AtjKpJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Short-term lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LeaseCost_iT_pn3n3_mtLCzRlC_zTZu4St3ZdOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,717</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,810</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zFPLPbLDV1p" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
paid for amounts included in the measurement of operating lease liabilities was $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_pn5n6_c20240101__20241231_zL5ZIrdbJvbj" title="Operating lease liabilities"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001058" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million and $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_pn5n6_c20230101__20231231_zeWin1E1j6S2" title="Operating lease liabilities"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact001060" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction> </span>million for the years ended December
31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001062" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgxclDHvdVR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments and obligations, which do not include short-term leases, related to the Company&#8217;s operating lease liabilities
as of December 31, 2024 were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zZoR7xzYjpv7" style="display: none">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future minimum lease payments and obligations</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zhpptrbDid29" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0kQ_zumIRufpw2E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">853</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0kQ_ztQolLdnqQ2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">791</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPz0kQ_zklCTUsrdfl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact001068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPz0kQ_zHitQCfr4kd9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-12-31" id="Fact001070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">823</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPz0kQ_zfwSYH0S5kUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-12-31" id="Fact001072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">859</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPz0kQ_ziwWsTMaOfIg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2024-12-31" id="Fact001074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">834</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0kQ_zJifI0OSsI41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact001076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,967</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zea4xJ417NWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact001078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">882</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zki4bC6ZxUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zTmBF6APUW41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining term of the Company&#8217;s operating leases was <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20241231_z9H7wjg1Xgw7" title="Weighted average remaining term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:durmonth" id="Fact001082" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">60</ix:nonNumeric></span> months and the weighted-average discount rate used to
measure the present value of the Company&#8217;s operating lease liabilities was <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_z3pMWvZrE9Pb" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact001084" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span>% as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received $<span id="xdx_907_eus-gaap--SubleaseIncome_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SubLeaseAgreementMember_zjQLwXKxKgbl" title="Sublease income"><ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2024-01-012024-12-31_custom_SubLeaseAgreementMember" id="Fact001086" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--SubleaseIncome_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SubLeaseAgreementMember_zhbWC7MpIEbc" title="Sublease income"><ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2023-01-012023-12-31_custom_SubLeaseAgreementMember" id="Fact001088" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million during the years ended December 31, 2024 and 2023, respectively, of sublease income which
is recorded in other income on the consolidated statements of operations and comprehensive loss. Future cash receipts from the Company&#8217;s
sublease agreements as of December 31, 2024 are as follows (in thousands):</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001090" name="ABEO:ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_zwqVEJqs2Nh3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zKmqxz9XUW8b" style="display: none">SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zjtUtumCZmt9" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future cash receipts</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subleases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_iI_pn3n3_maFCRFOzUBz_zkr9S0A8Ga6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left; padding-bottom: 1pt">2025</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><ix:nonFraction name="ABEO:FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">485</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--FutureCashReceiptsFromOperatingSublease_iTI_pn3n3_mtFCRFOzUBz_zE0u317Rznzh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total future cash receipts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ABEO:FutureCashReceiptsFromOperatingSublease" contextRef="AsOf2024-12-31" id="Fact001094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zF1ZDeYLOXTi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001096" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zCrJ4FSNwwmj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82D_zlAaFcgYdmoh">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001098" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zyxxvjuPhWjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s debt, net of debt issuance costs and discounts (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zqffGlfH4Sgl" style="display: none">SCHEDULE
OF DEBT AND NET OF DEBT ISSUANCE COSTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zoYDkBwaIEwi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zbywQZHxVMrc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_maLTDzr8F_zP3IwhDVIyIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Loan Agreement Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31" id="Fact001100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccretedFinalPaymentFee_iI_pn3n3_maLTDzr8F_zjXiZ8Qtzehg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accreted final payment fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:AccretedFinalPaymentFee" contextRef="AsOf2024-12-31" id="Fact001103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">354</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTDzr8F_zre8cPV9mPbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Unamortized debt issuance costs and discounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2024-12-31" id="Fact001106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,391</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzr8F_mtLTDNzuex_zf2GAldghadl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-12-31" id="Fact001109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1110">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtCurrent_iI_pn3n3_maLTDNzuex_z0qFJMsDr0Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: current maturities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2024-12-31" id="Fact001112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,926</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_maLTDNzuex_zXEECTBoo7Sd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current maturities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31" id="Fact001115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,037</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zIwKylnKLWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loan
and Security Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024 (the &#8220;Closing Date&#8221;), the Company entered into a Loan and Security Agreement, as supplemented by a Supplement,
dated as of January 8, 2024 (collectively, the &#8220;Loan Agreement&#8221;) with Avenue Venture Opportunities Fund, L.P., a Delaware
limited partnership, as administrative agent and collateral agent (&#8220;Avenue&#8221; and the &#8220;Agent&#8221;) and Avenue Venture
Opportunities Fund II, L.P., a Delaware limited partnership (&#8220;Avenue 2&#8221; and, together with Avenue, the &#8220;Lenders&#8221;).
The Loan Agreement provides for senior secured term loans (the &#8220;Loans&#8221;) in an aggregate principal amount up to $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zqppfvuO7xT7" title="Aggregate principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001118" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">50</ix:nonFraction></span> million,
with (i) a committed tranche of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember_zYpwadigIBb8" title="Aggregate principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember" id="Fact001120" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million advanced on the Closing Date (&#8220;Tranche 1&#8221;), (ii) a committed tranche of up to
$<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheTwoMember_zWyRo3ErNvL3" title="Aggregate principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheTwoMember" id="Fact001122" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million which may be advanced upon the request of the Company between June 30, 2024 and September 30, 2024, subject to the Company
obtaining FDA approval of pz-cel in recessive dystrophic epidermolysis bullosa, with the issuance of a Priority Review Voucher (&#8220;Tranche
2&#8221;), and (iii) a discretionary tranche of up to $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--DiscretionaryTrancheMember_zlkrfmmzjFe6" title="Aggregate principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_DiscretionaryTrancheMember" id="Fact001124" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million which may be advanced between March 31, 2025 and March 31, 2026 (the
&#8220;Discretionary Tranche&#8221;) provided at the discretion of the Lenders. The Loans are due and payable on July 1, 2027 (the &#8220;Maturity
Date&#8221;). As of December 31, 2024, the Tranche 2 is no longer available as the Company did not meet the Tranche 2 criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan principal is repayable in equal monthly installments beginning on May 1, 2025. The Loans bear interest at a rate per annum (subject
to increase during an event of default) equal to the greater of (i) the prime rate, as published by the Wall Street Journal from time
to time, plus <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250501__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__srt--RangeAxis__srt--MinimumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zatbGoC3Xkj5" title="Prime rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2025-05-01_custom_LoanAndSecurityAgreementMember_srt_MinimumMember_srt_ScenarioForecastMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.00</ix:nonFraction></span>% and (ii) <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250501__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zn7RFH12AA3f" title="Prime rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2025-05-01_custom_LoanAndSecurityAgreementMember_srt_MaximumMember_srt_ScenarioForecastMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.50</ix:nonFraction></span>%. The stated interest rate and effective interest rate as of December 31, 2024 was <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z7gSZs89oRql" title="Stated interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-12-31_custom_LoanAndSecurityAgreementMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.50</ix:nonFraction></span>% and <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zJ8Lau6PXYKf" title="Effective interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-12-31_custom_LoanAndSecurityAgreementMember" id="Fact001132" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22.09</ix:nonFraction></span>%,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may, subject to certain parameters, voluntarily prepay the Loans, in whole, at any time. If prepayment occurs on or before the
one-year anniversary of the Closing Date, <span id="xdx_900_eus-gaap--PropertyManagementFeePercentFeeDescription_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zMsKEvCer466" title="Percentage fee, description"><ix:nonNumeric contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001134" name="us-gaap:PropertyManagementFeePercentFeeDescription">the Company is required to pay a prepayment fee equal to 3.00% of the principal amount of the
Loans prepaid; if prepayment occurs after the one-year anniversary of the Closing Date and on or before the two-year anniversary of the
Closing Date, the Company is required to pay a fee equal to 2.00% of the principal amount of the Loans&#894; if prepayment occurs after
the two-year anniversary of the Closing Date, the Company is required to pay a fee equal to 1.00% of the principal amount of the Loans.
A final payment fee of 5.00% of the principal amount of the funded Tranche 1, Tranche 2 Loans and Discretionary Tranche Loans is also
due upon the Maturity Date or any earlier date of prepayment.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s obligations under the Loan Agreement are secured by a pledge of substantially all of the Company&#8217;s assets. Pursuant
to the Loan Agreement, the Company is subject to a financial covenant requiring the Company to maintain at all times $<span id="xdx_90B_eus-gaap--InvestmentsAndCash_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z7I5JaLR6y6c" title="Unrestricted cash"><ix:nonFraction name="us-gaap:InvestmentsAndCash" contextRef="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001136" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million in unrestricted
cash. The Loan Agreement also contains affirmative and negative covenants customary for financings of this type that, among other things,
limit the ability of the Company and its subsidiaries to (i) incur additional debt, guarantees or liens&#894; (ii) pay dividends&#894;
(iii) enter into certain change of control transactions&#894; (iv) sell, transfer, lease, license, or otherwise dispose of certain assets&#894;
(v) make certain investments or loans&#894; and (vi) engage in certain transactions with related persons, in each case, subject to certain
exceptions. The Loan Agreement also includes events of default customary for financings of this type, in certain cases subject to customary
periods to cure, following which the Agent may accelerate all amounts outstanding under the Loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Supplement to the Loan and Security Agreement, Avenue also has the right to convert up to $<span id="xdx_901_eus-gaap--PrincipalAmountOutstandingOnLoansManagedAndSecuritized_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z9yWtGaIpDGh" title="Outstanding principal amount of loan"><ix:nonFraction name="us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized" contextRef="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001138" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span> million of the outstanding principal
of the Loans into shares of Company common stock (the &#8220;Conversion Right&#8221;) at a price per share equal to 120% of the exercise
price of the Warrants (further discussed below) at any time while the Loans are outstanding, subject to certain terms and conditions,
including ownership limitations. The Conversion Right required bifurcation as certain adjustments to the conversion price were not indexed
to the Company&#8217;s own stock and therefore the Conversion Right was recorded as a derivative liability. On January 8, 2024, the Conversion
Right was recorded at the closing date fair value of $<span id="xdx_90A_ecustom--FairValueOfConversionRight_pn5n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zR8WcZwyW0Tl" title="Fair value of conversion right"><ix:nonFraction name="ABEO:FairValueOfConversionRight" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001140" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million which was based on a Monte Carlo simulation model. The derivative liability
is remeasured at each reporting period with the change in fair value recorded to change in fair value of warrants and derivative liabilities
in the condensed consolidated statement of operations until the derivative is exercised, expired, reclassified, or otherwise settled.
On September 30, 2024, pursuant to the Loan Agreement, the conversion price was fixed at $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zezejV664V1a" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-09-30_custom_LoanAndSecurityAgreementMember" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.88</ix:nonFraction></span> and is considered indexed to the Company&#8217;s
own stock. At September 30, 2024, the Conversion Right no longer met the criteria of a derivative liability and the derivative liability
of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240930__20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z3xJlAyrWfof" title="DerivativeLiabilities"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-09-302024-09-30_custom_LoanAndSecurityAgreementMember" id="Fact001144" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million was reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, subject to applicable law and specified provisions set forth in the Supplement to the Loan and Security Agreement and solely
to the extent permitted under applicable stock exchange rules without requiring stockholder approval, the Lenders may participate in
certain equity financing transactions of the Company in an aggregate amount of up to $<span id="xdx_901_eus-gaap--DebtInstrumentIssuedPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zbWhotfeXAD5" title="Aggregate transaction amount"><ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001146" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million on the same terms, conditions and pricing
offered by the Company to other investors participating in such financing transactions (such right, the &#8220;Participation Right&#8221;).
<span id="xdx_902_ecustom--ParticipationRightDescription_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zbbR5F4TEkg6" title="Participation right description"><ix:nonNumeric contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001148" name="ABEO:ParticipationRightDescription">The Participation Right automatically terminates upon the earliest of (i) July 1, 2027, (ii) such time that the Lenders have purchased
$1 million of the Company&#8217;s equity securities in the aggregate pursuant to the Participation Right, and (iii) the repayment in
full of all of the obligations under the Loan Agreement.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date and pursuant to the funding of Tranche 1 of the Loan Agreement, the Company issued to each of Avenue and Avenue 2 (collectively,
the &#8220;Warrant Holders&#8221;) warrants to purchase up to $<span id="xdx_90F_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueMember_zvWhcCBUEKW2" title="Warrants purchase amount"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember_us-gaap_WarrantMember_custom_AvenueMember" id="Fact001150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">480,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueTwoMember_zRHkPHHoHMz1" title="Warrants purchase amount"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember_us-gaap_WarrantMember_custom_AvenueTwoMember" id="Fact001152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,920,000</ix:nonFraction></span> of Company common stock, respectively which is
more fully described in Note 10 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001154" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z3D0xIpWowBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future payment obligations of the principal are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z5c7uFcASU82" style="display: none">SCHEDULE
OF FUTURE PAYMENT OBLIGATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20241231_zx7SiEVbuXuh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzeHi_z2frBGi0rYNc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,926</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzeHi_znqqtiYjHVsi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2024-12-31" id="Fact001158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,889</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzeHi_zzIIExoKjtm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2024-12-31" id="Fact001160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzeHi_zSiEbNNpn9qg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total principal</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31" id="Fact001162" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zXCTZC60DKdh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001164" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zCVPMtLTbta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_82A_zlJlVAVUbTyd">EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate number of authorized shares of the Company&#8217;s preferred stock is <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zqGTzgMupP1j" title="Preferred stock shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> shares with a par value of one cent ($<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_z1EfIEquYOj6" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>).
There is <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_zVZ1MdJYcLWk" title="Preferred stock shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zNo35nZLxPWe" title="Preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001170" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001172" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> preferred stock outstanding as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Public
Offerings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2021, the Company closed an underwritten public offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211220__20211221_zjw7Yp9fdStg" title="Stock issued at public offerings"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-12-202021-12-21" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,788,000</ix:nonFraction></span> shares of common stock at a public offering price
of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20211221_zwvluIKHsDM4" title="Public offering price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-12-21" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.75</ix:nonFraction></span> per share and stock purchase warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211221_z3M37BwmFEpl" title="Warrants issued to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-21" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,788,000</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211221_zkcdddGKi18a" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-21" id="Fact001180" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.75</ix:nonFraction></span>. The net proceeds
to the Company were $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20211220__20211221_zWAxVjCnQQz7" title="Proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-12-202021-12-21" id="Fact001182" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.0</ix:nonFraction></span> million, after deducting $<span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20211220__20211221_zCAUpgS3UTJf" title="Payments of underwriting discounts and comissions"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-12-202021-12-21" id="Fact001184" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million of underwriting discounts and commissions and offering expenses payable
by the Company. The net proceeds were allocated to the warrant liability as noted below with the remainder of $<span id="xdx_901_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_pn5n6_c20211221_zjwrYIPQvTAe" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-21" id="Fact001186" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million recorded in
common stock and additional paid-in capital. In the event of certain fundamental transactions involving the Company, the holders of the
stock purchase warrants may require the Company to make a payment based on a Black-Scholes valuation, using specific inputs that are
not considered indexed to the Company&#8217;s stock in accordance with ASC 815, <i>Derivatives and Hed</i>ging (&#8220;ASC 815&#8221;).
Therefore, the Company accounted for the stock purchase warrants as liabilities, which were recorded at the closing date fair value of
$<span id="xdx_905_ecustom--FairValueWarrantLiabilities_iI_pn5n6_c20211221_zVYP1L1dRUJ4" title="Warrant liabilities"><ix:nonFraction name="ABEO:FairValueWarrantLiabilities" contextRef="AsOf2021-12-21" id="Fact001188" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.0</ix:nonFraction></span> million which was based on a Black-Scholes option pricing model. The remainder of the proceeds were allocated to common stock issued
and recorded as a component of equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_z8s0KDpPVvMf" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,788,000</ix:nonFraction></span> stock purchase warrants outstanding related to this public offering. These stock purchase
warrants expire on <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zukbOeXQH48g" title="Warrants maturity date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001192" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">December 21, 2026</ix:nonNumeric></span>. During such time as each warrant is outstanding, the holder of the warrant is entitled to participate
in any dividends or other distribution of assets to holders of shares of common stock. There was no warrant activity during the year
ended December 31, 2024 and 2023, other than the change in fair value of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2024, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRE2lSf75jQ8" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-05-072024-05-07_us-gaap_CommonStockMember" id="Fact001194" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,285,056</ix:nonFraction></span> shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zke0RyAPzJx7" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-05-072024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,142,656</ix:nonFraction></span>
shares of its common stock (the &#8220;2024 Pre-Funded Warrants&#8221;), for an aggregate purchase price of $<span id="xdx_90B_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zIcRx29qLss9" title="Purchase price of common stock"><ix:nonFraction name="ABEO:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2024-05-072024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001198" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">75.0</ix:nonFraction></span> million gross, or $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_z3kYUcC4eht" title="Shares issuance costs"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-05-072024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001200" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">70.2</ix:nonFraction></span>
million net of related costs. The offering price for each share of common stock was $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjR3yBKwgaVi" title="Offering price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-05-07_us-gaap_CommonStockMember" id="Fact001202" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span>, and the offering price for the 2024 Pre-Funded
Warrants was $<span id="xdx_90D_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zeptkaw6Prn4" title="Offering price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001204" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.0699</ix:nonFraction></span>, which represents the per share offering price for the Company&#8217;s common stock less a $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zV8rGhpMo7q" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001206" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> </span>per share exercise
price for each 2024 Pre-Funded Warrant. The 2024 Pre-Funded Warrants are immediately exercisable at a nominal exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_ziZ0KaaK36td" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001208" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share and may be exercised at any time until the pre-funded warrants are exercised in full. On June 24, 2024, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240624__20240624__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zaFiM6mfNPP5" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-06-242024-06-24_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001210" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">700,000</ix:nonFraction></span> of the 2024
Pre-Funded Warrants were exercised and on December 2, 2024 <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241202__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zINMLwQIJzpc" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-02_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001212" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,228,531</ix:nonFraction></span> of the 2024 Pre-Funded Warrants were exercised, leaving <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zw9yyqqZxMQl" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPreFundedWarrantsMember" id="Fact001214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,214,125</ix:nonFraction></span>
2024 Pre-Funded Warrants outstanding as of December 31, 2024. The 2024 Pre-Funded Warrants are classified as equity in accordance with
ASC 815, <i>Derivatives and Hedging</i>, given the prefunded warrants are indexed to the Company&#8217;s own shares of common stock and
meet the requirements to be classified in equity. The 2024 Pre-Funded warrants were recorded at their relative fair value at issuance
in the stockholders&#8217; equity section of the consolidated balance sheet and the 2024 Pre-Funded Warrants are considered outstanding
shares in the basic and diluted earnings per share calculation for year ended December 31, 2024 given their nominal exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Open
Market Sale Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2018, the Company entered into an open market sale agreement (as amended, the &#8220;ATM Agreement&#8221;) with Jefferies
LLC (&#8220;Jefferies&#8221;) pursuant to which, the Company may sell from time to time, through Jefferies, shares of its common stock
for an aggregate sales price of up to $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20180816__20180817__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zam0q7cpvpj5" title="Aggregate sale price"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2018-08-162018-08-17_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember" id="Fact001216" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">75.0</ix:nonFraction></span> million. Any sales of shares pursuant to this agreement are made under the Company&#8217;s
effective &#8220;shelf&#8221; registration statement on Form S-3 that is on file with and has been declared effective by the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sold <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zsMBx08QVUfe" title="Company sold shares of its common stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember" id="Fact001218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,825,954</ix:nonFraction></span> and <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zGpGLkm34eBh" title="Company sold shares of its common stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-01-012023-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember" id="Fact001220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,659,882</ix:nonFraction></span> shares of its common stock under the ATM Agreement during the years ended December 31, 2024 and
2023, respectively, resulting in net proceeds of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zSCuJIGfyE5c" title="Net proceeds"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-01-012024-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember" id="Fact001222" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.5</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zAgC0z4vuAGg" title="Sale of stock value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-01-012023-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember" id="Fact001224" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.4</ix:nonFraction></span> million during the years ended December 31, 2024 and 2023, respectively.
Subsequent to December 31, 2024 and through March 1, 2025, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zIlbPWTNkb4k" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember" id="Fact001226" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">915,925</ix:nonFraction></span> shares of its common stock under the ATM Agreement resulting
in $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zPU6sDrmxWZi" title="value issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember" id="Fact001228" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million in net proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Private
Placement Offering</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2022, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zZ3TywXhELhf" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,065,946</ix:nonFraction></span> shares of its common stock, and in lieu of shares of common stock, pre-funded warrants exercisable
for <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zPmlZaJSfoNk" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">543,933</ix:nonFraction></span> shares of common stock and accompanying warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z7kOqsTnGKbh" title="Warrants purchase, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,609,879</ix:nonFraction></span> shares of its common stock to a group of new and existing
institutional investors in a private placement. The offering price for each share of common stock and accompanying warrant was $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockAndAccompanyingWarrantMember_zGpIDJRFyF0j" title="Offering price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_CommonStockAndAccompanyingWarrantMember" id="Fact001236" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.60</ix:nonFraction></span>,
and the offering price for each pre-funded warrant and accompanying warrant was $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantAndAccompanyingWarrantMember_zfqCXs7rhonh" title="Offering price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantAndAccompanyingWarrantMember" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.59</ix:nonFraction></span>, which equaled the offering price per share of
the common stock and accompanying warrant, less the $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zAHTjz4dh2Me" title="Offering price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share exercise price of each pre-funded warrant. Each accompanying warrant
represents the right to purchase one share of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_z9sEpZUOlgw3" title="Exercise price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember" id="Fact001242" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.75</ix:nonFraction></span> per share of common stock.
The pre-funded warrants were exercised in December 2022 and converted to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20221201__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zzXuOgDdkkG9" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-12-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">543,933</ix:nonFraction></span> shares of commons stock. Total shares sold and converted
during the year ended December 31, 2022 were <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z5vPksdnpo3c" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001246" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,609,879</ix:nonFraction></span> for an aggregate purchase price of $<span id="xdx_901_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zBYNNhBHJaC9" title="Purchase price of common stock"><ix:nonFraction name="ABEO:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001248" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">35.0</ix:nonFraction> </span>million gross, or $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zjidxjHA91Uh" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001250" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">32.6</ix:nonFraction></span> million net of
related costs of $<span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zZaMF9BVLCR6" title="Stock issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_PreFundedWarrantMember" id="Fact001252" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million which was expensed to general and administrative expenses and $<span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zaCQU5YOeAb4" title="Additional paid in capital stock reduction"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001254" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction> </span>million which was recorded as a reduction
to additional paid-in-capital. The net proceeds were allocated to the warrant liability as noted below with the remainder of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z9RbapXKbp89" title="Proceeds from warrant liability'"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001256" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.9</ix:nonFraction></span> million
and $<span id="xdx_900_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_pn5n6_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_ztSBdSUrKxTk" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember" id="Fact001258" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million recorded in additional paid-in capital and common stock, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of certain fundamental transactions involving the Company, the holders of the stock purchase warrants may require the Company
to make a payment based on a Black-Scholes valuation, using specific inputs that are not considered indexed to the Company&#8217;s stock
in accordance with ASC 815. Therefore, the Company is accounting for the stock purchase warrants as liabilities. On November 3, 2022,
the stock purchase warrants were recorded at the closing date fair value of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zmZ2nvQWucP6" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember" id="Fact001260" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">22.0</ix:nonFraction></span> million which was based on a Black-Scholes option pricing
model. The remainder of the proceeds were allocated to common stock issued and recorded as a component of equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zpEztix7VBx" title="Warrant outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-12-31_custom_PrivatePlacementOfferingsMember" id="Fact001262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,609,879</ix:nonFraction></span> warrants outstanding related to this private placement offering. The warrants expire on November
3, 2027. During such time as each warrant is outstanding, the holder of the warrant is entitled to participate in any dividends or other
distribution of assets to holders of shares of common stock. There was no warrant activity during the year ended December 31, 2024 and
2023, other than the change in fair value of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Direct
Placement Offering</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2023, the Company sold <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwOMkhcsXxrk" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-062023-07-06_us-gaap_CommonStockMember" id="Fact001264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,284,407</ix:nonFraction></span> shares of its common stock, and in lieu of shares of common stock, pre-funded warrants exercisable
for <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_z5pniHJteYWa" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-07-062023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember" id="Fact001266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,919,140</ix:nonFraction></span> shares of common stock (the &#8220;2023 Pre-Funded Warrants&#8221;), to a group of existing institutional investors for
an aggregate purchase price of $<span id="xdx_907_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zycai40UA0Ch" title="Purchase price of common stock"><ix:nonFraction name="ABEO:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-062023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember" id="Fact001268" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.0</ix:nonFraction></span> million gross, or $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zhYYni0HVDo" title="Shares issuance costs"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-062023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember" id="Fact001270" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">23.0</ix:nonFraction></span> million net of related costs. The offering price for each share of common
stock was $<span id="xdx_901_eus-gaap--SharePrice_iI_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD2JW35X3VNj" title="Offering price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-07-06_us-gaap_CommonStockMember" id="Fact001272" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.03</ix:nonFraction></span>, and the offering price for the 2023 Pre-Funded Warrants was $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zIBxzy2TpIa9" title="Offering price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember" id="Fact001274" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.0299</ix:nonFraction></span>, which represents the per share offering price for
the Company&#8217;s common stock less a $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zr1ChDX8xH7a" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember" id="Fact001276" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> </span>per share exercise price for each such 2023 Pre-Funded Warrant. The 2023 Pre-Funded Warrants
are immediately exercisable at a nominal exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_znEqPkaogfaf" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember" id="Fact001278" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, may be exercised at any time and do not have an expiration
date. On May 9, 2024, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240509__20240509__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zbRS7ESYk3xk" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-05-092024-05-09_custom_TwoThousandTwentyThreePreFundedWarrantsMember" id="Fact001280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> of the 2023 Pre-Funded Warrants were exercised, leaving <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zXiAfdIQ7qTd" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePreFundedWarrantsMember" id="Fact001282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,619,140</ix:nonFraction></span> 2023 Pre-Funded Warrants outstanding
as of December 31, 2024. The 2023 Pre-Funded Warrants are classified as equity in accordance with ASC 815, <i>Derivatives and Hedging</i>,
given the 2023 Pre-Funded Warrants are indexed to the Company&#8217;s own shares of common stock and meet the requirements to be classified
in equity. The 2023 Pre-Funded Warrants were recorded at their relative fair value at issuance in the stockholders&#8217; equity section
of the consolidated balance sheet and the 2023 Pre-Funded Warrants are considered outstanding shares in the basic and diluted earnings
per share calculation for the year ended December 31, 2024 given their nominal exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Common
Stock Warrants related to the Loan and Security Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, in connection with entering into the Loan and Security Agreement, the Company issued to each of Avenue and Avenue 2
(collectively, the &#8220;Warrant Holders&#8221;) warrants to purchase up to $<span id="xdx_902_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueMember_ztveWeRlMpr3" title="Warrants purchase amount"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember_custom_AvenueMember" id="Fact001284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">480,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueTwoMember_z5A8pnbCdpx" title="Warrants purchase amount"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember_custom_AvenueTwoMember" id="Fact001286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,920,000</ix:nonFraction></span> worth of shares, respectively, of
Company common stock (collectively, the &#8220;January Warrants&#8221;). The Warrants expire on January 8, 2029 (the &#8220;Expiration
Date&#8221;) and upon issuance, had an exercise price per share equal to the lesser of (i) $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zLu9wM0xfHse" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001288" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.75</ix:nonFraction></span> and (ii) the price per share of the
Company&#8217;s next bona fide round of equity financing before September 30, 2024 in which the Company sells or issues shares of its
common stock, excluding certain excluded issuances as defined in the Supplement. In connection with the underwritten common stock offering
consummated on May 7, 2024, and pursuant to the term of the January Warrants, the exercise price of the January Warrants was reduced
to $<span id="xdx_903_eus-gaap--WarrantExercisePriceDecrease_c20240507__20240507__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9M1Zhf7xe9" title="Exercise price per share"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2024-05-072024-05-07_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember" id="Fact001290" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share for <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zi1B1wWPj0Rk" title="Shares of common stock issuable upon exercise of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-05-07_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember" id="Fact001292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,681</ix:nonFraction></span> shares. In addition, upon a change of control where the per share price of the Company common stock is
less than or equal to two times that of the exercise price, the Warrant Holders would be entitled to receive the shares of common stock
underlying the January Warrants without payment of the exercise price. On January 8, 2024, the January Warrants did not include an explicit
share limit and the number of shares issuable under the warrant agreements were variable based on the exercise price and therefore the
January Warrants were liability classified based on a Black-Scholes valuation in accordance with ASC 815 and were recorded at the closing
date fair value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zrjfEBpqJOO6" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember" id="Fact001294" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million which was based on a Black-Scholes option pricing model. On September 30, 2024, per the terms of the
January Warrants, the exercise price and the number of shares issuable became set at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zJS4gA1xs99i" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-30_custom_LoanAndSecurityAgreementMember" id="Fact001296" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zmQOMlAwFG8g" title="Shares of common stock issuable upon exercise of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-09-30_custom_LoanAndSecurityAgreementMember" id="Fact001298" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,681</ix:nonFraction></span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Holders may exercise the January Warrants at any time, or from time to time up to and including the Expiration Date, by making
a cash payment equal to the exercise price multiplied by the quantity of shares. The Warrant Holders may also exercise the January Warrants
on a cashless basis by receiving a net number of shares calculated pursuant to the formula set forth in the January Warrants. The January
Warrants are subject to anti-dilution adjustments for stock dividends, stock splits, and reverse stock splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001300" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zQKqSSQ65Qxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_82D_zdyuTsPb3Ud4">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company previously granted stock options under its 2005 Equity Incentive Plan (the &#8220;2005 Incentive Plan&#8221;), under which no
further grants can be made. In addition, prior to May 17, 2023, the Company had previously granted stock options and stock awards under
the Abeona Therapeutics Inc. 2015 Equity Incentive Plan (the &#8220;2015 Incentive Plan&#8221;). As of May 17, 2023, no further grants
can be made under the 2015 Incentive Plan. The Company now grants stock options and stock awards under the Abeona Therapeutics Inc. 2023
Equity Incentive Plan (the &#8220;2023 Incentive Plan&#8221;) which was approved by stockholders on May 17, 2023. On April 24, 2024,
stockholders approved an amendment to the 2023 Incentive Plan to increase the shares authorized for issuance from <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240424__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zMJc4DjCKfWd" title="Increase in shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-04-24_srt_MinimumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember" id="Fact001302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,700,000</ix:nonFraction></span> shares to
<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240424__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zlKFIPwmfQi8" title="Increase in shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-04-24_srt_MaximumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,200,000</ix:nonFraction></span> shares. On December 20, 2024, stockholders approved an additional increase in the shares authorized for issuance under the
2023 Incentive Plan from <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241220__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_z4tCmGvXUzob" title="Increase in shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-12-20_srt_MinimumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,200,000</ix:nonFraction></span> shares to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241220__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zotA7lpId0x7" title="Increase in shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-12-20_srt_MaximumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember" id="Fact001308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,400,000</ix:nonFraction></span> shares. As of December 31, 2024, there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--InducementPlanMember_zn9XnyWOURwc" title="Shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_InducementPlanMember" id="Fact001310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,251,251</ix:nonFraction></span> shares available to be granted
under the 2023 Incentive Plan. In addition, in 2023, the Company&#8217;s board of directors approved various restricted stock awards
granted to certain new hires as inducement grants. On October 10, 2023, the Company&#8217;s board of directors approved the Abeona Therapeutics
Inc. 2023 Employment Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;). As of December 31, 2024, there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231_z1wEqKL4jcw3" title="Shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">584,700</ix:nonFraction></span>
shares available to be granted under the Inducement Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001314" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zhx79hHirrGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock-based compensation (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zaDyHTSQSI86" style="display: none">SCHEDULE
OF STOCK BASED COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_z9CUCC6VF1n4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zduZHkbXbUi3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTN8oypPqUAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001316" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,561</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001317" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,085</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zq3XjoK6NBM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001319" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,067</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,683</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_ztXtTAzvfhI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001322" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,628</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact001323" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,768</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_ziBa1OzRCu49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of each option award on the date of grant using the Black-Scholes option-pricing model. The Company
then recognize the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over
the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility &#8211; the Company estimates the volatility of the share price at the date of grant using a &#8220;look-back&#8221; period
    which coincides with the expected term, defined below. The Company believes using a &#8220;look-back&#8221; period which coincides
    with the expected term is the most appropriate measure for determining expected volatility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term &#8211; the Company estimates the expected term using the &#8220;simplified&#8221; method, as outlined in SEC Staff Accounting
    Bulletin No. 107, &#8220;Share-Based Payment.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate &#8211; the Company estimates the risk-free interest rate using the U.S. Treasury yield curve for periods equal to
    the expected term of the options in effect at the time of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    &#8211; the Company uses an expected dividend yield of zero because the Company has not declared nor paid a cash dividend, nor are
    there any plans to declare a dividend.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not grant any stock options in the year ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures
arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001325" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3xd7BT9pwj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock option activity during the year ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z1irdfs6brwl" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/>
 Average<br/>
 Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/>
 Average<br/>
 Remaining<br/>
 Contractual<br/>
 Term (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/>
 Intrinsic Value <br/> (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zs5KKlP8Tlxh" title="Number of options, Outstanding balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" id="Fact001327" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,770</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zxhjQjuzF3wi" title="Weighted average exercise price, Outstanding balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.04</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zoOgPUiMgYW3" title="Weighted average remaining contractual term (years), outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact001331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.42</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231_zhOuHtWkkTOh" title="Aggregate intrinsic value, Outstanding balance" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zC8vXntWN1Vb" title="Number of options, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1335">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zTv7A8olJ1Q8" title="Weighted average exercise price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zNZYO1nmE9i7" title="Number of options, cancelled/forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2023-01-012023-12-31" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,769</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z2OVPZwNT3Ib" title="Weighted average exercise price, cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="Fact001341" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zBjYOSihAHQa" title="Number of options, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zsrxxzBv3Dkc" title="Weighted average exercise price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zd8UBkJQtjkk" title="Number of options, outstanding balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zcQMxsCSTkuf" title="Weighted average exercise price, outstanding balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zCGEpC2NUIj6" title="Weighted average remaining contractual term (years), outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001351" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.83</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231_zeAxJOPu9b04" title="Aggregate intrinsic value, outstanding balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="Fact001353" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_z7avEf4FPrid" title="Number of options, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zihb5WU6BZde" title="Weighted average exercise price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zoZOpr5tj9ia" title="Number of options, cancelled/forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,414</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zpNtFtsI3sn9" title="Weighted average exercise price, cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact001361" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">33.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_znEJE6XmoK2l" title="Number of options, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1363">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zVTyqDs62Whh" title="Weighted average exercise price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zhWm5QnWfZD6" title="Number of options, outstanding balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">176,587</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zCh0HJ8zLHDi" title="Weighted average exercise price, outstanding balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001369" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.64</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziyX67aZ0Yv1" title="Weighted average remaining contractual term (years), outstanding"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001371" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.83</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231_z12PkmH0nqA3" title="Aggregate intrinsic value, outstanding balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="Fact001373" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zzr2mTlb8GN3" title="Number of options, exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">163,386</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z8WlgNDZrIw5" title="Weighted average exercise price, exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001377" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">39.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zmo7SlZz8WLl" title="Weighted average remaining contractual term (years), exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001379" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.77</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231_zuPlORunFxj6" title="Aggregate intrinsic value, exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31" id="Fact001381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231_z1yXwzJVUUFg" title="Number of options, unvested" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-12-31" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,201</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231_zDmPxnahLmei" title="Weighted average exercise price, unvested" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31" id="Fact001385" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">33.29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zq0oV7D3YJre" title="Weighted average remaining contractual term (years), unvested"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001387" name="ABEO:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1">6.65</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iI_pn3n3_c20241231_zYDYjRIXaGnc" title="Aggregate intrinsic value, unvested" style="text-align: right"><ix:nonFraction name="ABEO:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" contextRef="AsOf2024-12-31" id="Fact001389" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z47dxooNsrNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair
value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s
common stock. As of December 31, 2024, the total compensation cost related to non-vested option awards not yet recognized was $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyKb220Q7DGk" title="Compensation cost related to non-vested options not recognized"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001391" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million
with a weighted average remaining vesting period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDvC6KsTGWb9" title="Weighted average period total compensation costs related to non-vested options"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember31393828" format="ixt-sec:duryear" id="Fact001393" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember" escape="true" id="Fact001395" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_z7HjMJozkk1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there are no options outstanding under the 2005 Incentive Plan. Further information regarding options outstanding
under the 2015 Incentive Plan as of December 31, 2024 is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zSeaet6NdvZd" style="display: none">SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of <br/>
Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options<br/>
 Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining<br/>
 Life In<br/>
 Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options<br/>
 Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining<br/>
 Life in<br/>
 Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zC3Ncovv0UH5" title="Range of exercise price, lower limit" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember" id="Fact001397" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziZq3iXSNOGe" title="Range of exercise price, upper limit" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember" id="Fact001399" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zM5URYCJVBzk" title="Number of options outstanding" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember" id="Fact001401" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,088</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMvFZa0EqPoj" title="Weighted-average remaining life in years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001403" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zfo3vcC2SwY8" title="Weighted-average exercise price" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember" id="Fact001405" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.52</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zgLIwrVEzBFi" title="Number of options exercisable" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zW0FR4cf1qM" title="Weighted-average remaining life in years, exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001409" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.9</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zl9EygmFbHVg" title="Weighted-average exercise price, exercisable" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember" id="Fact001411" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.16</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOPNC5y7xldc" title="Range of exercise price, lower limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zLBO8t9Y5Oq6" title="Range of exercise price, upper limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">47.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4Q8iB0tETZg" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember" id="Fact001417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">104,279</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zudchz5beXQl" title="Weighted-average remaining life in years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001419" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8s82GKavb05" title="Weighted-average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember" id="Fact001421" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">33.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNAFz0O5ADF8" title="Number of options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember" id="Fact001423" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99,263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zd4kfk2GTaUj" title="Weighted-average remaining life in years, exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001425" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.4</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKR6wohT8Uec" title="Weighted-average exercise price, exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember" id="Fact001427" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">33.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zwoZNAivC8cb" title="Range of exercise price, lower limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">54.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztHtG4xg92H1" title="Range of exercise price, upper limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember" id="Fact001431" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVTgnJbAWxn4" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember" id="Fact001433" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1swoirEi3ck" title="Weighted-average remaining life in years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001435" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.2</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zgIQ5jY4dwg7" title="Weighted-average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember" id="Fact001437" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">56.96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzgl7yQYfE4b" title="Number of options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember" id="Fact001439" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,769</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z8yLbTdpJYV5" title="Weighted-average remaining life in years, exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001441" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.2</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVxSOjWG9AKj" title="Weighted-average exercise price, exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember" id="Fact001443" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">56.96</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWLspd65hyJ6" title="Range of exercise price, lower limit" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember" id="Fact001445" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">164.75</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zeHg76yuS3O5" title="Range of exercise price, upper limit" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember" id="Fact001447" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">183.50</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zQUYP1Cg4WRf" title="Number of options outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember" id="Fact001449" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zj2SBTcyV6x8" title="Weighted-average remaining life in years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001451" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.1</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z8a1QitP9HA1" title="Weighted-average exercise price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember" id="Fact001453" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">164.75</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBQTkGNTfDE8" title="Number of options exercisable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember" id="Fact001455" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z6mwY42PJ2Xk" title="Weighted-average remaining life in years, exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001457" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.1</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4AQfqqqQdm" title="Weighted-average exercise price, exercisable" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember" id="Fact001459" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">164.75</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zjJHzyr57zfa" title="Number of options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember" id="Fact001461" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">176,587</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zBC76UVisnV2" title="Number of options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember" id="Fact001463" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">163,386</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zL79QiLuZ3Y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted
Stock:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001465" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zg2zn1toFKU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock award activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zMgQXNlT6Ys9" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/>
Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average<br/>
 Grant Date Fair<br/>
 Value Per Unit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCtzlseGmGe5" title="Restricted common stock awards, balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember" id="Fact001467" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">816,958</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBFXcfp2FdUb" title="Weighted-average grant date fair value, balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember" id="Fact001469" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHBunrTltDJa" title="Restricted common stock awards, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468" id="Fact001471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,958,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB9nVUIef3i7" title="Weighted-average grant date fair value, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468" id="Fact001473" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaOPRmWEPmNj" title="Restricted common stock awards, cancelled/forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468" id="Fact001475" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,398</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkhEq2bGMIUe" title="Weighted-average grant date fair value, cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468" id="Fact001477" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.32</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1G3Cm4a5qHk" title="Restricted common stock awards, vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468" id="Fact001479" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">270,550</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVybEXlOJfMi" title="Weighted-average grant date fair value, vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468" id="Fact001481" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.59</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zS5Ax97waVh4" title="Restricted common stock awards, balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember" id="Fact001483" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,448,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwNwtQmU6Qdb" title="Weighted-average grant date fair value, balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember" id="Fact001485" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znUFmjRYMMdj" title="Restricted common stock awards, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484" id="Fact001487" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,065,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUkA9hlrNXFi" title="Weighted-average grant date fair value, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484" id="Fact001489" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.95</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXkymYkPuR88" title="Restricted common stock awards, cancelled/forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484" id="Fact001491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">183,114</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfGvEA8kitBi" title="Weighted-average grant date fair value, cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484" id="Fact001493" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyDyzKnZEExc" title="Restricted common stock awards, vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484" id="Fact001495" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,009,298</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdWv19Qb9lyf" title="Weighted-average grant date fair value, vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484" id="Fact001497" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.64</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSyyCfIAHalb" title="Restricted common stock awards, balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember" id="Fact001499" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,320,811</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zogNe2X9uHL9" title="Weighted-average grant date fair value, balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember" id="Fact001501" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.60</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zMLvF2ap3Y43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20240101__20241231_zPIIpnu6hJm6" title="Compensation cost related to restricted common stock not recognized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001503" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.9</ix:nonFraction></span> million of total unrecognized compensation expense related to unvested restricted stock awards,
which is expected to be recognized over a weighted average vesting period of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231_zPozE0gtYUJk" title="Weighted average compensation costs related to restricted common stock"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.1</ix:nonNumeric></span> years. The total fair value of restricted stock awards
that vested was $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_pn5n6_c20240101__20241231_z4T9EzPSTshl" title="Fair value of restricted stock awards that vested"><ix:nonFraction name="ABEO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001507" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span> million and $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_pn5n6_c20230101__20231231_zaInAj1um6Sf" title="Fair value of restricted stock awards that vested"><ix:nonFraction name="ABEO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" contextRef="From2023-01-012023-12-31" id="Fact001509" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001511" name="us-gaap:CollaborativeArrangementDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CollaborativeArrangementDisclosureTextBlock_zSj3kL8WKD5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8211; <span id="xdx_828_z67un7fKoIbg">LICENSE/SUPPLIER AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement Relating to Recessive Dystrophic Epidermolysis Bullosa (RDEB)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the Company entered into two licensing agreements between the Company and The Board of Trustees of Leland Stanford Junior University
(&#8220;Stanford&#8221;) to develop EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)) and EB-201 (AAV DJ COL7A1) and
to license the invention &#8220;Gene Therapy for Recessive Dystrophic EB using Genetically Corrected Autologous Keratinocytes&#8221;.
Under the terms of the licensing agreements, the Company paid an upfront of licensing fees in cash and is subject to annual license maintenance
fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments, and royalty
payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, the Company is subject to remaining
milestone payments totaling approximately $<span id="xdx_908_ecustom--RemainingMilestonePaymentsDue_iI_pn5n6_c20241231__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--LicenseAgreementMember_zX7Xtarg6rMa" title="Remaining milestone payments due"><ix:nonFraction name="ABEO:RemainingMilestonePaymentsDue" contextRef="AsOf2024-12-31_custom_LicenseAgreementMember" id="Fact001513" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million which is due upon FDA approval of pz-cel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement Relating to Novel AAV Capsids (&#8220;AIM&#8482; capsids&#8221;)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the Company licensed an international patent family from The University of North Carolina at Chapel Hill (&#8220;UNC&#8221;) covering
novel AAV capsids (&#8220;AIM&#8482; capsids&#8221;) that may potentially be used to deliver a wide variety of therapeutic transgenes
to human cells to treat genetic diseases. Under the terms of the licensing agreements, the Company paid an upfront licensing fees in
cash and is subject to on-going patent expenses incurred in relation to the patents licensed under this agreement and annual license
maintenance fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments,
and royalty payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty
payments under this agreement have been made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement Relating to CLN1 Disease</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the Company licensed from UNC rights to two patent families directed to treating CLN1 disease (also known as infantile Batten disease).
Under the terms of the licensing agreements, the Company paid an upfront of licensing fees in cash and is subject to on-going patent
expenses incurred in relation to the patents licensed under this agreement and annual license maintenance fees. In addition, the Company
is subject to the achievement of certain milestones, regulatory approval milestone payments, and royalty payments in the low single digits
on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty payments under this agreement have been
made. The Company subsequently sublicensed the license to Taysha Gene Therapies (&#8220;Taysha&#8221;), see detail of the sublicense
agreement below. As part of the agreement with UNC, the Company is obligated to pay to UNC a percentage of any sublicense revenue that
the Company receives under the agreement. The Company recognizes any payments under this agreement as royalties in the consolidated statement
of operations and comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement Relating to Rett Syndrome</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2019, the Company licensed rights to one patent family from UNC and two patent families from The University Court of the University of
Edinburgh (&#8220;U. Edinburgh&#8221;) and The University Court of the University of Glasgow (&#8220;U. Glasgow&#8221;) relating to gene
therapy for the treatment of Rett Syndrome. Under the terms of the licensing agreements, the Company paid an upfront of licensing fees
in cash and is subject to on-going patent expenses incurred in relation to the patents licensed under this agreement and annual license
maintenance fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments,
and royalty payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty
payments under this agreement have been made. The Company subsequently sublicensed the license to Taysha, see detail of the sublicense
agreement below. As part of the agreement with UNC, the Company is obligated to pay to UNC and U. Edinburgh a percentage of any sublicense
revenue that the Company receives under the agreement. The Company recognizes any payments under this agreement as royalties in the consolidated
statement of operations and comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sublicense
and Inventory Purchase Agreements Relating to CLN1 Disease</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the Company entered into sublicense and inventory purchase agreements with Taysha relating to a potential gene therapy for
CLN1 disease. Under the sublicense agreement, Taysha received worldwide exclusive rights to intellectual property and know-how relating
to the research, development, and manufacture of the potential gene therapy, which the Company had referred to as ABO-202. Under the
inventory purchase agreement, the Company sold to Taysha certain inventory and other items related to ABO-202. The Company assessed the
nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated whether such
functionality can be retained without ongoing activities by the Company and determined that the license has significant stand-alone functionality.
Furthermore, the Company has no ongoing activities associated with the license to support or maintain the license&#8217;s utility. Based
on this, the Company determined that the pattern of transfer of control of the license to Taysha was at a point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price of the contract includes (i) $<span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20200801__20200831__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zkVPL359Mhxj" title="Fixed consideration"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="From2020-08-012020-08-31_custom_SublicenseAndInventoryPurchaseAgreementsMember" id="Fact001515" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction> </span>million of fixed consideration, (ii) up to $<span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zPXJmd0lJJyg" title="Variable consideration"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="From2020-08-012020-08-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember" id="Fact001517" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.0</ix:nonFraction></span> million of variable consideration
in the form of event-based milestone payments, (iii) up to $<span id="xdx_904_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--SalesBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zJ52FYet98rh" title="Variable consideration"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="From2020-08-012020-08-31_custom_SalesBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember" id="Fact001519" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span> million of variable consideration in the form of sales-based milestone
payments, and (iv) high single-digit royalty-based payments based on net sales. The Company is obligated to pay a portion of milestone
payments and royalties on net sales received from Taysha to the UNC.. The event-based milestone payments are based on certain development
and regulatory events occurring. At inception, the Company evaluated whether the milestone conditions had been achieved and if it was
probable that a significant cumulative revenue reversal would not occur before recognizing the associated revenue and determined that
these milestone payments were not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, and
were not considered probable of being achieved until those approvals were received. Accordingly, at inception, the Company fully constrained
the $<span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zMChVZ2nusy" title="Variable consideration"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="From2020-08-012020-08-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember" id="Fact001521" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.0</ix:nonFraction></span> million of event-based milestone payments until such time that it is probable that significant cumulative revenue reversal
would not occur. The sales-based milestone payments and other royalty-based payments are based on a level of sales for which the license
is deemed to be the predominant item to which the royalties relate. The Company will recognize revenue for these payments at the later
of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has
been satisfied or partially satisfied. To date, the Company has not recognized any sales-based or royalty revenue resulting from this
licensing arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this arrangement, the Company has <span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_do_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z60TZGf1NiHe" title="Revenue recognized"><span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_do_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zipUDwAScJF6" title="Revenue recognized"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember" id="Fact001523" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember" id="Fact001525" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t recognized any revenue during the years ended December 31, 2024 and 2023, respectively based on
event-based-milestone payments. The Company has <span id="xdx_907_eus-gaap--ContractWithCustomerAssetNet_iI_pn5n6_do_c20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zcKsOiSdq4xh" title="Contract assets"><span id="xdx_908_eus-gaap--ContractWithCustomerAssetNet_iI_pn5n6_do_c20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zkrYUICKN45e" title="Contract assets"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="AsOf2024-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember" id="Fact001527" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="AsOf2023-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember" id="Fact001529" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> contract assets or liabilities as of December 31, 2024 and 2023 as a result of this
transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sublicense
Agreement Relating to Rett Syndrome</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a sublicense agreement with <span style="background-color: white">Taysha </span>for a gene therapy
for Rett syndrome, including intellectual property related to MECP2 gene constructs and regulation of their expression. The agreement
grants Taysha worldwide exclusive rights to intellectual property developed by scientists at UNC, U. Edinburgh and the Company, and the
Company&#8217;s know-how relating to the research, development, and manufacture of the gene therapy for Rett syndrome and MECP2 gene
constructs and regulation of their expression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assessed the nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated
whether such functionality can be retained without ongoing activities by the Company and determined that the license has significant
stand-alone functionality. Furthermore, the Company has no ongoing activities associated with the license to support or maintain the
license&#8217;s utility. Based on this, the Company determined that the pattern of transfer of control of the license to Taysha was at
a point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price of the contract includes (i) $<span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20201001__20201031__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_z49vKtRYCyJl" title="Fixed consideration"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="From2020-10-012020-10-31_custom_SublicenseAgreementRelatingToRettSyndromeMember" id="Fact001531" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span>
million of fixed consideration, (ii) up to $<span id="xdx_900_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zyUD8WqiTW22" title="Variable consideration"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="From2020-10-012020-10-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember" id="Fact001533" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.5</ix:nonFraction></span>
million of variable consideration in the form of event-based milestone payments, (iii) up to $<span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--SalesBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zo0tnsOWolc9" title="Variable consideration"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="From2020-10-012020-10-31_custom_SalesBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember" id="Fact001535" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span>
million of variable consideration in the form of sales-based milestone payments, and (iv) high single-digit royalty-based payments
based on net sales. The Company is obligated to pay a portion of milestone payments and royalties on net sales received from Taysha
to the UNC and U. Edinburgh. The event-based milestone payments are based on certain development and regulatory events occurring.
The Company evaluated whether the milestone conditions have been achieved and if it is probable that a significant cumulative
revenue reversal would not occur before recognizing the associated revenue. The Company determined that these milestone payments are
not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, and are not considered
probable of being achieved until those approvals are received. Accordingly, the Company has fully constrained the $<span id="xdx_90E_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zkbFYFeAtvN5" title="Variable consideration"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="From2020-10-012020-10-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember" id="Fact001537" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.5</ix:nonFraction></span>
million in event-based milestone payments until such time that it is probable that a significant cumulative revenue reversal would
not occur. The sales-based milestone payments and other royalty-based payments are based on a level of sales for which the license
is deemed to be the predominant item to which the royalties relate. The Company will recognize revenue for these payments at the
later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been
allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales-based or royalty revenue
resulting from this licensing arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this arrangement, the Company recognized <span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zcSroRFpu2n1" title="Revenue recognized::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1539">nil</span></span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zzEPyP49vWs6" title="Revenue recognized"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_SublicenseAgreementRelatingToRettSyndromeMember_us-gaap_LicenseMember" id="Fact001541" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million in revenue during the years ended December 31, 2024 and 2023. The revenue
recognized was related to clinical milestones achieved by our sublicensor as per the sublicense agreement noted above. As of December
31, 2024 and 2023, the Company does not have any contract assets or contract liabilities as a result of this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ultragenyx
License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2022, the Company and Ultragenyx Pharmaceutical Inc. (&#8220;Ultragenyx&#8221;) entered into an exclusive license agreement (the
&#8220;License Agreement&#8221;) for AAV gene therapy, ABO-102, for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the
License Agreement, Ultragenyx assumed responsibility for the ABO-102 program from the Company, with the exclusive right to develop, manufacture,
and commercialize ABO-102 worldwide. Also pursuant to the License Agreement, following regulatory approval, the Company is eligible to
receive tiered royalties from mid-single-digit up to 10% on net sales and up to $<span id="xdx_90A_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20220515__20220516__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--LicenseAgreementTermsMember__srt--RangeAxis__srt--MaximumMember_zuIE9Lgjx83g" title="Milestone payments"><ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="From2022-05-152022-05-16_us-gaap_LicenseAgreementTermsMember_srt_MaximumMember" id="Fact001543" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span> million in commercial milestone payments. Both
forms of consideration comprise the transaction price to which the Company expects to be entitled in exchange for transferring the related
intellectual property and certain, contractually-specified, transition services to Ultragenyx. The sales-based royalty and milestone
payments are subject to the royalty recognition constraint. As such, these fees are not recognized as revenue until the later of: (a)
the occurrence of the subsequent sale, and (b) the performance obligation to which they relate has been satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
pursuant to the License Agreement, Ultragenyx will reimburse the Company for certain development and transition costs actually incurred
by the Company. These costs are passed through to Ultragenyx without mark-up. The Company has determined that these costs are not incurred
for the purpose of satisfying any performance obligation under the License Agreement. Accordingly, the reimbursement of these costs is
recognized as a reduction of research and development costs. As of December 31, 2024 and 2023, the Company does not have any contract
assets or contract liabilities as a result of this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001545" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p id="xdx_809_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z8HCPp7xlJGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; <span id="xdx_828_zXq3gw5kLddg">401(k) PLAN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a tax-qualified employee savings and retirement plan (the &#8220;401(k) Plan&#8221;) covering all the Company&#8217;s
employees in the United States. Pursuant to the 401(k) Plan, employees may elect to reduce their current compensation by up to the
statutorily prescribed annual limit ($<span id="xdx_903_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20240101__20241231_zd6p6QprhXIl" title="Maximum annual contribution per employee under 401(k) plan"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001547" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,000</ix:nonFraction></span>
in 2024 and $<span id="xdx_90A_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20230101__20231231_zpjC064qTKp4" title="Maximum annual contribution per employee under 401(k) plan"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" contextRef="From2023-01-012023-12-31" id="Fact001549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,500</ix:nonFraction></span>
in 2023 for employees who are under age 50 and $<span id="xdx_903_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--UnderAgeFifftyMember_zftxr22wjCmc"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" contextRef="From2024-01-012024-12-31_custom_UnderAgeFifftyMember" id="Fact001550" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,500</ix:nonFraction></span>
in 2024 and $<span id="xdx_908_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20230101__20231231__us-gaap--RetirementPlanTypeAxis__custom--UnderAgeFifftyMember_zDx120x1SJ9k"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" contextRef="From2023-01-012023-12-31_custom_UnderAgeFifftyMember" id="Fact001551" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></span> in 2023 for employees who are age 50 and older) and to have the amount of such reduction contributed to the
401(k) Plan. The 401(k) Plan is intended to qualify under Section 401 of the Internal Revenue Code so that contributions by
employees or by us to the 401(k) Plan, and income earned on 401(k) Plan contributions, are not taxable to employees until withdrawn
from the 401(k) Plan, and so that contributions by us, if any, will be deductible by us when made. At the direction of each
participant, the Company invests the assets of the 401(k) Plan in any of over <span id="xdx_902_ecustom--NumberOfInvestmentOptions_pp0p0_uInteger_c20240101__20241231_zR4Aql5j2Eq4" title="Number of investment options"><ix:nonFraction name="ABEO:NumberOfInvestmentOptions" contextRef="From2024-01-01to2024-12-31" id="Fact001553" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Integer">50</ix:nonFraction></span>
investment options. Company contributions under the 401(k) Plan were $<span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20240101__20241231_zKDBx9Ox0a0h" title="Company contributions under 401 (k) Plan"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2024-01-01to2024-12-31" id="Fact001555" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million and $<span id="xdx_909_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20230101__20231231_z42yyUZWvjD8" title="Company contributions under 401 (k) Plan"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2023-01-012023-12-31" id="Fact001557" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001559" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_z5haTvmOyjp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 &#8211; <span id="xdx_82A_zxq5iVVvU7vf">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001561" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zIT3yL4xvrif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense differs from the statutory amounts for each of the following years (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z1W4eLi6yH3d" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zJrc5w5X32a5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_z1Lv5Z1LexAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBz0L9_zOi1p7PEgYla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Income taxes at U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001563" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,384</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001564" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,379</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBz0L9_znwLYfLORRV" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001566" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">679</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001567" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">242</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_iN_pn3n3_di_msITEBz0L9_zqbiZBf7ZUUc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ABEO:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" contextRef="From2024-01-01to2024-12-31" id="Fact001569" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,535</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ABEO:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" contextRef="From2023-01-012023-12-31" id="Fact001570" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,137</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_pn3n3_maITEBz0L9_zStgbwMgLEj8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" contextRef="From2024-01-01to2024-12-31" id="Fact001572" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1573">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBz0L9_z5VSxE5GRaok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,418</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001576" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,687</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_pn3n3_maITEBz0L9_zuCOYqaUcNqe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact001578" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" contextRef="From2023-01-012023-12-31" id="Fact001579" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_pn3n3_maITEBz0L9_zRVRCh5Pe861" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expired tax losses and credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,503</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maITEBz0L9_zT3AeU3O6XRl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Permanent differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" contextRef="From2024-01-01to2024-12-31" id="Fact001584" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">127</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" contextRef="From2023-01-012023-12-31" id="Fact001585" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBz0L9_zvM9t0sKr9v9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1588">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zvcIHMyzQjol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001590" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVO5kdlAUC96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes are provided for the temporary differences between the financial reporting bases and the tax bases of the Company&#8217;s assets
and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zhZZThYB4F77" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zlq4G6heDt6f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zoIEbYn8wVP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzzCb_zwhThLZPbTJ8" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001592" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">88,059</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78,698</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzzCb_zDyX3qoqWaKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">General business credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31" id="Fact001595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2023-12-31" id="Fact001596" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,752</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_maDTAGzzCb_zvT88LMPKyt2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextRef="AsOf2024-12-31" id="Fact001598" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextRef="AsOf2023-12-31" id="Fact001599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,780</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_iI_pn3n3_maDTAGzzCb_zE9MlxSq7I1f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Property, equipment and goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" contextRef="AsOf2024-12-31" id="Fact001601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" contextRef="AsOf2023-12-31" id="Fact001602" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">887</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzzCb_zSAaX1cUYVD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001604" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,983</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzzCb_z8KLfhLjrT97" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-12-31" id="Fact001607" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">661</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2023-12-31" id="Fact001608" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">615</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzzCb_zdMa7KV4X4M8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2024-12-31" id="Fact001610" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2023-12-31" id="Fact001611" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzzCb_z7UzmmDfG9qe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact001614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,843</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzzCb_zdaC636szIkg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001616" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001617" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzzCb_maDTALNzbeO_zK01rSVLRfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001619" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">114,406</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001620" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzbeO_zUXoTu7W4fbl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001622" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">114,406</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108,988</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzbeO_zeKO9OwMaNW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net deferred taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1625">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1626">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zwcBSgtJp9v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company identified adjustments related primarily to the recognition of deferred tax assets for stock-based
compensation. As a result, the Company has written off $<span id="xdx_901_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn5n6_c20241231_zEuoaTZsKFVh" title="Deferred tax assets"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2024-12-31" id="Fact001628" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.0</ix:nonFraction></span> million of deferred tax assets in the current period, with a corresponding
adjustment to the valuation allowance. There was no impact to total tax expense in the prior periods or current period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
operating Loss and Other Carryforwards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_z35pTDxJZTna" title="Operating loss carryforward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact001630" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">416.1</ix:nonFraction></span> million of U.S. federal net operating loss carryforwards and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_zqJuUBa6t2I2" title="General business credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact001632" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million of general business
credit carryforwards. These carryforwards expire as follows (in thousands):</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001634" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock"><p id="xdx_89D_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zJBwSyeSkln9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_zHBZp0r9iRDf" style="display: none">SUMMARY
OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net operating <br/>
loss carryforwards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">General <br/>
business credit<br/>
 carryforwards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zcPE0tjSieda" title="Net operating loss carryforwards" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyFiveMember" id="Fact001636" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,370</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zRqZRuEPytQ5" title="General business credit carryforwards" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyFiveMember" id="Fact001638" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_z49VMgrFdvK5" title="Net operating loss carryforwards" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySixMember" id="Fact001640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_zKHZRAT2I9d3" title="General business credit carryforwards" style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySixMember" id="Fact001642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_zHwFyUwFiuN" title="Net operating loss carryforwards" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySevenMember" id="Fact001644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_z7gbOPeerZq4" title="General business credit carryforwards" style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySevenMember" id="Fact001646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zB8s5xT6fb3l" title="Net operating loss carryforwards" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyEightMember" id="Fact001648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zKZTJqdh8Df6" title="General business credit carryforwards" style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyEightMember" id="Fact001650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zSSM4hZ2Rmr4" title="Net operating loss carryforwards" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyNineMember" id="Fact001652" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zxEdWHMLRcqi" title="General business credit carryforwards" style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyNineMember" id="Fact001654" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zsocbJx5H9H5" title="Net operating loss carryforwards" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_ThereafterMember" id="Fact001656" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,644</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zb3Dp0hxB5Qi" title="General business credit carryforwards" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31_custom_ThereafterMember" id="Fact001658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,429</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231_zC3pZOilpAO1" title="Net operating loss carryforwards" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001660" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99,945</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231_zStrXx0clpu2" title="General business credit carryforwards" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="AsOf2024-12-31" id="Fact001662" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z9nEDbVxWy58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the &#8220;Tax Cuts and Jobs Act&#8221; was signed into law. The tax reform has the following effects on the Company:
(1) permanently reduces the maximum corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017,
(2) allows temporary 100% expensing for certain business assets and property placed in service after September 27, 2018 and before January
1, 2023, (3) disallows NOL carrybacks but allows for the indefinite carryforward of those NOLs which applies to losses arising in tax
years beginning after December 31, 2018 and, (4) limits NOL deductions for each year equal to the lesser of the available carryover or
80% of a taxpayer&#8217;s pre-NOL deduction taxable income. This applies to losses arising in tax years ending on or after December 31,
2017. As of December 31, 2024 and 2023, the Company has concluded that it is more likely than not that the Company will not realize the
benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within
a three-year period results in an annual limitation on the Company&#8217;s ability to utilize its NOL carryforwards created during the
tax periods prior to the change in ownership. The Company has not completed an ownership change analysis pursuant to Section 382. Because
the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and
state income tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had $<span id="xdx_903_ecustom--NetOperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_zguj8oiCBdI5" title="Net operating loss carryforwards"><ix:nonFraction name="ABEO:NetOperatingLossCarryforwards" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact001664" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">316.2</ix:nonFraction></span> million of U.S. federal net operating loss carryforwards that do not expire and can be carried
forward indefinitely. Such net operating loss carryforwards can only be used to offset <span id="xdx_90D_ecustom--OperatingLossCarryforwardsTaxablePercentage_iI_pid_dp_uPure_c20241231_zixbpQwouUTj" title="Operating loss taxable percentage"><ix:nonFraction name="ABEO:OperatingLossCarryforwardsTaxablePercentage" contextRef="AsOf2024-12-31" id="Fact001666" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of taxable income in any given tax year. The
Company also has $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zQozZIDXFLKl" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_StateAndLocalJurisdictionMember" id="Fact001668" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.3</ix:nonFraction></span> million of state net operating loss carryforwards in varying amounts depending on the different state tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired MacroChem Corporation on March 25, 2009, and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both of these corporations
were loss-making entities at the time of acquisition. As a result, the net operating losses related to those acquisitions may be subject
to annual limitations. The Company has not performed a study to determine whether or not there is such a limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
Allowance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the Company maintained a full valuation allowance on its deferred tax assets based on a history of cumulative
losses. The Company will not record income tax benefits in the financial statements until it is determined that it is more likely than
not that the Company will generate sufficient taxable income to realize the deferred income tax assets. In 2024, the valuation allowance
increased by approximately $<span id="xdx_905_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zQt6YXJstBuc" title="Valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001670" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.4</ix:nonFraction></span> million. In 2023, the valuation allowance increased by approximately $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_zrLv5TRNMZ63" title="Valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31" id="Fact001672" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.7</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrecognized
Tax Benefits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the Company had no reserves for unrecognized tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are subject to taxation in the United States. The Company is subject to U.S. federal and state examinations
for 2020 and forward, and 2019 and forward, respectively. However, net operating losses are subject to audit in any tax year in which
those losses are utilized, notwithstanding the year of origin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001674" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkwXhYTV9jc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8211; <span id="xdx_828_zN5Pn6M3vGIb">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a liability for a contingency when it is probable that liability has been incurred and when the amount of loss can
be reasonably estimated. When a range of probable loss can be estimated, the Company accrues the most likely amount of such loss, and
if such amount is not determinable, then the Company accrues the minimum of the range of probable loss. As of December 31, 2024 and 2023,
there was no litigation against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001676" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zGaXqgV0FYLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16 &#8211; <span id="xdx_82C_zqktnkCmqim3">SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision making group, in deciding how to allocate resources in assessing performance. The Company is a
clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases and has one reportable segment.
The Company&#8217;s CODM is the chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies of the clinical-stage biopharmaceutical segment are the same as those described in the summary of significant accounting
policies. The CODM assesses performance for the clinical-stage biopharmaceutical segment based on net loss, which is reported on the
consolidated statements of operations and comprehensive loss as consolidated net loss. The measure of segment assets is reported on the
consolidated balance sheet as total consolidated assets. Expenditures for additions to long-lived assets, which include purchases of
property and equipment, are included in total consolidated assets reviewed by the chief operating decision maker and are reported on
the consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating
losses while it seeks regulatory approval for pz-cel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, the CODM uses cash forecast models in deciding how to invest into the clinical-stage biopharmaceutical segment. Such cash forecast
models are reviewed to make decisions about allocating resources and assessing the entity-wide operating results and performance. Net
loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used to make decisions about allocating
resources, assessing the performance of the segment and in establishing management&#8217;s compensation, along with cash forecast models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001678" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_ztJoAx3m1Wsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zdSjXWpHlcab">&#160;SCHEDULE
OF SIGNIFICANT EXPENSE CATEGORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zM6ttbo2Nyn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zL3Gwowwcknk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_ziFvzS9qLimj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">License and other revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1680">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact001681" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zRbz8EoaOmhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5LxCVkvrq4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Salaries &amp; related costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001686" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001687" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,373</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkJXMBLsopTd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001689" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,561</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,086</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0A7ZZ6YUKtf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other research and development costs <span id="xdx_F40_zLi6GOQFH6dj">(a)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001692" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,454</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001693" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,632</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_zDWbyShBkcu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001695" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact001696" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,091</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zgDi1AOLtp46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBqLHIsuFbff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Salaries &amp; related costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001701" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,729</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001702" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRio3dbbGYQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001704" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,067</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001705" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,682</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrecommercialPreparationCosts_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGJKmg7reyNj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Pre-commercial preparation costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:PrecommercialPreparationCosts" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001707" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ABEO:PrecommercialPreparationCosts" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001708" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPexKxOBGZWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other general and administrative costs <span id="xdx_F4D_zM7CZfeEvSul">(b)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001710" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,237</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001711" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,156</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_z1mlRoUsChqc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total general and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,851</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact001714" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OtherSegments_zUDbASdMShak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other segment items <span id="xdx_F42_z9oKAR73if38">(c)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ABEO:OtherSegments" contextRef="From2024-01-01to2024-12-31" id="Fact001716" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">477</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ABEO:OtherSegments" contextRef="From2023-01-012023-12-31" id="Fact001717" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,593</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zHsPrjrprioa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact001719" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">63,734</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001720" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,188</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zOCHrx46Bl7h">(a)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F17_z9sNosGHbGU8"><ix:footnote id="Footnote001721" xml:lang="en-US">Other
    research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial
    costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and
    manufacturing facilities, and consultant-related expenses.</ix:footnote></i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F06_zFw2pWHJlIQd">(b)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F19_zDoiH2kSjjxe"><ix:footnote id="Footnote001722" xml:lang="en-US">Other
    general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional
    fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.</ix:footnote></i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F01_zdB334Pd12I2">(c)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F16_zev26bldGfJg"><ix:footnote id="Footnote001723" xml:lang="en-US">Other
    segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and
    other income.</ix:footnote></i></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_z9utyDtdnWZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001725" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_z4L1BvoyZTBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17 &#8211; <span id="xdx_822_z3VIkUloOUk7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January of 2025, the compensation committee of the board of directors granted various employees and directors restricted stock awards,
under which the holders have the right to receive an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIfnj1oZVdY8" title="Restricted stock awards, issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-01-012025-01-31_us-gaap_CommonStockMember_srt_DirectorMember_us-gaap_SubsequentEventMember" id="Fact001727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,956,280</ix:nonFraction></span> shares of the Company&#8217;s common stock. Total stock compensation
estimated for these awards at the time of grant was $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXM3UcJ1wcZg" title="Estimated total stock compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember" id="Fact001729" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.3</ix:nonFraction></span> million, with $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__custom--ThreeEqualAnnualInstallmentsMember_zW2bl9QIEV9k" title="Estimated total stock compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember_custom_ThreeEqualAnnualInstallmentsMember" id="Fact001731" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.7</ix:nonFraction></span> million vesting in three equal annual installments and $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__custom--OneAnnualInstallmentsMember_zhCZJoRJ6SPi" title="Estimated total stock compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember_custom_OneAnnualInstallmentsMember" id="Fact001733" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span>
million vesting in one annual installment. Pursuant to the terms of the awards, the shares not vested are forfeited upon separation from
the Company.</span></p>

</ix:nonNumeric><p id="xdx_819_zHDltsdMW9Fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--  
     gpFZ2EaWGL7GbzxpeZKhC97AHi8gfHvb2eippF0F3XVZr7Q6LzvNOkcKe1crZbZWioNXIFedOsl7dHtFTfPwDg1OjYXXSaBl2Ih4v4dC4e+DAUvwaX6S7k/6Tq/VmBil6B0IXw+m+9Ck/cTsaNKvbPmelmTmSdlrfj3L/N7OuGLjv45lfxXn1fot1x/6tth42trg+j+xxQQy -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>2
<FILENAME>ex19.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABEONA
THERAPEUTICS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POLICY
ON INSIDER TRADING AND CONFIDENTIALITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Purpose</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of this Policy on Insider Trading and Confidentiality (the &ldquo;Policy&rdquo;) is to provide guidelines with respect to securities
of Abeona Therapeutics Inc. (&ldquo;Abeona&rdquo; or &ldquo;Company&rdquo;) and the handling of confidential and material nonpublic information
about the Company and the companies with which the Company does business. The Company&rsquo;s Board of Directors has adopted this Policy
to promote compliance with federal securities laws that prohibit certain persons who are aware of material nonpublic information about
a company from: (i) trading in securities of that company, or (ii) providing material nonpublic information to other persons who may
trade based on that information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Persons
    Subject to the Policy </U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to all officers of the Company and its subsidiaries, all members of the Company&rsquo;s Board of Directors, and all employees
of the Company and its subsidiaries. The Company may also determine that other persons should be subject to this Policy, such as contractors
or consultants who have access to material nonpublic information. This Policy also applies to family members, other members of a person&rsquo;s
household and entities controlled by a person covered by this Policy, as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">III.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
    Subject to the Policy </U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to transactions in the Company&rsquo;s securities (collectively referred to in this Policy as &ldquo;Company Securities&rdquo;),
including the Company&rsquo;s common stock, options to purchase common stock, or any other type of securities that the Company may issue,
including (but not limited to) preferred stock, convertible debentures and warrants, as well as derivative securities, such as restricted
stock awards, and derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating
to the Company&rsquo;s Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Administration
    of the Policy</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Chief Financial Officer shall serve as the Compliance Officer for the purposes of this Policy, and in his absence, the
Company&rsquo;s General Counsel or another employee designated by the Compliance Officer shall be responsible for administration of this
Policy. All determinations and interpretations by the Compliance Officer shall be final and not subject to further review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General
    Trading Policy</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
it is against the law to buy or sell any securities while in possession of material nonpublic information (&ldquo;MNPI&rdquo;) relevant
to that security, or to communicate such information to others who trade based on such information (known as &ldquo;tipping&rdquo;).
In recent years, Congress has toughened the penalties for trading on or tipping MNPI and the U.S. Securities and Exchange Commission
(&ldquo;SEC&rdquo;) has aggressively brought actions against such traders and tippers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANY
PERSON WHO ENGAGES IN INSIDER TRADING OR TIPPING CAN FACE A SUBSTANTIAL JAIL TERM (UP TO 10 YEARS) AND FINES UP TO THREE TIMES THE PROFIT
GAINED (OR LOSS AVOIDED) BY THAT PERSON AND/OR HIS OR HER &ldquo;TIPPEES&rdquo;, AS WELL AS SUBSTANTIAL CIVIL LIABILITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
may also be liable for the insider trading violations of an employee, if it is found that the Company failed to take appropriate steps
to prevent insider trading by an employee or director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona&rsquo;s
employees, officers, and directors <B>must not </B>engage in transactions in Company Securities if they possess MNPI as to Abeona and
<B>must not </B>communicate such information to any third party except persons who have a legitimate need to know such information and
understand their obligation not to trade on it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
a particular item was &ldquo;material&rdquo; will be judged with 20-20 hindsight. <B>Accordingly, when in doubt as to a particular item
of information, you should presume it to be material and not to have been disclosed to the public</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
generally, all our employees, officers, and directors are reminded to use extreme care to assure that confidential information is not
inadvertently disclosed to others. Be particularly careful to avoid discussing in public places, such as lobbies, trains, airports, or
restaurants, any matter that might be sensitive or confidential. Meetings in which confidential information is discussed should be conducted
behind closed doors. Even inadvertent &ldquo;leaks&rdquo; of confidential information can create problems for Abeona and our employees,
officers, and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AS
WITH OUR OTHER EMPLOYEE POLICIES, VIOLATION OF THIS POLICY BY ANY EMPLOYEE OF ABEONA OR ANY OF OUR SUBSIDIARIES (OR BY ANY FAMILY MEMBER
OF THE EMPLOYEE) IS GROUNDS FOR IMMEDIATE DISCIPLINARY ACTION, INCLUDING POSSIBLE DISMISSAL FROM EMPLOYMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VI.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definition
    of Material Nonpublic Information</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, information is &ldquo;material&rdquo; as to a security if a reasonable investor would consider the information significant in
deciding whether to buy, hold, or sell the security. Examples of events or developments that should be presumed to be &ldquo;material&rdquo;
in the context of Company Securities would be events such as the following, when they have not yet been fully disclosed to the public:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the execution of a licensing or collaboration agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
clinical results for an Abeona product candidate (whether favorable or adverse);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any significant regulatory action, including the receipt or non-receipt of a regulatory approval;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
knowledge of a trend in Abeona&rsquo;s results of operations not yet fully disclosed to the public;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
gain or loss not yet disclosed to the public;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
termination of a significant agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a significant acquisition;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
major litigation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
significant related party transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a purchase or sale of substantial assets or other significant corporate transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a change in management; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
impending bankruptcy or the existence of severe liquidity problems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
examples are illustrative only and are not intended to be exhaustive examples of material information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
that has not been disclosed to the public is generally considered to be nonpublic information. To establish that the information has
been disclosed to the public, it may be necessary to demonstrate that the information has been widely disseminated. Information generally
would be considered widely disseminated if it has been disclosed through newswire services, publication in a widely available newspaper,
magazine or news website, the Dow Jones &ldquo;broad tape,&rdquo; or public disclosure documents filed with the SEC that are available
on the SEC&rsquo;s website. By contrast, information would likely not be considered widely disseminated if it is available only to the
Company&rsquo;s employees, or if it is only available, for example, to a select group of analysts, brokers, and/or institutional investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
information is widely disseminated, it is still necessary to provide the investing public with sufficient time to absorb the information.
Generally, information should not be considered fully absorbed by the marketplace until after the first business day after the day on
which the information is released. If, for example, the Company were to make an announcement on a Monday, you should not trade in Company
Securities until the market opens on Wednesday. Depending on the particular circumstances, the Company may determine that a longer or
shorter period should apply to the release of specific material nonpublic information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VII.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Policy
    Procedures</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established additional procedures to assist the Company in the administration of this Policy, facilitate compliance with
laws prohibiting insider trading while in possession of material nonpublic information, and avoid the appearance of any impropriety.
These additional procedures are applicable only to those individuals described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pre-Clearance
    Procedures</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
persons designated by the Compliance Officer as being subject to these procedures, as well as the Family Members and Controlled Entities
of such persons, may not engage in any transaction in Company Securities without first obtaining pre-clearance of the transaction from
the Compliance Officer. A request for pre-clearance should be submitted to the Compliance Officer at least two business days in advance
of the proposed transaction. The Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance and may
determine not to permit the transaction. If a person seeks pre-clearance and permission to engage in the transaction is denied, then
he or she should refrain from initiating any transaction in Company Securities and should not inform any other person of the restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a request for pre-clearance is made, the requestor should carefully consider whether he or she may be aware of any material nonpublic
information about the Company and should describe fully those circumstances to the Compliance Officer. The requestor should also indicate
whether he or she has effected any non-exempt &ldquo;opposite-way&rdquo; transactions within the past six months and should be prepared
to report the proposed transaction on an appropriate Form 4 or Form 5. The requestor should also be prepared to comply with SEC Rule
144 and file a Form 144, if necessary, at the time of any sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this regard, directors and certain officers of the Company are subject to certain reporting requirements, trading restrictions and &ldquo;short
swing&rdquo; profit recovery provisions under Section 16 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
In particular, each director and executive officer of Abeona must, as a general rule pursuant to Section 16, report transactions in Company
Securities on a Form 4 filed with the SEC no later than 10:00 p.m. Eastern Time on the second business day following the day on which
the transaction occurs (the trade date, not the settlement date). This general requirement that a Form 4 be filed within two business
days of the trade date is modified in the case of purchases and sales of Company Securities made pursuant to a contract, instruction,
or written plan that satisfies the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (<I>i.e.</I>, a Rule 10b5-1 trading
plan) or discretionary transactions made pursuant to an employee benefit plan, provided that the director or executive officer of Abeona
does not select or has not selected the date of execution of the transaction. In these particular cases, a director or executive officer
of Abeona must file a Form 4 reporting the applicable transaction before the end of the second business day following the day on which
the executing broker, dealer or plan administrator, as applicable, notifies the director or executive officer of the execution of the
transaction (rather than two business days after the trade date), provided that the notification date is not later than the third business
day following the trade date. If the notification is provided after the third business day following the trade date, the two-day period
runs from that third business day and the transaction must be reported on a Form 4 no later than the fifth business day following the
trade date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Quarterly
    Trading Restrictions</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
persons designated by the Compliance Officer as subject to this restriction, as well as their Family Members or Controlled Entities,
may not conduct any transactions involving the Company&rsquo;s Securities (other than as specified by this Policy), during a &ldquo;Blackout
Period&rdquo; beginning 14 calendar days prior to the date of the public release of the Company&rsquo;s earnings results for each fiscal
quarter and ending at the market open of the second business day following such release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Event-Specific
    Trading Restriction Periods</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, an event may occur that is material to the Company and is known by only a few directors, officers, or employees. So long
as the event remains material and nonpublic, the persons designated by the Compliance Officer may not trade Company Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company&rsquo;s financial results may be sufficiently material in a particular fiscal quarter that, in the judgment of
the Compliance Officer, designated persons should refrain from trading in Company Securities even sooner than the typical Blackout Period
described above. In that situation, the Compliance Officer may notify these persons that they should not trade in the Company&rsquo;s
Securities, without disclosing the reason for the restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of an event-specific trading restriction period or extension of a Blackout Period may not necessarily be announced to the Company
as a whole, and when not announced to the Company as a whole should not be communicated to any other person. Even if the Compliance Officer
has not designated you as a person who should not trade due to an event-specific restriction, you should not trade while aware of material
nonpublic information. Exceptions will not be granted during an event-specific trading restriction period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIII.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
    by Family Members and Others</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to your family members who reside with you (including a spouse, a child, a child away at college, stepchildren, grandchildren,
parents, stepparents, grandparents, siblings and in-laws), anyone else who lives in your household, and any family members who do not
live in your household but whose transactions in Company securities are directed by you or are subject to your influence or control,
such as parents or children who consult with you before they trade in Company Securities (collectively referred to as &ldquo;Family Members&rdquo;).
You are responsible for the transactions of these other persons and therefore should make them aware of the need to confer with you before
they trade in Company Securities, and you should treat all such transactions for the purposes of this Policy and applicable securities
laws as if the transactions were for your own account. This Policy does not, however, apply to personal securities transactions of Family
Members where the purchase or sale decision is made by a third party not controlled by, influenced by, or related to you or your Family
Members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IX.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
    by Officer, Director, or Employee Fiduciary Accounts</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to any entities that you influence or control, including any trusts, partnerships, or corporations (collectively referred
to as &ldquo;Controlled Entities&rdquo;), and transactions by these Controlled Entities should be treated for the purposes of this Policy
and applicable securities laws as if they were for your own account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
    Under Company Plans </U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restricted
    Stock Awards</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy does not apply to the vesting of restricted stock, or the exercise of a tax withholding right pursuant to which you elect to have
the Company withhold shares of stock to satisfy tax withholding requirements upon the vesting of any restricted stock. The Policy does
apply, however, to any market sale of restricted stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stock
    Options</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing trading period restrictions do not apply to exercises of stock options under our stock option and equity incentive plans. Exercises
of stock options by directors and certain officers of Abeona, however, do require prior notice as described above. Sales of option shares
require prior notice and remain subject to other applicable restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
    Similar Transactions</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
other purchase of Company Securities from the Company or sales of Company Securities to the Company are not subject to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XI.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Special
    and Prohibited Transactions</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&ldquo;Short
    Sales&rdquo;</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Short
sales&rdquo; of Company Securities by any employee, officer, or director (<I>i.e.</I>, the sale of a security that the seller does not
own) are absolutely prohibited. Short sales may evidence an expectation on the part of the seller that the securities will decline in
value, and therefore have the potential to signal to the market that the seller lacks confidence in the Company&rsquo;s prospects In
addition, Section 16(c) of the Exchange Act prohibits officers and directors from engaging in short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hedging
    Transactions</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hedging
or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments
such as prepaid variable forwards, equity swaps, collars, and exchange funds. Such transactions may permit a director, officer, or employee
to continue to own Company Securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of
ownership. When that occurs, the director, officer or employee may no longer have the same objectives as the Company&rsquo;s other shareholders.
Therefore, directors, officers and employees are prohibited from engaging in any such transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XII.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rule
    10b5-1 Plans</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
10b5-1 under the Exchange Act provides a defense from insider trading liability. To be eligible to rely on this defense, a person subject
to this Policy must enter into a Rule 10b5-1 plan for transactions in Company Securities that meets certain conditions specified in the
Rule (a &ldquo;Rule 10b5-1 Plan&rdquo;). If the plan meets the requirements of Rule 10b5-1, Company Securities may be purchased or sold
without regard to certain insider trading restrictions. To comply with the Policy, a Rule 10b5-1 Plan must be approved by the Compliance
Officer and meet the requirements of Rule 10b5-1 and the Company&rsquo;s Guidelines for Rule 10b5-1 Plans, if any, which may be obtained
from the Compliance Officer. In general, a Rule 10b5-1 Plan must be entered into at a time when the person entering into the plan is
not aware of material nonpublic information. Once the plan is adopted, the person must not exercise any influence over the amount of
securities to be traded, the price at which they are to be traded or the date of the trade. The plan must either specify the amount,
pricing, and timing of transactions in advance or delegate discretion on these matters to an independent third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Rule 10b5-1 Plan must be submitted for approval to the Compliance Officer five days prior to the entry into the Rule 10b5-1 Plan. No
further pre-approval of transactions conducted pursuant to the Rule 10b5-1 Plan will be required. Please note that under Rule 10b5-1,
there is generally a 90-day &ldquo;cooling off&rdquo; period <B>after </B>the adoption of a 10b5-1 trading plan, before the expiration
of which no purchases or sales may occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XIII.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Confidentiality</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious
problems could be caused for Abeona by unauthorized disclosure of internal information about us, whether or not for the purpose of facilitating
improper trading in the stock. Abeona personnel should not discuss internal company matters or developments with anyone outside of Abeona,
except as required in the performance of regular corporate duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prohibition applies specifically (but not exclusively) to inquiries about us which may be made by the financial press, investment analysts
or others in the financial community. It is important that all such communications on behalf of Abeona be through an appropriately designated
officer under carefully controlled circumstances. Unless you are expressly authorized to the contrary, if you receive any inquiries of
this nature, you should decline comment and refer the inquirer to the Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XIV.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Post-Termination
    Transactions</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy continues to apply to transactions in Company Securities even after termination of service to the Company. If an individual is
in possession of material nonpublic information when his or her service terminates, that individual may not trade in Company Securities
until that information has become public or is no longer material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XV.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disclaimer
    of New Liabilities</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is not intended and shall not be deemed to impose on Abeona or its employees, officers, or directors any civil, criminal or other
liability that would not exist in the absence of this policy statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XVI.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certification</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
persons subject to this Policy must certify their understanding of, and intent to comply with, this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CERTIFICATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have read and understand the Abeona Therapeutics Inc. Policy on Insider Trading and Confidentiality (the &ldquo;Policy&rdquo;). I
    understand that the Compliance Officer is available to answer any questions I have regarding the Policy. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    will comply with the Policy for as long as I am subject to the Policy. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    name: ______________________ </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:
    _______________________ </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    ___________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>ex21.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
21</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries
of the Registrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics LLC, an Ohio company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MacroChem
Corporation, a Delaware company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We consent to the incorporation by reference in Registration Statement No. 333-280134 on Form S-3 and Registration Statement Nos. 333-284151,
333-279428, 333-274917, 333-272103, 333-270742, 333-267192, 333-238571, 333-221552, 333-214846, 333-204055, 333-189985, 333-169067, 333-161642,
and 333-125796 on Form S-8 of our report dated March 19, 2025, relating to the financial statements of Abeona Therapeutics Inc. appearing
in this Annual Report on Form 10-K for the year ended December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
DELOITTE &amp; TOUCH LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morristown,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
19, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PRINCIPAL
EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SECTION
1350, AS ADOPTED PURSUANT TO SECTION 302</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OF
THE SARBANES-OXLEY ACT OF 2002</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Vishwas Seshadri, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Abeona Therapeutics Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vishwas Seshadri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishwas
    Seshadri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PRINCIPAL
FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SECTION
1350, AS ADOPTED PURSUANT TO SECTION 302</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OF
THE SARBANES-OXLEY ACT OF 2002</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Joseph Vazzano, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Abeona Therapeutics Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joseph Vazzano</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Vazzano</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>ex32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CERTIFICATION
PURSUANT TO 18 U.S.C.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SECTION
1350 AS ADOPTED PURSUANT TO SECTION 906</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OF
THE SARBANES-OXLEY ACT OF 2002</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Abeona Therapeutics Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31,
2024 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we, Vishwas Seshadri, President
and Chief Executive Officer of the Company, and Joseph Vazzano, Chief Financial Officer of the Company, each certify, pursuant to 18
U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vishwas Seshadri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishwas
    Seshadri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joseph Vazzano </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Vazzano</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>8
<FILENAME>ex97.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
97</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPENSATION
RECOUPMENT POLICY OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abeona
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURPOSE
AND GENERAL TERMS x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
capitalized terms used, but not immediately defined, in this Policy have the meanings set forth in Section A-8 or Section B-1, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
A-1. </B><U>Purpose</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors (the &ldquo;<B><I>Board</I></B>&rdquo;) of Abeona Therapeutics Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;), on
recommendation of its Compensation Committee (the &ldquo;<B><I>Committee</I></B>&rdquo;), has adopted this Compensation Recoupment Policy
(this &ldquo;<B><I>Policy</I></B>&rdquo;) to implement a mandatory clawback policy in the event of a Restatement in compliance with the
Applicable Rules, which is set forth in Article B of this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
A-2. </B><U>Administration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the powers specifically designated to the Committee in Section B-4, this Policy shall be administered in the sole discretion of the
Board; <I>provided </I>that the Board may delegate its administrative responsibility to the Committee, in which case references herein
to the Board shall be deemed to include the Committee. The Board shall have the discretion to interpret the Policy and make all determinations
with respect to this Policy, consistent with the Applicable Rules, applicable law and this Policy, and compliance with this Policy shall
not be waived by the Board in any respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
interpretations and determinations made by the Board shall be final and binding on all affected individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
A-3. </B><U>Effective Date; Term</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is effective as of October 2, 2023 (the &ldquo;<B><I>Effective Date</I></B>&rdquo;) and applies to Incentive-Based Compensation
that is Received by any Executive Officer on or after the Effective Date as described in Section B-3 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
A-4. </B><U>Amendment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend this Policy from time to time in its discretion, subject to any limitations under applicable law or listing standards,
including the Applicable Rules. Without limiting the foregoing, the Board may amend this Policy as it deems necessary to reflect any
amendment of the Applicable Rules or regulations or guidance issued under the Applicable Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
A-5. </B><U>No Substitution of Rights; Non-Exhaustive Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights that may be available to the
Company pursuant to (a) the Abeona Therapeutics Inc. 2023 Equity Incentive Plan, the Abeona Therapeutics Inc. 2023 Employment Inducement
Equity Incentive Plan, the Company&rsquo;s annual bonus plan (if any), or any other incentive plan of the Company or any of its subsidiaries
or any successor plan to any of the foregoing, (b) the terms of any recoupment policy or provision in any employment agreement, compensation
agreement or arrangement, or other agreement, or (c) any other legal remedies available to the Company under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to recovery of compensation as provided for in this Policy, the Company may take any and all other actions it deems necessary,
appropriate, and in the Company&rsquo;s best interest in connection with the Board determining that this Policy should apply, including
termination of the employment of, or initiating legal action against, an Executive Officer, and nothing in this Policy limits the Company&rsquo;s
rights to take any such appropriate actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
A-6. </B><U>Governing Law.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy and all determinations made and actions taken pursuant hereto, to the extent not otherwise governed by mandatory provisions of
the Applicable Rules, shall be governed by and construed in accordance with the laws of the State of Delaware without regard to choice
of law principles. If any provision of this Policy shall be held illegal or invalid for any reason, such illegality or invalidity shall
not affect the remaining parts of this Policy, but this Policy shall be construed and enforced as if the illegal or invalid provision
had never been included in this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
A-7. </B><U>Acknowledgment.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Executive Officer shall be required to sign and return to the Company the Acknowledgment Form attached hereto as Exhibit A pursuant to
which such Executive Officer will agree to be bound by the terms of, and comply with, this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
A-8. </B>Defined Terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following capitalized terms used in this Policy have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Applicable
    Rules</I></B>&rdquo; means Section 10D of the Exchange Act and Rule 10D-1promulgated thereunder and Listing Rule 5608 of the Listing
    Rules of Nasdaq.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Board</I></B>&rdquo;
    means the Board of Directors of the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Clawback
    Compensation</I></B>&rdquo; means Incentive-Based Compensation, as determined to be subject to repayment pursuant to this Policy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Committee</I></B>&rdquo;
    means the Compensation Committee of the Board, or, in the absence of such committee, a majority of independent directors serving
    on the Board.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Exchange
    Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Regulators</I></B>&rdquo;
    means, as applicable, the Securities and Exchange Commission and the Nasdaq Stock Market (&ldquo;<B><I>Nasdaq</I></B>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ARTICLE
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECOUPMENT
POLICY FOR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE
OFFICERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
B-1. </B><U>Specific Defined Terms.</U> For the purposes of this Policy, the following terms have the following meanings, which will
be interpreted to comply with the Applicable Rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Executive
    Officer</I></B>&rdquo; means any person who is or was designated by the Board as(i)an &ldquo;executive officer&rdquo; of the Company
    according to the Applicable Rules or(ii)an &ldquo;officer&rdquo; in accordance with Rule 16a-1(f) promulgated under Section 16 of
    the Exchange Act.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Financial
    Reporting Measures</I></B>&rdquo; means (i) measures that are determined and presented in accordance with the accounting principles
    used in preparing the Company&rsquo;s financial statements, and any measures that are derived wholly or in part from such measures<SUP>1</SUP>,
    (ii) the Company&rsquo;s stock price, and (iii) total shareholder return in respect of the Company. A &ldquo;Financial Reporting
    Measure&rdquo; need not be presented within the financial statements or included in a filing with the SEC.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>&ldquo;Financial Reporting Measures&rdquo; include, but are not limited to, the following examples of accounting-based measures
and measures derived from: (i) revenues; (ii) net income; (iii) operating income; (iv) profitability of one or more reportable segments;
(v) financial ratios (e.g., accounts receivable turnover and inventory turnover rates); (vi)net assets or net asset value per share (e.g.,
for registered investment companies and business development companies that are subject to the rule); (vii) earnings before interest,
taxes, depreciation and amortization; (viii)funds from operations and adjusted funds from operations; (ix) liquidity measures (e.g.,
working capital, operating cash flow); (x) return measures (e.g., return on invested capital, return on assets); (xi) earnings measures
(e.g., earnings per share); (xii) sales per square foot or same store sales, where sales is subject to an accounting restatement; (xiii)
revenue per user, or average revenue per user, where revenue is subject to an accounting restatement; (xiv) cost per employee, where
cost is subject to an accounting restatement; (xv) any of such financial reporting measures relative to a peer group, where the Company&rsquo;s
financial reporting measure is subject to an accounting restatement; and (xvi) tax basis income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Incentive-Based
    Compensation</I></B>&rdquo; means any compensation that is granted, earned, or vested, based wholly or in part upon the attainment
    of a Financial Reporting Measure.<SUP>2</SUP> Incentive-Based Compensation does not include, among other forms of compensation, equity
    awards that vest exclusively upon completion of a specified employment period, without any performance condition, and bonus awards
    that are discretionary or based on subjective goals or goals unrelated to Financial Reporting Measures.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Received</I></B>&rdquo;
    &mdash; Incentive-Based Compensation is deemed &ldquo;Received&rdquo; for the purposes of this Policy in the Company&rsquo;s fiscal
    period during which the Financial Reporting Measure applicable to the Incentive-Based Compensation award is attained, even if the
    payment or grant of the Incentive-Based Compensation occurs after the end of that period. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Recovery
    Period</I></B>&rdquo; means the three completed fiscal years immediately preceding the date on which the Company is required to prepare
    a Restatement, which date is the earlier of (i) the date the Board, a committee of the Board, or the officer or officers of the Company
    authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company
    is required to prepare a Restatement or (ii) a date that a court, regulator or other legally authorized body directs the Company
    to prepare a Restatement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Restatement</I></B>&rdquo;
    means that the Company is required to prepare an accounting restatement due to material noncompliance of the Company with any financial
    reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously
    issued financial statements (i) that is material to the previously issued financial statements, or (ii) that would result in a material
    misstatement if the error were corrected in the current period or left uncorrected in the current period. Determination of whether
    noncompliance is material for the purpose of the preceding sentence will be determined consistent with the Applicable Rules.<SUP>3</SUP></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
B-2. </B><U>Recovery on a Restatement.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Company is required to prepare a Restatement, the Company shall reasonably promptly recover from an Executive Officer
the amount of any erroneously awarded Incentive-Based Compensation that is Received by such Executive Officer during the Recovery Period.
The amount of erroneously Received Incentive-Based Compensation will be the excess of the Incentive-Based Compensation Received by the
Executive Officer (whether in cash or shares) based on the erroneous data in the original financial statements over the Incentive-Based
Compensation (whether in cash or in shares) that would have been Received by the Executive Officer had such Incentive-Based Compensation
been based on the restated results, without respect to any tax liabilities incurred or paid by the Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
of any erroneously awarded compensation under this Policy is not dependent on fraud or misconduct by any Executive Officer in connection
with a Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the foregoing, for Incentive-Based Compensation based on the Company&rsquo;s stock price or total shareholder return, where
the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Restatement,
(a) the amount shall be based on the Company&rsquo;s reasonable estimate of the effect of the Restatement on the stock price or total
shareholder return upon which the Incentive-Based Compensation was Received and (b) the Company shall maintain documentation of the determination
of that reasonable estimate and provide such estimate to the Regulators as required by the Applicable Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP>&ldquo;Incentive-Based Compensation&rdquo;, includes, but is not limited to, (i) non-equity incentive plan awards that are earned
based wholly or in part on satisfying a Financial Reporting Measure performance goal; (ii) bonuses paid from a &ldquo;bonus pool,&rdquo;
the size of which is determined based wholly or in part on satisfying a Financial Reporting Measure performance goal; (iii) other cash
awards based on satisfaction of a Financial Reporting Measure performance goal; (iv) restricted stock, restricted stock units, performance
share units, stock options, and stock appreciation rights that are granted or become vested wholly or in part on satisfying a Financial
Reporting Measure performance goal; and (v) proceeds received upon the sale of shares acquired through an incentive plan that were granted
or vested based wholly or in part on satisfying a Financial Reporting Measure performance goal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP>The issuing release for the Applicable Rules suggests that determinations of materiality should be made on a facts and circumstances
basis, consistent with accounting rules and consistent prior SEC guidance on level of materiality. Specifically, they point to: <I>Staff
Accounting Bulletin No. 99, Materiality (Aug. 12, 1999) and Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year
Misstatements when Quantifying Misstatements in Current Year Financial Statements (Sept. 13, 2006)</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
B-3. </B><U>Covered Executive Officers and Covered Incentive-Based Compensation.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy covers all persons who are Executive Officers at any time during the Recovery Period for which Incentive-Based Compensation is
Received or during the performance period applicable to such Incentive-Based Compensation. Incentive-Based Compensation shall not be
recovered under this Policy to the extent Received by any person before the date the person served as an Executive Officer. Subsequent
changes in an Executive Officer&rsquo;s employment status, including retirement or termination of employment, do not affect the Company&rsquo;s
right to recover Incentive-Based Compensation pursuant to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall apply to Incentive-Based Compensation that is Received by any Executive Officer on or after the Effective Date and that
results from attainment of a Financial Reporting Measure based on or derived from financial information for any fiscal period ending
on or after the Effective Date. For the avoidance of doubt, this will include Incentive-Based Compensation that may have been approved,
awarded, or granted to an Executive Officer on or before the Effective Date if such Incentive-Based Compensation is Received after the
Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
B-4. </B><U>Methods of Recovery; Limited Exceptions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board shall determine, in its sole discretion, the method of recovering any Incentive-Based Compensation Received pursuant to this Policy,
consistent with applicable law, which may include, without limitation, the methods of recovery described in Article C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
recovery shall be required if any of the following conditions are met and the Committee (or an independent committee of the Board consistent
with the Applicable Rules) determines that, on such basis, recovery would be impracticable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    direct expense paid to a third party to assist in enforcing this Article B would exceed the amount to be recovered; <I>provided </I>that
    prior to making a determination that it would be impracticable to recover any Incentive-Based Compensation based on the expense of
    enforcement, the Company shall (i) have made a reasonable attempt to recover the Incentive-Based Compensation, (ii) have documented
    such reasonable attempts to recover, and (iii) provide the documentation to Nasdaq;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recovery
    would violate home country law where that law was adopted prior to November 28, 2022; <I>provided </I>that, prior to making a determination
    that it would be impracticable to recover any Incentive-Based Compensation based on a violation of home country law, the Company
    shall (i) have obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such violation, and
    (ii) provide a copy of such opinion to Nasdaq; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recovery
    would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees, to fail to
    meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended (the &ldquo;<B><I>Code</I></B>&rdquo;),
    and U.S. Treasury regulations promulgated thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
B-5. </B><U>Reporting; Disclosure; Monitoring</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall make all required disclosures and filings with the Regulators with respect to this Policy in accordance with the requirements
of the Applicable Rules, and any other requirements applicable to the Company, including the disclosures required in connection with
SEC filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ARTICLE
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
OF RECOVERY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
C-1. </B>Subject to Section B-4, in the event that the Board determines that this Policy should apply, to the extent permitted by applicable
law, the Company shall, as determined by the Board in its sole discretion, take any such actions as it deems necessary or appropriate
to recover Clawback Compensation. The actions may include, without limitation (and as applicable):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">forfeit,
    reduce, or cancel any Clawback Compensation (whether vested or unvested)that has not been distributed or otherwise settled;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    recovery of any Clawback Compensation that was previously paid to the Executive Officer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    recovery of any amounts realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based Clawback
    Compensation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recoup
    any amount in respect of Clawback Compensation that was contributed or deferred to a plan that takes into account Clawback Compensation
    (excluding certain tax-qualified plans, but including deferred compensation plans, and supplemental executive retirement plans, and
    insurance plans to the extent otherwise permitted by applicable law, including Section 409A of the Code) and any earnings accrued
    on such Clawback Compensation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    as otherwise required by this Policy, determine whether Clawback Compensation should be recouped on a pre-tax or after-tax basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">offset,
    withhold, eliminate or cause to be forfeited any compensation that could be paid or awarded to the Executive Officer after the date
    of determination; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">take
    any other remedial and recovery action permitted by law, as determined by the Board.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, (x) if a breach of fiduciary duty or other violation of law has occurred, the Board may authorize legal action for such breach
of fiduciary duty or other violation of law and take such other actions to enforce the obligations of the Executive Officer to the Company
as the Board deems appropriate or (y) in the event that an Executive Officer fails to repay or reimburse erroneously awarded compensation
that is subject to recovery, the Board may seek to compel such individual to reimburse the Company for any and all expenses reasonably
incurred (including legal fees) by the Company in recovering erroneously awarded compensation under this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
C-2. </B>Notice. Before the Company takes action to seek recovery of compensation pursuant to this Policy against an Executive Officer,
the Company may, in its discretion, take steps to provide such individual with advance written notice of such clawback; <I>provided </I>that
such provision of notice shall not in any way delay the reasonably prompt recovery of any erroneously awarded Incentive-Based Compensation
pursuant to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
C-3. </B>No Indemnification. The Company shall not indemnify any current or former Executive Officer against the loss of erroneously
awarded compensation, and shall not pay or reimburse any such person for premiums incurred or paid for any insurance policy to fund such
person&rsquo;s potential recovery obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABEONA
THERAPEUTICS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPENSATION
RECOUPMENT POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACKNOWLEDGMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Compensation Recoupment
Policy of Abeona Therapeutics Inc. (the &ldquo;<B><I>Policy</I></B>&rdquo;). Capitalized terms used but not otherwise defined in this
Acknowledgement Form (this &ldquo;<B><I>Acknowledgement Form</I></B>&rdquo;) shall have the meanings ascribed to such terms in the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to
the Policy and that the Policy will apply both during and after the undersigned&rsquo;s employment with the Company. Further, by signing
below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any erroneously awarded
Incentive-Based Compensation to the Company to the extent required by, and in a manner permitted by, the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Executive&rsquo;s
    Signature)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Executive&rsquo;s
    Printed Name) </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Date)
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>abeo-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauNybP9z5Z8SekhvWBzbalaDy8hLqyfbi3oNkVG4cgI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ABEO="http://abeonatherapeutics.com/20241231" elementFormDefault="qualified" targetNamespace="http://abeonatherapeutics.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999014 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Short-termInvestments" id="Short-termInvestments">
          <link:definition>999016 - Disclosure - SHORT-TERM INVESTMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999017 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>999018 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SettlementLiability" id="SettlementLiability">
          <link:definition>999019 - Disclosure - SETTLEMENT LIABILITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/AccruedExpenses" id="AccruedExpenses">
          <link:definition>999020 - Disclosure - ACCRUED EXPENSES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Leases" id="Leases">
          <link:definition>999021 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Debt" id="Debt">
          <link:definition>999022 - Disclosure - DEBT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Equity" id="Equity">
          <link:definition>999023 - Disclosure - EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999024 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/LicensesupplierAgreements" id="LicensesupplierAgreements">
          <link:definition>999025 - Disclosure - LICENSE/SUPPLIER AGREEMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/KPlan" id="KPlan">
          <link:definition>999026 - Disclosure - 401(k) PLAN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999027 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999028 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999029 - Disclosure - SEGMENT INFORMATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999030 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" id="Short-termInvestmentsTables">
          <link:definition>999033 - Disclosure - SHORT-TERM INVESTMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999034 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>999035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
          <link:definition>999036 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999037 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/DebtTables" id="DebtTables">
          <link:definition>999038 - Disclosure - DEBT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999039 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999040 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999041 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999042 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:definition>999043 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails" id="ScheduleOfAvailableForSaleShort-termInvestmentsDetails">
          <link:definition>999045 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" id="Short-termInvestmentsDetailsNarrative">
          <link:definition>999046 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999047 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999048 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" id="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails">
          <link:definition>999049 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails" id="ScheduleOfOutstandingWarrantLiabilitiesDetails">
          <link:definition>999050 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" id="ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical">
          <link:definition>999051 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails" id="ScheduleOfActivityOfWarrantLiabilitiesDetails">
          <link:definition>999052 - Disclosure - SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails" id="ScheduleOfEstimateFairValueOfWarrantsDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails" id="ScheduleOfActivityOfDerivativeLiabilitiesDetails">
          <link:definition>999054 - Disclosure - SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
          <link:definition>999055 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative" id="SettlementLiabilityDetailsNarrative">
          <link:definition>999056 - Disclosure - SETTLEMENT LIABILITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
          <link:definition>999057 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails" id="SummaryOfOperatingLeaseLiabilitiesDetails">
          <link:definition>999058 - Disclosure - SUMMARY OF OPERATING LEASE LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" id="ScheduleOfComponentsOfLeaseCostDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
          <link:definition>999060 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" id="ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails">
          <link:definition>999061 - Disclosure - SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999062 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" id="ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails">
          <link:definition>999063 - Disclosure - SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails" id="ScheduleOfFuturePaymentObligationsDetails">
          <link:definition>999064 - Disclosure - SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999065 - Disclosure - DEBT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/EquityDetailsNarrative" id="EquityDetailsNarrative">
          <link:definition>999066 - Disclosure - EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" id="ScheduleOfStockBasedCompensationDetails">
          <link:definition>999067 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999068 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails" id="ScheduleOfOptionsOutstandingAndExercisableDetails">
          <link:definition>999069 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails" id="ScheduleOfRestrictedStockAwardActivityDetails">
          <link:definition>999070 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999071 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative" id="LicensesupplierAgreementsDetailsNarrative">
          <link:definition>999072 - Disclosure - LICENSE/SUPPLIER AGREEMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/KPlanDetailsNarrative" id="KPlanDetailsNarrative">
          <link:definition>999073 - Disclosure - 401(k) PLAN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails" id="ScheduleOfIncomeTaxExpenseDetails">
          <link:definition>999074 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999075 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" id="SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails">
          <link:definition>999076 - Disclosure - SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999077 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails" id="ScheduleOfSignificantExpenseCategoriesDetails">
          <link:definition>999078 - Disclosure -  SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999079 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abeo-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abeo-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abeo-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abeo-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="ABEO_DonWuchterlMember" name="DonWuchterlMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwentyTwentyFourLoanAgreementWarrantsMember" name="TwentyTwentyFourLoanAgreementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_PreFundedWarrants2024Member" name="PreFundedWarrants2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_LoanAgreementWarrants2024Member" name="LoanAgreementWarrants2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_PreFundedWarrants2023Member" name="PreFundedWarrants2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_FurnitureSoftwareAndOfficeEquipmentMember" name="FurnitureSoftwareAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwentyTwentyFourLoanAgreementMember" name="TwentyTwentyFourLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwentyTwentyThreeLoanAgreementMember" name="TwentyTwentyThreeLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_MoneyMarketDepositAccountMember" name="MoneyMarketDepositAccountMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_WarrantLiabilitiesMember" name="WarrantLiabilitiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_PayableToLicensorMember" name="PayableToLicensorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" name="TwentyTwentyOnePublicOfferingWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" name="TwentyTwentyTwoPrivatePlacementOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_REGENXBIOMember" name="REGENXBIOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_OfficeSpaceOneMember" name="OfficeSpaceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_OfficeSpaceTwoMember" name="OfficeSpaceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_SeptemberTwoThouandTwentyFiveMember" name="SeptemberTwoThouandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_SubLeaseAgreementMember" name="SubLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TrancheOneMember" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TrancheTwoMember" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_DiscretionaryTrancheMember" name="DiscretionaryTrancheMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_AvenueMember" name="AvenueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_AvenueTwoMember" name="AvenueTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwoThousandTwentyFourPreFundedWarrantsMember" name="TwoThousandTwentyFourPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_OpenMarketSaleAgreementsMember" name="OpenMarketSaleAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_JefferiesLlcMember" name="JefferiesLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ATMAgreementMember" name="ATMAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_PrivatePlacementOfferingsMember" name="PrivatePlacementOfferingsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_PreFundedWarrantMember" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_CommonStockAndAccompanyingWarrantMember" name="CommonStockAndAccompanyingWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_PreFundedWarrantAndAccompanyingWarrantMember" name="PreFundedWarrantAndAccompanyingWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwoThousandTwentyThreePreFundedWarrantsMember" name="TwoThousandTwentyThreePreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyThreeEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_InducementPlanMember" name="InducementPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TwoThousandFifteenEquityIncentivePlanMember" name="TwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_SublicenseAndInventoryPurchaseAgreementsMember" name="SublicenseAndInventoryPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_EventBasedMilestonePaymentsMember" name="EventBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_SalesBasedMilestonePaymentsMember" name="SalesBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_SublicenseAgreementRelatingToRettSyndromeMember" name="SublicenseAgreementRelatingToRettSyndromeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_UnderAgeFifftyMember" name="UnderAgeFifftyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TaxYearTwoThousandTwentyFiveMember" name="TaxYearTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TaxYearTwoThousandTwentySixMember" name="TaxYearTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TaxYearTwoThousandTwentySevenMember" name="TaxYearTwoThousandTwentySevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TaxYearTwoThousandTwentyEightMember" name="TaxYearTwoThousandTwentyEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_TaxYearTwoThousandTwentyNineMember" name="TaxYearTwoThousandTwentyNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ThereafterMember" name="ThereafterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ThreeEqualAnnualInstallmentsMember" name="ThreeEqualAnnualInstallmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_OneAnnualInstallmentsMember" name="OneAnnualInstallmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_WarrantLiabilities" name="WarrantLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_GainLossOnRightofuseLeaseAssets" name="GainLossOnRightofuseLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" name="IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" name="IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering" name="IssuanceOfCommonStockInConnectionWithPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering" name="IssuanceOfCommonStockSharesInConnectionWithPublicOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" name="StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" name="StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_GainLossOfRightofuseLeaseAssets" name="GainLossOfRightofuseLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards" name="ProceedsFromRepaymentSettlementOfRestrictedShareAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" name="ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" name="DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ReclassificationOfDerivativeLiabilityToEquity" name="ReclassificationOfDerivativeLiabilityToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_DerivativeLiabiltyPolicyTextBlock" name="DerivativeLiabiltyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" name="ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock" name="ScheduleOfActivityWarrantyLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" name="ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" name="ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_NumberOfWarrantsOrRightsExercised" name="NumberOfWarrantsOrRightsExercised" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" name="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_FairValueAdjustmentOfWarrantsIssued" name="FairValueAdjustmentOfWarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue" name="GainLossRecognizedInEarningsFromChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_FairValueOfDerivativesIssued" name="FairValueOfDerivativesIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" name="ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" name="FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_FutureCashReceiptsFromOperatingSublease" name="FutureCashReceiptsFromOperatingSublease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_AccretedFinalPaymentFee" name="AccretedFinalPaymentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_FairValueOfConversionRight" name="FairValueOfConversionRight" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ParticipationRightDescription" name="ParticipationRightDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_FairValueWarrantLiabilities" name="FairValueWarrantLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_RemainingMilestonePaymentsDue" name="RemainingMilestonePaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_NumberOfInvestmentOptions" name="NumberOfInvestmentOptions" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" name="IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" name="IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" name="DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_NetOperatingLossCarryforwards" name="NetOperatingLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_OperatingLossCarryforwardsTaxablePercentage" name="OperatingLossCarryforwardsTaxablePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_PrecommercialPreparationCosts" name="PrecommercialPreparationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ABEO_OtherSegments" name="OtherSegments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>abeo-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheets" xlink:href="abeo-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="abeo-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="abeo-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:href="abeo-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:href="abeo-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="abeo-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:href="abeo-20241231.xsd#Short-termInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipment" xlink:href="abeo-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:href="abeo-20241231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SettlementLiability" xlink:href="abeo-20241231.xsd#SettlementLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/AccruedExpenses" xlink:href="abeo-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Leases" xlink:href="abeo-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Debt" xlink:href="abeo-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Equity" xlink:href="abeo-20241231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:href="abeo-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensesupplierAgreements" xlink:href="abeo-20241231.xsd#LicensesupplierAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/KPlan" xlink:href="abeo-20241231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxes" xlink:href="abeo-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:href="abeo-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SegmentInformation" xlink:href="abeo-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SubsequentEvents" xlink:href="abeo-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:href="abeo-20241231.xsd#Short-termInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="abeo-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:href="abeo-20241231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/AccruedExpensesTables" xlink:href="abeo-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LeasesTables" xlink:href="abeo-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/DebtTables" xlink:href="abeo-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:href="abeo-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxesTables" xlink:href="abeo-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SegmentInformationTables" xlink:href="abeo-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:href="abeo-20241231.xsd#Short-termInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="abeo-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="abeo-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:href="abeo-20241231.xsd#ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="abeo-20241231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative" xlink:href="abeo-20241231.xsd#SettlementLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails" xlink:href="abeo-20241231.xsd#SummaryOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:href="abeo-20241231.xsd#ScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LeasesDetailsNarrative" xlink:href="abeo-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFuturePaymentObligationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/DebtDetailsNarrative" xlink:href="abeo-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/EquityDetailsNarrative" xlink:href="abeo-20241231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:href="abeo-20241231.xsd#ScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="abeo-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:href="abeo-20241231.xsd#ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:href="abeo-20241231.xsd#ScheduleOfRestrictedStockAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="abeo-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative" xlink:href="abeo-20241231.xsd#LicensesupplierAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/KPlanDetailsNarrative" xlink:href="abeo-20241231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:href="abeo-20241231.xsd#ScheduleOfIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:href="abeo-20241231.xsd#SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative" xlink:href="abeo-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfSignificantExpenseCategoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative" xlink:href="abeo-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent" xlink:label="loc_us-gaapOtherLoansPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantLiabilities" xlink:label="loc_ABEOWarrantLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_ABEOWarrantLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GainLossOnRightofuseLeaseAssets" xlink:label="loc_ABEOGainLossOnRightofuseLeaseAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_ABEOGainLossOnRightofuseLeaseAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaapInterestIncomeOperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GainLossOfRightofuseLeaseAssets" xlink:label="loc_ABEOGainLossOfRightofuseLeaseAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ABEOGainLossOfRightofuseLeaseAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashContributionExpense" xlink:label="loc_us-gaapNoncashContributionExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNoncashContributionExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaapPaymentsToAcquireShortTermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireShortTermInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards" xlink:label="loc_ABEOProceedsFromRepaymentSettlementOfRestrictedShareAwards" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ABEOProceedsFromRepaymentSettlementOfRestrictedShareAwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" xlink:label="loc_ABEOProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ABEOProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:title="999016 - Disclosure - SHORT-TERM INVESTMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipment" xlink:title="999017 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:title="999018 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SettlementLiability" xlink:title="999019 - Disclosure - SETTLEMENT LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/AccruedExpenses" xlink:title="999020 - Disclosure - ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Leases" xlink:title="999021 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Debt" xlink:title="999022 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Equity" xlink:title="999023 - Disclosure - EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensesupplierAgreements" xlink:title="999025 - Disclosure - LICENSE/SUPPLIER AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/KPlan" xlink:title="999026 - Disclosure - 401(k) PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:title="999028 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SegmentInformation" xlink:title="999029 - Disclosure - SEGMENT INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:title="999033 - Disclosure - SHORT-TERM INVESTMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipmentTables" xlink:title="999034 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:title="999035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/AccruedExpensesTables" xlink:title="999036 - Disclosure - ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LeasesTables" xlink:title="999037 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/DebtTables" xlink:title="999038 - Disclosure - DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:title="999039 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SegmentInformationTables" xlink:title="999041 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999043 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:title="999045 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:title="999046 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999047 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999048 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:title="999049 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:title="999050 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:title="999051 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:title="999052 - Disclosure - SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:title="999054 - Disclosure - SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999055 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative" xlink:title="999056 - Disclosure - SETTLEMENT LIABILITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999057 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails" xlink:title="999058 - Disclosure - SUMMARY OF OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:title="999059 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="999060 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:title="999061 - Disclosure - SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)">
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FutureCashReceiptsFromOperatingSublease" xlink:label="loc_ABEOFutureCashReceiptsFromOperatingSublease" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" xlink:label="loc_ABEOFutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ABEOFutureCashReceiptsFromOperatingSublease" xlink:to="loc_ABEOFutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LeasesDetailsNarrative" xlink:title="999062 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:title="999063 - Disclosure - SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AccretedFinalPaymentFee" xlink:label="loc_ABEOAccretedFinalPaymentFee" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_ABEOAccretedFinalPaymentFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails" xlink:title="999064 - Disclosure - SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/DebtDetailsNarrative" xlink:title="999065 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/EquityDetailsNarrative" xlink:title="999066 - Disclosure - EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:title="999067 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999068 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:title="999069 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:title="999070 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999071 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative" xlink:title="999072 - Disclosure - LICENSE/SUPPLIER AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/KPlanDetailsNarrative" xlink:title="999073 - Disclosure - 401(k) PLAN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:title="999074 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" xlink:label="loc_ABEOIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_ABEOIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" xlink:label="loc_ABEOIncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_ABEOIncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" xlink:label="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" xlink:label="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:label="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999075 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaapDeferredTaxAssetsStateTaxes" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsStateTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" xlink:label="loc_ABEODeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_ABEODeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:title="999076 - Disclosure - SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative" xlink:title="999077 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails" xlink:title="999078 - Disclosure -  SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative" xlink:title="999079 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>abeo-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheets" xlink:href="abeo-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="abeo-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="abeo-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:href="abeo-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:href="abeo-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="abeo-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:href="abeo-20241231.xsd#Short-termInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipment" xlink:href="abeo-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:href="abeo-20241231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SettlementLiability" xlink:href="abeo-20241231.xsd#SettlementLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/AccruedExpenses" xlink:href="abeo-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Leases" xlink:href="abeo-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Debt" xlink:href="abeo-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Equity" xlink:href="abeo-20241231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:href="abeo-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensesupplierAgreements" xlink:href="abeo-20241231.xsd#LicensesupplierAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/KPlan" xlink:href="abeo-20241231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxes" xlink:href="abeo-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:href="abeo-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SegmentInformation" xlink:href="abeo-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SubsequentEvents" xlink:href="abeo-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:href="abeo-20241231.xsd#Short-termInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="abeo-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:href="abeo-20241231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/AccruedExpensesTables" xlink:href="abeo-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LeasesTables" xlink:href="abeo-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/DebtTables" xlink:href="abeo-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:href="abeo-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxesTables" xlink:href="abeo-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SegmentInformationTables" xlink:href="abeo-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:href="abeo-20241231.xsd#Short-termInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="abeo-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="abeo-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:href="abeo-20241231.xsd#ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="abeo-20241231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative" xlink:href="abeo-20241231.xsd#SettlementLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails" xlink:href="abeo-20241231.xsd#SummaryOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:href="abeo-20241231.xsd#ScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LeasesDetailsNarrative" xlink:href="abeo-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFuturePaymentObligationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/DebtDetailsNarrative" xlink:href="abeo-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/EquityDetailsNarrative" xlink:href="abeo-20241231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:href="abeo-20241231.xsd#ScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="abeo-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:href="abeo-20241231.xsd#ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:href="abeo-20241231.xsd#ScheduleOfRestrictedStockAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="abeo-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative" xlink:href="abeo-20241231.xsd#LicensesupplierAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/KPlanDetailsNarrative" xlink:href="abeo-20241231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:href="abeo-20241231.xsd#ScheduleOfIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:href="abeo-20241231.xsd#SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative" xlink:href="abeo-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfSignificantExpenseCategoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative" xlink:href="abeo-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" xlink:label="loc_ABEOIssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOIssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" xlink:label="loc_ABEOIssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOIssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering" xlink:label="loc_ABEOIssuanceOfCommonStockInConnectionWithPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOIssuanceOfCommonStockInConnectionWithPublicOffering_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering" xlink:label="loc_ABEOIssuanceOfCommonStockSharesInConnectionWithPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOIssuanceOfCommonStockSharesInConnectionWithPublicOffering_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:label="loc_ABEOStockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOStockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:label="loc_ABEOStockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOStockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:title="999016 - Disclosure - SHORT-TERM INVESTMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipment" xlink:title="999017 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:title="999018 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SettlementLiability" xlink:title="999019 - Disclosure - SETTLEMENT LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/AccruedExpenses" xlink:title="999020 - Disclosure - ACCRUED EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Leases" xlink:title="999021 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Debt" xlink:title="999022 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Equity" xlink:title="999023 - Disclosure - EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensesupplierAgreements" xlink:title="999025 - Disclosure - LICENSE/SUPPLIER AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/KPlan" xlink:title="999026 - Disclosure - 401(k) PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:title="999028 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SegmentInformation" xlink:title="999029 - Disclosure - SEGMENT INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:title="999033 - Disclosure - SHORT-TERM INVESTMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipmentTables" xlink:title="999034 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:title="999035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/AccruedExpensesTables" xlink:title="999036 - Disclosure - ACCRUED EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LeasesTables" xlink:title="999037 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/DebtTables" xlink:title="999038 - Disclosure - DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:title="999039 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_ABEOTwoThousandFifteenEquityIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOTwoThousandFifteenEquityIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SegmentInformationTables" xlink:title="999041 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999043 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAgreementMember" xlink:label="loc_ABEOLoanAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ABEOLoanAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="loc_ABEOLoanAndSecurityAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAndSecurityAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementWarrantsMember" xlink:label="loc_ABEOTwentyTwentyFourLoanAgreementWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOTwentyTwentyFourLoanAgreementWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrants2024Member" xlink:label="loc_ABEOPreFundedWarrants2024Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOPreFundedWarrants2024Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAgreementWarrants2024Member" xlink:label="loc_ABEOLoanAgreementWarrants2024Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOLoanAgreementWarrants2024Member_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrants2023Member" xlink:label="loc_ABEOPreFundedWarrants2023Member_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOPreFundedWarrants2023Member_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherReceivables_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NumberOfWarrantsOrRightsExercised" xlink:label="loc_ABEONumberOfWarrantsOrRightsExercised_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ABEONumberOfWarrantsOrRightsExercised_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_210" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:title="999045 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapMarketableSecuritiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaapCertificatesOfDepositMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCertificatesOfDepositMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_150" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:title="999046 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999047 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LaboratoryEquipmentMember" xlink:label="loc_ABEOLaboratoryEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ABEOLaboratoryEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FurnitureSoftwareAndOfficeEquipmentMember" xlink:label="loc_ABEOFurnitureSoftwareAndOfficeEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ABEOFurnitureSoftwareAndOfficeEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999048 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:title="999049 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_MoneyMarketDepositAccountMember" xlink:label="loc_ABEOMoneyMarketDepositAccountMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_ABEOMoneyMarketDepositAccountMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaapCertificatesOfDepositMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapCertificatesOfDepositMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantLiabilitiesMember" xlink:label="loc_ABEOWarrantLiabilitiesMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_ABEOWarrantLiabilitiesMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PayableToLicensorMember" xlink:label="loc_ABEOPayableToLicensorMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_ABEOPayableToLicensorMember_440" xlink:type="arc" order="442" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_530" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure_530" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_530" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_530" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_530" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:title="999050 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:label="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" xlink:label="loc_ABEOTwentyTwentyTwoPrivatePlacementOfferingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyTwoPrivatePlacementOfferingMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementMember" xlink:label="loc_ABEOTwentyTwentyFourLoanAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyFourLoanAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:title="999051 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:label="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" xlink:label="loc_ABEOTwentyTwentyTwoPrivatePlacementOfferingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyTwoPrivatePlacementOfferingMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementMember" xlink:label="loc_ABEOTwentyTwentyFourLoanAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyFourLoanAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" xlink:label="loc_ABEOClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ABEOClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:title="999052 - Disclosure - SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_160" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:title="999054 - Disclosure - SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999055 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="loc_ABEOLoanAndSecurityAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAndSecurityAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementMember" xlink:label="loc_ABEOTwentyTwentyFourLoanAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOTwentyTwentyFourLoanAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyThreeLoanAgreementMember" xlink:label="loc_ABEOTwentyTwentyThreeLoanAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOTwentyTwentyThreeLoanAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAgreementMember" xlink:label="loc_ABEOLoanAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative" xlink:title="999056 - Disclosure - SETTLEMENT LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_REGENXBIOMember" xlink:label="loc_ABEOREGENXBIOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ABEOREGENXBIOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaapSettlementLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSettlementLiabilitiesCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="loc_us-gaapLossContingencySettlementAgreementTerms_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLossContingencySettlementAgreementTerms_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLongTermDebt_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999057 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails" xlink:title="999058 - Disclosure - SUMMARY OF OPERATING LEASE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:title="999059 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="999060 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:title="999061 - Disclosure - SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LeasesDetailsNarrative" xlink:title="999062 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LeaseAgreementMember" xlink:label="loc_ABEOLeaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLeaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SubLeaseAgreementMember" xlink:label="loc_ABEOSubLeaseAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOSubLeaseAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OfficeSpaceOneMember" xlink:label="loc_ABEOOfficeSpaceOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ABEOOfficeSpaceOneMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OfficeSpaceTwoMember" xlink:label="loc_ABEOOfficeSpaceTwoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ABEOOfficeSpaceTwoMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SeptemberTwoThouandTwentyFiveMember" xlink:label="loc_ABEOSeptemberTwoThouandTwentyFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_ABEOSeptemberTwoThouandTwentyFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="loc_us-gaapGainLossOnTerminationOfLease_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainLossOnTerminationOfLease_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSubleaseIncome_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_100" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:title="999063 - Disclosure - SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails" xlink:title="999064 - Disclosure - SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/DebtDetailsNarrative" xlink:title="999065 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="loc_ABEOLoanAndSecurityAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAndSecurityAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TrancheOneMember" xlink:label="loc_ABEOTrancheOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEOTrancheOneMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TrancheTwoMember" xlink:label="loc_ABEOTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEOTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DiscretionaryTrancheMember" xlink:label="loc_ABEODiscretionaryTrancheMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEODiscretionaryTrancheMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueMember" xlink:label="loc_ABEOAvenueMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOAvenueMember_100" xlink:type="arc" order="104" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueTwoMember" xlink:label="loc_ABEOAvenueTwoMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOAvenueTwoMember_110" xlink:type="arc" order="114" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyManagementFeePercentFeeDescription" xlink:label="loc_us-gaapPropertyManagementFeePercentFeeDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPropertyManagementFeePercentFeeDescription_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaapInvestmentsAndCash_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInvestmentsAndCash_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:label="loc_us-gaapPrincipalAmountOutstandingOnLoansManagedAndSecuritized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPrincipalAmountOutstandingOnLoansManagedAndSecuritized_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueOfConversionRight" xlink:label="loc_ABEOFairValueOfConversionRight_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ABEOFairValueOfConversionRight_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ParticipationRightDescription" xlink:label="loc_ABEOParticipationRightDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ABEOParticipationRightDescription_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants_130" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/EquityDetailsNarrative" xlink:title="999066 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:label="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="loc_ABEOTwoThousandTwentyFourPreFundedWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwoThousandTwentyFourPreFundedWarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyThreePreFundedWarrantsMember" xlink:label="loc_ABEOTwoThousandTwentyThreePreFundedWarrantsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwoThousandTwentyThreePreFundedWarrantsMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrantMember" xlink:label="loc_ABEOPreFundedWarrantMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ABEOPreFundedWarrantMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_CommonStockAndAccompanyingWarrantMember" xlink:label="loc_ABEOCommonStockAndAccompanyingWarrantMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ABEOCommonStockAndAccompanyingWarrantMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrantAndAccompanyingWarrantMember" xlink:label="loc_ABEOPreFundedWarrantAndAccompanyingWarrantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ABEOPreFundedWarrantAndAccompanyingWarrantMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OpenMarketSaleAgreementsMember" xlink:label="loc_ABEOOpenMarketSaleAgreementsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOOpenMarketSaleAgreementsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ATMAgreementMember" xlink:label="loc_ABEOATMAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOATMAgreementMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="loc_ABEOLoanAndSecurityAgreementMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAndSecurityAgreementMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_JefferiesLlcMember" xlink:label="loc_ABEOJefferiesLlcMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOJefferiesLlcMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueMember" xlink:label="loc_ABEOAvenueMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOAvenueMember_320" xlink:type="arc" order="323" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueTwoMember" xlink:label="loc_ABEOAvenueTwoMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOAvenueTwoMember_330" xlink:type="arc" order="333" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PrivatePlacementOfferingsMember" xlink:label="loc_ABEOPrivatePlacementOfferingsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ABEOPrivatePlacementOfferingsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_400" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_400" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_400" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_400" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_400" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_400" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_400" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_400" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_400" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueWarrantLiabilities" xlink:label="loc_ABEOFairValueWarrantLiabilities_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ABEOFairValueWarrantLiabilities_400" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_400" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_400" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_400" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_ABEOGrossProceedsFromIssuanceOfCommonStock_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ABEOGrossProceedsFromIssuanceOfCommonStock_400" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_400" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice_400" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_400" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_400" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_400" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_400" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_400" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_400" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_400" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_400" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants_400" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_400" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:title="999067 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999068 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:title="999069 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_ABEOTwoThousandFifteenEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOTwoThousandFifteenEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeOneMember" xlink:label="loc_ABEORangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ABEORangeOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeTwoMember" xlink:label="loc_ABEORangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ABEORangeTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeThreeMember" xlink:label="loc_ABEORangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ABEORangeThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeFourMember" xlink:label="loc_ABEORangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ABEORangeFourMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:title="999070 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999071 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="loc_ABEOTwoThousandTwentyThreeEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOTwoThousandTwentyThreeEquityIncentivePlanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_InducementPlanMember" xlink:label="loc_ABEOInducementPlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOInducementPlanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" xlink:label="loc_ABEOShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ABEOShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative" xlink:title="999072 - Disclosure - LICENSE/SUPPLIER AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LicenseAgreementMember" xlink:label="loc_ABEOLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_ABEOLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaapLicenseAgreementTermsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_us-gaapLicenseAgreementTermsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SublicenseAndInventoryPurchaseAgreementsMember" xlink:label="loc_ABEOSublicenseAndInventoryPurchaseAgreementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOSublicenseAndInventoryPurchaseAgreementsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SublicenseAgreementRelatingToRettSyndromeMember" xlink:label="loc_ABEOSublicenseAgreementRelatingToRettSyndromeMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOSublicenseAgreementRelatingToRettSyndromeMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_EventBasedMilestonePaymentsMember" xlink:label="loc_ABEOEventBasedMilestonePaymentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ABEOEventBasedMilestonePaymentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SalesBasedMilestonePaymentsMember" xlink:label="loc_ABEOSalesBasedMilestonePaymentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ABEOSalesBasedMilestonePaymentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RemainingMilestonePaymentsDue" xlink:label="loc_ABEORemainingMilestonePaymentsDue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ABEORemainingMilestonePaymentsDue_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaapContractWithCustomerAssetNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractWithCustomerAssetNet_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaapLongTermPurchaseCommitmentAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentAmount_150" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/KPlanDetailsNarrative" xlink:title="999073 - Disclosure - 401(k) PLAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaapRetirementPlanTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRetirementPlanTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaapRetirementPlanTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRetirementPlanTypeAxis" xlink:to="loc_us-gaapRetirementPlanTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaapRetirementPlanTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRetirementPlanTypeAxis" xlink:to="loc_us-gaapRetirementPlanTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_UnderAgeFifftyMember" xlink:label="loc_ABEOUnderAgeFifftyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRetirementPlanTypeDomain" xlink:to="loc_ABEOUnderAgeFifftyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NumberOfInvestmentOptions" xlink:label="loc_ABEONumberOfInvestmentOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_ABEONumberOfInvestmentOptions_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:title="999074 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999075 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:title="999076 - Disclosure - SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyFiveMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentyFiveMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentyFiveMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentySixMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentySixMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentySixMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentySevenMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentySevenMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentySevenMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyEightMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentyEightMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentyEightMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyNineMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentyNineMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentyNineMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ThereafterMember" xlink:label="loc_ABEOThereafterMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOThereafterMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_80" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative" xlink:title="999077 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:label="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:label="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NetOperatingLossCarryforwards" xlink:label="loc_ABEONetOperatingLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_ABEONetOperatingLossCarryforwards_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OperatingLossCarryforwardsTaxablePercentage" xlink:label="loc_ABEOOperatingLossCarryforwardsTaxablePercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_ABEOOperatingLossCarryforwardsTaxablePercentage_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails" xlink:title="999078 - Disclosure -  SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PrecommercialPreparationCosts" xlink:label="loc_ABEOPrecommercialPreparationCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOPrecommercialPreparationCosts_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OtherSegments" xlink:label="loc_ABEOOtherSegments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOOtherSegments_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative" xlink:title="999079 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ThreeEqualAnnualInstallmentsMember" xlink:label="loc_ABEOThreeEqualAnnualInstallmentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEOThreeEqualAnnualInstallmentsMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OneAnnualInstallmentsMember" xlink:label="loc_ABEOOneAnnualInstallmentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEOOneAnnualInstallmentsMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" order="1000" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DonWuchterlMember" xlink:label="loc_ABEODonWuchterlMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ABEODonWuchterlMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>abeo-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DonWuchterlMember" xlink:label="ABEO_DonWuchterlMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DonWuchterlMember" xlink:to="ABEO_DonWuchterlMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_DonWuchterlMember_lbl" xml:lang="en-US">Don Wuchterl [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="ABEO_LoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LoanAndSecurityAgreementMember" xlink:to="ABEO_LoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Loan and Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementWarrantsMember" xlink:label="ABEO_TwentyTwentyFourLoanAgreementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyFourLoanAgreementWarrantsMember" xlink:to="ABEO_TwentyTwentyFourLoanAgreementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwentyTwentyFourLoanAgreementWarrantsMember_lbl" xml:lang="en-US">2024 Loan Agreement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrants2024Member" xlink:label="ABEO_PreFundedWarrants2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PreFundedWarrants2024Member" xlink:to="ABEO_PreFundedWarrants2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_PreFundedWarrants2024Member_lbl" xml:lang="en-US">Pre Funded Warrants 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAgreementWarrants2024Member" xlink:label="ABEO_LoanAgreementWarrants2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LoanAgreementWarrants2024Member" xlink:to="ABEO_LoanAgreementWarrants2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_LoanAgreementWarrants2024Member_lbl" xml:lang="en-US">Loan Agreement Warrants 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrants2023Member" xlink:label="ABEO_PreFundedWarrants2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PreFundedWarrants2023Member" xlink:to="ABEO_PreFundedWarrants2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_PreFundedWarrants2023Member_lbl" xml:lang="en-US">Pre Funded Warrants 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAgreementMember" xlink:label="ABEO_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LoanAgreementMember" xlink:to="ABEO_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LaboratoryEquipmentMember" xlink:label="ABEO_LaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LaboratoryEquipmentMember" xlink:to="ABEO_LaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FurnitureSoftwareAndOfficeEquipmentMember" xlink:label="ABEO_FurnitureSoftwareAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FurnitureSoftwareAndOfficeEquipmentMember" xlink:to="ABEO_FurnitureSoftwareAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_FurnitureSoftwareAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture, Software and Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementMember" xlink:label="ABEO_TwentyTwentyFourLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyFourLoanAgreementMember" xlink:to="ABEO_TwentyTwentyFourLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwentyTwentyFourLoanAgreementMember_lbl" xml:lang="en-US">2024 Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyThreeLoanAgreementMember" xlink:label="ABEO_TwentyTwentyThreeLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyThreeLoanAgreementMember" xlink:to="ABEO_TwentyTwentyThreeLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwentyTwentyThreeLoanAgreementMember_lbl" xml:lang="en-US">2023 Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_MoneyMarketDepositAccountMember" xlink:label="ABEO_MoneyMarketDepositAccountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_MoneyMarketDepositAccountMember" xlink:to="ABEO_MoneyMarketDepositAccountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_MoneyMarketDepositAccountMember_lbl" xml:lang="en-US">Money Market Deposit Account [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantLiabilitiesMember" xlink:label="ABEO_WarrantLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_WarrantLiabilitiesMember" xlink:to="ABEO_WarrantLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_WarrantLiabilitiesMember_lbl" xml:lang="en-US">Warrant Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PayableToLicensorMember" xlink:label="ABEO_PayableToLicensorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PayableToLicensorMember" xlink:to="ABEO_PayableToLicensorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_PayableToLicensorMember_lbl" xml:lang="en-US">Payable to Licensor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:label="ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:to="ABEO_TwentyTwentyOnePublicOfferingWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwentyTwentyOnePublicOfferingWarrantsMember_lbl" xml:lang="en-US">2021 Public Offering Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" xlink:label="ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" xlink:to="ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember_lbl" xml:lang="en-US">2022 Private Placement Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_REGENXBIOMember" xlink:label="ABEO_REGENXBIOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_REGENXBIOMember" xlink:to="ABEO_REGENXBIOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_REGENXBIOMember_lbl" xml:lang="en-US">REGENXBIO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LeaseAgreementMember" xlink:label="ABEO_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LeaseAgreementMember" xlink:to="ABEO_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OfficeSpaceOneMember" xlink:label="ABEO_OfficeSpaceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OfficeSpaceOneMember" xlink:to="ABEO_OfficeSpaceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_OfficeSpaceOneMember_lbl" xml:lang="en-US">Office Space One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OfficeSpaceTwoMember" xlink:label="ABEO_OfficeSpaceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OfficeSpaceTwoMember" xlink:to="ABEO_OfficeSpaceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_OfficeSpaceTwoMember_lbl" xml:lang="en-US">Office Space Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SeptemberTwoThouandTwentyFiveMember" xlink:label="ABEO_SeptemberTwoThouandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SeptemberTwoThouandTwentyFiveMember" xlink:to="ABEO_SeptemberTwoThouandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_SeptemberTwoThouandTwentyFiveMember_lbl" xml:lang="en-US">September 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SubLeaseAgreementMember" xlink:label="ABEO_SubLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SubLeaseAgreementMember" xlink:to="ABEO_SubLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_SubLeaseAgreementMember_lbl" xml:lang="en-US">Sub Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TrancheOneMember" xlink:label="ABEO_TrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TrancheOneMember" xlink:to="ABEO_TrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TrancheOneMember_lbl" xml:lang="en-US">Tranche 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TrancheTwoMember" xlink:label="ABEO_TrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TrancheTwoMember" xlink:to="ABEO_TrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TrancheTwoMember_lbl" xml:lang="en-US">Tranche 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DiscretionaryTrancheMember" xlink:label="ABEO_DiscretionaryTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DiscretionaryTrancheMember" xlink:to="ABEO_DiscretionaryTrancheMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_DiscretionaryTrancheMember_lbl" xml:lang="en-US">Discretionary Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueMember" xlink:label="ABEO_AvenueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_AvenueMember" xlink:to="ABEO_AvenueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_AvenueMember_lbl" xml:lang="en-US">Avenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueTwoMember" xlink:label="ABEO_AvenueTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_AvenueTwoMember" xlink:to="ABEO_AvenueTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_AvenueTwoMember_lbl" xml:lang="en-US">Avenue 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="ABEO_TwoThousandTwentyFourPreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:to="ABEO_TwoThousandTwentyFourPreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwoThousandTwentyFourPreFundedWarrantsMember_lbl" xml:lang="en-US">2024 Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OpenMarketSaleAgreementsMember" xlink:label="ABEO_OpenMarketSaleAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OpenMarketSaleAgreementsMember" xlink:to="ABEO_OpenMarketSaleAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_OpenMarketSaleAgreementsMember_lbl" xml:lang="en-US">Open Market Sale Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_JefferiesLlcMember" xlink:label="ABEO_JefferiesLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_JefferiesLlcMember" xlink:to="ABEO_JefferiesLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_JefferiesLlcMember_lbl" xml:lang="en-US">Jefferies LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ATMAgreementMember" xlink:label="ABEO_ATMAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ATMAgreementMember" xlink:to="ABEO_ATMAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ATMAgreementMember_lbl" xml:lang="en-US">A T M Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PrivatePlacementOfferingsMember" xlink:label="ABEO_PrivatePlacementOfferingsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PrivatePlacementOfferingsMember" xlink:to="ABEO_PrivatePlacementOfferingsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_PrivatePlacementOfferingsMember_lbl" xml:lang="en-US">Private Placement Offerings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrantMember" xlink:label="ABEO_PreFundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PreFundedWarrantMember" xlink:to="ABEO_PreFundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_CommonStockAndAccompanyingWarrantMember" xlink:label="ABEO_CommonStockAndAccompanyingWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_CommonStockAndAccompanyingWarrantMember" xlink:to="ABEO_CommonStockAndAccompanyingWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_CommonStockAndAccompanyingWarrantMember_lbl" xml:lang="en-US">Common Stock and Accompanying Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrantAndAccompanyingWarrantMember" xlink:label="ABEO_PreFundedWarrantAndAccompanyingWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PreFundedWarrantAndAccompanyingWarrantMember" xlink:to="ABEO_PreFundedWarrantAndAccompanyingWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_PreFundedWarrantAndAccompanyingWarrantMember_lbl" xml:lang="en-US">Pre-Funded Warrant and Accompanying Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyThreePreFundedWarrantsMember" xlink:label="ABEO_TwoThousandTwentyThreePreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwoThousandTwentyThreePreFundedWarrantsMember" xlink:to="ABEO_TwoThousandTwentyThreePreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwoThousandTwentyThreePreFundedWarrantsMember_lbl" xml:lang="en-US">2023 Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xml:lang="en-US">2023 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_InducementPlanMember" xlink:label="ABEO_InducementPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_InducementPlanMember" xlink:to="ABEO_InducementPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_InducementPlanMember_lbl" xml:lang="en-US">Inducement Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="ABEO_TwoThousandFifteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="ABEO_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TwoThousandFifteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2015 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeOneMember" xlink:label="ABEO_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RangeOneMember" xlink:to="ABEO_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeTwoMember" xlink:label="ABEO_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RangeTwoMember" xlink:to="ABEO_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeThreeMember" xlink:label="ABEO_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RangeThreeMember" xlink:to="ABEO_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeFourMember" xlink:label="ABEO_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RangeFourMember" xlink:to="ABEO_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LicenseAgreementMember" xlink:label="ABEO_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LicenseAgreementMember" xlink:to="ABEO_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SublicenseAndInventoryPurchaseAgreementsMember" xlink:label="ABEO_SublicenseAndInventoryPurchaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SublicenseAndInventoryPurchaseAgreementsMember" xlink:to="ABEO_SublicenseAndInventoryPurchaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_SublicenseAndInventoryPurchaseAgreementsMember_lbl" xml:lang="en-US">Sublicense And Inventory Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_EventBasedMilestonePaymentsMember" xlink:label="ABEO_EventBasedMilestonePaymentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_EventBasedMilestonePaymentsMember" xlink:to="ABEO_EventBasedMilestonePaymentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_EventBasedMilestonePaymentsMember_lbl" xml:lang="en-US">Event Based Milestone Payments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SalesBasedMilestonePaymentsMember" xlink:label="ABEO_SalesBasedMilestonePaymentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SalesBasedMilestonePaymentsMember" xlink:to="ABEO_SalesBasedMilestonePaymentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_SalesBasedMilestonePaymentsMember_lbl" xml:lang="en-US">Sales Based Milestone Payments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SublicenseAgreementRelatingToRettSyndromeMember" xlink:label="ABEO_SublicenseAgreementRelatingToRettSyndromeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SublicenseAgreementRelatingToRettSyndromeMember" xlink:to="ABEO_SublicenseAgreementRelatingToRettSyndromeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_SublicenseAgreementRelatingToRettSyndromeMember_lbl" xml:lang="en-US">Sublicense Agreement Relating to Rett Syndrome [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US">License Agreement Terms [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_UnderAgeFifftyMember" xlink:label="ABEO_UnderAgeFifftyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_UnderAgeFifftyMember" xlink:to="ABEO_UnderAgeFifftyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_UnderAgeFifftyMember_lbl" xml:lang="en-US">Under Age 50 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyFiveMember" xlink:label="ABEO_TaxYearTwoThousandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentyFiveMember" xlink:to="ABEO_TaxYearTwoThousandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TaxYearTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Tax Year 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentySixMember" xlink:label="ABEO_TaxYearTwoThousandTwentySixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentySixMember" xlink:to="ABEO_TaxYearTwoThousandTwentySixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TaxYearTwoThousandTwentySixMember_lbl" xml:lang="en-US">Tax Year 2026 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentySevenMember" xlink:label="ABEO_TaxYearTwoThousandTwentySevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentySevenMember" xlink:to="ABEO_TaxYearTwoThousandTwentySevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TaxYearTwoThousandTwentySevenMember_lbl" xml:lang="en-US">Tax Year 2027 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyEightMember" xlink:label="ABEO_TaxYearTwoThousandTwentyEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentyEightMember" xlink:to="ABEO_TaxYearTwoThousandTwentyEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TaxYearTwoThousandTwentyEightMember_lbl" xml:lang="en-US">Tax Year 2028 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyNineMember" xlink:label="ABEO_TaxYearTwoThousandTwentyNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentyNineMember" xlink:to="ABEO_TaxYearTwoThousandTwentyNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_TaxYearTwoThousandTwentyNineMember_lbl" xml:lang="en-US">Tax Year 2029 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ThereafterMember" xlink:label="ABEO_ThereafterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ThereafterMember" xlink:to="ABEO_ThereafterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ThereafterMember_lbl" xml:lang="en-US">Thereafter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ThreeEqualAnnualInstallmentsMember" xlink:label="ABEO_ThreeEqualAnnualInstallmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ThreeEqualAnnualInstallmentsMember" xlink:to="ABEO_ThreeEqualAnnualInstallmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ThreeEqualAnnualInstallmentsMember_lbl" xml:lang="en-US">Three Equal Annual Installments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OneAnnualInstallmentsMember" xlink:label="ABEO_OneAnnualInstallmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OneAnnualInstallmentsMember" xlink:to="ABEO_OneAnnualInstallmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_OneAnnualInstallmentsMember_lbl" xml:lang="en-US">One Annual Installment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Current portion of long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent" xlink:label="us-gaap_OtherLoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayableCurrent" xlink:to="us-gaap_OtherLoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLoansPayableCurrent_lbl" xml:lang="en-US">Current portion payable to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantLiabilities" xlink:label="ABEO_WarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_WarrantLiabilities" xlink:to="ABEO_WarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_WarrantLiabilities_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.01 par value; authorized 200,000,000 shares; 45,644,091 and 26,523,878 shares issued and outstanding as of December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">License and other revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GainLossOnRightofuseLeaseAssets" xlink:label="ABEO_GainLossOnRightofuseLeaseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossOnRightofuseLeaseAssets" xlink:to="ABEO_GainLossOnRightofuseLeaseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ABEO_GainLossOnRightofuseLeaseAssets_lbl" xml:lang="en-US">Gain on operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="us-gaap_InterestIncomeOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOperating" xlink:to="us-gaap_InterestIncomeOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant and derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Dilutive loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Change in unrealized gains related to available-for-sale debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of offering costs under open market sale agreement (ATM)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of offering costs under open market sale agreement (ATM), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" xlink:label="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" xlink:to="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering_lbl" xml:lang="en-US">Issuance of common stock, net of offering costs under direct placement offering</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" xlink:label="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" xlink:to="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares_lbl" xml:lang="en-US">Issuance of common stock, net of offering costs under direct placement offering, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering" xlink:label="ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering" xlink:to="ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering_lbl" xml:lang="en-US">Issuance of common stock in connection with public offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering" xlink:label="ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering" xlink:to="ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering_lbl" xml:lang="en-US">Issuance of common stock in connection with public offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:label="ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:to="ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_lbl" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants, net of shares settled</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:label="ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:to="ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_lbl" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants, net of shares settled, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Reclassification of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant and derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GainLossOfRightofuseLeaseAssets" xlink:label="ABEO_GainLossOfRightofuseLeaseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossOfRightofuseLeaseAssets" xlink:to="ABEO_GainLossOfRightofuseLeaseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ABEO_GainLossOfRightofuseLeaseAssets_lbl" xml:lang="en-US">Gain on operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion and interest on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use lease assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashContributionExpense" xlink:label="us-gaap_NoncashContributionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashContributionExpense" xlink:to="us-gaap_NoncashContributionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashContributionExpense_lbl" xml:lang="en-US">Non-cash interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">(Gain) loss on disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Change in payable to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Capital expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchases of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US">Proceeds from maturities of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from ATM sales of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from sales of common stock under direct placement offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards" xlink:label="ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards" xlink:to="ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards_lbl" xml:lang="en-US">Payments related to net settlement of restricted share awards</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" xlink:label="ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" xlink:to="ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from sales of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payment of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental non-cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset obtained in exchange for new operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" xlink:label="ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" xlink:to="ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement_lbl" xml:lang="en-US">Derivative and warrant additions associated with loan and security agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ReclassificationOfDerivativeLiabilityToEquity" xlink:label="ABEO_ReclassificationOfDerivativeLiabilityToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ReclassificationOfDerivativeLiabilityToEquity" xlink:to="ABEO_ReclassificationOfDerivativeLiabilityToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ReclassificationOfDerivativeLiabilityToEquity_lbl" xml:lang="en-US">Reclassification of derivative liability to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Changes in accrued property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SHORT-TERM INVESTMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">SETTLEMENT LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">LICENSE/SUPPLIER AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">401(k) PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Short-term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Licensed Technology</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xml:lang="en-US">Credit Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DerivativeLiabiltyPolicyTextBlock" xlink:label="ABEO_DerivativeLiabiltyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DerivativeLiabiltyPolicyTextBlock" xlink:to="ABEO_DerivativeLiabiltyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_DerivativeLiabiltyPolicyTextBlock_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantsPolicyTextBlock" xlink:label="ABEO_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_WarrantsPolicyTextBlock" xlink:to="ABEO_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" xlink:label="ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" xlink:to="ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OUTSTANDING WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock" xlink:label="ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock" xlink:to="ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" xlink:label="ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" xlink:to="ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF OPERATING LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF COMPONENTS OF LEASE COST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" xlink:label="ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" xlink:to="ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE PAYMENT OBLIGATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAX EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, cash equivalents, restricted cash and short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Unfounded exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NumberOfWarrantsOrRightsExercised" xlink:label="ABEO_NumberOfWarrantsOrRightsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_NumberOfWarrantsOrRightsExercised" xlink:to="ABEO_NumberOfWarrantsOrRightsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ABEO_NumberOfWarrantsOrRightsExercised_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Gross Unrealized Gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Gross Unrealized Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US">Available-for-sale securities realized gain loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful lives (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Subtotal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (loss) on disposal of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalents fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Short-term investments fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total assets measured at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value, liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total liabilities measured at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Outstanding warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" xlink:label="ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" xlink:to="ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_lbl" xml:lang="en-US">Warrants, expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants, exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_WarrantLiabilities" xlink:to="ABEO_WarrantLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ABEO_WarrantLiabilities_2_lbl" xml:lang="en-US">Beginning warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueAdjustmentOfWarrantsIssued" xlink:label="ABEO_FairValueAdjustmentOfWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueAdjustmentOfWarrantsIssued" xlink:to="ABEO_FairValueAdjustmentOfWarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_FairValueAdjustmentOfWarrantsIssued_lbl" xml:lang="en-US">Fair value of warrants issued in connection with the Loan Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GainLossRecognizedInEarningsFromChangeInFairValue" xlink:label="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue" xlink:to="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue_lbl" xml:lang="en-US">Loss recognized in earnings from change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_WarrantLiabilities" xlink:to="ABEO_WarrantLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ABEO_WarrantLiabilities_3_lbl" xml:lang="en-US">Ending warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Beginning derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueOfDerivativesIssued" xlink:label="ABEO_FairValueOfDerivativesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueOfDerivativesIssued" xlink:to="ABEO_FairValueOfDerivativesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_FairValueOfDerivativesIssued_lbl" xml:lang="en-US">Fair value of derivatives issued in connection with Loan Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLossOnDerivative_lbl" xml:lang="en-US">Loss recognized in earnings from change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US">Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" xlink:label="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" xlink:to="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_lbl" xml:lang="en-US">Reclassification of derivative liability in connection with the Loan Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Ending derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Estimated fair value of loan agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Shares of common stock issuable upon exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl" xml:lang="en-US">Settlement liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="us-gaap_LossContingencySettlementAgreementTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencySettlementAgreementTerms" xlink:to="us-gaap_LossContingencySettlementAgreementTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencySettlementAgreementTerms_lbl" xml:lang="en-US">Loss contingency settlement agreement terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-Term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued contracted services and other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Non-current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" xlink:label="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" xlink:to="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FutureCashReceiptsFromOperatingSublease" xlink:label="ABEO_FutureCashReceiptsFromOperatingSublease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FutureCashReceiptsFromOperatingSublease" xlink:to="ABEO_FutureCashReceiptsFromOperatingSublease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ABEO_FutureCashReceiptsFromOperatingSublease_lbl" xml:lang="en-US">Total future cash receipts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xml:lang="en-US">Annual lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Gain (loss) on termination of lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Loan Agreement Principal</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AccretedFinalPaymentFee" xlink:label="ABEO_AccretedFinalPaymentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_AccretedFinalPaymentFee" xlink:to="ABEO_AccretedFinalPaymentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_AccretedFinalPaymentFee_lbl" xml:lang="en-US">Accreted final payment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Unamortized debt issuance costs and discounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Total long-term debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtCurrent_2_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_2_lbl" xml:lang="en-US">Long-term debt, net of current maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xml:lang="en-US">Total principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Effective interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Stated interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyManagementFeePercentFeeDescription" xlink:label="us-gaap_PropertyManagementFeePercentFeeDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyManagementFeePercentFeeDescription" xlink:to="us-gaap_PropertyManagementFeePercentFeeDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyManagementFeePercentFeeDescription_lbl" xml:lang="en-US">Percentage fee, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US">Unrestricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl" xml:lang="en-US">Outstanding principal amount of loan</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueOfConversionRight" xlink:label="ABEO_FairValueOfConversionRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueOfConversionRight" xlink:to="ABEO_FairValueOfConversionRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_FairValueOfConversionRight_lbl" xml:lang="en-US">Fair value of conversion right</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xml:lang="en-US">Conversion Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">DerivativeLiabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Aggregate transaction amount</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ParticipationRightDescription" xlink:label="ABEO_ParticipationRightDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ParticipationRightDescription" xlink:to="ABEO_ParticipationRightDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ParticipationRightDescription_lbl" xml:lang="en-US">Participation right description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US">Warrants purchase amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Public offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants purchase, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueWarrantLiabilities" xlink:label="ABEO_FairValueWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueWarrantLiabilities" xlink:to="ABEO_FairValueWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ABEO_FairValueWarrantLiabilities_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GrossProceedsFromIssuanceOfCommonStock" xlink:label="ABEO_GrossProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GrossProceedsFromIssuanceOfCommonStock" xlink:to="ABEO_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Purchase price of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Shares issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">value issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Additional paid in capital stock reduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Proceeds from warrant liability'</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term (years), outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of options, cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, outstanding balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term (years), exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of options, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average exercise price, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" xlink:label="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" xlink:to="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term (years), unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:label="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:to="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise price, lower limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise price, upper limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted-average remaining life in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted-average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted-average remaining life in years, exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Restricted common stock awards, balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted common stock awards, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Restricted common stock awards, cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted common stock awards, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Restricted common stock awards, balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average grant date fair value, balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Increase in shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Compensation cost related to non-vested options not recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period total compensation costs related to non-vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Compensation cost related to restricted common stock not recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average compensation costs related to restricted common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" xlink:label="ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" xlink:to="ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_lbl" xml:lang="en-US">Fair value of restricted stock awards that vested</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RemainingMilestonePaymentsDue" xlink:label="ABEO_RemainingMilestonePaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RemainingMilestonePaymentsDue" xlink:to="ABEO_RemainingMilestonePaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_RemainingMilestonePaymentsDue_lbl" xml:lang="en-US">Remaining milestone payments due</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Fixed consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xml:lang="en-US">Variable consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Contract assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US">Milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US">Maximum annual contribution per employee under 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NumberOfInvestmentOptions" xlink:label="ABEO_NumberOfInvestmentOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_NumberOfInvestmentOptions" xlink:to="ABEO_NumberOfInvestmentOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_NumberOfInvestmentOptions_lbl" xml:lang="en-US">Number of investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Company contributions under 401 (k) Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Income taxes at U.S. statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">State tax, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" xlink:label="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" xlink:to="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_lbl" xml:lang="en-US">Research and development credit</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" xlink:label="ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" xlink:to="ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_lbl" xml:lang="en-US">Deferred true ups</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" xlink:to="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" xlink:to="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_lbl" xml:lang="en-US">Expired tax losses and credits</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:to="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xml:lang="en-US">General business credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xml:lang="en-US">State credits</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" xlink:label="ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" xlink:to="ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_lbl" xml:lang="en-US">Property, equipment and goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_lbl" xml:lang="en-US">Change in Unrecognized Tax Benefit, Reasonably Possible [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_lbl" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_2_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NetOperatingLossCarryforwards" xlink:label="ABEO_NetOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_NetOperatingLossCarryforwards" xlink:to="ABEO_NetOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ABEO_NetOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OperatingLossCarryforwardsTaxablePercentage" xlink:label="ABEO_OperatingLossCarryforwardsTaxablePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OperatingLossCarryforwardsTaxablePercentage" xlink:to="ABEO_OperatingLossCarryforwardsTaxablePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_OperatingLossCarryforwardsTaxablePercentage_lbl" xml:lang="en-US">Operating loss taxable percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salaries &amp; related costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Non-cash stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other general and administrative costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Total research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PrecommercialPreparationCosts" xlink:label="ABEO_PrecommercialPreparationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PrecommercialPreparationCosts" xlink:to="ABEO_PrecommercialPreparationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_PrecommercialPreparationCosts_lbl" xml:lang="en-US">Pre-commercial preparation costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Total general and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OtherSegments" xlink:label="ABEO_OtherSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OtherSegments" xlink:to="ABEO_OtherSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_OtherSegments_lbl" xml:lang="en-US">Other segment items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock awards, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Estimated total stock compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DonWuchterlMember" xlink:to="ABEO_DonWuchterlMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_DonWuchterlMember_doc" xml:lang="en-US">Don Wuchterl [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_WarrantLiabilities" xlink:to="ABEO_WarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_WarrantLiabilities_doc" xml:lang="en-US">Warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossOnRightofuseLeaseAssets" xlink:to="ABEO_GainLossOnRightofuseLeaseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_GainLossOnRightofuseLeaseAssets_doc" xml:lang="en-US">Gain (loss) on right of use lease assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" xlink:to="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering_doc" xml:lang="en-US">Issuance of common stock, net of offering costs under direct placement offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" xlink:to="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares_doc" xml:lang="en-US">Issuance of common stock, net of offering costs under direct placement offering, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:to="ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_doc" xml:lang="en-US">Stock issued during period value of common stock upon exercise of prefunded warrants net of shares settled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:to="ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled_doc" xml:lang="en-US">Stock issued during period shares of common stock upon exercise of prefunded warrants net of shares settled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossOfRightofuseLeaseAssets" xlink:to="ABEO_GainLossOfRightofuseLeaseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_GainLossOfRightofuseLeaseAssets_doc" xml:lang="en-US">Gain loss of rightofuse lease assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards" xlink:to="ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards_doc" xml:lang="en-US">Proceeds from repayment settlement of restricted share awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" xlink:to="ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts_doc" xml:lang="en-US">Proceeds fromUnderwritten sales of common stock net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" xlink:to="ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement_doc" xml:lang="en-US">Derivative and warrant additions associated with loan and security agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ReclassificationOfDerivativeLiabilityToEquity" xlink:to="ABEO_ReclassificationOfDerivativeLiabilityToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ReclassificationOfDerivativeLiabilityToEquity_doc" xml:lang="en-US">Reclassification of derivative liability to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LoanAgreementMember" xlink:to="ABEO_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LoanAndSecurityAgreementMember" xlink:to="ABEO_LoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_LoanAndSecurityAgreementMember_doc" xml:lang="en-US">Loan and Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyFourLoanAgreementWarrantsMember" xlink:to="ABEO_TwentyTwentyFourLoanAgreementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwentyTwentyFourLoanAgreementWarrantsMember_doc" xml:lang="en-US">2024 Loan Agreement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DerivativeLiabiltyPolicyTextBlock" xlink:to="ABEO_DerivativeLiabiltyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_DerivativeLiabiltyPolicyTextBlock_doc" xml:lang="en-US">Derivative Liabilty [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_WarrantsPolicyTextBlock" xlink:to="ABEO_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently Adopted Accounting Pronouncements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_NumberOfWarrantsOrRightsExercised" xlink:to="ABEO_NumberOfWarrantsOrRightsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_NumberOfWarrantsOrRightsExercised_doc" xml:lang="en-US">Number of warrants or rights exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PreFundedWarrants2024Member" xlink:to="ABEO_PreFundedWarrants2024Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_PreFundedWarrants2024Member_doc" xml:lang="en-US">Pre Funded Warrants 2024 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LoanAgreementWarrants2024Member" xlink:to="ABEO_LoanAgreementWarrants2024Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_LoanAgreementWarrants2024Member_doc" xml:lang="en-US">Loan Agreement Warrants 2024 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PreFundedWarrants2023Member" xlink:to="ABEO_PreFundedWarrants2023Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_PreFundedWarrants2023Member_doc" xml:lang="en-US">Pre Funded Warrants 2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LaboratoryEquipmentMember" xlink:to="ABEO_LaboratoryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_LaboratoryEquipmentMember_doc" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FurnitureSoftwareAndOfficeEquipmentMember" xlink:to="ABEO_FurnitureSoftwareAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_FurnitureSoftwareAndOfficeEquipmentMember_doc" xml:lang="en-US">Furniture, Software and Office Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PayableToLicensorMember" xlink:to="ABEO_PayableToLicensorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_PayableToLicensorMember_doc" xml:lang="en-US">Payable to Licensor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_WarrantLiabilitiesMember" xlink:to="ABEO_WarrantLiabilitiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_WarrantLiabilitiesMember_doc" xml:lang="en-US">Warrant Liabilities [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_MoneyMarketDepositAccountMember" xlink:to="ABEO_MoneyMarketDepositAccountMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_MoneyMarketDepositAccountMember_doc" xml:lang="en-US">Money Market Deposit Account [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" xlink:to="ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Outstanding Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" xlink:to="ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_doc" xml:lang="en-US">Warrants, expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:to="ABEO_TwentyTwentyOnePublicOfferingWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwentyTwentyOnePublicOfferingWarrantsMember_doc" xml:lang="en-US">2021 Public Offering Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyFourLoanAgreementMember" xlink:to="ABEO_TwentyTwentyFourLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwentyTwentyFourLoanAgreementMember_doc" xml:lang="en-US">2024 Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyThreeLoanAgreementMember" xlink:to="ABEO_TwentyTwentyThreeLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwentyTwentyThreeLoanAgreementMember_doc" xml:lang="en-US">Twenty Twenty Three Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock" xlink:to="ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock_doc" xml:lang="en-US">Schedule Of Activity Warranty Liability [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueAdjustmentOfWarrantsIssued" xlink:to="ABEO_FairValueAdjustmentOfWarrantsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_FairValueAdjustmentOfWarrantsIssued_doc" xml:lang="en-US">Fair value adjustment of warrants issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue" xlink:to="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue_doc" xml:lang="en-US">Gain (loss) recognized in earnings from change in fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueOfDerivativesIssued" xlink:to="ABEO_FairValueOfDerivativesIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_FairValueOfDerivativesIssued_doc" xml:lang="en-US">Fair value of derivatives issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" xlink:to="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_doc" xml:lang="en-US">Reclassification of derivative liablity in connection with loan agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_REGENXBIOMember" xlink:to="ABEO_REGENXBIOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_REGENXBIOMember_doc" xml:lang="en-US">REGENXBIO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OfficeSpaceOneMember" xlink:to="ABEO_OfficeSpaceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_OfficeSpaceOneMember_doc" xml:lang="en-US">Office Space One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OfficeSpaceTwoMember" xlink:to="ABEO_OfficeSpaceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_OfficeSpaceTwoMember_doc" xml:lang="en-US">Office Space Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SeptemberTwoThouandTwentyFiveMember" xlink:to="ABEO_SeptemberTwoThouandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_SeptemberTwoThouandTwentyFiveMember_doc" xml:lang="en-US">September 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" xlink:to="ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Operating Lease Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SubLeaseAgreementMember" xlink:to="ABEO_SubLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_SubLeaseAgreementMember_doc" xml:lang="en-US">Sub Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" xlink:to="ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_doc" xml:lang="en-US">Schedule of Future Cash Receipts From Operating Sublease [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" xlink:to="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_doc" xml:lang="en-US">Future cash receipts from operating sublease next twelve months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FutureCashReceiptsFromOperatingSublease" xlink:to="ABEO_FutureCashReceiptsFromOperatingSublease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_FutureCashReceiptsFromOperatingSublease_doc" xml:lang="en-US">Future cash receipts from operating sublease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_AccretedFinalPaymentFee" xlink:to="ABEO_AccretedFinalPaymentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_AccretedFinalPaymentFee_doc" xml:lang="en-US">Accreted final payment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TrancheOneMember" xlink:to="ABEO_TrancheOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TrancheOneMember_doc" xml:lang="en-US">Tranche 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TrancheTwoMember" xlink:to="ABEO_TrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TrancheTwoMember_doc" xml:lang="en-US">Tranche 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DiscretionaryTrancheMember" xlink:to="ABEO_DiscretionaryTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_DiscretionaryTrancheMember_doc" xml:lang="en-US">Discretionary Tranche [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueOfConversionRight" xlink:to="ABEO_FairValueOfConversionRight_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_FairValueOfConversionRight_doc" xml:lang="en-US">Fair value of conversion right.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ParticipationRightDescription" xlink:to="ABEO_ParticipationRightDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ParticipationRightDescription_doc" xml:lang="en-US">Participation right description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_AvenueMember" xlink:to="ABEO_AvenueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_AvenueMember_doc" xml:lang="en-US">Avenue [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_AvenueTwoMember" xlink:to="ABEO_AvenueTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_AvenueTwoMember_doc" xml:lang="en-US">Avenue 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueWarrantLiabilities" xlink:to="ABEO_FairValueWarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_FairValueWarrantLiabilities_doc" xml:lang="en-US">Fair value warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:to="ABEO_TwoThousandTwentyFourPreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwoThousandTwentyFourPreFundedWarrantsMember_doc" xml:lang="en-US">2024 Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GrossProceedsFromIssuanceOfCommonStock" xlink:to="ABEO_GrossProceedsFromIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_GrossProceedsFromIssuanceOfCommonStock_doc" xml:lang="en-US">Gross proceeds from issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OpenMarketSaleAgreementsMember" xlink:to="ABEO_OpenMarketSaleAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_OpenMarketSaleAgreementsMember_doc" xml:lang="en-US">Open Market Sale Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_JefferiesLlcMember" xlink:to="ABEO_JefferiesLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_JefferiesLlcMember_doc" xml:lang="en-US">Jefferies LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PrivatePlacementOfferingsMember" xlink:to="ABEO_PrivatePlacementOfferingsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_PrivatePlacementOfferingsMember_doc" xml:lang="en-US">Private Placement Offerings [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PreFundedWarrantMember" xlink:to="ABEO_PreFundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_PreFundedWarrantMember_doc" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_CommonStockAndAccompanyingWarrantMember" xlink:to="ABEO_CommonStockAndAccompanyingWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_CommonStockAndAccompanyingWarrantMember_doc" xml:lang="en-US">Common Stock And Accompanying Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PreFundedWarrantAndAccompanyingWarrantMember" xlink:to="ABEO_PreFundedWarrantAndAccompanyingWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_PreFundedWarrantAndAccompanyingWarrantMember_doc" xml:lang="en-US">Pre Funded Warrant And Accompanying Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwoThousandTwentyThreePreFundedWarrantsMember" xlink:to="ABEO_TwoThousandTwentyThreePreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwoThousandTwentyThreePreFundedWarrantsMember_doc" xml:lang="en-US">2023 Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" xlink:to="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:to="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award options unvested intrinsic value1 .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" xlink:to="ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award other than options vested in period fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="ABEO_TwoThousandFifteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwoThousandFifteenEquityIncentivePlanMember_doc" xml:lang="en-US">2015 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RangeOneMember" xlink:to="ABEO_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_RangeOneMember_doc" xml:lang="en-US">Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RangeTwoMember" xlink:to="ABEO_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_RangeTwoMember_doc" xml:lang="en-US">Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RangeThreeMember" xlink:to="ABEO_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_RangeThreeMember_doc" xml:lang="en-US">Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RangeFourMember" xlink:to="ABEO_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_RangeFourMember_doc" xml:lang="en-US">Range Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SublicenseAndInventoryPurchaseAgreementsMember" xlink:to="ABEO_SublicenseAndInventoryPurchaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_SublicenseAndInventoryPurchaseAgreementsMember_doc" xml:lang="en-US">Sublicense And Inventory Purchase Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_EventBasedMilestonePaymentsMember" xlink:to="ABEO_EventBasedMilestonePaymentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_EventBasedMilestonePaymentsMember_doc" xml:lang="en-US">Event-Based Milestone Payments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SalesBasedMilestonePaymentsMember" xlink:to="ABEO_SalesBasedMilestonePaymentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_SalesBasedMilestonePaymentsMember_doc" xml:lang="en-US">Sales-Based Milestone Payments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_SublicenseAgreementRelatingToRettSyndromeMember" xlink:to="ABEO_SublicenseAgreementRelatingToRettSyndromeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_SublicenseAgreementRelatingToRettSyndromeMember_doc" xml:lang="en-US">Sublicense Agreement Relating to Rett Syndrome [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_UnderAgeFifftyMember" xlink:to="ABEO_UnderAgeFifftyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_UnderAgeFifftyMember_doc" xml:lang="en-US">Under Age 50 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_NumberOfInvestmentOptions" xlink:to="ABEO_NumberOfInvestmentOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_NumberOfInvestmentOptions_doc" xml:lang="en-US">Number of investment options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" xlink:to="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_doc" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" xlink:to="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_doc" xml:lang="en-US">Income tax reconciliation income tax expense benefit changes of warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" xlink:to="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_doc" xml:lang="en-US">Income tax reconciliation income tax expense benefit expired tax lossed and credit tax rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" xlink:to="ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_doc" xml:lang="en-US">Deferred tax assets property plant and equipments and goodwill.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentyFiveMember" xlink:to="ABEO_TaxYearTwoThousandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TaxYearTwoThousandTwentyFiveMember_doc" xml:lang="en-US">Tax Year 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentySixMember" xlink:to="ABEO_TaxYearTwoThousandTwentySixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TaxYearTwoThousandTwentySixMember_doc" xml:lang="en-US">Tax Year 2026 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentySevenMember" xlink:to="ABEO_TaxYearTwoThousandTwentySevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TaxYearTwoThousandTwentySevenMember_doc" xml:lang="en-US">Tax Year 2027 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentyEightMember" xlink:to="ABEO_TaxYearTwoThousandTwentyEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TaxYearTwoThousandTwentyEightMember_doc" xml:lang="en-US">Tax Year 2028 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ThereafterMember" xlink:to="ABEO_ThereafterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ThereafterMember_doc" xml:lang="en-US">Thereafter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OperatingLossCarryforwardsTaxablePercentage" xlink:to="ABEO_OperatingLossCarryforwardsTaxablePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_OperatingLossCarryforwardsTaxablePercentage_doc" xml:lang="en-US">Operating loss carryforwards taxable percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_NetOperatingLossCarryforwards" xlink:to="ABEO_NetOperatingLossCarryforwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_NetOperatingLossCarryforwards_doc" xml:lang="en-US">Net operating loss carryforwards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_PrecommercialPreparationCosts" xlink:to="ABEO_PrecommercialPreparationCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_PrecommercialPreparationCosts_doc" xml:lang="en-US">Precommercial preparation costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OtherSegments" xlink:to="ABEO_OtherSegments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_OtherSegments_doc" xml:lang="en-US">Other segments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ThreeEqualAnnualInstallmentsMember" xlink:to="ABEO_ThreeEqualAnnualInstallmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_ThreeEqualAnnualInstallmentsMember_doc" xml:lang="en-US">Three Equal Annual Installments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LeaseAgreementMember" xlink:to="ABEO_LeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_LeaseAgreementMember_doc" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_InducementPlanMember" xlink:to="ABEO_InducementPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_InducementPlanMember_doc" xml:lang="en-US">Inducement Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember_doc" xml:lang="en-US">2023 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" xlink:to="ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_doc" xml:lang="en-US">Income tax reconciliation change in deferred tax assets true ups.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:to="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_doc" xml:lang="en-US">Income tax reconciliation income tax expense benefit permanent differences.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" xlink:to="ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember_doc" xml:lang="en-US">2022 Private Placement Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_RemainingMilestonePaymentsDue" xlink:to="ABEO_RemainingMilestonePaymentsDue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_RemainingMilestonePaymentsDue_doc" xml:lang="en-US">Remaining milestone payments due.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_LicenseAgreementMember" xlink:to="ABEO_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_TaxYearTwoThousandTwentyNineMember" xlink:to="ABEO_TaxYearTwoThousandTwentyNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_TaxYearTwoThousandTwentyNineMember_doc" xml:lang="en-US">Tax Year 2029 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_OneAnnualInstallmentsMember" xlink:to="ABEO_OneAnnualInstallmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_OneAnnualInstallmentsMember_doc" xml:lang="en-US">One Annual Installment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering" xlink:to="ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering_doc" xml:lang="en-US">Issuance of common stock in connection with public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering" xlink:to="ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering_doc" xml:lang="en-US">Issuance of common stock shares in connection with public offering.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeTermOfLeaseMember" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsefulLifeTermOfLeaseMember" xlink:to="us-gaap_UsefulLifeTermOfLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember_lbl" xml:lang="en-US">Useful Life, Lease Term [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossOnRightofuseLeaseAssets" xlink:to="ABEO_GainLossOnRightofuseLeaseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_GainLossOnRightofuseLeaseAssets_3_lbl" xml:lang="en-US">GainLossOnRightofuseLeaseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossOfRightofuseLeaseAssets" xlink:to="ABEO_GainLossOfRightofuseLeaseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_GainLossOfRightofuseLeaseAssets_3_lbl" xml:lang="en-US">GainLossOfRightofuseLeaseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_NumberOfWarrantsOrRightsExercised" xlink:to="ABEO_NumberOfWarrantsOrRightsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_NumberOfWarrantsOrRightsExercised_3_lbl" xml:lang="en-US">NumberOfWarrantsOrRightsExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue" xlink:to="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_GainLossRecognizedInEarningsFromChangeInFairValue_3_lbl" xml:lang="en-US">GainLossRecognizedInEarningsFromChangeInFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" xlink:to="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_3_lbl" xml:lang="en-US">ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" xlink:to="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_3_lbl" xml:lang="en-US">FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FutureCashReceiptsFromOperatingSublease" xlink:to="ABEO_FutureCashReceiptsFromOperatingSublease_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_FutureCashReceiptsFromOperatingSublease_3_lbl" xml:lang="en-US">FutureCashReceiptsFromOperatingSublease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_2_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_2_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_FairValueWarrantLiabilities" xlink:to="ABEO_FairValueWarrantLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_FairValueWarrantLiabilities_3_lbl" xml:lang="en-US">FairValueWarrantLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" xlink:to="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_3_lbl" xml:lang="en-US">IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ABEO_NetOperatingLossCarryforwards" xlink:to="ABEO_NetOperatingLossCarryforwards_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ABEO_NetOperatingLossCarryforwards_3_lbl" xml:lang="en-US">NetOperatingLossCarryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>abeo-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheets" xlink:href="abeo-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="abeo-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="abeo-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:href="abeo-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:href="abeo-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="abeo-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:href="abeo-20241231.xsd#Short-termInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipment" xlink:href="abeo-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:href="abeo-20241231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SettlementLiability" xlink:href="abeo-20241231.xsd#SettlementLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/AccruedExpenses" xlink:href="abeo-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Leases" xlink:href="abeo-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Debt" xlink:href="abeo-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Equity" xlink:href="abeo-20241231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:href="abeo-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensesupplierAgreements" xlink:href="abeo-20241231.xsd#LicensesupplierAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/KPlan" xlink:href="abeo-20241231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxes" xlink:href="abeo-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:href="abeo-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SegmentInformation" xlink:href="abeo-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SubsequentEvents" xlink:href="abeo-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:href="abeo-20241231.xsd#Short-termInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="abeo-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:href="abeo-20241231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/AccruedExpensesTables" xlink:href="abeo-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LeasesTables" xlink:href="abeo-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/DebtTables" xlink:href="abeo-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:href="abeo-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxesTables" xlink:href="abeo-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SegmentInformationTables" xlink:href="abeo-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:href="abeo-20241231.xsd#Short-termInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="abeo-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="abeo-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:href="abeo-20241231.xsd#ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="abeo-20241231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative" xlink:href="abeo-20241231.xsd#SettlementLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails" xlink:href="abeo-20241231.xsd#SummaryOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:href="abeo-20241231.xsd#ScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LeasesDetailsNarrative" xlink:href="abeo-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails" xlink:href="abeo-20241231.xsd#ScheduleOfFuturePaymentObligationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/DebtDetailsNarrative" xlink:href="abeo-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/EquityDetailsNarrative" xlink:href="abeo-20241231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:href="abeo-20241231.xsd#ScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="abeo-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:href="abeo-20241231.xsd#ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:href="abeo-20241231.xsd#ScheduleOfRestrictedStockAwardActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="abeo-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative" xlink:href="abeo-20241231.xsd#LicensesupplierAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/KPlanDetailsNarrative" xlink:href="abeo-20241231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:href="abeo-20241231.xsd#ScheduleOfIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:href="abeo-20241231.xsd#SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative" xlink:href="abeo-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails" xlink:href="abeo-20241231.xsd#ScheduleOfSignificantExpenseCategoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative" xlink:href="abeo-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent" xlink:label="loc_us-gaapOtherLoansPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantLiabilities" xlink:label="loc_ABEOWarrantLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_ABEOWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GainLossOnRightofuseLeaseAssets" xlink:label="loc_ABEOGainLossOnRightofuseLeaseAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_ABEOGainLossOnRightofuseLeaseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaapInterestIncomeOperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" xlink:label="loc_ABEOIssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOIssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" xlink:label="loc_ABEOIssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOIssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering" xlink:label="loc_ABEOIssuanceOfCommonStockInConnectionWithPublicOffering" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOIssuanceOfCommonStockInConnectionWithPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering" xlink:label="loc_ABEOIssuanceOfCommonStockSharesInConnectionWithPublicOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOIssuanceOfCommonStockSharesInConnectionWithPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:label="loc_ABEOStockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOStockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:label="loc_ABEOStockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOStockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GainLossOfRightofuseLeaseAssets" xlink:label="loc_ABEOGainLossOfRightofuseLeaseAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ABEOGainLossOfRightofuseLeaseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashContributionExpense" xlink:label="loc_us-gaapNoncashContributionExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNoncashContributionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaapPaymentsToAcquireShortTermInvestments" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards" xlink:label="loc_ABEOProceedsFromRepaymentSettlementOfRestrictedShareAwards" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ABEOProceedsFromRepaymentSettlementOfRestrictedShareAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" xlink:label="loc_ABEOProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ABEOProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" xlink:label="loc_ABEODerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ABEODerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ReclassificationOfDerivativeLiabilityToEquity" xlink:label="loc_ABEOReclassificationOfDerivativeLiabilityToEquity" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ABEOReclassificationOfDerivativeLiabilityToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DonWuchterlMember" xlink:label="loc_ABEODonWuchterlMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ABEODonWuchterlMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:title="999016 - Disclosure - SHORT-TERM INVESTMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipment" xlink:title="999017 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:title="999018 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SettlementLiability" xlink:title="999019 - Disclosure - SETTLEMENT LIABILITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures" xlink:label="loc_us-gaapLossContingencyDisclosures" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingencyDisclosures" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/AccruedExpenses" xlink:title="999020 - Disclosure - ACCRUED EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Leases" xlink:title="999021 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Debt" xlink:title="999022 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Equity" xlink:title="999023 - Disclosure - EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensesupplierAgreements" xlink:title="999025 - Disclosure - LICENSE/SUPPLIER AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaapCollaborativeArrangementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCollaborativeArrangementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/KPlan" xlink:title="999026 - Disclosure - 401(k) PLAN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:title="999028 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SegmentInformation" xlink:title="999029 - Disclosure - SEGMENT INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="loc_us-gaapCreditLossFinancialInstrumentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DerivativeLiabiltyPolicyTextBlock" xlink:label="loc_ABEODerivativeLiabiltyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ABEODerivativeLiabiltyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantsPolicyTextBlock" xlink:label="loc_ABEOWarrantsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ABEOWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_ABEORecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ABEORecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:title="999033 - Disclosure - SHORT-TERM INVESTMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipmentTables" xlink:title="999034 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:title="999035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" xlink:label="loc_ABEOScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_ABEOScheduleOfOutstandingWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock" xlink:label="loc_ABEOScheduleOfActivityWarrantyLiabilityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_ABEOScheduleOfActivityWarrantyLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/AccruedExpensesTables" xlink:title="999036 - Disclosure - ACCRUED EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LeasesTables" xlink:title="999037 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" xlink:label="loc_ABEOScheduleOfOperatingLeaseLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_ABEOScheduleOfOperatingLeaseLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" xlink:label="loc_ABEOScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_ABEOScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/DebtTables" xlink:title="999038 - Disclosure - DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:title="999039 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_ABEOTwoThousandFifteenEquityIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOTwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SegmentInformationTables" xlink:title="999041 - Disclosure - SEGMENT INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999043 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAgreementMember" xlink:label="loc_ABEOLoanAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ABEOLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="loc_ABEOLoanAndSecurityAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementWarrantsMember" xlink:label="loc_ABEOTwentyTwentyFourLoanAgreementWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOTwentyTwentyFourLoanAgreementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrants2024Member" xlink:label="loc_ABEOPreFundedWarrants2024Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOPreFundedWarrants2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAgreementWarrants2024Member" xlink:label="loc_ABEOLoanAgreementWarrants2024Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOLoanAgreementWarrants2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrants2023Member" xlink:label="loc_ABEOPreFundedWarrants2023Member" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOPreFundedWarrants2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NumberOfWarrantsOrRightsExercised" xlink:label="loc_ABEONumberOfWarrantsOrRightsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ABEONumberOfWarrantsOrRightsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails" xlink:title="999045 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapMarketableSecuritiesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaapCertificatesOfDepositMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCertificatesOfDepositMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:title="999046 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999047 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LaboratoryEquipmentMember" xlink:label="loc_ABEOLaboratoryEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ABEOLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FurnitureSoftwareAndOfficeEquipmentMember" xlink:label="loc_ABEOFurnitureSoftwareAndOfficeEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ABEOFurnitureSoftwareAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999048 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:title="999049 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_MoneyMarketDepositAccountMember" xlink:label="loc_ABEOMoneyMarketDepositAccountMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_ABEOMoneyMarketDepositAccountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaapCertificatesOfDepositMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapCertificatesOfDepositMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantLiabilitiesMember" xlink:label="loc_ABEOWarrantLiabilitiesMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_ABEOWarrantLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PayableToLicensorMember" xlink:label="loc_ABEOPayableToLicensorMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_ABEOPayableToLicensorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails" xlink:title="999050 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:label="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" xlink:label="loc_ABEOTwentyTwentyTwoPrivatePlacementOfferingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyTwoPrivatePlacementOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementMember" xlink:label="loc_ABEOTwentyTwentyFourLoanAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyFourLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical" xlink:title="999051 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:label="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember" xlink:label="loc_ABEOTwentyTwentyTwoPrivatePlacementOfferingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyTwoPrivatePlacementOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementMember" xlink:label="loc_ABEOTwentyTwentyFourLoanAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyFourLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" xlink:label="loc_ABEOClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ABEOClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails" xlink:title="999052 - Disclosure - SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantLiabilities" xlink:label="loc_ABEOWarrantLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_ABEOWarrantLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueAdjustmentOfWarrantsIssued" xlink:label="loc_ABEOFairValueAdjustmentOfWarrantsIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_ABEOFairValueAdjustmentOfWarrantsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GainLossRecognizedInEarningsFromChangeInFairValue" xlink:label="loc_ABEOGainLossRecognizedInEarningsFromChangeInFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_ABEOGainLossRecognizedInEarningsFromChangeInFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_WarrantLiabilities" xlink:label="loc_ABEOWarrantLiabilities_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_ABEOWarrantLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails" xlink:title="999054 - Disclosure - SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueOfDerivativesIssued" xlink:label="loc_ABEOFairValueOfDerivativesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_ABEOFairValueOfDerivativesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaapDerivativeLossOnDerivative" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativeLossOnDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaapDerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" xlink:label="loc_ABEOReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_ABEOReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999055 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="loc_ABEOLoanAndSecurityAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyFourLoanAgreementMember" xlink:label="loc_ABEOTwentyTwentyFourLoanAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOTwentyTwentyFourLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyThreeLoanAgreementMember" xlink:label="loc_ABEOTwentyTwentyThreeLoanAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOTwentyTwentyThreeLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAgreementMember" xlink:label="loc_ABEOLoanAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative" xlink:title="999056 - Disclosure - SETTLEMENT LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_REGENXBIOMember" xlink:label="loc_ABEOREGENXBIOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ABEOREGENXBIOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaapSettlementLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSettlementLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="loc_us-gaapLossContingencySettlementAgreementTerms" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLossContingencySettlementAgreementTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999057 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails" xlink:title="999058 - Disclosure - SUMMARY OF OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:title="999059 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="999060 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails" xlink:title="999061 - Disclosure - SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" xlink:label="loc_ABEOFutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_ABEOFutureCashReceiptsFromOperatingSubleaseNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FutureCashReceiptsFromOperatingSublease" xlink:label="loc_ABEOFutureCashReceiptsFromOperatingSublease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_ABEOFutureCashReceiptsFromOperatingSublease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LeasesDetailsNarrative" xlink:title="999062 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LeaseAgreementMember" xlink:label="loc_ABEOLeaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SubLeaseAgreementMember" xlink:label="loc_ABEOSubLeaseAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOSubLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OfficeSpaceOneMember" xlink:label="loc_ABEOOfficeSpaceOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ABEOOfficeSpaceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OfficeSpaceTwoMember" xlink:label="loc_ABEOOfficeSpaceTwoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ABEOOfficeSpaceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardDateAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SeptemberTwoThouandTwentyFiveMember" xlink:label="loc_ABEOSeptemberTwoThouandTwentyFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_ABEOSeptemberTwoThouandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="loc_us-gaapGainLossOnTerminationOfLease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainLossOnTerminationOfLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails" xlink:title="999063 - Disclosure - SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AccretedFinalPaymentFee" xlink:label="loc_ABEOAccretedFinalPaymentFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_ABEOAccretedFinalPaymentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails" xlink:title="999064 - Disclosure - SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/DebtDetailsNarrative" xlink:title="999065 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="loc_ABEOLoanAndSecurityAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVestingAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TrancheOneMember" xlink:label="loc_ABEOTrancheOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEOTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TrancheTwoMember" xlink:label="loc_ABEOTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEOTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DiscretionaryTrancheMember" xlink:label="loc_ABEODiscretionaryTrancheMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEODiscretionaryTrancheMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueMember" xlink:label="loc_ABEOAvenueMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOAvenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueTwoMember" xlink:label="loc_ABEOAvenueTwoMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOAvenueTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyManagementFeePercentFeeDescription" xlink:label="loc_us-gaapPropertyManagementFeePercentFeeDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPropertyManagementFeePercentFeeDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaapInvestmentsAndCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInvestmentsAndCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:label="loc_us-gaapPrincipalAmountOutstandingOnLoansManagedAndSecuritized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueOfConversionRight" xlink:label="loc_ABEOFairValueOfConversionRight" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ABEOFairValueOfConversionRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ParticipationRightDescription" xlink:label="loc_ABEOParticipationRightDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ABEOParticipationRightDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/EquityDetailsNarrative" xlink:title="999066 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwentyTwentyOnePublicOfferingWarrantsMember" xlink:label="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwentyTwentyOnePublicOfferingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="loc_ABEOTwoThousandTwentyFourPreFundedWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwoThousandTwentyFourPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyThreePreFundedWarrantsMember" xlink:label="loc_ABEOTwoThousandTwentyThreePreFundedWarrantsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ABEOTwoThousandTwentyThreePreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrantMember" xlink:label="loc_ABEOPreFundedWarrantMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ABEOPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_CommonStockAndAccompanyingWarrantMember" xlink:label="loc_ABEOCommonStockAndAccompanyingWarrantMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ABEOCommonStockAndAccompanyingWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PreFundedWarrantAndAccompanyingWarrantMember" xlink:label="loc_ABEOPreFundedWarrantAndAccompanyingWarrantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ABEOPreFundedWarrantAndAccompanyingWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OpenMarketSaleAgreementsMember" xlink:label="loc_ABEOOpenMarketSaleAgreementsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOOpenMarketSaleAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ATMAgreementMember" xlink:label="loc_ABEOATMAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOATMAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LoanAndSecurityAgreementMember" xlink:label="loc_ABEOLoanAndSecurityAgreementMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_JefferiesLlcMember" xlink:label="loc_ABEOJefferiesLlcMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOJefferiesLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueMember" xlink:label="loc_ABEOAvenueMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOAvenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_AvenueTwoMember" xlink:label="loc_ABEOAvenueTwoMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ABEOAvenueTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PrivatePlacementOfferingsMember" xlink:label="loc_ABEOPrivatePlacementOfferingsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ABEOPrivatePlacementOfferingsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_FairValueWarrantLiabilities" xlink:label="loc_ABEOFairValueWarrantLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ABEOFairValueWarrantLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_ABEOGrossProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ABEOGrossProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:title="999067 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999068 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" xlink:label="loc_ABEOSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_ABEOSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:label="loc_ABEOSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_ABEOSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails" xlink:title="999069 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_ABEOTwoThousandFifteenEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOTwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeOneMember" xlink:label="loc_ABEORangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ABEORangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeTwoMember" xlink:label="loc_ABEORangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ABEORangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeThreeMember" xlink:label="loc_ABEORangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ABEORangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RangeFourMember" xlink:label="loc_ABEORangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ABEORangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails" xlink:title="999070 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999071 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="loc_ABEOTwoThousandTwentyThreeEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_InducementPlanMember" xlink:label="loc_ABEOInducementPlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ABEOInducementPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" xlink:label="loc_ABEOShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ABEOShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative" xlink:title="999072 - Disclosure - LICENSE/SUPPLIER AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_LicenseAgreementMember" xlink:label="loc_ABEOLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_ABEOLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaapLicenseAgreementTermsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_us-gaapLicenseAgreementTermsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SublicenseAndInventoryPurchaseAgreementsMember" xlink:label="loc_ABEOSublicenseAndInventoryPurchaseAgreementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOSublicenseAndInventoryPurchaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SublicenseAgreementRelatingToRettSyndromeMember" xlink:label="loc_ABEOSublicenseAgreementRelatingToRettSyndromeMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ABEOSublicenseAgreementRelatingToRettSyndromeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtProductOrServiceAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_EventBasedMilestonePaymentsMember" xlink:label="loc_ABEOEventBasedMilestonePaymentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ABEOEventBasedMilestonePaymentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_SalesBasedMilestonePaymentsMember" xlink:label="loc_ABEOSalesBasedMilestonePaymentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ABEOSalesBasedMilestonePaymentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_RemainingMilestonePaymentsDue" xlink:label="loc_ABEORemainingMilestonePaymentsDue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ABEORemainingMilestonePaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaapContractWithCustomerAssetNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractWithCustomerAssetNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaapLongTermPurchaseCommitmentAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/KPlanDetailsNarrative" xlink:title="999073 - Disclosure - 401(k) PLAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaapRetirementPlanTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRetirementPlanTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaapRetirementPlanTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanTypeAxis" xlink:to="loc_us-gaapRetirementPlanTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_UnderAgeFifftyMember" xlink:label="loc_ABEOUnderAgeFifftyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanTypeDomain" xlink:to="loc_ABEOUnderAgeFifftyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NumberOfInvestmentOptions" xlink:label="loc_ABEONumberOfInvestmentOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_ABEONumberOfInvestmentOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:title="999074 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" xlink:label="loc_ABEOIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ABEOIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" xlink:label="loc_ABEOIncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ABEOIncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" xlink:label="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" xlink:label="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:label="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ABEOIncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999075 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaapDeferredTaxAssetsStateTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsStateTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" xlink:label="loc_ABEODeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ABEODeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails" xlink:title="999076 - Disclosure - SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyFiveMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentyFiveMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentySixMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentySixMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentySixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentySevenMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentySevenMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyEightMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentyEightMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentyEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_TaxYearTwoThousandTwentyNineMember" xlink:label="loc_ABEOTaxYearTwoThousandTwentyNineMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOTaxYearTwoThousandTwentyNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ThereafterMember" xlink:label="loc_ABEOThereafterMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_ABEOThereafterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative" xlink:title="999077 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:label="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:label="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_NetOperatingLossCarryforwards" xlink:label="loc_ABEONetOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_ABEONetOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OperatingLossCarryforwardsTaxablePercentage" xlink:label="loc_ABEOOperatingLossCarryforwardsTaxablePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_ABEOOperatingLossCarryforwardsTaxablePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails" xlink:title="999078 - Disclosure -  SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_PrecommercialPreparationCosts" xlink:label="loc_ABEOPrecommercialPreparationCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOPrecommercialPreparationCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OtherSegments" xlink:label="loc_ABEOOtherSegments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ABEOOtherSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative" xlink:title="999079 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_ThreeEqualAnnualInstallmentsMember" xlink:label="loc_ABEOThreeEqualAnnualInstallmentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEOThreeEqualAnnualInstallmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20241231.xsd#ABEO_OneAnnualInstallmentsMember" xlink:label="loc_ABEOOneAnnualInstallmentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ABEOOneAnnualInstallmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 11, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABEONA
THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-0221517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6555
Carnegie Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th
Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cleveland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">44103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">813-4701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABEO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,904,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,533,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Morristown,
New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 23,357<span></span>
</td>
<td class="nump">$ 14,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">74,363<span></span>
</td>
<td class="nump">37,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">2,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">100,853<span></span>
</td>
<td class="nump">55,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,430<span></span>
</td>
<td class="nump">3,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">4,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">108,931<span></span>
</td>
<td class="nump">64,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,441<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,333<span></span>
</td>
<td class="nump">5,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">5,926<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLoansPayableCurrent', window );">Current portion payable to licensor</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,587<span></span>
</td>
<td class="nump">13,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">13,037<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">32,014<span></span>
</td>
<td class="nump">31,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">64,900<span></span>
</td>
<td class="nump">49,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.01 par value; authorized 200,000,000 shares; 45,644,091 and 26,523,878 shares issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">856,824<span></span>
</td>
<td class="nump">764,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(813,258)<span></span>
</td>
<td class="num">(749,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">44,031<span></span>
</td>
<td class="nump">14,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 108,931<span></span>
</td>
<td class="nump">$ 64,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">45,644,091<span></span>
</td>
<td class="nump">26,523,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">45,644,091<span></span>
</td>
<td class="nump">26,523,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and other revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">34,360<span></span>
</td>
<td class="nump">31,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,851<span></span>
</td>
<td class="nump">19,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_GainLossOnRightofuseLeaseAssets', window );">Gain on operating lease right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,065)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">64,211<span></span>
</td>
<td class="nump">50,635<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(64,211)<span></span>
</td>
<td class="num">(47,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">2,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,208)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant and derivative liabilities</a></td>
<td class="num">(755)<span></span>
</td>
<td class="num">(11,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63,734)<span></span>
</td>
<td class="num">$ (54,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share</a></td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Dilutive loss per common share</a></td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic</a></td>
<td class="nump">41,048,206<span></span>
</td>
<td class="nump">21,380,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding - diluted</a></td>
<td class="nump">41,048,206<span></span>
</td>
<td class="nump">21,380,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gains related to available-for-sale debt securities</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (63,660)<span></span>
</td>
<td class="num">$ (54,125)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_GainLossOnRightofuseLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on right of use lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_GainLossOnRightofuseLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 722,049<span></span>
</td>
<td class="num">$ (695,336)<span></span>
</td>
<td class="num">$ (129)<span></span>
</td>
<td class="nump">$ 26,761<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">17,719,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,768<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement, shares</a></td>
<td class="nump">1,859,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs under open market sale agreement (ATM)</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">14,586<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs under open market sale agreement (ATM), shares</a></td>
<td class="nump">3,659,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering', window );">Issuance of common stock, net of offering costs under direct placement offering</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">22,948<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares', window );">Issuance of common stock, net of offering costs under direct placement offering, shares</a></td>
<td class="nump">3,284,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(54,188)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(54,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">764,151<span></span>
</td>
<td class="num">(749,524)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="nump">14,826<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">26,523,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,628<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="num">(545)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement, shares</a></td>
<td class="nump">1,780,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs under open market sale agreement (ATM)</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">15,447<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs under open market sale agreement (ATM), shares</a></td>
<td class="nump">2,825,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(63,734)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(63,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering', window );">Issuance of common stock in connection with public offering, net of offering costs</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">70,030<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering', window );">Issuance of common stock in connection with public offering, net of offering costs, shares</a></td>
<td class="nump">12,285,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled', window );">Issuance of common stock upon exercise of pre-funded warrants, net of shares settled</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled', window );">Issuance of common stock upon exercise of pre-funded warrants, net of shares settled, shares</a></td>
<td class="nump">2,228,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">$ 856,824<span></span>
</td>
<td class="num">$ (813,258)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 44,031<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">45,644,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, net of offering costs under direct placement offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, net of offering costs under direct placement offering, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock shares in connection with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares of common stock upon exercise of prefunded warrants net of shares settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value of common stock upon exercise of prefunded warrants net of shares settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63,734,000)<span></span>
</td>
<td class="num">$ (54,188,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,004,000<span></span>
</td>
<td class="nump">2,288,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,628,000<span></span>
</td>
<td class="nump">4,768,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant and derivative liabilities</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">11,695,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_GainLossOfRightofuseLeaseAssets', window );">Gain on operating lease right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,065,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and interest on short-term investments</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="num">(93,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use lease assets</a></td>
<td class="nump">903,000<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashContributionExpense', window );">Non-cash interest</a></td>
<td class="nump">1,538,000<span></span>
</td>
<td class="nump">417,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of property and equipment</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">792,000<span></span>
</td>
<td class="num">(2,041,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(564,000)<span></span>
</td>
<td class="num">(155,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">181,000<span></span>
</td>
<td class="num">(234,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,507,000<span></span>
</td>
<td class="nump">2,041,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(1,315,000)<span></span>
</td>
<td class="num">(1,196,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Change in payable to licensor</a></td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="num">(203,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(56,015,000)<span></span>
</td>
<td class="num">(37,009,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(2,446,000)<span></span>
</td>
<td class="num">(331,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(157,010,000)<span></span>
</td>
<td class="num">(51,636,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of short-term investments</a></td>
<td class="nump">120,198,000<span></span>
</td>
<td class="nump">51,971,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(39,240,000)<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from ATM sales of common stock, net of issuance costs</a></td>
<td class="nump">15,475,000<span></span>
</td>
<td class="nump">14,408,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sales of common stock under direct placement offering, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,981,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards', window );">Payments related to net settlement of restricted share awards</a></td>
<td class="num">(526,000)<span></span>
</td>
<td class="num">(182,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts', window );">Proceeds from sales of common stock, net of issuance costs</a></td>
<td class="nump">70,153,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(963,000)<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">104,139,000<span></span>
</td>
<td class="nump">37,057,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">8,884,000<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">14,811,000<span></span>
</td>
<td class="nump">14,555,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">23,695,000<span></span>
</td>
<td class="nump">14,811,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">23,357,000<span></span>
</td>
<td class="nump">14,473,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">338,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">23,695,000<span></span>
</td>
<td class="nump">14,811,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for new operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">419,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement', window );">Derivative and warrant additions associated with loan and security agreement</a></td>
<td class="nump">1,042,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ReclassificationOfDerivativeLiabilityToEquity', window );">Reclassification of derivative liability to equity</a></td>
<td class="nump">1,135,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Changes in accrued property and equipment</a></td>
<td class="nump">471,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,670,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative and warrant additions associated with loan and security agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_GainLossOfRightofuseLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss of rightofuse lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_GainLossOfRightofuseLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from repayment settlement of restricted share awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds fromUnderwritten sales of common stock net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ReclassificationOfDerivativeLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ReclassificationOfDerivativeLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashContributionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash charitable contributions made by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashContributionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (63,734)<span></span>
</td>
<td class="num">$ (54,188)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements - Don Wuchterl [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Don Wuchterl<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">member<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 23, 2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ABEO_DonWuchterlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ABEO_DonWuchterlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cybersecurity
Management and Strategy</i></b></span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zjSoFmBb4S05">In
the ordinary course of our business, we collect, use, store, and transmit confidential, financial, sensitive, proprietary, personal,
and health-related information.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zwWQTVgehmp8">The secure maintenance of this information and our information technology systems is important to our
operations and business strategy. To this end, we consider cybersecurity, along with other significant risks that we face, within our
overall enterprise risk management framework, and have implemented processes designed to assess, identify, and manage risks from potential
unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality,
integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by a dedicated
Director of Information Technology and an Information Technology Security and Risk Manager. We have developed a cybersecurity program
following the National Institute of Standards and Technology (&#8220;NIST&#8221;) cybersecurity framework that include mechanisms, controls,
technologies, and systems designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting
the data and maintain a stable information technology environment. For example, we conduct penetration and vulnerability testing, and
data recovery testing on a periodic basis. In addition, we consult with outside advisors and experts, when appropriate, to assist with
assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the
Company&#8217;s risk environment.</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span>Third-Party
Risk Management</span></i></b></span></p>

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have processes to evaluate <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_z7yDrIKIiRN">third-party service</span> providers and vendors that have access to sensitive systems and company data, which may
include due diligence procedures such as assessments of that service provider&#8217;s cybersecurity posture or a recommendation of specific
mitigation controls. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zykUN2Pwg5F1">Following an assessment, we determine and prioritize service provider risk based on potential threat impact and
likelihood, and such risk determinations drive the level of due diligence and ongoing compliance monitoring required for each service
provider.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Education
and Awareness</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We
also provide cybersecurity training to our employees and are formalizing an ongoing information security training program for active
employees and relevant consultants to address matters such as phishing, email security, social engineering and training on data privacy.</span></span></p>

&#160;Current
Cybersecurity Risk Posture<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zoteuryuGIDa">We
have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect
us.</span> However, like other companies in our industry, we and our third-party vendors have from time-to-time experienced threats to and security
incidents relating to information systems. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk
Factors,&#8221; under the heading &#8220;Risks related to cybersecurity.&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The secure maintenance of this information and our information technology systems is important to our
operations and business strategy. To this end, we consider cybersecurity, along with other significant risks that we face, within our
overall enterprise risk management framework, and have implemented processes designed to assess, identify, and manage risks from potential
unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality,
integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by a dedicated
Director of Information Technology and an Information Technology Security and Risk Manager. We have developed a cybersecurity program
following the National Institute of Standards and Technology (&#8220;NIST&#8221;) cybersecurity framework that include mechanisms, controls,
technologies, and systems designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting
the data and maintain a stable information technology environment. For example, we conduct penetration and vulnerability testing, and
data recovery testing on a periodic basis. In addition, we consult with outside advisors and experts, when appropriate, to assist with
assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the
Company&#8217;s risk environment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Governance</i></b></span>&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Our
Director of Information Technology, who reports to our CFO, and the Information Technology Security and Risk Manager are responsible
for assessing and managing cybersecurity risks. Our Director of Information Technology has over 25 years of experience managing information
technology and cybersecurity. He has a bachelor&#8217;s degree in electrical engineering from Wright State University as well as a master&#8217;s
degree in business administration from Ashland University. He has certifications from various information technology vendors as well
as experience in implementing security frameworks such as International Organization for Standardization (&#8220;ISO&#8221;) 27001 and
NIST. Our Information Technology Security and Risk Manager has a PhD in a scientific field and various information security certifications
such as Certified Ethical Hacker (&#8220;CEH&#8221;) and Holistic Information Security Practitioner (&#8220;HISP&#8221;). She also has
decades of experience in managing information technology environments and information security such as security architecture, security
operations and governance risk and compliance.</span></span></p>

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We
report on our information security program, including the results of periodic testing, to the Audit Committee of the Board of Directors
on a quarterly basis. Our Board&#8217;s <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zGKX8OoiDgM4">Audit Committee is responsible for overseeing our cybersecurity</span> and information security procedures.
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zFK8TWbLhJe9">The Audit Committee reviews management presentations concerning cybersecurity-related issues, including information security, technology
risks, policies, and risk mitigation programs.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zsQAzKxj5pkj">The Audit Committee reports matters to the Board of Directors as needed.</span> Our CFO, with
the support of our Director of Information Technology, Information Technology Security and Risk Manager and third-party consultants,
assesses and manages cybersecurity risk, including preventing, mitigating, detecting, and addressing cybersecurity incidents, if any.
Our CFO also works closely with other management positions and external legal counsel to ensure that we understand our cybersecurity
risk management responsibilities. In case of a cybersecurity incident or breach, our incident response plan defines in detail reporting
and escalation processes to management and the Board of Directors.</span></span></p>

</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The Audit Committee reviews management presentations concerning cybersecurity-related issues, including information security, technology
risks, policies, and risk mitigation programs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Audit Committee reports matters to the Board of Directors as needed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zUrjk3OEqezc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_828_zoWHYO4E0r3h">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. (together with the Company&#8217;s subsidiaries, &#8220;Abeona&#8221; or the &#8220;Company&#8221;), a Delaware corporation,
is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. The Company&#8217;s lead
clinical program is for pz-cel, an autologous, cell-based gene therapy currently in development for recessive dystrophic epidermolysis
bullosa (&#8220;RDEB&#8221;). The Company&#8217;s development portfolio also features adeno-associated virus (&#8220;AAV&#8221;)-based
gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM&#8482; capsids that the Company has exclusively
licensed from the University of North Carolina at Chapel Hill and developed internally through its AAV vector research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, <i>Going Concern</i>, the Company has evaluated whether
there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date the accompanying consolidated financial statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a biopharmaceutical organization, the Company has devoted substantially all of its resources since inception to research and development
activities for pz-cel and other product candidates, business planning, raising capital, establishing its intellectual property portfolio,
acquiring or discovering product candidates, and providing general and administrative support for these operations. As a result, the
Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses
and negative cash flows will continue for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its inception, the Company has funded its operations primarily with proceeds from sales of shares of its stock. The Company has incurred
recurring losses since its inception, including net losses of $<span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_pn5n6_di_c20240101__20241231_zYnOSQex5FYa" title="Net loss">63.7</span> million and $<span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_pn5n6_di_c20230101__20231231_zRf0cdkw4Y0a" title="Net loss">54.2</span> million for the years ended December 31, 2024 and
2023, respectively. As of December 31, 2024, the Company had an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zbTiRKSAkb6g" title="Accumulated deficit">813.3</span> million. To date, the Company has not generated
any significant revenues and expects to continue to generate operating losses for the foreseeable future. As of the issuance date of
these consolidated financial statements, the Company expects that its existing cash, cash equivalents, restricted cash and short-term
investments of $<span id="xdx_90C_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20241231_z0quEixtTTUf" title="Cash, cash equivalents, restricted cash and short-term investments">98.1</span> million as of December 31, 2024, in addition to the $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240101__20241231_zDInrsE969Qg">4.8</span> million in net proceeds from the Company&#8217;s subsequent
sale of common stock under the ATM Agreement, will be sufficient to fund its operating expenses and capital expenditure requirements
for at least the next 12 months from the issuance date of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes its capital resources are sufficient to fund the Company&#8217;s on-going operations for the next 12 months from
the issuance date of these consolidated financial statements, the Company&#8217;s liquidity could be materially affected over this period
by: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding;
(2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events
or unanticipated costs related to pz-cel; (4) any other unanticipated material negative events or costs. One or more of these events
or costs could materially affect the Company&#8217;s liquidity. If the Company is unable to meet its obligations when they become due,
the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to
its operating plan. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zR5OhxzNNCQ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_828_zdaTPeDcLxib">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhb68uFtp0X4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zwwaF8VVP8qh">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and the Company&#8217;s wholly-owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zEWGU3YCyry" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zwmC79jj3cqc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of
America (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amount of assets and
disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue
and expenses during the reported period. The Company&#8217;s significant estimates include, but are not limited to, fair value of warrant
and derivative liabilities, the incremental borrowing rate related to the Company&#8217;s operating leases and stock-based compensation.
Due to the uncertainty inherent in such estimates, actual results could differ from these estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeRlmtmAHMCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zjvDL2Gawxqa">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company
maintains deposits primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses related to amounts in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zQKeiPUgGIH7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zue9oDqMmvnk">Restricted
Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash serves as collateral for leased office space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zDPax6UfLVp7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zq2DsxgbxVYf">Short-term
Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
investments consist of investments in U.S. treasury securities, U.S. federal agency securities and certificates of deposit. The Company
determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications
at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to Accounting Standards
Codification (&#8220;ASC&#8221;) 320, <i>Investments &#8211; Debt and Equity Securities</i>. Investments classified as current have maturities
of less than one year. The Company reviews its short-term investments for other-than-temporary impairment whenever the fair value of
a marketable security is less than the amortized cost and evidence indicates that a short-term investment&#8217;s carrying amount is
not recoverable within a reasonable period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zN8OoRi4Xeq1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zYY5txwNVgY7">Other
Receivables</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
receivables include employee retention credits (&#8220;ERC&#8221;), sublease rent receivables and other miscellaneous receivables that
are expected to be collected within the next twelve months. As of December 31, 2024 and 2023, the Company had ERC receivables of $<span id="xdx_905_eus-gaap--OtherReceivables_iI_pn5n6_c20241231_zwUUmza4kJLe" title="Other receivables">1.6</span>
million and $<span id="xdx_906_eus-gaap--OtherReceivables_iI_pn5n6_c20231231_zULDFuyN0IGi" title="Other receivables">2.1</span> million, respectively which was recorded in other receivables and as a component of other income in the consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt3fea5spP2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zObdGPOOnok">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from
three to five years. Leasehold improvements are amortized over the shorter of the asset&#8217;s useful life or the life of the lease
term ranging from five to ten years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures
for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation
are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of
the respective period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zwbJyEb7mn8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zImOb0v3alFk">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, <i>Leases</i>. Right-of-use lease assets represent the Company&#8217;s right
to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising
from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the
Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available
at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement
of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial
direct costs incurred, as applicable. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over
the lease term. The Company does not have any leases classified as finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive
covenants or contingent rent provisions. The Company&#8217;s leases include both lease (e.g., fixed payments including rent, taxes, and
insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component
as the Company has elected the practical expedient to group lease and non-lease components for all leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
leases include one or more options to renew. The exercise of lease renewal options is typically at the Company&#8217;s sole discretion;
therefore, the majority of renewals to extend the lease terms are not included in the Company&#8217;s right-of-use assets and lease liabilities
as they are not reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain
of exercise, the Company includes the renewal period in its lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zKSi7YDFYYl6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zruRFsxsTbni">Licensed
Technology</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into agreements to license the rights to certain technologies. The Company records the purchase price paid for the
license, which represents fair value, on its consolidated balance sheet. Licensed technology is amortized over the life of the patent
or the agreement. The Company maintains licensed technology on its consolidated balance sheet until either the licensed technology agreement
underlying it is completed or the asset becomes impaired. When the Company determines that an asset has become impaired, as discussed
below, or the Company abandons a project, the Company writes down the carrying value of the related intangible asset to its fair value
and recognizes an impairment charge in the period in which the impairment occurs. The Company has fully written off the licensed technology
as of December 31, 2024 and December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zAZKlmt0JUr4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zrGAQVqoD054">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets consist of property and equipment, licensed technology, and right-of-use assets. The Company tests its long-lived assets for impairment
when events and circumstances indicate that the carrying value of an asset or group of assets may not be fully recoverable. If indicators
are present or changes in circumstance suggest that impairment may exist, the Company assesses the recoverability of the affected long-lived
assets or group of assets by determining whether the carrying value of such assets or group of assets can be recovered through undiscounted
future operating cash flows. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing
the carrying value of the asset or group of assets to its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_za4zh3mVui76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z6qyQQmeLqX6">Credit
Losses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its available-for-sale investments for credit losses on a collective basis by major security type and in line with the
Company&#8217;s investment policy. As of December 31, 2024, the Company&#8217;s available-for-sale investments were in securities that
are issued by the U.S. treasury, U.S. federal agencies and certificates of deposits, are highly rated, and have a history of zero credit
losses. The Company reviews the credit quality of its accounts receivables by monitoring the aging of its accounts receivable, the history
of write offs for uncollectible accounts, and the credit quality of its significant customers, the current economic environment/macroeconomic
trends, supportable forecasts, and other relevant factors. The Company&#8217;s accounts receivable are with customers that do not have
a history of uncollectibility nor a history of significantly aged accounts receivables. As of December 31, 2024, the Company did not
recognize a credit loss allowance for its investments or accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zdbON1eJvcA" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_ziOHC35w8WEf">Segments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines and presents operating segments based on the information that is internally provided to the Company&#8217;s chief
operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, in accordance with ASC 280, <i>Segment Reporting</i>. The
Company has determined that it operates in a single business segment, which is a clinical-stage biopharmaceutical company developing
cell and gene therapies for life-threatening diseases. Refer to Note 16 &#8211; Segment Information for further information related to
the Company&#8217;s segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgstkCMHlPc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zrTLMG0ABlf2">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for contracts with customers in accordance with ASC 606, <i>Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;).
ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an
entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an
entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a
customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance
obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research,
develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment
to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option
exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance
obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone
selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.
The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in
the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone
selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.
Amounts received prior to revenue recognition are recorded as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exclusive
Licenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred
to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct
from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the
Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt
of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance
obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable
from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment
to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over
time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company
evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may
change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount
of revenue the Company records in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Milestone
Payments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones
are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount
method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included
in the transaction price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone
payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of
being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant cumulative revenue reversal would not occur. At the end of each subsequent reporting
period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue
and earnings in the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Collaborative
Arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success
of such activities and therefore within the scope of ASC 808, <i>Collaborative Arrangements</i> (&#8220;ASC 808&#8221;). This assessment
is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration
arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration
are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship
and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an
appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration
partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements
of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zltyzeFQFeIe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z6j2XrlRwzw3">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel
expense, lab supplies, preclinical and development cost, clinical trial expense, manufacturing, regulatory, and consulting. The cost
of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses
are capitalized when acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zjAqwrMqszEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zw5h4m72fPEb">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses primarily consist of personnel, contract personnel, personnel-related expenses to support the Company&#8217;s
administrative and operating activities, facility costs, professional expenses (i.e., legal, audit, advisory expenses) and commercial
readiness costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zZug4jDZs1Jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zqr6FBR5Ln9">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain income tax positions in accordance with ASC 740, <i>Income Taxes</i>. Interest costs and penalties related
to income taxes are classified as interest expense and general and administrative costs, respectively, in the consolidated financial
statements. For the years ended December 31, 2024 and 2023, the Company did not recognize any uncertain tax positions, interest or penalty
expense related to income taxes. It is not reasonably likely for the amounts of unrecognized tax benefits to significantly increase or
decrease within the next 12 months. The Company files U.S. federal and state income tax returns as necessary. The federal return generally
has a three-year statute of limitations and most states have a four-year statute of limitations; however, the taxing authorities are
allowed to review the tax year in which the net operating loss was generated when the loss is utilized on a tax return. The Company currently
does not have any open income tax audits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zatUCAilBHGh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zfYJ7JF0PyTc">Net
Loss Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted-average number of
shares of common stock outstanding during the period. The weighted average number of shares of common stock includes the weighted average
effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price
is $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231_ztgEF9S494tl" title="Unfounded exercise price per share">0.0001</span> or less per share (Note 10). The Company does not include the potential impact of dilutive securities in diluted net loss
per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding restricted stock, stock
options, conversion features of loan agreements, and stock purchase warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the potential securities that could potentially dilute basic loss per share in the future that were not included
in the computation of diluted net loss per share because to do so would have been anti-dilutive for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSul6Rq5xdpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zabuy2wRZd61" style="display: none">SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Shares of common stock issuable upon exercise of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zmWm1k1bSY37" title="Shares of common stock issuable upon exercise of stock options">176,587</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z96GWyhJCia9" title="Shares of common stock issuable upon exercise of stock options">179,001</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Shares of common stock underlying restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHNOxrGn4DHb" title="Shares of common stock underlying restricted stock">3,320,811</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zBQvJ3d3JXK3" title="Shares of common stock underlying restricted stock">2,448,169</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Shares of common stock issuable upon exercise of conversion feature of loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zrovK2zgkxX3" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement">614,251</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zSOzvZv3c1R8" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Shares of common stock issuable upon exercise of warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zttbklb0nqE9" title="Shares of common stock issuable upon exercise of warrants">9,987,560</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmqEepOoFY76" title="Shares of common stock issuable upon exercise of warrants">9,397,879</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zIfMwJ4Xqds7" title="Total">14,099,209</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zgs6K3Hy0yV3" title="Total">12,025,049</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_za32erE5OrRg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2024 as part of the Loan and Security Agreement, see Note 9, the Company issued warrants to purchase $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zeUUkMmdhi28" title="Warrants to purchase shares">2,400,000</span> worth of shares
of the Company&#8217;s stock which have an exercise price equal to the lesser of (i) $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zoejlqdS0Pld" title="Warrants exercise price">4.75</span> and (ii) the price per share of the Company&#8217;s
net bona fide round of equity financing before September 30, 2024 (the &#8220;2024 Loan Agreement Warrants&#8221;). In connection with
the underwritten common stock offering consummated on May 7, 2024, pursuant to the terms of the 2024 Loan Agreement Warrants, the exercise
price was reduced to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zsDGYMKom5zk" title="Warrants exercise price">4.07</span> per share and the shares issuable was calculated at <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zMWEeVNWdeR1" title="Shares of common stock issuable upon exercise of warrants">589,681</span> shares. On September 30, 2024, per the terms of
the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zf2998vCfSC1" title="Warrants exercise price">4.07</span> per share and <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zuuh8KDxTpAl" title="Shares of common stock issuable upon exercise of warrants">589,681</span> shares, respectively.
The Company included these shares for the year ended December 31, 2024 as shares of common stock issuable upon exercise of warrants in
the table above and no shares for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zwfEFjAJz5n1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_ztD0jaU13w4f">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation expense in accordance with ASC 718, <i>Stock Based Compensation</i>. The Company measures
the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date
fair value for the employees and directors and vesting date fair value for consultants of the award. The Company uses the Black-Scholes
option pricing model to determine the fair value of options on the grant date which includes assumptions for expected volatility, risk-free
interest rate, dividend yield and estimated expected term. The Company uses the closing price of its common stock as quoted on the Nasdaq
to determine the fair value of restricted stock. The Company accounts for forfeitures as they occur, which may result in the reversal
of compensation costs in subsequent periods as the forfeitures arise. The Company estimates the expected term using the &#8220;simplified&#8221;
method, as outlined in SEC Staff Accounting Bulletin No. 107, &#8220;Share-Based Payment.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--DerivativeLiabiltyPolicyTextBlock_z6N5adY9gzV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zYnJzhu0QFWj">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the fair value of the conversion right embedded within the Loan and Security Agreement in accordance with the guidance
in ASC 815, which requires the Company to bifurcate and separately account for the conversion feature as an embedded derivative contained
in the Company&#8217;s Loan and Security Agreement. Accordingly, the Company accounts for the conversion feature as a derivative liability
in the consolidated balance sheet. Derivatives are measured at their fair value on the balance sheet. In determining the appropriate
fair value, the Company uses a Monte Carlo simulation model, which incorporated assumptions and estimates to value the derivatives. The
derivative liability is remeasured at each reporting period with the change in fair value recorded to change in fair value of warrant
and derivative liabilities in the consolidated statement of operations until the derivative is exercised, expired, reclassified, or otherwise
settled. At September 30, 2024, the conversion feature no longer met the criteria of a derivative liability, and the derivative liability
was reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_842_ecustom--WarrantsPolicyTextBlock_zoQGfsgsfiHj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zHFumLbJliQ9">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2024, the Company issued pre-funded warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zMVnB4QVGsG7" title="Warrants to purchase shares">6,142,656</span> shares of common stock, with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240507__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zlA8quO4olP8" title="Warrants exercise price">4.0699</span> per
share (&#8220;2024 Pre-Funded Warrants&#8221;). The prefunded warrants are classified as equity in accordance with ASC 815, <i>Derivatives
and Hedging</i>, given the prefunded warrants are indexed to the Company&#8217;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#8217;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On June 24, 2024 and December 2, 2024, <span id="xdx_90D_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zFGwr8FAY0Ek" title="Exercise of warrants">700,000</span> and <span id="xdx_90C_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20241202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zyLHJ2IPrvLd" title="Exercise of warrants">1,228,511</span>, respectively of the
2024 Pre-Funded Warrants were exercised, leaving <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zAw1cDtUxtqg" title="Exercise of warrants">4,214,125</span> of 2024 Pre-Funded Warrants outstanding as of December 31, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, the Company issued warrants to purchase up to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zQYCyZpIteB5" title="Warrants to purchase shares">2,400,000</span> worth of shares of the Company&#8217;s common stock. On January
8, 2024, the January Warrants did not include an explicit share limit and the number of shares issuable under the warrant agreements
were variable based on the exercise price and therefore the warrants were liability classified based on a Black-Scholes valuation in
accordance with ASC 815 and were recorded at the closing date fair value of $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_z60DybBTAuGk" title="Fair value of warrants">0.2</span> million which was based on a Black-Scholes option pricing
model. The warrants are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes
in the fair value between reporting periods recorded in the consolidated statements of operations and comprehensive loss. On September
30, 2024, per the terms of the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zjH43fPgA0Kc" title="Warrants exercise price">4.07</span> per share
and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zoa6IG21xxc3" title="Warrants to purchase shares">589,681</span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2023, the Company issued pre-funded warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_z49HJKFza3Mh" title="Warrants to purchase shares">2,919,140</span> shares of common stock, with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240706__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zJMeVqFRqfQ8" title="Warrants exercise price">4.0299</span>
per share (&#8220;2023 Pre-Funded Warrants&#8221;. The prefunded warrants are classified as equity in accordance with ASC 815, <i>Derivatives
and Hedging</i>, given the prefunded warrants are indexed to the Company&#8217;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#8217;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On May 9, 2024, <span id="xdx_903_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240509__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zc9lnxMnlpF2" title="Exercise of warrants">300,000</span> of the 2023 Pre-Funded Warrants were exercised, leaving
<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zwDD2RDpicle" title="Exercise of warrants">2,619,140</span> 2023 Pre-Funded Warrants outstanding as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2022, the Company issued warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221103_zXGfklcxIXq4" title="Warrants to purchase shares">7,609,879</span> shares of common stock, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221103_zauKxlMXp0P6" title="Exercise price">4.75</span> per share,
subject to customary adjustments thereunder. On December 17, 2021, the Company issued warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211217_zCFgs9L0UKG3" title="Warrants to purchase shares">1,788,000</span> shares of common
stock, with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211217_z0EzyAiq2LFl" title="Exercise price">9.75</span> per share, subject to customary adjustments thereunder. The warrants issued in 2022 and 2021 were
determined to be freestanding instruments as they are legally detachable and separately exercisable from each other and from the common
stock issued. The common stock warrants are accounted for as liabilities in the consolidated balance sheets at their estimated fair value
because they are not indexed to the Company&#8217;s own stock. The warrants are revalued on each subsequent balance sheet date until
such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded in the consolidated statements
of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRa96MeMTpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zbFG3tIfIBL1">Recently
Adopted Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standard Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Segment Reporting (Topic 280): <i>Improvements to Reportable Segment Disclosures</i>&#8221; (&#8220;ASU 2023-07&#8221;). ASU 2023-07
requires additional disclosures for segment reporting, including disclosure of the title and position of the Chief Operating Decision
Maker and requires a public entity that has a single reportable segment to provide all the disclosures required by the amendments in
ASU 2023-07, and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal periods beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 effective for its
Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent interim periods. Since ASU 2023-07 addresses only disclosures,
the adoption of ASU 2023-07 did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zPHaeJkS5ZBb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zGcXIvinM2ze">Recently
Issued Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): <i>Disaggregation of Income Statement Expenses</i>. The amendments in ASU 2024-03 address investor requests for more
detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories
of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating this guidance to determine the impact it may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): <i>Improvements to Income Tax Disclosures</i>. ASU 2023-09 is intended
to enhance the transparency and decision usefulness of income tax information through improvements to income tax disclosures primarily
related to the rate reconciliation and income taxes paid information. The standard is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The requirements of this ASU are disclosure related and will not have an impact
on the Company&#8217;s financial condition, results of operations, or cash flows. The Company is currently evaluating the impact of adopting
this ASU on its income tax disclosures.</span></p>

<p id="xdx_859_zMJjXJUx4oAa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">SHORT-TERM INVESTMENTS</a></td>
<td class="text"><p id="xdx_806_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zGObbkJx31vh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_821_zhUnedacw0M3">SHORT-TERM INVESTMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zwNNuCZofCsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the short-term investments (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zMj2EW0vkLLc" style="display: none">SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortized Cost</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Gain</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Loss</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Available-for-sale, short-term investments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">U.S. treasury securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zRlOOSqfwPgd" style="width: 12%; text-align: right" title="Amortized cost">23,990</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLbc29LuSFCh" style="width: 12%; text-align: right" title="Gross Unrealized Gain"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_ztnCRWa2fUK2" style="width: 12%; text-align: right" title="Gross Unrealized Loss">(22</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zuHhOyXkVYag" style="width: 12%; text-align: right" title="Fair Value">23,968</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">U.S. federal agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zlu9Qo9DHkw5" style="text-align: right" title="Amortized cost">40,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zqmu3Cv8iaH6" style="text-align: right" title="Gross Unrealized Gain">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zjRupTkeAZP3" style="text-align: right" title="Gross Unrealized Loss"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zmx6l6NAbQC8" style="text-align: right" title="Fair Value">40,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Certificates of deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zf7NvHz2a7ql" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized cost">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z5vVFpxiMux4" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gain">20</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z083lbHIR0r2" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Loss"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zGliwiQPj297" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">10,020</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total available-for-sale, short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zmmdnYd2SZZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized cost">74,355</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zyLr3YVS25Ob" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gain">30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zfmFTJPwYvuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Loss">(22</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zFWt8v2nZ742" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">74,363</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortized Cost</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Gain</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Loss</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Available-for-sale, short-term investments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">U.S. treasury securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zXcaNzGOo624" style="width: 12%; text-align: right" title="Amortized cost">8,406</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgT8qB6kIb34" style="width: 12%; text-align: right" title="Gross Unrealized Gain"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zjiTfCXntg3g" style="width: 12%; text-align: right" title="Gross Unrealized Loss">(13</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zROimDBYKWVb" style="width: 12%; text-align: right" title="Fair Value">8,393</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">U.S. federal agency securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_z7CBoHFwFu7d" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized cost">29,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zzOqtHoBUgy" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gain"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zYUjnYLo9vH" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Loss">(53</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zyzsGl2pa3S2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">29,360</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total available-for-sale, short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zGdqgrqcp1B" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized cost">37,819</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zx4c9m33Eq87" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gain"><span style="-sec-ix-hidden: xdx2ixbrl0749">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zsvhUjgGGRw" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Loss">(66</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zt4sJkdsAiT3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">37,753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zcIEF0M6ilba" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the available-for-sale securities classified as short-term investments mature in one year or less. The Company
carries its available-for-sale securities at fair value in the consolidated balance sheets. Unrealized losses on available-for-sale securities
as of December 31, 2024, were not significant and were primarily due to changes in interest rates, including market credit spreads, and
not due to increased credit risks associated with specific securities. None of the short-term investments have been in a continuous unrealized
loss position for more than 12 months. Accordingly, no other-than-temporary impairment was recorded for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20240101__20241231_zthi3VgtNzx4" title="Available-for-sale securities realized gain loss"><span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20230101__20231231_zgEDMqpGReec" title="Available-for-sale securities realized gain loss">no</span></span> significant realized gains or losses recognized on the sale or maturity of available-for-sale investments during the years ended
December 31, 2024 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zOqRscL1t5ma" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82A_zCd5veDxCTja">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_z3zpII5mkwEk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost and depreciated or amortized using the straight-line method based on useful lives as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zdJsbegO5u6g" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Useful
    lives (years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231_zVk9x1UGLBhi" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_zKDdVIgVTAQh" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful lives (years)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 35%; text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zcMuPkhN31Bj" title="Useful lives (years)">5</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_z3xNLAKXuDN2" style="width: 10%; text-align: right">8,868</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zRwQhlueoQT3" style="width: 10%; text-align: right">6,935</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture, software and office equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z9EQjlFyEREl" title="Useful lives (years)">3</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zzMa4GmEDpi8" title="Useful lives (years)">5</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_zOWoiR7cR2Ll" style="text-align: right">1,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_z7xhfJLN8Lsb" style="text-align: right">986</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9ss9QtDYD28" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0772">Shorter of remaining lease term or useful life</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVWATQYDPzn8" style="text-align: right">8,805</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9E0AHx7P5G5" style="text-align: right">8,603</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Construction-in-progress</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zHCVSHfZ7Wr1" style="border-bottom: Black 1pt solid; text-align: right">624</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z23Y7teNExGb" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maCzvcX_zktQhF5p3132" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msCzvcX_zUCEnoMEnzw" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14,980</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,991</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtCzvcX_z78B58J3xhb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,430</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,533</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zeoVlOzy9Bhf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization on property and equipment was $<span id="xdx_90E_eus-gaap--DepreciationAndAmortization_pn5n6_c20240101__20241231_zxj8N1R0cRw6" title="Depreciation expense">2.0</span> million and $<span id="xdx_906_eus-gaap--DepreciationAndAmortization_pn5n6_c20230101__20231231_z2vXRwMHBT49" title="Depreciation expense">2.3</span> million for the years ended December 31, 2024 and 2023, respectively.
The Company incurred a gain on disposal of equipment of $<span id="xdx_909_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_c20240101__20241231_zNXYFIZne613" title="Gain (loss) on disposal of equipment">2,000</span> and a loss on disposal of $<span id="xdx_90D_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn3d_di_c20230101__20231231_zjFkFDlMT9Ke" title="Gain (loss) on disposal of equipment">47,000</span> during the years ended December 31,
2024 and 2023, respectively, which is reflected in other income in the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_801_eus-gaap--FairValueDisclosuresTextBlock_zfRPP4kX3Yxi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_825_zA7nKOKVqx8j">FAIR VALUE MEASUREMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates the fair value of the Company&#8217;s assets and liabilities that qualify as financial instruments and includes additional
information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial
instruments. The estimated fair value of other receivables, prepaid expenses and other current assets, other assets, accounts payable,
accrued expenses, and payables to licensor approximate their carrying amounts due to the relatively short maturity of these instruments.
The estimated fair value of the Loan Agreement as of December 31, 2024, was $<span id="xdx_90D_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241231_zJ8gJMnukw45" title="Estimated fair value of loan agreement">24.7</span> million. Both observable and unobservable inputs were
used to determine the fair value of long-term debt, which was classified within the Level 3 category.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement
date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used
to measure fair value are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active
    markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
    and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use
    significant unobservable inputs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually)
into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement
date in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zipXxzDqIJZ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of financial assets measured at fair value on a recurring and non-recurring basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zb8vLDZeZlh9" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Description</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value at<br/>
 December 31,<br/>
 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Recurring Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zr4qQKTfUFxh" style="width: 12%; text-align: right" title="Cash equivalents fair value">17,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoU7BWvsLvdj" style="width: 12%; text-align: right" title="Cash equivalents fair value">17,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoe8909E2723" style="width: 12%; text-align: right" title="Cash equivalents fair value"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zf0zgOyrWeZg" style="width: 12%; text-align: right" title="Cash equivalents fair value"><span style="-sec-ix-hidden: xdx2ixbrl0807">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Money market deposit account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zQHAjJEDYsif" style="text-align: right" title="Cash equivalents fair value">5,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zXMBELUrecei" style="text-align: right" title="Cash equivalents fair value">5,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zKQvGmeek3Ci" style="text-align: right" title="Cash equivalents fair value"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_z13aXFb8YUU3" style="text-align: right" title="Cash equivalents fair value"><span style="-sec-ix-hidden: xdx2ixbrl0815">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z9rkQS1WfENd" style="text-align: right" title="Short-term investments fair value">23,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z28ai9lBLzpg" style="text-align: right" title="Short-term investments fair value">23,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zsPxZ8lc6gYa" style="text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zSVBi1CQsure" style="text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">U.S. federal agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zTREwELdc2X4" style="text-align: right" title="Short-term investments fair value">40,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zxaUO2jH9d0g" style="text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zdFB5KWMuU4i" style="text-align: right" title="Short-term investments fair value">40,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zRbgQjl5fUg6" style="text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0831">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; padding-bottom: 1pt">Certificates of deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zubR8RtOnT06" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value">10,020</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zsuCLigAJfzj" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0835">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zjbWgTF9Twx5" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value">10,020</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zdxoBDGubLc" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0839">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zA3Uzn1yrPff" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">97,099</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkAgvzzcD9X9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">46,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGlEpab97I9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">50,395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQylC3rqse7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0847">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_z0DNPX8IHBii" style="border-bottom: Black 1pt solid; text-align: right">32,014</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zufP1eiWhOH5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zcAP8OhzYiVj" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zlnzwh1yztLe" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities">32,014</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzbS8g42I3T8" style="border-bottom: Black 2.5pt double; text-align: right">32,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zY6FNtSidbc4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGCujSBBfiNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC4R6ZeMhQog" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value">32,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value at<br/> December 31,<br/>

    2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Recurring Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 36%">Money market fund</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z5MGhwssVxC1" style="width: 12%; text-align: right">1,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zcheNgrtHx4g" style="width: 12%; text-align: right">1,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zBjDh39isri" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ziutopJ1uSPa" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zGjt5pcE5o97" style="text-align: right">8,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zs1pZH54yzXk" style="text-align: right">8,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zgnDZ6HrS7Te" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zqH9RDjyWiy2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">U.S. federal agency securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zeImKI3jS6Vd" style="border-bottom: Black 1pt solid; text-align: right">29,360</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zvYZOOLA1Mx3" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zpsy8MZtA2Mj" style="border-bottom: Black 1pt solid; text-align: right">29,360</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zuBwpnkmg5vi" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRfh7q4IQ7sk" style="border-bottom: Black 2.5pt double; text-align: right">38,787</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQDEH1VRFQEd" style="border-bottom: Black 2.5pt double; text-align: right">9,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGYYJkQTK9K2" style="border-bottom: Black 2.5pt double; text-align: right">29,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWyylU5yoqgi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payable to licensor</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_z0wHJNRP9JZ" style="text-align: right">4,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zyn6DeUyfWj7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0879">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_ztz5ds9e83Z2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zYVb9hclTaF4" style="text-align: right">4,580</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zZ29UGiWdUQ5" style="border-bottom: Black 1pt solid; text-align: right">31,352</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zJQBGntILD9b" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zj7a1Qc104kg" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0884">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zVjrMjFFAtb6" style="border-bottom: Black 1pt solid; text-align: right">31,352</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT8eW20JRiN3" style="border-bottom: Black 2.5pt double; text-align: right">35,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJlwZzUmA6cg" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwEYU8pbUZQ3" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUHK8JzoUS7a" style="border-bottom: Black 2.5pt double; text-align: right">35,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z8bJis2UhRRk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant
Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_zLtp3yxAShJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had the following outstanding warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zTEGzuH7ylNc" style="display: none">SCHEDULE OF OUTSTANDING WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zVGrSMiVrbOl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_z30RTI2vUCn9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zI8eLCm3Xrsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants issued as part of the 2021 public offering, expiration date <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zXq2Wwadqni6" title="Warrants, expiration date">December 2026</span>, exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zfjX8HJRQEig" title="Warrants, exercise price">9.75</span> per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,788,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,788,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zf3tzd0ffCYh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants issued as part of the 2022 Private Placement Offering, expiration date <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zSWZlag3Xbi9" title="Warrants, expiration date">November 2027</span>, exercise price $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_z475wsbrTNUa" title="Warrants, exercise price">4.75</span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,609,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,609,879</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zgwOkqHcJMw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued as part of the 2024 Loan Agreement, expiration date <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zdoapL79LLR7" title="Warrants, expiration date">January 2029</span>, exercise price $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zJ5BPgaz46Vh" title="Warrants, exercise price">4.07</span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">589,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zYoS9AsvVNr6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding warrant liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,609,879</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,609,879</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8A1_z74iCmQvhRId" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock warrants related to the 2021 Public Offering and the 2022 Private Placement are not indexed to the Company&#8217;s own stock
and therefore have been classified as liabilities at their estimated fair value. The common stock warrants issued in connection with
the Loan Agreement issuance were determined to be liability classified under ASC 815 as the common stock warrants were not considered
indexed to the Company&#8217;s stock. Changes in the estimated fair value of the warrant liabilities is recorded as changes in fair value
of warrant liabilities in the consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2024, as part of the Loan and Security Agreement, see Note 9, the Company issued warrants to purchase $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zz8pyafuZUOk" title="Warrants to purchase shares">2,400,000</span> worth of shares
of the Company&#8217;s stock which have an exercise price equal to the lesser of (i) $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zBNO2XSoqBud" title="Warrants exercise price">4.75</span> and (ii) the price per share of the Company&#8217;s
next bona fide round of equity financing before September 30, 2024 (the &#8220;2024 Loan Agreement Warrants&#8221;). In connection with
the underwritten common stock offering consummated on May 7, 2024, pursuant to the terms of the 2024 Loan Agreement Warrants, the exercise
price was reduced to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementMember_zQqDbp7tTJ5f" title="Warrants exercise price">4.07</span> per share and the shares issuable was calculated at <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementMember_z7DJjC0HyD93" title="Shares of common stock issuable upon exercise of warrants">589,681</span> shares. On September 30, 2024, per the terms of
the 2023 Loan Agreement Warrants, the exercise price and the number of shares became set at $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyThreeLoanAgreementMember_zEJ18XkUsCL" title="Warrants exercise price">4.07</span> per share and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyThreeLoanAgreementMember_zNVwEminFSme" title="Shares of common stock issuable upon exercise of warrants">589,681</span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfActivityWarrantyLiabilityTableTextBlock_zKvlDGvHSJrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the activity on the warrant liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zZfNqip5VEV2" style="display: none">SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zAbCkqAeriP3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zk9vNzGrMyFl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilities_iS_pn3n3_zkLpCfSAfuEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">31,352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">19,657</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FairValueAdjustmentOfWarrantsIssued_pn3n3_zax4nmVrFkja" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fair value of warrants issued in connection with the Loan Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainLossRecognizedInEarningsFromChangeInFairValue_iN_pn3n3_di_zb74aMD7CPha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Loss recognized in earnings from change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">442</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,695</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WarrantLiabilities_iE_pn3n3_z7QIL8mstCR5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending warrant liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,352</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zFzpP8LHoEG5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities are valued using significant inputs not observable in the market. Accordingly, the warrant liability is measured
at fair value on a recurring basis using unobservable inputs and are classified as Level 3 inputs within the fair value hierarchy. Fair
value measurements categorized within Level 3 are sensitive to changes in the assumptions or methodology used to determine fair value
and such changes could result in a significant increase or decrease in the fair value. The Company&#8217;s valuation of the common stock
warrants utilized the Black-Scholes option-pricing model, which incorporated assumptions and estimates to value the common stock warrants.
The Company assessed these assumptions and estimates at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z29rlvcuTmU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the key inputs for the Black-Scholes option-pricing model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zzfRD4nJtovk" style="display: none">SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Common share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: center">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z7AlKWJUrUw5">5.57</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: center">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDiCi34HRqae">5.01</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zcVhk02hsKdl" title="Expected term (years)">1.96</span>
&#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zEa5d86fCkKc" title="Expected term (years)">4.02</span> </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zMC9dmNs2Fna" title="Expected term (years)">2.96</span>
&#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zS3QwkJb5q1d" title="Expected term (years)">3.84</span> </span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zwxA83DjHxne" title="Warrants measurement input">4.16</span>% &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zKrkBTFhT4Xh" title="Warrants measurement input">4.24</span></span>%</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRAegRZo0w9h" title="Warrants measurement input">3.84</span>% &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zgensBV8qG76" title="Warrants measurement input">3.92</span>%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zhl1fCHSRzK1" title="Warrants measurement input">92.64</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoraCYRSkFh4" title="Warrants measurement input">100.00</span>%</span></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcsgRdfr7tOh" title="Warrants measurement input">100.00</span>%</td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmv4kcxZolB" title="Warrants measurement input">0</span>%</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGQhwfkSThG4" title="Warrants measurement input">0</span>%</td><td style="text-align: left"></td></tr>
  </table>

<p id="xdx_8AB_zdsWkbpAnAxj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative
Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Conversion Right embedded within the Loan Agreement (see Note 9 below) required bifurcation as certain adjustments to the conversion
price were not indexed to the Company&#8217;s own stock and therefore the Conversion Right was recorded as a derivative liability. The
derivative liability is remeasured at each reporting period with the change in fair value recorded to changes in fair value of warrants
and derivative liabilities in the condensed consolidated statement of operations until the derivative is exercised, expired, reclassified,
or otherwise settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, pursuant to the Loan Agreement, the conversion price was fixed at $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zgBp5ZbjjBYf" title="Conversion price">4.88</span> and is considered indexed to the Company&#8217;s
own stock. At September 30, 2024, the Conversion Right no longer met the criteria of a derivative liability, and the derivative liability
was reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zpMU7P2RYzP5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the activity on the derivative liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8B9_z7J5r0VD8j8d" style="display: none">SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zcWsM91NpHgk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_zSJEn2Jm4WQ6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_zgKQWzylEaC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Beginning derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FairValueOfDerivativesIssued_zgOuKkKYcNna" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Fair value of derivatives issued in connection with Loan Agreement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">822</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLossOnDerivative_zfFbfwKv7rXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span id="xdx_903_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20240101__20241231_z5JWqb45Gh44" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"><span id="xdx_90B_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20230101__20231231_zun9QKFotl4f" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"><span style="-sec-ix-hidden: xdx2ixbrl0985"><span style="-sec-ix-hidden: xdx2ixbrl0986">Loss recognized in earnings from change in fair value</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_iN_zOvJ03xsAm81" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of derivative liability in connection with the Loan Agreement</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,135</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_zHXFxmIpvlzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending derivative liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zPCBaxmGtRZj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SETTLEMENT LIABILITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">SETTLEMENT LIABILITY</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zZSAZaApmfzj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82F_zfFw9jdS1Jfi">SETTLEMENT LIABILITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2021, the Company entered into a settlement agreement (&#8220;Settlement Agreement&#8221;) with the Company&#8217;s prior
licensor REGENXBIO Inc. (&#8220;REGENXBIO&#8221;) to resolve all existing disputes between the parties. In accordance with the Settlement
Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_905_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zEwu1gvduwK8" title="Settlement liabilities, current">30.0</span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zz8ou7zWJNTi" title="Loss contingency settlement agreement terms">(1) $20.0 million paid in November 2021
after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement
(paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement
or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement (paid in November 2024).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the payable due to REGENXBIO in the consolidated balance sheet based on the present value of the remaining payments
due to REGENXBIO under the Settlement Agreement using an effective interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_znVsSSoGPVrj">9.6</span>%. The Company paid all amounts due in November
2024 and therefore there were no amounts outstanding as of December 31, 2024. The present value of the amount due as of December 31,
2023 was $<span id="xdx_906_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_z41pAKc5Haq8">4.6</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-20/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-30/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zCF2pdtOPzbi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_82E_z8swC3D3KsM6">ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0klTybGiMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the components of accrued expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhHL2yHiwIrf" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zgf4LoVT2Kc3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231_zvLG8hnRct3b" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz9Ql_zyVyMa7TPaHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued employee compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,688</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCz9Ql_ze73B163aD3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued contracted services and other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,941</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,297</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz9Ql_zPeVdkGjBeY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_z5zrktVjewKc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zujyXqb0Dln3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_822_zWlQ7cfA1YGa">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases space under operating leases for administrative, manufacturing and laboratory facilities in Cleveland, Ohio. The Company
also leases office space in New York, New York, that the Company sublets. The Company also leases certain office equipment under operating
leases, which have a non-cancelable lease term of less than one year and the Company has elected the practical expedient to exclude these
short-term leases from the Company&#8217;s right-of-use assets and lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, the Company signed a lease for <span id="xdx_900_eus-gaap--AreaOfLand_iI_usqft_c20241231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zCwLK6jtSFIc" title="Lease cost">16,566</span> square feet of office space at 6700 Euclid Avenue, Cleveland, Ohio. Pursuant to the lease
agreement, the lease term commences on January 1, 2025 with an initial term through December 30, 2030. Annual lease payments during the
term of the lease are approximately $<span id="xdx_90F_eus-gaap--OperatingLeasePaymentsUse_pn5n6_c20240101__20241231_za46fa05eibg" title="Annual lease payments">0.3</span> million. The total lease payments over the duration of the lease term are approximately $<span id="xdx_90E_eus-gaap--OperatingLeasePayments_pn5n6_c20240101__20241231_zPtGr1jSwOWd" title="Total lease payments">1.5</span>
million. The additional space at the 6700 Euclid Avenue facility will allow the Company to convert office space at the 6555 Carnegie
Avenue facility into additional manufacturing space to increase pz-cel manufacturing capacity. As the lease does not commence and the
Company does not have access to the leased space until January 1, 2025, the impact of this lease agreement is not reflected in the consolidated
financial statements of the Company as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company terminated one of its operating leases for office space. The termination resulted in a gain of $<span id="xdx_905_eus-gaap--GainLossOnTerminationOfLease_pn5n6_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceOneMember_zJBI1L0xa0Y8" title="Gain (loss) on termination of lease">1.1</span> million representing
the difference between the carry value of the right-of-use assets and the related lease liabilities. This gain was recorded in the year
ended December 31, 2023, and is included in gain on operating lease right-of-use assets in the consolidated statement of operations and
comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company modified one of its operating leases for office space to add up to <span id="xdx_906_eus-gaap--AreaOfLand_iI_usqft_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zvtL4x96Rfjf" title="Area of land">14,032</span> square feet to the Company&#8217;s existing
facility in Cleveland, Ohio. The lease modification resulted in the recognition of $<span id="xdx_90B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zPpxYS5Tdx5k" title="Right-of-use assets"><span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_pn5n6_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_z5J77HKxd5d1" title="Lease liabilities">0.4</span></span> million of additional right-of-use assets and
related lease liabilities in the Company&#8217;s consolidated balance sheet during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022 and 2023, the Company entered into two sublease agreements with unrelated third parties to occupy the Company&#8217;s administrative
offices in New York, New York. The Company expects to receive $<span id="xdx_90D_eus-gaap--SubleaseIncome_pn5n6_c20240101__20241231__us-gaap--AwardDateAxis__custom--SeptemberTwoThouandTwentyFiveMember_znBZUuU9JCN1" title="Sublease income">0.5</span> million in future sublease income through September 2025 from the
two subleases noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zHqncXgOgfI8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s operating lease liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zSXKYa6qpv1a" style="display: none">SUMMARY OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zywhxeVoY6Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zExrjeakqDU7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzJ5e_zzftb7jKYr4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Current operating lease liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">823</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">998</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzJ5e_z3ptF5BnuDR1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Non-current operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,262</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,402</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzJ5e_zbEYM6NwI84k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z1NMcCerDdFb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs and rent are reflected in general and administrative expenses and research and development expenses in the consolidated statements
of operations and comprehensive loss, as determined by the underlying activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zLO5vmxyZoff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the components of lease costs and rent (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAqOuKsMyG1i" style="display: none">SCHEDULE OF COMPONENTS OF LEASE COST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zPbyK4BgezUg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zEe20696qzHk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_maLCzRlC_zexGgZSlOph4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,389</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--VariableLeaseCost_pn3n3_maLCzRlC_zOknanic4gh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">358</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzRlC_zWFA1AtjKpJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Short-term lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">63</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LeaseCost_iT_pn3n3_mtLCzRlC_zTZu4St3ZdOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,717</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,810</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zFPLPbLDV1p" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
paid for amounts included in the measurement of operating lease liabilities was $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_pn5n6_c20240101__20241231_zL5ZIrdbJvbj" title="Operating lease liabilities">1.3</span> million and $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_pn5n6_c20230101__20231231_zeWin1E1j6S2" title="Operating lease liabilities">1.2 </span>million for the years ended December
31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgxclDHvdVR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments and obligations, which do not include short-term leases, related to the Company&#8217;s operating lease liabilities
as of December 31, 2024 were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zZoR7xzYjpv7" style="display: none">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future minimum lease payments and obligations</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zhpptrbDid29" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0kQ_zumIRufpw2E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">853</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0kQ_ztQolLdnqQ2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">791</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPz0kQ_zklCTUsrdfl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">807</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPz0kQ_zHitQCfr4kd9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">823</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPz0kQ_zfwSYH0S5kUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">859</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPz0kQ_ziwWsTMaOfIg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">834</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0kQ_zJifI0OSsI41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,967</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zea4xJ417NWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">882</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zki4bC6ZxUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zTmBF6APUW41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining term of the Company&#8217;s operating leases was <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20241231_z9H7wjg1Xgw7" title="Weighted average remaining term">60</span> months and the weighted-average discount rate used to
measure the present value of the Company&#8217;s operating lease liabilities was <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_z3pMWvZrE9Pb" title="Weighted average discount rate">7.0</span>% as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received $<span id="xdx_907_eus-gaap--SubleaseIncome_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SubLeaseAgreementMember_zjQLwXKxKgbl" title="Sublease income">0.6</span> million and $<span id="xdx_90E_eus-gaap--SubleaseIncome_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SubLeaseAgreementMember_zhbWC7MpIEbc" title="Sublease income">0.5</span> million during the years ended December 31, 2024 and 2023, respectively, of sublease income which
is recorded in other income on the consolidated statements of operations and comprehensive loss. Future cash receipts from the Company&#8217;s
sublease agreements as of December 31, 2024 are as follows (in thousands):</span></p>

<p id="xdx_892_ecustom--ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_zwqVEJqs2Nh3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zKmqxz9XUW8b" style="display: none">SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zjtUtumCZmt9" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future cash receipts</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subleases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_iI_pn3n3_maFCRFOzUBz_zkr9S0A8Ga6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left; padding-bottom: 1pt">2025</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">485</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--FutureCashReceiptsFromOperatingSublease_iTI_pn3n3_mtFCRFOzUBz_zE0u317Rznzh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total future cash receipts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zF1ZDeYLOXTi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zCrJ4FSNwwmj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82D_zlAaFcgYdmoh">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zyxxvjuPhWjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s debt, net of debt issuance costs and discounts (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zqffGlfH4Sgl" style="display: none">SCHEDULE
OF DEBT AND NET OF DEBT ISSUANCE COSTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zoYDkBwaIEwi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zbywQZHxVMrc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_maLTDzr8F_zP3IwhDVIyIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Loan Agreement Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">20,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccretedFinalPaymentFee_iI_pn3n3_maLTDzr8F_zjXiZ8Qtzehg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accreted final payment fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTDzr8F_zre8cPV9mPbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Unamortized debt issuance costs and discounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,391</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzr8F_mtLTDNzuex_zf2GAldghadl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1110">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtCurrent_iI_pn3n3_maLTDNzuex_z0qFJMsDr0Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: current maturities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,926</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_maLTDNzuex_zXEECTBoo7Sd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current maturities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,037</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zIwKylnKLWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loan
and Security Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024 (the &#8220;Closing Date&#8221;), the Company entered into a Loan and Security Agreement, as supplemented by a Supplement,
dated as of January 8, 2024 (collectively, the &#8220;Loan Agreement&#8221;) with Avenue Venture Opportunities Fund, L.P., a Delaware
limited partnership, as administrative agent and collateral agent (&#8220;Avenue&#8221; and the &#8220;Agent&#8221;) and Avenue Venture
Opportunities Fund II, L.P., a Delaware limited partnership (&#8220;Avenue 2&#8221; and, together with Avenue, the &#8220;Lenders&#8221;).
The Loan Agreement provides for senior secured term loans (the &#8220;Loans&#8221;) in an aggregate principal amount up to $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zqppfvuO7xT7" title="Aggregate principal amount">50</span> million,
with (i) a committed tranche of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember_zYpwadigIBb8" title="Aggregate principal amount">20</span> million advanced on the Closing Date (&#8220;Tranche 1&#8221;), (ii) a committed tranche of up to
$<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheTwoMember_zWyRo3ErNvL3" title="Aggregate principal amount">10</span> million which may be advanced upon the request of the Company between June 30, 2024 and September 30, 2024, subject to the Company
obtaining FDA approval of pz-cel in recessive dystrophic epidermolysis bullosa, with the issuance of a Priority Review Voucher (&#8220;Tranche
2&#8221;), and (iii) a discretionary tranche of up to $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--DiscretionaryTrancheMember_zlkrfmmzjFe6" title="Aggregate principal amount">20</span> million which may be advanced between March 31, 2025 and March 31, 2026 (the
&#8220;Discretionary Tranche&#8221;) provided at the discretion of the Lenders. The Loans are due and payable on July 1, 2027 (the &#8220;Maturity
Date&#8221;). As of December 31, 2024, the Tranche 2 is no longer available as the Company did not meet the Tranche 2 criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan principal is repayable in equal monthly installments beginning on May 1, 2025. The Loans bear interest at a rate per annum (subject
to increase during an event of default) equal to the greater of (i) the prime rate, as published by the Wall Street Journal from time
to time, plus <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250501__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__srt--RangeAxis__srt--MinimumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zatbGoC3Xkj5" title="Prime rate percentage">5.00</span>% and (ii) <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250501__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zn7RFH12AA3f" title="Prime rate percentage">13.50</span>%. The stated interest rate and effective interest rate as of December 31, 2024 was <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z7gSZs89oRql" title="Stated interest rate">13.50</span>% and <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zJ8Lau6PXYKf" title="Effective interest rate">22.09</span>%,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may, subject to certain parameters, voluntarily prepay the Loans, in whole, at any time. If prepayment occurs on or before the
one-year anniversary of the Closing Date, <span id="xdx_900_eus-gaap--PropertyManagementFeePercentFeeDescription_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zMsKEvCer466" title="Percentage fee, description">the Company is required to pay a prepayment fee equal to 3.00% of the principal amount of the
Loans prepaid; if prepayment occurs after the one-year anniversary of the Closing Date and on or before the two-year anniversary of the
Closing Date, the Company is required to pay a fee equal to 2.00% of the principal amount of the Loans&#894; if prepayment occurs after
the two-year anniversary of the Closing Date, the Company is required to pay a fee equal to 1.00% of the principal amount of the Loans.
A final payment fee of 5.00% of the principal amount of the funded Tranche 1, Tranche 2 Loans and Discretionary Tranche Loans is also
due upon the Maturity Date or any earlier date of prepayment.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s obligations under the Loan Agreement are secured by a pledge of substantially all of the Company&#8217;s assets. Pursuant
to the Loan Agreement, the Company is subject to a financial covenant requiring the Company to maintain at all times $<span id="xdx_90B_eus-gaap--InvestmentsAndCash_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z7I5JaLR6y6c" title="Unrestricted cash">5</span> million in unrestricted
cash. The Loan Agreement also contains affirmative and negative covenants customary for financings of this type that, among other things,
limit the ability of the Company and its subsidiaries to (i) incur additional debt, guarantees or liens&#894; (ii) pay dividends&#894;
(iii) enter into certain change of control transactions&#894; (iv) sell, transfer, lease, license, or otherwise dispose of certain assets&#894;
(v) make certain investments or loans&#894; and (vi) engage in certain transactions with related persons, in each case, subject to certain
exceptions. The Loan Agreement also includes events of default customary for financings of this type, in certain cases subject to customary
periods to cure, following which the Agent may accelerate all amounts outstanding under the Loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Supplement to the Loan and Security Agreement, Avenue also has the right to convert up to $<span id="xdx_901_eus-gaap--PrincipalAmountOutstandingOnLoansManagedAndSecuritized_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z9yWtGaIpDGh" title="Outstanding principal amount of loan">3</span> million of the outstanding principal
of the Loans into shares of Company common stock (the &#8220;Conversion Right&#8221;) at a price per share equal to 120% of the exercise
price of the Warrants (further discussed below) at any time while the Loans are outstanding, subject to certain terms and conditions,
including ownership limitations. The Conversion Right required bifurcation as certain adjustments to the conversion price were not indexed
to the Company&#8217;s own stock and therefore the Conversion Right was recorded as a derivative liability. On January 8, 2024, the Conversion
Right was recorded at the closing date fair value of $<span id="xdx_90A_ecustom--FairValueOfConversionRight_pn5n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zR8WcZwyW0Tl" title="Fair value of conversion right">0.8</span> million which was based on a Monte Carlo simulation model. The derivative liability
is remeasured at each reporting period with the change in fair value recorded to change in fair value of warrants and derivative liabilities
in the condensed consolidated statement of operations until the derivative is exercised, expired, reclassified, or otherwise settled.
On September 30, 2024, pursuant to the Loan Agreement, the conversion price was fixed at $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zezejV664V1a" title="Conversion Price">4.88</span> and is considered indexed to the Company&#8217;s
own stock. At September 30, 2024, the Conversion Right no longer met the criteria of a derivative liability and the derivative liability
of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240930__20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z3xJlAyrWfof" title="DerivativeLiabilities">1.1</span> million was reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, subject to applicable law and specified provisions set forth in the Supplement to the Loan and Security Agreement and solely
to the extent permitted under applicable stock exchange rules without requiring stockholder approval, the Lenders may participate in
certain equity financing transactions of the Company in an aggregate amount of up to $<span id="xdx_901_eus-gaap--DebtInstrumentIssuedPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zbWhotfeXAD5" title="Aggregate transaction amount">1</span> million on the same terms, conditions and pricing
offered by the Company to other investors participating in such financing transactions (such right, the &#8220;Participation Right&#8221;).
<span id="xdx_902_ecustom--ParticipationRightDescription_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zbbR5F4TEkg6" title="Participation right description">The Participation Right automatically terminates upon the earliest of (i) July 1, 2027, (ii) such time that the Lenders have purchased
$1 million of the Company&#8217;s equity securities in the aggregate pursuant to the Participation Right, and (iii) the repayment in
full of all of the obligations under the Loan Agreement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date and pursuant to the funding of Tranche 1 of the Loan Agreement, the Company issued to each of Avenue and Avenue 2 (collectively,
the &#8220;Warrant Holders&#8221;) warrants to purchase up to $<span id="xdx_90F_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueMember_zvWhcCBUEKW2" title="Warrants purchase amount">480,000</span> and $<span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueTwoMember_zRHkPHHoHMz1" title="Warrants purchase amount">1,920,000</span> of Company common stock, respectively which is
more fully described in Note 10 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z3D0xIpWowBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future payment obligations of the principal are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z5c7uFcASU82" style="display: none">SCHEDULE
OF FUTURE PAYMENT OBLIGATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20241231_zx7SiEVbuXuh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzeHi_z2frBGi0rYNc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,926</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzeHi_znqqtiYjHVsi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,889</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzeHi_zzIIExoKjtm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzeHi_zSiEbNNpn9qg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total principal</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zXCTZC60DKdh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zCVPMtLTbta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_82A_zlJlVAVUbTyd">EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate number of authorized shares of the Company&#8217;s preferred stock is <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zqGTzgMupP1j" title="Preferred stock shares authorized">2,000,000</span> shares with a par value of one cent ($<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_z1EfIEquYOj6" title="Preferred stock par value">0.01</span>).
There is <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_zVZ1MdJYcLWk" title="Preferred stock shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zNo35nZLxPWe" title="Preferred stock shares outstanding">no</span></span> preferred stock outstanding as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Public
Offerings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2021, the Company closed an underwritten public offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211220__20211221_zjw7Yp9fdStg" title="Stock issued at public offerings">1,788,000</span> shares of common stock at a public offering price
of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20211221_zwvluIKHsDM4" title="Public offering price">9.75</span> per share and stock purchase warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211221_z3M37BwmFEpl" title="Warrants issued to purchase of common stock">1,788,000</span> shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211221_zkcdddGKi18a" title="Exercise price">9.75</span>. The net proceeds
to the Company were $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20211220__20211221_zWAxVjCnQQz7" title="Proceeds from public offering">16.0</span> million, after deducting $<span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20211220__20211221_zCAUpgS3UTJf" title="Payments of underwriting discounts and comissions">1.5</span> million of underwriting discounts and commissions and offering expenses payable
by the Company. The net proceeds were allocated to the warrant liability as noted below with the remainder of $<span id="xdx_901_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_pn5n6_c20211221_zjwrYIPQvTAe" title="Additional paid-in capital">7.0</span> million recorded in
common stock and additional paid-in capital. In the event of certain fundamental transactions involving the Company, the holders of the
stock purchase warrants may require the Company to make a payment based on a Black-Scholes valuation, using specific inputs that are
not considered indexed to the Company&#8217;s stock in accordance with ASC 815, <i>Derivatives and Hed</i>ging (&#8220;ASC 815&#8221;).
Therefore, the Company accounted for the stock purchase warrants as liabilities, which were recorded at the closing date fair value of
$<span id="xdx_905_ecustom--FairValueWarrantLiabilities_iI_pn5n6_c20211221_zVYP1L1dRUJ4" title="Warrant liabilities">9.0</span> million which was based on a Black-Scholes option pricing model. The remainder of the proceeds were allocated to common stock issued
and recorded as a component of equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_z8s0KDpPVvMf" title="Warrants outstanding">1,788,000</span> stock purchase warrants outstanding related to this public offering. These stock purchase
warrants expire on <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zukbOeXQH48g" title="Warrants maturity date">December 21, 2026</span>. During such time as each warrant is outstanding, the holder of the warrant is entitled to participate
in any dividends or other distribution of assets to holders of shares of common stock. There was no warrant activity during the year
ended December 31, 2024 and 2023, other than the change in fair value of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2024, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRE2lSf75jQ8" title="Shares issued">12,285,056</span> shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zke0RyAPzJx7" title="Warrants exercised">6,142,656</span>
shares of its common stock (the &#8220;2024 Pre-Funded Warrants&#8221;), for an aggregate purchase price of $<span id="xdx_90B_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zIcRx29qLss9" title="Purchase price of common stock">75.0</span> million gross, or $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_z3kYUcC4eht" title="Shares issuance costs">70.2</span>
million net of related costs. The offering price for each share of common stock was $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjR3yBKwgaVi" title="Offering price">4.07</span>, and the offering price for the 2024 Pre-Funded
Warrants was $<span id="xdx_90D_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zeptkaw6Prn4" title="Offering price">4.0699</span>, which represents the per share offering price for the Company&#8217;s common stock less a $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zV8rGhpMo7q" title="Exercise price">0.0001 </span>per share exercise
price for each 2024 Pre-Funded Warrant. The 2024 Pre-Funded Warrants are immediately exercisable at a nominal exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_ziZ0KaaK36td" title="Exercise price">0.0001</span>
per share and may be exercised at any time until the pre-funded warrants are exercised in full. On June 24, 2024, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240624__20240624__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zaFiM6mfNPP5" title="Warrants exercised">700,000</span> of the 2024
Pre-Funded Warrants were exercised and on December 2, 2024 <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241202__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zINMLwQIJzpc" title="Warrants outstanding">1,228,531</span> of the 2024 Pre-Funded Warrants were exercised, leaving <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zw9yyqqZxMQl" title="Warrants outstanding">4,214,125</span>
2024 Pre-Funded Warrants outstanding as of December 31, 2024. The 2024 Pre-Funded Warrants are classified as equity in accordance with
ASC 815, <i>Derivatives and Hedging</i>, given the prefunded warrants are indexed to the Company&#8217;s own shares of common stock and
meet the requirements to be classified in equity. The 2024 Pre-Funded warrants were recorded at their relative fair value at issuance
in the stockholders&#8217; equity section of the consolidated balance sheet and the 2024 Pre-Funded Warrants are considered outstanding
shares in the basic and diluted earnings per share calculation for year ended December 31, 2024 given their nominal exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Open
Market Sale Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2018, the Company entered into an open market sale agreement (as amended, the &#8220;ATM Agreement&#8221;) with Jefferies
LLC (&#8220;Jefferies&#8221;) pursuant to which, the Company may sell from time to time, through Jefferies, shares of its common stock
for an aggregate sales price of up to $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20180816__20180817__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zam0q7cpvpj5" title="Aggregate sale price">75.0</span> million. Any sales of shares pursuant to this agreement are made under the Company&#8217;s
effective &#8220;shelf&#8221; registration statement on Form S-3 that is on file with and has been declared effective by the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sold <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zsMBx08QVUfe" title="Company sold shares of its common stock">2,825,954</span> and <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zGpGLkm34eBh" title="Company sold shares of its common stock">3,659,882</span> shares of its common stock under the ATM Agreement during the years ended December 31, 2024 and
2023, respectively, resulting in net proceeds of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zSCuJIGfyE5c" title="Net proceeds">15.5</span> million and $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zAgC0z4vuAGg" title="Sale of stock value">14.4</span> million during the years ended December 31, 2024 and 2023, respectively.
Subsequent to December 31, 2024 and through March 1, 2025, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zIlbPWTNkb4k" title="Shares issued">915,925</span> shares of its common stock under the ATM Agreement resulting
in $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zPU6sDrmxWZi" title="value issued">4.8</span> million in net proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Private
Placement Offering</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2022, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zZ3TywXhELhf" title="Shares issued">7,065,946</span> shares of its common stock, and in lieu of shares of common stock, pre-funded warrants exercisable
for <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zPmlZaJSfoNk" title="Warrants exercised">543,933</span> shares of common stock and accompanying warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z7kOqsTnGKbh" title="Warrants purchase, shares">7,609,879</span> shares of its common stock to a group of new and existing
institutional investors in a private placement. The offering price for each share of common stock and accompanying warrant was $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockAndAccompanyingWarrantMember_zGpIDJRFyF0j" title="Offering price">4.60</span>,
and the offering price for each pre-funded warrant and accompanying warrant was $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantAndAccompanyingWarrantMember_zfqCXs7rhonh" title="Offering price">4.59</span>, which equaled the offering price per share of
the common stock and accompanying warrant, less the $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zAHTjz4dh2Me" title="Offering price">0.01</span> per share exercise price of each pre-funded warrant. Each accompanying warrant
represents the right to purchase one share of the Company&#8217;s common stock at an exercise price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_z9sEpZUOlgw3" title="Exercise price">4.75</span> per share of common stock.
The pre-funded warrants were exercised in December 2022 and converted to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20221201__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zzXuOgDdkkG9" title="Warrants exercised">543,933</span> shares of commons stock. Total shares sold and converted
during the year ended December 31, 2022 were <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z5vPksdnpo3c" title="Sale of stock">7,609,879</span> for an aggregate purchase price of $<span id="xdx_901_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zBYNNhBHJaC9" title="Purchase price of common stock">35.0 </span>million gross, or $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zjidxjHA91Uh" title="Proceeds from issuance of common stock">32.6</span> million net of
related costs of $<span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zZaMF9BVLCR6" title="Stock issuance costs">1.5</span> million which was expensed to general and administrative expenses and $<span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zaCQU5YOeAb4" title="Additional paid in capital stock reduction">0.9 </span>million which was recorded as a reduction
to additional paid-in-capital. The net proceeds were allocated to the warrant liability as noted below with the remainder of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z9RbapXKbp89" title="Proceeds from warrant liability'">12.9</span> million
and $<span id="xdx_900_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_pn5n6_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_ztSBdSUrKxTk" title="Additional paid-in capital">0.1</span> million recorded in additional paid-in capital and common stock, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of certain fundamental transactions involving the Company, the holders of the stock purchase warrants may require the Company
to make a payment based on a Black-Scholes valuation, using specific inputs that are not considered indexed to the Company&#8217;s stock
in accordance with ASC 815. Therefore, the Company is accounting for the stock purchase warrants as liabilities. On November 3, 2022,
the stock purchase warrants were recorded at the closing date fair value of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zmZ2nvQWucP6" title="Fair value of warrants">22.0</span> million which was based on a Black-Scholes option pricing
model. The remainder of the proceeds were allocated to common stock issued and recorded as a component of equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zpEztix7VBx" title="Warrant outstanding">7,609,879</span> warrants outstanding related to this private placement offering. The warrants expire on November
3, 2027. During such time as each warrant is outstanding, the holder of the warrant is entitled to participate in any dividends or other
distribution of assets to holders of shares of common stock. There was no warrant activity during the year ended December 31, 2024 and
2023, other than the change in fair value of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Direct
Placement Offering</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2023, the Company sold <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwOMkhcsXxrk" title="Shares issued">3,284,407</span> shares of its common stock, and in lieu of shares of common stock, pre-funded warrants exercisable
for <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_z5pniHJteYWa" title="Warrants exercised">2,919,140</span> shares of common stock (the &#8220;2023 Pre-Funded Warrants&#8221;), to a group of existing institutional investors for
an aggregate purchase price of $<span id="xdx_907_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zycai40UA0Ch" title="Purchase price of common stock">25.0</span> million gross, or $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zhYYni0HVDo" title="Shares issuance costs">23.0</span> million net of related costs. The offering price for each share of common
stock was $<span id="xdx_901_eus-gaap--SharePrice_iI_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD2JW35X3VNj" title="Offering price">4.03</span>, and the offering price for the 2023 Pre-Funded Warrants was $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zIBxzy2TpIa9" title="Offering price">4.0299</span>, which represents the per share offering price for
the Company&#8217;s common stock less a $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zr1ChDX8xH7a" title="Exercise price">0.0001 </span>per share exercise price for each such 2023 Pre-Funded Warrant. The 2023 Pre-Funded Warrants
are immediately exercisable at a nominal exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_znEqPkaogfaf" title="Exercise price">0.0001</span> per share, may be exercised at any time and do not have an expiration
date. On May 9, 2024, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240509__20240509__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zbRS7ESYk3xk" title="Warrants exercised">300,000</span> of the 2023 Pre-Funded Warrants were exercised, leaving <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zXiAfdIQ7qTd" title="Warrants outstanding">2,619,140</span> 2023 Pre-Funded Warrants outstanding
as of December 31, 2024. The 2023 Pre-Funded Warrants are classified as equity in accordance with ASC 815, <i>Derivatives and Hedging</i>,
given the 2023 Pre-Funded Warrants are indexed to the Company&#8217;s own shares of common stock and meet the requirements to be classified
in equity. The 2023 Pre-Funded Warrants were recorded at their relative fair value at issuance in the stockholders&#8217; equity section
of the consolidated balance sheet and the 2023 Pre-Funded Warrants are considered outstanding shares in the basic and diluted earnings
per share calculation for the year ended December 31, 2024 given their nominal exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Common
Stock Warrants related to the Loan and Security Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, in connection with entering into the Loan and Security Agreement, the Company issued to each of Avenue and Avenue 2
(collectively, the &#8220;Warrant Holders&#8221;) warrants to purchase up to $<span id="xdx_902_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueMember_ztveWeRlMpr3" title="Warrants purchase amount">480,000</span> and $<span id="xdx_900_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueTwoMember_z5A8pnbCdpx" title="Warrants purchase amount">1,920,000</span> worth of shares, respectively, of
Company common stock (collectively, the &#8220;January Warrants&#8221;). The Warrants expire on January 8, 2029 (the &#8220;Expiration
Date&#8221;) and upon issuance, had an exercise price per share equal to the lesser of (i) $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zLu9wM0xfHse" title="Warrants exercise price">4.75</span> and (ii) the price per share of the
Company&#8217;s next bona fide round of equity financing before September 30, 2024 in which the Company sells or issues shares of its
common stock, excluding certain excluded issuances as defined in the Supplement. In connection with the underwritten common stock offering
consummated on May 7, 2024, and pursuant to the term of the January Warrants, the exercise price of the January Warrants was reduced
to $<span id="xdx_903_eus-gaap--WarrantExercisePriceDecrease_c20240507__20240507__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9M1Zhf7xe9" title="Exercise price per share">4.07</span> per share for <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zi1B1wWPj0Rk" title="Shares of common stock issuable upon exercise of warrants">589,681</span> shares. In addition, upon a change of control where the per share price of the Company common stock is
less than or equal to two times that of the exercise price, the Warrant Holders would be entitled to receive the shares of common stock
underlying the January Warrants without payment of the exercise price. On January 8, 2024, the January Warrants did not include an explicit
share limit and the number of shares issuable under the warrant agreements were variable based on the exercise price and therefore the
January Warrants were liability classified based on a Black-Scholes valuation in accordance with ASC 815 and were recorded at the closing
date fair value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zrjfEBpqJOO6" title="Fair value of warrants">0.2</span> million which was based on a Black-Scholes option pricing model. On September 30, 2024, per the terms of the
January Warrants, the exercise price and the number of shares issuable became set at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zJS4gA1xs99i" title="Warrants exercise price">4.07</span> per share and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zmQOMlAwFG8g" title="Shares of common stock issuable upon exercise of warrants">589,681</span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Holders may exercise the January Warrants at any time, or from time to time up to and including the Expiration Date, by making
a cash payment equal to the exercise price multiplied by the quantity of shares. The Warrant Holders may also exercise the January Warrants
on a cashless basis by receiving a net number of shares calculated pursuant to the formula set forth in the January Warrants. The January
Warrants are subject to anti-dilution adjustments for stock dividends, stock splits, and reverse stock splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zQKqSSQ65Qxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_82D_zdyuTsPb3Ud4">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company previously granted stock options under its 2005 Equity Incentive Plan (the &#8220;2005 Incentive Plan&#8221;), under which no
further grants can be made. In addition, prior to May 17, 2023, the Company had previously granted stock options and stock awards under
the Abeona Therapeutics Inc. 2015 Equity Incentive Plan (the &#8220;2015 Incentive Plan&#8221;). As of May 17, 2023, no further grants
can be made under the 2015 Incentive Plan. The Company now grants stock options and stock awards under the Abeona Therapeutics Inc. 2023
Equity Incentive Plan (the &#8220;2023 Incentive Plan&#8221;) which was approved by stockholders on May 17, 2023. On April 24, 2024,
stockholders approved an amendment to the 2023 Incentive Plan to increase the shares authorized for issuance from <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240424__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zMJc4DjCKfWd" title="Increase in shares authorized">1,700,000</span> shares to
<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240424__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zlKFIPwmfQi8" title="Increase in shares authorized">3,200,000</span> shares. On December 20, 2024, stockholders approved an additional increase in the shares authorized for issuance under the
2023 Incentive Plan from <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241220__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_z4tCmGvXUzob" title="Increase in shares authorized">3,200,000</span> shares to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241220__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zotA7lpId0x7" title="Increase in shares authorized">8,400,000</span> shares. As of December 31, 2024, there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--InducementPlanMember_zn9XnyWOURwc" title="Shares available for grant">5,251,251</span> shares available to be granted
under the 2023 Incentive Plan. In addition, in 2023, the Company&#8217;s board of directors approved various restricted stock awards
granted to certain new hires as inducement grants. On October 10, 2023, the Company&#8217;s board of directors approved the Abeona Therapeutics
Inc. 2023 Employment Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;). As of December 31, 2024, there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231_z1wEqKL4jcw3" title="Shares available for grant">584,700</span>
shares available to be granted under the Inducement Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zhx79hHirrGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock-based compensation (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zaDyHTSQSI86" style="display: none">SCHEDULE
OF STOCK BASED COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_z9CUCC6VF1n4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zduZHkbXbUi3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTN8oypPqUAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,561</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,085</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zq3XjoK6NBM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,067</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,683</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_ztXtTAzvfhI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,768</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_ziBa1OzRCu49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of each option award on the date of grant using the Black-Scholes option-pricing model. The Company
then recognize the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over
the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility &#8211; the Company estimates the volatility of the share price at the date of grant using a &#8220;look-back&#8221; period
    which coincides with the expected term, defined below. The Company believes using a &#8220;look-back&#8221; period which coincides
    with the expected term is the most appropriate measure for determining expected volatility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term &#8211; the Company estimates the expected term using the &#8220;simplified&#8221; method, as outlined in SEC Staff Accounting
    Bulletin No. 107, &#8220;Share-Based Payment.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate &#8211; the Company estimates the risk-free interest rate using the U.S. Treasury yield curve for periods equal to
    the expected term of the options in effect at the time of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    &#8211; the Company uses an expected dividend yield of zero because the Company has not declared nor paid a cash dividend, nor are
    there any plans to declare a dividend.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not grant any stock options in the year ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures
arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3xd7BT9pwj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock option activity during the year ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z1irdfs6brwl" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/>
 Average<br/>
 Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/>
 Average<br/>
 Remaining<br/>
 Contractual<br/>
 Term (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/>
 Intrinsic Value <br/> (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zs5KKlP8Tlxh" style="width: 11%; text-align: right" title="Number of options, Outstanding balance">240,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zxhjQjuzF3wi" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding balance">37.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zoOgPUiMgYW3" title="Weighted average remaining contractual term (years), outstanding">6.42</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231_zhOuHtWkkTOh" style="width: 11%; text-align: right" title="Aggregate intrinsic value, Outstanding balance"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zC8vXntWN1Vb" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1335">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zTv7A8olJ1Q8" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zNZYO1nmE9i7" style="text-align: right" title="Number of options, cancelled/forfeited">(61,769</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z2OVPZwNT3Ib" style="text-align: right" title="Weighted average exercise price, cancelled/forfeited">32.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zBjYOSihAHQa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zsrxxzBv3Dkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zd8UBkJQtjkk" style="text-align: right" title="Number of options, outstanding balance">179,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zcQMxsCSTkuf" style="text-align: right" title="Weighted average exercise price, outstanding balance">38.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zCGEpC2NUIj6" title="Weighted average remaining contractual term (years), outstanding">6.83</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231_zeAxJOPu9b04" style="text-align: right" title="Aggregate intrinsic value, outstanding balance">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_z7avEf4FPrid" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zihb5WU6BZde" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zoZOpr5tj9ia" style="text-align: right" title="Number of options, cancelled/forfeited">(2,414</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zpNtFtsI3sn9" style="text-align: right" title="Weighted average exercise price, cancelled/forfeited">33.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_znEJE6XmoK2l" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1363">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zVTyqDs62Whh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1365">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zhWm5QnWfZD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding balance">176,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zCh0HJ8zLHDi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding balance">38.64</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziyX67aZ0Yv1" title="Weighted average remaining contractual term (years), outstanding">5.83</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231_z12PkmH0nqA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding balance">6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zzr2mTlb8GN3" style="text-align: right" title="Number of options, exercisable">163,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z8WlgNDZrIw5" style="text-align: right" title="Weighted average exercise price, exercisable">39.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zmo7SlZz8WLl" title="Weighted average remaining contractual term (years), exercisable">5.77</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231_zuPlORunFxj6" style="text-align: right" title="Aggregate intrinsic value, exercisable">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231_z1yXwzJVUUFg" style="text-align: right" title="Number of options, unvested">13,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231_zDmPxnahLmei" style="text-align: right" title="Weighted average exercise price, unvested">33.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zq0oV7D3YJre" title="Weighted average remaining contractual term (years), unvested">6.65</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iI_pn3n3_c20241231_zYDYjRIXaGnc" style="text-align: right" title="Aggregate intrinsic value, unvested">2</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z47dxooNsrNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair
value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s
common stock. As of December 31, 2024, the total compensation cost related to non-vested option awards not yet recognized was $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyKb220Q7DGk" title="Compensation cost related to non-vested options not recognized">0.3</span> million
with a weighted average remaining vesting period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDvC6KsTGWb9" title="Weighted average period total compensation costs related to non-vested options">0.5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_z7HjMJozkk1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there are no options outstanding under the 2005 Incentive Plan. Further information regarding options outstanding
under the 2015 Incentive Plan as of December 31, 2024 is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zSeaet6NdvZd" style="display: none">SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of <br/>
Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options<br/>
 Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining<br/>
 Life In<br/>
 Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options<br/>
 Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining<br/>
 Life in<br/>
 Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zC3Ncovv0UH5" style="width: 9%; text-align: right" title="Range of exercise price, lower limit">4.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziZq3iXSNOGe" style="width: 9%; text-align: right" title="Range of exercise price, upper limit">22.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zM5URYCJVBzk" style="width: 9%; text-align: right" title="Number of options outstanding">20,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMvFZa0EqPoj" title="Weighted-average remaining life in years">7.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zfo3vcC2SwY8" style="width: 9%; text-align: right" title="Weighted-average exercise price">16.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zgLIwrVEzBFi" style="width: 9%; text-align: right" title="Number of options exercisable">15,154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zW0FR4cf1qM" title="Weighted-average remaining life in years, exercisable">6.9</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zl9EygmFbHVg" style="width: 8%; text-align: right" title="Weighted-average exercise price, exercisable">17.16</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOPNC5y7xldc" style="text-align: right" title="Range of exercise price, lower limit">25.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zLBO8t9Y5Oq6" style="text-align: right" title="Range of exercise price, upper limit">47.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4Q8iB0tETZg" style="text-align: right" title="Number of options outstanding">104,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zudchz5beXQl" title="Weighted-average remaining life in years">5.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8s82GKavb05" style="text-align: right" title="Weighted-average exercise price">33.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNAFz0O5ADF8" style="text-align: right" title="Number of options exercisable">99,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zd4kfk2GTaUj" title="Weighted-average remaining life in years, exercisable">5.4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKR6wohT8Uec" style="text-align: right" title="Weighted-average exercise price, exercisable">33.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zwoZNAivC8cb" style="text-align: right" title="Range of exercise price, lower limit">54.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztHtG4xg92H1" style="text-align: right" title="Range of exercise price, upper limit">58.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVTgnJbAWxn4" style="text-align: right" title="Number of options outstanding">52,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1swoirEi3ck" title="Weighted-average remaining life in years">6.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zgIQ5jY4dwg7" style="text-align: right" title="Weighted-average exercise price">56.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzgl7yQYfE4b" style="text-align: right" title="Number of options exercisable">48,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z8yLbTdpJYV5" title="Weighted-average remaining life in years, exercisable">6.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVxSOjWG9AKj" style="text-align: right" title="Weighted-average exercise price, exercisable">56.96</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWLspd65hyJ6" style="padding-bottom: 1pt; text-align: right" title="Range of exercise price, lower limit">164.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zeHg76yuS3O5" style="padding-bottom: 1pt; text-align: right" title="Range of exercise price, upper limit">183.50</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zQUYP1Cg4WRf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options outstanding">200</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zj2SBTcyV6x8" title="Weighted-average remaining life in years">4.1</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z8a1QitP9HA1" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price">164.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBQTkGNTfDE8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options exercisable">200</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z6mwY42PJ2Xk" title="Weighted-average remaining life in years, exercisable">4.1</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4AQfqqqQdm" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price, exercisable">164.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zjJHzyr57zfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding">176,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zBC76UVisnV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">163,386</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zL79QiLuZ3Y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted
Stock:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zg2zn1toFKU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock award activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zMgQXNlT6Ys9" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/>
Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average<br/>
 Grant Date Fair<br/>
 Value Per Unit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCtzlseGmGe5" style="width: 16%; text-align: right" title="Restricted common stock awards, balance">816,958</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBFXcfp2FdUb" style="width: 16%; text-align: right" title="Weighted-average grant date fair value, balance">5.35</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHBunrTltDJa" style="text-align: right" title="Restricted common stock awards, granted">1,958,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB9nVUIef3i7" style="text-align: right" title="Weighted-average grant date fair value, granted">3.99</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaOPRmWEPmNj" style="text-align: right" title="Restricted common stock awards, cancelled/forfeited">(56,398</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkhEq2bGMIUe" style="text-align: right" title="Weighted-average grant date fair value, cancelled/forfeited">4.32</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1G3Cm4a5qHk" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted common stock awards, vested">(270,550</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVybEXlOJfMi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value, vested">5.59</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zS5Ax97waVh4" style="text-align: right" title="Restricted common stock awards, balance">2,448,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwNwtQmU6Qdb" style="text-align: right" title="Weighted-average grant date fair value, balance">4.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znUFmjRYMMdj" style="text-align: right" title="Restricted common stock awards, granted">2,065,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUkA9hlrNXFi" style="text-align: right" title="Weighted-average grant date fair value, granted">4.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXkymYkPuR88" style="text-align: right" title="Restricted common stock awards, cancelled/forfeited">(183,114</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfGvEA8kitBi" style="text-align: right" title="Weighted-average grant date fair value, cancelled/forfeited">3.78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyDyzKnZEExc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted common stock awards, vested">(1,009,298</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdWv19Qb9lyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value, vested">4.64</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSyyCfIAHalb" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted common stock awards, balance">3,320,811</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zogNe2X9uHL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant date fair value, balance">4.60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zMLvF2ap3Y43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20240101__20241231_zPIIpnu6hJm6" title="Compensation cost related to restricted common stock not recognized">11.9</span> million of total unrecognized compensation expense related to unvested restricted stock awards,
which is expected to be recognized over a weighted average vesting period of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231_zPozE0gtYUJk" title="Weighted average compensation costs related to restricted common stock">2.1</span> years. The total fair value of restricted stock awards
that vested was $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_pn5n6_c20240101__20241231_z4T9EzPSTshl" title="Fair value of restricted stock awards that vested">4.7</span> million and $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_pn5n6_c20230101__20231231_zaInAj1um6Sf" title="Fair value of restricted stock awards that vested">1.5</span> million during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE/SUPPLIER AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">LICENSE/SUPPLIER AGREEMENTS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CollaborativeArrangementDisclosureTextBlock_zSj3kL8WKD5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8211; <span id="xdx_828_z67un7fKoIbg">LICENSE/SUPPLIER AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement Relating to Recessive Dystrophic Epidermolysis Bullosa (RDEB)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the Company entered into two licensing agreements between the Company and The Board of Trustees of Leland Stanford Junior University
(&#8220;Stanford&#8221;) to develop EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)) and EB-201 (AAV DJ COL7A1) and
to license the invention &#8220;Gene Therapy for Recessive Dystrophic EB using Genetically Corrected Autologous Keratinocytes&#8221;.
Under the terms of the licensing agreements, the Company paid an upfront of licensing fees in cash and is subject to annual license maintenance
fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments, and royalty
payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, the Company is subject to remaining
milestone payments totaling approximately $<span id="xdx_908_ecustom--RemainingMilestonePaymentsDue_iI_pn5n6_c20241231__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--LicenseAgreementMember_zX7Xtarg6rMa" title="Remaining milestone payments due">0.2</span> million which is due upon FDA approval of pz-cel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement Relating to Novel AAV Capsids (&#8220;AIM&#8482; capsids&#8221;)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the Company licensed an international patent family from The University of North Carolina at Chapel Hill (&#8220;UNC&#8221;) covering
novel AAV capsids (&#8220;AIM&#8482; capsids&#8221;) that may potentially be used to deliver a wide variety of therapeutic transgenes
to human cells to treat genetic diseases. Under the terms of the licensing agreements, the Company paid an upfront licensing fees in
cash and is subject to on-going patent expenses incurred in relation to the patents licensed under this agreement and annual license
maintenance fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments,
and royalty payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty
payments under this agreement have been made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement Relating to CLN1 Disease</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the Company licensed from UNC rights to two patent families directed to treating CLN1 disease (also known as infantile Batten disease).
Under the terms of the licensing agreements, the Company paid an upfront of licensing fees in cash and is subject to on-going patent
expenses incurred in relation to the patents licensed under this agreement and annual license maintenance fees. In addition, the Company
is subject to the achievement of certain milestones, regulatory approval milestone payments, and royalty payments in the low single digits
on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty payments under this agreement have been
made. The Company subsequently sublicensed the license to Taysha Gene Therapies (&#8220;Taysha&#8221;), see detail of the sublicense
agreement below. As part of the agreement with UNC, the Company is obligated to pay to UNC a percentage of any sublicense revenue that
the Company receives under the agreement. The Company recognizes any payments under this agreement as royalties in the consolidated statement
of operations and comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreement Relating to Rett Syndrome</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2019, the Company licensed rights to one patent family from UNC and two patent families from The University Court of the University of
Edinburgh (&#8220;U. Edinburgh&#8221;) and The University Court of the University of Glasgow (&#8220;U. Glasgow&#8221;) relating to gene
therapy for the treatment of Rett Syndrome. Under the terms of the licensing agreements, the Company paid an upfront of licensing fees
in cash and is subject to on-going patent expenses incurred in relation to the patents licensed under this agreement and annual license
maintenance fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments,
and royalty payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty
payments under this agreement have been made. The Company subsequently sublicensed the license to Taysha, see detail of the sublicense
agreement below. As part of the agreement with UNC, the Company is obligated to pay to UNC and U. Edinburgh a percentage of any sublicense
revenue that the Company receives under the agreement. The Company recognizes any payments under this agreement as royalties in the consolidated
statement of operations and comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sublicense
and Inventory Purchase Agreements Relating to CLN1 Disease</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the Company entered into sublicense and inventory purchase agreements with Taysha relating to a potential gene therapy for
CLN1 disease. Under the sublicense agreement, Taysha received worldwide exclusive rights to intellectual property and know-how relating
to the research, development, and manufacture of the potential gene therapy, which the Company had referred to as ABO-202. Under the
inventory purchase agreement, the Company sold to Taysha certain inventory and other items related to ABO-202. The Company assessed the
nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated whether such
functionality can be retained without ongoing activities by the Company and determined that the license has significant stand-alone functionality.
Furthermore, the Company has no ongoing activities associated with the license to support or maintain the license&#8217;s utility. Based
on this, the Company determined that the pattern of transfer of control of the license to Taysha was at a point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price of the contract includes (i) $<span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20200801__20200831__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zkVPL359Mhxj" title="Fixed consideration">7.0 </span>million of fixed consideration, (ii) up to $<span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zPXJmd0lJJyg" title="Variable consideration">26.0</span> million of variable consideration
in the form of event-based milestone payments, (iii) up to $<span id="xdx_904_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--SalesBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zJ52FYet98rh" title="Variable consideration">30.0</span> million of variable consideration in the form of sales-based milestone
payments, and (iv) high single-digit royalty-based payments based on net sales. The Company is obligated to pay a portion of milestone
payments and royalties on net sales received from Taysha to the UNC.. The event-based milestone payments are based on certain development
and regulatory events occurring. At inception, the Company evaluated whether the milestone conditions had been achieved and if it was
probable that a significant cumulative revenue reversal would not occur before recognizing the associated revenue and determined that
these milestone payments were not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, and
were not considered probable of being achieved until those approvals were received. Accordingly, at inception, the Company fully constrained
the $<span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zMChVZ2nusy" title="Variable consideration">26.0</span> million of event-based milestone payments until such time that it is probable that significant cumulative revenue reversal
would not occur. The sales-based milestone payments and other royalty-based payments are based on a level of sales for which the license
is deemed to be the predominant item to which the royalties relate. The Company will recognize revenue for these payments at the later
of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has
been satisfied or partially satisfied. To date, the Company has not recognized any sales-based or royalty revenue resulting from this
licensing arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this arrangement, the Company has <span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_do_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z60TZGf1NiHe" title="Revenue recognized"><span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_do_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zipUDwAScJF6" title="Revenue recognized">no</span></span>t recognized any revenue during the years ended December 31, 2024 and 2023, respectively based on
event-based-milestone payments. The Company has <span id="xdx_907_eus-gaap--ContractWithCustomerAssetNet_iI_pn5n6_do_c20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zcKsOiSdq4xh" title="Contract assets"><span id="xdx_908_eus-gaap--ContractWithCustomerAssetNet_iI_pn5n6_do_c20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zkrYUICKN45e" title="Contract assets">no</span></span> contract assets or liabilities as of December 31, 2024 and 2023 as a result of this
transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sublicense
Agreement Relating to Rett Syndrome</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a sublicense agreement with <span style="background-color: white">Taysha </span>for a gene therapy
for Rett syndrome, including intellectual property related to MECP2 gene constructs and regulation of their expression. The agreement
grants Taysha worldwide exclusive rights to intellectual property developed by scientists at UNC, U. Edinburgh and the Company, and the
Company&#8217;s know-how relating to the research, development, and manufacture of the gene therapy for Rett syndrome and MECP2 gene
constructs and regulation of their expression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assessed the nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated
whether such functionality can be retained without ongoing activities by the Company and determined that the license has significant
stand-alone functionality. Furthermore, the Company has no ongoing activities associated with the license to support or maintain the
license&#8217;s utility. Based on this, the Company determined that the pattern of transfer of control of the license to Taysha was at
a point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction price of the contract includes (i) $<span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20201001__20201031__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_z49vKtRYCyJl" title="Fixed consideration">3.0</span>
million of fixed consideration, (ii) up to $<span id="xdx_900_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zyUD8WqiTW22" title="Variable consideration">26.5</span>
million of variable consideration in the form of event-based milestone payments, (iii) up to $<span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--SalesBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zo0tnsOWolc9" title="Variable consideration">30.0</span>
million of variable consideration in the form of sales-based milestone payments, and (iv) high single-digit royalty-based payments
based on net sales. The Company is obligated to pay a portion of milestone payments and royalties on net sales received from Taysha
to the UNC and U. Edinburgh. The event-based milestone payments are based on certain development and regulatory events occurring.
The Company evaluated whether the milestone conditions have been achieved and if it is probable that a significant cumulative
revenue reversal would not occur before recognizing the associated revenue. The Company determined that these milestone payments are
not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, and are not considered
probable of being achieved until those approvals are received. Accordingly, the Company has fully constrained the $<span id="xdx_90E_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zkbFYFeAtvN5" title="Variable consideration">26.5</span>
million in event-based milestone payments until such time that it is probable that a significant cumulative revenue reversal would
not occur. The sales-based milestone payments and other royalty-based payments are based on a level of sales for which the license
is deemed to be the predominant item to which the royalties relate. The Company will recognize revenue for these payments at the
later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been
allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales-based or royalty revenue
resulting from this licensing arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this arrangement, the Company recognized <span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zcSroRFpu2n1" title="Revenue recognized::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1539">nil</span></span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zzEPyP49vWs6" title="Revenue recognized">3.5</span> million in revenue during the years ended December 31, 2024 and 2023. The revenue
recognized was related to clinical milestones achieved by our sublicensor as per the sublicense agreement noted above. As of December
31, 2024 and 2023, the Company does not have any contract assets or contract liabilities as a result of this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ultragenyx
License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2022, the Company and Ultragenyx Pharmaceutical Inc. (&#8220;Ultragenyx&#8221;) entered into an exclusive license agreement (the
&#8220;License Agreement&#8221;) for AAV gene therapy, ABO-102, for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the
License Agreement, Ultragenyx assumed responsibility for the ABO-102 program from the Company, with the exclusive right to develop, manufacture,
and commercialize ABO-102 worldwide. Also pursuant to the License Agreement, following regulatory approval, the Company is eligible to
receive tiered royalties from mid-single-digit up to 10% on net sales and up to $<span id="xdx_90A_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20220515__20220516__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--LicenseAgreementTermsMember__srt--RangeAxis__srt--MaximumMember_zuIE9Lgjx83g" title="Milestone payments">30.0</span> million in commercial milestone payments. Both
forms of consideration comprise the transaction price to which the Company expects to be entitled in exchange for transferring the related
intellectual property and certain, contractually-specified, transition services to Ultragenyx. The sales-based royalty and milestone
payments are subject to the royalty recognition constraint. As such, these fees are not recognized as revenue until the later of: (a)
the occurrence of the subsequent sale, and (b) the performance obligation to which they relate has been satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
pursuant to the License Agreement, Ultragenyx will reimburse the Company for certain development and transition costs actually incurred
by the Company. These costs are passed through to Ultragenyx without mark-up. The Company has determined that these costs are not incurred
for the purpose of satisfying any performance obligation under the License Agreement. Accordingly, the reimbursement of these costs is
recognized as a reduction of research and development costs. As of December 31, 2024 and 2023, the Company does not have any contract
assets or contract liabilities as a result of this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) PLAN</a></td>
<td class="text"><p id="xdx_809_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z8HCPp7xlJGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; <span id="xdx_828_zXq3gw5kLddg">401(k) PLAN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a tax-qualified employee savings and retirement plan (the &#8220;401(k) Plan&#8221;) covering all the Company&#8217;s
employees in the United States. Pursuant to the 401(k) Plan, employees may elect to reduce their current compensation by up to the
statutorily prescribed annual limit ($<span id="xdx_903_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20240101__20241231_zd6p6QprhXIl" title="Maximum annual contribution per employee under 401(k) plan">23,000</span>
in 2024 and $<span id="xdx_90A_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20230101__20231231_zpjC064qTKp4" title="Maximum annual contribution per employee under 401(k) plan">22,500</span>
in 2023 for employees who are under age 50 and $<span id="xdx_903_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--UnderAgeFifftyMember_zftxr22wjCmc">30,500</span>
in 2024 and $<span id="xdx_908_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20230101__20231231__us-gaap--RetirementPlanTypeAxis__custom--UnderAgeFifftyMember_zDx120x1SJ9k">30,000</span> in 2023 for employees who are age 50 and older) and to have the amount of such reduction contributed to the
401(k) Plan. The 401(k) Plan is intended to qualify under Section 401 of the Internal Revenue Code so that contributions by
employees or by us to the 401(k) Plan, and income earned on 401(k) Plan contributions, are not taxable to employees until withdrawn
from the 401(k) Plan, and so that contributions by us, if any, will be deductible by us when made. At the direction of each
participant, the Company invests the assets of the 401(k) Plan in any of over <span id="xdx_902_ecustom--NumberOfInvestmentOptions_pp0p0_uInteger_c20240101__20241231_zR4Aql5j2Eq4" title="Number of investment options">50</span>
investment options. Company contributions under the 401(k) Plan were $<span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20240101__20241231_zKDBx9Ox0a0h" title="Company contributions under 401 (k) Plan">0.5</span>
million and $<span id="xdx_909_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20230101__20231231_z42yyUZWvjD8" title="Company contributions under 401 (k) Plan">0.3</span>
million for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_z5haTvmOyjp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 &#8211; <span id="xdx_82A_zxq5iVVvU7vf">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zIT3yL4xvrif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense differs from the statutory amounts for each of the following years (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z1W4eLi6yH3d" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zJrc5w5X32a5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_z1Lv5Z1LexAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBz0L9_zOi1p7PEgYla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Income taxes at U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(13,384</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(11,379</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBz0L9_znwLYfLORRV" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(679</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(242</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_iN_pn3n3_di_msITEBz0L9_zqbiZBf7ZUUc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,535</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,137</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_pn3n3_maITEBz0L9_zStgbwMgLEj8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,032</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1573">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBz0L9_z5VSxE5GRaok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,418</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,687</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_pn3n3_maITEBz0L9_zuCOYqaUcNqe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,456</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_pn3n3_maITEBz0L9_zRVRCh5Pe861" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expired tax losses and credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,503</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maITEBz0L9_zT3AeU3O6XRl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Permanent differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(127</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBz0L9_zvM9t0sKr9v9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1588">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zvcIHMyzQjol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVO5kdlAUC96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes are provided for the temporary differences between the financial reporting bases and the tax bases of the Company&#8217;s assets
and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zhZZThYB4F77" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zlq4G6heDt6f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zoIEbYn8wVP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzzCb_zwhThLZPbTJ8" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,059</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">78,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzzCb_zDyX3qoqWaKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">General business credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,752</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_maDTAGzzCb_zvT88LMPKyt2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,780</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,780</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_iI_pn3n3_maDTAGzzCb_zE9MlxSq7I1f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Property, equipment and goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">887</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzzCb_zSAaX1cUYVD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,983</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzzCb_z8KLfhLjrT97" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">661</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">615</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzzCb_zdMa7KV4X4M8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzzCb_z7UzmmDfG9qe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,843</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzzCb_zdaC636szIkg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">83</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzzCb_maDTALNzbeO_zK01rSVLRfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,406</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,988</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzbeO_zUXoTu7W4fbl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(114,406</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(108,988</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzbeO_zeKO9OwMaNW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net deferred taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1625">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1626">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zwcBSgtJp9v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company identified adjustments related primarily to the recognition of deferred tax assets for stock-based
compensation. As a result, the Company has written off $<span id="xdx_901_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn5n6_c20241231_zEuoaTZsKFVh" title="Deferred tax assets">8.0</span> million of deferred tax assets in the current period, with a corresponding
adjustment to the valuation allowance. There was no impact to total tax expense in the prior periods or current period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
operating Loss and Other Carryforwards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_z35pTDxJZTna" title="Operating loss carryforward">416.1</span> million of U.S. federal net operating loss carryforwards and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_zqJuUBa6t2I2" title="General business credit carryforwards">6.0</span> million of general business
credit carryforwards. These carryforwards expire as follows (in thousands):</span></p>

<p id="xdx_89D_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zJBwSyeSkln9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_zHBZp0r9iRDf" style="display: none">SUMMARY
OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net operating <br/>
loss carryforwards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">General <br/>
business credit<br/>
 carryforwards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zcPE0tjSieda" style="width: 16%; text-align: right" title="Net operating loss carryforwards">2,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zRqZRuEPytQ5" style="width: 16%; text-align: right" title="General business credit carryforwards">182</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_z49VMgrFdvK5" style="text-align: right" title="Net operating loss carryforwards">7,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_zKHZRAT2I9d3" style="text-align: right" title="General business credit carryforwards">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_zHwFyUwFiuN" style="text-align: right" title="Net operating loss carryforwards">9,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_z7gbOPeerZq4" style="text-align: right" title="General business credit carryforwards">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zB8s5xT6fb3l" style="text-align: right" title="Net operating loss carryforwards">6,886</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zKZTJqdh8Df6" style="text-align: right" title="General business credit carryforwards">141</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zSSM4hZ2Rmr4" style="text-align: right" title="Net operating loss carryforwards">7,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zxEdWHMLRcqi" style="text-align: right" title="General business credit carryforwards">83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zsocbJx5H9H5" style="border-bottom: Black 1pt solid; text-align: right" title="Net operating loss carryforwards">65,644</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zb3Dp0hxB5Qi" style="border-bottom: Black 1pt solid; text-align: right" title="General business credit carryforwards">5,429</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231_zC3pZOilpAO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net operating loss carryforwards">99,945</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231_zStrXx0clpu2" style="border-bottom: Black 2.5pt double; text-align: right" title="General business credit carryforwards">6,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z9nEDbVxWy58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the &#8220;Tax Cuts and Jobs Act&#8221; was signed into law. The tax reform has the following effects on the Company:
(1) permanently reduces the maximum corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017,
(2) allows temporary 100% expensing for certain business assets and property placed in service after September 27, 2018 and before January
1, 2023, (3) disallows NOL carrybacks but allows for the indefinite carryforward of those NOLs which applies to losses arising in tax
years beginning after December 31, 2018 and, (4) limits NOL deductions for each year equal to the lesser of the available carryover or
80% of a taxpayer&#8217;s pre-NOL deduction taxable income. This applies to losses arising in tax years ending on or after December 31,
2017. As of December 31, 2024 and 2023, the Company has concluded that it is more likely than not that the Company will not realize the
benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within
a three-year period results in an annual limitation on the Company&#8217;s ability to utilize its NOL carryforwards created during the
tax periods prior to the change in ownership. The Company has not completed an ownership change analysis pursuant to Section 382. Because
the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and
state income tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had $<span id="xdx_903_ecustom--NetOperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_zguj8oiCBdI5" title="Net operating loss carryforwards">316.2</span> million of U.S. federal net operating loss carryforwards that do not expire and can be carried
forward indefinitely. Such net operating loss carryforwards can only be used to offset <span id="xdx_90D_ecustom--OperatingLossCarryforwardsTaxablePercentage_iI_pid_dp_uPure_c20241231_zixbpQwouUTj" title="Operating loss taxable percentage">80</span>% of taxable income in any given tax year. The
Company also has $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zQozZIDXFLKl" title="State net operating loss carryforwards">13.3</span> million of state net operating loss carryforwards in varying amounts depending on the different state tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired MacroChem Corporation on March 25, 2009, and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both of these corporations
were loss-making entities at the time of acquisition. As a result, the net operating losses related to those acquisitions may be subject
to annual limitations. The Company has not performed a study to determine whether or not there is such a limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
Allowance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the Company maintained a full valuation allowance on its deferred tax assets based on a history of cumulative
losses. The Company will not record income tax benefits in the financial statements until it is determined that it is more likely than
not that the Company will generate sufficient taxable income to realize the deferred income tax assets. In 2024, the valuation allowance
increased by approximately $<span id="xdx_905_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zQt6YXJstBuc" title="Valuation allowance">5.4</span> million. In 2023, the valuation allowance increased by approximately $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_zrLv5TRNMZ63" title="Valuation allowance">8.7</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrecognized
Tax Benefits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the Company had no reserves for unrecognized tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are subject to taxation in the United States. The Company is subject to U.S. federal and state examinations
for 2020 and forward, and 2019 and forward, respectively. However, net operating losses are subject to audit in any tax year in which
those losses are utilized, notwithstanding the year of origin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkwXhYTV9jc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8211; <span id="xdx_828_zN5Pn6M3vGIb">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a liability for a contingency when it is probable that liability has been incurred and when the amount of loss can
be reasonably estimated. When a range of probable loss can be estimated, the Company accrues the most likely amount of such loss, and
if such amount is not determinable, then the Company accrues the minimum of the range of probable loss. As of December 31, 2024 and 2023,
there was no litigation against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zGaXqgV0FYLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16 &#8211; <span id="xdx_82C_zqktnkCmqim3">SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision making group, in deciding how to allocate resources in assessing performance. The Company is a
clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases and has one reportable segment.
The Company&#8217;s CODM is the chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies of the clinical-stage biopharmaceutical segment are the same as those described in the summary of significant accounting
policies. The CODM assesses performance for the clinical-stage biopharmaceutical segment based on net loss, which is reported on the
consolidated statements of operations and comprehensive loss as consolidated net loss. The measure of segment assets is reported on the
consolidated balance sheet as total consolidated assets. Expenditures for additions to long-lived assets, which include purchases of
property and equipment, are included in total consolidated assets reviewed by the chief operating decision maker and are reported on
the consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating
losses while it seeks regulatory approval for pz-cel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, the CODM uses cash forecast models in deciding how to invest into the clinical-stage biopharmaceutical segment. Such cash forecast
models are reviewed to make decisions about allocating resources and assessing the entity-wide operating results and performance. Net
loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used to make decisions about allocating
resources, assessing the performance of the segment and in establishing management&#8217;s compensation, along with cash forecast models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_ztJoAx3m1Wsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zdSjXWpHlcab">&#160;SCHEDULE
OF SIGNIFICANT EXPENSE CATEGORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zM6ttbo2Nyn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zL3Gwowwcknk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_ziFvzS9qLimj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">License and other revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1680">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zRbz8EoaOmhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5LxCVkvrq4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Salaries &amp; related costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,345</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,373</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkJXMBLsopTd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,561</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,086</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0A7ZZ6YUKtf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other research and development costs <span id="xdx_F40_zLi6GOQFH6dj">(a)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,454</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,632</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_zDWbyShBkcu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,091</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zgDi1AOLtp46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBqLHIsuFbff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Salaries &amp; related costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,942</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRio3dbbGYQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,067</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,682</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrecommercialPreparationCosts_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGJKmg7reyNj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Pre-commercial preparation costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,224</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPexKxOBGZWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other general and administrative costs <span id="xdx_F4D_zM7CZfeEvSul">(b)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,237</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,156</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_z1mlRoUsChqc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total general and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19,004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OtherSegments_zUDbASdMShak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other segment items <span id="xdx_F42_z9oKAR73if38">(c)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(477</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,593</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zHsPrjrprioa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(63,734</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(54,188</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zOCHrx46Bl7h">(a)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F17_z9sNosGHbGU8">Other
    research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial
    costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and
    manufacturing facilities, and consultant-related expenses.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F06_zFw2pWHJlIQd">(b)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F19_zDoiH2kSjjxe">Other
    general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional
    fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F01_zdB334Pd12I2">(c)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F16_zev26bldGfJg">Other
    segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and
    other income.</i></span></td></tr>
  </table>
<p id="xdx_8AC_z9utyDtdnWZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_z4L1BvoyZTBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17 &#8211; <span id="xdx_822_z3VIkUloOUk7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January of 2025, the compensation committee of the board of directors granted various employees and directors restricted stock awards,
under which the holders have the right to receive an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIfnj1oZVdY8" title="Restricted stock awards, issued">1,956,280</span> shares of the Company&#8217;s common stock. Total stock compensation
estimated for these awards at the time of grant was $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXM3UcJ1wcZg" title="Estimated total stock compensation">10.3</span> million, with $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__custom--ThreeEqualAnnualInstallmentsMember_zW2bl9QIEV9k" title="Estimated total stock compensation">8.7</span> million vesting in three equal annual installments and $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__custom--OneAnnualInstallmentsMember_zhCZJoRJ6SPi" title="Estimated total stock compensation">1.6</span>
million vesting in one annual installment. Pursuant to the terms of the awards, the shares not vested are forfeited upon separation from
the Company.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhb68uFtp0X4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zwwaF8VVP8qh">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and the Company&#8217;s wholly-owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zEWGU3YCyry" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zwmC79jj3cqc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of
America (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amount of assets and
disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue
and expenses during the reported period. The Company&#8217;s significant estimates include, but are not limited to, fair value of warrant
and derivative liabilities, the incremental borrowing rate related to the Company&#8217;s operating leases and stock-based compensation.
Due to the uncertainty inherent in such estimates, actual results could differ from these estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeRlmtmAHMCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zjvDL2Gawxqa">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company
maintains deposits primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses related to amounts in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zQKeiPUgGIH7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zue9oDqMmvnk">Restricted
Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash serves as collateral for leased office space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Short-term Investments</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zDPax6UfLVp7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zq2DsxgbxVYf">Short-term
Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
investments consist of investments in U.S. treasury securities, U.S. federal agency securities and certificates of deposit. The Company
determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications
at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to Accounting Standards
Codification (&#8220;ASC&#8221;) 320, <i>Investments &#8211; Debt and Equity Securities</i>. Investments classified as current have maturities
of less than one year. The Company reviews its short-term investments for other-than-temporary impairment whenever the fair value of
a marketable security is less than the amortized cost and evidence indicates that a short-term investment&#8217;s carrying amount is
not recoverable within a reasonable period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Other Receivables</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zN8OoRi4Xeq1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zYY5txwNVgY7">Other
Receivables</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
receivables include employee retention credits (&#8220;ERC&#8221;), sublease rent receivables and other miscellaneous receivables that
are expected to be collected within the next twelve months. As of December 31, 2024 and 2023, the Company had ERC receivables of $<span id="xdx_905_eus-gaap--OtherReceivables_iI_pn5n6_c20241231_zwUUmza4kJLe" title="Other receivables">1.6</span>
million and $<span id="xdx_906_eus-gaap--OtherReceivables_iI_pn5n6_c20231231_zULDFuyN0IGi" title="Other receivables">2.1</span> million, respectively which was recorded in other receivables and as a component of other income in the consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt3fea5spP2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zObdGPOOnok">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from
three to five years. Leasehold improvements are amortized over the shorter of the asset&#8217;s useful life or the life of the lease
term ranging from five to ten years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures
for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation
are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of
the respective period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zwbJyEb7mn8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zImOb0v3alFk">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, <i>Leases</i>. Right-of-use lease assets represent the Company&#8217;s right
to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising
from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the
Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available
at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement
of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial
direct costs incurred, as applicable. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over
the lease term. The Company does not have any leases classified as finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive
covenants or contingent rent provisions. The Company&#8217;s leases include both lease (e.g., fixed payments including rent, taxes, and
insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component
as the Company has elected the practical expedient to group lease and non-lease components for all leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
leases include one or more options to renew. The exercise of lease renewal options is typically at the Company&#8217;s sole discretion;
therefore, the majority of renewals to extend the lease terms are not included in the Company&#8217;s right-of-use assets and lease liabilities
as they are not reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain
of exercise, the Company includes the renewal period in its lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Licensed Technology</a></td>
<td class="text"><p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zKSi7YDFYYl6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zruRFsxsTbni">Licensed
Technology</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into agreements to license the rights to certain technologies. The Company records the purchase price paid for the
license, which represents fair value, on its consolidated balance sheet. Licensed technology is amortized over the life of the patent
or the agreement. The Company maintains licensed technology on its consolidated balance sheet until either the licensed technology agreement
underlying it is completed or the asset becomes impaired. When the Company determines that an asset has become impaired, as discussed
below, or the Company abandons a project, the Company writes down the carrying value of the related intangible asset to its fair value
and recognizes an impairment charge in the period in which the impairment occurs. The Company has fully written off the licensed technology
as of December 31, 2024 and December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zAZKlmt0JUr4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zrGAQVqoD054">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets consist of property and equipment, licensed technology, and right-of-use assets. The Company tests its long-lived assets for impairment
when events and circumstances indicate that the carrying value of an asset or group of assets may not be fully recoverable. If indicators
are present or changes in circumstance suggest that impairment may exist, the Company assesses the recoverability of the affected long-lived
assets or group of assets by determining whether the carrying value of such assets or group of assets can be recovered through undiscounted
future operating cash flows. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing
the carrying value of the asset or group of assets to its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Credit Losses</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_za4zh3mVui76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z6qyQQmeLqX6">Credit
Losses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its available-for-sale investments for credit losses on a collective basis by major security type and in line with the
Company&#8217;s investment policy. As of December 31, 2024, the Company&#8217;s available-for-sale investments were in securities that
are issued by the U.S. treasury, U.S. federal agencies and certificates of deposits, are highly rated, and have a history of zero credit
losses. The Company reviews the credit quality of its accounts receivables by monitoring the aging of its accounts receivable, the history
of write offs for uncollectible accounts, and the credit quality of its significant customers, the current economic environment/macroeconomic
trends, supportable forecasts, and other relevant factors. The Company&#8217;s accounts receivable are with customers that do not have
a history of uncollectibility nor a history of significantly aged accounts receivables. As of December 31, 2024, the Company did not
recognize a credit loss allowance for its investments or accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zdbON1eJvcA" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_ziOHC35w8WEf">Segments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines and presents operating segments based on the information that is internally provided to the Company&#8217;s chief
operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, in accordance with ASC 280, <i>Segment Reporting</i>. The
Company has determined that it operates in a single business segment, which is a clinical-stage biopharmaceutical company developing
cell and gene therapies for life-threatening diseases. Refer to Note 16 &#8211; Segment Information for further information related to
the Company&#8217;s segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgstkCMHlPc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zrTLMG0ABlf2">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for contracts with customers in accordance with ASC 606, <i>Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;).
ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an
entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an
entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a
customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance
obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research,
develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment
to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option
exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance
obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone
selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.
The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in
the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone
selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.
Amounts received prior to revenue recognition are recorded as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exclusive
Licenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred
to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct
from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the
Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt
of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance
obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable
from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment
to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over
time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company
evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may
change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount
of revenue the Company records in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Milestone
Payments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones
are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount
method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included
in the transaction price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone
payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of
being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant cumulative revenue reversal would not occur. At the end of each subsequent reporting
period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue
and earnings in the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Collaborative
Arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success
of such activities and therefore within the scope of ASC 808, <i>Collaborative Arrangements</i> (&#8220;ASC 808&#8221;). This assessment
is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration
arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration
are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship
and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an
appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration
partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements
of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zltyzeFQFeIe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z6j2XrlRwzw3">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel
expense, lab supplies, preclinical and development cost, clinical trial expense, manufacturing, regulatory, and consulting. The cost
of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses
are capitalized when acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zjAqwrMqszEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zw5h4m72fPEb">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses primarily consist of personnel, contract personnel, personnel-related expenses to support the Company&#8217;s
administrative and operating activities, facility costs, professional expenses (i.e., legal, audit, advisory expenses) and commercial
readiness costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zZug4jDZs1Jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zqr6FBR5Ln9">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain income tax positions in accordance with ASC 740, <i>Income Taxes</i>. Interest costs and penalties related
to income taxes are classified as interest expense and general and administrative costs, respectively, in the consolidated financial
statements. For the years ended December 31, 2024 and 2023, the Company did not recognize any uncertain tax positions, interest or penalty
expense related to income taxes. It is not reasonably likely for the amounts of unrecognized tax benefits to significantly increase or
decrease within the next 12 months. The Company files U.S. federal and state income tax returns as necessary. The federal return generally
has a three-year statute of limitations and most states have a four-year statute of limitations; however, the taxing authorities are
allowed to review the tax year in which the net operating loss was generated when the loss is utilized on a tax return. The Company currently
does not have any open income tax audits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zatUCAilBHGh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zfYJ7JF0PyTc">Net
Loss Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted-average number of
shares of common stock outstanding during the period. The weighted average number of shares of common stock includes the weighted average
effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price
is $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231_ztgEF9S494tl" title="Unfounded exercise price per share">0.0001</span> or less per share (Note 10). The Company does not include the potential impact of dilutive securities in diluted net loss
per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding restricted stock, stock
options, conversion features of loan agreements, and stock purchase warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the potential securities that could potentially dilute basic loss per share in the future that were not included
in the computation of diluted net loss per share because to do so would have been anti-dilutive for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSul6Rq5xdpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zabuy2wRZd61" style="display: none">SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Shares of common stock issuable upon exercise of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zmWm1k1bSY37" title="Shares of common stock issuable upon exercise of stock options">176,587</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z96GWyhJCia9" title="Shares of common stock issuable upon exercise of stock options">179,001</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Shares of common stock underlying restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHNOxrGn4DHb" title="Shares of common stock underlying restricted stock">3,320,811</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zBQvJ3d3JXK3" title="Shares of common stock underlying restricted stock">2,448,169</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Shares of common stock issuable upon exercise of conversion feature of loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zrovK2zgkxX3" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement">614,251</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zSOzvZv3c1R8" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Shares of common stock issuable upon exercise of warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zttbklb0nqE9" title="Shares of common stock issuable upon exercise of warrants">9,987,560</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmqEepOoFY76" title="Shares of common stock issuable upon exercise of warrants">9,397,879</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zIfMwJ4Xqds7" title="Total">14,099,209</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zgs6K3Hy0yV3" title="Total">12,025,049</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_za32erE5OrRg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2024 as part of the Loan and Security Agreement, see Note 9, the Company issued warrants to purchase $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zeUUkMmdhi28" title="Warrants to purchase shares">2,400,000</span> worth of shares
of the Company&#8217;s stock which have an exercise price equal to the lesser of (i) $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zoejlqdS0Pld" title="Warrants exercise price">4.75</span> and (ii) the price per share of the Company&#8217;s
net bona fide round of equity financing before September 30, 2024 (the &#8220;2024 Loan Agreement Warrants&#8221;). In connection with
the underwritten common stock offering consummated on May 7, 2024, pursuant to the terms of the 2024 Loan Agreement Warrants, the exercise
price was reduced to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zsDGYMKom5zk" title="Warrants exercise price">4.07</span> per share and the shares issuable was calculated at <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zMWEeVNWdeR1" title="Shares of common stock issuable upon exercise of warrants">589,681</span> shares. On September 30, 2024, per the terms of
the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zf2998vCfSC1" title="Warrants exercise price">4.07</span> per share and <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zuuh8KDxTpAl" title="Shares of common stock issuable upon exercise of warrants">589,681</span> shares, respectively.
The Company included these shares for the year ended December 31, 2024 as shares of common stock issuable upon exercise of warrants in
the table above and no shares for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zwfEFjAJz5n1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_ztD0jaU13w4f">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation expense in accordance with ASC 718, <i>Stock Based Compensation</i>. The Company measures
the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date
fair value for the employees and directors and vesting date fair value for consultants of the award. The Company uses the Black-Scholes
option pricing model to determine the fair value of options on the grant date which includes assumptions for expected volatility, risk-free
interest rate, dividend yield and estimated expected term. The Company uses the closing price of its common stock as quoted on the Nasdaq
to determine the fair value of restricted stock. The Company accounts for forfeitures as they occur, which may result in the reversal
of compensation costs in subsequent periods as the forfeitures arise. The Company estimates the expected term using the &#8220;simplified&#8221;
method, as outlined in SEC Staff Accounting Bulletin No. 107, &#8220;Share-Based Payment.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_DerivativeLiabiltyPolicyTextBlock', window );">Derivative Liability</a></td>
<td class="text"><p id="xdx_84E_ecustom--DerivativeLiabiltyPolicyTextBlock_z6N5adY9gzV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zYnJzhu0QFWj">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the fair value of the conversion right embedded within the Loan and Security Agreement in accordance with the guidance
in ASC 815, which requires the Company to bifurcate and separately account for the conversion feature as an embedded derivative contained
in the Company&#8217;s Loan and Security Agreement. Accordingly, the Company accounts for the conversion feature as a derivative liability
in the consolidated balance sheet. Derivatives are measured at their fair value on the balance sheet. In determining the appropriate
fair value, the Company uses a Monte Carlo simulation model, which incorporated assumptions and estimates to value the derivatives. The
derivative liability is remeasured at each reporting period with the change in fair value recorded to change in fair value of warrant
and derivative liabilities in the consolidated statement of operations until the derivative is exercised, expired, reclassified, or otherwise
settled. At September 30, 2024, the conversion feature no longer met the criteria of a derivative liability, and the derivative liability
was reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_842_ecustom--WarrantsPolicyTextBlock_zoQGfsgsfiHj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zHFumLbJliQ9">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2024, the Company issued pre-funded warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zMVnB4QVGsG7" title="Warrants to purchase shares">6,142,656</span> shares of common stock, with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240507__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zlA8quO4olP8" title="Warrants exercise price">4.0699</span> per
share (&#8220;2024 Pre-Funded Warrants&#8221;). The prefunded warrants are classified as equity in accordance with ASC 815, <i>Derivatives
and Hedging</i>, given the prefunded warrants are indexed to the Company&#8217;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#8217;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On June 24, 2024 and December 2, 2024, <span id="xdx_90D_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zFGwr8FAY0Ek" title="Exercise of warrants">700,000</span> and <span id="xdx_90C_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20241202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zyLHJ2IPrvLd" title="Exercise of warrants">1,228,511</span>, respectively of the
2024 Pre-Funded Warrants were exercised, leaving <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zAw1cDtUxtqg" title="Exercise of warrants">4,214,125</span> of 2024 Pre-Funded Warrants outstanding as of December 31, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, the Company issued warrants to purchase up to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zQYCyZpIteB5" title="Warrants to purchase shares">2,400,000</span> worth of shares of the Company&#8217;s common stock. On January
8, 2024, the January Warrants did not include an explicit share limit and the number of shares issuable under the warrant agreements
were variable based on the exercise price and therefore the warrants were liability classified based on a Black-Scholes valuation in
accordance with ASC 815 and were recorded at the closing date fair value of $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_z60DybBTAuGk" title="Fair value of warrants">0.2</span> million which was based on a Black-Scholes option pricing
model. The warrants are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes
in the fair value between reporting periods recorded in the consolidated statements of operations and comprehensive loss. On September
30, 2024, per the terms of the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zjH43fPgA0Kc" title="Warrants exercise price">4.07</span> per share
and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zoa6IG21xxc3" title="Warrants to purchase shares">589,681</span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2023, the Company issued pre-funded warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_z49HJKFza3Mh" title="Warrants to purchase shares">2,919,140</span> shares of common stock, with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240706__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zJMeVqFRqfQ8" title="Warrants exercise price">4.0299</span>
per share (&#8220;2023 Pre-Funded Warrants&#8221;. The prefunded warrants are classified as equity in accordance with ASC 815, <i>Derivatives
and Hedging</i>, given the prefunded warrants are indexed to the Company&#8217;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#8217;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On May 9, 2024, <span id="xdx_903_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240509__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zc9lnxMnlpF2" title="Exercise of warrants">300,000</span> of the 2023 Pre-Funded Warrants were exercised, leaving
<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zwDD2RDpicle" title="Exercise of warrants">2,619,140</span> 2023 Pre-Funded Warrants outstanding as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2022, the Company issued warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221103_zXGfklcxIXq4" title="Warrants to purchase shares">7,609,879</span> shares of common stock, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221103_zauKxlMXp0P6" title="Exercise price">4.75</span> per share,
subject to customary adjustments thereunder. On December 17, 2021, the Company issued warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211217_zCFgs9L0UKG3" title="Warrants to purchase shares">1,788,000</span> shares of common
stock, with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211217_z0EzyAiq2LFl" title="Exercise price">9.75</span> per share, subject to customary adjustments thereunder. The warrants issued in 2022 and 2021 were
determined to be freestanding instruments as they are legally detachable and separately exercisable from each other and from the common
stock issued. The common stock warrants are accounted for as liabilities in the consolidated balance sheets at their estimated fair value
because they are not indexed to the Company&#8217;s own stock. The warrants are revalued on each subsequent balance sheet date until
such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded in the consolidated statements
of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRa96MeMTpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zbFG3tIfIBL1">Recently
Adopted Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standard Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Segment Reporting (Topic 280): <i>Improvements to Reportable Segment Disclosures</i>&#8221; (&#8220;ASU 2023-07&#8221;). ASU 2023-07
requires additional disclosures for segment reporting, including disclosure of the title and position of the Chief Operating Decision
Maker and requires a public entity that has a single reportable segment to provide all the disclosures required by the amendments in
ASU 2023-07, and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal periods beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 effective for its
Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent interim periods. Since ASU 2023-07 addresses only disclosures,
the adoption of ASU 2023-07 did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_843_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zPHaeJkS5ZBb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zGcXIvinM2ze">Recently
Issued Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): <i>Disaggregation of Income Statement Expenses</i>. The amendments in ASU 2024-03 address investor requests for more
detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories
of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating this guidance to determine the impact it may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): <i>Improvements to Income Tax Disclosures</i>. ASU 2023-09 is intended
to enhance the transparency and decision usefulness of income tax information through improvements to income tax disclosures primarily
related to the rate reconciliation and income taxes paid information. The standard is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The requirements of this ASU are disclosure related and will not have an impact
on the Company&#8217;s financial condition, results of operations, or cash flows. The Company is currently evaluating the impact of adopting
this ASU on its income tax disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_DerivativeLiabiltyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Liabilty [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_DerivativeLiabiltyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Adopted Accounting Pronouncements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.2.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3D<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSul6Rq5xdpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zabuy2wRZd61" style="display: none">SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Shares of common stock issuable upon exercise of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zmWm1k1bSY37" title="Shares of common stock issuable upon exercise of stock options">176,587</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z96GWyhJCia9" title="Shares of common stock issuable upon exercise of stock options">179,001</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Shares of common stock underlying restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHNOxrGn4DHb" title="Shares of common stock underlying restricted stock">3,320,811</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zBQvJ3d3JXK3" title="Shares of common stock underlying restricted stock">2,448,169</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Shares of common stock issuable upon exercise of conversion feature of loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zrovK2zgkxX3" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement">614,251</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zSOzvZv3c1R8" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Shares of common stock issuable upon exercise of warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zttbklb0nqE9" title="Shares of common stock issuable upon exercise of warrants">9,987,560</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmqEepOoFY76" title="Shares of common stock issuable upon exercise of warrants">9,397,879</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zIfMwJ4Xqds7" title="Total">14,099,209</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zgs6K3Hy0yV3" title="Total">12,025,049</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zwNNuCZofCsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the short-term investments (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zMj2EW0vkLLc" style="display: none">SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortized Cost</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Gain</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Loss</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Available-for-sale, short-term investments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">U.S. treasury securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zRlOOSqfwPgd" style="width: 12%; text-align: right" title="Amortized cost">23,990</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLbc29LuSFCh" style="width: 12%; text-align: right" title="Gross Unrealized Gain"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_ztnCRWa2fUK2" style="width: 12%; text-align: right" title="Gross Unrealized Loss">(22</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zuHhOyXkVYag" style="width: 12%; text-align: right" title="Fair Value">23,968</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">U.S. federal agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zlu9Qo9DHkw5" style="text-align: right" title="Amortized cost">40,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zqmu3Cv8iaH6" style="text-align: right" title="Gross Unrealized Gain">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zjRupTkeAZP3" style="text-align: right" title="Gross Unrealized Loss"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zmx6l6NAbQC8" style="text-align: right" title="Fair Value">40,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Certificates of deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zf7NvHz2a7ql" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized cost">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z5vVFpxiMux4" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gain">20</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z083lbHIR0r2" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Loss"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zGliwiQPj297" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">10,020</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total available-for-sale, short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zmmdnYd2SZZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized cost">74,355</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zyLr3YVS25Ob" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gain">30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zfmFTJPwYvuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Loss">(22</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zFWt8v2nZ742" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">74,363</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortized Cost</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Gain</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gross Unrealized Loss</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Available-for-sale, short-term investments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">U.S. treasury securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zXcaNzGOo624" style="width: 12%; text-align: right" title="Amortized cost">8,406</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgT8qB6kIb34" style="width: 12%; text-align: right" title="Gross Unrealized Gain"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zjiTfCXntg3g" style="width: 12%; text-align: right" title="Gross Unrealized Loss">(13</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zROimDBYKWVb" style="width: 12%; text-align: right" title="Fair Value">8,393</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">U.S. federal agency securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_z7CBoHFwFu7d" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized cost">29,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zzOqtHoBUgy" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gain"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zYUjnYLo9vH" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Loss">(53</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zyzsGl2pa3S2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">29,360</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total available-for-sale, short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zGdqgrqcp1B" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized cost">37,819</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zx4c9m33Eq87" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gain"><span style="-sec-ix-hidden: xdx2ixbrl0749">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zsvhUjgGGRw" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Loss">(66</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zt4sJkdsAiT3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">37,753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_z3zpII5mkwEk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost and depreciated or amortized using the straight-line method based on useful lives as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zdJsbegO5u6g" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Useful
    lives (years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231_zVk9x1UGLBhi" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_zKDdVIgVTAQh" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful lives (years)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 35%; text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zcMuPkhN31Bj" title="Useful lives (years)">5</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_z3xNLAKXuDN2" style="width: 10%; text-align: right">8,868</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zRwQhlueoQT3" style="width: 10%; text-align: right">6,935</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture, software and office equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z9EQjlFyEREl" title="Useful lives (years)">3</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zzMa4GmEDpi8" title="Useful lives (years)">5</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_zOWoiR7cR2Ll" style="text-align: right">1,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_z7xhfJLN8Lsb" style="text-align: right">986</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9ss9QtDYD28" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0772">Shorter of remaining lease term or useful life</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVWATQYDPzn8" style="text-align: right">8,805</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9E0AHx7P5G5" style="text-align: right">8,603</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Construction-in-progress</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zHCVSHfZ7Wr1" style="border-bottom: Black 1pt solid; text-align: right">624</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z23Y7teNExGb" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maCzvcX_zktQhF5p3132" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msCzvcX_zUCEnoMEnzw" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14,980</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,991</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtCzvcX_z78B58J3xhb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,430</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,533</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zipXxzDqIJZ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of financial assets measured at fair value on a recurring and non-recurring basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zb8vLDZeZlh9" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Description</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value at<br/>
 December 31,<br/>
 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Recurring Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 36%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zr4qQKTfUFxh" style="width: 12%; text-align: right" title="Cash equivalents fair value">17,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoU7BWvsLvdj" style="width: 12%; text-align: right" title="Cash equivalents fair value">17,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoe8909E2723" style="width: 12%; text-align: right" title="Cash equivalents fair value"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zf0zgOyrWeZg" style="width: 12%; text-align: right" title="Cash equivalents fair value"><span style="-sec-ix-hidden: xdx2ixbrl0807">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Money market deposit account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zQHAjJEDYsif" style="text-align: right" title="Cash equivalents fair value">5,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zXMBELUrecei" style="text-align: right" title="Cash equivalents fair value">5,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zKQvGmeek3Ci" style="text-align: right" title="Cash equivalents fair value"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_z13aXFb8YUU3" style="text-align: right" title="Cash equivalents fair value"><span style="-sec-ix-hidden: xdx2ixbrl0815">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z9rkQS1WfENd" style="text-align: right" title="Short-term investments fair value">23,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z28ai9lBLzpg" style="text-align: right" title="Short-term investments fair value">23,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zsPxZ8lc6gYa" style="text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zSVBi1CQsure" style="text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">U.S. federal agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zTREwELdc2X4" style="text-align: right" title="Short-term investments fair value">40,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zxaUO2jH9d0g" style="text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zdFB5KWMuU4i" style="text-align: right" title="Short-term investments fair value">40,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zRbgQjl5fUg6" style="text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0831">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; padding-bottom: 1pt">Certificates of deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zubR8RtOnT06" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value">10,020</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zsuCLigAJfzj" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0835">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zjbWgTF9Twx5" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value">10,020</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zdxoBDGubLc" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"><span style="-sec-ix-hidden: xdx2ixbrl0839">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zA3Uzn1yrPff" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">97,099</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkAgvzzcD9X9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">46,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGlEpab97I9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">50,395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQylC3rqse7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0847">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_z0DNPX8IHBii" style="border-bottom: Black 1pt solid; text-align: right">32,014</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zufP1eiWhOH5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zcAP8OhzYiVj" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zlnzwh1yztLe" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities">32,014</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzbS8g42I3T8" style="border-bottom: Black 2.5pt double; text-align: right">32,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zY6FNtSidbc4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGCujSBBfiNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC4R6ZeMhQog" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value">32,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value at<br/> December 31,<br/>

    2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Recurring Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 36%">Money market fund</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z5MGhwssVxC1" style="width: 12%; text-align: right">1,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zcheNgrtHx4g" style="width: 12%; text-align: right">1,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zBjDh39isri" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ziutopJ1uSPa" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zGjt5pcE5o97" style="text-align: right">8,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zs1pZH54yzXk" style="text-align: right">8,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zgnDZ6HrS7Te" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zqH9RDjyWiy2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">U.S. federal agency securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zeImKI3jS6Vd" style="border-bottom: Black 1pt solid; text-align: right">29,360</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zvYZOOLA1Mx3" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zpsy8MZtA2Mj" style="border-bottom: Black 1pt solid; text-align: right">29,360</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zuBwpnkmg5vi" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRfh7q4IQ7sk" style="border-bottom: Black 2.5pt double; text-align: right">38,787</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQDEH1VRFQEd" style="border-bottom: Black 2.5pt double; text-align: right">9,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGYYJkQTK9K2" style="border-bottom: Black 2.5pt double; text-align: right">29,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWyylU5yoqgi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payable to licensor</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_z0wHJNRP9JZ" style="text-align: right">4,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zyn6DeUyfWj7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0879">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_ztz5ds9e83Z2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zYVb9hclTaF4" style="text-align: right">4,580</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zZ29UGiWdUQ5" style="border-bottom: Black 1pt solid; text-align: right">31,352</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zJQBGntILD9b" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zj7a1Qc104kg" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0884">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zVjrMjFFAtb6" style="border-bottom: Black 1pt solid; text-align: right">31,352</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT8eW20JRiN3" style="border-bottom: Black 2.5pt double; text-align: right">35,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJlwZzUmA6cg" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwEYU8pbUZQ3" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUHK8JzoUS7a" style="border-bottom: Black 2.5pt double; text-align: right">35,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock', window );">SCHEDULE OF OUTSTANDING WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_zLtp3yxAShJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had the following outstanding warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zTEGzuH7ylNc" style="display: none">SCHEDULE OF OUTSTANDING WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zVGrSMiVrbOl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_z30RTI2vUCn9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zI8eLCm3Xrsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants issued as part of the 2021 public offering, expiration date <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zXq2Wwadqni6" title="Warrants, expiration date">December 2026</span>, exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zfjX8HJRQEig" title="Warrants, exercise price">9.75</span> per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,788,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,788,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zf3tzd0ffCYh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants issued as part of the 2022 Private Placement Offering, expiration date <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zSWZlag3Xbi9" title="Warrants, expiration date">November 2027</span>, exercise price $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_z475wsbrTNUa" title="Warrants, exercise price">4.75</span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,609,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,609,879</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zgwOkqHcJMw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued as part of the 2024 Loan Agreement, expiration date <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zdoapL79LLR7" title="Warrants, expiration date">January 2029</span>, exercise price $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zJ5BPgaz46Vh" title="Warrants, exercise price">4.07</span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">589,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zYoS9AsvVNr6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding warrant liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,609,879</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,609,879</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock', window );">SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfActivityWarrantyLiabilityTableTextBlock_zKvlDGvHSJrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the activity on the warrant liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zZfNqip5VEV2" style="display: none">SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zAbCkqAeriP3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zk9vNzGrMyFl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilities_iS_pn3n3_zkLpCfSAfuEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">31,352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">19,657</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FairValueAdjustmentOfWarrantsIssued_pn3n3_zax4nmVrFkja" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fair value of warrants issued in connection with the Loan Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainLossRecognizedInEarningsFromChangeInFairValue_iN_pn3n3_di_zb74aMD7CPha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Loss recognized in earnings from change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">442</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,695</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WarrantLiabilities_iE_pn3n3_z7QIL8mstCR5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending warrant liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,352</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z29rlvcuTmU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the key inputs for the Black-Scholes option-pricing model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zzfRD4nJtovk" style="display: none">SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Common share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: center">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z7AlKWJUrUw5">5.57</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: center">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDiCi34HRqae">5.01</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zcVhk02hsKdl" title="Expected term (years)">1.96</span>
&#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zEa5d86fCkKc" title="Expected term (years)">4.02</span> </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zMC9dmNs2Fna" title="Expected term (years)">2.96</span>
&#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zS3QwkJb5q1d" title="Expected term (years)">3.84</span> </span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zwxA83DjHxne" title="Warrants measurement input">4.16</span>% &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zKrkBTFhT4Xh" title="Warrants measurement input">4.24</span></span>%</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRAegRZo0w9h" title="Warrants measurement input">3.84</span>% &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zgensBV8qG76" title="Warrants measurement input">3.92</span>%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zhl1fCHSRzK1" title="Warrants measurement input">92.64</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoraCYRSkFh4" title="Warrants measurement input">100.00</span>%</span></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcsgRdfr7tOh" title="Warrants measurement input">100.00</span>%</td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmv4kcxZolB" title="Warrants measurement input">0</span>%</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGQhwfkSThG4" title="Warrants measurement input">0</span>%</td><td style="text-align: left"></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zpMU7P2RYzP5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the activity on the derivative liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8B9_z7J5r0VD8j8d" style="display: none">SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zcWsM91NpHgk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_zSJEn2Jm4WQ6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_zgKQWzylEaC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Beginning derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FairValueOfDerivativesIssued_zgOuKkKYcNna" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Fair value of derivatives issued in connection with Loan Agreement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">822</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLossOnDerivative_zfFbfwKv7rXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span id="xdx_903_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20240101__20241231_z5JWqb45Gh44" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"><span id="xdx_90B_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20230101__20231231_zun9QKFotl4f" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"><span style="-sec-ix-hidden: xdx2ixbrl0985"><span style="-sec-ix-hidden: xdx2ixbrl0986">Loss recognized in earnings from change in fair value</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_iN_zOvJ03xsAm81" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of derivative liability in connection with the Loan Agreement</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,135</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_zHXFxmIpvlzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending derivative liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Activity Warranty Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Outstanding Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0klTybGiMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the components of accrued expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhHL2yHiwIrf" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zgf4LoVT2Kc3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231_zvLG8hnRct3b" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz9Ql_zyVyMa7TPaHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued employee compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,688</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCz9Ql_ze73B163aD3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued contracted services and other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,941</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,297</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz9Ql_zPeVdkGjBeY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock', window );">SUMMARY OF OPERATING LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_896_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zHqncXgOgfI8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s operating lease liabilities (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zSXKYa6qpv1a" style="display: none">SUMMARY OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zywhxeVoY6Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zExrjeakqDU7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzJ5e_zzftb7jKYr4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Current operating lease liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">823</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">998</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzJ5e_z3ptF5BnuDR1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Non-current operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,262</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,402</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzJ5e_zbEYM6NwI84k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF COMPONENTS OF LEASE COST</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zLO5vmxyZoff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the components of lease costs and rent (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAqOuKsMyG1i" style="display: none">SCHEDULE OF COMPONENTS OF LEASE COST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zPbyK4BgezUg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zEe20696qzHk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_maLCzRlC_zexGgZSlOph4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,389</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--VariableLeaseCost_pn3n3_maLCzRlC_zOknanic4gh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">358</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzRlC_zWFA1AtjKpJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Short-term lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">63</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LeaseCost_iT_pn3n3_mtLCzRlC_zTZu4St3ZdOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,717</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,810</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgxclDHvdVR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments and obligations, which do not include short-term leases, related to the Company&#8217;s operating lease liabilities
as of December 31, 2024 were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zZoR7xzYjpv7" style="display: none">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future minimum lease payments and obligations</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zhpptrbDid29" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0kQ_zumIRufpw2E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">853</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0kQ_ztQolLdnqQ2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">791</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPz0kQ_zklCTUsrdfl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">807</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPz0kQ_zHitQCfr4kd9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">823</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPz0kQ_zfwSYH0S5kUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">859</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPz0kQ_ziwWsTMaOfIg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">834</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0kQ_zJifI0OSsI41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,967</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zea4xJ417NWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">882</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zki4bC6ZxUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock', window );">SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_zwqVEJqs2Nh3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zKmqxz9XUW8b" style="display: none">SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zjtUtumCZmt9" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future cash receipts</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subleases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_iI_pn3n3_maFCRFOzUBz_zkr9S0A8Ga6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left; padding-bottom: 1pt">2025</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">485</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--FutureCashReceiptsFromOperatingSublease_iTI_pn3n3_mtFCRFOzUBz_zE0u317Rznzh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total future cash receipts</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Future Cash Receipts From Operating Sublease [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Lease Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zyxxvjuPhWjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s debt, net of debt issuance costs and discounts (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zqffGlfH4Sgl" style="display: none">SCHEDULE
OF DEBT AND NET OF DEBT ISSUANCE COSTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zoYDkBwaIEwi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zbywQZHxVMrc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_maLTDzr8F_zP3IwhDVIyIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Loan Agreement Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">20,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccretedFinalPaymentFee_iI_pn3n3_maLTDzr8F_zjXiZ8Qtzehg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accreted final payment fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTDzr8F_zre8cPV9mPbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Unamortized debt issuance costs and discounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,391</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzr8F_mtLTDNzuex_zf2GAldghadl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1110">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtCurrent_iI_pn3n3_maLTDNzuex_z0qFJMsDr0Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: current maturities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,926</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_maLTDNzuex_zXEECTBoo7Sd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current maturities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,037</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">SCHEDULE OF FUTURE PAYMENT OBLIGATIONS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z3D0xIpWowBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future payment obligations of the principal are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z5c7uFcASU82" style="display: none">SCHEDULE
OF FUTURE PAYMENT OBLIGATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20241231_zx7SiEVbuXuh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzeHi_z2frBGi0rYNc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,926</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzeHi_znqqtiYjHVsi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,889</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzeHi_zzIIExoKjtm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzeHi_zSiEbNNpn9qg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total principal</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zhx79hHirrGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock-based compensation (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zaDyHTSQSI86" style="display: none">SCHEDULE
OF STOCK BASED COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_z9CUCC6VF1n4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zduZHkbXbUi3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTN8oypPqUAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,561</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,085</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zq3XjoK6NBM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,067</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,683</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_ztXtTAzvfhI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,768</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3xd7BT9pwj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock option activity during the year ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z1irdfs6brwl" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/>
 Average<br/>
 Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/>
 Average<br/>
 Remaining<br/>
 Contractual<br/>
 Term (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/>
 Intrinsic Value <br/> (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zs5KKlP8Tlxh" style="width: 11%; text-align: right" title="Number of options, Outstanding balance">240,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zxhjQjuzF3wi" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding balance">37.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zoOgPUiMgYW3" title="Weighted average remaining contractual term (years), outstanding">6.42</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231_zhOuHtWkkTOh" style="width: 11%; text-align: right" title="Aggregate intrinsic value, Outstanding balance"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zC8vXntWN1Vb" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1335">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zTv7A8olJ1Q8" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zNZYO1nmE9i7" style="text-align: right" title="Number of options, cancelled/forfeited">(61,769</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z2OVPZwNT3Ib" style="text-align: right" title="Weighted average exercise price, cancelled/forfeited">32.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zBjYOSihAHQa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zsrxxzBv3Dkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zd8UBkJQtjkk" style="text-align: right" title="Number of options, outstanding balance">179,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zcQMxsCSTkuf" style="text-align: right" title="Weighted average exercise price, outstanding balance">38.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zCGEpC2NUIj6" title="Weighted average remaining contractual term (years), outstanding">6.83</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231_zeAxJOPu9b04" style="text-align: right" title="Aggregate intrinsic value, outstanding balance">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_z7avEf4FPrid" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zihb5WU6BZde" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zoZOpr5tj9ia" style="text-align: right" title="Number of options, cancelled/forfeited">(2,414</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zpNtFtsI3sn9" style="text-align: right" title="Weighted average exercise price, cancelled/forfeited">33.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_znEJE6XmoK2l" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1363">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zVTyqDs62Whh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1365">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zhWm5QnWfZD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding balance">176,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zCh0HJ8zLHDi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding balance">38.64</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziyX67aZ0Yv1" title="Weighted average remaining contractual term (years), outstanding">5.83</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231_z12PkmH0nqA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding balance">6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zzr2mTlb8GN3" style="text-align: right" title="Number of options, exercisable">163,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z8WlgNDZrIw5" style="text-align: right" title="Weighted average exercise price, exercisable">39.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zmo7SlZz8WLl" title="Weighted average remaining contractual term (years), exercisable">5.77</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231_zuPlORunFxj6" style="text-align: right" title="Aggregate intrinsic value, exercisable">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231_z1yXwzJVUUFg" style="text-align: right" title="Number of options, unvested">13,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231_zDmPxnahLmei" style="text-align: right" title="Weighted average exercise price, unvested">33.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zq0oV7D3YJre" title="Weighted average remaining contractual term (years), unvested">6.65</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iI_pn3n3_c20241231_zYDYjRIXaGnc" style="text-align: right" title="Aggregate intrinsic value, unvested">2</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zg2zn1toFKU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock award activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zMgQXNlT6Ys9" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/>
Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average<br/>
 Grant Date Fair<br/>
 Value Per Unit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCtzlseGmGe5" style="width: 16%; text-align: right" title="Restricted common stock awards, balance">816,958</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBFXcfp2FdUb" style="width: 16%; text-align: right" title="Weighted-average grant date fair value, balance">5.35</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHBunrTltDJa" style="text-align: right" title="Restricted common stock awards, granted">1,958,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB9nVUIef3i7" style="text-align: right" title="Weighted-average grant date fair value, granted">3.99</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaOPRmWEPmNj" style="text-align: right" title="Restricted common stock awards, cancelled/forfeited">(56,398</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkhEq2bGMIUe" style="text-align: right" title="Weighted-average grant date fair value, cancelled/forfeited">4.32</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1G3Cm4a5qHk" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted common stock awards, vested">(270,550</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVybEXlOJfMi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value, vested">5.59</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zS5Ax97waVh4" style="text-align: right" title="Restricted common stock awards, balance">2,448,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwNwtQmU6Qdb" style="text-align: right" title="Weighted-average grant date fair value, balance">4.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znUFmjRYMMdj" style="text-align: right" title="Restricted common stock awards, granted">2,065,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUkA9hlrNXFi" style="text-align: right" title="Weighted-average grant date fair value, granted">4.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXkymYkPuR88" style="text-align: right" title="Restricted common stock awards, cancelled/forfeited">(183,114</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfGvEA8kitBi" style="text-align: right" title="Weighted-average grant date fair value, cancelled/forfeited">3.78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyDyzKnZEExc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted common stock awards, vested">(1,009,298</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdWv19Qb9lyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value, vested">4.64</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSyyCfIAHalb" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted common stock awards, balance">3,320,811</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zogNe2X9uHL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant date fair value, balance">4.60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_z7HjMJozkk1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there are no options outstanding under the 2005 Incentive Plan. Further information regarding options outstanding
under the 2015 Incentive Plan as of December 31, 2024 is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zSeaet6NdvZd" style="display: none">SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of <br/>
Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options<br/>
 Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining<br/>
 Life In<br/>
 Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/>
 Options<br/>
 Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining<br/>
 Life in<br/>
 Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zC3Ncovv0UH5" style="width: 9%; text-align: right" title="Range of exercise price, lower limit">4.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziZq3iXSNOGe" style="width: 9%; text-align: right" title="Range of exercise price, upper limit">22.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zM5URYCJVBzk" style="width: 9%; text-align: right" title="Number of options outstanding">20,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMvFZa0EqPoj" title="Weighted-average remaining life in years">7.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zfo3vcC2SwY8" style="width: 9%; text-align: right" title="Weighted-average exercise price">16.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zgLIwrVEzBFi" style="width: 9%; text-align: right" title="Number of options exercisable">15,154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zW0FR4cf1qM" title="Weighted-average remaining life in years, exercisable">6.9</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zl9EygmFbHVg" style="width: 8%; text-align: right" title="Weighted-average exercise price, exercisable">17.16</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOPNC5y7xldc" style="text-align: right" title="Range of exercise price, lower limit">25.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zLBO8t9Y5Oq6" style="text-align: right" title="Range of exercise price, upper limit">47.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4Q8iB0tETZg" style="text-align: right" title="Number of options outstanding">104,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zudchz5beXQl" title="Weighted-average remaining life in years">5.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8s82GKavb05" style="text-align: right" title="Weighted-average exercise price">33.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNAFz0O5ADF8" style="text-align: right" title="Number of options exercisable">99,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zd4kfk2GTaUj" title="Weighted-average remaining life in years, exercisable">5.4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKR6wohT8Uec" style="text-align: right" title="Weighted-average exercise price, exercisable">33.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zwoZNAivC8cb" style="text-align: right" title="Range of exercise price, lower limit">54.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztHtG4xg92H1" style="text-align: right" title="Range of exercise price, upper limit">58.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVTgnJbAWxn4" style="text-align: right" title="Number of options outstanding">52,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1swoirEi3ck" title="Weighted-average remaining life in years">6.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zgIQ5jY4dwg7" style="text-align: right" title="Weighted-average exercise price">56.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzgl7yQYfE4b" style="text-align: right" title="Number of options exercisable">48,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z8yLbTdpJYV5" title="Weighted-average remaining life in years, exercisable">6.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVxSOjWG9AKj" style="text-align: right" title="Weighted-average exercise price, exercisable">56.96</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWLspd65hyJ6" style="padding-bottom: 1pt; text-align: right" title="Range of exercise price, lower limit">164.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zeHg76yuS3O5" style="padding-bottom: 1pt; text-align: right" title="Range of exercise price, upper limit">183.50</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zQUYP1Cg4WRf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options outstanding">200</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zj2SBTcyV6x8" title="Weighted-average remaining life in years">4.1</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z8a1QitP9HA1" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price">164.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBQTkGNTfDE8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options exercisable">200</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z6mwY42PJ2Xk" title="Weighted-average remaining life in years, exercisable">4.1</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4AQfqqqQdm" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price, exercisable">164.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zjJHzyr57zfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding">176,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zBC76UVisnV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">163,386</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAX EXPENSE</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zIT3yL4xvrif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense differs from the statutory amounts for each of the following years (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z1W4eLi6yH3d" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zJrc5w5X32a5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_z1Lv5Z1LexAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBz0L9_zOi1p7PEgYla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Income taxes at U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(13,384</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(11,379</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBz0L9_znwLYfLORRV" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(679</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(242</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_iN_pn3n3_di_msITEBz0L9_zqbiZBf7ZUUc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,535</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,137</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_pn3n3_maITEBz0L9_zStgbwMgLEj8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,032</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1573">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBz0L9_z5VSxE5GRaok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,418</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,687</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_pn3n3_maITEBz0L9_zuCOYqaUcNqe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,456</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_pn3n3_maITEBz0L9_zRVRCh5Pe861" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expired tax losses and credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,503</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maITEBz0L9_zT3AeU3O6XRl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Permanent differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(127</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBz0L9_zvM9t0sKr9v9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1588">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVO5kdlAUC96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes are provided for the temporary differences between the financial reporting bases and the tax bases of the Company&#8217;s assets
and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zhZZThYB4F77" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zlq4G6heDt6f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zoIEbYn8wVP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzzCb_zwhThLZPbTJ8" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,059</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">78,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzzCb_zDyX3qoqWaKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">General business credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,752</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_maDTAGzzCb_zvT88LMPKyt2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,780</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,780</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_iI_pn3n3_maDTAGzzCb_zE9MlxSq7I1f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Property, equipment and goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">887</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzzCb_zSAaX1cUYVD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,983</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzzCb_z8KLfhLjrT97" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">661</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">615</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzzCb_zdMa7KV4X4M8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzzCb_z7UzmmDfG9qe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,843</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzzCb_zdaC636szIkg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">83</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzzCb_maDTALNzbeO_zK01rSVLRfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,406</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,988</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzbeO_zUXoTu7W4fbl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(114,406</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(108,988</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzbeO_zeKO9OwMaNW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net deferred taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1625">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1626">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zJBwSyeSkln9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_zHBZp0r9iRDf" style="display: none">SUMMARY
OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net operating <br/>
loss carryforwards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">General <br/>
business credit<br/>
 carryforwards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zcPE0tjSieda" style="width: 16%; text-align: right" title="Net operating loss carryforwards">2,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zRqZRuEPytQ5" style="width: 16%; text-align: right" title="General business credit carryforwards">182</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_z49VMgrFdvK5" style="text-align: right" title="Net operating loss carryforwards">7,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_zKHZRAT2I9d3" style="text-align: right" title="General business credit carryforwards">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_zHwFyUwFiuN" style="text-align: right" title="Net operating loss carryforwards">9,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_z7gbOPeerZq4" style="text-align: right" title="General business credit carryforwards">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zB8s5xT6fb3l" style="text-align: right" title="Net operating loss carryforwards">6,886</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zKZTJqdh8Df6" style="text-align: right" title="General business credit carryforwards">141</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zSSM4hZ2Rmr4" style="text-align: right" title="Net operating loss carryforwards">7,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zxEdWHMLRcqi" style="text-align: right" title="General business credit carryforwards">83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zsocbJx5H9H5" style="border-bottom: Black 1pt solid; text-align: right" title="Net operating loss carryforwards">65,644</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zb3Dp0hxB5Qi" style="border-bottom: Black 1pt solid; text-align: right" title="General business credit carryforwards">5,429</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231_zC3pZOilpAO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net operating loss carryforwards">99,945</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231_zStrXx0clpu2" style="border-bottom: Black 2.5pt double; text-align: right" title="General business credit carryforwards">6,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_ztJoAx3m1Wsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zdSjXWpHlcab">&#160;SCHEDULE
OF SIGNIFICANT EXPENSE CATEGORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zM6ttbo2Nyn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zL3Gwowwcknk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_ziFvzS9qLimj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">License and other revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1680">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zRbz8EoaOmhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5LxCVkvrq4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Salaries &amp; related costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,345</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,373</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkJXMBLsopTd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,561</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,086</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0A7ZZ6YUKtf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other research and development costs <span id="xdx_F40_zLi6GOQFH6dj">(a)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,454</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,632</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_zDWbyShBkcu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,091</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zgDi1AOLtp46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBqLHIsuFbff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Salaries &amp; related costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,942</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRio3dbbGYQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,067</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,682</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrecommercialPreparationCosts_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGJKmg7reyNj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Pre-commercial preparation costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,224</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPexKxOBGZWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other general and administrative costs <span id="xdx_F4D_zM7CZfeEvSul">(b)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,237</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,156</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_z1mlRoUsChqc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total general and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19,004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OtherSegments_zUDbASdMShak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other segment items <span id="xdx_F42_z9oKAR73if38">(c)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(477</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,593</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zHsPrjrprioa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(63,734</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(54,188</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zOCHrx46Bl7h">(a)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F17_z9sNosGHbGU8">Other
    research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial
    costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and
    manufacturing facilities, and consultant-related expenses.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F06_zFw2pWHJlIQd">(b)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F19_zDoiH2kSjjxe">Other
    general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional
    fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F01_zdB334Pd12I2">(c)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F16_zev26bldGfJg">Other
    segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and
    other income.</i></span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="nump">$ 54,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">813,258<span></span>
</td>
<td class="nump">$ 749,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, restricted cash and short-term investments</a></td>
<td class="nump">98,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">14,099,209<span></span>
</td>
<td class="nump">12,025,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">176,587<span></span>
</td>
<td class="nump">179,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,320,811<span></span>
</td>
<td class="nump">2,448,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ABEO_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">614,251<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">9,987,560<span></span>
</td>
<td class="nump">9,397,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ABEO_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ABEO_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 02, 2024</div></th>
<th class="th"><div>Jul. 06, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>May 07, 2024</div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
<th class="th"><div>Dec. 21, 2021</div></th>
<th class="th"><div>Dec. 17, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Unfounded exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,609,879<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 755,000<span></span>
</td>
<td class="nump">$ 11,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_PreFundedWarrants2024Member', window );">Pre Funded Warrants 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_LoanAgreementWarrants2024Member', window );">Loan Agreement Warrants 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_PreFundedWarrants2023Member', window );">Pre Funded Warrants 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Pre Funded Warrants 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,214,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,142,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_NumberOfWarrantsOrRightsExercised', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Loan Agreement Warrants 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Pre Funded Warrants 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,919,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_NumberOfWarrantsOrRightsExercised', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Exercise of warrants</a></td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyFourLoanAgreementWarrantsMember', window );">2024 Loan Agreement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Exercise of warrants</a></td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_NumberOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_NumberOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ABEO_PreFundedWarrants2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ABEO_PreFundedWarrants2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ABEO_LoanAgreementWarrants2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ABEO_LoanAgreementWarrants2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ABEO_PreFundedWarrants2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ABEO_PreFundedWarrants2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyFourLoanAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyFourLoanAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 74,355<span></span>
</td>
<td class="nump">$ 37,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">30<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">74,363<span></span>
</td>
<td class="nump">37,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">23,990<span></span>
</td>
<td class="nump">8,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">23,968<span></span>
</td>
<td class="nump">8,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">US Government Corporations and Agencies Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">40,365<span></span>
</td>
<td class="nump">29,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">10<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">40,375<span></span>
</td>
<td class="nump">$ 29,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 10,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Available-for-sale securities realized gain loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 19,410<span></span>
</td>
<td class="nump">$ 16,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(14,980)<span></span>
</td>
<td class="num">(12,991)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 4,430<span></span>
</td>
<td class="nump">3,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 8,868<span></span>
</td>
<td class="nump">6,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_FurnitureSoftwareAndOfficeEquipmentMember', window );">Furniture, Software and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_FurnitureSoftwareAndOfficeEquipmentMember', window );">Furniture, Software and Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_FurnitureSoftwareAndOfficeEquipmentMember', window );">Furniture, Software and Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 8,805<span></span>
</td>
<td class="nump">8,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Useful Life, Lease Term [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_FurnitureSoftwareAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_FurnitureSoftwareAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (loss) on disposal of equipment</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="num">$ (47,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 97,099<span></span>
</td>
<td class="nump">$ 38,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">32,014<span></span>
</td>
<td class="nump">35,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">46,704<span></span>
</td>
<td class="nump">9,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">50,395<span></span>
</td>
<td class="nump">29,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">32,014<span></span>
</td>
<td class="nump">35,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents fair value</a></td>
<td class="nump">17,627<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents fair value</a></td>
<td class="nump">17,627<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Deposit Account [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents fair value</a></td>
<td class="nump">5,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Deposit Account [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents fair value</a></td>
<td class="nump">5,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Deposit Account [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Deposit Account [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="nump">23,968<span></span>
</td>
<td class="nump">8,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="nump">23,968<span></span>
</td>
<td class="nump">8,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Corporations and Agencies Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="nump">40,375<span></span>
</td>
<td class="nump">29,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Corporations and Agencies Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Corporations and Agencies Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="nump">40,375<span></span>
</td>
<td class="nump">29,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Corporations and Agencies Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="nump">10,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="nump">10,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, liabilities</a></td>
<td class="nump">32,014<span></span>
</td>
<td class="nump">31,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liabilities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liabilities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, liabilities</a></td>
<td class="nump">$ 32,014<span></span>
</td>
<td class="nump">31,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Payable to Licensor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Payable to Licensor [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Payable to Licensor [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Payable to Licensor [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ABEO_MoneyMarketDepositAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ABEO_MoneyMarketDepositAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ABEO_WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ABEO_WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ABEO_PayableToLicensorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ABEO_PayableToLicensorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember', window );">2021 Public Offering Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrant liabilities</a></td>
<td class="nump">1,788,000<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember', window );">2022 Private Placement Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrant liabilities</a></td>
<td class="nump">7,609,879<span></span>
</td>
<td class="nump">7,609,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyFourLoanAgreementMember', window );">2024 Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrant liabilities</a></td>
<td class="nump">589,681<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyFourLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyFourLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
<th class="th"><div>Dec. 21, 2021</div></th>
<th class="th"><div>Dec. 17, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember', window );">2021 Public Offering Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable', window );">Warrants, expiration date</a></td>
<td class="text">December 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price</a></td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember', window );">2022 Private Placement Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable', window );">Warrants, expiration date</a></td>
<td class="text">November 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price</a></td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyFourLoanAgreementMember', window );">2024 Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable', window );">Warrants, expiration date</a></td>
<td class="text">January 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, expiration date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyFourLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyFourLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_WarrantLiabilities', window );">Beginning warrant liabilities</a></td>
<td class="nump">$ 31,352<span></span>
</td>
<td class="nump">$ 19,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_FairValueAdjustmentOfWarrantsIssued', window );">Fair value of warrants issued in connection with the Loan Agreement</a></td>
<td class="nump">220<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_GainLossRecognizedInEarningsFromChangeInFairValue', window );">Loss recognized in earnings from change in fair value</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">11,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_WarrantLiabilities', window );">Ending warrant liabilities</a></td>
<td class="nump">$ 32,014<span></span>
</td>
<td class="nump">$ 31,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_FairValueAdjustmentOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_FairValueAdjustmentOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_GainLossRecognizedInEarningsFromChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) recognized in earnings from change in fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_GainLossRecognizedInEarningsFromChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">5.57<span></span>
</td>
<td class="nump">5.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (years)</a></td>
<td class="text">1 year 11 months 15 days<span></span>
</td>
<td class="text">2 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 7 days<span></span>
</td>
<td class="text">3 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">4.16<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">4.24<span></span>
</td>
<td class="nump">3.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">92.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">100.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Beginning derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_FairValueOfDerivativesIssued', window );">Fair value of derivatives issued in connection with Loan Agreement</a></td>
<td class="nump">822<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Loss recognized in earnings from change in fair value</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change in fair value of warrant and derivative liabilities<span></span>
</td>
<td class="text">Change in fair value of warrant and derivative liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement', window );">Reclassification of derivative liability in connection with the Loan Agreement</a></td>
<td class="nump">$ 1,135<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Ending derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_FairValueOfDerivativesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivatives issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_FairValueOfDerivativesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liablity in connection with loan agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes loss from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>May 07, 2024</div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
<th class="th"><div>Dec. 21, 2021</div></th>
<th class="th"><div>Dec. 17, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants to purchase shares</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyFourLoanAgreementMember', window );">2024 Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyThreeLoanAgreementMember', window );">2023 Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyFourLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyFourLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyThreeLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_TwentyTwentyThreeLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SETTLEMENT LIABILITY (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,963<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABEO_REGENXBIOMember', window );">REGENXBIO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement liabilities, current</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Loss contingency settlement agreement terms</a></td>
<td class="text">(1) $20.0 million paid in November 2021
after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement
(paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement
or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement (paid in November 2024).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencySettlementAgreementTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencySettlementAgreementTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABEO_REGENXBIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABEO_REGENXBIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee compensation</a></td>
<td class="nump">$ 4,392<span></span>
</td>
<td class="nump">$ 3,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued contracted services and other</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="nump">2,297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 6,333<span></span>
</td>
<td class="nump">$ 5,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF OPERATING LEASE LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">$ 823<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 4,085<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF COMPONENTS OF LEASE COST (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="nump">$ 1,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td>
<td class="nump">$ 1,717<span></span>
</td>
<td class="nump">$ 1,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">4,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 4,085<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_FutureCashReceiptsFromOperatingSublease', window );">Total future cash receipts</a></td>
<td class="nump">$ 485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_FutureCashReceiptsFromOperatingSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash receipts from operating sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_FutureCashReceiptsFromOperatingSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash receipts from operating sublease next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Annual lease payments</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Total lease payments</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">$ 4,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">4,085<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=ABEO_SeptemberTwoThouandTwentyFiveMember', window );">September 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_OfficeSpaceOneMember', window );">Office Space One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain (loss) on termination of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_OfficeSpaceTwoMember', window );">Office Space Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LeaseAgreementMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="nump">16,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SubLeaseAgreementMember', window );">Sub Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=ABEO_SeptemberTwoThouandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=ABEO_SeptemberTwoThouandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_OfficeSpaceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_OfficeSpaceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_OfficeSpaceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ABEO_OfficeSpaceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_SubLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_SubLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan Agreement Principal</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_AccretedFinalPaymentFee', window );">Accreted final payment fee</a></td>
<td class="nump">354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance costs and discounts</a></td>
<td class="num">(1,391)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">18,963<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current maturities</a></td>
<td class="nump">5,926<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current maturities</a></td>
<td class="nump">$ 13,037<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_AccretedFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accreted final payment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_AccretedFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 5,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">8,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">5,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">DerivativeLiabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 755,000<span></span>
</td>
<td class="nump">$ 11,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyManagementFeePercentFeeDescription', window );">Percentage fee, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is required to pay a prepayment fee equal to 3.00% of the principal amount of the
Loans prepaid; if prepayment occurs after the one-year anniversary of the Closing Date and on or before the two-year anniversary of the
Closing Date, the Company is required to pay a fee equal to 2.00% of the principal amount of the Loans&#894; if prepayment occurs after
the two-year anniversary of the Closing Date, the Company is required to pay a fee equal to 1.00% of the principal amount of the Loans.
A final payment fee of 5.00% of the principal amount of the funded Tranche 1, Tranche 2 Loans and Discretionary Tranche Loans is also
due upon the Maturity Date or any earlier date of prepayment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized', window );">Outstanding principal amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_FairValueOfConversionRight', window );">Fair value of conversion right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">DerivativeLiabilities</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ParticipationRightDescription', window );">Participation right description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Participation Right automatically terminates upon the earliest of (i) July 1, 2027, (ii) such time that the Lenders have purchased
$1 million of the Company&#8217;s equity securities in the aggregate pursuant to the Participation Right, and (iii) the repayment in
full of all of the obligations under the Loan Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Warrant [Member] | Avenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Warrants purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Warrant [Member] | Avenue 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Warrants purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Minimum [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Maximum [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Tranche 1 [Member] | Warrant [Member] | Avenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Warrants purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Tranche 1 [Member] | Warrant [Member] | Avenue 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Warrants purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Tranche 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Discretionary Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_FairValueOfConversionRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of conversion right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_FairValueOfConversionRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ParticipationRightDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Participation right description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ParticipationRightDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the sum of principal amount outstanding for both securitized and unsecuritized loans of all types.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyManagementFeePercentFeeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of what the property management fee percentage is taken against to determine the fee charged to clients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyManagementFeePercentFeeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ABEO_AvenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ABEO_AvenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ABEO_AvenueTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ABEO_AvenueTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ABEO_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ABEO_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ABEO_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ABEO_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ABEO_DiscretionaryTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ABEO_DiscretionaryTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>May 07, 2024</div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Jul. 06, 2023</div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
<th class="th"><div>Dec. 21, 2021</div></th>
<th class="th"><div>Aug. 17, 2018</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 02, 2024</div></th>
<th class="th"><div>Dec. 17, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,609,879<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_FairValueWarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Shares issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,475,000<span></span>
</td>
<td class="nump">$ 14,408,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">value issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,475,000<span></span>
</td>
<td class="nump">14,623,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 755,000<span></span>
</td>
<td class="nump">11,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ABEO_PrivatePlacementOfferingsMember', window );">Private Placement Offerings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,065,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,609,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_OpenMarketSaleAgreementsMember', window );">Open Market Sale Agreements [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,825,954<span></span>
</td>
<td class="nump">3,659,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant liability'</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,285,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,284,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,825,954<span></span>
</td>
<td class="nump">3,659,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">value issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | A T M Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">value issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ABEO_PreFundedWarrantMember', window );">Pre Funded Warrant [Member] | Private Placement Offerings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,609,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_GrossProceedsFromIssuanceOfCommonStock', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Shares issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,609,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Additional paid in capital stock reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant liability'</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ABEO_PreFundedWarrantMember', window );">Pre Funded Warrant [Member] | Private Placement Offerings [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ABEO_CommonStockAndAccompanyingWarrantMember', window );">Common Stock and Accompanying Warrant [Member] | Private Placement Offerings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ABEO_PreFundedWarrantAndAccompanyingWarrantMember', window );">Pre-Funded Warrant and Accompanying Warrant [Member] | Private Placement Offerings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Loan and Security Agreement [Member] | Avenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Warrants purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Loan and Security Agreement [Member] | Avenue 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Warrants purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember', window );">2021 Public Offering Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
<td class="nump">1,788,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwoThousandTwentyFourPreFundedWarrantsMember', window );">2024 Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,214,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwoThousandTwentyFourPreFundedWarrantsMember', window );">2024 Pre-Funded Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,142,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_GrossProceedsFromIssuanceOfCommonStock', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Shares issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwoThousandTwentyThreePreFundedWarrantsMember', window );">2023 Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwoThousandTwentyThreePreFundedWarrantsMember', window );">2023 Pre-Funded Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,919,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_GrossProceedsFromIssuanceOfCommonStock', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Shares issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_FairValueWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_FairValueWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ABEO_PrivatePlacementOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ABEO_PrivatePlacementOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_OpenMarketSaleAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_OpenMarketSaleAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ABEO_JefferiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ABEO_JefferiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ABEO_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ABEO_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ABEO_CommonStockAndAccompanyingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ABEO_CommonStockAndAccompanyingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ABEO_PreFundedWarrantAndAccompanyingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ABEO_PreFundedWarrantAndAccompanyingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ABEO_AvenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ABEO_AvenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ABEO_AvenueTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ABEO_AvenueTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwentyTwentyOnePublicOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwoThousandTwentyFourPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwoThousandTwentyFourPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwoThousandTwentyThreePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ABEO_TwoThousandTwentyThreePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK BASED COMPENSATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,628<span></span>
</td>
<td class="nump">$ 4,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,067<span></span>
</td>
<td class="nump">$ 3,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding balance</a></td>
<td class="nump">179,001<span></span>
</td>
<td class="nump">240,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding balance</a></td>
<td class="nump">$ 38.58<span></span>
</td>
<td class="nump">$ 37.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (years), outstanding</a></td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">6 years 9 months 29 days<span></span>
</td>
<td class="text">6 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding balance</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, cancelled/forfeited</a></td>
<td class="num">(2,414)<span></span>
</td>
<td class="num">(61,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled/forfeited</a></td>
<td class="nump">$ 33.84<span></span>
</td>
<td class="nump">$ 32.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding balance</a></td>
<td class="nump">176,587<span></span>
</td>
<td class="nump">179,001<span></span>
</td>
<td class="nump">240,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding balance</a></td>
<td class="nump">$ 38.64<span></span>
</td>
<td class="nump">$ 38.58<span></span>
</td>
<td class="nump">$ 37.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding balance</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable</a></td>
<td class="nump">163,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 39.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (years), exercisable</a></td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of options, unvested</a></td>
<td class="nump">13,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, unvested</a></td>
<td class="nump">$ 33.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (years), unvested</a></td>
<td class="text">6 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1', window );">Aggregate intrinsic value, unvested</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award options unvested intrinsic value1 .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">176,587<span></span>
</td>
<td class="nump">179,001<span></span>
</td>
<td class="nump">240,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining life in years</a></td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">6 years 9 months 29 days<span></span>
</td>
<td class="text">6 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price</a></td>
<td class="nump">$ 38.64<span></span>
</td>
<td class="nump">$ 38.58<span></span>
</td>
<td class="nump">$ 37.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">163,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining life in years, exercisable</a></td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">$ 39.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">176,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">163,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan [Member] | Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise price, lower limit</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price, upper limit</a></td>
<td class="nump">$ 22.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">20,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining life in years</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price</a></td>
<td class="nump">$ 16.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">15,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining life in years, exercisable</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">$ 17.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan [Member] | Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise price, lower limit</a></td>
<td class="nump">25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price, upper limit</a></td>
<td class="nump">$ 47.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">104,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining life in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price</a></td>
<td class="nump">$ 33.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">99,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining life in years, exercisable</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">$ 33.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan [Member] | Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise price, lower limit</a></td>
<td class="nump">54.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price, upper limit</a></td>
<td class="nump">$ 58.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">52,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining life in years</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price</a></td>
<td class="nump">$ 56.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">48,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining life in years, exercisable</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">$ 56.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan [Member] | Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise price, lower limit</a></td>
<td class="nump">164.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price, upper limit</a></td>
<td class="nump">$ 183.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining life in years</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price</a></td>
<td class="nump">$ 164.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining life in years, exercisable</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">$ 164.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ABEO_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ABEO_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ABEO_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ABEO_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ABEO_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ABEO_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ABEO_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ABEO_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ABEO_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details) - Restricted Stock [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted common stock awards, balance</a></td>
<td class="nump">2,448,169<span></span>
</td>
<td class="nump">816,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, balance</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="nump">$ 5.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted common stock awards, granted</a></td>
<td class="nump">2,065,054<span></span>
</td>
<td class="nump">1,958,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, granted</a></td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="nump">$ 3.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted common stock awards, cancelled/forfeited</a></td>
<td class="num">(183,114)<span></span>
</td>
<td class="num">(56,398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, cancelled/forfeited</a></td>
<td class="nump">$ 3.78<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted common stock awards, vested</a></td>
<td class="num">(1,009,298)<span></span>
</td>
<td class="num">(270,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, vested</a></td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted common stock awards, balance</a></td>
<td class="nump">3,320,811<span></span>
</td>
<td class="nump">2,448,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, balance</a></td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th"><div>Apr. 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">584,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Compensation cost related to restricted common stock not recognized</a></td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average compensation costs related to restricted common stock</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue', window );">Fair value of restricted stock awards that vested</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation cost related to non-vested options not recognized</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period total compensation costs related to non-vested options</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ABEO_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">5,251,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2023 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Increase in shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2023 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Increase in shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award other than options vested in period fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ABEO_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ABEO_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE/SUPPLIER AGREEMENTS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAndInventoryPurchaseAgreementsMember', window );">Sublicense And Inventory Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAndInventoryPurchaseAgreementsMember', window );">Sublicense And Inventory Purchase Agreements [Member] | Event Based Milestone Payments [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAndInventoryPurchaseAgreementsMember', window );">Sublicense And Inventory Purchase Agreements [Member] | Sales Based Milestone Payments [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAndInventoryPurchaseAgreementsMember', window );">Sublicense And Inventory Purchase Agreements [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAgreementRelatingToRettSyndromeMember', window );">Sublicense Agreement Relating to Rett Syndrome [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAgreementRelatingToRettSyndromeMember', window );">Sublicense Agreement Relating to Rett Syndrome [Member] | Event Based Milestone Payments [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAgreementRelatingToRettSyndromeMember', window );">Sublicense Agreement Relating to Rett Syndrome [Member] | Sales Based Milestone Payments [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAgreementRelatingToRettSyndromeMember', window );">Sublicense Agreement Relating to Rett Syndrome [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ABEO_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_RemainingMilestonePaymentsDue', window );">Remaining milestone payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Milestone payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_RemainingMilestonePaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining milestone payments due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_RemainingMilestonePaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAndInventoryPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAndInventoryPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ABEO_EventBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ABEO_EventBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ABEO_SalesBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ABEO_SalesBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAgreementRelatingToRettSyndromeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ABEO_SublicenseAgreementRelatingToRettSyndromeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ABEO_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ABEO_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) PLAN (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Maximum annual contribution per employee under 401(k) plan</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_NumberOfInvestmentOptions', window );">Number of investment options | Integer</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company contributions under 401 (k) Plan</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=ABEO_UnderAgeFifftyMember', window );">Under Age 50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Maximum annual contribution per employee under 401(k) plan</a></td>
<td class="nump">$ 30,500<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_NumberOfInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_NumberOfInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=ABEO_UnderAgeFifftyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=ABEO_UnderAgeFifftyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAX EXPENSE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">Income taxes at U.S. statutory rate</a></td>
<td class="num">$ (13,384)<span></span>
</td>
<td class="num">$ (11,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">State tax, net of federal benefit</a></td>
<td class="num">(679)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit', window );">Research and development credit</a></td>
<td class="num">(1,535)<span></span>
</td>
<td class="num">(1,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps', window );">Deferred true ups</a></td>
<td class="nump">8,032<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">5,418<span></span>
</td>
<td class="nump">8,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate', window );">Expired tax losses and credits</a></td>
<td class="nump">2,116<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(127)<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation change in deferred tax assets true ups.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense benefit changes of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense benefit expired tax lossed and credit tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense benefit permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 88,059<span></span>
</td>
<td class="nump">$ 78,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">4,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State credits</a></td>
<td class="nump">2,780<span></span>
</td>
<td class="nump">2,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill', window );">Property, equipment and goodwill</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">2,463<span></span>
</td>
<td class="nump">11,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">13,264<span></span>
</td>
<td class="nump">8,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">114,406<span></span>
</td>
<td class="nump">108,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(114,406)<span></span>
</td>
<td class="num">(108,988)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets property plant and equipments and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 99,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">$ 4,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyFiveMember', window );">Tax Year 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentySixMember', window );">Tax Year 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">7,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentySevenMember', window );">Tax Year 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">9,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyEightMember', window );">Tax Year 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">6,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyNineMember', window );">Tax Year 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">7,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ABEO_ThereafterMember', window );">Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">65,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">$ 5,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ABEO_TaxYearTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ABEO_ThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ABEO_ThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Deferred tax assets</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">State net operating loss carryforwards</a></td>
<td class="nump">99,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 4,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_OperatingLossCarryforwardsTaxablePercentage', window );">Operating loss taxable percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">State net operating loss carryforwards</a></td>
<td class="nump">416,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryforwards</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_NetOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">316,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">State net operating loss carryforwards</a></td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_NetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_NetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_OperatingLossCarryforwardsTaxablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards taxable percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_OperatingLossCarryforwardsTaxablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong> SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development costs</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,628<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,360<span></span>
</td>
<td class="nump">31,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,851<span></span>
</td>
<td class="nump">19,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_OtherSegments', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(477)<span></span>
</td>
<td class="nump">7,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63,734)<span></span>
</td>
<td class="num">(54,188)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development costs</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries &amp; related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,345<span></span>
</td>
<td class="nump">11,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other general and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">17,454<span></span>
</td>
<td class="nump">18,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development costs</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries &amp; related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,729<span></span>
</td>
<td class="nump">6,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,067<span></span>
</td>
<td class="nump">3,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other general and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">9,237<span></span>
</td>
<td class="nump">7,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ABEO_PrecommercialPreparationCosts', window );">Pre-commercial preparation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,818<span></span>
</td>
<td class="nump">$ 1,224<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other
    segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and
    other income.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Other
    research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial
    costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and
    manufacturing facilities, and consultant-related expenses.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Other
    general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional
    fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_OtherSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_OtherSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ABEO_PrecommercialPreparationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Precommercial preparation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ABEO_PrecommercialPreparationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ABEO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Estimated total stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,628<span></span>
</td>
<td class="nump">$ 4,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Estimated total stock compensation</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Subsequent Event [Member] | Three Equal Annual Installments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Estimated total stock compensation</a></td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Subsequent Event [Member] | One Annual Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Estimated total stock compensation</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Director [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock awards, issued</a></td>
<td class="nump">1,956,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ABEO_ThreeEqualAnnualInstallmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ABEO_ThreeEqualAnnualInstallmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ABEO_OneAnnualInstallmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ABEO_OneAnnualInstallmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -4[=%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( -4[=%J(9-X5\0   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ;8%#U.6RB1-(2$P"<8L2
M;XO6-%%BU.[M:</6@> !.,;^\_FSY%8'H7W$Y^@#1K*8;D;7]4GHL&('HB
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MB$45  >=:6=)'YIK@]*!IPX[ H-!SMC69@ 9\A1E-L.PC\ZU2T@4H0%\'>E
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M#\=\ABF9Q6C@# IW*@6'5<H^TNWADZA,Q2_M6XFUT2I"^4]%7?GA@'9-)LD
M)^%.H.!C=OEJL$M[P;J2Q6@E9^/O,8,D0T.0]TZ;PX+$H?IVS;TP!,\!L^_P
MPF/G.[R8[KT=L:^F_J3RCM?*"-2%&1>=I,:!W+SMV=QHL6I?F-P*K4757BX9
M-=BM@?E](81^NK'O8';OW.;_ E!+ P04    " #5.W1:K1EDS]\"  #;"0
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MAHA/0@N@Y8^[!PXXP6&>@SI>,!#OCNU863%U:9N;QC6TNYJ%?*FV-&%7(TB
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M%/7/C%'8KQ@#^'\MA'Y\, ,<KB,7_P-02P,$%     @ U3MT6F7M\"9H!P
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MX9\:#@^LV%:7\)<%8\6F^K@FF%<>T8!_ORH*]O@@[O4?_[5D]B]02P,$%
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M5]7'I120CDX ?E]H;?=?W N:>[/S/P%02P,$%     @ U3MT6H@!?)E7 @
MK 4  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RM5&UKVS 0_BO"*Z.%
M-8Y?DH;,-C3)1@OK"$V[?1C[H-B76%26/$F.VW\_27:\M#AAC'VQ=-(]SSUW
MUEU4<_$D<P"%G@O*9.SD2I53UY5I#@66 UX"TS<;+@JLM"FVKBP%X,R""NKZ
MP^'8+3!A3A+9LZ5((EXI2A@L!9)546#Q,@/*Z]CQG/W!/=GFRARX253B+:Q
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MY6YRR;&"6T&?2:GK>3 -4 E;W%*]$?NO<,AG9/D*097[HGWG.TH#5+1*"W8
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MD-;!K&^%T$?#!N@?ONP=4$L#!!0    ( -4[=%J?8<1%KPD  .HB   8
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MOIAJRAQ_= 0O! M],;=F;K7R4(8+6&@JK$A(3JYDX?-?K"I@6R9T%< 0H#)
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MJ]4&D=H5R7XG\4E#O>8HPS12Z7#B"X29=C:A=X,]=H=IT'[OT@1]Q]Q"Z0
M<:XY1+_&G1>CX^_Y(L X'>*&9$1K'>;].D_[!_X1U4?(S'BR]F'R5_MPC (<
M-N!_M!(/!7_]0GE\\.WNKN W/)<[.$ R&=])R7<DXK Q?V5K#3L_/RB5G?&/
M+"B-=>7#+Q'BW?A#CO/P\X7U\O KD+?28I X4>#H?-H;#9X]Z0D;?E@1+KR9
M\X\9[HSWIN2/N<)4LK0 SZ?&^/:"%,2?MYS]!U!+ P04    " #5.W1:4:N5
M)Y<'  #>$   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RU6-MN(S<2
M?>^O*"B+8 S(DB5K9KSC"R#+GHF ^ )?$BP6^T!U4VJNV62'9-M6OCZGR)8L
M)1KO/NR^6'UCU:E358=%G[Q8]^1+*0.]5MKXTTX90OVEW_=Y*2OA>[:6!F_F
MUE4BX-8M^KYV4A1Q4:7[PX.#3_U**-,Y.XG/;MW9B6V"5D;>.O)-50FW/)?:
MOIQV!IW5@SNU* ,_Z)^=U&(A[V5XK&\=[OIK*X6JI/'*&G)R?MH9#[Z<C_C[
M^,$O2K[XC6OB2&;6/O'-M#CM'# @J64>V(+ S[.<2*W9$&#\UMKLK%WRPLWK
ME?6O,7;$,A->3JS^516A/.T<=:B0<]'H<&=??I)M/!_97FZUCW_II?WVH$-Y
MXX.MVL5 4"F3?L5KR\-_LV#8+AA&W,E11'DA@C@[<?:%''\-:WP10XVK 4X9
M3LI]<'BKL"Z<78\?'N\NZ>8KW=Q>WHT?IC?7]S2^OJ#[QZNK\=T_^,W]]-OU
M].MT,KY^H/%D<O-X_3"]_D:W-S]/)]/+^Y-^ ! VU\];I^?)Z? [3@=#NK(F
ME)XN32&+;0-]1+ .8[@*XWSXKL4+F??H<-"EX<%P](Z]PS4MA]'>X7?LW;B%
M,.IWP973I8DUWFI5B%1(IJ!;)[TT(3VP<_JJC#"Y$IKN\5"B:H.G?XYG/CC4
MW;]V490 C'8#X%[\XFN1R]-.S;[<L^R<_?C#X-/!\3OAC=;AC=ZS_O_*^KM.
M=X=T??-PF0WHQQ^.AH/!,?T/@-&YR)\6SC9(TW@FK1'90RF=J&435.YI:E J
M'X)=R(#':+=0$JZ0Y*H69AF1?#[VD*F95X423DG?C0"'!\?)8+P!6NOBRO;=
MA@&\W.N2H NIQ8MPDG+K:NM2.67*XU4.>E0N]+X/$#^:*5N7 C*31Y@HI#R9
M@\0\0SIK91:40[QB^2VDD>P:40$=09M)J[G<#R6$.4C#'Q?*2\B5[]'#CN@T
M!#Q;8:#:V843%:EDJ_Y]'ZX0 (J]"5;;A6W  ;O?9PG< K"$3#F'@M=+4F8%
MESL@VG(RE]Y#>:E8HAL0I<I)UJJ0KK)ZZ97/9HW6U@OZT!)Y=W%YOF)Q-_I-
M)^ US-&=EH3VEN8@H$%YD2BDL?O">XN^#,#\K%SCUT[&XU]6/E),V9](+:17
M"X-UP5)@6@G80RETA0!6Y*;R*2']U)@*>ZB16-%X3H"Q $GCZ17\C(Z&QY2+
M&A7EX0/&-DJ.2N%)ON:Z89[T,M,JQ[8'0W-GJ_CEH\$;YU58LMI<(^22)L(A
M;",(UB8EZEO33ZHMD)8@F% F2&>$1G90';8!4@5M0OCTC)TQ9@BQN+Q<50$J
MYF?U6X/:A[>IR42.ZBT@;S)%.\9]8P*'"+$SA7"(:6(+-4<M14%<<WP_67$,
M8?ZX/SKHTC?+"Z&H.6#1V&=B1^W;+?G],U4(SG)"N4,!(*@8'?XP-QP<(K*-
M0]T1$@'8_*>.R)#+=;@;/'$A97% 4&'54*D)XE<V*@7H*9H\((VFX+V 96'&
MJ49]4ZV%X;;KDA,JIA_95D&@BR1 SK3R)3]E>)P2S6-)DUJOE@Y,K^NX"R2@
MW_'GP(%2RU%)\787! :(Y\_(%[[@(G8BP18%!@;%6Q!//J"K9A\Q. 3D);'G
MR#%2/F91 C>89B+CV2;C()![')2C)6*>35BMAE-T+_<"^S1RD;SEPI<TQ\SG
M4Q6_^5HE)3*Q2DS$BU3FJN:P !892G:S[]E]X6K/+9=B(U=A\2]BDZ <UPUK
M08_NV5&VY?&O935O>!B)N#; UDYA6E4HL%C\8#I'B[=!>:&!%57G4;_IBI=C
M:LN?MI1KB\4,FHB+#>9V,-+E2]W$I!H(2_LE//R-/AWV/M/'46](1X/#WB']
M_:@WH%'OB'XME9;99F SJ15JW$?C;4EN] ?O3;Z9(Z.*M13MP2SLW ^MV5_$
MWMT@9\6YD:^!,-55::IC;B(*Y7T3A8-KE;&GNLO7\Q1KW'IT\NO1J;L3@5ZK
M$@1(%X@-DS#4K>W_^1PM!8/<+%B/O0Q E2VRV?(+?1CL10K$3&FVP$* 1I5H
M$EA$,+SCMO2L=%+"713<>>P^H"KD+*P QP>(/XF# 3V%TDVL43AWQ7XMN*V9
M3WQ[G'T8[@&W9PQO>U*L*8.S"PS)5_0J$QP[5BZPS2 PQ?PE3VE;X"^X(S#Y
M:S%KAPHDT@FS2.P=TX?#O;>.<7+1: &E7Q(J >\SV&K,6[<5+2Z':26D#2^)
M'PR-]HC+* 6YO6C%_9NG9)ZA1H,]NL&.BKL*+?F6_3<0R6U*YE\R^7X)]&@Z
MW^I@I!OPN.D!O^+C;&QD".^B+=:74AI>PDV!X0I%V<CN5K-4@AOU.9HH0 8(
M>\7I%_YXHH"T2ZAOG!$(FES+C?UFYY:RWE%C^BKQ)+<$-"\Y99@';+8A.BSS
MV$R2?/#>&['%'>4_M0T5%H486N60,7.B^#=.D>EU'#PJ/J>V2O\V8."\SIQD
M,4N12^S/ 8=ZIGK7B:._<>:LI%O$DW5,I@GI^+E^NCZ\C].9]>WS=/*_$FZA
M#,^D<RP]Z'W^V"&73M/I)M@ZGF!G-N \'"]+S*_2\0=X/[>8!]H;=K#^E\;9
M'U!+ P04    " #5.W1:OJ-<)<(:  ",3   &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6RM7%MOV\B2?N>O:.0<'"0 K4B*XTLR$T"QG1DO<H,OY^QB
ML0\4V9(XH4@-F[2C^?5;7U5WLRE13@YV7Q*+(JNKZ_I5=5&_/%;U-[/2NE'?
MUT5I?GVV:IK-FY<O3;K2Z\2,JHTNZ9M%5:^3AC[6RY=F4^LDXX?6Q<OI>'SR
M<IWDY;-WO_"UK_6[7ZJV*?)2?ZV5:=?KI-Z^UT7U^.NSR3-WX29?KAI<>/GN
METVRU+>ZN=]\K>G32T\ER]>Z-'E5JEHO?GTVF[QY?XS[^89_YOK1!'\K[&1>
M5=_PX3K[]=D8#.E"IPTH)/3?@[[010%"Q,:?EN8SOR0>#/]VU#_PWFDO\\3H
MBZKX5YXUJU^?G3U3F5XD;='<5(^_:[N?UZ"75H7A?]6CW'O\ZIE*6]-4:_LP
M<;#.2_D_^6[E$#QP-C[PP-0^,&6^92'F\C)IDG>_U-6CJG$W4<,?O%5^FIC+
M2RCEMJGIVYR>:][=WG_Z-+OY+_7E@[J]_NWS]8?KB]GG.S6[N/AR__GN^O-O
MZNN7C]<7UU>WO[QL:#T\]3*UM-\+[>D!VI.I^E25S<JHJS+369_ 2V+4<SMU
MW+Z?/DGQ4J<C]6H2J^EX>OP$O5=^]Z^8WJL#]&9I6K5EDY=+];4J\C371OWW
M;&Z:FJSE?X9V+/2.A^G!@]Z839+J7Y^1BQA=/^AG[_[QM\G)^.T3W!Y[;H^?
MHOY_U-63M(<Y__SE[BJ:JG_\[6PZF;Q5/[^^FD76RU6U4,U**Y,ORWR1ITG9
MD"=ZJ6^<U)/-ILAUIO*2;R<>-DF=L.-:"GAJO4G*+9Y+J]+0HUG2T#.+O$S*
M-$\*91JZ0"&C,6I1%11PS!OUM<[IRTVA3424+OR#('VWTM&/2='S19MIYF+P
M!J([F^NJ3$"P3C:Z;?+4J.N2K#4I,W[P0IAG69Z^->IQ10QNCZK'DI8U[=SD
M69[4)(I1-"L*6K/1M=TPA9V"%H640*Q.2I-P3#-JE3QH-=>Z5+K(*3SP)DB&
M:;C-D;HW&IN_,DU.@8P(8>,[,OX9.> F)(*\V5*<:E8]57HYJZ4N20RT/7RO
M-TVGU_LRQZ?;AKFH%M%LK6NR"O4<@IF.W]Z/;D?JM]GL*W^>O'U!D?_/-B>3
MI*A74IH *ZJIZ-,WK;3?$"23&#*ZC0BF625D:(L%!7]>F/9:U5@Z68-A;)AN
MUPT_&66Y28O*M+6VDL".L%!WCRKR9)X7></6*D0A*V>>/Q:?LX0=5MA\:OV@
MRU9'N$=_IXQK:)6LK2'8WC,;$E>5C:# /9,*?:R3C+7>6,U;V@_ML*P:!6,!
MN::*U2+):_60%"WOY3&IR< :YB2CQ1X2I,UP]S%S1&1KWAAM<E[5%,K :PV)
MU+I(A/B@Y1.@@-71W85.C-4=);KTVQ'R:Z9@]B0!L=WHDOBRE%IR@KHAI$'F
MEY?D:E 1699ITU6WXQBIOB6VR&@H-QNBUQ:TF9RLH5:+NEJ#F'G">D;J(C$K
M%@'^4%=D@20@UB(\Q^Z(=9Z3D(@ N>R*  "9?)'3W3#X!Z(OFA=7(9-M2*.-
MC8FUUFHMZ;&J210&,8$<>=/6Z8KE0+N>DV&! ]UQT--]!-P%B9"UD(F8G%8C
M1Z3(FQ>046")=$^3-RUO,*:E<I+9.MFR+1/,,F1WJ0ZL,JT>2,"9FH,.N08B
M$-&N'FC'?)7]&>[Z06=P]^A2.*"XYVZ_J&JR6PDQSL,_7%Y?..?N[86"F6'C
MA -0)"0"Q U=)\^$F01FY7BD#8)KPSX$PF+8)*,;$CX%%KH_8A4&GUF@G.%(
M;]AG ;JT <H9M=AD1O3(D2AM(26.U.V*O.^(;EI'UX%>@\NANMDL#,>8\#(Q
MR^)J"#R3@+;$0PI[8)?B;Q8B2$5AKDS#[]E 8?OLWA(ZG<+[]I!IL$/)W4C2
MW)#&R"#@EFE!)BX$@K0:+B)1#=: /[8<+9*4PV_&+&B$"5Y_AWAI=<">V%_(
M1$17)W3=IC$EU08B95__[CD$+9*7\=+MB9%4ECPD>9',"WU$&CLRY!?P&M,F
MDAH"5$>)ILR2.C/DLUFW=V>+LUMOBNK5=!RK4+L.]ESJ><.[1Q@@[[WM)/:%
MQ%!'-SK5Y)WSPE^I@RL./>CUIJBV&N&1Y,5L4 3-L%/'SM6-9R<&)F!;5!SE
M0HK@I<(Z5!"8E J:I-15:WKW(/]%T!^<*6VZ:$+6+I\1E&Q6+O5W$MRC+AY<
M2!JI&>N3 +=>SVDE![IY<?KC51S&=G)=$L_-18\%>OSO:C(Z4=/1A% 8PGZS
MC9P@-YS(>Y>UOPS&B515(]20^:25(3NG^$(7<U%A;KI@U!J7)X'<48<= =^J
MM6Y6%<F* ID/]KA;+]J"(@4" ,6I)1Y&6H@D*).@%DAY6YW4)(B/4 *!-0KI
M:ZSHLCE\8TT6FO^E[1+, (R6_G:@%?C!9SZ_\D(CYN,&^5MN9G5';/ A6\(-
M4B!E!\O4%3 "V4X+8(2PM4[^H'_)5/1C4HB)S'4#6LPMPR'2LK88I"<#;"5-
M-CFE<FRF3ST"]1(%<*$XV>B2G1@K $#FM1"PJ 5Y%";?UK6V, 7*"_"6@2B)
M9C(G$A6AWSA 1A+A"36VZU;^S@*EBT%W0-?E<@=#;2(G>UQR2D0XE]SA#(H
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MX< $DU;2V[,2&:E/#I%%7]VYYJR)I)X%_K)HD'4:Y%9;X;KC(K]%LJ9PA_O
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MB=(8T'HFA-X.S ;M"SSY'U!+ P04    " #5.W1:L^3P+30,   _(P  &0
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M)@$]5J8I*GNRWD=I=/:T*$EE!Y:ALF,1:26RN7A1B"MPHFX[INT:0"GF&5<
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M-F^]6YG],'S>L=' ;X]&N.@=^8-V#Q=];#[JUTQX4>6J]Q<Z-P*">OZ^8]W
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MVZ""R=:-1-JX>7O[:D:88OIQ#763Q5[K2\>GM^??SF__2=>_@*4G_$&DZ2X
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MD:N5P"A<+*AX@]W[%;NWW1B9A!E\[ P@;RQ3C@S4M I-JQ%7!FFHMLZ_EZ)
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M&<3 ?[9I6\C:VRZ+\N*CS7@D3EH(?"O,LVB=_OY;?[]W] ;2O1KIWEO27_7
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M#ZP_:/<&!RMM&5DF(*P/(J)ERX:9[E3PA:N<O#TJ\HSMD,]I;]@[.D>F4(B
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MA@V7"T<H/:C)H>PX4&0MMC/Y#?^,F1-4UR!#\<DAU283%:#@T;NXOZ49ZLM
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M@<\^F>8NU;PXO?'WEZ5VN WY88[KIS2\ -]76KO]"QOH+K37?P-02P,$%
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MTL:<M2HA2MV*ZHNW%;UWF14P7,"U265D(SIH%)M20^O-S;AQU=#F_4)B5P*
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MLA;6^\ WI?2D(LF W$Z=LFEX,Y'<@[#8.+QF-D]*$Y##+>;ML4T_I.^V/I$
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M)VC4/>L'H)O1TQA65;[=9\K2\/#;@J8U:A= YW.E[,9P"=KY/_X+4$L#!!0
M   ( -4[=%KK#X.+>0H  !X8   9    >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;)U9:V_CMA+]KE]!N-LB ;2.)+_W$<!)O-L4V22(DSYP<3_0,FVS*XDJ
M2<5Q?_T]0\J.G#K;]@(+1Q(YPWF<.3/2?E@K_=6LA+#L*<\*\[&ULK9\=W)B
MTI7(N6FK4A1862B=<XM;O3PQI19\[H3R["2)HOY)SF71.OW@GMWJTP^JLIDL
MQ*UFILISKC=G(E/KCZVXM7UP)Y<K2P].3C^4?"FFPCZ4MQIW)SLM<YF+PDA5
M,"T6'UOC^-U9E_:[#3]+L3:-:T:>S)3Z2C>7\X^MB P2F4@M:>#X\RC.19:1
M(ICQ1ZVSM3N2!)O76^V?G._P9<:-.%?9+W)N5Q];PQ:;BP6O,GNGUC^*VI\>
MZ4M59MPO6_N]G4Z+I96Q*J^%84$N"_^7/]5Q: @,HU<$DEH@<7;[@YR5%]SR
MTP]:K9FFW=!&%\Y5)PWC9$%)F5J-50DY>WIY?7[S9<+NQ[].IA].+#32\Y.T
MEC[STLDKTG'"OJC"K@R;%',QWU=P E-V]B1;>\Z2;VJ\$&F;=>*0)5'2_8:^
MSLZ_CM/7><V_(E6Y8/?\B5U(DV;*5%JP_XQGQFH@XK^'?/8:NX<U4I6\,R5/
MQ<<6RL (_2A:IS]\%_>C]]^PM[NSM_LM[7^;CV]*'[;M^N9^$L1=]L-WPR2.
MW[/F$<S')["(CWA"I1O!YG*Q$-JPA58YLRO!C.6VLDIO&,]555@L*<T$3U=,
M+=R.A<I0W;)8LHW@$#V2!9ZKRO!B;H[?L>GYCY.+AZM)</.I<3R;_'H[N9Y.
M LHU);P3H-*<0E+#!&&* 1$BGPE-J&CLK!,+PX5AW+*']K3=L%1S*]@;=A1W
MPLZPRX[==1QV!B-V'$PMK4(T9 5X#TXLQ%QHGK&9*,1"6G;4IXWL*.DFV'^'
M4'(-=^$.2OX15%:"F"Q+M9C3[CCL=7JT/P[CS@ 2%P(AQ"*SNA*L*@T;AE$G
M\3E(W@<_\ZSBGI8H<KQ(!>N%W7B(??WA(#A?\6(I&,*XX%*S1VP79.>::\UQ
M<";Y3&;22C@?]T8L";N]?C!Y*J4[%-D$T@U%!A9[*PTVQ7&?P=:H$]P*4%I!
M/OAT"UB O,4)K&=QG 3WRB(>35R\V5K?N-KZ&=1Y0&V56CU*2MRBSJ45>:DT
M&'_OJ)FP:R$*#Q]9( (2YVF!K9: 1%3KS7<Z8(=_4B/N7.4E+S;.CL%[;(2W
MU@2TOQ&;-KM_U0"[ FJ6: E,2WAG%9%YG32<YA6R%PK9&N)8JQ'_.M(9D'XQ
M^32YNYM<.*R/I]/)_92-KR_8U>7X[/+J\OYR,OV_H']QP,ZCAI''[X)K@G4)
M2+M8$A98"NALD!- :&Z0PB$0">2\80- ;C0,/@/ZK@0J U8A 0_N?;E^&$41
MZX:#7E*7T3.Z!L/(_P:WF@ZWFY")/RKI:X4BN51JOI99!A!&40(3!E"BTJ\N
MMP JD@JH^<( I/L=0#$<#:G:+0I"SC*Q=;C?CUD_[@7C--45SU &T8!UNB@=
M7DI 5_X)A?JUP@4M)/TNBFW8[00W"+MF@XCAH,^:8G4("7'<#;L1ZB<:PJ3A
MP1(^VFXB*O#[0 :4C*9&80[6TM@$ '<SYZX)ADV\,U168>5"0A.?_X[Y@-PQ
M<#1#+N8H/HG92F8;PC/):9&J92&=G=!^R#&J4T-9>.NR$#2ST(95C%,<,>7L
M6[)"%:RUM%:0Y@4AJATQ^!H\ ^^*@DFQ]R$^WX/2/_)WQ>?0W(W[;:0;^J</
M7[Z,[WZC1G(]N6<WMY.[\?WE]6=V=3/UU?5Y<HUG5^SL87IY/<'#<Y3@Y3T[
M']_=_?;IYNZ7\=W%]$6!U-BG&NOAN 1](L+?>)C0HSX;A&CO;.#N!FP4C@;X
M[=#=$!4Q' (5W9AN1]@ZBH:$)# /IN2%A6O]7MCO=HG@DU'PAHV@H$OG^&*Z
M*8)=$)*$@A /?! (&4GTGH:7\ZHFHY_4#*%+K5M#-U\C#48N"^14%DAZQM<U
MZT$*$RY&5Y>J_38MP(,I-*JB&>UWP5%\S,IM:P"* )7*DZ6@J5/F58XJU42G
MEMK3M@?[?NLFAD[O>P)?$G]?GT(4ZWH!MOGQ8":6LBC(#A^?%QB ^\%1<NSK
MRC3H.XZB[^MV1,*D- 7-X-7CF;4:O%W6+,3*#",1Q8?12"11J/[<J2AM'?>!
M.WCHY&84-<%^XD6%4P./RT[(CCK'Z""F-NOZYLISXXRG7^%39;<&;QN?!(FC
MM4DBR0;R?0M3Z#E0@1I:22*HLLRHOU &Z\Z-MD1>4H/A3\$_BYQS )9VC]&U
M<J)E,G-.6:1R;DQNOLW\45&3]U21(7S05#=8_LAEQHEPG>WJD99T,$0&L(.3
M327?"+WKP!@XW^X=1EN< @\30J4T?^MH#1$T0'I&K*4/^!H02APY':(0ET6?
MLY>,E:HBS2IJKJ[_H[_!IIS2G<FO@G@3DQ<KE/7K37'7N&@%94WMA1:#[< (
M,RC:A_AU7KGI@I81 #>=8K=W'BZDJ"?R-=MX:XL7W6*K9L511S,:F195YDK3
MS??S-F;X@#LMK@>MI5T!V3X%G6&R32A:J- %TGV'/EA4Y-?<S93Q:-@/::;A
MN1L[<,W2W?Q)#1PEI-9@2+.2)4DL$0'*B(M5#XB@,R6LP!,MQ%N'+92>5/.Z
M=1A2Q>E?08ASV/3-<Y^!GN<Y-\RX-E99Z<*]1?/^0)(Z6]#=*TV H9Q0T/SI
MA$I)U>@1_NS5SAW/E4V$4(:I!6:"U/+&WJT\1Q0W!K@I*VTJ&L>AOQ'Q-CL3
M*:\,+'FA&Y50N;RF55ZA8Q,U%G\9U00Q.J62?DK2&A*U-*I#"_K>0F(%G2V>
M>(X1VIT_V_A7H>T;#4HA,/8%6_,*!*3K$?E?].$.^C#&M@CS4[M#D0NVZSP%
M3LBS+SS5ZGPE<HCZ/E%G^8L;Q)(>:8]&H:O1J4*GL9S=KCAZ3BJ0ZA2S7$BO
MI6T2JCD8 R=)#1%99;=OG2#0]/D($[C1G.+W-N=?79/#I.2&]KJ0K<P=X)VM
M1KXRWQS,QW:^<D BZF[H '_P#2J3F6KV.U 08--?<&X. PWG4(<FH&$&J^8;
M_QZ"XD)"4<LKX08G0-A3$KD(X)F*6D9#?9OMQM%@O!M'QS;XI]Q(>*)&ZBPA
M@G'OG"_G6]R\QG)^@J?=399[QGFP);S[PY1*_-6$:$VLCCCVWQ$=FOW86R'#
M64WBNZA]D]J#UZE]Z89 2WE<+&0JZ3UAOX51<AKD_QR'9FFY<! I-ZKH0"P#
MR$ 7!0TEBZZH%<8K' ]#W[!>&R\G[0%[*.H!'F\S <V!9]NP_(O<4NT6:MLP
M_ Q0-13OQ;N]7]902*<!VD;.)5IU_99?8]T5!&+D?*LS]4 3#VJ;TO0BWPZZ
M.\&7/.4SVV0S$Y"M\"ARZS7IA[6?\6C_*1PL_;R9;=KL1[5&H]/AX8)^X0.O
MZ%77]:C-CF?IWDUG@:_YAFC=DW H\$3=#Z;[B67W"@_T@V(QKK79H>^")XUO
MMKG02_=EFN838-I_OMT]W7W\'OMOOL_;_9=S,"N.,1C@%A"-VH->BVG_-=K?
M6%6Z+\ S9:W*W>5*<,2=-F!]H93=WM !N_\2./T?4$L#!!0    ( -4[=%HF
MVL%&"0,  -$&   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)55W6_:
M,!!_YZ\XI5*?*@*!=E4+2'QMJS1HU;+U8=J#DQR)U=C.;*>4_?4[.Y RB2+M
M);&=^WV<[;L,-DJ_F!S1PILHI!D&N;7E31B:)$?!3%N5*.G+6FG!+$UU%II2
M(TL]2!1AU.E<A8)Q&8P&?NU!CP:JL@67^*#!5$(PO9U@H3;#H!OL%QYYEENW
M$(X&)<OP">WW\D'3+&Q84BY0&JXD:%P/@W'W9M)W\3[@!\>-.1B#RR16ZL5-
M[M)AT'&&L,#$.@9&KU><8E$X(K+Q>\<9-)(.>#C>LW_VN5,N,3,X5<4S3VT^
M#*X#2''-JL(^JLU7W.5SZ?@251C_A$T=>QD%D%3&*K$#DP/!9?UF;[M]. !<
M=SX 1#M Y'W70M[EC%DV&FBU >VBB<T-?*H>3>:X=(?R9#5]Y82SH^G]8G&W
M6LR7JR<8+V<PO5^N[I9?YLOIW?QI$%J2<(%ALJ.;U'31!W3="!9*VMS 7*:8
M_DL0DK?&8+0W.(E.,LXP:4.O>P%1)^J?X.LU"?<\7^^CA)40W-*UL@:83&%*
M=KG,4"8<#<RX20IE*HWP<QP;J^G6_#JV#;5(_[B(JZ0;4[($AP&5BD']BL'H
M_*Q[U;D]D4*_2:%_BOW_S^PDW7&SR_O5O-6]A/.SZZC;O863FO"-6YXQ7V:K
M'%NTQR636RK:1&62_Z&-95!P%O."VRU0*Z%YTFS\%C8Y2N 6N(%2JYC%!8+-
MF3T Y<Q C"Y,)I76F/K3\T";(S"A*FE!K8&.ST#"9"M&,L",DD2W!3264Q%C
MVH9G!V*@&:D[1".YAY+0>_R%Y]^GQ))$5Y2/6Q/*.(<O2/3O^J9*<L]TX1RV
M^&YE%T 92F6I;UC45,Y.U@O(CU6XY*(2CMI-C[MNP]BX1:H6%#'JIF+\+M&@
M=]$B-%WK#7,.R'9S8BRCWDV9'!AHP[%K&AZT&8$Z\\V4-LPE5G><9K7IU^.Z
M3;V'U\U^P71&HE#@FJ"=]J?+ '3=0.N)5:5O6K&RU +],*=_#FH70-_72MG]
MQ DT?['17U!+ P04    " #5.W1:2 S>A]X'  # $@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6R56&U/Y#@2_IY?8?6.1B"%[D[ZE>%%8IAF%FF!
M$;!W)YWN@SMQ=RR2.&L[,.ROOZ?L)!-V&YB51HS;J2I7/57UE)/C)Z4?3":$
M9=^+O#0G@\S:ZM-H9)),%-P,525*/-DH77"+GWH[,I46/'5*13Z*Q^/YJ."R
M')P>N[UO^O18U3:7I?BFF:F+@NOGSR)73R>#:-!NW,IM9FEC='I<\:VX$_;W
MZIO&KU%G)96%*(U4)=-B<S(XBSY]GI*\$_B7%$^FMV84R5JI!_IQF9X,QN20
MR$5BR0+'?X_B7.0Y&8(;?S0V!]V1I-A?M]8O7.R(9<V-.%?YOV5JLY/!<L!2
ML>%U;F_5TZ^BB6=&]A*5&_>7/7G9^'# DMI8533*\*"0I?^??V]PZ"DLQZ\H
MQ(U"[/SV!SDOOW#+3X^U>F*:I&&-%BY4IPWG9$E)N;,:3R7T[.G=ZNO5ZOJ>
M75Y?W-Q>G=U?WEP?CRP,T^-1TACY[(W$KQB)8G:E2IL9MBI3D;XT,()'G5MQ
MZ];G^$V+7T0R9),H9/$XGKYA;]*%.7'V)J^%*;:H),MN1:6TE>66_?=L;:Q&
M4?QO5[S>VG2W-6J43Z;BB3@9H!.,T(]B</KQEV@^/GK#UVGGZ_0MZS^;DC>-
M[';Q^N9^%41S]O&791Q%1VS'2>RF$IH30H'QF!G&M:!"QPDIXX8EJJA4Z9ZH
M#>,EPU+H2DLC&%^C\=E3)I.,&5%QF(*N-(D66,C2LPBUHX3=1RYSOLX%PS83
MCSRO_;/U,[.98.>9%)L?#C$4A71D<,4?A&9[%$8\/CJ_^7+EEM'1?LA@*6WE
M"OY >ENMZBK$Z>Y)2EL94F(5XWFN$G(1$*E:)\*0%#=&&$-B.-IY7"9BR.[)
M)<3.RV?G?9  =)GP_,!8\!=;2U5E'-*)J"WM.Z1(.A6/8+^*+";@'V"6LJTH
M!46I>25Q+"&0RXTXL!FXU8J2A &< .,8IY !>L .5ZF$'6Q-AH9!SS67V\61
M800+^4E()@Y)\5TD-9$@\K:1B= NIH GB:I+AW"E<IF0.TBLTWLOPL8#5R*D
M8'@AJ$9LI@P5#1(OUR@;H.H>>^HG\T9N2PDO.&EW'@2M!PW<%(-/!YSJ9</A
M]8\\).I. 2 K,>ER94S8E"D@\I#ZQS :)*HT\"/EM ?#5A1MN2M?C1!P2:$,
M:Y'1D *L9-9W2$^_/<]'5""AM18.@18[! ?C[_FQYKF+W,]JPEA95V,]&6]J
MR%;?,;13:7&2+RV>XI?S&E6?JW)[D,/A5J&#HDSR.A6L0BMDKO#4)J@TQ6R?
M7;SBCUI6Y'7H4MXH^/R^Y@[">L0PI1">>]6HNK[N]ROZFLXAXSTT J?V>E82
M;C*VP06#4%8!B82>0IH.I.8IE75=I[UOV$5H:9U8<E"4]5]:7 ##Q#K <#(<
MK06M$7*M7U0O"99MEW91!91S; )9=*JT2+=X("RV=<ZM0A/P"N>#]%R"JC\/
M0 U#=F8"4R=9XSV5?TU6?(!*"RPL*U0J<K.+T&3Y*" @2ZS_27L,V1U.?7E,
MT!SC<]&D$'8I2UW.3$/Y#9.2*S^XU&6R(U/R!T=)^WR .X[H%0 T<(GR\B\H
M]UI8AR,U1VV:XU4I@1];U^D6C? HM*D-W>YJA--8&M)]A*3(NA>$\D[1%Z;?
MCBSH(@O_$E:?F1KJ[+J[=-V!K("RI<E(!8+(!CWNV)J(!%7DJ 76J45Q$[39
MSLQ[WO8S8$WWZH98Y9_"\_V.\F0TY[9 1+1%J//GO[6FJ[B66Y\%UP8IHP;'
M[!7%&MW97LI"%QE6DT_L[OS7U9???UL%-Q?L[O+K]>7%Y?D9[A6K_WQ;7=^M
MV/G9_>KKS>WEZBX@5:<57/1.V7%(3_(WS"J*P/47C<RV80W[X.\R\1%6DW V
M'@>WN.QPT)>3;@:O2T2BC#7!'5C48?"1%]41#.6.#=Q#%LW"R73&HBB<+";!
MM2H/'/JXA"</!WZ ]//$HG VC_!WO)P'-XUC;YW.]O@^BQ;A=#9ET3*<3^+@
MWK'F.VJ3:3B9CPF5\6$4?'4<YF\1/,4[@:2+K)OK/Q'C!Q:-PT5\B,4\/)S&
M/Q'F+!S/%X!WOHR#;UH<X&$A="+A X:?N^21F+<_#9?1$IC$\;3!9/N.OVQO
MO<\.PWBR8(LPFLT;3-Y5^\#BPW YBRBDPW \;L]K.T]B0,!XLL_VIHL%VX?U
MV2'2VLQCJ.W-)^%B,L4CK&?3,%HNV7Y 27*6@E?3TE%^,P!#D(R_!-&0R64A
MK6<47&_1FU652R(-H-42\NY,AQUA,ZN!;]#L@C#J#?&6(S12?;F#E<Q!K)T5
M!Q X2B%+Y(JCDAVS![*I(+>DSR'^]5VFHX*=1[EX_ VH)!X%TQRTA=:B,PPH
MLQ[*-[+9@8E7""*Q_-D9A8"[<+FKZM\BK&JP:=+<$=S%NAG;+ZJ=(%<;(FI5
M LV-P"E[8K@=ABP76[C3GKW?(Y?6U1_SJ?.0LNN$GNAEIW_[>;=4 $;2@O&R
M0ALSH&7US'./K*17*C_)$9CH;33VD..,EUMR MA(S>CMR0V?)ZXU;P9/*K1\
M]"CGDJ^;Q+FL^EB]^2';]=HZZGU50+]OW;<3FE2XJOL/#-UN]WGFS'^5^"'N
MO^U<<;V5F*BYV$!U/%S,!DS[[R7^AU65^T:Q5M:JPBTSP>$^">#Y1BG;_J #
MNH]6I_\'4$L#!!0    ( -4[=%I&^,U#G@(  )$%   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;(V474_;,!2&[_D51T'BJFH^^D&!-A*%3MLD&*/
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M\O;E,3$SHTE!O0L2.!.5804MVIM*YE*#76NXT>-/W$R&C]S\;O)DQ&B6H:=
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M[GYP)0?7#U/@#.2#<_LPG5W,QM,)N/O^/'9FD_'WF0.^CHC GL^_@0OPY(S
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M3NOLF78 LPODV@WD6$ZSPKS_<7.W;&[* &11<+(H. F>NP=OS&1=,/'20.,
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M[*0O\ED68^U/-C,Z6\_(V#.C"S[YQ$S] S,TPZHX_/SXPTWY\'X>VVV C6V
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MHW;(#%7-]IL!2,_ 2:^N&?#-']ZI\OEL@P,-X$"C6QQHD'(@E9H</.!  ^=
M53-0\1^!D#QCX#\#Y[^ZCL)W5GBGRHNBC>R? 9QIN-UR%"FH4JG)P0-0-?!<
MI*JCJ/*/!$+RC($N#9PN)4==\'F2A8(-)Y-D$0O<-*1)2"HU^:H68*O9K2RD
M20JT5&IR\ !H33P+J6@:LR+[J&L[%P/;X$P3.-/$.?,H6S38T>#=*R^ 5JX)
MERX*F]UR#RD!4ZG)P0,"-O$+U*KNV;W<7.6>-L#4!# U<3!M[AY\"X1WK[P
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M$*B-$VCNK=^3)4_C8K[L/$GG21H47]%;+Y[A"X\GQ<HY<FN#]Z:\)MI(N-J
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MC_.7&T:73&0#U/LKSN731E;@M/9Z\C]02P,$%     @ U3MT6M9(I&'O P
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MYUKA>=77JD"RTK2&!9.JT9AAIGX%P'6"6E\R)@^![C;-SR7Z!U!+ P04
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M^C3-BTM]WT%A&NC_<\[5:\4<J<4-*O@+4$L#!!0    ( -4[=%K\A48PA0(
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MO## J0<XEP[HUP/ZQP/Z+PP8U ,&QP.&+PP8U@.&EV[2J!XPNG2&<3U@?.F
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M5(M1+4$U@6H2U5)4RU!-H5I.:7J4.DV47M1H>?D8W#R^<V*B7194\U#-1[4
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M6HAJ$:K%J):@FD UB6HIJF6HIE MIS0]2IL6TOBU6DACM(6$:BZJ>:CFHUJ
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M!#N$1@/$Y[,PY-N3:()L5WGT'U!+ P04    " #5.W1:J?.C+YX'  #L0P
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M9Q'29A%"VBRB#JQ]'T0?+$($BQ!@%B%M%IE,L$V:)H&R")2:;))@$?*#6.1
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M:WO5!Y=0P244F$MHYXU:38M J01*3;9(4 GMCTH.2-/MK2!EH8/L_64.*)-
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M7#=0WR\9DR\GNH/B'8_!?U!+ P04    " #5.W1:EP]#OL@&  #K10  &0
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MX0P$SGM.OW$U[)AX&_ EP;7<:8-1,N7\T72N9SW',X0PQ5@9!*+_5CC$-#5
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MV4U*MD07:FJ)L/%K;[Y\@?H,+5)8BQ,4,^CY:415GI,,A7B!1)HDH>8#6Q:
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MG0N^Q2%,#;FL<& [,/Q??[$]Z_<NJ73" DVPEHR#6L9!']U?<)'(104B)*C
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MIAK(YVM*Q=.%ZJ"N1/L_ %!+ P04    " #5.W1:PUOU)SD#  #N$P  #0
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" #5.W1:\,WU_B4&   Z,0  #P   'AL+W=O<FMB;V]K+GAM;,6;WW.:2A2
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MOXFSC5^RYJ5]K- PFR>(=O=9YLA]7KXHXNWAT?_#ORU\^@]02P,$%     @
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MA2)KA2)KA2)KA2)KA2)K]96RWCFW_\_QT[/L;3N\Y+/IG[7K/U!+ 0(4 Q0
M   ( -4[=%I&QTU(E0   ,T    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ U3MT6HADWA7Q    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( -4[=%JM&63/WP(  -L)   8
M  " @9,6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #5
M.W1:LT8,+%8%  ":%   &               @(&H&0  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ U3MT6F7M\"9H!P  9C(  !@
M         ("!-!\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( -4[=%H_R?[ WP@  $,K   8              " @=(F  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #5.W1:B %\F5<"  "L!0
M&               @('G+P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ U3MT6CB[/OU[ @  ! <  !@              ("!=#(  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -4[=%J?8<1%KPD
M .HB   8              " @24U  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " #5.W1:4:N5)Y<'  #>$   &0              @($*
M/P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -4[=%J^
MHUPEPAH  (Q,   9              " @=A&  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ U3MT6CO#3OR7!   \@H  !D
M     ("!T6$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -4[=%JVT#%,308  %$/   9              "
M@<E]  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ U3MT
M6D,I]#/U!P  PQ,  !D              ("!380  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " #5.W1:[<)?,9<&  #<#@  &0
M        @(%YC   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( -4[=%KZ2$L]A D  &P8   9              " @4>3  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ U3MT6CCZ-4&7"@  C2,
M !D              ("! IT  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " #5.W1:=!7^_\\"   +!@  &0              @('0IP
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -4[=%KK#X.+
M>0H  !X8   9              " @=:J  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ U3MT6B;:P48) P  T08  !D
M ("!AK4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #5
M.W1:2 S>A]X'  # $@  &0              @('&N   >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -4[=%I&^,U#G@(  )$%   9
M          " @=O   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#
M%     @ U3MT6M7'2/]J'   [E@  !D              ("!L,,  'AL+W=O
M<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #5.W1:RLP/[#8#  #X
M!@  &0              @(%1X   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;%!+ 0(4 Q0    ( -4[=%JY/ZH>8@,  "X(   9              " @;[C
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ U3MT6O@'
M+JAR P  *0<  !D              ("!5^<  'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6Q02P$"% ,4    " #5.W1:C9RAG)@&  !H%   &0
M    @($ ZP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M -4[=%J7NJ5'LP(  .$%   9              " @<_Q  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ U3MT6H6%D;U2!   \@L  !D
M             ("!N?0  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " #5.W1:.\/W5VX#   *"   &0              @(%"^0  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -4[=%J3)@;NNP4
M )H0   9              " @>?\  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ U3MT6H_]-Z:+!0  H P  !D              ("!
MV0(! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #5.W1:
MXGKC NX$    "P  &0              @(&;" $ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( -4[=%HLNN6+3P,  'X(   9
M      " @< - 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ U3MT6CGM7HOI P  1A$  !D              ("!1A$! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #5.W1:;0KG9(@+  #6L@
M&0              @(%F%0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( -4[=%JJ;Z#^F 0  ,,6   9              " @24A 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ U3MT6O^S&J)_
M @  S 4  !D              ("!]"4! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " #5.W1:M%?['[$$  !A&0  &0
M@(&J* $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( -4[
M=%J+P\&8EP(  &4&   9              " @9(M 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ U3MT6N^7L>D""@  <&P  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( -4[=%JR_A!2@P,  $@+   9
M  " @4U* 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MU3MT6FP[Y$G\!0  AST  !D              ("!!TX! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " #5.W1:UDBD8>\#   A#P  &0
M            @($Z5 $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( -4[=%J^3AH3C (  &@&   9              " @6!8 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ U3MT6J!G_R1\ @
M;@8  !D              ("!(UL! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " #5.W1:RY2#E<4"  ",!P  &0              @('6
M70$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( -4[=%IW
M;I&7) ,  #4+   9              " @=)@ 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ U3MT6D]EPP Y @  HP0  !D
M     ("!+60! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -4[=%J]KDH0$AL  .\! @ 9              "
M@59[ 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ U3MT
M6MUJ(HU( P  Q@L  !D              ("!GY8! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " #5.W1:-,0,]4H%  !A'@  &0
M        @($>F@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( -4[=%JI\Z,OG@<  .Q#   9              " @9^? 0!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ U3MT6L><^:>^ P  S@P
M !D              ("!=*<! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    " #5.W1:ZY'1RC8%  #O(0  &0              @(%IJP$
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( -4[=%J7#T.^
MR 8  .M%   9              " @=:P 0!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ U3MT6L1*?Z(; P  ,0H  !D
M ("!U;<! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " #5
M.W1:0AX*%<,#  !U"P  &0              @($GNP$ >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( -4[=%K:Z"TGUP,  ((,   9
M          " @2&_ 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#
M%     @ U3MT6LL(K$9I!   6!P  !D              ("!+\,! 'AL+W=O
M<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #5.W1:> J;*/8#  #P
M$   &0              @('/QP$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM
M;%!+ 0(4 Q0    ( -4[=%IO!D_Z% 8  *D8   9              " @?S+
M 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ U3MT6EA\
M,5#V P  E18  !D              ("!1](! 'AL+W=O<FMS:&5E=',O<VAE
M970W-2YX;6Q02P$"% ,4    " #5.W1:PUOU)SD#  #N$P  #0
M    @ %TU@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -4[=%J7BKL<P
M !,"   +              "  =C9 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M -4[=%KPS?7^)08  #HQ   /              "  <': 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #5.W1:9_Q20DP"  !H+   &@
M@ $3X0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #5
M.W1:AJ9C2 P"  !A*P  $P              @ &7XP$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     4P!3 +P6  #4Y0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>263</ContextCount>
  <ElementCount>394</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - SHORT-TERM INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Short-termInvestments</Role>
      <ShortName>SHORT-TERM INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - SETTLEMENT LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SettlementLiability</Role>
      <ShortName>SETTLEMENT LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Equity</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - LICENSE/SUPPLIER AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LicensesupplierAgreements</Role>
      <ShortName>LICENSE/SUPPLIER AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - 401(k) PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/KPlan</Role>
      <ShortName>401(k) PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - SHORT-TERM INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Short-termInvestmentsTables</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Short-termInvestments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/PropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/AccruedExpenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Debt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Stock-basedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/SegmentInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails</Role>
      <ShortName>SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Short-termInvestmentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails</Role>
      <ShortName>SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - SETTLEMENT LIABILITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative</Role>
      <ShortName>SETTLEMENT LIABILITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/SettlementLiability</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - SUMMARY OF OPERATING LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>SUMMARY OF OPERATING LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails</Role>
      <ShortName>SCHEDULE OF COMPONENTS OF LEASE COST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails</Role>
      <ShortName>SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/LeasesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails</Role>
      <ShortName>SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails</Role>
      <ShortName>SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/DebtTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/EquityDetailsNarrative</Role>
      <ShortName>EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Equity</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails</Role>
      <ShortName>SCHEDULE OF STOCK BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - LICENSE/SUPPLIER AGREEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative</Role>
      <ShortName>LICENSE/SUPPLIER AGREEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/LicensesupplierAgreements</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - 401(k) PLAN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/KPlanDetailsNarrative</Role>
      <ShortName>401(k) PLAN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/KPlan</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAX EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999076 - Disclosure - SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails</Role>
      <ShortName>SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999077 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999078 - Disclosure -  SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails</Role>
      <ShortName> SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999079 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/SubsequentEvents</ParentRole>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abeo-20241231.xsd</File>
    <File>abeo-20241231_cal.xml</File>
    <File>abeo-20241231_def.xml</File>
    <File>abeo-20241231_lab.xml</File>
    <File>abeo-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="849">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "ABEO",
   "nsuri": "http://abeonatherapeutics.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "abeo-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "abeo-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abeo-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abeo-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abeo-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 346,
   "keyCustom": 48,
   "axisStandard": 29,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 57,
   "hidden": {
    "total": 130,
    "http://fasb.org/us-gaap/2024": 110,
    "http://abeonatherapeutics.com/20241231": 17,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 263,
   "entityCount": 1,
   "segmentCount": 97,
   "elementCount": 721,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 849,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 10,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://abeonatherapeutics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://abeonatherapeutics.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31_custom_DonWuchterlMember",
      "name": "ecd:TrdArrIndName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31_custom_DonWuchterlMember",
      "name": "ecd:TrdArrIndName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies",
     "longName": "999014 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://abeonatherapeutics.com/role/Short-termInvestments",
     "longName": "999016 - Disclosure - SHORT-TERM INVESTMENTS",
     "shortName": "SHORT-TERM INVESTMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://abeonatherapeutics.com/role/PropertyAndEquipment",
     "longName": "999017 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://abeonatherapeutics.com/role/FairValueMeasurements",
     "longName": "999018 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://abeonatherapeutics.com/role/SettlementLiability",
     "longName": "999019 - Disclosure - SETTLEMENT LIABILITY",
     "shortName": "SETTLEMENT LIABILITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://abeonatherapeutics.com/role/AccruedExpenses",
     "longName": "999020 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://abeonatherapeutics.com/role/Leases",
     "longName": "999021 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://abeonatherapeutics.com/role/Debt",
     "longName": "999022 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://abeonatherapeutics.com/role/Equity",
     "longName": "999023 - Disclosure - EQUITY",
     "shortName": "EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://abeonatherapeutics.com/role/Stock-basedCompensation",
     "longName": "999024 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://abeonatherapeutics.com/role/LicensesupplierAgreements",
     "longName": "999025 - Disclosure - LICENSE/SUPPLIER AGREEMENTS",
     "shortName": "LICENSE/SUPPLIER AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://abeonatherapeutics.com/role/KPlan",
     "longName": "999026 - Disclosure - 401(k) PLAN",
     "shortName": "401(k) PLAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://abeonatherapeutics.com/role/IncomeTaxes",
     "longName": "999027 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://abeonatherapeutics.com/role/CommitmentsAndContingencies",
     "longName": "999028 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://abeonatherapeutics.com/role/SegmentInformation",
     "longName": "999029 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://abeonatherapeutics.com/role/SubsequentEvents",
     "longName": "999030 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://abeonatherapeutics.com/role/Short-termInvestmentsTables",
     "longName": "999033 - Disclosure - SHORT-TERM INVESTMENTS (Tables)",
     "shortName": "SHORT-TERM INVESTMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://abeonatherapeutics.com/role/PropertyAndEquipmentTables",
     "longName": "999034 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://abeonatherapeutics.com/role/FairValueMeasurementsTables",
     "longName": "999035 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://abeonatherapeutics.com/role/AccruedExpensesTables",
     "longName": "999036 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://abeonatherapeutics.com/role/LeasesTables",
     "longName": "999037 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ABEO:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ABEO:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://abeonatherapeutics.com/role/DebtTables",
     "longName": "999038 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
     "longName": "999039 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://abeonatherapeutics.com/role/IncomeTaxesTables",
     "longName": "999040 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://abeonatherapeutics.com/role/SegmentInformationTables",
     "longName": "999041 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999042 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "999043 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)",
     "shortName": "SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails",
     "longName": "999045 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details)",
     "shortName": "SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative",
     "longName": "999046 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)",
     "shortName": "SHORT-TERM INVESTMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999047 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999048 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails",
     "longName": "999049 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
     "longName": "999050 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details)",
     "shortName": "SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ABEO:ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ABEO:ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical",
     "longName": "999051 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF OUTSTANDING WARRANT LIABILITIES (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2022-11-03",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "ABEO:WarrantsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember",
      "name": "ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ABEO:ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails",
     "longName": "999052 - Disclosure - SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "ABEO:WarrantLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ABEO:WarrantLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ABEO:ScheduleOfActivityWarrantyLiabilityTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)",
     "shortName": "SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails",
     "longName": "999054 - Disclosure - SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ABEO:FairValueOfDerivativesIssued",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ABEO:FairValueOfDerivativesIssued",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
     "longName": "999055 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DebtInstrumentFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DebtInstrumentFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative",
     "longName": "999056 - Disclosure - SETTLEMENT LIABILITY (Details Narrative)",
     "shortName": "SETTLEMENT LIABILITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-11-12_custom_REGENXBIOMember",
      "name": "us-gaap:SettlementLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails",
     "longName": "999057 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails",
     "longName": "999058 - Disclosure - SUMMARY OF OPERATING LEASE LIABILITIES (Details)",
     "shortName": "SUMMARY OF OPERATING LEASE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)",
     "shortName": "SCHEDULE OF COMPONENTS OF LEASE COST (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "longName": "999060 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)",
     "shortName": "SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails",
     "longName": "999061 - Disclosure - SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)",
     "shortName": "SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ABEO:FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ABEO:ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ABEO:FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ABEO:ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://abeonatherapeutics.com/role/LeasesDetailsNarrative",
     "longName": "999062 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePaymentsUse",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePaymentsUse",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails",
     "longName": "999063 - Disclosure - SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details)",
     "shortName": "SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ABEO:AccretedFinalPaymentFee",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails",
     "longName": "999064 - Disclosure - SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details)",
     "shortName": "SCHEDULE OF FUTURE PAYMENT OBLIGATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
     "longName": "999065 - Disclosure - DEBT (Details Narrative)",
     "shortName": "DEBT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-08_custom_LoanAndSecurityAgreementMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
     "longName": "999066 - Disclosure - EQUITY (Details Narrative)",
     "shortName": "EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-12-202021-12-21",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
     "longName": "999067 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)",
     "shortName": "SCHEDULE OF STOCK BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999068 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
     "longName": "999069 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details)",
     "shortName": "SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails",
     "longName": "999070 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999071 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
     "longName": "999072 - Disclosure - LICENSE/SUPPLIER AGREEMENTS (Details Narrative)",
     "shortName": "LICENSE/SUPPLIER AGREEMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2020-08-012020-08-31_custom_SublicenseAndInventoryPurchaseAgreementsMember",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://abeonatherapeutics.com/role/KPlanDetailsNarrative",
     "longName": "999073 - Disclosure - 401(k) PLAN (Details Narrative)",
     "shortName": "401(k) PLAN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails",
     "longName": "999074 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (Details)",
     "shortName": "SCHEDULE OF INCOME TAX EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999075 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails",
     "longName": "999076 - Disclosure - SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)",
     "shortName": "SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TaxYearTwoThousandTwentyFiveMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999077 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
     "longName": "999078 - Disclosure -  SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)",
     "shortName": " SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ABEO:OtherSegments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999079 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ABEO_ATMAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ATMAgreementMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A T M Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r70",
      "r1071"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r848"
     ]
    },
    "ABEO_AccretedFinalPaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "AccretedFinalPaymentFee",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accreted final payment fee",
        "documentation": "Accreted final payment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion and interest on short-term investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued employee compensation",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued contracted services and other",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r145",
      "r690"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r80",
      "r151",
      "r685",
      "r714",
      "r715"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r22",
      "r565",
      "r568",
      "r633",
      "r710",
      "r711",
      "r993",
      "r994",
      "r995",
      "r1003",
      "r1004",
      "r1005",
      "r1007"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r848",
      "r1146"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r1003",
      "r1004",
      "r1005",
      "r1007",
      "r1081",
      "r1147"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r482"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital stock reduction",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r105"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of derivative liability",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r46",
      "r105"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r906",
      "r920",
      "r946"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r909",
      "r923",
      "r949"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r899",
      "r910",
      "r924",
      "r941",
      "r950",
      "r954",
      "r962"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "verboseLabel": "Estimated total stock compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r516"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r123",
      "r147",
      "r179",
      "r209",
      "r215",
      "r234",
      "r237",
      "r283",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r559",
      "r561",
      "r601",
      "r679",
      "r747",
      "r806",
      "r807",
      "r848",
      "r866",
      "r1038",
      "r1039",
      "r1098"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r152",
      "r179",
      "r283",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r559",
      "r561",
      "r601",
      "r848",
      "r1038",
      "r1039",
      "r1098"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets measured at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r836"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r880",
      "r902"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r880",
      "r902"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r880",
      "r902"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r303",
      "r678"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r303",
      "r576",
      "r673",
      "r836",
      "r839",
      "r1015",
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "ABEO_AvenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "AvenueMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avenue [Member]",
        "documentation": "Avenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_AvenueTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "AvenueTwoMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avenue 2 [Member]",
        "documentation": "Avenue 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in accrued property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r143",
      "r795"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents fair value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r111"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, cash equivalents, restricted cash and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r89",
      "r175"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r89",
      "r175"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r89"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, expiration date",
        "documentation": "Warrants, expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Warrants, exercise price",
        "terseLabel": "Warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to purchase shares",
        "label": "Warrants purchase, shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants",
        "verboseLabel": "Outstanding warrant liabilities",
        "terseLabel": "Shares of common stock issuable upon exercise of warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LICENSE/SUPPLIER AGREEMENTS",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r137"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r114",
      "r681",
      "r733"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r322",
      "r323",
      "r789",
      "r1033",
      "r1035"
     ]
    },
    "ABEO_CommonStockAndAccompanyingWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "CommonStockAndAccompanyingWarrantMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock and Accompanying Warrant [Member]",
        "documentation": "Common Stock And Accompanying Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity",
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r856",
      "r857",
      "r859",
      "r860",
      "r861",
      "r862",
      "r1003",
      "r1004",
      "r1007",
      "r1081",
      "r1144",
      "r1147"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r734"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r734",
      "r753",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $0.01 par value; authorized 200,000,000 shares; 45,644,091 and 26,523,878 shares issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r684",
      "r848"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r108"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r159",
      "r161",
      "r167",
      "r675",
      "r695",
      "r696"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r796"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract assets",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r404"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable consideration",
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed consideration",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Losses",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r308"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r974"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r974"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r967"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r975"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r973"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r970"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r177",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r334",
      "r335",
      "r345",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r361",
      "r368",
      "r369",
      "r371",
      "r612"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement Principal",
        "totalLabel": "Total principal",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r113",
      "r372"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "verboseLabel": "Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r348"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r612",
      "r613",
      "r815",
      "r816",
      "r846"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated fair value of loan agreement",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r600",
      "r815",
      "r816",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r375",
      "r612",
      "r613",
      "r846"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r347"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate transaction amount",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r846",
      "r1001",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate principal amount",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r47",
      "r48",
      "r62",
      "r103",
      "r104",
      "r181",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r846",
      "r1001",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized debt issuance costs and discounts",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r373",
      "r611",
      "r612",
      "r613",
      "r815",
      "r816",
      "r846"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale securities realized gain loss",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Short-termInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred taxes",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "ABEO_DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, equipment and goodwill",
        "documentation": "Deferred tax assets property plant and equipments and goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsStateTaxes",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General business credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlanDetailsNarrative",
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company contributions under 401 (k) Plan",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum annual contribution per employee under 401(k) plan",
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r209",
      "r220",
      "r237",
      "r806",
      "r807"
     ]
    },
    "ABEO_DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative and warrant additions associated with loan and security agreement",
        "documentation": "Derivative and warrant additions associated with loan and security agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning derivative liabilities",
        "periodEndLabel": "Ending derivative liabilities",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ABEO_DerivativeLiabiltyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "DerivativeLiabiltyPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "documentation": "Derivative Liabilty [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLossOnDerivative",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss recognized in earnings from change in fair value",
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes loss from derivative."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1145"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r484",
      "r512",
      "r513",
      "r515",
      "r833"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_DiscretionaryTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "DiscretionaryTrancheMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discretionary Tranche [Member]",
        "documentation": "Discretionary Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r880",
      "r902"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r880",
      "r902",
      "r942"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ABEO_DonWuchterlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "DonWuchterlMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Don Wuchterl [Member]",
        "documentation": "Don Wuchterl [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic loss per common share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r197",
      "r200",
      "r203",
      "r204",
      "r205",
      "r208",
      "r554",
      "r557",
      "r573",
      "r574",
      "r676",
      "r697",
      "r798"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive loss per common share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r200",
      "r203",
      "r204",
      "r205",
      "r208",
      "r554",
      "r557",
      "r573",
      "r574",
      "r676",
      "r697",
      "r798"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r207"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period total compensation costs related to non-vested options",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation cost related to non-vested options not recognized",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity",
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r139",
      "r163",
      "r164",
      "r165",
      "r182",
      "r183",
      "r184",
      "r186",
      "r191",
      "r193",
      "r195",
      "r210",
      "r284",
      "r285",
      "r313",
      "r391",
      "r544",
      "r545",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r614",
      "r616",
      "r633",
      "r693",
      "r710",
      "r711",
      "r712",
      "r722",
      "r774"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r61",
      "r282"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r906",
      "r920",
      "r946"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r917",
      "r943"
     ]
    },
    "ABEO_EventBasedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "EventBasedMilestonePaymentsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event Based Milestone Payments [Member]",
        "documentation": "Event-Based Milestone Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      },
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant and derivative liabilities",
        "label": "Change in fair value of warrant and derivative liabilities",
        "verboseLabel": "Fair value of warrants",
        "terseLabel": "DerivativeLiabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "ABEO_FairValueAdjustmentOfWarrantsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "FairValueAdjustmentOfWarrantsIssued",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants issued in connection with the Loan Agreement",
        "documentation": "Fair value adjustment of warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r590",
      "r836"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r590",
      "r836"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r839"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r839"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r839"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r591",
      "r837"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r591",
      "r837"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r575",
      "r577",
      "r578",
      "r579",
      "r580",
      "r589",
      "r590",
      "r592",
      "r642",
      "r643",
      "r644",
      "r815",
      "r816",
      "r822",
      "r823",
      "r824",
      "r836",
      "r839"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r580",
      "r836",
      "r1086",
      "r1089"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r587",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r672",
      "r836",
      "r840"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r432",
      "r437",
      "r577",
      "r590",
      "r642",
      "r822",
      "r823",
      "r824",
      "r836"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r432",
      "r437",
      "r577",
      "r578",
      "r590",
      "r643",
      "r815",
      "r816",
      "r822",
      "r823",
      "r824",
      "r836"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r577",
      "r578",
      "r579",
      "r580",
      "r590",
      "r644",
      "r815",
      "r816",
      "r822",
      "r823",
      "r824",
      "r836",
      "r839"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r580",
      "r836",
      "r1086",
      "r1089"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r575",
      "r577",
      "r578",
      "r579",
      "r580",
      "r589",
      "r590",
      "r592",
      "r642",
      "r643",
      "r644",
      "r815",
      "r816",
      "r822",
      "r823",
      "r824",
      "r836",
      "r839"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1089"
     ]
    },
    "ABEO_FairValueOfConversionRight": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "FairValueOfConversionRight",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of conversion right",
        "documentation": "Fair value of conversion right."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_FairValueOfDerivativesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "FairValueOfDerivativesIssued",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivatives issued in connection with Loan Agreement",
        "documentation": "Fair value of derivatives issued."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_FairValueWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "FairValueWarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liabilities",
        "documentation": "Fair value warrant liabilities.",
        "label": "FairValueWarrantLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r290",
      "r291",
      "r292",
      "r293",
      "r298",
      "r307",
      "r308",
      "r309",
      "r370",
      "r388",
      "r570",
      "r597",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r694",
      "r813",
      "r836",
      "r837",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r849",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1082",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value, liabilities",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1084",
      "r1088"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r924",
      "r950"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r924",
      "r950"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r924",
      "r950"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r924",
      "r950"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r924",
      "r950"
     ]
    },
    "ABEO_FurnitureSoftwareAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "FurnitureSoftwareAndOfficeEquipmentMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture, Software and Office Equipment [Member]",
        "documentation": "Furniture, Software and Office Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_FutureCashReceiptsFromOperatingSublease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "FutureCashReceiptsFromOperatingSublease",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future cash receipts",
        "documentation": "Future cash receipts from operating sublease.",
        "label": "FutureCashReceiptsFromOperatingSublease"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails": {
       "parentTag": "ABEO_FutureCashReceiptsFromOperatingSublease",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFutureCashReceiptsFromOperatingSubleaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "documentation": "Future cash receipts from operating sublease next twelve months.",
        "label": "FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_GainLossOfRightofuseLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "GainLossOfRightofuseLeaseAssets",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on operating lease right-of-use assets",
        "documentation": "Gain loss of rightofuse lease assets.",
        "label": "GainLossOfRightofuseLeaseAssets"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_GainLossOnRightofuseLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "GainLossOnRightofuseLeaseAssets",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on operating lease right-of-use assets",
        "documentation": "Gain (loss) on right of use lease assets.",
        "label": "GainLossOnRightofuseLeaseAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on disposal of property and equipment",
        "label": "Gain (loss) on disposal of equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on termination of lease",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ABEO_GainLossRecognizedInEarningsFromChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "GainLossRecognizedInEarningsFromChangeInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss recognized in earnings from change in fair value",
        "documentation": "Gain (loss) recognized in earnings from change in fair value.",
        "label": "GainLossRecognizedInEarningsFromChangeInFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "verboseLabel": "Total general and administrative costs",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r758"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Technology",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312"
     ]
    },
    "ABEO_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price of common stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r880",
      "r902"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r97"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r320",
      "r321",
      "r582",
      "r586",
      "r591",
      "r707",
      "r709",
      "r759",
      "r792",
      "r838",
      "r1115"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r582",
      "r586",
      "r591",
      "r707",
      "r709",
      "r759",
      "r792",
      "r838",
      "r1115"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r525",
      "r526",
      "r532",
      "r541",
      "r835",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r525",
      "r526",
      "r532",
      "r541",
      "r835",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r521",
      "r525",
      "r529",
      "r530",
      "r531",
      "r533",
      "r539",
      "r546",
      "r548",
      "r549",
      "r550",
      "r721",
      "r835"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135",
      "r194",
      "r195",
      "r209",
      "r221",
      "r237",
      "r524",
      "r525",
      "r547",
      "r698",
      "r835"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r522",
      "r523",
      "r533",
      "r534",
      "r538",
      "r543",
      "r718"
     ]
    },
    "ABEO_IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred true ups",
        "documentation": "Income tax reconciliation change in deferred tax assets true ups."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r835",
      "r1075"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax, net of federal benefit",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r835"
     ]
    },
    "ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities",
        "documentation": "Income tax reconciliation income tax expense benefit changes of warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired tax losses and credits",
        "documentation": "Income tax reconciliation income tax expense benefit expired tax lossed and credit tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Income tax reconciliation income tax expense benefit permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development credit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development credit.",
        "label": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes at U.S. statutory rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r835",
      "r1075"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r174",
      "r540",
      "r541"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in payable to licensor",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r998"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r924",
      "r941",
      "r950",
      "r954",
      "r962"
     ]
    },
    "ABEO_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Plan [Member]",
        "documentation": "Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r965"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r965"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r965"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r215",
      "r219",
      "r222",
      "r237",
      "r610",
      "r806",
      "r807"
     ]
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r756",
      "r785",
      "r786",
      "r806",
      "r863",
      "r864",
      "r996",
      "r1149"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r172",
      "r173"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted cash",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1110",
      "r1112"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term investments fair value",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1084",
      "r1088"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Short-termInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHORT-TERM INVESTMENTS",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r138",
      "r250",
      "r251",
      "r598",
      "r599",
      "r1107"
     ]
    },
    "ABEO_IssuanceOfCommonStockInConnectionWithPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IssuanceOfCommonStockInConnectionWithPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with public offering, net of offering costs",
        "documentation": "Issuance of common stock in connection with public offering."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net of offering costs under direct placement offering",
        "documentation": "Issuance of common stock, net of offering costs under direct placement offering."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net of offering costs under direct placement offering, shares",
        "documentation": "Issuance of common stock, net of offering costs under direct placement offering, shares."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_IssuanceOfCommonStockSharesInConnectionWithPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "IssuanceOfCommonStockSharesInConnectionWithPublicOffering",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with public offering, net of offering costs, shares",
        "documentation": "Issuance of common stock shares in connection with public offering."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_JefferiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "JefferiesLlcMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_LeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "LeaseAgreementMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement [Member]",
        "documentation": "Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r847"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF COMPONENTS OF LEASE COST",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r632"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r65",
      "r66",
      "r67",
      "r69",
      "r70",
      "r71",
      "r72",
      "r179",
      "r283",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r560",
      "r561",
      "r562",
      "r601",
      "r732",
      "r799",
      "r866",
      "r1038",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r115",
      "r687",
      "r848",
      "r1002",
      "r1031",
      "r1090"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r142",
      "r179",
      "r283",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r560",
      "r561",
      "r562",
      "r601",
      "r848",
      "r1038",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities measured at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r1083"
     ]
    },
    "ABEO_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Terms [Member]",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ABEO_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_LoanAgreementWarrants2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "LoanAgreementWarrants2024Member",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement Warrants 2024 [Member]",
        "documentation": "Loan Agreement Warrants 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan and Security Agreement [Member]",
        "documentation": "Loan and Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails",
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "totalLabel": "Total long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r113",
      "r358",
      "r374",
      "r815",
      "r816",
      "r846",
      "r1111"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of long-term debt",
        "verboseLabel": "Less: current maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r181",
      "r363"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r181",
      "r363"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r181",
      "r363"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/ScheduleOfDebtAndNetOfDebtIssuanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt",
        "verboseLabel": "Long-term debt, net of current maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payments",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://abeonatherapeutics.com/role/SettlementLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SETTLEMENT LIABILITY",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r517"
     ]
    },
    "us-gaap_LossContingencySettlementAgreementTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencySettlementAgreementTerms",
     "presentation": [
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss contingency settlement agreement terms",
        "documentation": "Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r99"
     ]
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r914"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r915"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r916"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r916"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r916"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r916"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r330",
      "r331",
      "r477",
      "r517",
      "r580",
      "r670",
      "r706",
      "r708",
      "r716",
      "r724",
      "r725",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r790",
      "r791",
      "r812",
      "r819",
      "r832",
      "r839",
      "r840",
      "r844",
      "r845",
      "r851",
      "r1040",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r839"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r839"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r330",
      "r331",
      "r477",
      "r517",
      "r580",
      "r670",
      "r706",
      "r708",
      "r716",
      "r724",
      "r725",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r790",
      "r791",
      "r812",
      "r819",
      "r832",
      "r839",
      "r840",
      "r844",
      "r851",
      "r1040",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ABEO_MoneyMarketDepositAccountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "MoneyMarketDepositAccountMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Deposit Account [Member]",
        "documentation": "Money Market Deposit Account [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r91",
      "r118",
      "r140",
      "r157",
      "r160",
      "r165",
      "r179",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r201",
      "r283",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r554",
      "r557",
      "r574",
      "r601",
      "r692",
      "r755",
      "r772",
      "r773",
      "r864",
      "r1038"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r187",
      "r188",
      "r189",
      "r190",
      "r197",
      "r198",
      "r202",
      "r205",
      "r557"
     ]
    },
    "ABEO_NetOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "NetOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "documentation": "Net operating loss carryforwards.",
        "label": "NetOperatingLossCarryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_NoncashContributionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashContributionExpense",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest",
        "documentation": "Noncash charitable contributions made by the entity during the period."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental non-cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ABEO_NumberOfInvestmentOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "NumberOfInvestmentOptions",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of investment options",
        "documentation": "Number of investment options."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_NumberOfWarrantsOrRightsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "NumberOfWarrantsOrRightsExercised",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of warrants",
        "documentation": "Number of warrants or rights exercised.",
        "label": "NumberOfWarrantsOrRightsExercised"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_OfficeSpaceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "OfficeSpaceOneMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Space One [Member]",
        "documentation": "Office Space One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_OfficeSpaceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "OfficeSpaceTwoMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Space Two [Member]",
        "documentation": "Office Space Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_OneAnnualInstallmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "OneAnnualInstallmentsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Annual Installment [Member]",
        "documentation": "One Annual Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_OpenMarketSaleAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "OpenMarketSaleAgreementsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Market Sale Agreements [Member]",
        "documentation": "Open Market Sale Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r800",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r847"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liability",
        "label": "Present value of operating lease liabilities",
        "verboseLabel": "Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease liability",
        "verboseLabel": "Current operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/SummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term operating lease liabilities",
        "verboseLabel": "Non-current operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r627"
     ]
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual lease payments",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r627"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "verboseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use lease assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r847"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r847"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "State net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "ABEO_OperatingLossCarryforwardsTaxablePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "OperatingLossCarryforwardsTaxablePercentage",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss taxable percentage",
        "documentation": "Operating loss carryforwards taxable percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r92",
      "r93",
      "r110"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in unrealized gains related to available-for-sale debt securities",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r693"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustments",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r693"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r19",
      "r158",
      "r161",
      "r166",
      "r191",
      "r602",
      "r603",
      "r608",
      "r674",
      "r693",
      "r993",
      "r994"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r848"
     ]
    },
    "us-gaap_OtherLoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion payable to licensor",
        "documentation": "Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r730",
      "r731"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other receivables",
        "label": "Other Receivables [Default Label]",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r742",
      "r807",
      "r1113"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other general and administrative costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "ABEO_OtherSegments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "OtherSegments",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other segment items",
        "documentation": "Other segments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r908",
      "r922",
      "r948"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r911",
      "r925",
      "r951"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r911",
      "r925",
      "r951"
     ]
    },
    "ABEO_ParticipationRightDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ParticipationRightDescription",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Participation right description",
        "documentation": "Participation right description."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r929"
     ]
    },
    "ABEO_PayableToLicensorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "PayableToLicensorMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable to Licensor [Member]",
        "documentation": "Payable to Licensor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase amount",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capital expenditures",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of short-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) PLAN",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r429",
      "r431",
      "r437",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r472",
      "r473",
      "r474",
      "r824"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ABEO_PreFundedWarrantAndAccompanyingWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "PreFundedWarrantAndAccompanyingWarrantMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrant and Accompanying Warrant [Member]",
        "documentation": "Pre Funded Warrant And Accompanying Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrant [Member]",
        "documentation": "Pre Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_PreFundedWarrants2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "PreFundedWarrants2023Member",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants 2023 [Member]",
        "documentation": "Pre Funded Warrants 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_PreFundedWarrants2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "PreFundedWarrants2024Member",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants 2024 [Member]",
        "documentation": "Pre Funded Warrants 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_PrecommercialPreparationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "PrecommercialPreparationCosts",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commercial preparation costs",
        "documentation": "Precommercial preparation costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "verboseLabel": "Preferred stock par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r377"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r734"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r377"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r734",
      "r753",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r683",
      "r848"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrincipalAmountOutstandingOnLoansManagedAndSecuritized",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding principal amount of loan",
        "documentation": "This is the sum of principal amount outstanding for both securitized and unsecuritized loans of all types."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ABEO_PrivatePlacementOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "PrivatePlacementOfferingsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Offerings [Member]",
        "documentation": "Private Placement Offerings [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from ATM sales of common stock, net of issuance costs",
        "verboseLabel": "Shares issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of long-term debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r719"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sales of common stock under direct placement offering, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares",
        "verboseLabel": "Proceeds from warrant liability'",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r719"
     ]
    },
    "ABEO_ProceedsFromRepaymentSettlementOfRestrictedShareAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ProceedsFromRepaymentSettlementOfRestrictedShareAwards",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments related to net settlement of restricted share awards",
        "documentation": "Proceeds from repayment settlement of restricted share awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from maturities of short-term investments",
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from disposal of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ABEO_ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sales of common stock, net of issuance costs",
        "documentation": "Proceeds fromUnderwritten sales of common stock net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r671",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r794",
      "r821",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r1036",
      "r1037",
      "r1041",
      "r1114",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "auth_ref": [
      "r241",
      "r671",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r794",
      "r821",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r1036",
      "r1037",
      "r1041",
      "r1114",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_PropertyManagementFeePercentFeeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyManagementFeePercentFeeDescription",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage fee, description",
        "documentation": "A description of what the property management fee percentage is taken against to determine the fee charged to clients."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r632"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r130",
      "r133",
      "r134"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subtotal",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r144",
      "r691"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r632",
      "r677",
      "r691",
      "r848"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r130",
      "r133",
      "r689"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r632"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful lives (years)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ABEO_REGENXBIOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "REGENXBIOMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REGENXBIO [Member]",
        "documentation": "REGENXBIO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r330",
      "r331",
      "r429",
      "r477",
      "r507",
      "r508",
      "r509",
      "r517",
      "r580",
      "r645",
      "r654",
      "r670",
      "r706",
      "r708",
      "r716",
      "r724",
      "r725",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r790",
      "r791",
      "r812",
      "r819",
      "r832",
      "r839",
      "r840",
      "r844",
      "r845",
      "r851",
      "r857",
      "r1034",
      "r1040",
      "r1086",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "ABEO_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "RangeFourMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Four [Member]",
        "documentation": "Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": [
      "r327",
      "r329",
      "r330",
      "r331",
      "r429",
      "r477",
      "r507",
      "r508",
      "r509",
      "r517",
      "r580",
      "r645",
      "r654",
      "r670",
      "r706",
      "r708",
      "r716",
      "r724",
      "r725",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r790",
      "r791",
      "r812",
      "r819",
      "r832",
      "r839",
      "r840",
      "r844",
      "r845",
      "r851",
      "r857",
      "r1034",
      "r1040",
      "r1086",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "ABEO_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "RangeOneMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range One [Member]",
        "documentation": "Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Three [Member]",
        "documentation": "Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Two [Member]",
        "documentation": "Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r1014"
     ]
    },
    "ABEO_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Recently Adopted Accounting Pronouncements [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_ReclassificationOfDerivativeLiabilityToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ReclassificationOfDerivativeLiabilityToEquity",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of derivative liability to equity",
        "documentation": "Reclassification of derivative liability to equity."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfActivityOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassification of derivative liability in connection with the Loan Agreement",
        "documentation": "Reclassification of derivative liablity in connection with loan agreement.",
        "label": "ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r892",
      "r903",
      "r917",
      "r943"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r455",
      "r634",
      "r635",
      "r680",
      "r688",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r752",
      "r754",
      "r779"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r455",
      "r634",
      "r635",
      "r680",
      "r688",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r752",
      "r754",
      "r779",
      "r1097"
     ]
    },
    "ABEO_RemainingMilestonePaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "RemainingMilestonePaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining milestone payments due",
        "documentation": "Remaining milestone payments due."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r1074"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r1074"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Total research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r792",
      "r806",
      "r1106"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r918",
      "r944"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r905",
      "r919",
      "r945"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r912",
      "r926",
      "r952"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1000",
      "r1108",
      "r1112"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r111",
      "r143",
      "r175",
      "r682"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r105",
      "r686",
      "r713",
      "r715",
      "r720",
      "r735",
      "r848"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r182",
      "r183",
      "r184",
      "r186",
      "r191",
      "r193",
      "r195",
      "r284",
      "r285",
      "r313",
      "r544",
      "r545",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r564",
      "r566",
      "r567",
      "r569",
      "r572",
      "r614",
      "r616",
      "r710",
      "r712",
      "r722",
      "r1147"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r458",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r479",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r458",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r479",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and other revenues",
        "verboseLabel": "Revenue recognized",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r209",
      "r216",
      "r217",
      "r233",
      "r237",
      "r241",
      "r243",
      "r244",
      "r402",
      "r403",
      "r671"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r793"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r847"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalties",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries &amp; related costs",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock value",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_SalesBasedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "SalesBasedMilestonePaymentsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Based Milestone Payments [Member]",
        "documentation": "Sales-Based Milestone Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r478",
      "r1006"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "auth_ref": [
      "r196",
      "r478",
      "r980",
      "r1006"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_ScheduleOfActivityWarrantyLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ScheduleOfActivityWarrantyLiabilityTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES",
        "documentation": "Schedule Of Activity Warranty Liability [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME TAX EXPENSE",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEBT AND NET OF DEBT ISSUANCE COSTS",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlanDetailsNarrative",
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK BASED COMPENSATION",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1084"
     ]
    },
    "ABEO_ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE",
        "documentation": "Schedule of Future Cash Receipts From Operating Sublease [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FUTURE PAYMENT OBLIGATIONS",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ABEO_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ScheduleOfOperatingLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF OPERATING LEASE LIABILITIES",
        "documentation": "Schedule of Operating Lease Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OUTSTANDING WARRANT LIABILITIES",
        "documentation": "Schedule Of Outstanding Warrant Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r632"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r107"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r223",
      "r224",
      "r225",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r244",
      "r801",
      "r804",
      "r805",
      "r806",
      "r808",
      "r810",
      "r811"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r240",
      "r243",
      "r802",
      "r803",
      "r809"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ABEO_SeptemberTwoThouandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "SeptemberTwoThouandTwentyFiveMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2025 [Member]",
        "documentation": "September 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SettlementLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/SettlementLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement liabilities, current",
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Non-cash stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted common stock awards, cancelled/forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value, cancelled/forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted common stock awards, granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value, granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restricted common stock awards, balance",
        "periodEndLabel": "Restricted common stock awards, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average grant date fair value, balance",
        "periodEndLabel": "Weighted-average grant date fair value, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average compensation costs related to restricted common stock",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted common stock awards, vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation cost related to restricted common stock not recognized",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value, vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, exercisable",
        "verboseLabel": "Number of options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercisable",
        "verboseLabel": "Weighted-average exercise price, exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, cancelled/forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, cancelled/forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, outstanding balance",
        "periodEndLabel": "Aggregate intrinsic value, outstanding balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, outstanding balance",
        "periodEndLabel": "Number of options, outstanding balance",
        "label": "Number of options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, outstanding balance",
        "periodEndLabel": "Weighted average exercise price, outstanding balance",
        "label": "Weighted-average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489"
     ]
    },
    "ABEO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of restricted stock awards that vested",
        "documentation": "Sharebased compensation arrangement by sharebased payment award other than options vested in period fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfRestrictedStockAwardActivityDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, lower limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, upper limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term (years), exercisable",
        "verboseLabel": "Weighted-average remaining life in years, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, unvested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, unvested",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term (years), outstanding",
        "verboseLabel": "Weighted-average remaining life in years",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, unvested",
        "documentation": "Sharebased compensation arrangement by sharebased payment award options unvested intrinsic value1 ."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term (years), unvested",
        "documentation": "Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfounded exercise price per share",
        "verboseLabel": "Exercise price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r991"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r847"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r176"
     ]
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Unrecognized Tax Benefit, Reasonably Possible [Table]",
        "documentation": "Disclosure of information about unrecognized tax benefit for which significant change is reasonably possible within 12 months. Includes, but is not limited to, nature of uncertainty, nature of event that could cause significant change within 12 months, and estimate of range of reasonably possible change or statement of fact that estimate of range cannot be made."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity",
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r77",
      "r78",
      "r139",
      "r163",
      "r164",
      "r165",
      "r182",
      "r183",
      "r184",
      "r186",
      "r191",
      "r193",
      "r195",
      "r210",
      "r284",
      "r285",
      "r313",
      "r391",
      "r544",
      "r545",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r614",
      "r616",
      "r633",
      "r693",
      "r710",
      "r711",
      "r712",
      "r722",
      "r774"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r210",
      "r616",
      "r671",
      "r717",
      "r723",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r743",
      "r744",
      "r745",
      "r746",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r754",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r774",
      "r858"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r478",
      "r980",
      "r981",
      "r1006"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSignificantExpenseCategoriesDetails",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r210",
      "r245",
      "r616",
      "r671",
      "r717",
      "r723",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r743",
      "r744",
      "r745",
      "r746",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r754",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r774",
      "r858"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r907",
      "r921",
      "r947"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net of offering costs under open market sale agreement (ATM), shares",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r73",
      "r74",
      "r105",
      "r719",
      "r774",
      "r787"
     ]
    },
    "ABEO_StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of pre-funded warrants, net of shares settled, shares",
        "documentation": "Stock issued during period shares of common stock upon exercise of prefunded warrants net of shares settled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock awards, issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r105"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement, shares",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r73",
      "r74",
      "r105"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r73",
      "r74",
      "r105",
      "r493"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net of offering costs under open market sale agreement (ATM)",
        "verboseLabel": "value issued",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r73",
      "r74",
      "r105",
      "r722",
      "r774",
      "r787",
      "r865"
     ]
    },
    "ABEO_StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of pre-funded warrants, net of shares settled",
        "documentation": "Stock issued during period value of common stock upon exercise of prefunded warrants net of shares settled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r105"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r94",
      "r736",
      "r753",
      "r775",
      "r776",
      "r848",
      "r866",
      "r1002",
      "r1031",
      "r1090",
      "r1147"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r178",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r571",
      "r777",
      "r778",
      "r788"
     ]
    },
    "ABEO_SubLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "SubLeaseAgreementMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sub Lease Agreement [Member]",
        "documentation": "Sub Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r847"
     ]
    },
    "ABEO_SublicenseAgreementRelatingToRettSyndromeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "SublicenseAgreementRelatingToRettSyndromeMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublicense Agreement Relating to Rett Syndrome [Member]",
        "documentation": "Sublicense Agreement Relating to Rett Syndrome [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_SublicenseAndInventoryPurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "SublicenseAndInventoryPurchaseAgreementsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublicense And Inventory Purchase Agreements [Member]",
        "documentation": "Sublicense And Inventory Purchase Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r638"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ABEO_TaxYearTwoThousandTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TaxYearTwoThousandTwentyEightMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2028 [Member]",
        "documentation": "Tax Year 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TaxYearTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TaxYearTwoThousandTwentyFiveMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2025 [Member]",
        "documentation": "Tax Year 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TaxYearTwoThousandTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TaxYearTwoThousandTwentyNineMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2029 [Member]",
        "documentation": "Tax Year 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TaxYearTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TaxYearTwoThousandTwentySevenMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2027 [Member]",
        "documentation": "Tax Year 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TaxYearTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TaxYearTwoThousandTwentySixMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2026 [Member]",
        "documentation": "Tax Year 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_ThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ThereafterMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfNetOperatingLossAndGeneralBusinessCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter [Member]",
        "documentation": "Thereafter [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_ThreeEqualAnnualInstallmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "ThreeEqualAnnualInstallmentsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Equal Annual Installments [Member]",
        "documentation": "Three Equal Annual Installments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1096"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche 1 [Member]",
        "documentation": "Tranche 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche 2 [Member]",
        "documentation": "Tranche 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r370",
      "r388",
      "r570",
      "r597",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r694",
      "r836",
      "r837",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r849",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1082",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ABEO_TwentyTwentyFourLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwentyTwentyFourLoanAgreementMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Loan Agreement [Member]",
        "documentation": "2024 Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TwentyTwentyFourLoanAgreementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwentyTwentyFourLoanAgreementWarrantsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Loan Agreement Warrants [Member]",
        "documentation": "2024 Loan Agreement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TwentyTwentyOnePublicOfferingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwentyTwentyOnePublicOfferingWarrantsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Public Offering Warrants [Member]",
        "documentation": "2021 Public Offering Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TwentyTwentyThreeLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwentyTwentyThreeLoanAgreementMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Loan Agreement [Member]",
        "documentation": "Twenty Twenty Three Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TwentyTwentyTwoPrivatePlacementOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwentyTwentyTwoPrivatePlacementOfferingMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfOutstandingWarrantLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Private Placement Offering [Member]",
        "documentation": "2022 Private Placement Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TwoThousandFifteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsOutstandingAndExercisableDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2015 Equity Incentive Plan [Member]",
        "documentation": "2015 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TwoThousandTwentyFourPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwoThousandTwentyFourPreFundedWarrantsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Pre-Funded Warrants [Member]",
        "documentation": "2024 Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Equity Incentive Plan [Member]",
        "documentation": "2023 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_TwoThousandTwentyThreePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "TwoThousandTwentyThreePreFundedWarrantsMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Pre-Funded Warrants [Member]",
        "documentation": "2023 Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/FairValueMeasurementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/LeasesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensesupplierAgreementsDetailsNarrative",
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailableForSaleShort-termInvestmentsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r822",
      "r824",
      "r836",
      "r1109"
     ]
    },
    "ABEO_UnderAgeFifftyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "UnderAgeFifftyMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Under Age 50 [Member]",
        "documentation": "Under Age 50 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r127",
      "r129",
      "r131",
      "r132"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r847"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price per share",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "ABEO_WarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "WarrantLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/ScheduleOfActivityOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "periodStartLabel": "Beginning warrant liabilities",
        "periodEndLabel": "Ending warrant liabilities",
        "documentation": "Warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ABEO_WarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "WarrantLiabilitiesMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities [Member]",
        "documentation": "Warrant Liabilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://abeonatherapeutics.com/role/DebtDetailsNarrative",
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r856",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants maturity date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "ABEO_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://abeonatherapeutics.com/20241231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r205"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r205"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.2.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-20/tableOfContent"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-30/tableOfContent"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001493152-25-010978-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-010978-xbrl.zip
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M/,ZTSJV?=:MUW4401Z@X$&4#5N5;K__?6ROY1X()&EI)KS0E!+)/5X&SW;D
M19RVP6CUZ8J VKN[N7MS>W=_^T\0^_IUZZ8DY T9_"\O+]>O2^Q>^WC=O[NY
MN8^1+[=4\N*T"A-;3"TO][2.6\"S3ZF@$GH &6R[GS*?5A Z(2D^S[U&(N\!
MC]&_H.2NN6PK.11![G<4>4SJ_QZR@H*VE;6DT]])XL'A+=]#;K"NMG(7#?([
MB3W,7L)*_;%O[G:.M_*3%/CM>7YL!VD2".[C4/+,+0IVIM4DE..1%0,+. B@
MJ]V:8]^B5344(;]Z:;D>2>K=WO7N;Z]? _O :1LF#LW0CHFTW E,T-H"9%VO
M_6< U>D3I:A^?U!'3AZH,O&^=&4&2RI"%/36IKGC>6EEF3YRPR!-.9D%8B;!
M^3S0:EHQ48#3#G&?5$$JO>L!CO>W]>P<*TE_!R<I ;+L-DJ0DI.'5L(7:J%W
M7N%]FQ?GBZ0_3E.! (>MT$_I8^3AUQER[ULU=DI.'JI>BN+#3/'=U0_*[)]#
MW_L<69L087>"MDN$KRA'X%HK,AR7WCWUZ2K$$7'%\&;G [AHQ[<-VI/847QQ
MXI44]RR@>+'6?[#]K>EX:HBVA!*D@0$M./&(4#]B/]I]NHJK<X"DB>&Q;WKD
M6L;X$KU]MC!0Y/XHE0BB&"_P<Q__'_D1IDRGG*:'@(MRM2LB@I P_!Q%GHWL
ME#NBE46AFDE$$**RF5E!CI.)($Q5<]\?1^1>*"$*3=V @EA,FTL?7N+C?799
M5(GU!@(1!!A%&(;;$4:ZOPI?3(S Q\Y6*\="-0*U*2""@(W^M84K%E8H Z9W
MB%.J!EH1Q)KX'MI/3/P-A4.T\P,GO1JU*-%Q,A&$8>]Y*4K1D"\"^W-S3W@P
M_'C?AH]+_4EMM@C,YW5^YJ%YM'0="[P4PH>;F!K&8<>+B":D\>+/Z>TC:.["
MS(.>[4AX;_ &'(5$$%13'I7IEP=U5A2%31:!67HBKFX<4YTG MMQ%ZZ3:2MH
M?Y'MFCS!V 9MKF4[GR<"VSK:A90?8,S8^)'IV<FPPWDN-3X?J1!"1<LFY:_/
M%H%Y _R[M6%UOR)=('89G:](%X%=LDB)$2EFXGW"8RDXU40A@@CR,_*B$M.E
M-''89/2"31:!V<2E!0>?!K,N)E)1'L"T*B."F+,=\N+I"KG@_[#QN=1=':,2
M093_1'2 B(*Q:Q79K\P1@679F-3T2)4Y(K!<-RHO:<QQ,C&$*=IF<UQ2*-8'
M_G;K>_$9(\\F08;MSO3VAPEA419^<A&$*[<\CX0MRX@@)M-?T!A8VT[F2"%Q
M!8W/HZN>!2DP82 G-WA$;2HF@K"J9T>QTV,EJLD3@>U<8X^<58B0UP8?CB(B
M"*F9WIJ=2#&IPK#*#):95'%8);99Q6PA71AVR="\@MM"L@C,)D<3ZZ)V=;DB
ML*[3.#7ES[/)1Z4\LM8XC["UR<=:2OU;ZU(BB$KW2=/+.2:.BX+0]])KC$K2
M\1"*(!"9YP4\ O$0"B'00:U2%=*02\\B&;Z&PE#?>S;VM^409^MB(@B[@)$@
MEL&;.:M5N"]*5),G MN&^?H5F9@-HS"19RY*D472G5<^B?*$0@N$P+-QBE0@
M%5DHQ5EOREL6N$A%%FKJ, L)/)1"B+1!&)DPTR@-W2K2Q6 WGJZ:KNQY\%\E
MN_-=MZ(7Y:(40228)1V3I9E$!"'8[2WU&U]X6(Y/781IUM)TR1F,3U<6/<Z<
M"A)G;F& %)IX?P$Q'J$UR#GJF:<1Y^.OH@#%RYCTG'TJTW&R%IC\6 G3VU[I
M!>UI_)+>!9O&D^D]L'1(,W0PLD(FX)Q%7BY2U9^YI>BWWX,+ME=686N;CRD"
M6OY[-8[J#7S/ [ZAML].N"GNJFILAJ-%_V^I28S3&>W!6<$?K08Q=B  LH<1
MX6E.WYU\!RTGSV+G>\DU??3KR6A5"*U3*XAECK_88V>SQ>_Y!F&5JD;JF/_O
MVK 7>L4?K9A9#[WBZ\AKR815D3GV+81L^I$%#>WB -'A<U>%:Q-)J])K$S/!
M3RY]>GO8:/F#FH/VH"_8"4/DT6 :V^,6+KVO:I03ZA"U:0Y?*I2];"G7MNFQ
MZP 4W;<<$W F'4S=L;MLW]9%JA+6IC1DN680T-M72.&JKSSN#3]>DLL6.5H6
M$E;Z,MOA?N[#<&-OH-?PP06M9[6@GO",26F85G.Y>6E0(TE]MB#\DT_I>*&[
MEVU_!X:5G'PAO37V/7B,IP=UXIU<6A#I.3^M;="S*67A3RTLG.SI7<<)[_N#
M4SDB-W]!X62N_9384:RY"PHG,^<'M(ZUP*G5"-(>TXB$-0\?T9YA.C0/TAE(
M-H'A(>2/,WZ76<B # PR#F,&@W!(OA8.D'S>.-:FQ'WN*OMLG^&9E9PZ%0O)
MI/ "C9!]4EFV_R<*PGAZD7(<3T!34?E(11UGIY-),#M_[3F_(UOU%!-[9(\N
M@6JP(=MA5"^3LCP+;5-0V%%DQF1^'%R'<S6-J  ?&^F[=*->,617.'[-.V7@
MJ4C41N+L?J;091@OR'U&$]\+-]D<_/3B)Z\I"=$>+>475U[R?6X$DXV1XYEN
MLF]IA#+YZK-%71/,.2NPR&>$ ZB!]K,5[HRE$-5.YR8.'<O9T7=39H<HL+"S
MBWE)S_TW$PDSMJA??VXF$57I@#@(\O'(RE6B; #!2RVJ,M(8,_,5&)D MJ:D
M#_L#2>(U:$@Z^1[4 JPN((%'1'04V3(8H;E&&B+;&^C"JA=BTPHCTS40WMYF
MLZ8?_]X3329-%:BQ58^8<>!8U+PNWJ9L]8+V>%0:YC."K, /C,#D1FD#!O>)
MY$^)W/%*'#--^ 'O$=4_9 ;%[(@>'MKG&)&HOCX-9*A4\>FD-\:I'.FH(CC1
MG3A>B-8(7^1L5O+U 3)[]2SH6NGKICY9(XY@^@+<)??8:RA )K8VLF</T3-R
M?7I_V"!IW?0XUZ6J$W:&7"-B.LMGONYB /^+77"DA3B*BVK=-1*5/U[T@#RT
M<L)8T$-$K&+,=\D*_QR-!K^<6"E(H D&*IX=&PJIP S1:2W'4>N?H_F@I]R:
M'E0P=,CF*P0,GJAL-36)VDR,-YG'=[KOR3E4<B \NP:2?GO(]^T7$.6P4'QB
M:4%'>N7/+14^JY3UUD>(!)6MGF= CS ,FDM6DV%ZDVU+;U6D[5K,87EI%U=S
MD5U"8*/;+5D>,5WXL3-CJRIM VHF$M56Z3!?1VMJ3QE&I<0_GOF/_?@F='C\
M7U!+ P04    " #5.W1:P7[BAHP:  #'2P$ %0   &%B96\M,C R-#$R,S%?
M8V%L+GAM;.U=[6_C-I/_?L#]#[H<<.@#G#>;?6F[V^X]4&PE%>K8?BQ[V_WT
M0)%H1[>RY.K%B>^O/Y*2;5D4*5*61.9P1=%NLB0U,[\A9S@<#G_]^\O&UW8@
MBKTP^')U\^;ME08")W2]8/WE:FD-=&MHFE=:G-B!:_MA +Y<!>'5W__K7_]%
M@__\^F^#@7;G =_]K(U"9V &J_ 7;6)OP&?M'@0@LI,P^D7[:OLI^DUXY_D@
MTH;A9NN#!,"_R#[\6?OXYMW'1VTPX!CW*PC<,%K.S>.X3TFRC3]?7S\_/[\)
MPIW]'$;?XS=.N.$;T$KL)(V/H[U]>9O_DW7_U?>"[Y_1?Q[M&&A07D'\^27V
MOERA[^:??7[_)HS6U^_>OKVY_O-A;#E/8&,/O #)S0%7AUYHE*I^-Y\^?;K&
M?WMH2K1\>8S\PS?>7Q_(.8X,_]9CM"]0$GN?8TS>.'3L!,->^QF-V@+]-#@T
M&Z!?#6[>#=[?O'F)W:N#\+$$H] '<[#2T/\A>L>OVH\@#.SD"2K+%J2)YV#H
MKE&SZV$(51/2C =XBL#JRQ5J#K_S[L/-N^PK_W[6*-EOH8K&'M*P*^WZ8@IN
M;1_)S7H"((GK**ELW"E%,SL" 6P'F]B^$'F5/=NF%4TML('?B:>KZ18M!U#?
M8CUPT1(0@2<0Q-X.C,.X5K3B(W7)BY6$SO>GT'?A^F7\E7K)7H1^>N\N:1[:
M\=.='SX+B9KHU(1"O&+$P'FS#G?7SM[-Y_;^$?(/G#2" IA[\?<'.[#7^,,0
M5BN!$(/U?N3%CA_&:03.R3ZL^<38B!7T!\Q3MCXT_%![K#[ +T2>[9]18@:.
MYT(:6N!0</RVM6P"[6<$2O/22C<;.]I#;??6@;>"JPP4M^.$:9! WV(6^I[C
M@5I=;&'HUN=4*XQ)YN$IC)(!5)J-&>Q G.#97DLRJU/;%,ZB$$*>["'<:(G<
MHH_5$<CJTS9]=[8788?Q =AH;G%)D-FI=8Q!DOCX$V//?O1\'B-%[](V=5#7
MHQ2XQLL66N[ZZ4)IWC958XA+/3'GK=JF800>:S6]V*;M[_/Y,UW[+=!#&J M
M!?;O(.9X\:_W7)C=6M<6S\':F&ZWO@<B?1T!OG6@MF/;E/X^@YY_'55GC=JF
M 'HCX08L[)?ZZ571M&UJH'9LO,R X2T$-KH@X#'<'%W;7\G7Z'LH9A%M^"8"
MM4?[WM!C#/Y*X<>,'9<306DOQTMKUUM3P_-<V(]^6QR=C]6+%\I)?GW7/CQ2
M/F+K>_;BG?(1R]&U8U^0CTYFIV[\0C["JMIVX2/R44.V[,E7XYS'/)T[]$7X
MJ*1VZ-[2<XJQII]"$9\12&S/CR=VA'KN0!UK'7RJ==2<)^"F/B12A]\?N)Z?
MHL]962 .$F*\.'[J O<N"C=(S=,$<S)=&7840(+C&8BL)SL".<6U<'?U03D>
MBZA**(O^#GX0S;N[,+)L'U0Z*>(0-QBU%T]-&#:10;I#J<H;$P:%8Y ^_$]1
M"$3&Z Z!HXNIQS' V^A#N!%.V]SM=*?!'"UG$9S1L,$D# ;1X>=;._;$YU$7
M7^U.1M,TP3D7\,-_(&1.(=G3TL;/N\AH<GD2.M!N8>@.K8$#9Y.70#/5 H "
M@W7'D1$G'O0NP7$F':D19XA_K#X0&H'(V^'5KQV0>,;K9<\O:B"$!NGAQ$K8
MQ^ ?HDN].@M--- C5O_.?/1\AQ6L<02CP400':@[!-">)PRR%!9,Q#",Q9T\
MGE&ZX^$!;7RQV%J YJ)1._0$4[2Y1TE&T.T"WC:)T8[U2)>5PFT/)$W<UVLT
M;C=10]$EC-VK.RQ0I!#YO"#)_FS&<8K2!9'2B^N9R&A=Z]?,WB.+,'WTO746
M0FJH4+4#=1'G%=4?5I]N<@5$*63WZDX;<+#YMAQK%M8%KF$ZYF*Z1=\\.)S-
M6&".T>$N$'\V+NS84#3B!42.%Z,PE_CF5FS [CB;@SB)/"<!+I:O_FQ';F.(
M! ;KZ41'V!<7&Z:W[!QA@RPZ4"?9.Z)4,SMU-P>.1V7Y[D58[VL&Z-+_68$H
M B[\=%6$L($')#)>9[LZY($=_?PP1E1D-[/\VS3V A#'0TBDEPRACNQ78836
M&>$=7QL?Z?"45W3N<'3MT+Z?#K7R*3!$%Q3"J(D2"@S6=6:8^"D?7W\6W8[M
M.ZF/S<X8_GS6 [PD('"!>Q@'$2U^*2WQ$M0MOS%XHPW0]<(4F0?XQ[QE#S15
MWSP[H^T=).AXM0<3%\2A[[GP-ZZ6]]?R 7*"#R3[H7-&IH]N#H:EBWEG]U56
M=OR(+PFF\6!MV]OLT@KPD_CPF]/ME?P7_\Q6R6$:186\?1]R[>,O_C-O5VIV
M+856%%I Z9_P?V@WL[-]G!":+7!P$<0Q5#H/G-W+O!541X\<+8Q<$'VYNCE\
MQXZ<,X4A;VOF+:YCM'"C808>U(=#_U44;EBBSL4:-F&E" FDXDI[!M[Z*<'4
MRX$0'T<OJF^SD(A5M^8#Z)U4@%A\JH3':<.#=(F.1+D='P;OI6)0S9M*TI\B
MNX*#I3N<.08]NMJ5F-6'#Y4/4E&IYUDEA&81V-K>X50(+KF8?$ZCR=69#[./
M4C$3D()*X&4$UCDUJEA\BNR5E_(AO0F%/I)BCA.<V:RYP>JEAHFGSH9ZAE4"
MZ/S$<8ZHF:Z6<9:2Q3 T[&YJ>  T(\/#LE(8G1;421@X7$X V5P-^\\R_#06
M5<*B$"^L-?%5;249NRP7.Y[9>^17U>_H*>UE&T.Z],N&D<FP2@J5IQ:)Z!6C
MBVS;* (0FVV5,!J'P1KMU]%!?OVLKVHLVR!RX\)@525$JA.E]O4;Y)I^LHTD
M-TY\ E *,F3BQZ$=<%LA>@_9^V)^F&J85@\@ 3M$[< 'SX^JP/,Z;-")2BZ/
M4REGC69L7H7D*4LMUU:LOJM"'IN8J5%\GU;P8WB0HK57R''C\-@ZQ:2BXL.M
M,?TG>?VI0LJH955#A?RMLGAI)*NGZ_3JI16GIA5MI9V>9.E8F*2:X_G*QK(-
M'*-J+'%$0F-5)3U"A;3"@ <.LJ5L,\:-!8U)E8#07==#+-O^S/9<,QC:6R\Y
MW9"MB C1.L@V7]RPU+"L$CISE/86 /=0N4-WG'2#A K<$5AYCL=P,WCZRK:)
MW)CQ"T(E^ I4XNW?6;GR+,\4)<SB>U(+^X49AA4;2';4@G\R-A.12B@77#9<
M4IS?0ZKO*=OOX.6-OMM6$3&.,I[5C@BUDVR?I"%.W/5,ZW"3N%<5X;?N\04:
MF[]>E[D<PY][SNRN+F%REN;]GC_-6_OA;+R_]9*IWN ACS/^/K#X.PVNA2OM
M-+QF!ZYV]@$-?T%NA*]<S9P1T3LUE>2%AGO;3_8Y&0R/L]1.MO&BRKKL7%;R
MIY+!FH,80$I0KOT([( ?XCRO>D#8W60;+6Y\>+A7":[\^AND5W<W7N#%279K
MJ1:PVHZR[2XO9)P2Z#YD? ^WC6BUGP8X^RY<I3' APO4I%S4K;:7[(US+0Y<
M7%!!&,@_ 3OM_3@L9+&QK!5Z!X(49#57 ZCM3O*'ESP-TSB!E$593594G0"*
M'O[K,K?[C093QMJ2R!'K>6-97;(;Z<&0U;).G[<J3<()2'BF7ZF9; 6LI)HF
M_XJ6"CD09I" ",0Y/T>BZ5!0.\B>&CR@U'"K(C"UGAS14+;G)@)$O9<F;VTZ
M5?)U_SO-;K2>JH?2\:CI)MN?XT&'BW.EL)J$07B^X-;.&T87V6<:/!C5<JS2
M8E9QUE)_%,7L)-L%X."H#%@EJ J!Q#H5(UX'.+X!<5HBZA%M[PNRG0UQ^-N6
M[FO1',@2)"_(4F&=_0+:D!ANPQ!0@8M_RF%K28\N^9YLSZE=K;I<\FH>57&^
M<7YVG/.1_SBG..1_V-LP_D4KGY'WQ!SY*OH93S_R\X1&TK*A9&WS$0FS*-QY
M4"JW^V4,7#,X;L#RBI/,4W&1,?X_F"'D; IB\]H<FQ& RZ/CV5E9T*T/\C50
MWX11XOV/77RXE(2+K[=LA^1B%$6$I!*X^'TQHDPR'4Y:>]FV_V( V8)0";+_
MLX&5RP!L&G7IZAQSU>@<D]9+@9A*0WBXV%,P)H:J$62K>&$)GZY&7IR5D8"+
M^RP"&R_=Q%RU"9N.)_OB[,43\S)!*J43S#)!1?9JPZ?B(_'IP4_JZD%3X:ED
M>]%E2B@$?!KN/:9<4+/Z\('ZL[J@U@M$)?A.B38H3GAZ(!179CN696.D?7'V
MYX/UD[JPB@E*J34:;J:C[-FH[/^0[5(%4=9A<'U?SH##6W7!Y9>0XL#F948/
M;SA4EAL5 9MO/$X%4#CD=)DD%5<*3/&IZ(&X%E &X(1=X1B5H*P4Q[E4S@_%
MVHCZ<2*P\XW'J04*![HNDZ1*WER%/E>7I1&:_;0A.)%7.$(F+"^UP1ZE8!'.
M ;Z2/+,CT?E>V9T39!7C;&*,O@: L]/YS#0U7-2I0W "K7!835A>*H%-X3Z+
M_UUVHETYAJ1R1ME+M/$BU!VX9XX M1(\G4N1,10]"V>@6BZ*)"PPI9Q42*T#
M@(N?L:Z(FW "+C*(HN?F HB+BTRE=8Q06+'WJCB[*WJX?L&\%GSN2ITI_6 G
M*+=TCTLA^#YPLL,LS$_"#?LE@RIZ4-]\RC<0J4I+ $4>=UY@!\YEKDSE&/+G
M@1G'*2I0,ET5"N?Q:3NEJZ*."P-#ADXSQ:.2YE83/8N\'=PJ0O/K 'Y/A=5?
M42?E4G1I@NH^QZA(SQQL,^-J@23Q09;V5'B6'J6UX6?I::E'30=3U"GA0/42
MKF5 O R@*)^AB4P /HZ-SU86?.O@H)7#,*;FF%TVI*)N1P.XFXI3_:6[6/9;
M=-D^[ZMHNN&E2W:5@)2"-=\G35>(PKI)7=I<5792-'M0 ,AZD2BU843<EI[9
M/G]7&&YSSG]1:#D#D1>Z9&0WK[-BO#A/=K &<^AV&*L5W"G1M:)O.F2[\'+D
M3M[E$0WJ*UDG1V5AL@(-2I9 55F8K'58VNU5+.T8.&_6X>[:V;O9U<[A_A%$
M<7:U>S_WXN\/=F"OL;>.*\O"&0;6>Y15[H=Q&IWR3XNW/F_>:0/MU 9=^RP.
MJZ%QM=/ N"+I86BM.'9+=UFK67V WXL\VS^C#6(.D0N2.@[?ESD\C%9B]3!>
M%VRQKNA.4+@/E,K*6F@J1?OIRO+6@;?R'!3[S])2H'+.0M\[*W6<,?SITZ>W
M-Q_*[$[TQ7)N:-,[;3HSYOK"G$XL39^,-&OY\*#/OZ&_L<S[B7EG#O7)0M.'
MP^ERLC G]]IL.C:'IF'U<U6Y,<L?RRRKQAF*W YHH=L"(S\2C/PVG2\&"V/^
MH)F3KX:U># FBWZ(/AP[59XX%6C^J4SS;([T;/$-ZYCQCZ4Y0T3W0O/QRML#
M- J0&JJ@?RX3?:>;<^VK/EX:VH.A6W#"]"?I4Y2%3#@JT/R)4 YCL1AC.K6Q
MJ=^:8W/QK1>"\VPXHA+@B=AW;\O$PKDW7QI0(?Z<&1.KIXF'L[@JZ;LITS>&
MJ/=$U=EFNT 388I'QFT_\Z:RU 6FB3">:$+WI&8X_#1XI%Y!+I!)&#UK,1W^
M/KB%F(ZTX?0!Z1RV?/VHG>?@B9%NM[X'(GT= >I2](XP7M PH1ER;2UGL[%I
MS#7]?F[TN!S]CA(-JB@EK-.'MS<_?/^;-AOK_<@U*PNQL%^JYS1AB<P)A-[0
M%OJ?/<ULGE<I"@035@B2^V!F-AY;S^$4>RO&I#]7!:P1^6:P"J,-=;I5F*)[
M;(?,R=UT_M#?3+/2QQC\E:*BZCO*!'M/F")K>6O!90S1:WSMS\ISN;<,-_<]
M8;/XW5SMA\/ /3V7P<7LXOQN58%5PA2*L)H-VQ.C5:X]G2_"G%8[^/WR4.7I
MTUD@3&VUO]\O"Y6./YT'PN92W/]^F2BYU73R"4-<=J[[I3OSLNGD$G8Y\[7[
M)1(YW702"4N,7.^>5Y)J;Y=.,VF$*3YOOWP4G#0J[1\(FUQTU7J6.^'QT,DF
M+3#I]_1+_07!PQ%ZF=*/)Z@B$'KAI(IAP@ZW$$S4?LB_K!T_W1/2SA-P4Y12
MK4-!#%S/3]''3]51L_<;@)N][[#9IDE>FN7P>.<,1#CY)6>@2F*DA1_^9HR6
M8RPS*!%S,#+'RX7YU8#*,US.S042B?'G<+P<P7E[-Y\^X,F[7&3:!'L9^GP"
M!6AI4.+08="A_ \B5,F;X]$G<I_^JM2F7%>WROECZ 89IR[JQE?='.NW\ >X
ME&B6#O] <P[[!9_!)!-KSF"V KA6.< ,& E_I@@CS1L^8B8K/:KZ#LD$L!.C
M&+VD)7I5TW0?,:NDUO63G:[!@Q"9TL4A"I72N<X>OZZO#]K@LEA[7Y"=<M)
M(=H6;TT>F:R"W8SEFFF0B$U>S5HMSR"=2G?B B20T<+UY3S$X4Z#.?)<(Y2L
M$K@3J$_1X>=;._98C@BY=2Q8L%,LY#\UW;*,/!9].&)$KE@>(QEIT$&=(R]V
MCCPUU&HRG0Q.OX%[4;-W?^4HQ6F:Q(D=H+2@O.QI08ITZ7PD \8%Z4R7"VL!
M.47L_:'/YWKA]+7HI:K(+.L=9LPYN;]MPKF<!YI/7GJ6N;4_%KOE0YT,.1>=
M\R'<L9D+O$]1"74C3CQH3,!QP3A5^&6PRMRC0K_<?- 71C$F>N):'JLG6$<
M7S1"[VUS(4MN.BG(CHRY^57'>W-YX%:&LCG,VT?^H+8L^T;FN?#P1>XC*_)>
M%##:I? ]0R&9&T@REB]WZTB6OLHKJC"=<%H7>:6K$32;K1_N ;@% 5AY"3<C
MU'ZR-XVUV%14GJZ7@V([1D0Q=/E7((ZA0&S_#O"K(+6?[-U=0^1JY*#H TN'
M\'%U=36V\28V;86(<7X$ ?U1?*)(,=H*%$;G*+S'769/*OVU\ZZNG^P5LZ[
M'ZM".TT**JV7%(I/)4V%H2MVE;UJMH(>*0M%E\VC9XG.(L,@N_2)>4&W/1EK
M)C.\@PX7IQ.\$8 _90OG<&I)/Z(X,D;7T$(3%687F]BJMK)7/X)LYHPY:ZC0
M&O?5CCQT"LL!0D53V6M8'094[E2"X%BNC .#JK:RKZ#6@4#G3W5;D1</\U 5
MCP;^]H_,X/<#RO[)_&NUW>\QW"0!0'$ #A441BGCD1K^$>3,0%[Z)E"G%L_
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M$3@$I#3 I"*C\X-H!] :B$N+VGY,EB2]:+7@_(+L8$S;*X208)56&A,]$.)
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M.IF=FK$+Q0@K:]N$C2A&3;%E2[::X#P6Z=R@+2)&);5#\SN]H!@Y_33R^ Q
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M+'=6Q\\Q9>K3K-')'9?BQ47%;ZR063FLXDCWUQ_4Z$&=4U\]YK2[<6>S\26
M87CGHPW,P\Q\85=SJCK4&>%-Y4Z[#;X2'V/T+TF XZ'.%_ #=]I=RA=\KWL>
MCCD2QYDV0J?A93,E<'VNR,?.\*0SJY84WJ7D^,R557LN>^^4<550>,$R>U5
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M2=AQ$15&4!2C*C)M8&V&9*^. D MO\-9X#Y;$9AYEDTT=$>?,%3<,52YXT]
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M!&-=T*CBMB+W*ZHCU25P(QRR+N];VL2N-Z%RU"AVV5AI7]9R#D* R'M"_ W
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MJX(<F@ZJO-0*TU6<NEI @B+7J598U:)6"JR;,F6E%;5BFBZ2:X[LXUD+^_>
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M;%\X93;N:N2-2%4GK-[T"G&X [5]IZ#B<Z*=I4%1*UQN2\1W+-2]4QA69DS
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M.6(:"BU.+V+%8,=2\\J]#"R2J8F7FD>0FU$IR_@_#VAW1K_Y_U!+ P04
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M5:$U8&D^OA_TX=*S' 1NV)7&. YZ>U=5 Q"&?KEA)B% 5QLL9;60^X0$92/
MG.L"\YO?'CR2[5?$BU./GP%+K_;U7Q13\3X-V"VXV]>P9A5>4VTP[.T-N5NO
MEXOEV7%)3(J_,K7QRHM+EBT7TT_3^[]=S>;RA<F.B+6E1PFX:G&Q];MS1BA
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M)K)-:ND.U\F..L#]=1+((Q2-EEU2&9G0I)92!1#!3'!*:-90O<AS4E!"4-$
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MVTS59B?J8TR]4YCH@2%Y#["=TI,UU?QBHYJ.<RJ6%5B;)\A4\PJ!L/6CLU+
MG:E:1](JI5XQ>4I2K)VKR5".>3COA-]DY/KZ<)*3S'#"*:XOV>RH+M-:][_E
M3*9B_Y8S-?CN+6=B>2BW-_3 >LZWG$U\G^2#96W48T5"4S_9T4Y$Q] '@C?A
M;I/.XE=<1'>R4'-@8U;G%$<9W)@U#&H)"K]'L:(S 2@;XSXT+*_)X45B:>N7
M].\;^L]5,\[I7\UQ>*_FG7R^?BSZ=_V-J.\PZ=^,D\O?>AHIO!G.L TP(<)
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MR+^-@VI1=Y;AC38CU5S?05UB<[,$98KURF"BO[Z(E?%?7%8T[A4#VHDAFJ7
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M0HC-RG0-$3 T$N,2+O?RXMTL) 5S!4U^3?'*>\.ICAU=0<M%#25 6]4+6U*
M:"*!IF9*QA1&I0D-\?[TG+Q^B_V@8(@?'(A!__+KP^MVQ8IUMBQI_F3CXXO
ML,]=_W?G'U@ 1I "C%Y3]( )7Z)AR;]LOSI*4CKHH%^XZO^V_)&G;S349]'5
M-9T&/"=D/WD+VVOI"CE;GU\)L^2"4 @$,53(VBRI9%$IC'YAXK:9,0G^>Y6P
M^Y@EC&C];HL)0E@E QH_@OCR(D2=<O+5Q<IL8E._ MO-E_^,/>:1)-^]\:NM
MKRZ 5'[SVD\@OG@73_M[%Q)N/FXY1JWP6W85=4L^2&1LC_,=>.T!OQ( \=%E
MJ'J% !>(MV&9$-?)$K/:5#@H>'GO;40QGT3.%C&4,$MR"(5 $$2%K!/ZTQ'
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MJ20(^FCA=99HZ,A$0LH4KL7S5[NTLNYE&'+YM+CUNSV_(H!U<"BU'R'-=$7
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M=&RC5@?'45Y 8PP]JD4P!!_%C,[*+5.XO&(:J%!!$T*H"(:68F)L_U7=?FU
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M? 3X3IY4U11;I&1-7/(V4-Z(<W)?$QR$&2OG5=U$,XOI='YG'H'V:\+J M
MXQH+/CWTP9!W .C.>B9O K$V $00[22)W 8S;AKJNDQK49JC2FP1*H*A81^T
MD@PK]]1;X%<<[_ M_8 L]Y E1OP<9B_7NS1+-BSMWVSQIU\C=A>$AAC87"3J
MTP(8>@Z"W5WXYHVPY:3D.0Y![$8O<(KI.V5K^#<47I3PU83I&SN1A94S+"--
MN^0T-J7)2*T:(!J:8A5LNG!-OFI4TT6%LGOGN<01;>[Y$XXQ\=C,<!)LPCAD
M^67L$&N)TW0@']:8W9']&(.;0_V0EL"P^BCX;:(7K>0U7AOMP*%Z=8#&<!E
M*N[D*)/)=%XB"X9R&H#R0W( V#/U2$R[2_J ":\_848BK9;5/6LS$QJ[UFH5
M,,PRP]FY>A?G\V=$U1#7<TXS6<T3TYQ80VU7Q14,3)(55E"H@J%A/[R=&34K
M?584<:JW="PIJ5["F?;AX_<?.-LF5]/YKS>8A*]\C,Y+76>:Y1I3)1O<ZF<
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MC2.\D[P9J(2M&SF4KZR-LZ1K#;B K?]Z7FR55XKHWPQ8MDJJ2O1MXSS9*J]
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M!_=R4O'8\3P&\NZRX02PY2%631@,9W0(.Q2*XQV['!W6)$YL12^3(;#(G$+
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MOJXT)&&BJ0@O .H'N_W%\O,G^FR)4P<6:95IK<DWD D#_#!:J)WC^L6<%$A
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MW' [U *#\7.T^AWNI[ZE]4YGOSU!@!H73_*"1YT#]T)P/B/?*<SN/=09>0+
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M'HS!I]8Y:/TKM<&3C<$-\BY*HX*)_,IO?))W1E\,LJ.&41P@M^(A/1HTQN,
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M;EPV,0>Z>6:T+0/FA*2U"!V/W9 J%T]_5)L@.A8VK:W,<?Y@H<&E+S? OE:
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MI,:O!^:J_TVJ>P_J#:++11P7M*+).<NB]$;6ECBGINX<=+AT-0RRKQM-399
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MA'6LJJR./2*L-^62'>W5@.,84EGC7@362VX%_2L]$$9)/8,L/D,268X;3JV
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MT5OVZ0_+GV>+U;O5:/'0&T\_CY8KEKMLB1WJ?2'K4T35*KVOR84S 3*(PMO
MF1P>K.!W"C,E^]PGB?^HH(H9-P3JS!4&OD!"?._.JLZ59C(8:Q/3_"^EV@@@
M:F*27^0IQ<C8HQH7RSTCN16NDR"N..A.CLE&@"[78>(>QA[-H&?%7$Z8<X=#
MY@\85O])=H7:[E?,T &)3A>=7%M% -OAY'&Y"HA%MS6YQ43F>2*J@VV)US$*
M"@H@APS=,O.X_.33[;C'A!GXP=X_)_?L;XG' DE4Z*[1&+:1MA,]J TRNH(,
M2! EH781$WU(]G[H2$-LA96P36X=$ X #9W8XE&7G1=RQX0=2U3\[_1%5)8C
M5)0Z1KDEY*MXT#FB&.U0$R[#>?X4^&'XZ-%ERF7=_R3.X:+>%/8JWS[5 L2N
MBVN6&K@EKM.FL*_?M7.=1^RJ\^"6S)PGB2_EAZL'OP7L_5T;6B'#QZPL"0*;
MM3 IPH\EX[78.HV> .'KL%,7=AH%U5SDUB'QC*[:#OKS5@U-V?5P,VLHGRZF
MYH&_IX>*0P;#GN$BN(?ZB^@>:KY@3VJL?DV>TQC]XW$\3U[,0;YT.DK(')6C
MO)CR,0RHBIW;A-M%<,8260MF6$C!+'+3D<CDQ+^&XO:PM*U04-6):1=2JKI;
M=E25"HI_2<7MY=V!V7XD@7V0RF^;S+RDZ/=:?-'H1Z41?Y#*9I"IH+10'O-"
M:DK3D;HD^<'A]%%Q!!N_/+9-24'/+N+99 AHBF2[CP//88^W+?U-](5E^//6
ML\W&L0F,"87ZV&?]FLPH(X1NZ)L0*R3L!:_Q;A_X+ZG[G^Q61E@)VZFQ!G40
ML0SAB[W&$P5QXGPY]JBL6PJOE#!Q+2!C/YG'& 0-/92%092CB_YVIHK^\MN"
M^<IR-GWT[[D_F[$3J+NMNY1%3XH9"-3< 7#LH"'9T2[QJL:RI2QGM<!\<#QG
M%^]$<!:*H*W41;A*8%;*@C(;/%BO4E0OBZ#%G,E1K9(%?5GDSEJ/(=G$[L39
M"$QCH,K(1FRXJ0AZ4BLC8RZ+R?5I#0*S>L:>\VJ3=P&(N;R==6Q(0CMP]FFF
M>/:LYXA=980.W5.,O'B7/07>:(Q"/X'M7:!S**O!C*XX%Z\#4QYL)^D?_=DE
MV7.CF4-4\N]<  3N!:U]P5B3A$QMV@;YJAU6N-)-29U[P:06=H* ]B>4'!BU
M8S,C/[)<8R(S!=?>0E>6OQ;OOR5WWNBN+&_Q]CL_;15F*Y&7BJ"2J;MYJ2>*
M% CT-?WH!S/STC>]+V0%K-C0^L9NZB4<JN%CJ!?1.:P_#$F2+V#B6$^.FP6>
ML% ELIYY"^8U%3C>-DTH\"XX_IYXM@O<CGX2N1W=]\>+WN?^Y''T/WO]Y7*T
M6B:3\63<OQM/TB?1'T;]Y>-B-.S-IKT%>RE]P5Y>8J6FL^F[\[_<]9=C]"CY
M$YAGB0'^AN):V&DR5-3B4BLD?DPM?L(,TSN$?6Y2C<88X#M!M2%,::.K1V\F
MIKE6M3[>-"C:Q"0WK9- =X>L^VRQO0_('S'Q[(,DKP"D\E>F&"(HT/VX3KVL
MZJ/,CPM4V3"VY5K-XU$D)';"@*I.AB?5E?D^P&ICGR845!5 (0\=],-A3E.3
MF2E)*0B>=8M5#!M]^N?:(@#H;_H49*^0-A'OT?.?0A(DR<3'WCZ.Z)]]SZ88
M)5SE!0-/RZU_T3!MXHT0\1:M13RPI_T'WR.'-.B2/2<@=7+CE3=F:M<T1HKY
MO(2P:7(-SGTT2U*1O2,L= B6UL+.\-$5=2 P#%G"D=(W:?,^[7AXWE(YM9?*
MZ;VVR_;.E>*6UTDYK]-[;2$$';/?09(GSK*=)6*^.*\(UFM^<:A/U9M8J66H
M:2)K;AU8MU?^Q+&)%_J!^!$Q7FFHM\J;H$J"&?KDF3OMG7[\V2$![=+S84)>
MB LVC@CK&W:VU6\I$:*!_GIHI<VNW.4Z)FI!,X8I 4CE(<9.OL38)HQ3SY()
M+$RD>P\V6%=5PG9>KJ6Y/!+YJ)@S,>?Z^*$.<Q\4F=-_I&F9N0]7P!S_O56!
M8*I/KFKS[]7%G&EOL@ZL\)DN^>P_S _NQ7(O!#W[QPC.E? FD%U M;B]% ^6
MJH"BJT N5YL2[[)ZAMT!:&$;AATZQ2D"2NP*JABS'])(K!0Q=$Y/><USPBLQ
M#&[ F%V41KX5T41GOR[I+7&M?]^ED>O:%)L0!9![(;9L$^5[]__PG<B[?_:X
M6J[ZTR%SS_^EOUCTIZL+U_Z;L[[.MW0EWO>B.H:9E^#N]"*A\/WC*WM7FE:
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M:2V 'U,25A3[MGRF "0F0&GV36E-['.\7/DD1/' 0+=]%SLZ>MT3FYXQV0.
MJKQ5U<4^&39FC@^(<=PMG/#W^X"0L1<1"G.TH <^50Y%;0"YU)9;KS&7<H",
MXS29,S[[+@69+OP'53HYU:'SJ;D3JA 7XU@\3B)#Y\59$V]=9V2*VH#RJ2W>
MN;5IEH^0'E(ESZ\G#YISCA'']\Z_UC/#I?QZWA. T,,=2,4'Z9$INL2K&LMC
M5[5LYB5@/CB>LXOYNSY:IE $;7-7A*L$9J4L*#/(@_4J1?6R"%KN"CFJ5;*@
M+[;'BPPZEZ4.)KEPF.(RPU]NU5HQQ2] LY6VL&C70=IH]6"'NGHJD=;$MDL8
MJ =Y2 W-/7-VTAJ2Q"/8>2$P/ZWOH7Y:P]%B_+E/?Q_=7+7T/.M=01Q5;:;8
M1/1$M+2B*3,[_$H2B(7I'F#YT0AT_:JL8LR<K.KS)0  ?1'-Z5CR_OCY=]!0
M*]6Y)E\O@#A&LD1';)2%N8P]N@R263#P=Q3I9^*%M$SZCR.VGH8./=^/O'A'
MTM=CH*0V^@3VU4!C'6@!8$U>G'3#QQSSTY=AZ.>*.QUF,AU[ ]_SB,W^_HL3
M/5]$X'!FWA;:-28S(W!Z;@U*3*]/8_=;"LZC^A^5:6W+]2:=22M3R6?GF2D[
M$%XLA;E#TP_%0U/.8?1AU%\^+D8/H[S':._4W.V<U%"2\Z%WX+NTRWZ*:Y^=
MW[<IA:E-P.;\>45_"JUD9I-YC.KXEF&W*O 90@<8^-ZA+<A2LBU5!%"V^A4S
M5$C?0"Q&9+8*'KY?)[M)GFUR/14[=7**?V5*P$$!W8FS+*E5+9S,.4*Y(3,4
M0*C,Q:<;5$74DPPF.<MXZ^P-V0,L8X6L$K;YIZ8>YL^%,%S>="X1;6?T%NC!
MSR]RD7N&EB3U2.)7Q3XWM\R2#"---,%9:4+"CP:38'*2VR%YBL8>/6G%K'.B
MH/.39893 3NWCH:34\DH)<0*G<MYX-N$K)/8>':]97GY[#!\2F7UL"_\.J 6
M!ATZPU>52$G;YK(#?<!)NQ21H)1TR0 %ZS;GN;[4ADAJTV:*='P-N5P$![[W
M0H*(7;ZF/X84IF1\"*8=A2:P#TJ=[RH @)KE]$>BR$UD/E[4'2!75C^6_/Q&
MJ]4DN:8Z^?/]:LY]U<#?[9SH2#PE)J*#F7@V<V8\22&_P%)L!OM&:T@V5'?7
M=\2C/T1SE^IT[GX&?%D%:L8,\V$MGKD74R#!\>^<RMT\][(T>57-YJ#J9A!<
M2[E+$S9(8/R;G05QF5_+W JB0WY%NCOD_R*^[E%IX^U0K"(U^IU/ODNRA!U5
M9<V@35U9!9SI3=^_&'T:3?]Y-YX)K9FE4MAF%+Z>7+CC50N';OHH;S3IHCR0
M><>):R&;+)46WN(N P '.F?,A_>\B3J<^WRRAK-@)L'J VX >VPUH5(1)716
M+P^L^50?B;_V>DX"FV&_!=\BB-O -C<VX58=*W1Z)WX:8\BZ+AJ9^5+8IKUF
MPZ\LKUDFEEQ<I1W$9,U2>7BA,([R+^(XRL'B<33LC?XY'TV7^%&3<^O ]N+L
MR)U(:+D 9V!A)23GJXR>W=[U#X1DVBC?I,CJ(6]3 /04/:M 0*#/=%DWYX&_
M(2&SLUKN/0%L*F7UL#<CM0F3(&$*82H' $$5['U%;9I .W[%>R4_LEQC(F&6
M\6YG!8?99K9/POF\[818(3"%P%]+2]_CPT-_D60-F,U'B_Z*O;$[&?671J4.
M2"0$K'O%<C@CL9J8@W0XRNHA+W75)!1&(4SVVD.Q^NTE(^B%Q","JF*OCTU8
M;C'M@\%$*].+OYHV(?6M+9^Y*)C=WO?8=>9LDX@\\,-(L';^)#HV#F8/\]DT
M"22EOZ4+Z&"V7-U6SOHCCO$!'6QIV>M;(?,RHA\A/EL!RRE  .A7%+V*E8LK
M(CKXRV<_2(S9 /2KRE[%&L,7$AU_ .SJ:&LSZH+0%H'\-M;P!RMB 7#TT%OK
M//SC=Z(U_:&_>ERDY]_;\;C-WH8A(9S=YMPZI*D]8C*E^K'Z0MP7\N![T;/H
M)K1VB]>P86B*EP$S*TR 7XD5K+[XS7D^-7056Y*:\%P7K2R\LB5BTZ:N8KM3
M&Z*K(I=%.+?#;=K2E>RMZ@%T7<P*4VRJMX0=L=(^LR8EX(1VO+^)2- >O87F
ML!,#M,IQ)5170W1S;O%3#+1*IY9SL$'</WIK>ICU8R]BCE V+=K?L=]J*@*_
M.>S'V)IKA0PJ]$'>^>W37PTRBXMNGTRR/]W'41R0@14^+XA-G'V4)$DXR;*,
MGUPFCL "]5YD@;I_7#TN1KU!?_ES;S$:C,;SU;)WOY@]Y*Q1R\>[U"#U-1FA
M>.G\870 +$M);ORZK1EM56HD&?ZM?C/FFS%MND%)290W=2.0X@((KO_Q0W&^
M329/@](_7Y<Q_Y;BN;N[TUM2YUM29\WZ4*EXMZ3.MZ3.MZ3.MZ3.;>W5D]4.
MF/6TLBCV+KR-M*<"##3EFJ5;?P7DN:6QK4DM@"]! MWT-P]\>EZ+#BQ6-Z(R
MCOZ(G3WKY]V!#7?Q<@6J;,;<U=GB!<)$SQOR;=#.^BA+7@.J; ;M"NH-Y3$O
MI)Y%:[;9.#99[BV;S#PBG#JKBV)[-2AH5WZN%,FM::'*?7+UQ8="G2N*[6;0
M'.J2W.AK4O^+%:R'5B19?0K%S)AP.EMG"M+GAC0R:;+5HU30#.(JE8Z'N=[Y
M?TGV43(BZ=!</?NQY:VS]SVHJHAWTI":V%XS'$VYV#7#$<"?K0)BS383VD71
M@?]<YNV_SU!&!)VDRRO_HYO.8^4M7:67P$45;*- !QQ* 3.44E4^\;V[T<@T
MALE/=!5(GYIGX7J.9Z7/3T\XM^A9-7$M["-0!ZQ"8$/G]E+UTG<8-G0:Z8<A
M 4=<EZIAG[HZ'[,<X&XY+U2\#K7M:#M7A_8R9IB@"$='H3%%:B=RRBB4P_87
M[X#V:F@,F]6S/)C0@7LJCNW9W?FP+0!E&(V_$+;(D'6?S@G6EBP(.YT?_\BV
M&(*GA-1;PK[;ZYQ\.+QFZ\4PBV5@R9.SM,DU]:*R):!>_/16]4( KZ&!"2QA
M,P.'1.G/QW<;638044*,CZ)PA.'H;M7K3X>]Z6AU^GV\7#[VIX,TW15Z*@PF
MJ\JK4[SR)F2/'UA!<* :*8OA$M="?\=!1(CXN;=*^35=.K+TL82.^'MZ9G<S
M:\Q]9<X"5IQ;&ML*"8-;*((AZ]VE+CQZULX/(N??9'V<C.<!V3GQCLYRI0EN
M*C)C-&X8VSC98$C5AE']+/M3NB1Y9,O><L"-F;W*5QL42)8\TW!U,<XY<:19
MDRL+8]LB:[/WEA(EY^6"9$?FE<>V)-8F4WL^9!-.&FG 8;:!F#VYSC;YE.B0
M\3T@YGG>_S5Y\'9V-QE_ZJ_&L^GM;-'::#RG35R0?7;S.-O, \>SG;WECCV%
MW'O-FKVFTTDK"+Z9&5V*@#R=7ZW6KN.$U4C$KU)3)!D":[9W56>U9J!=M;X@
M6K[,.,(IFKZN.5E#@@L@5<,/Q6UB8F\V)E'#=6\'+_5-DGFALK 9+N(-!IDQ
M.1 NNS61IS/@5C"'$XYN"0F9W+($8!-R"_._A?FW=*,V\2V/?GY);+:1/0 #
M_B65L$]_;83^@W!!OW_[3$+F#B&>]2X*F3%2X'/=1>?1H[^SWL@B]0K%S,"\
M0E>JL=8;H\?&G_TLC<\N%\.V$E1RGY\S>))I<H;(/B>+OBX7PSYR0X%L/;Z:
M R0[F02$26\%A^S;0DA%%; O-:7@RJ75LZJ%092;8>EOY]F5_O+;@JW/G'6,
M_CWW9S-F4\ *=MEM/7'F$%2YNGSLH"&[Z$N\JK%L:3=<"\P'QW-V\4X$9Z$(
MVJ5X$:X2F)6RH S\!^M5BNIE$;3H%3FJ5;*@H+JD<"0'EJ5-Z$3O^/RIE5/T
MFJ99C@BYM;9#Y+,N/'KAGMC.QB%K[G&!=9U?''\Z%FI1'G^^$!@3];$[]WY
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MYR35S* *H((PKDRY9_Y$/!)8+KON6.\<SV'^QLSU?/2Z)U[(W_AF]8'5H?=
MVOS90#I98$X)&O3)<7X,"4MF_^4S127LQ]&S'\C"D\7UD-/SP)S(2\'($"RN
M.FKR4L2Y%<R"-,]%$D8X)T$B-91V?GWL/#\M\"\#YPWI0:KJN>![M7%_41$[
MI4]K([\"CJNF/!$M#1\=QFR?GN:S2H6=DB_)GX1^EK#ZV/E_:BF &CC7K0?G
MPUZ2#D ^Z?-K8*?WJ<>U! #T/5FE5-.8[1MIO[,T*"0<6*Y+UG>'HSMW5E U
M[$JE82/C2V1\MP2GF6HQ>B6![80DT>1SK/.Q\X(\*#6;P_81;D\%H-!=<0*-
M>>#;A*S#>XHB6\(LSR9CCZJ[Y5X&6XDV?. FC(QIDF_]%"%"GP?FI^?C3[L6
MUNF!'T*2/537PLYT5(\Z !#H;/77:R=Y0LV=6\YZ[ VLO1-9;LZSF\\9I"YV
MQJ):S,%!P=QJR]+#93)/'.O)<9,]!.<&2%@#/1V1&H-2>?!YT[/3 IE'Y#71
M\Q^UMX%JTT*"OU<Z[O_ZWCK= .;$>["BQ)%P:$6"<S*\!?3$2K640!4A]+4W
M.=;?62%9LZ@1XH49P"=OTKO#N4BVF^A_L0+F<SI+DGRE,2?G%%3A\= @N!K1
M^U5T-_5Z-I<.F-#DD?8I\,.PZI3 LJ2*-G&L-K0RE%5#+&DJHADR%]1A4'!$
MK,F?69:Q.NQ=WVXNF5@2(X]DSL[*H(>BU)]A+Z1$'W(Y0_O ]T*'PI9FTB0V
M<5[(>N;E_,Q UP^09M"]Z9I>2L"Q,HGADT$]N3)+K]+&R@0#6D'/H="47S!2
M^/16WXHF1__Z-\;%ZE!"S3)A*6%S_>MG>$H\#;HQYE=!3[Y1?W4587#5#)_3
MQX<KGV.;S>D[\,:A6:OH.4!J&K:;(XD^[5<?"P#YQ"7UH)2:9?6"H7'5XQ_U
M+8T/9EFJ]+ZI80+;(C-N/>,VG&M#[%<@F4R9C;&?=] 77M'HUE_]E0>487;A
M930D=D!H=Z7#C%,+RIA9IBD($D8]RK&TG\DZ/AW82_<6V8L;I[[G7NGX2_&5
MCN7@Y]'P<3+JS>Y[R]5L\/?>77\Y&O8&LX?Y:+KLK\:SZ>D-#Z27.\X=3JR_
M)SD7Q&7A#\GN-#GM/.6N9T+Y2Q]-VT4Z[Y[8'^WVKG\@9$F"%ZJSG$LLU\W"
MPF:;!;']K<>BA5)K0"*AY%$139\S(_"Q'<TJ'L;U((;_]$D[XI2FXXITS&U_
MR QMTSIRBPF@VX80_R&7MQHHWZ5:0&+L\5Z"N<78*XB%'6._H"A2!)[IZ71(
M7HCK[Y,<]; (>U!E["C=.N'U"JB@'P&-RI*@S<SV]I,D9"L"65<O&%FG!3<A
MP/K(21,T;3^+5R1*8)IL%T@=$_LV5=SS&YY51H&_RHT"LWEB".@/5N//^5<]
M;Q8!$RP"=;U74PW)FY53YP_)S7F[GT*>5?28 '0Q4OMF9Y\F#(BL(,+WUF@'
MF5\(L^Z2=?^%3H9;<F&_[42#Q1W WKV:KM@0^MZ&NC_)\7I2QFM!V/Z5_OO
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MG#>/C >N7AM&D2P)6HW(N#@I8*[Q/D'@FU;G20R=U=!+A$\B:%P%!.SW/.<
M#Z4:()JA$/D=JU]-"*.!!@_4B7%2JMQ''H JL"G<::C(T#7;S'G0R BD592
M>)\2M 1H3'-.$&23$O"!*2/<Q>/FAB3@E0E0)?I4NI]'=9C^!%C\VPXLWH'%
M.Y[T>,'B'1+FRR%A6@2%<?ECD<2K- E,B%F".KQ+^X;D9PHA+;=4XT$<U6%H
M12=:E:LLZ&*;U>/Q!!ZR._5&F21DK@,;V5QO)QSN]RB]L,LLS#CB>M3>GXHF
MEZR3A%$F E<KHU,MIDZB?,FA@R;?@ 1/)K0[1DX*,V89"QI:*R:[AB6RH$D4
M.NJR+3XESO" 4_O7V,!#$3EL$9]*S?YQ).>]8U?MOWNXO(#$^/VN)%%DN$7N
M44L$C'=\=;'7,AIB.Z><J?=<4O-*E0*7<G<D:7@IEHL0CD+1@,P0: >I(B0I
M3K'RI=X1)(D<$(L"L'4GF6%2?;)#P08.(H]A(75^<Y@OG\%VVV,_4$.5HJX.
M3:*II]Y8+47RTN9Y99#?-8VY0NL(3-\ZJ5F?*-9&A[=\PH1"9*AL)*](K=(X
M-YJV:!E"/A\G?K!EG@ANRQ"FJ1IR1>[VH+C\P@:QL\X6)&%S*_R8-^</[6!5
M_N3,F _9CA;I798WH"4O^K6Q&!A39&*+]D;X*>[W%NR$7Y2SG9HY1C[1LBE"
MD^N<ZV#\GEV"M'C&-I9RO.2@,@Q9!)=[\VD8JMH]I%]IN^A[CBOLK:4.Q4XK
MC]'>8DPYA^-Y'KL2-%[M07&NE;4Y),*N(3S7[>F[:Y5(KT[,%3,VR\$U(^W=
M-PI?!UL#H<0A*$ICX#<:LIN#(!UE/C<8HT<C0."G^6B6JS(6+UG!Y6-SL[_6
MKG)+/5 =;UOKK,N8",E^5$M8DD7MB#$T?@63%5(R$?@[2?,[[S>RB\>U1"2G
M>#R_0\KIK^_O&[/7FR2S0M,T.2#087==H(ONU7??$87HT8-KBUJ%[RA;2NG5
M&"CQD9*W0M89@4#=+?"5#VE,CGIRT]SH%+B(%_.+D:A2;.?.6@UIK=R!>YSW
M+7(9W'DV)2\.Q^"&_&W))[@?.4;D,NGWLG65^ PW_MPBJHY*#6S8>Y;1F\S#
M)X8/PZL?''4>_RI3F T# FF_^O%OWY'LI9<,0O%+/_D/U_.N51ZA@3(:Q"\W
M35PD@8,.$.PB D95  HS3'"'#@J@4CA8")G+"L2_P;15(QB41WYWEHN:<XN\
M8G+@=SC<0;9!("+%,D/;+U^_?*E6!\L#-8(+R*0Q;0WG\LH,AB'7G7QE](SG
MZ.,89Q;_:C=1 &1E/)OLD<.8@@&+0M1^GD?LS,,?GDO9BG)*JFWB/&DR,,IX
MZL:&-Z@G#(+,A=)@):-*M\2YDM#.K0F=T!2(G\U!%>7>U0(WVB'Z(.^K+9,N
M*W<,R'V?%APA0$4\UBD*B#'&GTL=IPS863;G].)P=<+.( YWBZEFYR;../+;
MEKFH\+Z%99I]O_]J+WCN1E7;P'N'XS?V &_5\1O85/XK[FR!K@(4/.<$4\ K
M#=F4TCH0=<?8O-Q4,U@4/'+8T,!YJ[U\6.7>)U_NG5L?5@=+A^$.$%@$/._P
M0/R-)"ND-</@,3]X9UMLCIT6Y;EG<25Q)NZER2_(1AE??&;VG7=;B;7.6=O\
M#<Y>-$8NQJ$C\,\<&R$/09&$"8$[U\ V)-)I]W@&S23ENZ.DB4Z4+7?5)Y=B
M*R:*\"[^P/:@FX6[);95K<K37YVOY[MV!=,E$"1W"G&IO4N(FJ$,.K4CW)BR
MJB/2E;8:MUG5O4=>K=T=*^%?2_1YG>SC4^R?[_?2 @X&:4DRIJWV7*Y,?_IH
M/U%":-Q$G-RSW%GU*YBQ%'.XHN^FTI6$H]$_*DFCL^&VSX;[X ;3H_88=O^W
MT CGB3;U3-/7GBC;F7?;-Z0_9=YM5GCS])FF8=>F3=,NL.H=EMT!9S%%ABD)
M@9H6.M0#;I/H]JXB/Y[HNI=4+!W)96S95IDVX.,AO(+&0*<"$4B*"J1>$5MT
M6MC,P'J1??C5=UCK!F0@$+](0EC!<ZFSNCA1SD-W>R"W760;G<:40,F/4R8=
M:P[R*R9V_XU/GM2CXR*^>1/4]_LD,C*="T$=>^W8ZR-GK\?M8:^8Y2S?GP@*
M]DX>J_A:ZEAM"X=TRHY#RX!V_'= =@?*EXW,CXQ(K'V1[T'\!/72:5PW)U-<
M+V&VD:@,-0<ZPJKP:Y7!+O%2VQVH24(8[7Y/_*[<>VJ6F!VPF?TR=G%"7%+A
M#P@)CI>S-K=M77H"S.=^'/??.AQWA^/N+LC'B^-&SY+#- YV2O[SLBZ<$_W%
M75R%/T6>NYC"&CW;+ZL'RFD'R#8&SMJ/690Y<FA^%U1EX%_DC2+>-<R$<UKM
M!D@@_X"+*(EK-L[-BE(O.6U*I!;$B#B4IIXEMT:,VN@LL'FAZU.UFZ/ RCDS
MN-#L++";G5%1.R;>=R(-2AR0Q'%6>8XPF5Q91J-#=K1G2&32J*57<%+6?AEE
MML,3ZP+5R)608]HTEZ"GL8U+X<;Y_]&Z@2@/"=D+&Q(;R5H:\^-'AK'1E(P/
M6[CK%56]L17)6";I#UU2?A^*Y/(ES^\X1_V><T%YQQ]#"JE'@3-A*O^MPQ06
MQGG*ZG-9L_[LC$YD&'F)@G%76K]W1VS[B"H+"' $PT=Y[#>8IQH30XO1Y@^L
MZE,XM$_6V/$E(H5:%"HT]6RF3"CH:3OPM9=X;726A!8.:>K5UF7G../^-IC'
MGAM52UEIO,OA/L2 >X+'X 6]5^5TU"I;)46&C$D%<$V'Y1]X7V\4%3.((G,#
M3V"5+_HI-4 CWL9A^;'?0R =H9SPL?(#/57]9.&R1V,W%__=QP"DYU1X  1(
M9:+,$+V1O34$^Z$!+9 ^3L!+@454BFQKC&'"E17PW>U7U0S8]YK0DG<5T/&*
M:"*?8EL*&SEPSA#K5$=[40_ MZ*"Y8R4\3%)!)/ALO#*R.E'F2JB%C&C(/)7
M2U+A*S9;(?TUUP:M1I!SG4D0U$TJ^,6JMDK]K'M(KO?(Y]/MZLT-I[Z#%*'3
MPA,M,@< 2)E68?.4L0"^758,GB +QL$JXSEB8^L#):WDWI'R8GOB1(XE'*AH
MAZNB6='[B5+9O&\J8$NUU!(#IUW1I 9J%9,R8-NTU%2?- A 8,L%OB6M.YP/
MIHE>8R:O097F@*=.1_[V:DXUKU>_=UYN9R-0FZW$<IB@.A,0"(&8L*Z>\JLR
MB0?-^==FG!>#]RA_3-(R1Q_O8N5&V""D$YHZH>DO&$#^T2J1B<&#(BV5-I(3
ML:C3J1DYA."I#8O (JIPR/=!)T6U<$AW25'(AXS $MBZA'?D3D;O)<=FM$)!
MR:[P)H[A EW8%3M@7))/NO%WLW *>*AX^ Z(A&/DS!EK3&3FC&([7O."*XB%
M2A37/>P2TX+?P2]5G5UN[F&1CVJO=,SCRS*/=O&.AKK]CN(RG$A[%<'OZHDR
MB"=[0CH 3LL2%SB0#7)B)'.2)\$'-025MD/;M'%(->FNC,2II1]TJ2=!^DG+
MU5<9+OR@2M-M4E"Y7:$/_9$L&6A2(D<#5<CT XDX#R0*C!SS(^5C*R\L)7N4
M)D TTRF+7]0K/LUA4YOMKKQ(0E6L)&[-&P(VW!P&A[]ZDP"B'<Z 9ZD0@5>@
MI"Y[_59#CVIO=+RJXU5MCL4@WL047JZZT(N6#HEP"F@,OTD(=2+.:X$AU&+$
MV;E1<2_'E3S6D8C#G(/"41GWO^?@ > @6"PQ#M"\<6LHW!(K++O6.+U.K;G9
MYG>$Q'-LJ<=4PL3Q*PF/0.0.IG;Q$[4)!&CB8I"%4N:)6)IZ5P-Q*&!5WQ/#
M7@K/8.%/7L>Z.M;UR%E7B^(<"'0@&I:%5G2J? -*Q\?:-Z0A0MS$45SZ*W>F
ME)#H\DH1$K?F72DHFJ XJ:#3##]D_>8)W//WAQ1\UX44="$%'?Z^$Y3^/1Z;
M%B$D*<P2\<=((ZH45Y(#&[223AIYNH>DTR9:YK01L,2$\^:14H'BI" EGNCQ
M;?>0:BN:>:MYAXZ  $@$[ @VJXQ\'G *.,D/5L\<1XDRQ-.A';IE4^7RRDR$
M"<F<UPBTFW7\G&L1S$!"+G($[JQ*GG&@B%Q193 ZR&!V+LYEK,Q'X#:Y=@E+
M78&M*F$']>7U[:6HCB)$?$:85-G&_=ZMC@H)(:I@N.A>XE:3W'"]870C86Q/
M&3LNWIWF %'LSPBA*^3N#IC#H6*,39ZI>E1CE;CQKHQ];I*RREZ(U%<F15()
M*;^SQ!AFU50^ 8VNX[5/F]>VR.GTUH0W)4:VDY+;/:1R,8$W+I/8Y/9?S*%J
ML-) QQ38&G#E(*I0Y(KP:A47&"5 2663C(-)E@;O?ILM,Q\:ZUY![E"P<;"*
M?>=,L@1K\,)F,"^W#=6M3JV6*!5"X@R<$RM;:\36DJ5)RLH"IQ7.,R_B$'.=
M;,6)+#G?)98EJ'*FUD4&)T@0'A=QOC;FP%?$MNZ0/[ARA#<Q._/(4@00V4C7
M%H.M*!Q)(L\I+V8!K#ZUV8=,7%PT6@K?AWX92GR@,&<],W'.-SRH)4$MQ^$/
M0X*576'.4EC(-"8_)CLJ!5M).I@FYV>S+KGD$(B"02%4L(EEC\&NC#.\%"[C
M#$E-E:BTS>\I]*JY4!WG?\2<_PN8HEIDB^(R TB@)+(FO'#'4]LW)"D8P:O(
M,(Q=^A"JAIAKP65!E\(T]<)[$; ]+-NW.5!3JE1A8"C$8JDL1K1A59+*WU S
M Z^F#KO'B('Y09"4JAF&C@6 8LKG[N=/I]3;%!AR1WRL[Y=#%K0T!M0Z!P?Q
M<KE7Z399G>SWJ)^],LFFWRWN]C)"U:6[)EJX?5=[I80^UC/%#W9GKJ=\',X9
M22D]0&T/^SW'<KG:@U^RH;D -00)KH%?'B0O097-+/171+GDQ)9B2CORI/5[
M9395+)]D3/ZI@9;)MYL<^N<"BZ]CLD]:O28Q&54J@1<& DV5R7%B2[]7<\HV
M*\:,8U>CX-Z1TJZB!<=]A<)5#F>%\YQ4N>/X,>;[8IB@E4:@+L&;F@E"[J@!
MKK (O?^ZTF&RRJ4(E.N,:,-F2P@O%\TLP[ANY8#J)<8KD:R5U7S/,TF:[MI-
M"8&4J[+6.[ND_2<=;-C/ TN_,!)W54Z:L2Q9T5G9>'1@)#UT!+,DAAZ[%(!O
M\V!*"3"R<YD(=G1NO)H'8FO*4 +,<Y3+.'D+7G]8[YU+391QPT]!XFKUD AE
M<><!K%=HXXNGGCJRD4YK3H4XMO(7 ^WIICJ>S?X.U$4"-T:1,MHC-?ME5\T-
M*EF<,;F8!X_?U2C;.6?E]1<>P->4,AE.KV%FP^S4O_@)49]2E06YH2@-YH\O
MJ:B!<)H@22(^/?.RG@[#*P^/WG#MA,,71V_H](6"/R2;<+VHB)0"\6M@?%Q9
MCN<DS"3?"*!F5>552FA+F=GS*1RQ3JEY0*6F15K-L?@4T!T!4FRGSK1O2/A]
M4F0HCB2@>"SQ2I<X\D 7F; :*2L$$FX1ZP*DZQ2:"%TVQ8+E.8MR7TS&OF:=
MPR(;E'43&>;=C$XG<Z$K8DXV2RX?[@GKXK:2D"<AB<7 V$1^/CJDJ\BRBJ)
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M^/L.6-P!BSNN<"]6NE-\'D[Q^:4]>L]5DN7[4_0PQV(=Z- 2[3_LM5P2#A/
M!M4RG\2GO2:4*E\*=E8[A")X37J+MN5ZO!.Y0]AB:V]M6*#^E&&M>,);@, D
M;]]O+6<C/(I&6'X63<ZN,Z'!$(P :\Y4_=3+M^P<3K]7P#Q$[M6J/\PO/C,@
M;)45T*!CJH7J0 B.X"<@6'5\X>'X0HO8P@F:0S0\)J&O<&KQ_3/Q\L)QZMA"
M^X948PM2[1D-2S%59HXIO4]45B\(C5FR7HLZ>4:EYT73Q@LRSRK05*-\EY^
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MNNUQ78B8>L?4.6WA8^JCGU!+ P04    " #5.W1:06"D3RD#  !5#0  "@
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MAL\\0 3S!IC&X$38P.7*C9?03, 8  <B!'E8<'=!=(R_UOT?F&+)(&C%DNN
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MW+3A(A >%14W\'T21@@H_6OWZIZC#UOW0Q\CM?6Z==#A&\#^2H0[2Z VL%W
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MDG;_KC%9+;-[BJOR0YE=N);,;DG><5TH6Y+(; 0S$MDP'J9GHW7D4&-H!CY
M9N2@S.##/.-_I1GYM$:8C:2@Y1!98.@$/JVRF5-1TZ3LI&6'SX*LEAT^Q57Y
MH>Q0K2,[M)8V)K<?Y,TB'\4+J*  )H91KA7['/"TG0]OWC)\"^9&J)9I/0^R
M6J;U%%?EAS*MT3HRK4M.K@*Y:;D05T.3ZM59&#H,'!LC^4Y3%!-C#2CC'1!7
M>1I\%:<R^ZIRL5&A@I^HY[<N87TF1O4'.B6W__8N2AKGW7P9D8SY46S]<)?4
MVH,X8BB01=([X"B@]473*S$HNQT#0OGI_')=1S/XY^#P\_7QWV%ESC]].CX<
M7%X],[?^VI#OA\X<>$!P5P9R1]3#:#[O8]P5H_,P6-QB1&8U=(/C/%;$=%@$
M+8S!ZG:&JL2C8>.B%V_5F$[;QH2T,2%M3,C3$-M<9"73:\(KFQ5."BU7F<;<
MMG&*R;K 6&X9Q<-"?%7P@*3>B#9E8J%(E(OB3+D;VWS5L\J4<*0\\:-T64;_
M1N0W7VNT(=J>(U;>RZT=D+&%'[7" 2LNZN4]!?HC&?7(EU:+;J,-ON^$?8H2
MV(&1C$VHDYJF&85$G2JIBVQ9!!:<'/R+GN!\4<P&\;QXJ!3!G:M1VEN:6X+?
M%0EU5^:),"$VD'.*WK_,(G/4$UQ'EGKAD#8U1U53>FT#@1EA @&#0/ _3L_%
M/! &)2$SO'UK[^KSQ?[.WDO\I\=$X8ENI$.3S@=C"$Q"+CR)CZ8YDC:&KJ'#
MD! !*!H=>K5P=[6X#=&W#,.M3+DH3(59&;L@B5*,00"B3CGC.,?&S] T23ST
M,@5%PE,QSK);FZO!X2]33%NQ^AZQ>FT)IS.$I3GPC^4;VW&;\GJDO<GI6'AR
M<8-3VC<)\76E0-U)Q.AEK ?'5+:&%&Q@#W2W0R"4EBE87H G_R,QM RQ>PNE
M=_F@)PISYD%=4+OF/*<@7\B<$]+M]S.ZJD=1+@T>)Y"0)@H/V"3-,"D%QTB"
M@5:4::)WNYT->*T\EX05"TQ5;=]L]^P -&(,J&C&T!# -3!SSV3[(\8PYOZY
MKZ$%I3>!GEFTB71+K16?<O=)S&1<*!21F".9[A@>-5,W)8;I3.F<XBT"8DK6
M]C4L-+!VC3,W4W$ZK3WBF*P7ND$)=R#6,&4P@TIFC/#.R=4.G #(R.4=;J50
M 1,+$"_ F-;D!/?(O^D+;B;:'(%$I)EGFS6Q*) RQ&V,R]KT""[8W29LI&\%
MYPBZW6 GXS;-OGJI!3UOS0.IQV($.PY'<[=I>7FM"?LU08K@3 (MKK'R-UX@
M:LF?EG*OFM;<+V[=^!UX24O<\?3]MP(G?I2F!$FBY43AE81K(0VFM+(?"%G:
M!]?R;^&L1*SF7J)-A.VF8T$]P;6<,:H+[#I,8U_\D?NRWW]/;W F@E3GU!;#
M2* OG-KK=NB7[VAMMFG!8>A6]PZ;8SINY3*%P%LS2M:2T#WT?Y.EQ=0.IA%H
M8D6+#Z>39(6[&<H*\DX OR*,(>0MSRS':#4XQ>L6G*(%IWBZ M[/E.5:\UQK
MGEO7,.!:6.]#HX'Q7JY@9EG,WIM,HO+*4H^B:#G!(E1/L"R_J+@74Q/[AJG;
M4<+H=102AR4X5N@:VZ2<O&;59&6$L@A3F*.$8/Z,6@)"*<*&$U07,&)&F0LJ
M4<V*$/2,N? 6\4AYG#@@4%B@(0W=P6!H!.25<-4"I"U2 )1X@%H@&$4IS(5%
MW3 F3R2 #"M!FC!"&1LA&)&/^[;V0FL(<5"KB%<*T\G3"[T;N06EH9M4QHQ%
M2G\4"<E)[$59I<2U5L@VQ/9[PS,8K+LQ...W20B:U^[J(QII6[_"-&R;M*QG
MM-K-N Q";P0'Q1I'^?B)L"![)'L9\9T59\&';S3Z\,IAT&'%P3 W(UXX0[@8
M4T&$R##9$'@PD6%:$^+*AM,@*#+MH9TCDC&]*"U?06]M>V[;6-#O.[>$@LGD
M7M V6AX.FH\1$,7<=&BBH;,EYG#;ZTJA0+0 *8?:'1+H5.(=.(OB$ND*Y@O[
M"LPIJ93?LC$!U%3$U$"O<81E $9D_',]><'ZLHS)7PCCIT^I+260V3_KB9B&
MF (N[(QQ*@PP)8-2LD</3K=Q20:6F:&T8<=&-7!(\- ]1@I'^"O@*0Z9D\(A
M[$-A3[B*0A4JFJ>K5J@,X6K1NB3M;*#$ &T76=ZS&.5I5B+=$N854.(-<9B&
M<Y.HH!>I6-9S*S6T09W?RWW<YEF9FE,]"TN/P3(K'5SX='E/X'.&MWR2)EXI
MJ1J,-3G0\(]1U;-:&@E-YQ60<70.N$!3A-SS8'8-Y)VA> F-%-B495QR0*@L
M,RI2IF916NC8L0 J)M#H$F0NR)J8&ZL16LIV5C71<]R#VKDEW@14%G'.3D;;
MK%D?:*HLD&C@@XGR6[2ZFO&49=5@@K)2#:*2#VJ$<WC/D]OB2-60BF_'"KD7
MTU%=3W_T-:'1KG5Y/Y&WE7W:L2FBYES@#RE<QDKH&U9"6W?KTR"_&L58EG:\
M=)C?R<+5U<("/B8R>UEX]<'<OBH>^F\PGJ G9&$HUC2/YQ;TG;V*3:CE3(F<
M((>V=0>0HR6*>2>I=T#(2E6MJ8+5$IQ!HXIBIVYSLA2^W>U<5TCQR7 MKZ3#
MLC3&HT7T^0=IFC[9I+,NDKUAV"]!TJ-7-36^3;U9&J+L;4!$HS J+7<',?.&
M2O@U1[;,S(VZ8)VLD-E$ _QIR? N,!*N";2U-K2&!4&45UJKU47*J+7*2,U=
M;J]+W?.@=5U=3$*NE'<";BH*-D!A <0$O.SH.IS*:#EMS\RAN#[DETKR"HY0
ML8<WEIY!C;#, X>G1IDL:-E!CD++;P&;9&FQNTKQ!U-Q=8GZM6[SN^;;PY0@
MZW:6U2!#(70EQZTPDA6AB62U6!*2Z.(L\J6W1N-6-1O3BW8 X7FLX#^H@..-
M*>/ U#4S-H'8EH!#S.R$G!>YJ<##%UEY+W<[MOJ1(<EA_:X<L[N[X0:!]9H8
MU'*Z41@)W'RJ&#Y,[>:&^>IV&F(XR6U3VJ167Z72N\XIYF.XV2!S(#(YFGU%
MF 8%$N7T%;).^4H,,1.ZI)H&R]&W5(6&KR/WB]'GRGQ(3'IT I*Y.]H*<T^$
M?'91UN(G5^TT8_^PU@-L&R,HS2GU RA1VP?%=XO=E/7:7+[#$L5E=LB"X++$
M"XN.0R! C^9DL%CI$O$]ENA9-.&6Y*W$@#848EC"MKX<4UHL3>.>,_#0686I
M8FT>3V%4@9'Z:91B'"@)CB@U=CMFIDK_*35N#+GW^: ;>YAMDC0(' C7BOA1
M;^$;D!$BE!*]!@R7LK_P8^F4 A_9(<Q?824D%V'IEZ7#EXT+GES""N/0C /^
M>V:RVWG(0(D-<O1LH%1HPUTQW<6Z]#%@D2+X2"@7,K!ZW#A+BQLTL]7W+8OM
MJAP(U8XS0_@96Z)EC8_)&M]8UHBZ+AHFV2P:PV(I9[Q;2,W2Q<T-[ BSZVN%
M6F"[6?,?%Q$A'1 D#JK@0I8?/-T<;1Q$&5S46' VP)A=BM_L+1C^?),M$6 +
MKYB'0-@ 4J\&AV715^@GQBCK&CG;PF;2HL^%S!9SX(L1&8 _BKWC_:M<CD;=
M3K_L\J"(,; D$6?IMOCPH2=.O>%M](N;;;'SNB=V/GSXP*6VJ0FQK(6=5[_W
MX,H!XC& WDBK7#J;)N^"!O,%+HQNY]0S\&H4,!/Q?XC?%_%)J_X,[1\:LRV^
M[9W"*\]&?:6F.1#Q!FN)OWJ_B7;_9W8$5T?*OFDC9=M(V?_0N&W']JL +'[.
M*-:=?L_%\,:Y& [14J3"10,.7QKVYU4J0.N,>$3R*Z7@R.RGJ1H<)Z9KRDQ'
M,;MI?3F>$_1TM<*N3U(-ZSOWQ,.A%&X$ZK3B*?!%6.-*K4:IW6O WE[=-QLS
M."45TX<"LVL7S9K5:G>^>=W+YC>I8I4 '?.35MF,:[ U>6.VJ0P[79UYM\-9
M\ES"N^%A9SSRXFU1.BDJKGB,F<U<H$S-J5R^V1-A2A/@%9YKKE3KU1)>/:GW
M8A^OVU%Y3B>==SS51\;U^6[W7K/-'G=5YH5LLI2-3QQ9(Q\VAD>,?$;&:N+B
MX.\W/SBK!7((+Q_6\ZSY%EI;?]$$[AGFH1(N!KV:W&T']"-GJ=5R1G!.BF%N
MZIZ1P]$8KAXPAU@]N_3-47UGH+]G3#(F?<#:,S@-;]D<>RRF-LG1Z'YV6%E-
M-_YNIS8!:[O5U_RD5F6MMT[6.E7Y. U):;67[*XX,2;2P5V@IK9*>"M//6K!
M-XZ-91[K++P$HXU5X$&;]?-9.)9C0FN+2VLN5QM'][#0A267;0_3D&NVG5)R
MBN6MC3-&UN1RA:PCGZSOLDZC]HB<(U91D$5#CF3KH[8,#1^VK..1R#]+G?PZ
M;Z@S&HULCGD5CL+E86D2]B<J=R"A)2[\!EVF%7#WYFASSU1H'/=-5LW-\FBP
M8;/'V5RP&XU9T@WDUIHTH\DT0T\%-=/BWK6)M<\PL79=<.]<>A<'28!.C/>2
M8G<HX5+ 103, #U6I&1(C4P![PFN1<[J/=Q5]MHX, <=8_>X]*&-HN 2.TXQ
MWT7'@0D7" 6:U%FMH&0S,N=36,=7]HY5_"5&F\F7\!1?N[WW]JU&_IGA6Z0[
M4V]]6;0F>K-)%R OC?2#(D ? L6\HFC?%Z_18X\T-6A#,6QZ,W'4Q>:UU[X/
M 6:C,,AZ48GJ@.?/" ^Z13-_%F2UT/=/<57^D@B/624MDUGS+$HQ>5^,,::#
M7+L@"8+*XB".@(_31S2FAND4E6#'_,^@N<D0..?KW]'Q^OIU\Y71N^^Z\% (
M?O"=(<T C2FV/LK*G6$8>?7B2(><<(TR>3J-DJ:&\%^M8H)H4]/<4LMLO&?#
M\2I2=IG]1!>'(Y+N" ]5TMX3F&HY+6&K+"7E92'2K&4!SX&L]KYXBJOREP3U
M:;HOXN@KIN('LM"4&TLQC[<1?,CEW=:W J@A>!K/(X81>#WCY6,[V% E:H1&
M.C2##+-4AAA'/I-1;'FGQ?D#ZN#3"'Z!?VWZKLI-;HQ+F"5KF07"?OMJ!]2[
MC9TWFVC#=]_NX+=EJA)</PDY/QB0\# -%1>@^OV]7X!*;.#CM<)_8;WFWZ9!
M D8!__/VU;:XSLB5,K>I\63T::XXW\+I/A'RJPZ!=UY^I_&/[8JC2 =QBCZR
M77&:)E&>H@49/0&M+?8Q70'U?(FO2G"RIK'(AF[=.&"&4:UUF8#M)3[0=UYV
M70T-J FPW.=$)@-CT1); I!SG'B%?2WB 9DA^5$&9"SP1E(:G/TL+B*KV\&X
M43/,9[8W5T="OFTC(=M(R+]X#.&OCN3\Z:75#M>]M-KIX/K/\Z,K+$4FL,S:
MWP>77]9U+&LN,/ABWJ$M1G95)JI:A>%@ZZVKR5T#D6#_:\VQ6A$43'X(A7[U
M:O&,4WPK-W6'RHN_VZD;I%B<(6W$SV#SBQ4M#78@$2B9^WABE-,9Y02(J 5(
M"TIK _-)45+3#''6NAW/T'8() WQ5JR&>1*$A&GSGI@&L4%2CR_A;+8NY=:E
MW+J4'\VL ]+>2$5YSP*0A066)THQ<Q4DZ)C81N/!+\%13.8DO%.88A:;Q +'
M4IL ;X5I_9B;.BS,DZ6E2*L\CU78VB!;G]6]A&JEOMJ-:F&V1BNV*&?Z2NU#
MT]E8B4;\FW87MI;P_V 7<N@,88O$A')J E60*Q),B[I360!<KV?8'H>J8 H[
M2&F93/3(E,YAJQ PS6FJ(P<3@+A !,5@JE;97;\(JM]NY$?<R.L"KX[;MYA:
M9X7=OK7"@_=PU@ :]>[U4,$.-C!ZTH-;0!4$TZKP:TX:;V[8>+NI] &9.8$I
M$]I-U:&$#6L#6^(LHJ[O"OB0>92@+0I0.^C,R5B4I5QKWBGMN=VC1!<9)\'%
MA!-;T=U*(6:)%L=1!26%I5/J0[_$A W5IK,&NU)>,$M98>/);)!NXY2U1_T1
MC_JZ(+(K2E4Q1UU[.[<*Z^155'=&!HN#NX03E. 7S$YLJ V(7%N(0VC3O;9<
M\;)VPS[BAET7$.]T- (1R:BE:$E"8#40H-"8E!!66V;B#CA0V>BQ*EQ2.2BP
MNY3D?]R4!JENF2K@)2F&9 DC1CRJQJH10E&[G1]O.]^LR79&^:<4M*S/EZI9
MQ'3Y.U7"H()5) H2(Y8;?MN@D2="/L),R]"6U\+ZKYC])="SBG&:(S&*PB*(
MT,X>%OF\5/0J<:D888NV,RK'DW&I#FOB1P.[JZ+!=37LCL'$:T[EHNXH].#!
M_5'JF2LYP@]9HSY&8'%F!2,K#V'^I /":F:>U;@%F!5=\96@S\%S,U!)@/EF
M@X.E,1\;(\!,+L54SKG:2309%IE6]X*1(BB@K!>)M8>O/M.HZ7/5!&@@YKF)
MDC":P;1RW8.R8]]58W/@2:J/8YNHXH&.PI0X4.:-4D'@!1TI KF>5S'*$S]-
M]?OA@9]9W,?ZD%]U,9I* 6<I7/1J6QR4H )VH5E5-H<:D59P$_J6IN !D!]"
MWH#6K)L/4(^1,6V'L--=HO2"VU#G:JH9%-^#BO4. 6<XAS,.@LKPSDK0[!\Q
M=@,]'AC-85D2&3U$WVO#DTP#)4H,(;+,Q:W$_.=8SDVH50U_?\$B][W ^MU.
MBZ'RM,BO'I\W]OC *H9JDA#,8>F'KH;^\;[AQQ@_Q=9\2;DB)W#(!KG?G!S<
M8''*!0V\;>2@0VJE/,G Y+I=N)><^]V@$N$5 2KR)"HF#?C\]@+Q[$\.# F+
MUE-3L%>I+8=*-$W1+,75QNTQ*"_K9[:#5P?^O6L#_]K OS4+G%OW\,6?%?@W
MN!M'PPC$A/ZZ!_[]RJOXIZQ&_V!P?M;O=J[_'%SV+P:?KX\/K\3Q&8+/K.^J
MP+@.ST\O!F=7_>OC\[-N!V,R/U^<#J#]B_.3X\,O:SZZ_N'_GIW_XV1P] >.
MJ=OY='YYNLY#6G.)]@!D2 V-HQX_5'%JXCQ)8\?OJ8#CUR2]C55XHQP2^"C"
M$O(N[-1_?"P]9'RV)LXB=8L?7*JPU?A\(*NTF$X(,<@HC?!8?ZA HT)A.I-3
M!9)QH%%AVFY(?>.7ZLEOV^)03J/<!$"@O5*+ M4L=-:B:%SZGD(U(ELFF7T0
M*;%?#IO<L9] 1L>.00NK]-ST7)T.(XQ3WC8C:4GC6;7H61;%E&DTMJ=6VWLR
M9X.!:AJ6^@'G1=YD2BTY+1$_0DB2&+X0)87U(I4V03:16&.*0='T=@B_SFB>
MH#J,+7@N=>X\1UZW3=BQ+F?,Z*W;XE.1X?'H43T_G@>L!-?,),P84R&':)DQ
M!D/>SN;$6V^N,S$V0\T-YZ9BD87 :[";=#NKX3;3JA6K$BGA>9E94S:57I,$
M)LIW=?2>\2%L(\,K!+]#7?67>BA7:_K<YM,:0NM._K7N9&<-+!&XD:PKF#X)
M[+$:[?,77IP?=9+:T_,7.#T7(!CA[7XF)VI3M O4GJ!U6*!'.4&( ;]I2'G6
M,3VKO3?O=\4Y ZM_%"=2YZTS9[4SYQFX6WA[E.XD(O_EP?G1%]SL+_^\/CW9
M_W]02P,$%     @ U3MT6M6^1"4H<P, P\ =  P   !F;W)M,3 M:RYH=&WL
MO6E[V\:2*/P=OP)7<V?&?EY2YJ+5=G0?6HNC1-N19"?G?/'3!)HD8A!@L$AB
M?OU;5=V-A00E2@(E@NHSF80BL5175U777I__W]W0-6]X$#J^]\O_-M<;_VMR
MS_)MQ^O_\K^=J_WCX__]?WO&YT$$E\&E7OC+VB"*1A\_?+B]O5V_;:_[0?]#
M<W=W]\,=7K,F+OIX5WA=J]%H?OCS].3*&O AJSM>&#'/XLE-KN/]G/U\_#6Y
MM!NX3NY2_$:]I/UAZM'PJYW>D+UXZX/X,7=I5'CIIK@T4I<ZH;_1:F[?!X>X
M(KGA;M:U38095LC__')YDEX>%5^?7OHA"I@7]OQ@R"+80GS29KW1JK>V,@^I
MA]S*/0C^7N_[-P\^9Z?>;JKG3&U.?J7X<Y>%"<9M/H%N]4[X >YH;:@+X[#>
M9VR47-QC89<>*W^8O#@:CWA8>#7]DKO<CH*)ZW. P\\?\&>\IU5OM#.KY99=
M##[\D'N%Y<=>%(R++Y8_YFX(@V@:>O@R_]3QC-?##WF$1,',3=G] +^J"SM?
M#L^3*UF7^QZ+!CQ@(QY'CA6N6_Z0'MQL 1*0XSFS]PP3__<Y<B*7[WW^(/YK
M?![RB)GXJ#K_.W9N?EG;][V(>U']&I"Y9EKBKU_6(GX7?2"Q\ 'N^B >^?G_
MU.OFD<-=^Z-YQ:-/YAD;\H_FG7WWR3P^H \_&JW=']^N_KMU\+73N8#_(&#P
MGW>W3C2 _Q[N'\"_F6?#O_?_??#>K-?G?&Y[^P<BXD<Q GXH!,S_P(U]NJG1
M;#2?</?F[@\._ #+@'\Z0^[9\/_1D<OZ/WK,#?DCGM3)/.G MV)ZD!-:S+W@
M@>/;1_!=^./HWX]XY$;FD8<>;/YX'QX:,/?8L_G=[WS\HP'_:S=WVHVM^1^[
M]06V]N!'\X>4C>+Y\-4C'M'Z<35@ 0]_M'[022">$=)WCWC, 4)R(1_5G@+H
M6<_>_?$5)&K$X<F-Y..C[K^( _YC(PO$"+YYU/+"OWL1O![$@%P%_/V(!VS\
M. :P^SSXL:D^S7_W]I<?5^<_\$1I-N#5/]?A6XF KF^/S3 :N_R7M1X(BX]F
MLS&*S&MG""@ZX[?FI3]D7DU\48-7!$X/99+MW*C;;"<<N6S\T?1\C^-OSMU'
ME"\\ *%%?SBVS3V48/@77'4&+!$XEI!.=]$E[_VR=A3X0^3:>J,)_T0^?6ZV
MZ!QP0 (?,2MJ$)&OF1ZL$=[+G8\Y1EW;(T[]_"'WEK+>NY%][TRV7ML[^O>"
M -C, E H!-;V4BDP&XBC )X(BH5\FCS;/Y[X7O^:!\,#WHWVXR" 1Z_E .V$
MYST KIT%#@BIY2!;-)HM4*UBSQ'7 LO":1=^]!P7SIX@!KI0 *G7/PS1.1X*
M)SXH0Q=LS+HNOP^LC1E@M5ME@Y5%U)GO64_ U<9FV4#M^\.A$R%)AAW/1B4
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M,E^S@V:')9'XSR9L3<&K1@NMZ;R0"%@CXO:*] :;D=M8N,Y7VN36HE6\>].
MIM& *:T;&UNKF-+ZZMN^Q.'SI'F<E@BO+1':+V_TS2$1=C;TMB]8(BRU(:0E
MP@HK@A-&P0F81U[(5VB6<7&V;Z;KQCX@)6!6=.U?\*#G!\,C/SB/!CP LS$E
M#M&5HQ [*T<:\K!HU!L[XK"@3RF17,5=5V+"LX^]&UB 'XPO8L R"Z>&F5>9
M>.YKT?(X++S:T2)W\5%'B]SOQ:43SB2M0T0C.7E.'1?DL._Q"S;.X'%VY??J
M4R56>E\$OAU;T7EPQ8,;6&Z&(!_$72GNN!>M/M?\]\+\AU-&0LU_3^*_!W&G
M^4_SWP/!U\<A-3'-I&):7=9Z!8)['L<K@'.8U_Z#^]W/FL@UD:^8VUS+;TW:
MR^O)F8CM:"+51+JTL:E&O=E0-BE\*B17A?Y+[K+(\?K7_B6/HJNQ9\,SW@YE
MSH.&5S2X:!\?:7#1CB_2X3&#N,IQ.*XJ76J/H^; 17-@.2['-\J!;]?GJ#EP
M$4['>;#Z9@V"4DBNXA;!:K@=-9EK,J^JXS%M=[59;VXFG[8FZ379QVL>#&>J
M4E6FYY)2NR:(K0AORZ%%+8J^)2D]BKXET;V"MD(57IT^/W)ZO6B\"E0<.4'2
M57\BX[!HL?JXG^NXUW2BS\N"0-U*G(#+=)2\1K;ZM$=(*3_45Q44 FRKZOX6
M!TYH.U:UIW6\J/=%=*>]9G>RI%K-Y\U-BYR-WU4G/%4[S>[^#:KGU"2D(^=F
M%>Q$=G=!J,K63#^XXC>^]5?.W=O:^63!;WWCP?2L\.GRI*U/E_S&-__0Z0]6
MH$CN,9N?6?(;W_PS9Q7Z-C]F[],5OY6M'_" LU[$5Z"74^%&3ZQOY;95>HDV
M$R\1?<I4M>_[PZ'O92J]R;@\< )N17XP:5W&W9#_'<,J*?6E^C21C"$1'9"P
MLY;O8?9 WNJ;0E)I#O%K)W+Y>>_8LYT;QXZ9FQJY^3THU<J=V,?I6$#A1K^:
M0VWS"0XU2>>+<[Q.L]1;8!Q-LV^;9E/%0,R\QAE-'OS[&(\LUUV!"M>5HN['
M@/"=AYCND-..'MIDS5Z+8:]SCVN^6EF^NF=WWS!#Q9XCN.G;U<$DD0\Y"^.
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MLH<3JEV&5+LN>3\6K=',J_JU^0X1N_W);+5;ZXEBYE#R^ B3QTMF:F.2J07
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MMF4HE65BLAG<))EGMV; &S:U9K=@^X@%D:=<)7CF$_=;C"+YB<;/,80KL_-
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MY&KVUPU/AN"9HN$X_*P:)R6#^DX[URE;?\%#3Y8'RJ&/X]KT[+^+@\*A?IE
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MZ\-SX5&Y36-2&1=Z7SX^9_DC4FU%U("X+A?BRL39P.AC=<7TCO>7*!9<ER;
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MN AY'-'<;E7B0<(M&<$]<$8BI;AXPC>E85.++_(.82)0ZG%"#Y,4S[*@CLI
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MJ/P#X8%NOWX5'W\K._[$] D*.C%9OR933):;(IWD3\30+<OW)B3"@V'P9"%
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M'AQA[=5H0CUDPL2CJ33(4$%GB^QNER!QHSY4):2ZFRAH@L_-.E<I^&';CV$
M"XR2.8VE-\ MW6=1=<OTG(@.&:VEQGW?H)?3?D,48OMI%$!,\)O2_7!F!L 7
M.L'^HD7_'*"VW4<4MZOH* "-*:-9X=IRTLKH^>F/.;<HKTHQR6TK2:+\83S.
M*3[;^%[A77_C" ZC0&!F9_FLZF;KI98NBOS:,/X>-\SD[X)A4!(-&C"#QE;
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M 9_'NE 85,E"M*'+E@HP;=B^*-_(T:$'2B$XX6HL<RQ'I$^>WO'G *EZN42
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M8X0G5@Y3TC0ST;7AT@NB2*LMAI2#B5T(EG2Q;B3YU=Z"TW=$Y\J;D2*SH?S
M55^Z@(-$U=+1D(ZA:4>+@*C3YI;1%1[%CWRJ!:FZ8<].3I_D[^B*B[6FE_^K
MO>S96(Y7019/@O><^FMZ-X7NS]?&8+-0!]*'T7<0JQQ\D:^5Z4#*7)<U1^;K
M/J0\ DXR=%$I*GVGT0[PXFI >($5'^_HI%#"NN*R=\3\I(8@LC]%>C;&9W;*
MO*=)D12-DA*KP#IB#T=(%-]8LL.&:C<!(V29%I+FET;'H#O:-#OT4VVSEV@@
MMI[''0=-/"OQ1XGF )E9/?=@99CBT%+E\=\MZ 1.JRD>1BL\5D#U>;J-B&$M
M:F')P%2M4\:@A#[1@/.XO8\L [L=R#T# G;K/.'I1B.!AY^PW>;TK#/B<JZJ
M4V@THB@OA6INFZ*<DSW6;**@RA$ZA7^C[IP]WGRY$8^UYR@]SE^ONYXGS#Z:
M/;?8=:N)AL!QTH4.X*;'\\@'0\*;-\I-15YA?N.$-%TT/&/1T 1NXI>O Z^U
M9E=X?R##DG9I26;G./_1/,^"D2K(>RU46I,3?L,MYV4F^;PS7_^,F3M5 T?W
M:-Q3+V>PW)QYV1I1+XR^NJG7X-,KQF=)7WQ @XZM7*E L'T*(C?6Q#,!N=9V
M$>_%T<5;_ESBY3!GLQLJS'@9N92:K$N?#+_87BK0V-YE0<*F&-FZ:W#?)GM=
M1[UE>'%?NXZ17E*T""/Y-Y_I]R0P594VD,GNE*-!'807:T8-TQ_^UEC7B,JA
M"O*,EX7X;#/VFJQ;;L]/];L11D\."*//B##Z]H P^O,[HOLT5.3O7GS@9L*!
MJ<*W=$@L58LJR"&C]_5J&)QY,5 &#GNG7VFJ8*&ZCAU:,#?HO[0*Q@\E!3KO
M.C;+^AFW&&(FLEVA2<NJ>:X/X0FZ$"RC&%=,Y<2>@'I(O)".11X4FN@U/(CJ
M)=KTH]FTE[\\/\Z?;2'LV05S]#F0_N(!1$_9SFEM\/=3F4QKLI^2U?01@%2Q
M0W9)WMYG9R(M^VTA^^!!^=L=[QHLPCR!CLD%,<7=CLY>KXLR,?U)_!KZ'L%?
M-$_JN/ KX7J;?Q,B/H0<WF/-X(%?898Z3&E7:GDZ5F5(,]'"^S_$*[@WKAPL
MQ6A"N#P6=Y"EK9N&;RJR0,7]OF%&*P:Y:PNG/$43A1K(I+_S6>X^3O$F798"
M,V2-@Y1"P1.PT.*97;OYNG:9?6*F(I&V]X-6ZM<9,,5>/MDQR54K/.T*18@A
M>5+N'9LG,96*?DD,C#9<D:N'-<OW]C@!LRQ9;+&GC]6PK^#31<(@"$F3Y)*O
MP<;9Q1EYS$YRW!Z2L4<?;&J%A<@@C@3&D<+O?JDD4-@94/P'.\11U/#I]Y^(
M+_Y#O>L04OSNX9X<GSVNFJ_]'2@.V9^1/_WVR=//-/0O[6I7?WL6;7.,<V*K
M_Q7\4N]:U0S?>)]ATD9X,S61([+JU1V^#@8QY>],)3\+DZ#CM' #SF?+^3H^
M&SF0Q3/5[5!,7BSWE P/9>D@+<!#B1&\5<2IS%[/!+R^WB0$-/268.;I15;
MTS\/1H(SZG+HG7L?R?[0G\D@$L=XQZSO@E,*I(Y%">G)?Y6Y[SFWYM.XPA3A
M?)9:BV[A@-!O^CT&$VZ@,ENF1MC3AQ+=$8K859 +79X,YG40=U@LO)90J3V]
ML'2@K<8_46#KVKX_XCIB1<X.OJN<,: ^PR!&SE2\W9"QN"=6<X_,Y&&HNX=Z
M6%+W<ZA[==2^5G]9[!?LUE_Y8 4CY40S7.+?CYUM 4#A[.RC1$$H"T(MJ I8
M8'##>2KY4HZ5Z*2*SS;K:XDY +;YQSRTJ##"M@J9"J:7Y-R#:CY-C T=2<P\
M#(?#"L:)[J%'MU<"=/:=0Q'.,X:D6@P2EZ*UQRZ@5 T.HDTD'@Z+<208T\.Q
MLC<V8(^'>EA2]W.H>W6LG(>4"X9I:1>)VIZ/L#<A1ZV)5@OFJFXWX22?!VSL
MD9^](R5-$4R#KFH9"-*2I4]4&JR(FXUBA(3F=,<1DITN?8H'F$HPY><3/\7C
M>HUIRR&?:CG33%J@K)>#SS?2^CYO, BYNCY2T4 &48W[I3W_>P*=,J 1CR,\
M6"F+9)HE)** CZ(L_J4%C1[ ZH'#W.3VW@D=)1VS%-/R>_F!Z$P"C[SU*O8T
M";";^#K_0*-MXM6Y[FXJI0^N.C[2.T'S4KA[6<T5-[%D=<7:0!2X>GLT@P"8
MZ0&@3VO7S6"I!BD1 736E3C(-:"G)[N(ASSQ:R9 5ET@^(THAL,:HB72H__8
M;N.[I!@U88.9;. KT^A[#&;;&7D#B3NU+K7CY\[%A2'=W:BVH],M"%?I6_12
MYTH!8],#Z]Q1C+>A_UJV@LK!>)9<5)%'_T"3CP1%:PP!@<H@92]6/8I"\S:+
MBM]\:Y'D*@@]>F5_L; 7<PXC^5A,!15W'F]]G)&0L&4ZK+BLM)B39[)"'OYG
M"6OYO^-=B4?]8=4P@N>O^9'D*/]7ETRXX)%M%1^+SUB/R.<M8%/:$08KI'Z_
ME$,]VHT!5B)>'96YX[Q8],<>3YV_4&K7<.!(WM3@YW':4,Q;[WRQ)JU,UKSC
M,H9ISMW6D<(M)75+K] !/-JGAE*>I4\V)80N']]KJ)9.-<JE4.T)_I*7@P:<
MZN JYGSO^T;O!IE]=P"9?4:0V9,#R.S/C-G:OU.FDNXUP?^ORIXY(,S9/#O]
MSWZ]^EL_T O1_^87M W6W2:_ -@;;/\1G-W_U&C_.5QZ3B[@\I(L\]G)Z;=%
M?D%F&@B<&#[E?9@LG%*3G3KBBDG4EA);=TX:&N'MHNEH)G>VXE)(+8X3BA"!
MB,[/S+=4ENEM%:$<<.D/!+0CR!EAABQAP_C$B!'LW_@ 9JO>5["F#'W3(I?(
MPHE_"$K5.T/,R1:(CQ<!K?X7$8+!5[Q6!-$47"K;!9>2/IN)@4C:TBN6(%ZX
MZQ-M4C"83J8KF20ZQBYE,78I_Q04AQ]#P ]QO^.V#P7O.KR]+!$)JB;2SME.
MGRKHW_HPME4 UA*J$"&LW7=P^OT>L,!G7\<Q6!83L1WPLE]^P&^JJ[9C+(-4
MP*U<+KZUZ8RP>=C.RG$*H&K6SB@Z @$2]$QF='%G_(1,HF;L%F.JPN/\5>!2
M[/HL%GP<Z1W&BMH)CY^6@?3>7N<QAJF9.*%F+F"#[&?HB .^0+K8<0B P:9=
MH-.<XRUA8)(NLE)LZ*_29+53 RD>+QNUK3DT0YH*(/);L-J5%H?X' "06!K_
M\[CY.>+A5B9Q-'\!S%S'/#N!V2@4KPI]MZ/WSJT$HA#K12:#HO. #S^H@:2_
M7*_F,+!I3E:(N!,6/V%=XH_)EXG(..LP=2T=@3H4X1#"0;/NTH]\L,5?$C??
M9M>N7N6069'L :U-SN;2EP5IM6=;'!+.4%X7Z!.%PMJ5+ [^P]<_O3W/W9*9
MJ$",B(N7O&A,W2VE:=1]V6>13DJ?WX)GKQQTZ?:<N]3@GFG(R+.![OV"-7'%
MI\%SP7P34,?BRH:66O5-JJ4>^ R%6O?HQ:3M2C;0@82HKX:U%6C!YR"L#B8'
ME\]+I#0XPPWZ &8(K)DD7W+>7#B6*G/+[F*\ZZ4Y]\;02)RF +.;0(HJ!,)Z
MTTQN*DY=8;V+WCL7NX>2A[J7CO?<S$.=(G.HX\)CM[\EDTPRHX1HL"I%.ELN
M8Z;+)JD[^)'6% H6M][X'$0.I>JCPGZ<$_)L<)<)^U$+;!?3&Z*-M.9'>WKT
MJ$/\(Y=$1 Z%IE7#(:,(9^8UXUH]_%_H+/$-0@P3+9<BZ#_+063/8=#TT,Y:
M.O:LGYL+),LE>_>Z9RA^ ;=!LN9]#,?/M%)!1&W*]EMDZS0+'XH^=$5*JH?3
MP9+U$8T?I["%5D'N1-?3M:*:T"ZC%:E] O).UCR./UT([YTGQ=N5RY?4>I\I
M0$ZH'%1\CFY;1FCRB.TA9#/;&,AAA]E(96(+V[%UH![.B"_;6]6I[)1(5\/_
M$^X?*'=I9CB(D"6^4,A71_"90EJ-Y\*P&/<ACZM&R]1)#.(<QE*@$$]/6!)O
M-?ANL5Q#3#T857BWN-@DW\R,,G3LK!$0BTR'_W<6^(?[F-)'MW3OQ"H*V8 E
MUL?TU'#Y(I6(Q _3SB/AL;3=C1P^\ZC D\T2QS2==S#=:1O4"@24&%E%?I\0
M1B0S^QEWT/_JS7*>62U6SCE1T R1C"X33_80M=; U1ZJWI,:^NKF:&&$QC)A
M./56=EZQ@OK1T'*=E@XCUV7)3?4HO:XNM<3<V#.$<#XP%JR9(@SID2E:VCQP
MM;9@:&*RU"TF6/^.MN,RHX;-'_B6,R-06RR.A!&6GNS523DI1A/8;8YT4CG<
M   <G7HX&^A)I7)6 Z^M1/[Q]"6_RL1>V&'WDO,_C6,6"K]19B7D;QAU#BU:
M[+\:.#],MG R1=4S/QT3'%_'^6M3H$%<*D@69F4 "8ABUQ="\P%,B"3S_K&>
M7PET$8>\,M(RG_45,/PA;99^N,:/(>8)GOY@V8X/YK^3!\@(G805JWE"!N'V
M"FG@T5L_JUHRZ^2'S&!AR]K4<Q/&*69UB8-^^69.X3[^S? AK*=C\@7!^;4M
MAJ5O=Z,D,D$'4NZ %X5/E9GM5L(@L]K2 T!/5_=:/*3RMM=D9G"R_<8*&DFZ
M>^FIR?KN33G*%IPEH1>L[\0]<.@1!=Y5]/AT6N:C^TRXT3%@EDX:291&^9#
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M-@+-"K:Q?Q_ PK: X*EB 97C<62ZA/1@T']9!!BUWBFZ45L20A761'/&2U,
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MH]*[^)L$KT1ZN2&SP^?1JW.T&"#7J6M*OU.L['7GZLI"HLW.U+M6@] NKU8
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ME."!8 ?MDJAZ$.E&=IM8^H$)0$0]UO7?'%;M%^\5^!5=JC\%=<>?R]LQZ/A
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M1^?2UGGZ].FWWG_^Z>7K0._,ZLZ2[)(5\C\KJWK+XH.(.TNKA;_=3/5$YHH
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M +4"P -D2%'Y4)PF&Q'=\CFMI-M2.E[^:TU+Y^%)P6-X"B0HY$+XE.&\CC)
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MS#:;73J[8X7C]V_"JRGX4(EU2S*+Y#0MH\\4SK$4_@=FOZ(R(?%"./2Q^<)
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M/3A ")F>S$@5\0'S4]^=(R^XO7#4K405[[%O)WF,& KSTRXFWKVH2DHH?.=
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M1;V>CC2& =4XN=LN)MVD?L#S 5&>FN'KS-55'ZM&?D,X%0B ^F;ZR0B;U82
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M,RN02UYH#XS"'A/P7"+*!K28K\W06$672SJEC>&VNZT:D7T2/RS%TKPN*J1
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MARRWE\-]T\&KS 8&ZCLBO>>SM"8N;R-'1']1:D&RA&R9J7,EZU06?#IW^X;
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MBB/P,T:HIX6C$! \CFBV0+[?]E6WS1]<I+$+ ;HJ:&3<V3K6L^E:[U\P?J#
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M\J87PBA<[#TV!6$5F&H*ABK<%CBU8,F8/()FX/$O.TUF>&C)C<=HEM86CQI
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M\H(@GC1>"]<TKN*AW=X#2Z-:![03J@RD_$.BF7RPF@DV%/8:>A=7Z= EK<\
M_C-C9IGB$0F!MAT[!\LH)D:*@2<+PY8NNQ0(AX!0E$Y=G'ONM2:1:A?AE618
M@%%6I04CLJBTJ#0/PY7@;A%<5?L"\9J%<^;VD0HBJL,9A5R!VJRZTI.B)GY"
MKPK$')+/Y6F*\'M@K<;HW:'M'F%G>")R1N!\.",X 8G1+3:I/JN7I7=+XA*3
MFVS@:PWOM;8W;]TX>M@WCMYAX^A!WSCZ!?AT&S34SFCTX9+<T2+=FUV]C@_.
M#G=ODSLZ:.>.]K_Z_IA*FTNO9G[PG?N.BU'^4KAZ66/+LS]'DT_I\]'['PYO
M,X?#]AP.UCYFO;P0;MD%YO[G>L^-9V/_<P7Q_73P],5/6;'WQ\ODAH 7[WBK
M;^EDN4.KJ4"/! ?E+'^O45\7B'&<+"ZRYK?>JPE%I--2(A^ONEV/K%15OJA^
M.'T9;HCKT1'Y&(-5VG1#;NI4^>N+:JLJ$6A-2K-C:CU8+(6<XCX+*KNVQ7LN
MVZO&NJF8#2=W('Z1Z@8'QF9FXR=>M=RW_3&[4@2-FG0A8L<Z+,C8L52\I>UO
MURO128@52'7-%+,:*I3G0KDE82GE(!T ;74L+Q>W*>U$.)+.&PQ)(5!;53 8
MDX_E;/YI() M1P:C!67 >\4<]X'$\H5&CMCU%)- .]^N8<74\U#R^YM+%?KJ
ML(?NT3^L]^CO#OQW[\_>G;R_.#WIL2GN><"8T!YE.3C-F%[%(R6A?V[42K*1
M-&KZQU2D2;"[9],XT^"[V$?#AARJ/H)?HCZ93S%J/_CL<#< 5>\7^%Q0 $J5
M#&CGH.F"S@N'.(),(Y8A0JORT1=4V$$6EO)HT%]QSNK04%KM;N]M4T<7A3WX
M>SO;P7[[I>YCW:GA<OU&K7WZGP9>]TO/U;S4;]T]D$[ PA\JE2)\;@+O";L)
MMWK8CX>BF;^2WCYIB ME%\?,6^=(YLYA<'!X>*V04-B,&/=F2I!YL7Z08E<_
M@0AC/S5O\ '+J7>3G%Y@+ZO+["KOP4H&K--VL0<%#A1C%_5AA4RM85@W^:5Q
MRB63\FBOCEC-OW3I)>9_;HU4T@"V'H48@"D7O;S>;Z>/88A@=.8:'BZ*HX7)
M)DN2A)-@3DG74HA<M]YBDT<5<TC-$2?$T.?&7:38Y2]3'R.'U_% 6'YJ%O$<
MBV>EK*07@(>T@9[6;:"]@?_ZY(>CUV@)'9^<O#Q]^T-O"CT,X0#ZB=:B<=@T
M:J#;A(I/FA=3)91<4,3UW1^;ASPVS^K'9G_@OSE]>^*?'[TZN?C-?WEZ?OSZ
M[/S#^]Z/> B,N_ ^,.[^UMS7TS[W=8>YK\,^][5FBH#W=A-27_<PTN9=\MR,
M_MW1^POO]/0^[XR[G\_&71G-#=C9KE_FX%&_.7K_\\F%_^KLO?_^Y(?3\XOW
M1V\OI +UG/!KS][Z)__Z<'KQ6P#?>'UT0>"V9\<__WCV^N7)>WC Q<7)^W/_
MZ.U+__3\_ -\].[#^^,?C\Y/SOVS5_);__SD^,/[TP>*-\J'<8I!=OC2X"!.
MOVA!X!CD;(:9!>)4P)!:F8<1]YHS[E(1A?_UCX65ZDV8?P2'V, KT5]-QX!-
M$12+V3!+=(;@Z,6);I#P"V3O\'^J4N7O[F( 9^>@M]P? -LDQ1R7'ZE1$F+;
M/G';Q)*-0PH&N)@Q^<2,7A3P< 2#*^(L;Y*#EC0/F?[DAN=X+&!"*8A61*$4
MV6,,M\2<K? PS<]KGJ.K[ +S8R$^*C20'.%AQ<4H5QHT(]-%\XT*QS3R*$(3
M*70C]0A52#6W"/@E8B[H!K;?Q-)H(%)6;,'W*%MHNJ@QFL<,F=:1)02_R.%0
M"9/$DSG8-^LYPM?X78S/(#!IIF".2?.:$)+] ;K' 8-<>L(E#,N. "T@5DPQ
M8_@]:TJ4\Q!OL/G(WY$8M7\%G^[M;/<[=;]VS0F<VW)!>&PJ+3@I_BZI(Q7V
M$8G[/S .>"-'QY'E"]ETI\&R/%W000U'=$[,Z>Z>,(0,Q")HW8%KH^V8:\(F
M"52@'ILCI.%UOD:1?#"EE)8/+&C>>!5ZJ]C&ZI-:+0KR%;KTU\0]. SSE3C^
M-MIQ4Q2'9D[LF24^)(FZ73DZX,>(6IOE"XYHV'?(<IB7[+@K"%\U8X*9X8+^
M\ZO=9@QHZ?@Z_<IU=E5!0[[55UE##?KK/G I*(JID6#3!C]4W+L5^=4<5([Z
MA!F_0FW:-,C<L;HW8ZKN8-.F<17F>:A->T(Y*!I3N*T6Z17.TL7^E?0WUH,@
MUO=DXV1>GU4FG-Q Q=EQ8C=M"OV!_3LL!-]>N9LF,#G"TU$CM?$--FT*Z,J8
M4!=[-)LV!7; V.?:M+&W7<1-F\$3]4FW/&_R01XGW/(18X]84LU2_TGXS3=_
M5?UCROOSG-:N*7=?+"WW=>5K947'%Q;B=N]\T,$-UWEPH]L.;E6!^0[AUCY.
M\@R4'\9-LOQ;/Y\,G^QN[P>[>\^"W8.#;ZX7*BX*.5D6J>):ZDNF;3&-/A*0
M_E;/JG.]EKZL>Q?<[Y'1M<H7NQ[8#Z;[@7]%IGY%9+.V($E4;O_P?]J51M_Y
M6BWBOVDEBQE87Z3M-,4#@N#@&%-K3D:>O?L_W:>Q_JV=C@$L6R7]D_W&;V1I
M=YX>!@?/GB[[U>U?]%=F\/4M![_W;'"XOQY#_ZS%IZ*/W:6_NO%%#ZLWK8C7
M;O[ERI2RV:LHU%M[BY_A(5ZW3;=YSO5;US&#U8=Q_]-O'; O9N9KN/'W<$/=
M?&1W!P?S)9?518;E&4NS>#?-F)Y\^UVCG_E1AGV&?W'CEC_J^LMNR1I]KO#>
MTT*L=G9O7(/..W,S5N N16'%8[S20NB#+%7>WB;FN-=ZP/\8?O]>H?7LG8<)
MURQ\2'."Q%!8<'>^+ 2S[A/;N)UXFZ5WV0?3+_!#M1K<SZD\Q;Q[[KU7\RH?
M3<."SZ9X!/VI_#NKPH0+J>BH_*IMEMA[;@4(]EXS_(_1L/ 33)-0R^@Y(GG"
MPW9V->#VR2?D]9TH[VA44ID8?HA(/$1K5DZ)YQJ>TJI+^W:#%GGC*\/Z%.UG
MIVA1[-D]2C>VQ&M*O0E/L&2S2N.R:*9YUGX&6FU%?7E"7T_4/?XC'C:7$VW:
MX*EG:(Z<]7A4-VWT3S+6*W]#]GB34L2K#N'&+-@#)@)XN_&?O_6QA0O[X-L1
MD7/N)XA4@KQ3W :'3613)%5R[4?X%M)BH9J1IIZK,(^*:U>H3VC>8T+S$+$6
MNB+"9Z,R0VM'K'5_R]>?: /^P3-IS=RK+.CNP<YZY &7IC"7#/QP<+"WIOF_
M+HEXFUVR!V=%PGRTMUV7B7L[.YV1V[L]R:UMO*N!W,,I[DP]=6V><;_MYK4\
M\CXS]T6G9!]&HZR0C'PTB::.FVDSLFUWE&_LNN#N)LNV>>'"M1XP>#/>>ZX(
M+I8U!Q>$O!"1>2]D5QK5=4RH%P9BH@P_L?4//A UQPP3(40KN-HX326,3&BT
M^*1+9G?T" F@[B+T*:=[SN,@--'AP/__WI^<G[S_Y>3E__\@*1L+7K;V:[1!
MVUD;ZG5 @,]Z(, [! )\^H4  6[^66Y"M.W4(=J>(D3;VZ,?3MZ<.+AL"+OZ
MX?S\].PMX:[!%U[_=GY*>&NO3M\>O3T^/7KM'Y^]?7EZH;\#RO3#ZPOZ"C(_
M'.$?[AB+C?\7P=96067;ZF'9_A%__UM6><4TJY(("6XB <W2V7,A<=$@5&$:
M)HLBQ@S@1!$@%9-.$C!12HJ0"!<LB%51P@<6W4ISMZ192<EX;!OCCJMR&A?>
MJRR?P="V?A80_66O1W:7,$X)Z 7#I5M)EGVD]C/S.B2OB$=3>/1EEEPJX:?!
MIU1(?8L_9ZK*(_A4^+6%M6+AC861QA"]E].L0(RL8I3'0\16H'Y# 9U[)8-X
M+8,XMX/06'0.@8TO=#?Z3T1BF12*N39D)7Q<"0]7@LDQ$;N?T,*8!GP6+F!M
MQF.B^C0$1,P%1".UL&FRN(KI$98LUH#9UC9&;C?OH V_/_L%;,G3DU_[\I_[
M'?#14&5IZ"$%AS]*XI2L(1!UN.Z'<38'5VX6CE1%5I*P;RTT^AVQ8X!QQ@AX
M*B5HO#R<8]$#NG1)/%9;3*JE4M&/R+,!:@2)>1-4H/J=FNH:1\(T'(@[16X=
MNW[PE; JD9,XJV ^QV>OGQ[MT%O!!,QS[D55\Q@TS0PUZ50I5&LNWE\-M0\'
M"+]")F'0=]$"G$:8;CS2S\A(=WK#"I1[$1IDS?<O3UYH7$TB[MW=1KA,(A]+
MLXIXQ)A$&)\:EJ'6,\K_Y?3TXN@U_'C_V>YWL'E5M/#5)1C1(5.*(7\)4ER$
MHP6HTG"LA'09)JW0<$P000UT+B\/ S-V/7.F2HRT@3(O4?=OS?-XAK0L^N%8
M4#7/8KQD(@7^.7+#E5K#(1[7B/0CLL7$^(NT#,PV)0MOID+<S'&5^/&,&G3X
MPH+UO<*0'G(F)1H!;([ BN#Q5^ROP[\D(-I@XT_S#![HXW+RSY@&N48GM$?K
M6E1#HLQ&XIH7,0I /"J\US%8WZ"ECQABG9ZN]^C%ZR,#?4JA!:9UD:##A\'Y
M "Z,+*(!OLRKB7\4S6!ZO [.<UZ]/*IMM<E6\-C@81Y\!6Z;$8XZ$B!(6"^4
M@3S.F.F-R.5I'(1^^?K(&1/C=\(,"S+Y04P#!ZSU74XW*$&#\$ _%/"G5PJF
M/;)@K^]>?GAE!AH0_3<.JT#J);_$Y2[Q1L2':*:>-W C[AX(#Q-.[0C&FPC<
MFWZ  ".%%*9)%/SRO>::?JV0M-R,X/C]:[/@M-_\-4]SFK\^8FF%[Y$M(QPM
M8EBXY#]NP:&PLL!#L)6D&"\X9C15,]RJ!?*0.S0]N)#'H-WR+"GLP-X<ZX%Y
M->Q0*3X4R<!-F8%N1888?A<9':!0<2YH$$4^>U;TJ]"1.3@>Q"LCK6IVGE$<
MN0R+"Y\5)U/8P/\7GL/,AT\UFM"<4Q 3\Z'H ](H JT*HPX,6S=NF'XESA04
M)[TQ!=DS#RG1]"G<YWKT0%QB(8R7^<%DX/N.LD$9J2:X1BPDR'(F8H$B@OZM
M?^2_ :6+FV'B<C@L>+I8IDSK@VB#\%O\'EIH<+K)9O4T/BQL!LX*9JDSQN:5
M\GW2!O)=7G%\#TR=F2S=T&)</[;[+'FR?(3^J8^OQS<"GM9 :*Y - LAS:)#
MMN0TR>%Y+K17&W3[;YRYHE&3#2LQ2M<\5W.L.7;IH'Y !5_7$.]RW#>X\8UZ
M&/WPYIV]*9AN:M%![4?,4+,Z*YAAAT*5'QE5$J&:AN.#-YY[KG!LV J'LN3\
M-@G!9)C:@\: PT:9O..'TKWNU1Y-Y&U@>N%SNXP )#\EGP:UG6'DLW/ 4\NC
M,G,U*T!>'C[ A='E 7LT!V(HO+*[@!-5Z02-1CHX8$A\5!J*-QSE65%H@M($
MSCZQ>1%C:B!.+:[HO!J"5F6K(8\O!<.:_,I0K K^K2?EZ3F5U@[Y*J);D^"T
M4!H_TB%%XXZ?9TB]L+@/7V:O8$*%)IDBML2AFE2IXTDSF+4_C2=3_Q)A3N!6
M0X.6;$@. '(I_">TA"EJ!X/*TB&A7,.D9ZX)XMX<!#AH1T:6A"C>7H7TX7C-
M ^#Z+*A)QED""HED=0QR6&&J#?1/FFW!797!&<6[\3+.*ZOFCHY^,5INB$70
M36<M4G++H2F"TNV#*P0793*# ZF=-@]!S=E-24$[)?[1Z1NM<T;AO(@C:?_0
M=),$<X3>%5% D[D>66_H0XJE?@4J7#@^;]$H\(]#L-[B-$35=#P-Y_"2'V/Q
M+V4=X)Y&X/8\)1\%G,NLFG!(#6;I7Q*@/)H)BF"^Q:G<>!3AM1[P/X;?@Z=B
M+,IW,>Q;G#:+D-=]%ANW[*@<YG;=C:Q3^Y43.I$S6Q5DJ\K1A;.BSRR8._"O
M6ZP8Z@$<\#;C#!0)JHL20R,+9=2!<W5[1R_.M@ZV]^DWYV@CP]U7ZF\&/O]Y
MC_[\[RT8[T>%L6T86E:,IC&&J+6J^O?K]^=&5^&QY]\>L+U3E5F1870G0O<!
M2X(1-Q-L!HK=+#RC\%Z>.9[[KZZK BNV==J(*^&:<QR@(YA /WC[T@QJQBY.
M4?=Q<H5SEK6N;4M-?S-.%$7V)U5"],YU3@O'8AS'8,]LQ>G6M )Q$-^M5V0/
MTBK^TFY:WX!ZWWHL]4RM^+/ ^OH=;-4K\%.#Y7#X='O;/ZG@!(+ZN%3@GP1-
MAXZ#!OQ@365=>'#J&Q36)KS"7P6[8X8II-%4L4-#'^C0GB$S.#PX.$!;)E63
M6,D0'.<*7]WBNY:@!([=JXW=^J4.)795W,2$?>T8FL38#<9K>I#WI1!C7U_G
M\KRO<[G#.I=G7TB=RQKZJ[PZVU@KVY#)[>[ZV36]DFZ8AWS&Y> /8S)PI8YW
M7Y4ZZS7AQ[V7E#7(XX*S$;^I,"_\DV[X"<X>-C[=>[3[#HNCM[XYP\< 9-'1
MM7O[_O[#E?O[5VP2?B5P* L0Q X8E)5Z=F[L*E[O)3@F<)B[F.GG(XNO-!7Z
MKNYQ_NK[)U]SFC:K"E 4Q<W-WI^SVJL#2JRXVBMV\3VT5-W'/&]L+'H,\VSU
M83W&2?[/WZ,=;@G.<!T$P^;^^GYZ/K]_KRA@T</F]X-9(\B+=J^Q,47WFBCM
M/"!=I>A24K-D/R1\Q.[](,C_K8/?"PZVMS=SZ$]N/_:6^7CO6"G+QKZS=.1[
MW2/_GWN]*-96_?2#V8C!W.$M\?W))T2][XV6?C!_BSA^'BC3^VP1)HRS?,^K
M\0#(2RN/9B<XW#Y8D[$\67$PW]S[.-I7^_W<Y[<PK]L#>*]K^YRB0*S3N.?5
MV=L/]@Y76)\'$9F]G6#[>0L:Z.\:3+![^'Q-QK*SPJ+<JT%Z.UG^0:4J#[F^
M-71ZT"[5/:_3[O/@61M;ZN_:M.?!]G8K[/QW#68[>+;?8OGYFP9SL,) _EY]
MO"0 _ .V]67P?W,EO:5<0$7SVLK&6UB-&A:%*F^DANI! ]=U^F"X;!^V#)<5
M9]^*:&S0Q/_*O!_!KK?-Q%7W_&^X>G=OH[:$Q4[\^ W>I$-8H+8M]*6(Z,%V
M<+CWQ1[0G;W@X.GAESK[W1L9&I?,_.[MJ/4-,_6#V8C!/#2U_6OLTZ8&3;';
ML_2^PX)/NF^JOR'ZM?\TV&E?&G]'&.YIL-W6WP\_D+T5QM KS7XP:S:8=8CK
MG6)A&B+PQ.DHF]UW, _&N[_"67V0'=L-=G;6)7H&8]E=F\#T]L-$IO]2:L6(
MK7C ]W[E!KO;S_[^B^[)_LXZC&(O>/I\E03</8_C^?;#!)WO2M=R@P 6VX_#
M./<13Y& #J["'*'X)$U(@$((R9C$C*1X_QGO)T\/UL*<W D.GZ_!0':V@^?[
MZY) ??)\A7S3WYSJ7A*C/*,RTKIAL8%QFIU@I[T'7TR0"H[":OTGCW#R3W:"
MI_LMN^P+2!L].?CL63_(?7NS A*VJ+>J]).LN#%!LM[D4D\.P>+:NU$'+>67
MNE$4UWSZ!_O!SK.6X?O%3/]Y<-#VFM=^]K=01C<N0=OK67GZ#7UT![1JZ]7M
MKI?Y,3;RQ]^__=\C;XN0H@6/%/OWLYP^L>CN=TARL5XK\)@WUWT2O2M2HXQ3
M.=\R1BY",YK&-*^K,4W6Y1$NSR/>^>4;2OADUZ!(,)H)(J&G,1(2%$SS(32-
M7^\-#GP84H*8B/I)13A3_AS!(2,,M6 W/<&:Y8J?DWF"]XI:I38:C-,P>@I^
MS>]$282WJ:+,4ACZ%3X2^2SD9PR>5G_6'I$IQ06C^NN_,?</@E-20C,<36-U
M2:AE-[R2OVE(BT)D9]"S"2>Y(J!&Q*>C[G,B#()E(C#(BW!13$,?JWII-1A(
MT^+8>S#:;29U(J3(#!'FFR0G%HO3 >EEBLSWJ@3_8I%&,"-U5ZAKZR7&C_B$
MKJR;G9:<7A5OX-2HBM#+:1<7IIJ0=1FHV)7T<5L/[PP.5];#OKS<DY<;38G:
M.6*\_EQ+F9]=\2L0PY(U79875H%:R&Y'2^)#Z'/1>0Z72:^E-GEJJVLIZ</R
M6GU8O=+:P*DMVTZKOX1^,O"'54D8X^@N)O$LYG,?(%M'G@E:/RBE FFZ335U
MX"?AD+"MDQC'X4)D-U\YRL"8"[PZ;9%\VL"@9;X/]Q.#<2O?I__R'6X$,M4<
M_&U-N@'?C10.*V8 \ RYRH:>'O+R5]%\\*]HAX+.#&%IM3[4J]?KP0V;FESB
M2YI-_0*V-=)$,BLY5U_O[0_V]0W>X6;M#':NN]\]N=\#]AD$EQD^! =M3_^0
M+W_S5[CUK?4!+V0B0&0U$QL@]+_>'VR;U[H_+,($OBIB__6V=0(]^&.:I5NC
ML$"BGVST4=P5G Z\BP\/GSIYC7XND?A$HZQ*2]=@Z$:5QJ&'*9'9,K^3N]J&
M-L=K$R@1\Q&Q@V3C,9+@#>&,P^;9N2U5/%=9_E&&CBN[8U?66$U(90C#-ON?
MV<=Y0J\6,C;X+/R#&0 UB5*#A8TX4I#Z-P&QBXA :%X:,/$D2R=; B_.D-_S
M.Z8 6*_S]HA527U2UX"-PP+T8.-W!S;^_$L &U]G47\DDWK$JNE712&"$3,!
M+K5VD#?QD@Q=H9U@UK\0@QI\:989<J4C$]DE4MGCQ8B$AT)6.(('$M=]8;YH
MB>^L*>YI4SR #\<)#(N9%KL,>+QA^6:$[WS[*#>G2^ZL,G>5=U.YWWKZ-=V^
M] YH8FVO_OR.*Z%=?W+KX6X/=@_B]!Z7O"-KOQ:#?'[X]/D=C?*>95C-YDFV
M4(H&>(./7)M11ZW3WR1NZRE?7ZI .7$C(U/.5:7C1+TL];)TXUAK@N0$&7OA
MZ87GQK$BSR..#24&0SSA"&D<NV/2C4CV#*X]"N5\A]_MA:T7MALU%:HEON]6
M2&0,.D5*%VGV%&+KY>:MG'$5M$"O"RVPS[ENX-26;ZC-V]B<C52Y4:JC,],J
M"4]A VWF0>=4Q@;Z LF%.:XR@XDL=";&T]_+L[$J"BY&&RL8PA,UF P".-(3
M!QSK&TKA;A%Y:C["6TTR,1(K6NBXC:E'G C8I<4$-)/$3#)]Z2HNE">)9JRL
M6QZ2ZA.K&SHU3JQ.EB*?-@JFOMY]/GC>2HS>LG3JN9/D='.K7KUVJIU;W=FV
M+[]E<K6/2?8QR36SGON8)(W5E"/0"*G084&*2 <D;07 WN"9/O[?^;VCUCMJ
MMY.MAH7$=2RA4R##,F8*>_O 4R]BMQ2QFTNQN))IW^JQ/N;4R]FMY8Q].-9:
M184.&;8(C/(J+G7,L^TYHNCMVKK&ORDNM08F\B.9VNJAJC!.O57Q__O8U09.
M#7QA;[(ZRP.70'?5.%_CRDLSTRJO\>0U^%33Z>34&..;L)HV3LVEB 5*C4?R
M[R6 ALXL]E^&U.V99E22"X.KL)G!=D?!V$(>(O9#>?BB*!Z/54[%AD-57BF5
MTOM'89XO\"<&HPP_K2T63TSF@CJ5OB'3X#\Z &;UGEM6RS@2+^*TTTV1DK\>
M.^L0LL\2USL&.-#G[I$"&*RLAC6@HZ?APGI5NX%3:^PBJ]+]P>Y?C(HZAADJ
ML6O[24W4D_4>V(34_#D%W07O@-<B9DB!2KJ89GG)C0O<V8[1^L*/\O@2U.!P
MH7\3:ZS1G,I"4=?9-I$0W JLC>Y\F#\,DQ!T:Q_ZW[2IW5YO&2#:7G%MX-2:
MVWA7FFO;1C-6UUSP;J_5 (<_/6+ $/A:%)<V;5J#]P"]A5\]EI0IO/2G,*TP
M;LPCK)F#X!9GDY2:NN(&HC*,S7.#RKT*V["IK:S"&);8^RQ8XE[9;>#4T"$>
M?386-:G&D% U*6JV;77$[96D1ZV]YED[.X.GJ^C+1[DMCUCB?@7U4A05=B-C
M[-^?5SD((%UU)&X%!R\0JB%76)S*U^<0[KHD+(IX'*.I36(G@LAI4!);^$O)
M4@RS^JA*$6;X4(6CJ5-&Q$(T\$Y3'[/])76W4[@C Y,]IP;NL0K+*J>#P;W-
ML (62RLN[FQ\WM+QD3%@SR>UCWW.&>TT(=RB$)B@)_N18QB)3FT&*V'/L-N7
MKAO*R<F!8=#H)31D]G'YF ;^40D",B]%'6QK=8#ER2OO@ UN(=8:;5X>4XTR
M539WO7L1F/A4UU\E_F8W$G42;G*YZ/7,ADUM]?[UG;Y__>[ZUP^W^_[U_A0_
MO.="!!-]Q'B3I^9NH<Z\_?5P\?.5@RYB9]5#+J%$29I5 623.*0FS;1=#(,8
ME=HFT@W%\"T"$,!2*H[<<*:.S0Z\!2*->AAXW9! N1J#V-/M\D<VQ,=P;K ,
M/^EGLBMF 7#AT2J^-(^^@PS:.HK/(SX9_QA^__KT7Q].7YY>_.8=O7WI'Q^]
M.[TX>NV_/SD_^_#^^.3\'_\[[/7=ADT-=O4X+*;>JR2[LGC7OX%^*_R3)9AL
MZ+V@=OBB]OM6MO3JTU_-ZFZ6ZG=SURRE@JTMRI7"L@G\31(M(<KJHMZ <>%R
M_/.KPZ;'L-0GZ7A=V]S_ZOM7UU^J*Q'_M%[U><RF[0+,E>9(W_W6CTMXV.BK
M[Y]\S==\5A5P5(H6X<F=;,/N76\#'NV[6.L-F.=J!&)W+E.K$/0Y\[[FZW_Q
MUP_-CDZ-:S[66@?TGQ3.N@P3I2-TF.C+XQ%UD.#?GU0%68K?8&7L98PJ8;CX
M]IZ9#;]H_N9;L"W*O72(P:#V@,Y,7:"%/FM.0YZP^S_7LCSI^Z_S-2TN*_WM
MP\;7#6?78;"]TR+SO/8=+<7]=XQ[[VFPO=UBOUMEW.M ,7O*%!V=TG!O;,#/
M@]U5Z%+OF[9U)8;FO^'\WDQ62+?RJS@5/,+E!WF#*"1W0)IW]CZ71G+CJ4-1
MC1RTZ*D_8_8/J55V5Y17AUS3S2>N;G!L-B'CL^#9L\\GXUQ-M-=[!78//I^/
MLDNX>U;&S9G:/^);)&BT<>JY=YHLRB-M>7C$6P\*WR/U+NZBTY3DX"Y3%N?@
ML /(Y/HTCHL?-(-_P7=(\U,J-,Y4E'JXYQ2)<;T)WT%%8TBV-\DMC<%$28W?
MHBOE@B\T_<JC*2RS_')G=[#C&9B5M\VO"/*1BIS9-(OD)#WT^15X :R!0[$%
MOUG641U@.NW _::95*O>E]@S=IU=@V_76&;@"UXXPUJE/^F#/J.T85.[Q?'=
M>WJ[X[NWZO$%S; _V/7<XZM-R-6/[XYSFFYW>AUXI8&W\NFME:6N>'S=\XH*
MY]F2\^K5$!#D$.Y>=PC]NSV$?6/DNEM1)JC36U&/86HM-1QW!.U$#3^_=3',
M$C6L*ZY)#]IF1<_M?"15=^!J?H+!#^>8:&,[(8JQ-E?#9=Q@1,WS;*145##]
MY@S+>HT.[VZ^]-C$VK:S[HV,#9N:D6XGDW2-A&_?3L"7VQG+A,U;*FQLC>PX
MQ6("#>,\AS$2BGE6(!PHO04,%*GNQR 70WRRB;^[_#AX>!RZCV#7D Y7.X';
M#I_>HQ2F1WQ.;F, F-1 ;P \AJEUJLAQ1_I'"F*W]V\'1G.-%:"5&VJ/I]N.
M(X94F7!KU[4?^FYO0NX<9GF\ J5:*G1+Q@J!6S# <.!$&/AGH*9TKQ/H3596
M""Z(H NZ_ZNHT$OBPEGOZ.*-?V1Z?)X@];>"!<&544EV]0VIP=KXFMZ<'?"U
MW=&-=NA>:V[8U&YY=/:>WA+&:;63L[,_V/?^FLC[GR?RNWL-D?=0Y'^JD@5C
M245QCA1Y\R0<*;%,^* VQ]-+_H9-;?76MMV^M>T.6]MV^M:V_A3?92,\D6E/
M8]#".<HW:&[L[<%;QJ+\9:G;OEU.\ZR:3+LOEEZ1;]C4SJH<6\W 8)F#3U_
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M5BH UEY2?X\9.WK!9"4IF(RQ8+*<%$PF4AQS7.(:$[7)AIU=/=HU;TC3J-,
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M@O3J--(Y>NA52/E'?'DFJI4I9#<FD7T)6(D'V[].?SZ=_&Q<JE=5%]OX^-U
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M/@0 >/,I/VNXRKM=D*[CC+QIT;I.=/-2\E1Y\ZD.^SNHJX)1YD-%QR+"=I_
MRAS%F>Z*P.@T_2$/$K4;;)A+-/S.<&1U@B,]-QQ4_CE;S2(VLD*5L$7ZQ+"A
MIO[$M%D/SHZR:3[1EEO-F[GL7-[TMW?QP5!2X^\(%J'O,%,6$MVY,_PIS^7/
MNF)CO?S#3BO)8J(DMYL)<SAUAG4E!KC1&P_O\>7N\%WI998_OM2TWB1K-B]#
MDYM*T:PAT=N))6L6JZ1'[8AK//:UC@;BS0_P$J*S/Q4&&RH+B4[8%(3>'MW#
M[V_-R/XHQ&F]%U_F.G31HC^='2>9A&Z9FZ&:7]\@ T2"W&O-Z:][30*QNY:&
MP[GQ#-#?S-M_DQWN$ZPQC^!;#/XKHEW^0-XTX83KTG><H?WA_7MHY;=)]^#6
MO']?L[I]6.KXGJBWBO6>.C'*^[Q<R6=+[[/9K"P7"KEL0:YF<\5<67[OW!=S
MV5*U>D,>\QGYH.\,W'LA0Y^8H:^WE"X%EC#]%2?B6H2OW:L#O7N4X@YA"3)1
M0,Y'D\QJN\=),5ZM>6 ,$W7CN,J5*('$D)ECTQK0MV>^N^.7@PM:3A6*/9XS
MD*M>NDIY=5R=:*3=I5W^(+=#&JE0S<O%7(X*7"57++]_ 44TH7]JL$-)C&)[
M*255R7SC,^#HX[^.#"+ELYC)S"5:*=%*NTB[_$%^9PD7@WXK9'.E4B$;7;_5
MV"HWB<VPY%KH<*PK#_;Z]8T^EJJL< )&.2KAL;#]Y]E$W^PN[?('A9VT@J@9
M5'T)*PC5 "1<@X;.$>Y/=\V<"U>;T$>UM-N^PVI:3GR[MJ&J@+Z$OKT&N31D
M&PA(MHA*R !CD^PQ%F9[S>Y='$KK5!E+.6XB'20V4J*S=I!V^8/BSA(N9NV7
MBZ+]UJ&S#N/66;G(.BNQLW:3]5^USBH<R/]WAPPM'@ O9G/57#[[_KX@4\>L
M>$,>"YLVN*BV*XI22^JY$0-';%_H]/'15 O%//S352WM3(6K%M K,HMB%Y-X
M4:)7=I%VA8/<#NJ54K::SQ:K5*_DB\5R^48E/;F@;(UB\6+;\U4,Z)0CTM,,
MC7UW8M03-5W:W3Y1<=MIH>89-+6AI>D2;ON42XGF233/+M*N\+HCU?3' M4@
M[\$D*D317+YZ'E:Q/Z1NE<Z]I.>'J@L'A<G\_3<W?S\FBDC>3_3\8?X^\:AV
MDXU?N?[9>.1ZF_0/53[E<JGR/K)+)J) %Q;)'(]0%USCVO!%5H[?D9H;H\GS
M7%BB4':5+U^Y0MEX6#D.-4!=B%(VNAJ(#U]">U 5<3&BP"HVP6U.X/: 48,[
MSR""W"'. R%&F(639B8.?*IV3XP1D7Y0SPF6LYT/813("%PK"A4HK+1T<G!Q
MD)98QYF"T>BOBC%2K+%4X?,+8M!D$X],W+-$F^TB[0H'I=W69I%26[NKS:1F
M,TZ%-B=]EBBT1*'M >WD[ NDT+;!X\NR'[/L/WG?KS+9;(;]\L!Y=!;I2NHQ
MOKU[MTSJC*(\EUT^JB17JTE4*=$R.TD[8/E7K66*J%!*[]5L,</2<KDHRB67
MS3XO3>]Z9)-9M(FLF8QF3+:X>PHFA('6R%2^)V\]9F(5WXUGI9Z5#L_F2W*V
M0@6.NC[4[:'W:ZZT6<='+,T.U /6;BW"Q(\Y)V?F/;O?Y2**7SGM^D%LR?Q@
M""NDP?-IU\_=Y-:%8CD&K (_.:DO87.4 C9'.R/[X\S0>\JJ=K*5Q)?9V:OJ
MM5L9N]1VX58#%JJY2@ZJ 2MR5;Y!=;7AH+.GF$#7H'U!=<4IL6Z))2(ID(LJ
MLK(^-VJC#$S83N_IJC1\V1XHEX3J$_9]J3WJ\$WU8<EXT&'X4F6D2[4#Z8OR
M<*?!^GK-D&"X?E>!,3+4_E%L^D#4EBTRM(A-H570'(JL 8,5BW-:\7T]KTD-
M8Z(-=Y-VE.%W,/-&?ZH62Z7W+Z$%12X?1G4-#-;3$3#;9IMG*C?W6'.'V:/?
M!0,--X1XGUQ14P7BSN?T-6@REC#PG$W44Z*>=I%VE,M+NU1C[;:)92NY8I7I
MIPW[E"?$ 1O%IXZ89294 M,(\FPM]4.S^P_4CFH3NZ^HEA9=(956J8+,R8ER
M2I33+M*.<GQYUY63O&'K:99V:I.APZ-<"Q74(=4]*H7GG&\#.%5TG2QC-TU-
M6TOT5**G]I=VE.4K.ZFGY+Q<+KR(DS=+31V3CH4%/3E6T9.;K:6^FC89]J4?
MRM.38IC+>'4KC(),AJXERFDW:4<YOKI#NHF'XRO90K&0P^FTV6RI6H9X_*9U
MU/F08$[NCCA26]')M+:JC6[IF26YC#'JRE09Y93*(CVJDZ!*<HF<(5-8TR$H
M_O(<"Y GZ<)$/^TD[>!&SNZ0@N+&DYS-50M9&8RG35=S>QW\9^:!A$'JQ:K*
M*W*H"O=/@>=H/'/H?X(_TKZ$0INA%2/KN5RXGIN"?+:F$ZM9?)L\ OLYIK=S
M>,*':S/^)Y.1CC6BJQ^D"^66?*0T^#L"2#](Y=Q':FOJ(R"#E,EPEE2U>_&F
M1<L7)EY=PIHV;T^'?R_'Y-Z.X!NF%VY,+.:8+IWSU$CHRB&_D,#&)OB&*VO3
MRTL"KZ.?]6%-X.NC=#D>TO?7+*6C=3]*9Y39&$[/3,!>6?9_Z[WX&OS)(ZF@
MYS_O*9I#$&X1Y2[3(=1ZI\\>(KW\Y&88GN $W,CBI[K_X7Z0 %:D\S/6PN#+
MO/]+EKZ\T'VUOJ4N&.WZ?_,VND1>WO+R=UHP<!EI\$-\F&P3Q]%9]4NP#N9T
MY(P476H1G2@VF;[/<HO"F:W&Y\;9S\/F^3(C)X"P*PV=2,*8B26^F[0#EM_-
MM1%\9.C+U:JT27=DL?Y'M\'2TV)SNBJ]IDK0*II!3XOU*_1?%G%,UZ3&]H <
M,X!SJ\8Z9PX>3116HK!VD'; X+O4$1&FL#8<.Q *JT5N-=OANVOX0&2?PO+7
M%2^AM0SJY:E,=VG&<W57Q*')B>Y*=-<.T@[]BU#'<=N55TZNEKCRRF\X::QU
MB1&TK!:.K?!4U95.(;LEQOA1NN@KUD#IXB>H:\G:(KS^"EXALX2NRD?-*2=[
MO!+=M?.T ]WUJK=4Y+.YLIPM+*$$6\2!MG%JNQR:QLB66/V+4#JH%5CW:2Z?
M!MWBJQ'N8I%PFBJM@Z,EHE?%5512?O<ZSQ.5E*@DII(V/A-L:U52I-#]LBHI
M6&^7Z*-$'R7Z:*X^*N\LZ>+61\5UZ*/P+H5$+R5Z*=%+<_529?>B3E2;Y'/Y
MXHOD^.;F]CSUI(L9\?E8TG/^!R9QHD39["+M@,-WJ?=@:E#S"_1%F?1!.&F,
M:9UQ2#'NS+1<FD>R3Y6N9=;[9"#5N1JB5M7,N3_IZ-/I%4@2(BB;'P.]0%T&
MGYDHS$1A[B#M<";QCBO,#1<TM$?#(2\;I<H"O+9$A:Y65)&,TD]TZ(O1#EA3
MWABFIWM"UJD<Q2ZSB VL5X9*K ?P.$%%33J:OEUDRS601EUM-MP1CDFD?7>E
M/4:+:0<7 >6S^7*QA*VCI1>:N]&SS(%TW=<<F.MS00QJ,*FJ16P;RC>9&75%
MK1"8&P2SZFU_@3O8+8W';E\Q;MD6(<VVT3@*CD%C[9_1HV&E>6K*?6@EB8@E
MZFIW:;?Y<%C\.4&JMJJHM#Y=F+K6'8-\-@U;HU:+=&DIV%$..J)N&CWZ2\/1
M*%#..$F8[2KE7[7$@E>RHW3S26R.F1F?VJ,.%51-P9$-?"RRQ5M!#"<1T5TE
M]>L6T?S!?@AIGGL#G^C5"8L50$*/B&YJU&:7_E<9##]*E^:H"S'.DXM$6'>5
MY*]:6//R?@AK7D3S/EU8U,'5AHI.?5GJ)>,RE'.V>D"J VW<#087(\L>\3V\
MK9%.)#FO9.3"6^6=N(M];K;K8M>ZJ CD:KYPD C]KK+.:Q?ZC0^66)/0YR:%
M_E@S%/HC_2D1^D3H$Z'WA'X_1)X+_&RAEBO2U4'[H'X @HQ_E?/%+,OTJ^80
M@M[^CXL/5;,E5P$H5D<QB)TY?X1X/)?]7#:;2V1_9WGH5<M^=0]Z7\ACM1R(
M<[>(KF!2'FYRTC4I2<8@J W+,@UBCFR=RNZ#8D&S",R?(X:-VB*1X5WEA5<M
MPW)6/FB>M1E\NTK!IJ%K!D'P?AZV3B!1Y2B0>CXRNR.HJWFEQ$T$<W=I!X+9
MKG_9+\&\5!Y-PQR,J0OLT(L3+.1VMT\&RBLE<B*@NTL[$-!Z[63O!;2NZ-V1
MSCSB$\VXZRAV<K$F<KNSM .Y/6H<[[W<'I&>!CTFB=@F8KL'M .Q/:D=[KW8
MGB@=HB<2FTCLSM,.)/:BU=A[B;VP"-1QS;"0I5=*_41R=Y=V<K:PLX2K0\8&
MH</=7DU89:9TL5[K2'$4Z5C3B?2V9UH#Q>&MUAK*.)-OZ&GHTF<J]#<J_8NO
MK=JW\L?/#F(=76P+Q&:@*+#";N5W\1UY0V=Z2Y[O=[ >;DZ_;&S$^K^I4\6@
M9$)%"6@'4DFF17_FF373&DM#G;[.(G]'FL4ZUSJ$-XTIT*@F.NA83YMFTX]"
M@[TT].7CFPX92'+QK?+N;?Z=NX$0ECT=!+>K[0EB_U_J@J* 7DB\ 8!B16"I
MKU!1Z, @=7.@H0A,(:J4E=]VWKV5L^_>:O?O^"8)$0-J[RO.PI;M[<G1_NGP
MAVGJOV\&Y"8K%]^(;'7SLG&:DDL'TO%YZQ1%0FI?G9[66K_^>=_YM)?HV&-*
MGYD&>37B.7^5:SY9Y1KC*M?<?J]R#4-:!"G85:TT?=RU7#=^CE1)ET]8^B"-
M8/H)&-UO)N^EDGLOM9N?SVJ75ZU&VT7)IJZC]6)GCV\?40*;XN,EN-$.YKW-
M-RCRVEDP\JD]KD:MCT]/=+%2,]:65!B?VE5&.-#"9_DS%\&FIR1JBKY.HV_O
MD+ZB]V R!3P(&9!](,U6F8T,^BU\H#)R^J9%3Z6^FHLT62I-'[>9Z!><&G[[
M[YO<T@B-$\+:8>/\K(9077YIM&H7C:O+9KTM-<_J!]L:]N+L5$0C9A.T6A7"
M_+8#6"BO&<+M89LXSWFD..0# G*J6-V^E&.+ D+79+TDG(?C#_- 6N3YO 3(
M_VB?WMOO$5+?6BS<BB7]\U[;TMKZ[13S_8>*LPB"(M@DX9 $*I\K8A$;!U,A
M,#BJJJ^1WG3[?L(V"50>5&_=GF^$9HI;UI4#W'X7<4^.MBA$$3$6H=E2BP4;
M(!"!Z3063J _Z^:#B#/TJ(MK/D [X9!8-J;C#!&*8"]+^6(:H*4T [_85< /
M=T=QFNRW*H[IU P56I23^,3KBD^LR_]=IU/S8AYQ7"[.NCSFQ-W9SOM_.Z%*
MW)WMH<5V0N6Z.VF$9H:O@[;$$35WNHZ9.#X)5,]V?!)V2:#::Y[8E8C_YBSB
M-5G!P<7SB0F<0!6$BO$'<Y@$CR3\D4 EH$*+%P&9FM69,$H"U4Q#U^,67-78
M[9HC ^>_)79O E5B]R9V[YKMWA.BZ8I4TW6J?A*K-X%J<I,?Y0X$A'%(.HG>
M)5 EUU)R+:W[6J+HO9.^'E"U<Z\EX9@$JDFH@#]8W$[P2'(U)5 E5U-R-:W_
M:M*Z?87H4FU@6J:=W$U[ =7:JPHYUS!?BG%.<F/M#U3KGRO55S2+?A !Y'7"
MAZ9BJ0GO)% EUDYB[:S)VCE6-*<OG1Q(5 %9.K$3<R>!*@@5<@C+);A<DI@V
M"53)]91<3VN_GAJ6UI7JECGHD*>T='J47$\)5$&H@$-83X+')<GUE$"57$_)
M];3VZZG>MS3;@>G>;4VG[& [1#.2.RJ!:C*XQ]D$@?&Q2G)1)5 E%U5R4:W]
MHCHR#457I=J!=#WJ]AUBZ<DME4 U(8S((RR#Z?%)<D4E4"575')%K?V*.B26
MT5<LU9$^'TB_B=8G%HOE'-?K%_3_U^H7R9V50#4QB58P#0(SDW$67&*O8+[>
M_%TFA62728R[3/+)+I,U[S+YI^.>LO,IP.<[NK1C>H-6^8TX6*MQ<=ZZ3)T?
M2\VSH\9%@_Z_LTNIU?C<;%\V6HTCZ>+J\*19EVKU^OG5V67S[+-TW&R=[@MJ
M]GA8Z*69@CH_VS&[=WU3AYTAV";N%O]!):"XN7!\:*U#J)<F7=([3AF2$55W
MMM0TNGN)G3TF/!7W\Z%F:*:1XJ-7O3D!;8=Z'#@O-EF0MWM'NR8IW("IC%3-
M(4R4E2[L&U6,,<Q]Z)H&&DTP8%?J*+H"IH'=)\29)^#26WC0__Z?2BZ7_5AG
M3\-_R1_?P9I2T!.D2P8=8DEY.9VB'FH!50G](2^6&^GXS@  MLML\ AS2-@*
M+9LOJAT,+=*'/=3T1+IITW/[=14 ()<_2C#BV!FSKRAV7^KIYH--46-)1.GV
M4[R:V7DPI3%1+%O,(*8OTTQ5(H9* ?%##T 7TJXF%( ;)DPG?@N&(<&-N_J8
M_JU'++ZVE:(!!AYS)/5<@?+.*#!V0%$JF2.+'AB%D"$H[!O2D&W?EGJ*9NGC
M-,"NZ#KE*GK+P4?IGX<4&AL?D?(>,31M#7=1\=-SFH702IJ@E7=L>Z0SNL""
MJ0G:P*]"D$T_G5H)V?1CE#%@;S&0\@&*0A5O6,F0S331*?YOB4$!T6&15;=+
MA@YQ9TI?&<#Q*=1?C)<']*5=Y?6,D=Z3H]';Z5"Q-3L%7,7OJ>0NVKVCT4O$
MGJ'6%(L()3.D*D7K:#K(?5!9<?UN4[C%%NT#Z9RJS8EO:3:H7_((NA(W9G.U
M*L;*3SPN%0I11X$U>R;3RWA['DC7! %5I.&HHVM=OT;J:=: [^LCH/]18\'+
M+MA'A;[U3URZQYU\?8?9UJFW3&$Q@\M^)[V]J-?.#]^A>H773JP$UZCJ'(+^
MI+<!OHVK?HE/^A=OA!N"OM12\69WX;HZ:!](/:*"\I1L=P- 2E<>/*-?&0XI
M\!@WL4:@;>$/EKL<.VR# 'S"W2) 81AHM@VX%X_$0R4J>,>.1CF?7L?JJ L,
MZDJ$/8NYJ!P9*N5IET$8U:D9:=K^OW*6IA]1*!-3JX":G\@IU#R NY\Q(;P*
MN-KL.(IFI"RBV-0F!:94;'MDX:N5CCFBC^@3V&XYVWP".>I9A !<KLT$+"H^
MDG:?H8X(JA'+HK<._6_/HH# $5S12E%%0XW @&""L9VFO[7H<>B[Z)F(<4N5
M%?Z1GPIL*GXJ;DQI$*0P*"@4R8YEZI))=8/O!&S1)U4:!U*-VH"*A=_TZ)!.
M/9 I'<'0!>]BZS\!ZZ!WX)U1WR=U*%;AC'#UHMTVLH9 0_H0KF#A4YZ.%?XC
MZ?6846R #IZAQY<Y-G(9_1&,7L JU^Z&*=DCL#/9ZQ/%LI&CG?LU0%<?@1'/
MF9N9YV:7J"-*(.8'V4 IO-XU^\Z>*7N"3<(D-UPN4T(NTWZM,0D"*!=F(JCL
M<@0&1E .I#8PC^_#[G'((R6601^5!B- H7BP'3 *- H*N8?9\UU<T*L@5Z*3
MHPS@:F=7H*K97>JA\F?./!:S7S@J%=TV?0#<*_I(02$43ONT]X.[@.%]L(U'
MZ]&[VG!2%%)M@$[/0%$)[.;Q#*8T>'P/A+J,]'\G7@'2!\XD]S$5O[\8#CR]
M%CI$U\@]5^&^FX'B%+"44B2?OD;\H2[Q>;L'&^7HO9;+6'VN.EAT745/U?"J
M.E4<!X;+)G[79HX&AD:7DX!;"P,D <3!!B.#[<3B^[>H5"GBSPI5;>B26"8S
MH*AM;E%YS?"8BVMYS+22F#E&%83_3:!K)UR0 "#<[6!/A[]H%!K"[7[ZO+?R
M.QXZ8[<"TV<VF%9^98F?!5/&O2+X@UU(4WY[CC[];>X=U9KWIG[/;5/T@S2,
M"5$_1->I!89ZW!YU_C"C) UOA7"B3AXIQM5;KL\0Y^ZAN/H+)8*=4DW"S#]%
M!ZRCI36F6!O[=9MP.<.O-$>Y(P8H8H7>;J9.V"W&33GZZ#3H;A\\7$\' 4IQ
MLB,CI+G>1:.,NG745*2OFX0FG*U *QO^NV::-B:%4Z,7IN8(4FY6>;\^+0")
M6.W3B:D8*> -[FB/I=HM]6+0:,)=GY1'*.W:$ R7KA4+UNO9&)Z7<Q^E%@2E
M@7AG&+&NXE?D[)1@^7B3539UM@,%L6:U-9?&XH3;0^LXR]A";V_IB-A4^(<.
M1E"UO3V\G\1;<T+JN0],B#^,X&92D1(=EJZ(+ICHC7Q5C)%BC:6*R);XXWU8
M\("/A5M6 M4A^55'RE4=Z O8HR&]!>&?8$R,Z3?:[F_2+*)3HUX\=;I^T-_0
M:T Z'X)73J\DC/<=CV!,[\G!Q0&;*+_HLU*SR3Z>@LL6H?-T&7<:F(M ?1 -
M_X?"#?8%L0:23C_/HD[TO[>WX'_1ZVTH1MQS%TP:#0&'_REFJ7^IZ^!C2&(1
MJD"N=TJQ&G4*4Y(/4_Q<Z*+U%>'-0O"6?KMK&E#K)5Z;%V\51I8Y<MSHBP<K
M_^,)/Y)CINR^8K%4E2!FEREVS').Y%P-#!_3/[8 #"_YZD!\VM*ZF&.3\)&0
M$66&E)S+_E>\F#P2JZO9A'^:_U;<'BEX$(6 NI($;GV=^*"%9_H.Y9I6B R*
M"8@[ ;U$WI9^"N/%:>[>8ACJP: 'Z&M#2=>HK<@"RM0?GF;O%$L&&F"[T?,B
M3R*7PV.0S1>2+Q 0M^T1LU=YAM(EKL>_S2:UY/@U"H&[D44M29ND.(4+E6PZ
MF\WB-_XCIZLY]L\'RNOX0$;(M C)8VXX/8NNB0FU*T>[)BE<.JCU-%%*@;$M
M?_#*GQ/B,=,YG,D3*JR@(-R*0_= 6.RI@,7>(5UE9+NBRQT:3($9F+L9AT2/
M>I8R()13[]R4C"]VY#E#(;$C'LA*J01DFUY._@ 1?:_M8% ,0L,#>K%!$$NE
MF+Q7<+&>KBF8GQ-)HJY.D8>OG:A+",&!P! 3]=0<A!Y(:._P<]N8MJ :Q\9L
ME>N^*E*?*DUZD%N>"T"T4G*)X[.DFP'J"L)7& ]T.)5)CQ+622+-.W8T:A9^
M,1\P4"ML8RE@&U]32:NI*J05O"(2_,26&9+[;RJ[07%_:-ZG!%90LN&*Q8VV
M![;7I\&.-&Y3)B0<[ _;@)'UBGBR;]X';O8@5]2,>%%>+96KZQS\>DUXNI>G
M@^BEQ0T4(01@2-@F]28=?W7*'*D)&.O^NL<P2?+>D\8X%63+O&K3D:5TQVX)
MIT[-!W]6V&]^,*?!9V0%#1 0=IZ!=C^%-DZ(P9&*9G $/"QA\Q\D[7RK\V+2
MT[N%^D$(/(@ N.W,3J>W:X]@?9:B8U@%4A=8RM97[E&N'H> -)L(>\AW\SI4
MR3BN6*JDPRY:7GVM&;9CC28524I(&"OB8/EGKB@FJT."ECM/M,\& FO5O#S4
M GL@%6H/3*H\H8BXRF":M6O>&FXM=8CBP:?0#T!=RY3*"?M\"ET\H:[&Z1G:
M:HY[Z'Z7U2A"D&H^;NU1Q\8^0$CD!%\EZN-#7+=QZ!TR&8K"R IC @ 7:K)9
M<7=6U);;D$!B^47#ICAFX4J5/'KDFZS1-!^\:,F6Z0&AI>*76M^3M^O 7%W%
M?^)&@&L#U@)ZY,*6$#SJ2TX&8P2K^0,'KZX/>U^.!E,;O([51_7QIIHMW!"5
M:)E,C05WH"_ZI@L:*"MGY9L;^$G.Y>6;I[/^A7W=^'5V88-+_/C!,(VS$3:+
M8&4BA;Q%>O^^.;;, 7PIDY7I?QT3?Y9SF;S\!M]ZK'2=+/U/N?A&,NC+_GU#
M7__!]_8WGXZ(;D)=A/2_RF#X4;HT1UW@U1,8)>%_K^>,[R&M]I@-)UFP$F3!
M$Y/=L>%L^.W;X]].<5AL#8KQ\&$IA \%"&\^G9H6C &D-VLZ!2?\2B]Q,GY-
MC(@3=%)R=6*"SCX=<8]E3;2VVL2"RB^>E)VT=$5DW]; YX&6QE<3N9\_8Z7X
M43K'0A#[ [RFS;*KKW3P2N#18?,CCC.KC%Z1D\DK(;*QJ_IMTR-7*N[(E=IA
MX_RLEKK\TFC5+AI7E\UZ6VJ>U0^DVMF1U+XZ;#>/FK56L]'>ER$K==]0@-0A
MGTK0QJD$^W"\MTTCY?3-D4T]4>@G>83.=5ZKPQM9Q+]83\F[?3CU_,S3W+MA
M-*#@CM&J_N!-))$RDI]1I""CO''M\'PV>R/+\LW0R!OYFZ?/U?:O'X-!]_Z\
ML$)2*]H%-9G4FKR2&-J]*$P@UA,,IV0>"(35X#LZO6(YGES"R7[4^B,R%"[
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M^RSZ<IZY'&L9SVS//-DRL-,,NDTA!CF6 .$V\&BB2;>:42?8+HZA.S-C)=O
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MU= =H^,1'1LO-Y\T1W?#5);_62U>_;#:U:5U94RD+.XJ51V6%PWYVT HKG\
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M8[#HZ)/<J/2LM@.?U@:P83@P=HK&-Q7=+^GCD( 3P8>"9^0NT2JO-9!\^BG
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M7]1P%;"%'()V&.Z#-PF @F3-M5F&*7-#(LI2Y-Q,)>!=[)ZIC( KTB'4[*!
MG^,D:X7JZI)>NIN<UR_L*Z/\BSP4-EK@']U-?O^N>,]/YS]ZOVL[GR^P&X<$
MF:VL7^NCL?MT@OOTX_V4Z9KVF$ @@@I"E"\=*C"!;0LYT[HZ"'J*N=!2'0:!
MHF"05PSZ30P,%W)V-8O8(S?T#+!9!00S*U0,'&@VMI7@)0X\_H5E(MX3,1^%
M%RZQR!8_SHIRH]6V=/>A+<15,5;D=I=P! GS8VL5GVYO!Q.M_.?K*?%K%?%%
M^5/S2N&B7TI?8%A//<EO1K%;8:^:5.RFS*Q*KZ:&%J\TOST]/!J-S_,GQ\:2
MH15;2=Y(/3]A!K2*\ZLQPP7AW'W[I"$%0*XZ!G;MZ+EY/ TZ\E&LI<H4"[BR
MYPPLLA<!83ELJH13<Z0J*U;M,Q@ZI _U/Q"/M-VMNS4SM:,QY6Z]Y)UP+DW(
MN[;TEIA!-EL).0S7WZ9:XF[BE;I$J[C#RR+9:)7D\&YRT=:/+R\N+/L/Y"<R
M "G"D.%#WK9JR1H?+72I_N0^M-Q]GDGM,C#<]JC0IRP-"B&Q"ML-XERLVR6Z
M SQ'P_GFID&-T@&Z\5B!ITA?@*=)=V2JI@%N6ZB"A)=Y"2K$^Z"H%9@F-@'9
M4W%(-?0R :N4?E'DISBR96D+"Q7M1_JSR!&'C!C??/2_W"6B<RO[F3V,:I6"
MMJ>\+;8;2.H@EMB4//@/S>B!=H^--"WR1"49BH V\6"MH)*/7B7A634A&&"W
M/5;+"H<)KXY5XQ8(3U/%.":QT L"7X"4*,-A"_ \')1DHB<1<PB@U1UD$+D
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MN$^'=,%1X_I]3* G-XH9Q8_T\0VQUD \J1;<)(3WD,;X',\_LETR_6$JM^U
M5/O'<0)B9@G9TO!CD5TCH"'K/0F@]6$H[9GJ B WV?'8J#>LWX?-NQX9NG^K
M'XR/*K2= P074,";_.!^Y-W'%0'O3_3IZ./\$XB4\ISBH#<,KH:OTG<#,,!?
MI7E*+)<+'GO\B!XK'FX-/:2PA"^NI:7^-"@J'QX_!C@51JD/F(C_408<#*YP
ML6FBEO"9/47VQ=H6^/$$W>"LJD>R"R!6![9.3,QQ"^B((3+O%M%F\YXCZ :Y
MI,*'/HV=_&U\UB0ZU,1-(V,,*L)[",\NNC%M[FYEU[NG-CU_EUC)-&3U'E#D
M$0(I?%O6/;%9%D-*)1DI8T/1TUOT*9AC.;:Y%%_.A5/0;)<$#$>Z*$7&!SX9
MA'U3Q*EQU1"SD#:!Y\,YYIU(ZIX'5R?GCP7L*1Q!ABC&%'K[MH= <-_B"+=N
MB,&W:51->(ZN+K!WV_]AW8XFJP7H;719#BU+@<&\!BF;=I:D]2D/LS^%O2?2
M0SKFR&7MP$0^;I"+*^; YQ1N\$'5EC6"N FD7_ ^7@.H;,#6+"J;'&'K(ZAP
MI'_&G%7.70P'2J\<S\_G964?C$ @:R<D]/SB$U'5PJNVE+!=CIJ$7._2#0NX
MO['JB<IV>G86P!H-J5YD>?YINX2XG^A)C4%[Y+A^K:Y(0\:RK4^2GH&,4/$K
M:-CK'#S,H&:E(QC@"4,(VK 1NHX5U)<RB>388\W$6",TE2.>"F%)!(V?\,2A
MNJW06K>C-5T%L%X>RLN;)W/1'$']2%(2W1#6N,LQTON1WA.#TWP92/4WC4D#
M:X010M" $\1@R"$F5F R@_$(5%=0P]/:]B/H8NV/\6I:Y(7@#=2T.A]YUROZ
M+PICBOF*2TR3#YCC84@F?Q-$&%,PI4''ON(A-!LN0$7/[:D-0C"?[>Z1;RZL
ML&&Q>RQ(?0W!IULWJ.U\U!R#1;!D;2QD"?EDG8.V6S"UK$WD\C8E'J+HS7,[
MCM&&TE#N]L*<><XWIX\842-F0=1FO9^A@/=QULU@ID8.SQ'DO,LE&!&33$/8
MB%*X1(V<H4OH(D%N!7J*TAS($6AD?;SZ/LY<"G=B \A1?1;R!OG#[\(OMZPQ
MG<=+7@F_I<--(J;\S5MZ4#+<^=P26HK"2W&"0,X&@F6#;_R$=:?S*[_B8RP0
MCD%K%QH'^*G@<8:FL,R"3GN,.2?Z WQQHH@6>X'HS<UC<?B1)'T2%,%I8TZ<
MU.>+XA=08,VM;X=9[;+]'21,B5\ BT?G@&AY \+$(EU#.CM?&^8E<"M73L=.
M<E_(%JZ2#HYA2 4#['A"E<CQ%N8LLR'"2G)@1Z I$[$DF-^MHPV#5CG^8%;3
MI$*<^SY L[(D</'DOG NN^O:T)^1L%FLU !Q_;HN/MH6R. /\88FC$!"Z.FZ
MP<2Y%SNI+Y3B'KLCEL<N75 B^(-,+"B+!WDW<H;@S0!;SAZ)@;=4& []+C8.
M@<)!%-:QB^9".PQEIL]  @)=-='^8= 96;Y83E E0]]Q6((<5X_H4K;(CV,C
M6T7OH70'X(7U+.:'GA*7#3@&4U70,;89\G%VWJ)[ZA$&)9D("8QFBGEM9"KH
MY)R%^9$V29YA(H,0VB.0,2,\IHAKWBBP2?VO)-Q K.:9YD79S<-[^U NC-E\
M,#%D:!MLKB[^EH(UIQI=7K)*?\..) ^R$5UIN[PD@NF$=L^!<P&V<@3EHXX9
MFV1=5)C*%9J8$VZ?P(LLN'N>+8G:JB/"VZ+64FS4(M!61H,46TT'D32]D 06
M5M/)HL(QZB+3_&,VX:>H.J0]YEO@?;9$]3!;+%#D@TY++)'7';7OT4-K2Z.(
M,=/9'W0-WQAH8X7[9OVR84H?CBN5L#*.J;*AS3[3Y'.KI]P_>^HU\EM>'\2I
MC6<1^UUVH(:EXY,V\TXJP:SJ*=D'%=8P^I-5VG"(;+T/:W:TQ?(]2]M\SRSS
M/1O;?,\M?;^S"7TF7%C*)7<];[()'4GOW< 3-CV%93/RT"QVLM*PLYQOT/(8
MH^@QY>L55(63U8KIJ$18S0TT.%DK#7RB"M.AF6W$0A4LD$VWU":HJD#6Y*,8
M<N@K1U*8E)GST=9?,=YF?Y+" +KVF\8?, >X-L,45U9$'1-2UR*%1MC!'YR@
M@:)(189+=:4GU*"@I <[>^2B=F0 ,69:&7[S-=^O,+7U/;5)+VGD#:E%QS5L
M^AHW0$UT0Z/70"BGOGKLV4^:H_N=6KBNSY>&PN)@.WMJ0.9^ET/?S('S2/%!
M*5,F%% +]9$A.=^8E\-:8"W0H_,2-E@X_OZ5R/VS=C4L6.\O(GRXZ.T-Q]@#
MU(MS+;@=@YF!G9R?NBJ'WW*23R&G2 5@AON'PP7C*VVFBF/+&K#@V&Z9M0P!
MRPYT@I,NW<!L7X:(X)=!B\_O[8.%@D%4  #A1Q<,Z]$V'QF6Q)7,9XJVF,3!
M\DATGSU0*\5%!<0+3"Z%:?=1_]=NV'1CN_)=*QQ*(EX*Z6%2F$0RA@ 2T(26
M&3!)-IWAN8K@# (EL4Z?KAM+2V.."OA^,/+$CP6PRM, 6AW-Z_1W1T,1V.##
MKQ!DK-V! "B;]:(Y<#-^"E$P(C/XXF9:0YLO.U,K30>!:^^1*$TI2KO)RM,&
MJ\MR4HUF:>9X0ES>8DUVXH9347R?GN#2C/'(SW"^KMZCKRVH#@&F]<C\U]Q+
MQ>K'>1Z,XLMF[%6L\:POE#G&4.-3K5G:@+\0:S4.#CC4%T+MF5&P,1\8* TQ
M/ETI&X4> ]BPXC=E"7_#$]U<$Y.*ZODZ)AR'R$0-DTDDRYB^XF<94V$9DIZ*
M(4.)]WT1#G"YLYZLXOJI#%)S')%%!R)8CA^ +.&05Z?#/\P['$($)73),\ @
MW-S8RX\J%:9G4&4-FC3'Z--=PZ%*AY2\R$21>#@VTH$ZM@[^OG".9?QNF.]\
M[J*(>9@VQ9.?X?I0HV3>^UT_^L3R!2@\^\9028<<U7R5053>PBPR$Z00;HL=
M&CPN<$ZC\) <UG(^0*!:2\%"3/O$E%Q==)DB4&^?D_3O-N,(T"^1?PI/(+(1
M_.W93^P*PM?#PSY3@[PT["L(_1&(-_66G#O!*)!_#)M-\-$ HMU$;)B)09CI
MTP+.2@R5I 3N='[NC#SF($<%DVIX9H< W+9%X7(JL&(FBC.KOFGIAX%1WV*C
M(V)[%3=#95=SW[Z;F!Z5DT??C\C)9@_T/+B;5.^+OQSSZFGR5():*P8<A77A
M##PF'#[;<N+U/EKH?F6/&!O.DCPU\BHI0L<?]]U!.;4]"IPO,!B2Y8;DP-7F
MV+QREBH]KFU9Q%3X^SF5LGIL9&-B]B!,F.3^C:E/PEX#]P>UE0T^!P+7":59
MA'TC+.?"<D%9L7K!*$R0'R)JZ(8;,()SB*XF5"I)JM G'"Y4DL.74?U2$P-F
M3"R_1O6#QQLA*5.)S/UD233B6YMI?+]+5>]4V]MKE@EZS)0C*AN:.CBJP(T#
MER387_K&MXLM>#>Y;SX\.6</[J1UO]&2IWDW>:KTRX-:L7O9:N]\YH!"QA0&
MU5;V;,;1Y!O6PC?L"Q%JWM!=&>8XU!I7"(M<D$$M_<[_<5>DP?C+@;. ]4:+
MR[I4(KM =WF,(R,G),"8B4F03G:737X*)(^K?C#VR!X59*0'3GEMI!L>>'L?
M#1<B".*QCY'4/\4AFLX:5.#J_QXNOR%'6RSAI+Q-.,DRX:20WV:<K!R!+UN-
M*TRU/SZQ(*1YHSW/5M1D?T#2*W>3?T:]\OWA/V[AJ[G1JMC!W>3!J1[M7U5.
MK<;.9P80Y09& VY5KK4^&K]*G/(8XPP-*M-8\W:6;2LBWB*WY%#4E]%E0M/G
MI*F^$1^P*%3DIBV\"/H<9\I4\?*HT=X>>:*^0S>Z]!OX-[5-O"="_(2-8 Q0
M5W0BAQ(^CWEY(QWO73;=#DL[>HE[9<Y\PU&DO@.PQ3;.% QK@:R'K,4.S_O*
MXD?I$9]8%Y>T\.%I+CK/Z"&6!O,&X')4UK2,-5EAOG9P0Z-;GOX9H618;+X0
M \R8:*PKCBA4Q%X09$!57<T9A^ I?#IBY="H >SZX$$7#98G3EA:@&T%584S
M3H6!$YZ"#1OS3Q*>R@MC_4*[YYD%X5PMEK9!88*!,;CR/;6ILGP,#)WXC7Q9
MO@CK6=?%S*[IK?+J(AR\Z+'KAC&%HM"&Y2^INCUJ;VA.PP9SM9ND]E$C2_0P
MX/@&"(&=QT5KG+@F4K4R:SO(F*7*Y1YT'#S!26ZN[QU%QZ7%^Q9P8Y-UGQ%?
MX_06'AIMB&7$=&O1.]#ASLV('<J-S( [0=C.F,41%9\CNB(^)G@$*["*'[,%
MD[5BNVE+S8*PZL>':PB@N>!D$%E#R(R%0U?J5!B"#X6J-)C$GQO*TQK]"O>
MG8\LB94@FV8U9FXD%8 USG!P=JCM*#KA/TO16HOBI5HH0@MXKQ]I*-^%3*Y(
M2WM+9Z)&1B>'4)%F8>\;/Z>+K21>8T\$<5:ECX..H2DDV85+P45'+.D+'>1:
MT*H'<SSQHZZH9^G:(V?6>Y_4OOT$"7'L*NDF4?B-J%!P?.FC(/MDU\%ZYXN'
M$4_"<]Z@'T=$!#YI(G/3([I4VPE_H[?)Z\)X#EH IS",>6M["I+I<>OT>R&R
M1??)O\@9LG1;::K_<HOG^UT2Y[I/421]Y^4Y;]Y1&7M[T#3,_2_'_8VVG IW
MD^[OK[6O1_G+\4UGY_,Y8=-@5 H9%4&S-:#6^FC[FFMT6+#4,$? ^H W(M<;
M0EI<7Q.YSX,A_AD&@QE4-07&Z3\:-7? ^4L9);[=MTVLK^8Y+T\$6E$1?5>#
M3.">U-I&P<=Y3A%[WZ/$!@GVV-($FPV/_+DF3,=F_%<LJDXMJB8L&M+*HZ\K
MPDKHACX^=,@N- D ^8"9.%PKP]V(H;7)GPRW70D*FT<67]1O0(4)T9 Z]W]A
M>FSDY9G42'[N"0ZPN80W!+>Z,T[NAH9^UP'&62B6*!%[O=91X[K<*'OFCHI=
M!?^W<VM1P1OSX>#B=P27/G)XJG8DIIBT@YT0/V^Z%UV9AX>X=F5'9<V?_[=C
M/'M_TXO3;0\Z< \TNE7^@_N_G9/SHQT**H,M>7M]>,F^OO,YOT<7*@CY(K8J
M.!%H;B8)H?,'UI\Z_S$LO'V1+=J3X;W:8%_)Q;9=1BG8:2<8* 2V5H2 %/^+
M.5'=$*SA89,H@^JTJ%Y07#)VQ;I[ZJ7_U;AOT5./3-Z"0,9/4%3I+< >$.-R
M[#\*GVN/P24H*\ .!00+V5E#,AOZIOJ=YW)<+P2<]=%:(/QF)H%M,(,'6S+H
M#<LXM)B0R<9Q23@>F9 EFCR(OYMCCN18<-&9$A-6R"<&"^#H+8FF_%HJ)D\T
M4? T0_BT24<;L<8R.K6';%[?@7IU&_QH(=H)&#*O]^=#!(C^]T9>;QSF9JY9
M3R4H7G?Z1!^9Y*+;I, 7L+_VL:?%HC\Z:_WNW_1%-ZI8)RCCC5"B2>8?NYM<
MC\SJU4/E61]JFZ*__PM6\O%COT9-L/9H7'RZ^D>O%OPKU UW:&IC[!!*M9?K
M@R^MP]O3EG)QI#;/;TYV#T].;V].?K34Z];![=7)S4GK6FW].CB]/6P=JD=7
M%V?JP<79Y>U-\^;DXERE;[6:5^<GY\?7ZF7K2KW^TKQJ1:N$8O^#9/BB6'5Z
MY$L7U=Z! *T4QPY!YI,:#6LSS-WA45T()R^+0\':0; <GV;J-VS"U)?(&^F7
MQ?$ 9O#;_^T4=Q*W$A^]SVY[P'Q7 RS;"Q$74EH-L& RAS(C#66*7L4:<[;]
M2>6\R)=5!7D'L3=2C2;4)*;LI+PQV7\?X[Z/'B)FQS&?"AV"P2_$ -\3@L6L
M(<A8Q^O!M ;G+*T$.LP[]XS'7_EVVJU3Q8#"&$;36SHH![;SM^KTVA^*^7*N
M6*KGBI7*Q^!XD62U:C17S5=0KQ/<9ZX[0O5F-+2MP'\$SB_FLV,NA^C=\<\5
M_Q./2)$,NO_$9=K%HZ]XI1IY!_O>1]7'1E[V];_2J&#%A(&_+5_(%^[N?,_;
M75;?V1_'+]!\-ESI*ZW!T+3'A%S#-5S@+9PA9[V;#'X."G\*[>O?I9KO WS=
M]<[S#V8"VIT9%FQ@OPH(W"4"(&+3-A;R.PJ?8Z%6S57JM22G8Q)ZOARCWYU4
M\DLCE9)/*J55(Y5&]?CGN/_UP- ::T\J)9]42HN12K'P2E)IY&;XYQ<FE=<(
MQI]]PR/3TO E$I"U%!G'^=UGBOV83\VBUG>ET/<69E<^8!%%!75^.;]X=HZM
M\N&7]CSJG'%+JRB\8@\<H<;2JZBQE"L5\[EZ(34]SD/4-T+RPL:*H00DW__^
M^+6DE[[^^E9:2R1/%CMID'RQJ+! \F*N7*[G"M5&-DB^7!,L&[-K.K0['=E]
M8Y)M;9I<8JUS=G=/*52; JB"7AW[\5MQTOOS_&LNO;[N%E=);C&(W,4 )$+/
MM5?1<[5 ":BR;B*KN&DB:R;^7U],'O]Y+'4*5_6EX[_L>=]U26?7>-[M&[I.
MZ&50V!>-Y[9C4JQKP.W5BX7BIVB [JW8?WI#(\'?^F(0BD2=%&[3F9Z%>1[<
MM(3RDG42"*FT:8+$_\I/=EF"ACRO_<=LYZV'UBO<#@(!5DE."-4O=-ZPB"B]
MSLO0R#7JM5REFD\K)&+#"&F1>HV)J;II4BF)F 8/+3*\L(]^UZKK3$S)=M0L
M8GJ=DZ"1*S5JN7HMM?VT #$MUZ@2&V+95P5,R(INLKA7P01)V]/,>0?BS[Z4
MQ/$U+,(TR2NI/'FI=Y>:DY/NV=/7\J\'W0TB2PC6=Y=!X13'$(F\SL5 +9)\
MHY$KYA>F$;S0Q47.&F)D[<U$SZ3G5K^5OHSSXQ^E5<'(*48>P<?7F<B%8BY?
MK.3RY>7BH^#:O,],3%F?E,7;+-Y-M%*1.*W*A7/5VY!$VPVN%3BQE*^:-8(&
M"ZR$VE7E.>>G:(=;NLH)8ZSZ7H"<ZA*B8EU-(UQP;6!U4% PY=E!4<E4>=.1
MQ"$N';M#B.X"^4")$=2T7W2YTN-&!5&^$-(XH9?215=J6Q[CP;!T<8XI9P:Y
MO?US-M#[1C%P9OR,.X'+R6\V4YE]E+DV%/TIXFM+W'J$IZ1-<LB'2ZO0@Y[/
MY^@:B6553U@^XE>[B0[5T;F_3,%F96^\%#I:;D8>8":P&*Y+7)<5[GTP/DXC
MB*S4'$ / A^,E,. U&GQM;$<+8 Q_ZM;@-JX3O8(8Y-[\T&_SE^:^C3"A,\[
M#UD6.E9"P=W"F%->S!J7R_+*>[5*(O8 %_E@T!MF4VA"58=J/"HI4!O4MBU-
M[<+$630(L!O.PPA8$6\58?54UM^,,JFAQW-*\[PEQ =8ED\NP%\@1_,!H0JP
M!N,,3BP K$7814&G!85-T:7JT!.%HD>L2+$J]*6!76 ;WL$ NPG0OYYI8[7&
MMI$+]6C')@7$&?CM_&=M+,=[OC!D4!C@GG"0DS[JL.8'4S13S8YF*E2'2TTS
M-T_T5V/VOT?VR FYC<5'! &YA\>_S[[9@\KDSTH14&67'ID3T L.%*&FQ<SQ
M,#7E$[/-)-(10[-Y";+OV  <H:8U3+W".F=/G15@CX7@15!I^A8(<?:S17Z<
M_]3)56'Y[IMY!UXN=KS.$JW4&[EJ/;G^F:'"GGIAQ;!$;"X;XD'*RW@09]X"
M[Z;J[J%Z<X 5IX!TRY3GC5)^2:C8+38:]<>#[O5!8:5X4V.7'OG5V+>8W;D@
M;XK>?W,AKK.\JQZ-^O5OA\\WPZ:YNEPGFWM_70)T.JX3[O'%.O#YAJ$8#,I:
M(7!^T9U=&^3;I4EM/>9>"OVNPAI#P6-LS U@IF6_8 NE?T_;I@TYVF(]K"O;
M'M:9]K N;'M8KQR!+[LO6V6JAS5( &*YZ$*_8DT4#Z CY.S^;/NRJI!NA;O)
M4[=U=-_\.JE8A0UQ/R=VN/8.\_?:;:'T5.[N?,;,VMU]&*2HR,#:=FM;ZZ,E
M-H9%[6>7#<[L2/?M=V1-:@U;8.,^$5]4Q!<UC"_0)E96VWB39U?Q^&PIX;<B
MO)J(<E:'P&#OO_@D*G!TN<1Y-#K8NXK-!(<-4?[*6BO#"2"T@$/1 Y>> 4.F
M1VR4I#\3%#[5 TU.A1:Q2E<S'#ZQ7>AM8B.LWZC8#?O7(V&=L^%=-?)NL%W?
M%X<["I]_Y/*F<2CLH3F-;8+[>^B/LH;UV3A%:%DD)E:RUDC!%Z&W'"L-FSX5
M]Y?[/>JHF3 :\(=AIWZWZT<;9GA",_,<#HK=[5+-7_&;UD(OTQQKUP?SPL<@
MY-CT+SZ56Y<:9]-M)IRT8]HNZW\'IC[=.)NN*ZG=5"%_&-E><$/GFJMK#\H<
M $2K%<+?#R$X_?\N,5C+,M9,;<PFHHNIWP-M+!JC^>-BV0QUA1D) 4VP9L?T
M*6EPNF@7Q1NUA3Y'(4LB,^PY_'A3;QF&O/FYY&EV#8J0V"N9^Y45UG@>N\+9
M(\_$>:9T.]>M _7:T[I=M<F.#@OMCTR3T)_4<WN/<H%:3BR+EAAC\53%&N.X
M6_Z!C>1][Z*[^#UEF_NMB[\/Z;*/&ABSI]@DWAO/5EE:=T1X(>:^>C>IGE<T
M_7>C-_E1WFA=I7$W^6U]G?1'^>]'/^]W/@>@44[%;(:MGK+61TO44Z9E ._Y
M+M+^,75(!6>+CGU6@][F,[(/XK0;E*@C W\#30=QT'2A(L2%0W#DI!O*58#A
M$49WY'1 !F,33#+40(B:_C'\4\24*K#!T/[>=1^OQ13QH/UA-$P^XW![* T<
M<!1 FWPO24+.V)2\%7_\B1+7<+^MF0A"MT^(!Y,_Q'N1"1^:&#DA7R9;+[+$
MB>6K $(N2G.^)?TM?#14/C3U#%BX>J Y)K3"'XS8R'*F7N4"-<EV8"X(1K8D
M54G6=#!M@^T3/A, A'7)5^(@Q*9\R&<F&J(.S-M#A8B-^?#Q+9@4(H$%FOL[
M.A\P'O= X)SD0VNG=B(-MP_=5C F!K5)P@:)NRJH#F;DG' 8X0^EJ@?566#B
M*CAH@UD..6B6:\,<^"<(+XO!*6K3BPT=)6"<9:NF38_IP( =]A#%:)@]R^:I
MQ($ZYT>08E&5A;BEH1,4ELQ(V$Q'[/L/):]40IJ/B"3,UG>*@;Z3\,+=Q/Y^
MW'5[;M?XLMGC7_?O)E^.1H/3]E?3^-[8^2P LM5LUOIH%Y822N6)276,:Q,O
MYPR^.#_G'(/J%]T@'_E HT:AOC^.AHJ3$C.NA:!H(=.$#=L6^%4B)30':-3+
M?0B"OUU2L0X._7!T]=(A1WA6L17XNI_#\</:+W__<>P>U[)(HWPE<&8F<8BB
MFFD(\$#KC(-&..<K:YUSA7(Q5ZU4YX16HZ'/'%-#IM,KZ7-3:1>M+-(N@G*0
M,+(M@"AFL_XPNBC;YF5,ONV*9'^E1X#%(NN1C(IJ(S&3'_1.A8\RD+,9Z0YW
MV19C,AEO,-&21!G3]# OW_D:ZS!&$XJ*.\DR0*WU"]$I&^Z!6,NI/?IK/@@O
M_HL&_=4S4^/BK"'[R4H*\.,(*<+U2F[$H8=889/_I+. AYGIB$F'Q^[TOGZN
M!6/T3*: 2DHZ#/+CF=M"%<<-\>DF?.L*!Y[+$T8#^S;!Q/+5WJ2K@2'A.IMD
M*$UZ$.E]PN*"9OR$EZ)(V"$R_F K_IW0(UDVM<9PL+=,69@B]G5D$14$FS]#
MS<]]* J9%]--45"YX,91"A,$J <2JEHLO[^$.CI^<NI'S=_Y5I!VVGI!*@\J
MQW,/G<1>JKL4!ME)GNKK2JAK<S+^X_*W#A:Y>JAJ>/^K'Y]^^5H\N70>3_6W
MOWIJ?U$89'CUKROX+>2*Q7JNDMP5+)S(Q?F:DB1U&&.5O TFT1Z!;[TX_3,N
M_2]27/Y.Z--\*G0.O=MG[Z&W$/J\,@DP7 J> 0*]+@FYG"L6RKE",;GB@X(D
M$5UDT::AS)_*^=M(8W*S[6112EB?82O'&LBC86P=R^$R[.1"OOXFO"0V+U?F
M)]]_'XS_&9YX9+^RPK9R89?":R[7F7/8".=YG;W\XDK%A/*RD)G!5&&&OTH(
M?P52^U<C!@J+H7%H@ ]-HV-X/.\=)]DF5T@$*<O^L'I.%=),-@4EZJ/F&/AH
M*!LFOA3#855PTG)<+ ?A#<E6\A?4PGDMTGARPU(2#$+\9)PMY6>.1--MXGP2
M98F\C^BCF'C;U($W 0BDTM^A5;&J,OVN%B57\X?C]OY-<W0<V!1'<>&>N40\
M$PPSRH;KRR/6M+Z-7<K%7&I_$IP?$BXNSN\5$XF52AL32RTQM =QGT34#*=<
M*1@3Y.- 91/:(0AW7 +C=U+63]@61RQEL3-WA('%(/],DQ5:E>5@&3#9D7O=
MQCRVYXJPJH3M;>(]P:"Z:.#0#>AE9G3/C83W@-P@H<DA?6*Y&"FSW4B%EY)<
MX?7"*M-75GAE[&H,E_XL2*'W7\JE[F6OF?_662EWHUS8\R*RK&51KIVFB$N)
M<P+,O>)%%+-,+MK6JB?'Q<+S<Z>TPDK5XM?^.JM_H1JNC;16-MP0&YECM<H*
MUS*)6#:60?"U?/7=O#HEP3#*C2]?OQU-M-)9?X491FV7PFHAWT\IEHV\MMMZ
MH]#(%<K)%E@&$<M,"L4#-2*,; L@RM<S\N/AZ.JA^WVU(I:(&B]&@$QJP(O)
M$<M@%+H<L2S-B%AN Y;;@&6J@"5DXS22(I.EA2*3%2K@WET2=1JF]7QFF<.C
MXCM$)BM4*\U2PKRNV4!ICH<OL&EC64I2.$IYL2&S<N$H'UV>#@^+5X=#HV.2
M-0M'Q2),_76A[&*N.D<E2<25%+&HK0VT9D=;K/E#==O\(=/F#\5M\X<M@2_-
MR7%N/W(NC4RZF#[<O&1WIC ZBX4"U4<GOXZ[?\S.\\FOA_*J>AB*NX7";KX4
MD<BO\S76<M5\8]9(@2R<!$=9.@GX?6FC;\_FV:]A_K(ZK5B]L7T??S&+>6]2
MMVKU3?><XH[:]]10Q$HV5.@@$J[YL4F7Q9TQCHVVF:\Y%5B]1&%QHLRX2$)<
M<J% K>"[R<%1SVV<YF^_':]LG*  .G:A%KG[5S:-S]7J]9F6590HE9<3925+
MHN3WE6]-QDWCH7AZ9+X[4<9?S.MK !KIB%)]$5&&HN.<_@P+!29Z=N \:"XK
M?M\.='JUB0JM17S+*!0:Y^TX,->%]"A2CZ'D5Z,4@RWVPG74'&/P3UW''K"8
M/!:=XJ/X.^:#"A".;Y7M/^1>"SF?>#TTW3)VE''G%M"&7%MNX% +^J,$'C4%
M MTCEP2'96D_\QV#06N35R<F*(LG)JA+2$Q04B4F;*3*^1[M2!I3K=3H?H->
M,9>.;=$?.^QN6.7M[()=.9#WTJ7N)D=76J-Z1LYNAMI&E_(>W4W:1\<E[Z1[
MLG]:V/E\1< 2-L=*4[>'0!!2NYXPX+;%OFM]M!/)K R"YT=LTH!FRO=^#9(1
MVI?MV_"_(LIUU+S>%S5X0M[&O.6JMT-D\N*]YO6M_QJ;'53+*:+Q$^EANM:5
MS[4_W-A#RF"*]?S'OR'6=4)9,.R;</65/8DB5[Q\:+B0G D-K@ [^<?D[XOO
M!B6$TB\5OW\*>+& ^U-PZ,&:K"D=_Y8O7G(\2Q930OV'A?L>]3B4(4/;->1P
MU$'?(%WU@@D:^BZU*PQH.:&<:7^XVA#LARKK;1/"2Q3$WIB^3Z5Z'[N@0"JJ
M2?AV$!IBAZ#B4XC!7 FJOK ^%-)A^.)47QBS!B;T)9U!U[ 4"2RLC04L09X-
MUFE.?$)>CPI5_\9"8,4F'=TN2[9A?<\,R*+TY7*;4/S'1BI:E^IGOH6E0)23
MH2CL #O &0/_-=Y&AR\&C8V3EU+Y4N5(-S;!ZZ3=AK=J4'V@:5DPS(4A'"@V
M1U0)IM2T^RUE9V=0%@,U*'*./?7: *U(W@/%/P=FQD ;/5 \ S#GL$4A[IOC
MDOR>R-MF0VDH;O0LHVMT(.W:H"?N>"*]>CI/7%*%NCXO")2BK;Z3F;X3;K\F
MY"X7N[.UE2251PH)+[;>W>3RBT:^_KFN_+/?WG2]Y[CSZ^31L,Z*$R+I/2=3
M@NS?I_;,;]&S(0>-*$&\#@84&U^AH6P5NE,R J<BZ,2B5B!1_5"XNBLI*P<A
M Y$_NJNV>*-:JIAHO9Y#>BP+1-)3E _7H[;'Y&8QOUOFRD[D!<KFIS[/UW:#
M;K8A"2[D FQ>R!/Z:^@5:SLH_(G+FZP-;.8:T0R3-T]ES769KP>^+RDC$=U(
M[!):PX65 <RKMWF3LCB1POK3$@>:R*G0G:YG.P8;NL;WX#)%A^4J\<$*MC#X
M.[Z.93#0^"L#-*C.(1KE)>H?LU4&H7U4L],^:MR!01\VQX$0'X)/RO-(I"DO
MW79GY#B,.Q%>LX3=YN3#376CY8+>\+![+&H"4.CD;87\YAV-LK&@DT5@RT78
M&-,.&SX+N]&>Z5>X?54K)]A7P<-1NTK6[AN ID ;H/M"]A^Q^@POP?AQ-(N>
ME:)P9\SZ5G,;!SHA=D>F!3P)6B^S3WGT4S+7\?J./>KU :-#.Y,>EWG.D)*G
MYE X*@[KGB_\E^"D1><?Q7?3"#A:L Z\K1FZ_'5&BZZP@*=XB,:,@FDOH\\$
ME 03)!43D),J&9^C.P"P S.4S$QQ5*Q6-*B-%JC_%F<%2H+.'W  "AG&TW.\
MVW2D. M;*'8TMZ]V3?O)3693:HA-^;P(.B3B.2E0_(-PIA1_F7NS=7))]ZTT
M[B9G7^]_?;U]+MO-3?'9O8MA4HDZ8D]074 </+$.2=MK6OJ9YOPAZ&A@N8!!
MY(_^\8!)\QM' W=(DUJPGALPCP3K)10&7=8GJ=9_T6[_^?I<*CSV-P1)J+9^
M?G'34DK8/;U0^!0),-/?W4WZMQ;1M<Y3_JRT\_GZR\75S>Y-Z^I,/3G_T;J^
M.6N=WUS[:+:ARGX<,65./+4H\0#R2ICZ2+5K0.$CV[G63'(#/R<01$.>*?^2
M9>XF3^?GHX-_[.Z!NRE(#GV,N[9)Y0X*%?1P<K<FNC]A'*TCFO>H;I]*XUT<
M66 $G$3]@/:(/7*IF'0__OVOP?(-.=KJKN33['Z)JB'WQ=;/_..?T]..3WQ4
MIQF:&EV?<AM"&?#!E];A[6E+O3A2FS^:)Z?-??J/HXLK];I)?YC#GV/_@Q?]
MH@S<],B0+E=W!]).9V3G,M39X<FI04[N=,*NP&'(G V>0]@_$4A7@<5,_9/*
M3^EC96$8?MO_%-TPP.E_.X5R- ,Y,<<YYGMQ&<,Q[9S"^X[99,SBX5-#OO!B
MT)RSZZ4#N)@U?*,ISYPG37.DG<_- 1AA$YSSY'HL'?KU=[%! #IV;&IJWUH.
MH6L G(ZISKR%TWPXG=)__UO@A/U\L#ID<SA9:ABFA-$BG]WN;\/WEQ;5J4)%
M*;/GV"-+!Z7*=OY6G5[[0S%?SA5+]5RQ4OF81DWRK<#=KNWLNM0.S"58/G^+
MD\2"Z85ZF/P<CC1*\V#<@MO-K,%F7H/4/_N&1Z8Q68@19C<6T)3D=D2I^I\X
M+G^[=[VG>@Y.*\*"?NX'B1Z%KU+\3SP_B!0!QG[J__PU_33_NIQ*&G6]1!PS
M0@,%!71?<PU6D6&5K%)L1;6?;W?BISU':JEOKV_XN8.OB,+H*_/BXOJA^W39
M"]H\!SHPC(+<B9ZY&#DTQXS9!04O/7.J0NKD@T5<:JG;\I7\MGRE:%N^8BG7
M:,25@L3B3SQFQ%-/!B@763C N_W4>(<*:Z"O@EHO8UV^D"^P5I*9XM]INU-L
MG(ZNCPZ"CD*Q)D9J-)3],KN4SG>-Y]V^H>N$/D-A4C2>VXZ9K^4+.YC662@&
MGJZ5OLG*HC<)AL>=<<XO4S>6>I^>=7#U4RMV;[\5D^\3=I3V/C^\AJ_$0&)&
M7]#"XBRFED];_SF3Q<0U_GP!4GY\(V%6G8&* 9C"5[%,(3;ZTK\8__KSX[?6
M"[>411-T.0(LZ9Q9"JY:/FWQZCS!5:UG)[B6:Z/$:78)VER7Z,313%7K85K(
MM$[W*ATX0/>C=]7=CFT*7@O^=,#G>$(B1=/2FW!L^M%I>C!'C>]VX_#+GZ?*
M/*5N512Y%Y\R0BAI*WUG$4HYGRM5XXI*W]#R"K#N8"4TMP6P[V$P*AT\U@WM
M2S6E2I<Q$L; X\52_[7XF(7%49AO;;P1+C972/=< "/OKT;#FS^D^<]E*:52
M^@K#HC#7L'BC2YLEMI:GI2UP/8/GJED];[:_']1GJ6_OK;*]DB44LK 00$3%
M]CU807]<=!,)D2E(N\/2,H]UTM )UC>F"!S--&KF1;*6POVRU_]DZ%QT#QEL
M!.%T:^>/7R9%K?9@SM/S7@*.]],#9YPV0DQ9&$:%I+:9*4*6:3U"[XBVLZST
MMU(@9Z)OY?''T?#9.!L]EU,JBF^,Q:]7)-,C=!8&3'%SD7EU--"9*)VOE\SV
MEY.KO)/6_;D(2J?51!OS--%UQ8;W4&UGWONQ:3P9WR_OBXW:+!5VZ?SK52IN
M:F953-M^>)[T70[#>DL'93&EJEO<JV .NNV!PS)UUL4\:/!E7TIU^)JJVR.Z
MA[1._T+&6O!D,-"MWWKQ^I]_[A?27I,/\>8*;(0\LK#T:N5<J3+?THM%B,5Y
M^)+P*9&1IT^+>)F..AF?.J7?/ZZ+E8OV:W3+I>+8"]7+< %1".&RL(9*+^?%
M:X9L^:7JD)/NX.CFZ^73[\?1C%2&^;K?7)1[RXCX#)S+Q&"9'_!.C7-3P>]W
ME)6'&>FGDZ.?7OVQ:/U3*Q=?K%=FS+L642TC*)-%4 3D8K6T'%8E%$?>97]S
MRMXVN:)OH>$5M>WPBDR'5Y2VPRM6CL"WE9SO7\E9>M_ZIVW9YD:7V6W+-K=E
MFUG":57*-K<UFMO]K>[^MC6::UN)N-W,MD8SV6N7OL)J7H2KE&EYRZ^.=CXY
MOK"KQ?+JUVB6%BQU*6414Z[GROGJNI5HUC**@97\@$2VZ->[J3_L5_^<M$MI
MT[0R*M$LE=:L1'.6V__E :9EW>>]<=,]^&5YO5)OC4HT2WZ.W<(<)I.<T?FA
MAY4HT9P5ZTP7@<H6Z:XNC,'A_N]O/W^T5[-$<V&LRB(.6L^5&J]$K-6JT$QP
M9Z0KVUR!!,/T;1.6H0HN4$-3.]BWOQP]'8UJ<_MXK&8IP#3]O;+>II1)TX]&
MKIR"Y:]K'NUJJ)X+H/ODXL'[8N_?]L9+K!Q(J::6YQ;\K2MZ+-P\9@GZ[ )(
M\OOVWOI]:C<>ORPO%__===]7<LER%KFJE<PXY-PDKC?$_M:[J- +X/EXXAZ;
MQ:%6NGYYDMB[%1]DC\F9]$IIY$K5E2M*2.5@_?=4(J3OC)%..9\<ZP\]YZ$S
M+.RO;2%"*2[ALIR%;5JJY>J%QJ;GAI>7I E/GLN=QJ!4:CW4:\LM1$BKK;ZX
M*'#-;C+;+/^I^W0?^[?WO>/CJZ?U3_*?TBO#[*.214BF.C\>LY8I_O6,M,.)
M5W:__M'=IG%36JL4_WB4R<*<H!*GMH!)L6"*_XR)<,WBW:1STCK*GU4-L_TN
M$^'\%+9M+<#\HS5QY.O4-!4VRW):U95<SVK'U%S7Z!HP -%-&OY$T7J$$V15
MV^*3VFV'(ID;'F2H=#0'YL_B5,+9G]4\M0NT#L,.B9AU&YJNVM9,G(+I]@GQ
MZ'<D,6/:?+#[[(\H&O;5B0'+$W%PLFYHO#O.?X0_^%,P57V$TV$[?<WJL9&\
M.,.6P@4G8M(;84-U8:[6 $?LJ1V'Z 9=>$AWJ[LX^%:!+_&EZ/,070'UFCWH
M&.X?"@[7M:E]#.?&R9;ND#(,NB_I-'OJ.0!_]I0N'%O9)@0VJFK(O0QK9(]<
MRFD$^!0 GXHU[L 9Q?AB&!1LJ84B_8?E]>GG8(RW T<SQSD*+-6FWW5VX2GZ
MW0'8J<X8QU,:#DY3?J+@AA&A#LP8AE5AGX@K.-ET^AZVLW+7[&B4U!VB((V$
M9W<U0@,H9\_;NY+L!]0\=3N^K-3K&Z4?/>]\(G7)F4X)E)F*SR!Z, \;T#PZ
M9*R1;[QZHU.:<:]U>/8P/+XBI/.:C<[46%ZVU<4J6RMA1Q+84J#'/%&*=HDE
M*S'YJ.:R],W/T]AK"V_=LF,4KJE?R /C0E(C=)4NBD4FG8 5TL<FP<!UQ +@
MMB!-#0\G+L8(,)F?Z_1!/@B8S4=G0Z*G6"DL"[!Y/4N-82$+,:,U'^5;JS2B
MTT@O'1CG[(TOJ5X",W5ADNX0KFG^>-Z2Q'1>LLS=Y.+ARNV<%KS*8%/F,HN1
MN^7$D;O-N\F!7GDDA\\'-_?:SN?+JXO+UM7-;[5Y?JBVOM^>7,),QTT?N4OA
M)/ ^>L*L<;U:2(WK"1C>J*;!< FO2Y/AR4EE\.>I]6=#\%J<6@$[@H@CX[!Y
MUV,#YCWTJ:.AH1-J('"-G_)NS?>ZCUS!\%W/T<"9L6L:5.\?$*]O@U7D,H$R
M<DEW9*JF\0C6E*NR ;_;.;UK?K3572F8TUN_F^A?W3;I751&U5Z:.;US./B:
M#.4-'?"3.J^H;WD(/[=J:YE??N&HR>S]>+?(^7 ;C/M]0-7XXXJ!1R[.$[13
M;C0E _?'G\9SX?;X=+]OO+1^+[L3L*G+JP"YE;VS@F3K?SO4?YST?MPTO_??
M]<Y*JP$Y%E9X0:5S1KE^KZAI7:3@O)IUP7ESRC/]/H7G2P!:MH"ZE=5<G]&O
M0T^!K,;9K\$YWZG9RX)%Q?'\8A[49CS^RK>76[0B"H\KL<4SIUH;\@UM9QR8
MK*\JU)KZ3ECZ!7[X0AJ' :/^4Z-+((- ]W['MK!.?'U_#-V[6*9IA]IJ]F!W
M-SBQ_YA()^V<C2[_],]+A?V@+V\<_]F9Y6V,M)AFG[U+_.JTVUH?.?"9B(>F
ME-I#$\!LYW-ERDTZLYPTZUJ\HS1WC#D[LWN49W7!I>?ST^:W7Z/#\^)4X5VT
M+URJ/)+9AYK9>WP^8H3NOYQ)L5T]RW&(2T>?5"PB!GVBV>=9H<_5T_>^.2+V
M=TA8>B?T*2V&/EFDB%=SC=+\OMQO4JN9D!<^_<&CD4//,'(@N]ON>D_@C07W
MJ]WM&ATR+?->JD-$I5HJCK<$J>:?\YJ?DKYP@6>,8O&=ZWB[NU>0T,*6P'^?
M&98Q& T$IC=:W^_-HW'KJF5F+0G3[Y1N["ZTK[2RLK:0K"PER$K(VMF8:]:>
MY6N>G&GEXT'K<&C4W_F:Y7VEO>;T =J7J$2O:DT4GR7[9JI/>J!/+G[:QE6M
M<U4\-1>?,_AZ]2?UCL-W7\MGT=$B5TA1X;S45E;Q\R#>3-=Y ;[4GOO=KZ?G
M]5.W_:;X4LH&7[)(Z&_4YV?TOV=[BACK'C)-^[:I0YJF8S^24$';&^LZA\3M
M.,80P';1O2'.H/7L$<LUVB9I6<"+L>P11>7SZ>*\T'_:/_R)='9?P7'=QG?O
M\/=A,9!\?__]Z_#7WW_W/6_XGU+S/\4C^G]=S6WOV4Z/_L@7IC_!UOY3+ 5'
M@]-<=/&#'/M25R75BCN?KR&7ESC@$7;(0*,JC]6C-TA74S'!UW:":'^71..D
MF;*A_;<46^FNZL?/YLWWWX>7$ZO^+I)*U.G.V&2$V611"D)M]?S*3&1_4^&4
MDH!;^>:7Y]IEY;CR+O+HY5B1C0>GFG^MRK+$>NQ0%.+ QEI_W.*N8>U2\/0<
MXKZZV=&T:)H?!EF-O@JI<N0R9Z[R/9Q8E_P6!!U].?AQ_:7[3^VG4UA>OX0,
MN.^L4T0(+1-?%\3N-K3WT<&[<//9:%@L_:YYY+SU?-Q^%1JFU;JJ2^A<)#%6
M/W<DOX@?8* =3!X[O^XF?[SO_:/*L%0H!?&*Y3:TH\KHJ.U!AXPE1E73*B!O
MK^Q%.$D]"R\#-%*;WUCEG3IF+TL_B@ RBXYTA6JNDH(K+T"CH7GQG<YH,#(A
M+_M0I&C3S]"?30(_0%<>EJN-OT^$T)UQ?A(T5!BXG*)O#UJ6?=:R)D\+$/0+
MVHVG;$MY2EGPWZH6G#G(2Z>'^[=I:HO+G7E-*S)"JO2LJY[)H.IRKE'/K"?4
M^W<X6\_[C>6H]6(6]UO,-1J%C.\WEL.F<A6>$\HU;WPER.,LLU;?K]2_EI[[
M[<8;*$$+-1,;\B.IH=*?G&J1J62JES=N2<-%IU=YSUXQBZWR.HV$(L\+N&,6
MOIARKKPQDZ-7\^[B.5\F([]SE=)*]-EIW$V(_<.\F(P;^_WNAE1";G!YGBS>
ML=!3D^0ZE&7&BP+LC?)_T0!:*]2*(E@XHBY0@5BQJO$],I[OZ^>%JWSGZJGJ
MQ['DI53R/"262^9W:$C\_&*]).JI.S!6?#*M3C4EW8MCL"PKA]Z?">< .$]!
MMOIBR$XU]2@^_KIZ.ONR?U-NO"EDYS2ZJ*<VI6?"-8[YA>$J-_!QDSKX(/1A
MJSG5(="SR#,>B3G>4Z2F4-#R:.0X4/_,VIW0Q:&2TG:IYF1W)2*A_YBZ23GT
M)!J$7%C0-N2B&Q(H@>4=2RCGOWX?G?QCD6HA:#8'ZZD?H%W'Q\1-S;O>='M:
MC(8::8VXJ9XFQ1Q]/_&*D6]AFY+HL:? ?_AR\%/U74]L(GE_].?HT#R[:7PC
MJW(-<PBN\:)H+I4[]*<I5;$V\S[BF[R$J$V906TY]:EO=/JJ 3UGNB;]-7T9
MZ SZ=0'UV8/X#FO8EH#UF:&P!H"QSM/X'?H695Q]R-!X)(@L_YYV7<ON+=.H
M1%,7H>\EMKT,FL"X2<UDY+3XF>_=3;I7EY?E/[]*OY^-#=$M1?>82F+WF,K=
MI%FSOEU\^_'P7+_?^7S4/+E2?S1/;UOJ6:MY?7O5@MX#UYO>/F:#E7"J7"A"
MN: :3@<];R[R-ZFG)&^4R!]$;*E]PDZ+Q&,LSC2TMF&RCFQ>7_/4AQ'=='>,
M[53$Q +*.<7( O86Z_@(35>H=0C\4C,5PV(B @03Y[26C7NRI]ENL+3$@)\H
MIXV>@#)TW>AVB0/*$79GQ+4TQQF#O)"/Z9)@647:,6O/2>@5#-BW0_!A$H*J
MI\1X!&N5PISR_*%FZ$*[94=FSZ$6!QUM$((Y_EOQ+ZW3L4=PDJ$VAK5R"OT-
MY7S!4M@+4_P906,:'?H7:'\SI';3,^X13D/WZ)^2&E@CU@F-"&@ZA%XXBC[6
M!C/44(T!0P:!,@L$L-ZI34';[#F$L(X]B5U#XXRXPT@_P6#"A<^;6637M^&8
M)O2UWOMZ9HW^/,'X!JX)M1(V:<(&-;'!--WV8G:1WCW6R,1V*^_5YAD9>^H^
M12+5;KO$001$#!E9TB\,:S@"\H#&DR-H?41Q0">0%@E-D:9)WK2M'FN+JE,P
M"-4(;DYJ= LM5CF9GA**1VJ)XIM'>K8S_O<H.1MRM*G.:.09^?/G__Z_W5WU
MR""F_K=ZJ?7()[K$PXA8'?IJO?Z)=1FGJZB[N]R)JAN/:6-$D8-7<2<O:E:4
MK@51W(&3$_?HQ<2Y)V.J\_+1>D61OG&T*\--0.R3"AD]?ZM-ATK,SB?UG#(<
M!M5S&^!7*,MO_25>@S\%7E'A$OWO7Q30,2!WB/9GMTTHYZ%K#_'&9(1C,/:Q
MEOT)<2[ [V%H<7E+L%>V'0E%-H<*-IC 872F<MQL7E*.3G4<^J[$\36F]M$+
MQ1;=T+J[0Y@R]V2/3%UM$Z[?\)[4($A!8X&D>E1T0*=P-,OM@B[CJX1C]8,&
M+C[#8TM^I()(@2_1?U$E:PCN"6B;#=W\]$?-\BAZ09=MW@1<.,_\3P7K0E]N
M:IL#\5/]!3_-I7B;>$_0N9NO,=2 N.FG4/'T<+T!#F9%+4 !91+4.ZHE]D94
MM01ZHUH.)3'#[8/B1M^@&@.])Y!P$LSZ!C7TG4Y_S.!$3V1#8]X)5Z&YQ!7"
MEG]26H#IE/XJB@->&FIWJG177)FFKT%%'UT3EZ1KH;HY)=9!W ^@Q#/R9(P*
MP+Z*1U+Q2*BE29M58C>+_1>#]HC_GGZ(@3"2A4]4.+WX^"$!DBC#HIWSTJ\?
M(]*F0_8OWFY^KU@QK+?OB_?NFVQ4:XV,=KED'$9%''='-3+U^\@&,PAY+\Y=
MT-#9R7FCBPS6T('A=&"8&[/I)3X+\Q*F^Y2M DZN)A*NYJ[>FG%N$>6-=[6.
M[*E(V=/%E";#G&'HI'N(\"ZT-3 BPYP-A9SJCCI]T$K"CP)3<ZDN9&I.DIO2
MYX2X%<X-/\6L$S#'5(L*OHH:H<:'X[ O?8(51"P)S^H_%"AIN!T;W':@QU(]
MP'%L[$P#@WS&LN;'M5NJO6I;#KWVN]IRZ)6[DBV'+E$.?1OC1/;YECL:#J'D
M'GD398(>F\MBV8([(><S>!97\)HT]H6'(J:#"8S'XCXB?)8;ZW[\J$-Q$5(?
M@&OC #%;IU9M#A(@,)0",\(TMZ]VJ>'*V__;IMTS>%!&,'7X.HL\>:33MXR'
MD0AG4:L8]R'O.\ZRCJ4ND;^XR3;RAAQ-CH?V88@?Z3FDQT9.F*84;YP5^P0$
MY^X3/3*=#[+LP(LV<C!/I0VSF-4/]!GH40'C+*P1_<[XHV)8G"R88PR">A2Y
M(:C'G%!2W"76'^4/MXCQ0R4&?1)<8R(.R_P@;4*)Z-\3V\D\866JU]9UIT_T
M$:1:^0'&)F)7T])/ ]PZXQAU85T)_,%1WC=P*TFS9.1!QIE^YVYB#'\]3PX?
M3K[^LR'Y,$#[S+>)*62([-"(PL ,!2KI!@,8TTB%TQ0;2$?MP"PH+NU.T?^_
M8,Y,=/!)XV[2KC^>'OY#_C'[0372C,$G0?)13FU>7[=NKG$$RNE)<__D].3F
MI'4MDI(.U8MS]:IU<'MU=7)^C$^=7YSO!K_9;UZ?^%E+R^(>*SM[95XO\+2!
MVR>HH=V% Q"XKR='&\9V)I>Z54UU.$VUQ')[LZ?=0VR(UY^Q32G_OVWG+[J3
MT"0"]JNX_O6QGWU=4_MUAR;WZ6PAE1)2Q2VD4D)J:JI"9I!Z^:B%D*Q9:%9%
M:L"FA-$BG]WN;\/W]P8--G68<([^EK]5^C9Q8#IC7-:5;XBHS&!9<B>7^0^^
M85N9[6:RW,P2._;-ZAFS\_D W(^0W4,MPT4ZQ_[;+FJ[F??I?!S7PD/,(ZK&
M#J(XHY;ZV,_6HQ^;:DNYI)DF\B1P(*^FI<-_6@&1Q91TS6X'Z;^P/SX+G*!'
M#DO"'4?Z\/E/2\^ZOJP2TP/B%D<Q=@!9])$E$9AG",LC *5HZN>4'[Y_N^G>
M'CWW_1*'*$N1/$]3,U6*B\Q420W45&TG4T%+/!P/AY GM9[/I#%3+5<MQE57
MQ*+P"DSRJ2\5Z_T?OXA( AI028A_@H$%?*0P"]]7BYCLV]K^ST?W]%&_7WMB
MBKF!Y1%<%MVXUX[@EBMF%B>XXAH1'*DW\HU6L58L94IPZ5K4UO.5>2UJ5P?;
M&BN*;:7UP;9N?M*[&#L_R3^]=\&V6F;8MG1K-;Y%7T2GU\G0=@U/E"5G8A(%
M"%_;'"U>S *2$/.0P:[)0"<P]/N7YOW7UN%OU^B^"$-71>F8!2D^76@.#"**
M119-C2NY0KZQ*F,^\BO*QE='2T]-++_.]ENGMUAYN);$\EH-?1&"*F1A&J\4
M0156E*!61PM/35#?OC\>#PCY4SIX/4&EU(D*I7DZT1NAT?Z*HM'JJ->IT:A0
MTGX=M>N_;V]?9M2]!HWF&G*KXSI/"@3AA#K65L6P'HGK+31(\-\6]-AN9N5L
M1&@FH7H.\INQZ@*OP?SA)=J')P'!K(U1Z#]S>WW#@77MP\H?P>?\^7Y=^-EM
MG>L^+XUG%)EHNK/AF'TT)_GH$;4U=;>L&6IKL91K5.NKHK>6LT??3;#^4E%%
ML:X9#7/_=#+LK1M59!6624TY67A0MI2S!F9>*LIQ+Y__J9N=:N^WEA'EI-30
MBX45,?3JJX0]JV/=I<*>ZQ_[1N'@.^-Z;XH]KW03O'UJ5():W"4Z11%3U7IP
MF\M3CAN;HQP?V_2N+%CJP':&/"\82A.; $,*NFD\O;EJ/;5.]4[Q5WG=](-T
MLO_%, DK!<4LYON4\[E2;67&IZ^44K"2ZO0"=/2LW5X4[[\T]'Q6>G9:?C\W
M5/Y&:-5<);1:25US ;32C_8KWWZ>C6[+QKJQYYC;>"<6GH5=MUHL_&"5:&TE
M-?,%:.VJW?M^;U:ZM[WJV[+PTBL-OC=R7\>6IQ[ EZ"9#XR7L+LBT2EZ@#<?
MKAO02G53]'L9U!=='E 4R#MJ7]6OO OK)K\(\BXP@WBU]/P9L D+@U(F^=?Y
M7+Z8V23J^(C5.U+,X2I)EQ4T$&82HCLZ.#5ZS:_=R?T;$6):*3,W\+^N^+I2
M!NT*6AXS\?6^_;-W<]2X>7JN;)K@R,H"22]<LHB];KAP62DWP0J:+C.)57^V
M]P^/1^W3SHK)EL829,M;1B)*L9&(:9N'#[R_L;UYC>OF 8"O]%*B2QYZGUP/
M):?_L.8?JV#\3)JEVXE5&#N7W:""(P5@9^-S,GQ2B9]$\&1FLH0E1CF+)/-&
M+9=OS,\RC\7 Q67&&R)P*U,$7G%;9/*GV7N<3#J'C5^-3:.+5Z;T1&@G"U.^
M7,W5\N4-IIULF?^*VT638[,UU-J-VDG#V&#:6<2:B=!.%F'M2CY7:LR/B:PO
M[1RN".V\B9DR^3XV#TK.@TMJ;TH[*4V,\MPX]T)X]O_9>]/FQ)ED#?0[OT*W
MXTS<[@CL0>R\[]R.P"PVWL" UR^$0 )D"PE++(9??RNKM.^ P( Y,7/&;8-4
M2V965B[/$V'N9'_[&TZ#.8C!?!=<Y*^_)NCZ/5R7TV .8C#?A OID9A^9F09
M&&8$IVCO+@KJYE0D34Y%52-!,"G@/L1F5NIR55?:0G]!/(I$^;[QDJ]=7?#\
M]C(&(=<P<G0.KVG;'.U\!(YV*AE/T*M?4O<L)>"F#)DM*L.>QWDBTK%IOT%S
M_/.P?F7D[ZJZ<QXWV[]=9 (RB0//,KM):78OI71_,LW!4MHK-O+UX?*5?WK?
M"RE-'J&45O922O<GQ1HLI8*XG _IQ7)RRVU52G?OS[ALR/9\GDQZKWV>O<\K
MF\D0]SZY;"Z^VK-;S'+9;>4'Z60MU<YO-<*_HYN'3<NB".&OJ66'$\(O1"^>
M>WZO6+YFJ_>3%L]V>VE;'#_8L.PHF)_93C!_+R2.WB>)VU'6M31];UU<]/G[
MP=Y*W,H5:H<C<5LX@O?<WU^6TLWL&W<W?)!V+W$[<P4V=-JM[D(VBDJS;;H+
M=J;WHZ'MU29Y]&2VJ_'6[I@ <VTV6A<R6CP.I+D.2LS->$+W<T4\&&6/=ZH.
M2MCCG6HD GRB;SV-[RC'=Z)O/=QBE--@]JQ,YT3?>AK,/HCPIO2M+F2M]L%O
MB=:LN#GO0FI/2L?TSWCQCV7N+H=S17GZ*M'[0!V9VC8/:S891>=X/)$*#L[L
M#T]?9:L"O>=IFFCTI#?D[@?RY.HK/=AK/=DEQ6HV$HB? ].ETI[JTOX4J07J
MTL5[>9@J\(K,AU:ED,FG;#HH^;0_@I394T':GSJR0$'BIQ-I?$U/6PTF<DF*
MCH;WV^Z!)_:FTV .^S;H',^.B)S6Q7W=NWN?'W7"Y?LD,^Y5,E(AMU,DXXTN
M>6%)9K+9")S3?#Q52!TZ%O%/N;KY<LS0X[>K3'JQ?/G8#U'?->=2-@K$O+U2
MAW7!4W_*[<M/'09B^2U[);=R[4APM;/Y(&=Y1S*1V2>9V,.+E)],?%X5FN7W
MQ3._2$8B$X%UH-]\:W+W,#UJ1L(1)?D4=T3<EN:I 1?'X[BNP2S U48WM=1[
M*_O$[A5R[H8>[X:\'+E$%'R+A7@J>[QHN<E].CGVTKE>0QUGKV_U^FV1OOM*
M[:+9.!=([W&HTKDNM<;/\777D,ZQLLC?O4V*R;OWPS@L]H;H*1=%$OW(#Y33
M560+*CN]F(_%C]$@,]L,YRCL@1)(\7J,7?&'@K:>7!TT= >WG&6S/\Q]IFL/
M.>5CJPUPJZ'=KG,#L1G]2, F\O%</G?$;?!KH$ ?[A5B^5"N7-%/S>I#)>"^
MO1^R'BDJ>BX*6(A"/)T\9G7([(DZ[*@]__7U^N.A?5.X"6@CVSMUV!SH/!=%
MOG7-.\'AZ,/%GNC#;L #GA<+X3&SD#X' >YZ9.@3N;T'+P_=LK='A3^GP1S$
M8$ZPY@>P2:?![%V=;(-98)20B40)?(\3%4E>;WFV@D*^+YE9#=537:VV=*NN
ME0Y"/K^ZOF\V"M=OZY=8;8+)N5:25<7;])B4S<6- F(\'<_D@SW<:-7632[S
M6Y3+/0];1"/N"S%;YAX7_>=W_^K9L)[KAO4R4<A$:2]E8G_RC8$R,5EF6*7
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M$C.^S15N;YNY'^5$>2R(56?I1)2NTS4C3AEY 6)56-MSRN^1Y^0I5->9B\:
M6::S3\.3OQ3N* \GCV%;]OV\I(0;%O$Q>TFAEC81ECO1_7C.Y OQ;)[>6\\H
M7"<%,B^1$;H9W@6]9W&;5ZE5*"JSIWLYZUY&Y543M%$8)[KJAKJS!LX**&/9
MN-T4I.Q@VKZ%.$$ROUDIWCY?ZNC-@K=^]XJ0!F#+6WP2X'T4X.@NQO1ZH9]#
M$6!2>!:N4XKN+'-IOC1ZF V;-?9(2KZ/N ^C/>1B/6DTDN!Q4N]#+TFG9$Y
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M9+?BB67#2M6C:>LJ7T#V5,0Y/L,X+CDF_76=IG/WS[V=&T08^S_ )S4E_>"
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M%O<^>9Q,1Z6WT:3PR_/A 65OJPUN@]*V*&L4+3;Y,*!2-#/WTPH,34="R(/
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M:)I0#II7'XVK*^GJ#M#"?H9T>B A9,(&K!P"2L<+GK0$1$0]LD40 #7Z$]1
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M2X)#@"L--! -C$R!/H!SL]14T9I*W1 ,SFP(!J;*>*CK%S'\!4[QX4>01[I
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M PK=JU>.0("Q7Q2 H^X@ !>Y<0!NZQCX89=J->A8A^5N$H"C?@)P]^;>O-<
M7.R& ;@MNI$Z95FAM%&$W^O1_ X!N(.]H:G+0G"$/X@?SL.[:@3.2V>'-Q&X
M+8232UH*,'M2%2,_$;AC,9/V( 9'OH3/P<X?(74?BO,#Q>!27L;@MAB(F,PE
MZ?9$RA/"W<3@Z.\8@SLIG>,Z,;BMPV_6%Y\)E29:P^&=QN#HGQC<3PSNSF-P
MNQ9DCA@Y$*$[.%#S2I-*=LJ;X'5#?,G=[&C8FE!O8JO?2=#GAOBN,6[E:Z*
M[IKJI5% VD^%3Q\>=N^S=:Z.K/NCBWM0.#X,9'+A92&3.*$^[X$1^N0 I#N:
M>Q* I \;9(^!Z"?H#(<Q82/VN>4NNU'L<]OEO&C3(:83>)_B7QK[=/46'!7]
M#-U']),Z/OKY&.C_A7Q^,ZJ:W!=5Q8G*>)()B)]1\M*HZIUS]2,"KZY\/.1%
MX)6^[N@X#]Q*EIL(=F[R.)J1]!#/':NTE._L2G,Q<'JI$).ZT VG2^01[A_X
MJ-MYBK?V<P)B4I?IT33I)\.'$?/ZD6(ONYXXX+E?W]W"FG!+&)02'24[HT[V
M&]T-#GFCNH;.L]#65-?(2^"PC78GN7,I#_7'W8>Q2]W!=^N/$RE4$SH -0O"
M9?JC$T^OJS]&O-8?SP HU!]#H;O)GO/2/'% 8UVAP1%+6REZ!@+I%:%<U<74
MW)%\N4>]\XZ=766+QW.P\+'1T+TS?V^8+;>G.J(APJ&>GN><;"4&7'"$)<E<
MHZ'3F%UY51>IBR_:LV6NV6BD!OMT-=U\WNVP<L>63D#)8^V('>H:Z2?NHO;A
M*GBRP=E1NE\"L*@4PRNF&;N%.HE)92XRP\*$.\$M>4>(='#/)^#6>:; 1O('
M<;<%V)L*6^2#Z^DJ8)V7HV##_33.4-8^ U(SE"#?<\J>_-)CE#4;1Z^JJ85#
MEJ86C27+%Z/UJ7"$%0XT=4\ZFM<8=8Q^]IYX'U6S;28M]H[1S\[G7IZ>\?EJ
MV;$QD7UJ&>&16F:-(/)M(:%CRD"4^E@&0^Q<DDJJ4F(>9C" M>&'[( /QP,P
MNZC H1?"X<X 27JZP" >:XRE8?E^GU/0T) NI\TX3C1'^3DU 6N6'U"Y.458
M0(9L/13.#T#C;8 <]MFO=(S+0KD;H7]4.#!G(L$MPW$%< "/-I34U7Q ;<AH
MV)!A-UZM8H(TX^#%C&B_"-OW(I_S12]85(77;>5<^(T9A)(&!,K6*!\@> P@
M:1(<&/!L$+(]8P$2N3$";,'!:WO20 0'PF(S -3_V12_88<*F)S(@K3@.'"6
M4[ Y=U^6K?,@;J+6X1J=O\?!"DN2]LX!,K=>[<S\,W@G)=(.WOEA+P$]%$Z5
MB<YYU?&]O;35DXH(9!_+1;Y+$(&W4"*]*KR.GP0S UHK2!U2&[\$3OLXL067
MCYU@6>?5D:--:,KFU?0FKPZ\N)6<(::$ =X@@,\^-+B=P6:[524($_BO.?T=
M(/\F1@:_ B.-K,24I)A?P>MVZX,7X6=B&J?S:CW=ZNY)@3?!L8/BU?WH>X)R
M>0H.D0!QR# 1/E()C9";[L*O/3V(H;N44#1E1GW4*3)N"L 9!VXHQ1_UF50W
MQR*D^+X&9&KR4^>U15:$\Q7X*5<1&)N+[)X*%3E]*A0R3Z,ZD*QP-A#;@/+:
M@77PO6ILL1;HJ$)UMLZY3XU:"[I?_>4?0_ME\&(X[,Q@ I:Q<0)@/Y:AS*B8
MDY;C,3YX&$4TJOIV*BMP3BCX3Y1LF>K,+T"J&=)IB$" PFR(8! D+UA*5^ C
M@'IH<!K(]Z#&J+!.9<[Q0)_S@?CF Z'VZ+90J&/:HZE8H%$"Y>WO!^4)5WP2
M'$,%3D$X:H2OR9LVYES%/Y8UCN$TNL1..RL3=\><*ZR<,B=<U;!RHUZK1TN)
M;"F-@7^P9#M9C6=KT5@AN3F>ZM&'5;E-R#F4\7Y"<OPY>?3_X15Y,NJ(/KKF
MY,3)4,_63*ACB@R.'N_T<PJW.X73ATE=<8-(TT'&&)JHM3Z![3\QD6[7,#[S
MTTKU^"\ 8W/D7('O<T#',C^]0UOJOP &BPS,??]GQA'NIP67Y-+O# Q76N!_
M:,$C6KA$#-[OR,.?N\^Y^TL&11X_ ^IP9]"CG$K;+J4"C!D9?_$37MM9K??A
MH</IPXNMN/G'UI>$OBJ+G.7FBI.EGC2=!AJ952:VK6QN)O08L30!PF1S<E7$
MN_%_WAS:OLXN%_E<K5O6(;GA>[T\J3OX$GBD.9>'NU:>>:P-6?ZOT"+?^23Y
M=JU43G.':5&'<+E76MPXM-O2XN6UP03Q$J+NE!B_I 6G2QN&S131;T!_1:I1
M?8_GFK'EG@[Q:^7!UR.\*W6'N Z- 5Y\6:N^@#\0/MS]^RX([+@3WTB9V.K=
M="=%\]^!:*>I#A-(?E:DT5;VQO-V>HM@> >,?(/S\C*\(Z%CTC:"@:VTC9MT
M"0B]!!YN2#!^B^8NWU P]B5RVHL3M=G[]CC59_?JCWL3C><6ZUY+8%Y>1(+3
M+]3A].R[D)G7F79Z1'N";T![@T)VIC23RUB*WZ.4NA63WI+R3FJU<"T:N[#W
M&>7'J<-EJ7=!8.NWA+]>*?6R$O\;$&TKD*H&>WW\LWBR3GIN_X ;*JCWT8:
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M?I/#W\S17C)9,3K"]0E=ZW^GP]]*A-XX^F/MU[UR\<4MCV#]Z $O1 W, .M
M7 3C1!8 <DL-0S@"5^N'\(:2CI]RPN+E097-?[NVLKS9@7"3QWK<U(_"MX8O
MQF&#,&!=,A"F#KQ+\&I/D%1=V=6C+Y!TZ <G/.5C61N1XT*XE4]0O8>Q;L"9
ME<KUI \GL/_[_X4)'/]G0U\*$^&/)1W2Q5 _+V6[@U]_"MEXLE1+OM8:E4HA
MFZQBT70UF2PF2_6:?>C?J@/EPRP>'&:![T%UVQ<=*!S"5*P*=4#$CB3P=X]3
M58#*6&(!^+LD ST;2\H\"[0A25BH0...Z0) ; ;[74TD8W\]\$GNX48/LX>L
MZ",".(W,=0P*4D9< &&B =N=Q7@1G*@VDS !G3D*+%BGK@)K29MQG+AV)Q0W
M4)^-2;!O)I#R=06LF0-+ G\7 )Z WVM AP9"DL5R0.Y)J(L>T*)5H'O[?D,.
M003^L2Y!'_%__H*8Q7) <DDREHP] UT#^UWH5&M)R#Y#41Q+B@!V'%IT5-<D
M01I(NFKA'="L:T.. TO^74A&D[6__D+K! \BX(.BT2:6R&'Q<@$\"?WDTZPM
M<VAW/# G1:1_F.M+<R(']ZDP\@(*_!UH'\-T!#1X.8K^" L *44Q#$['0O,<
MY/^BU%MHG&IN^L6'YDJA!6C0ED"V,/C@=ACKYR<S/##:1$R7^PHX<'CCZJ8^
M/ T>V&^,.D1P "2IZMT16!0$,R.*P'BQMP_M&HT3H4?5!^]\P;) \619'H)C
M_:WKSX&_,+TA#TX-,0FPAAZG:.!Q4(D!*I<D0KQ4N($.N(>D -R1944"ZN'J
M=["1A;D]N%!%6C "P!+K6[@+!!!IAL&M"1S&\@,>_("48[0/ 'A,!7K6!O0
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M7@)H]W#.VP.(EQN)6;36RZ7H_0#:J\6< :(C>QZ?I6#8K1W7-KNA=I#;W;.
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M><VS:<04\,#_KKL:X69VA!NB#D6I( %YS"D3*_D;K&G"HS.-3B1@\SJT(B)
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M[2;D<D!!.P&R9Q+/T6D:>XB'\@?Q\-T2SRW@?D@$GF>1;+(L.GR."#S&RW9
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MD43Y@\3A^0*7]22X8MW@[@JU6Y:SK>@F?#;+7L9)N5/F!3E:QCUBP(<KZ:[
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M#R1#J(.#(]%99 NP0"E7@*X+S)PAAWJ9 .W>,)#A%H%.KD+IR3@>_X/_M^E
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MG<?A4PUT-?1\E.L$6;.*\BPE$?T"@\\BAEQULL+#,')7TC4S(5WE9 :%9%B
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MD!@Z#PP& !-34#HFP'.%&\(*GJFIV!E5&:O[K?<9.YH &@(R%D' @ITY1>W
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MO[7$J/G]!U!+ 0(4 Q0    ( -4[=%IW3MKI1!4  /CJ   1
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M,RTQ+FAT;5!+ 0(4 Q0    ( -4[=%I*..^WE@@  #Q,   *
M  "  9&5 0!E>#,Q+3$N:'1M4$L! A0#%     @ U3MT6M'5>3"%"   FDX
M  H              ( !3YX! &5X,S$M,BYH=&U02P$"% ,4    " #5.W1:
MH4CWM/,$  "J,0  "               @ '\I@$ 97@S,BYH=&U02P$"% ,4
M    " #5.W1:QL0T]H @  #C 0$ "               @ $5K $ 97@Y-RYH
M=&U02P$"% ,4    " #5.W1:U;Y$)2AS P##P!T #               @ &[
ES $ 9F]R;3$P+6LN:'1M4$L%!@     -  T !0,   U !0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ABEO="http://abeonatherapeutics.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abeo-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2025-03-11</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31_custom_DonWuchterlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ABEO:DonWuchterlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:TwentyTwentyFourLoanAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_TwentyTwentyFourLoanAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:TwentyTwentyFourLoanAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-07_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="AsOf2024-05-07_custom_PreFundedWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="AsOf2024-06-24_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-24</instant>
        </period>
    </context>
    <context id="AsOf2024-12-02_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-02</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-08_us-gaap_CommonStockMember_custom_LoanAgreementWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:LoanAgreementWarrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_us-gaap_CommonStockMember_custom_LoanAgreementWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:LoanAgreementWarrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_LoanAgreementWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:LoanAgreementWarrants2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-07-06_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-06</instant>
        </period>
    </context>
    <context id="AsOf2024-07-06_custom_PreFundedWarrants2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-06</instant>
        </period>
    </context>
    <context id="AsOf2024-05-09_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:PreFundedWarrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-11-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="AsOf2021-12-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2021-12-17</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ABEO:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ABEO:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:FurnitureSoftwareAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:FurnitureSoftwareAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:FurnitureSoftwareAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:FurnitureSoftwareAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:TwentyTwentyFourLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_TwentyTwentyThreeLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:TwentyTwentyThreeLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:MoneyMarketDepositAccountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:MoneyMarketDepositAccountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:MoneyMarketDepositAccountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:MoneyMarketDepositAccountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:PayableToLicensorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:PayableToLicensorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:PayableToLicensorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:PayableToLicensorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ABEO:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyOnePublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyOnePublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyTwoPrivatePlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyTwoPrivatePlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwentyTwentyFourLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyFourLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwentyTwentyFourLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyFourLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyOnePublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyTwoPrivatePlacementOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwentyTwentyFourLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwentyTwentyFourLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-12_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ABEO:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-12</instant>
        </period>
    </context>
    <context id="From2021-11-112021-11-12_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ABEO:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-11</startDate>
            <endDate>2021-11-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ABEO:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ABEO:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OfficeSpaceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:OfficeSpaceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OfficeSpaceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ABEO:OfficeSpaceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeptemberTwoThouandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ABEO:SeptemberTwoThouandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SubLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SubLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SubLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SubLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_DiscretionaryTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:DiscretionaryTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-01_custom_LoanAndSecurityAgreementMember_srt_MinimumMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-01</instant>
        </period>
    </context>
    <context id="AsOf2025-05-01_custom_LoanAndSecurityAgreementMember_srt_MaximumMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-01</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-09-302024-09-30_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember_us-gaap_WarrantMember_custom_AvenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:AvenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember_us-gaap_WarrantMember_custom_AvenueTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:AvenueTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="From2021-12-202021-12-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-21</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2021-12-21</instant>
        </period>
    </context>
    <context id="From2024-05-072024-05-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <context id="From2024-05-072024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="AsOf2024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="From2024-06-242024-06-24_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-24</startDate>
            <endDate>2024-06-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-02_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-02</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyFourPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2018-08-162018-08-17_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:OpenMarketSaleAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-16</startDate>
            <endDate>2018-08-17</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:OpenMarketSaleAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:OpenMarketSaleAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_CommonStockAndAccompanyingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:CommonStockAndAccompanyingWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantAndAccompanyingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantAndAccompanyingWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="From2022-12-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ABEO:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrivatePlacementOfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ABEO:PrivatePlacementOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-062023-07-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="From2023-07-062023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="AsOf2023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="From2024-05-092024-05-09_custom_TwoThousandTwentyThreePreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ABEO:TwoThousandTwentyThreePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember_custom_AvenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:AvenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember_custom_AvenueTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ABEO:AvenueTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="From2024-05-072024-05-07_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-07_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="AsOf2024-04-24_srt_MinimumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-24</instant>
        </period>
    </context>
    <context id="AsOf2024-04-24_srt_MaximumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-24</instant>
        </period>
    </context>
    <context id="AsOf2024-12-20_srt_MinimumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-20</instant>
        </period>
    </context>
    <context id="AsOf2024-12-20_srt_MaximumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-20</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember31393828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ABEO:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ABEO:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ABEO:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2020-08-012020-08-31_custom_SublicenseAndInventoryPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="From2020-08-012020-08-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ABEO:EventBasedMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="From2020-08-012020-08-31_custom_SalesBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ABEO:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAndInventoryPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2020-10-012020-10-31_custom_SublicenseAgreementRelatingToRettSyndromeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-10-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ABEO:EventBasedMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-10-31_custom_SalesBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ABEO:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SublicenseAgreementRelatingToRettSyndromeMember_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SublicenseAgreementRelatingToRettSyndromeMember_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ABEO:SublicenseAgreementRelatingToRettSyndromeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-05-152022-05-16_us-gaap_LicenseAgreementTermsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-15</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_UnderAgeFifftyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">ABEO:UnderAgeFifftyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_UnderAgeFifftyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">ABEO:UnderAgeFifftyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:TaxYearTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ThereafterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ABEO:ThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_us-gaap_CommonStockMember_srt_DirectorMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember_custom_ThreeEqualAnnualInstallmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:ThreeEqualAnnualInstallmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember_custom_OneAnnualInstallmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ABEO:OneAnnualInstallmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Grantees">
        <measure>ABEO:Grantees</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Integer">
        <measure>ABEO:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0000318306</dei:EntityCentralIndexKey>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLoansPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:GainLossOnRightofuseLeaseAssets
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:GainLossOfRightofuseLeaseAssets
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:ReclassificationOfDerivativeLiabilityToEquity
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember"
      id="xdx2ixbrl0629"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-012024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CertificatesOfDepositMember"
      id="xdx2ixbrl0719"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0733"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2023-01-012023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      id="xdx2ixbrl0741"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0749"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      id="xdx2ixbrl0772">http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ConstructionInProgressMember"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0805"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember"
      id="xdx2ixbrl0815"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0821"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0823"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember"
      id="xdx2ixbrl0835"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember"
      id="xdx2ixbrl0839"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0847"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember"
      id="xdx2ixbrl0850"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember"
      id="xdx2ixbrl0852"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0857"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0868"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0869"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      id="xdx2ixbrl0871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      id="xdx2ixbrl0873"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0877"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember"
      id="xdx2ixbrl0879"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember"
      id="xdx2ixbrl0880"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember"
      id="xdx2ixbrl0883"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember"
      id="xdx2ixbrl0884"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0887"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0888"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_TwentyTwentyFourLoanAgreementMember"
      id="xdx2ixbrl0908"
      unitRef="Shares"
      xsi:nil="true"/>
    <ABEO:FairValueAdjustmentOfWarrantsIssued
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0935"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0977"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0978"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:FairValueOfDerivativesIssued
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0981"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0985">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0986">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <ABEO:ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0989"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0991"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0992"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1101"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:AccretedFinalPaymentFee
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1335"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1337"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1343"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1345"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1355"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1357"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1363"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1365"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_SublicenseAgreementRelatingToRettSyndromeMember_us-gaap_LicenseMember"
      id="xdx2ixbrl1539"
      unitRef="USD"
      xsi:nil="true"/>
    <ABEO:IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1625"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1680"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000015">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000016">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000017">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000018">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000019">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">001-15771</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000022">ABEONA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000024">83-0221517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000025">6555 Carnegie Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000026">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000027">Cleveland</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000028">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000029">44103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000030">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000031">813-4701</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000032">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000033">ABEO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000035">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000036">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000037">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000038">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000039">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000040">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000042">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000043">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000044">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000045"
      unitRef="USD">170904508</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-11"
      decimals="INF"
      id="Fact000046"
      unitRef="Shares">48533798</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000053">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cybersecurity
Management and Strategy&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zjSoFmBb4S05"&gt;In
the ordinary course of our business, we collect, use, store, and transmit confidential, financial, sensitive, proprietary, personal,
and health-related information.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zwWQTVgehmp8"&gt;The secure maintenance of this information and our information technology systems is important to our
operations and business strategy. To this end, we consider cybersecurity, along with other significant risks that we face, within our
overall enterprise risk management framework, and have implemented processes designed to assess, identify, and manage risks from potential
unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality,
integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by a dedicated
Director of Information Technology and an Information Technology Security and Risk Manager. We have developed a cybersecurity program
following the National Institute of Standards and Technology (&#x201c;NIST&#x201d;) cybersecurity framework that include mechanisms, controls,
technologies, and systems designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting
the data and maintain a stable information technology environment. For example, we conduct penetration and vulnerability testing, and
data recovery testing on a periodic basis. In addition, we consult with outside advisors and experts, when appropriate, to assist with
assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the
Company&#x2019;s risk environment.&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span&gt;Third-Party
Risk Management&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have processes to evaluate &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_z7yDrIKIiRN"&gt;third-party service&lt;/span&gt; providers and vendors that have access to sensitive systems and company data, which may
include due diligence procedures such as assessments of that service provider&#x2019;s cybersecurity posture or a recommendation of specific
mitigation controls. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zykUN2Pwg5F1"&gt;Following an assessment, we determine and prioritize service provider risk based on potential threat impact and
likelihood, and such risk determinations drive the level of due diligence and ongoing compliance monitoring required for each service
provider.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Education
and Awareness&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;We
also provide cybersecurity training to our employees and are formalizing an ongoing information security training program for active
employees and relevant consultants to address matters such as phishing, email security, social engineering and training on data privacy.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&#160;Current
Cybersecurity Risk Posture&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zoteuryuGIDa"&gt;We
have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect
us.&lt;/span&gt; However, like other companies in our industry, we and our third-party vendors have from time-to-time experienced threats to and security
incidents relating to information systems. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#x201c;Risk
Factors,&#x201d; under the heading &#x201c;Risks related to cybersecurity.&#x201d;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000054">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000055">The secure maintenance of this information and our information technology systems is important to our
operations and business strategy. To this end, we consider cybersecurity, along with other significant risks that we face, within our
overall enterprise risk management framework, and have implemented processes designed to assess, identify, and manage risks from potential
unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality,
integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by a dedicated
Director of Information Technology and an Information Technology Security and Risk Manager. We have developed a cybersecurity program
following the National Institute of Standards and Technology (&#x201c;NIST&#x201d;) cybersecurity framework that include mechanisms, controls,
technologies, and systems designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting
the data and maintain a stable information technology environment. For example, we conduct penetration and vulnerability testing, and
data recovery testing on a periodic basis. In addition, we consult with outside advisors and experts, when appropriate, to assist with
assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the
Company&#x2019;s risk environment.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-01-01to2024-12-31" id="Fact000057">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000061">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Governance&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;Our
Director of Information Technology, who reports to our CFO, and the Information Technology Security and Risk Manager are responsible
for assessing and managing cybersecurity risks. Our Director of Information Technology has over 25 years of experience managing information
technology and cybersecurity. He has a bachelor&#x2019;s degree in electrical engineering from Wright State University as well as a master&#x2019;s
degree in business administration from Ashland University. He has certifications from various information technology vendors as well
as experience in implementing security frameworks such as International Organization for Standardization (&#x201c;ISO&#x201d;) 27001 and
NIST. Our Information Technology Security and Risk Manager has a PhD in a scientific field and various information security certifications
such as Certified Ethical Hacker (&#x201c;CEH&#x201d;) and Holistic Information Security Practitioner (&#x201c;HISP&#x201d;). She also has
decades of experience in managing information technology environments and information security such as security architecture, security
operations and governance risk and compliance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;We
report on our information security program, including the results of periodic testing, to the Audit Committee of the Board of Directors
on a quarterly basis. Our Board&#x2019;s &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zGKX8OoiDgM4"&gt;Audit Committee is responsible for overseeing our cybersecurity&lt;/span&gt; and information security procedures.
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zFK8TWbLhJe9"&gt;The Audit Committee reviews management presentations concerning cybersecurity-related issues, including information security, technology
risks, policies, and risk mitigation programs.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zsQAzKxj5pkj"&gt;The Audit Committee reports matters to the Board of Directors as needed.&lt;/span&gt; Our CFO, with
the support of our Director of Information Technology, Information Technology Security and Risk Manager and third-party consultants,
assesses and manages cybersecurity risk, including preventing, mitigating, detecting, and addressing cybersecurity incidents, if any.
Our CFO also works closely with other management positions and external legal counsel to ensure that we understand our cybersecurity
risk management responsibilities. In case of a cybersecurity incident or breach, our incident response plan defines in detail reporting
and escalation processes to management and the Board of Directors.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2024-01-01to2024-12-31" id="Fact000062">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000063">The Audit Committee reviews management presentations concerning cybersecurity-related issues, including information security, technology
risks, policies, and risk mitigation programs.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000064">The Audit Committee reports matters to the Board of Directors as needed.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000065">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember"
      id="Fact000067">November 23, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember"
      id="Fact000069">Don Wuchterl</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember"
      id="Fact000071">member</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember"
      id="Fact000072">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="From2024-10-012024-12-31_custom_DonWuchterlMember"
      id="Fact000073">true</ecd:NonRule10b51ArrAdoptedFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000074">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000075">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000076">Morristown, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">23357000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">14473000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">74363000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">37753000</us-gaap:ShortTermInvestments>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">338000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">338000</us-gaap:RestrictedCash>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">1652000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">2444000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000096"
      unitRef="USD">1143000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">729000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">100853000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">55737000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">4430000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">3533000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">3552000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">4455000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">96000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">277000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">108931000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">64002000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">3441000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">1858000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">6333000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">5985000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">5926000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">823000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">998000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLoansPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">4580000</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">64000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">1000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">16587000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">13422000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">3262000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">4402000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">13037000</us-gaap:LongTermDebtNoncurrent>
    <ABEO:WarrantLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000147"
      unitRef="USD">32014000</ABEO:WarrantLiabilities>
    <ABEO:WarrantLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">31352000</ABEO:WarrantLiabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">64900000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000151"
      unitRef="USD">49176000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000162"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000164"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000181"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000183"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">45644091</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">45644091</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">26523878</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">26523878</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">457000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">265000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">856824000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">764151000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">-813258000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">-749524000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">8000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000204"
      unitRef="USD">-66000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">44031000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000207"
      unitRef="USD">14826000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">108931000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000210"
      unitRef="USD">64002000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">3500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RoyaltyExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">1605000</us-gaap:RoyaltyExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">34360000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">31091000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">29851000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">19004000</us-gaap:GeneralAndAdministrativeExpense>
    <ABEO:GainLossOnRightofuseLeaseAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">1065000</ABEO:GainLossOnRightofuseLeaseAssets>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">64211000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">50635000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">-64211000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">-47135000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">4246000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">2117000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">4208000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">418000</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">755000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">11695000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">1194000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">2943000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">-63734000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">-54188000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000254"
      unitRef="USDPShares">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000256"
      unitRef="USDPShares">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000258"
      unitRef="USDPShares">-2.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000260"
      unitRef="USDPShares">-2.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">41048206</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">41048206</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000266"
      unitRef="Shares">21380476</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000268"
      unitRef="Shares">21380476</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000273"
      unitRef="USD">74000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">34000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">29000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">-63660000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">-54125000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000288"
      unitRef="Shares">17719720</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000283"
      unitRef="USD">722049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">-695336000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">-129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">26761000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">4768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">4768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">1859869</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">18000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">-200000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">-182000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">3659882</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">37000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">14586000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">14623000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000318"
      unitRef="Shares">3284407</ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOfferingShares>
    <ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">33000</ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering>
    <ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">22948000</ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering>
    <ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000316"
      unitRef="USD">22981000</ABEO:IssuanceOfCommonStockNetOfOfferingCostsUnderDirectPlacementOffering>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">-54188000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">-54188000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000329"
      unitRef="USD">63000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000330"
      unitRef="USD">63000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">26523878</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000333"
      unitRef="USD">764151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000334"
      unitRef="USD">-749524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">-66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000336"
      unitRef="USD">14826000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000346"
      unitRef="Shares">26523878</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">764151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000342"
      unitRef="USD">-749524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000343"
      unitRef="USD">-66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">14826000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">6628000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">6628000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">1780713</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000354"
      unitRef="USD">19000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">-545000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000358"
      unitRef="USD">-526000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000368"
      unitRef="Shares">2825954</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000362"
      unitRef="USD">28000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">15447000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000366"
      unitRef="USD">15475000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ABEO:IssuanceOfCommonStockSharesInConnectionWithPublicOffering
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000376"
      unitRef="Shares">12285056</ABEO:IssuanceOfCommonStockSharesInConnectionWithPublicOffering>
    <ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000370"
      unitRef="USD">123000</ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering>
    <ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">70030000</ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering>
    <ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000374"
      unitRef="USD">70153000</ABEO:IssuanceOfCommonStockInConnectionWithPublicOffering>
    <ABEO:StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000384"
      unitRef="Shares">2228490</ABEO:StockIssuedDuringPeriodSharesOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled>
    <ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">22000</ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled>
    <ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000379"
      unitRef="USD">-22000</ABEO:StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000387"
      unitRef="USD">1135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000390"
      unitRef="USD">1135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">-63734000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000396"
      unitRef="USD">-63734000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">74000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">74000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000410"
      unitRef="Shares">45644091</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">856824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">-813258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000407"
      unitRef="USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000408"
      unitRef="USD">44031000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000418"
      unitRef="Shares">45644091</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000413"
      unitRef="USD">856824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000414"
      unitRef="USD">-813258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000415"
      unitRef="USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">44031000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">-63734000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000424"
      unitRef="USD">-54188000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">2004000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">2288000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000432"
      unitRef="USD">6628000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">4768000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">755000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">11695000</us-gaap:FairValueAdjustmentOfWarrants>
    <ABEO:GainLossOfRightofuseLeaseAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">1065000</ABEO:GainLossOfRightofuseLeaseAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">-276000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">93000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">903000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">910000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:NoncashContributionExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">1538000</us-gaap:NoncashContributionExpense>
    <us-gaap:NoncashContributionExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">417000</us-gaap:NoncashContributionExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000450"
      unitRef="USD">2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000451"
      unitRef="USD">-47000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">-792000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">2041000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">564000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">155000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000462"
      unitRef="USD">-181000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000463"
      unitRef="USD">234000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">1507000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">2041000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">-1315000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">-1196000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000471"
      unitRef="USD">-5000000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000474"
      unitRef="USD">16000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">-203000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">-56015000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">-37009000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000483"
      unitRef="USD">2446000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000484"
      unitRef="USD">331000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">18000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">204000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">157010000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">51636000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000492"
      unitRef="USD">120198000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000493"
      unitRef="USD">51971000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">-39240000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000496"
      unitRef="USD">208000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">15475000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000502"
      unitRef="USD">14408000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">22981000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <ABEO:ProceedsFromRepaymentSettlementOfRestrictedShareAwards
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">-526000</ABEO:ProceedsFromRepaymentSettlementOfRestrictedShareAwards>
    <ABEO:ProceedsFromRepaymentSettlementOfRestrictedShareAwards
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000508"
      unitRef="USD">-182000</ABEO:ProceedsFromRepaymentSettlementOfRestrictedShareAwards>
    <ABEO:ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">70153000</ABEO:ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">20000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">963000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">150000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">104139000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000520"
      unitRef="USD">37057000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">8884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000523"
      unitRef="USD">256000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">14811000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000526"
      unitRef="USD">14555000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000528"
      unitRef="USD">23695000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000529"
      unitRef="USD">14811000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">23357000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">14473000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">338000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000538"
      unitRef="USD">338000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">23695000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">14811000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">419000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ABEO:DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000549"
      unitRef="USD">1042000</ABEO:DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement>
    <ABEO:ReclassificationOfDerivativeLiabilityToEquity
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000552"
      unitRef="USD">1135000</ABEO:ReclassificationOfDerivativeLiabilityToEquity>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">471000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000558"
      unitRef="USD">2670000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000561"
      unitRef="USD">7000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000562"
      unitRef="USD">14000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000564">&lt;p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zUrjk3OEqezc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_828_zoWHYO4E0r3h"&gt;NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Abeona
Therapeutics Inc. (together with the Company&#x2019;s subsidiaries, &#x201c;Abeona&#x201d; or the &#x201c;Company&#x201d;), a Delaware corporation,
is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. The Company&#x2019;s lead
clinical program is for pz-cel, an autologous, cell-based gene therapy currently in development for recessive dystrophic epidermolysis
bullosa (&#x201c;RDEB&#x201d;). The Company&#x2019;s development portfolio also features adeno-associated virus (&#x201c;AAV&#x201d;)-based
gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM&#x2122; capsids that the Company has exclusively
licensed from the University of North Carolina at Chapel Hill and developed internally through its AAV vector research programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-40, &lt;i&gt;Going Concern&lt;/i&gt;, the Company has evaluated whether
there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern within one year after the date the accompanying consolidated financial statements were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a biopharmaceutical organization, the Company has devoted substantially all of its resources since inception to research and development
activities for pz-cel and other product candidates, business planning, raising capital, establishing its intellectual property portfolio,
acquiring or discovering product candidates, and providing general and administrative support for these operations. As a result, the
Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses
and negative cash flows will continue for the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
its inception, the Company has funded its operations primarily with proceeds from sales of shares of its stock. The Company has incurred
recurring losses since its inception, including net losses of $&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_pn5n6_di_c20240101__20241231_zYnOSQex5FYa" title="Net loss"&gt;63.7&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_pn5n6_di_c20230101__20231231_zRf0cdkw4Y0a" title="Net loss"&gt;54.2&lt;/span&gt; million for the years ended December 31, 2024 and
2023, respectively. As of December 31, 2024, the Company had an accumulated deficit of $&lt;span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zbTiRKSAkb6g" title="Accumulated deficit"&gt;813.3&lt;/span&gt; million. To date, the Company has not generated
any significant revenues and expects to continue to generate operating losses for the foreseeable future. As of the issuance date of
these consolidated financial statements, the Company expects that its existing cash, cash equivalents, restricted cash and short-term
investments of $&lt;span id="xdx_90C_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20241231_z0quEixtTTUf" title="Cash, cash equivalents, restricted cash and short-term investments"&gt;98.1&lt;/span&gt; million as of December 31, 2024, in addition to the $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240101__20241231_zDInrsE969Qg"&gt;4.8&lt;/span&gt; million in net proceeds from the Company&#x2019;s subsequent
sale of common stock under the ATM Agreement, will be sufficient to fund its operating expenses and capital expenditure requirements
for at least the next 12 months from the issuance date of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company believes its capital resources are sufficient to fund the Company&#x2019;s on-going operations for the next 12 months from
the issuance date of these consolidated financial statements, the Company&#x2019;s liquidity could be materially affected over this period
by: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding;
(2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events
or unanticipated costs related to pz-cel; (4) any other unanticipated material negative events or costs. One or more of these events
or costs could materially affect the Company&#x2019;s liquidity. If the Company is unable to meet its obligations when they become due,
the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to
its operating plan. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000566"
      unitRef="USD">-63700000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000568"
      unitRef="USD">-54200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000570"
      unitRef="USD">-813300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000572"
      unitRef="USD">98100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000573"
      unitRef="USD">4800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000575">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zR5OhxzNNCQ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_828_zdaTPeDcLxib"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhb68uFtp0X4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zwwaF8VVP8qh"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and the Company&#x2019;s wholly-owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zEWGU3YCyry" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zwmC79jj3cqc"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of
America (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amount of assets and
disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue
and expenses during the reported period. The Company&#x2019;s significant estimates include, but are not limited to, fair value of warrant
and derivative liabilities, the incremental borrowing rate related to the Company&#x2019;s operating leases and stock-based compensation.
Due to the uncertainty inherent in such estimates, actual results could differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeRlmtmAHMCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zjvDL2Gawxqa"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company
maintains deposits primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal
Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company has not experienced any losses related to amounts in excess of FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zQKeiPUgGIH7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zue9oDqMmvnk"&gt;Restricted
Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
cash serves as collateral for leased office space.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zDPax6UfLVp7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zq2DsxgbxVYf"&gt;Short-term
Investments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term
investments consist of investments in U.S. treasury securities, U.S. federal agency securities and certificates of deposit. The Company
determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications
at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to Accounting Standards
Codification (&#x201c;ASC&#x201d;) 320, &lt;i&gt;Investments &#x2013; Debt and Equity Securities&lt;/i&gt;. Investments classified as current have maturities
of less than one year. The Company reviews its short-term investments for other-than-temporary impairment whenever the fair value of
a marketable security is less than the amortized cost and evidence indicates that a short-term investment&#x2019;s carrying amount is
not recoverable within a reasonable period of time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zN8OoRi4Xeq1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zYY5txwNVgY7"&gt;Other
Receivables&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
receivables include employee retention credits (&#x201c;ERC&#x201d;), sublease rent receivables and other miscellaneous receivables that
are expected to be collected within the next twelve months. As of December 31, 2024 and 2023, the Company had ERC receivables of $&lt;span id="xdx_905_eus-gaap--OtherReceivables_iI_pn5n6_c20241231_zwUUmza4kJLe" title="Other receivables"&gt;1.6&lt;/span&gt;
million and $&lt;span id="xdx_906_eus-gaap--OtherReceivables_iI_pn5n6_c20231231_zULDFuyN0IGi" title="Other receivables"&gt;2.1&lt;/span&gt; million, respectively which was recorded in other receivables and as a component of other income in the consolidated
statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt3fea5spP2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zObdGPOOnok"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from
three to five years. Leasehold improvements are amortized over the shorter of the asset&#x2019;s useful life or the life of the lease
term ranging from five to ten years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures
for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation
are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of
the respective period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zwbJyEb7mn8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zImOb0v3alFk"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. Right-of-use lease assets represent the Company&#x2019;s right
to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising
from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the
Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available
at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement
of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial
direct costs incurred, as applicable. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over
the lease term. The Company does not have any leases classified as finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive
covenants or contingent rent provisions. The Company&#x2019;s leases include both lease (e.g., fixed payments including rent, taxes, and
insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component
as the Company has elected the practical expedient to group lease and non-lease components for all leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Most
leases include one or more options to renew. The exercise of lease renewal options is typically at the Company&#x2019;s sole discretion;
therefore, the majority of renewals to extend the lease terms are not included in the Company&#x2019;s right-of-use assets and lease liabilities
as they are not reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain
of exercise, the Company includes the renewal period in its lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zKSi7YDFYYl6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zruRFsxsTbni"&gt;Licensed
Technology&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into agreements to license the rights to certain technologies. The Company records the purchase price paid for the
license, which represents fair value, on its consolidated balance sheet. Licensed technology is amortized over the life of the patent
or the agreement. The Company maintains licensed technology on its consolidated balance sheet until either the licensed technology agreement
underlying it is completed or the asset becomes impaired. When the Company determines that an asset has become impaired, as discussed
below, or the Company abandons a project, the Company writes down the carrying value of the related intangible asset to its fair value
and recognizes an impairment charge in the period in which the impairment occurs. The Company has fully written off the licensed technology
as of December 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zAZKlmt0JUr4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zrGAQVqoD054"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets consist of property and equipment, licensed technology, and right-of-use assets. The Company tests its long-lived assets for impairment
when events and circumstances indicate that the carrying value of an asset or group of assets may not be fully recoverable. If indicators
are present or changes in circumstance suggest that impairment may exist, the Company assesses the recoverability of the affected long-lived
assets or group of assets by determining whether the carrying value of such assets or group of assets can be recovered through undiscounted
future operating cash flows. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing
the carrying value of the asset or group of assets to its fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_za4zh3mVui76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z6qyQQmeLqX6"&gt;Credit
Losses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its available-for-sale investments for credit losses on a collective basis by major security type and in line with the
Company&#x2019;s investment policy. As of December 31, 2024, the Company&#x2019;s available-for-sale investments were in securities that
are issued by the U.S. treasury, U.S. federal agencies and certificates of deposits, are highly rated, and have a history of zero credit
losses. The Company reviews the credit quality of its accounts receivables by monitoring the aging of its accounts receivable, the history
of write offs for uncollectible accounts, and the credit quality of its significant customers, the current economic environment/macroeconomic
trends, supportable forecasts, and other relevant factors. The Company&#x2019;s accounts receivable are with customers that do not have
a history of uncollectibility nor a history of significantly aged accounts receivables. As of December 31, 2024, the Company did not
recognize a credit loss allowance for its investments or accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zdbON1eJvcA" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_ziOHC35w8WEf"&gt;Segments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines and presents operating segments based on the information that is internally provided to the Company&#x2019;s chief
operating decision maker (&#x201c;CODM&#x201d;), its Chief Executive Officer, in accordance with ASC 280, &lt;i&gt;Segment Reporting&lt;/i&gt;. The
Company has determined that it operates in a single business segment, which is a clinical-stage biopharmaceutical company developing
cell and gene therapies for life-threatening diseases. Refer to Note 16 &#x2013; Segment Information for further information related to
the Company&#x2019;s segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgstkCMHlPc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zrTLMG0ABlf2"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for contracts with customers in accordance with ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;).
ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an
entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an
entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a
customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance
obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research,
develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment
to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option
exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance
obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone
selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.
The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in
the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone
selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.
Amounts received prior to revenue recognition are recorded as deferred revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Exclusive
Licenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred
to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct
from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the
Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt
of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance
obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable
from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment
to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over
time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company
evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may
change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount
of revenue the Company records in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Milestone
Payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones
are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount
method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included
in the transaction price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone
payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of
being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant cumulative revenue reversal would not occur. At the end of each subsequent reporting
period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue
and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Collaborative
Arrangements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success
of such activities and therefore within the scope of ASC 808, &lt;i&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC 808&#x201d;). This assessment
is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration
arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration
are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship
and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an
appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration
partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements
of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zltyzeFQFeIe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z6j2XrlRwzw3"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel
expense, lab supplies, preclinical and development cost, clinical trial expense, manufacturing, regulatory, and consulting. The cost
of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses
are capitalized when acquired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zjAqwrMqszEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zw5h4m72fPEb"&gt;General
and Administrative Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses primarily consist of personnel, contract personnel, personnel-related expenses to support the Company&#x2019;s
administrative and operating activities, facility costs, professional expenses (i.e., legal, audit, advisory expenses) and commercial
readiness costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zZug4jDZs1Jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zqr6FBR5Ln9"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertain income tax positions in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;. Interest costs and penalties related
to income taxes are classified as interest expense and general and administrative costs, respectively, in the consolidated financial
statements. For the years ended December 31, 2024 and 2023, the Company did not recognize any uncertain tax positions, interest or penalty
expense related to income taxes. It is not reasonably likely for the amounts of unrecognized tax benefits to significantly increase or
decrease within the next 12 months. The Company files U.S. federal and state income tax returns as necessary. The federal return generally
has a three-year statute of limitations and most states have a four-year statute of limitations; however, the taxing authorities are
allowed to review the tax year in which the net operating loss was generated when the loss is utilized on a tax return. The Company currently
does not have any open income tax audits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zatUCAilBHGh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zfYJ7JF0PyTc"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted-average number of
shares of common stock outstanding during the period. The weighted average number of shares of common stock includes the weighted average
effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price
is $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231_ztgEF9S494tl" title="Unfounded exercise price per share"&gt;0.0001&lt;/span&gt; or less per share (Note 10). The Company does not include the potential impact of dilutive securities in diluted net loss
per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding restricted stock, stock
options, conversion features of loan agreements, and stock purchase warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the potential securities that could potentially dilute basic loss per share in the future that were not included
in the computation of diluted net loss per share because to do so would have been anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSul6Rq5xdpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zabuy2wRZd61" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Shares of common stock issuable upon exercise of stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zmWm1k1bSY37" title="Shares of common stock issuable upon exercise of stock options"&gt;176,587&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z96GWyhJCia9" title="Shares of common stock issuable upon exercise of stock options"&gt;179,001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Shares of common stock underlying restricted stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHNOxrGn4DHb" title="Shares of common stock underlying restricted stock"&gt;3,320,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zBQvJ3d3JXK3" title="Shares of common stock underlying restricted stock"&gt;2,448,169&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Shares of common stock issuable upon exercise of conversion feature of loan agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zrovK2zgkxX3" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"&gt;614,251&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zSOzvZv3c1R8" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Shares of common stock issuable upon exercise of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zttbklb0nqE9" title="Shares of common stock issuable upon exercise of warrants"&gt;9,987,560&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmqEepOoFY76" title="Shares of common stock issuable upon exercise of warrants"&gt;9,397,879&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zIfMwJ4Xqds7" title="Total"&gt;14,099,209&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zgs6K3Hy0yV3" title="Total"&gt;12,025,049&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_za32erE5OrRg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2024 as part of the Loan and Security Agreement, see Note 9, the Company issued warrants to purchase $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zeUUkMmdhi28" title="Warrants to purchase shares"&gt;2,400,000&lt;/span&gt; worth of shares
of the Company&#x2019;s stock which have an exercise price equal to the lesser of (i) $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zoejlqdS0Pld" title="Warrants exercise price"&gt;4.75&lt;/span&gt; and (ii) the price per share of the Company&#x2019;s
net bona fide round of equity financing before September 30, 2024 (the &#x201c;2024 Loan Agreement Warrants&#x201d;). In connection with
the underwritten common stock offering consummated on May 7, 2024, pursuant to the terms of the 2024 Loan Agreement Warrants, the exercise
price was reduced to $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zsDGYMKom5zk" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share and the shares issuable was calculated at &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zMWEeVNWdeR1" title="Shares of common stock issuable upon exercise of warrants"&gt;589,681&lt;/span&gt; shares. On September 30, 2024, per the terms of
the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zf2998vCfSC1" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share and &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zuuh8KDxTpAl" title="Shares of common stock issuable upon exercise of warrants"&gt;589,681&lt;/span&gt; shares, respectively.
The Company included these shares for the year ended December 31, 2024 as shares of common stock issuable upon exercise of warrants in
the table above and no shares for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zwfEFjAJz5n1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_ztD0jaU13w4f"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation expense in accordance with ASC 718, &lt;i&gt;Stock Based Compensation&lt;/i&gt;. The Company measures
the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date
fair value for the employees and directors and vesting date fair value for consultants of the award. The Company uses the Black-Scholes
option pricing model to determine the fair value of options on the grant date which includes assumptions for expected volatility, risk-free
interest rate, dividend yield and estimated expected term. The Company uses the closing price of its common stock as quoted on the Nasdaq
to determine the fair value of restricted stock. The Company accounts for forfeitures as they occur, which may result in the reversal
of compensation costs in subsequent periods as the forfeitures arise. The Company estimates the expected term using the &#x201c;simplified&#x201d;
method, as outlined in SEC Staff Accounting Bulletin No. 107, &#x201c;Share-Based Payment.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--DerivativeLiabiltyPolicyTextBlock_z6N5adY9gzV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zYnJzhu0QFWj"&gt;Derivative
Liability&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the fair value of the conversion right embedded within the Loan and Security Agreement in accordance with the guidance
in ASC 815, which requires the Company to bifurcate and separately account for the conversion feature as an embedded derivative contained
in the Company&#x2019;s Loan and Security Agreement. Accordingly, the Company accounts for the conversion feature as a derivative liability
in the consolidated balance sheet. Derivatives are measured at their fair value on the balance sheet. In determining the appropriate
fair value, the Company uses a Monte Carlo simulation model, which incorporated assumptions and estimates to value the derivatives. The
derivative liability is remeasured at each reporting period with the change in fair value recorded to change in fair value of warrant
and derivative liabilities in the consolidated statement of operations until the derivative is exercised, expired, reclassified, or otherwise
settled. At September 30, 2024, the conversion feature no longer met the criteria of a derivative liability, and the derivative liability
was reclassified to equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--WarrantsPolicyTextBlock_zoQGfsgsfiHj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zHFumLbJliQ9"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 7, 2024, the Company issued pre-funded warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zMVnB4QVGsG7" title="Warrants to purchase shares"&gt;6,142,656&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240507__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zlA8quO4olP8" title="Warrants exercise price"&gt;4.0699&lt;/span&gt; per
share (&#x201c;2024 Pre-Funded Warrants&#x201d;). The prefunded warrants are classified as equity in accordance with ASC 815, &lt;i&gt;Derivatives
and Hedging&lt;/i&gt;, given the prefunded warrants are indexed to the Company&#x2019;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#x2019;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On June 24, 2024 and December 2, 2024, &lt;span id="xdx_90D_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zFGwr8FAY0Ek" title="Exercise of warrants"&gt;700,000&lt;/span&gt; and &lt;span id="xdx_90C_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20241202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zyLHJ2IPrvLd" title="Exercise of warrants"&gt;1,228,511&lt;/span&gt;, respectively of the
2024 Pre-Funded Warrants were exercised, leaving &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zAw1cDtUxtqg" title="Exercise of warrants"&gt;4,214,125&lt;/span&gt; of 2024 Pre-Funded Warrants outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 8, 2024, the Company issued warrants to purchase up to $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zQYCyZpIteB5" title="Warrants to purchase shares"&gt;2,400,000&lt;/span&gt; worth of shares of the Company&#x2019;s common stock. On January
8, 2024, the January Warrants did not include an explicit share limit and the number of shares issuable under the warrant agreements
were variable based on the exercise price and therefore the warrants were liability classified based on a Black-Scholes valuation in
accordance with ASC 815 and were recorded at the closing date fair value of $&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_z60DybBTAuGk" title="Fair value of warrants"&gt;0.2&lt;/span&gt; million which was based on a Black-Scholes option pricing
model. The warrants are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes
in the fair value between reporting periods recorded in the consolidated statements of operations and comprehensive loss. On September
30, 2024, per the terms of the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zjH43fPgA0Kc" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share
and &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zoa6IG21xxc3" title="Warrants to purchase shares"&gt;589,681&lt;/span&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 6, 2023, the Company issued pre-funded warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_z49HJKFza3Mh" title="Warrants to purchase shares"&gt;2,919,140&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240706__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zJMeVqFRqfQ8" title="Warrants exercise price"&gt;4.0299&lt;/span&gt;
per share (&#x201c;2023 Pre-Funded Warrants&#x201d;. The prefunded warrants are classified as equity in accordance with ASC 815, &lt;i&gt;Derivatives
and Hedging&lt;/i&gt;, given the prefunded warrants are indexed to the Company&#x2019;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#x2019;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On May 9, 2024, &lt;span id="xdx_903_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240509__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zc9lnxMnlpF2" title="Exercise of warrants"&gt;300,000&lt;/span&gt; of the 2023 Pre-Funded Warrants were exercised, leaving
&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zwDD2RDpicle" title="Exercise of warrants"&gt;2,619,140&lt;/span&gt; 2023 Pre-Funded Warrants outstanding as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 3, 2022, the Company issued warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221103_zXGfklcxIXq4" title="Warrants to purchase shares"&gt;7,609,879&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221103_zauKxlMXp0P6" title="Exercise price"&gt;4.75&lt;/span&gt; per share,
subject to customary adjustments thereunder. On December 17, 2021, the Company issued warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211217_zCFgs9L0UKG3" title="Warrants to purchase shares"&gt;1,788,000&lt;/span&gt; shares of common
stock, with an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211217_z0EzyAiq2LFl" title="Exercise price"&gt;9.75&lt;/span&gt; per share, subject to customary adjustments thereunder. The warrants issued in 2022 and 2021 were
determined to be freestanding instruments as they are legally detachable and separately exercisable from each other and from the common
stock issued. The common stock warrants are accounted for as liabilities in the consolidated balance sheets at their estimated fair value
because they are not indexed to the Company&#x2019;s own stock. The warrants are revalued on each subsequent balance sheet date until
such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded in the consolidated statements
of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRa96MeMTpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zbFG3tIfIBL1"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standard Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07,
&#x201c;Segment Reporting (Topic 280): &lt;i&gt;Improvements to Reportable Segment Disclosures&lt;/i&gt;&#x201d; (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07
requires additional disclosures for segment reporting, including disclosure of the title and position of the Chief Operating Decision
Maker and requires a public entity that has a single reportable segment to provide all the disclosures required by the amendments in
ASU 2023-07, and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal periods beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 effective for its
Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent interim periods. Since ASU 2023-07 addresses only disclosures,
the adoption of ASU 2023-07 did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zPHaeJkS5ZBb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zGcXIvinM2ze"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): &lt;i&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;. The amendments in ASU 2024-03 address investor requests for more
detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories
of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating this guidance to determine the impact it may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): &lt;i&gt;Improvements to Income Tax Disclosures&lt;/i&gt;. ASU 2023-09 is intended
to enhance the transparency and decision usefulness of income tax information through improvements to income tax disclosures primarily
related to the rate reconciliation and income taxes paid information. The standard is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The requirements of this ASU are disclosure related and will not have an impact
on the Company&#x2019;s financial condition, results of operations, or cash flows. The Company is currently evaluating the impact of adopting
this ASU on its income tax disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_859_zMJjXJUx4oAa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000577">&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhb68uFtp0X4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zwwaF8VVP8qh"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and the Company&#x2019;s wholly-owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000579">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zEWGU3YCyry" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zwmC79jj3cqc"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of
America (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amount of assets and
disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue
and expenses during the reported period. The Company&#x2019;s significant estimates include, but are not limited to, fair value of warrant
and derivative liabilities, the incremental borrowing rate related to the Company&#x2019;s operating leases and stock-based compensation.
Due to the uncertainty inherent in such estimates, actual results could differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000581">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeRlmtmAHMCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zjvDL2Gawxqa"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company
maintains deposits primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal
Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company has not experienced any losses related to amounts in excess of FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000583">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zQKeiPUgGIH7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zue9oDqMmvnk"&gt;Restricted
Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
cash serves as collateral for leased office space.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000585">&lt;p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zDPax6UfLVp7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zq2DsxgbxVYf"&gt;Short-term
Investments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term
investments consist of investments in U.S. treasury securities, U.S. federal agency securities and certificates of deposit. The Company
determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications
at each balance sheet date. The Company classifies its short-term investments as available-for-sale pursuant to Accounting Standards
Codification (&#x201c;ASC&#x201d;) 320, &lt;i&gt;Investments &#x2013; Debt and Equity Securities&lt;/i&gt;. Investments classified as current have maturities
of less than one year. The Company reviews its short-term investments for other-than-temporary impairment whenever the fair value of
a marketable security is less than the amortized cost and evidence indicates that a short-term investment&#x2019;s carrying amount is
not recoverable within a reasonable period of time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000587">&lt;p id="xdx_84E_eus-gaap--ReceivablesPolicyTextBlock_zN8OoRi4Xeq1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zYY5txwNVgY7"&gt;Other
Receivables&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
receivables include employee retention credits (&#x201c;ERC&#x201d;), sublease rent receivables and other miscellaneous receivables that
are expected to be collected within the next twelve months. As of December 31, 2024 and 2023, the Company had ERC receivables of $&lt;span id="xdx_905_eus-gaap--OtherReceivables_iI_pn5n6_c20241231_zwUUmza4kJLe" title="Other receivables"&gt;1.6&lt;/span&gt;
million and $&lt;span id="xdx_906_eus-gaap--OtherReceivables_iI_pn5n6_c20231231_zULDFuyN0IGi" title="Other receivables"&gt;2.1&lt;/span&gt; million, respectively which was recorded in other receivables and as a component of other income in the consolidated
statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000589"
      unitRef="USD">1600000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000591"
      unitRef="USD">2100000</us-gaap:OtherReceivables>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000593">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt3fea5spP2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zObdGPOOnok"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from
three to five years. Leasehold improvements are amortized over the shorter of the asset&#x2019;s useful life or the life of the lease
term ranging from five to ten years. Expenditures for major renewals and betterments that extend the useful lives are capitalized. Expenditures
for normal maintenance and repairs are expensed as incurred. The cost of assets sold or abandoned, and the related accumulated depreciation
are eliminated from the accounts and any gains or losses are recognized in the accompanying consolidated statements of operations of
the respective period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000595">&lt;p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zwbJyEb7mn8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zImOb0v3alFk"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. Right-of-use lease assets represent the Company&#x2019;s right
to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising
from the lease. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the
Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available
at the lease commencement date in determining the present value of future lease payments. The right-of-use asset is based on the measurement
of the lease liability and includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial
direct costs incurred, as applicable. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over
the lease term. The Company does not have any leases classified as finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive
covenants or contingent rent provisions. The Company&#x2019;s leases include both lease (e.g., fixed payments including rent, taxes, and
insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component
as the Company has elected the practical expedient to group lease and non-lease components for all leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Most
leases include one or more options to renew. The exercise of lease renewal options is typically at the Company&#x2019;s sole discretion;
therefore, the majority of renewals to extend the lease terms are not included in the Company&#x2019;s right-of-use assets and lease liabilities
as they are not reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain
of exercise, the Company includes the renewal period in its lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000597">&lt;p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zKSi7YDFYYl6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zruRFsxsTbni"&gt;Licensed
Technology&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into agreements to license the rights to certain technologies. The Company records the purchase price paid for the
license, which represents fair value, on its consolidated balance sheet. Licensed technology is amortized over the life of the patent
or the agreement. The Company maintains licensed technology on its consolidated balance sheet until either the licensed technology agreement
underlying it is completed or the asset becomes impaired. When the Company determines that an asset has become impaired, as discussed
below, or the Company abandons a project, the Company writes down the carrying value of the related intangible asset to its fair value
and recognizes an impairment charge in the period in which the impairment occurs. The Company has fully written off the licensed technology
as of December 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000599">&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zAZKlmt0JUr4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zrGAQVqoD054"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets consist of property and equipment, licensed technology, and right-of-use assets. The Company tests its long-lived assets for impairment
when events and circumstances indicate that the carrying value of an asset or group of assets may not be fully recoverable. If indicators
are present or changes in circumstance suggest that impairment may exist, the Company assesses the recoverability of the affected long-lived
assets or group of assets by determining whether the carrying value of such assets or group of assets can be recovered through undiscounted
future operating cash flows. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing
the carrying value of the asset or group of assets to its fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000601">&lt;p id="xdx_842_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_za4zh3mVui76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z6qyQQmeLqX6"&gt;Credit
Losses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its available-for-sale investments for credit losses on a collective basis by major security type and in line with the
Company&#x2019;s investment policy. As of December 31, 2024, the Company&#x2019;s available-for-sale investments were in securities that
are issued by the U.S. treasury, U.S. federal agencies and certificates of deposits, are highly rated, and have a history of zero credit
losses. The Company reviews the credit quality of its accounts receivables by monitoring the aging of its accounts receivable, the history
of write offs for uncollectible accounts, and the credit quality of its significant customers, the current economic environment/macroeconomic
trends, supportable forecasts, and other relevant factors. The Company&#x2019;s accounts receivable are with customers that do not have
a history of uncollectibility nor a history of significantly aged accounts receivables. As of December 31, 2024, the Company did not
recognize a credit loss allowance for its investments or accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000603">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zdbON1eJvcA" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_ziOHC35w8WEf"&gt;Segments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines and presents operating segments based on the information that is internally provided to the Company&#x2019;s chief
operating decision maker (&#x201c;CODM&#x201d;), its Chief Executive Officer, in accordance with ASC 280, &lt;i&gt;Segment Reporting&lt;/i&gt;. The
Company has determined that it operates in a single business segment, which is a clinical-stage biopharmaceutical company developing
cell and gene therapies for life-threatening diseases. Refer to Note 16 &#x2013; Segment Information for further information related to
the Company&#x2019;s segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000605">&lt;p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgstkCMHlPc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zrTLMG0ABlf2"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for contracts with customers in accordance with ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;).
ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an
entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an
entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a
customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance
obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research,
develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment
to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option
exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance
obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone
selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.
The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in
the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone
selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.
Amounts received prior to revenue recognition are recorded as deferred revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Exclusive
Licenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred
to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct
from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the
Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt
of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance
obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable
from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment
to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over
time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company
evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may
change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount
of revenue the Company records in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Milestone
Payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones
are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount
method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included
in the transaction price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone
payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of
being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant cumulative revenue reversal would not occur. At the end of each subsequent reporting
period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue
and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Collaborative
Arrangements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success
of such activities and therefore within the scope of ASC 808, &lt;i&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC 808&#x201d;). This assessment
is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration
arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration
are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship
and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an
appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration
partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements
of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000607">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zltyzeFQFeIe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z6j2XrlRwzw3"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel
expense, lab supplies, preclinical and development cost, clinical trial expense, manufacturing, regulatory, and consulting. The cost
of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses
are capitalized when acquired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000609">&lt;p id="xdx_848_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zjAqwrMqszEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zw5h4m72fPEb"&gt;General
and Administrative Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses primarily consist of personnel, contract personnel, personnel-related expenses to support the Company&#x2019;s
administrative and operating activities, facility costs, professional expenses (i.e., legal, audit, advisory expenses) and commercial
readiness costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000611">&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zZug4jDZs1Jl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zqr6FBR5Ln9"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertain income tax positions in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;. Interest costs and penalties related
to income taxes are classified as interest expense and general and administrative costs, respectively, in the consolidated financial
statements. For the years ended December 31, 2024 and 2023, the Company did not recognize any uncertain tax positions, interest or penalty
expense related to income taxes. It is not reasonably likely for the amounts of unrecognized tax benefits to significantly increase or
decrease within the next 12 months. The Company files U.S. federal and state income tax returns as necessary. The federal return generally
has a three-year statute of limitations and most states have a four-year statute of limitations; however, the taxing authorities are
allowed to review the tax year in which the net operating loss was generated when the loss is utilized on a tax return. The Company currently
does not have any open income tax audits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000613">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zatUCAilBHGh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zfYJ7JF0PyTc"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted-average number of
shares of common stock outstanding during the period. The weighted average number of shares of common stock includes the weighted average
effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price
is $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231_ztgEF9S494tl" title="Unfounded exercise price per share"&gt;0.0001&lt;/span&gt; or less per share (Note 10). The Company does not include the potential impact of dilutive securities in diluted net loss
per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding restricted stock, stock
options, conversion features of loan agreements, and stock purchase warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the potential securities that could potentially dilute basic loss per share in the future that were not included
in the computation of diluted net loss per share because to do so would have been anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSul6Rq5xdpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zabuy2wRZd61" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Shares of common stock issuable upon exercise of stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zmWm1k1bSY37" title="Shares of common stock issuable upon exercise of stock options"&gt;176,587&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z96GWyhJCia9" title="Shares of common stock issuable upon exercise of stock options"&gt;179,001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Shares of common stock underlying restricted stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHNOxrGn4DHb" title="Shares of common stock underlying restricted stock"&gt;3,320,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zBQvJ3d3JXK3" title="Shares of common stock underlying restricted stock"&gt;2,448,169&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Shares of common stock issuable upon exercise of conversion feature of loan agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zrovK2zgkxX3" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"&gt;614,251&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zSOzvZv3c1R8" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Shares of common stock issuable upon exercise of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zttbklb0nqE9" title="Shares of common stock issuable upon exercise of warrants"&gt;9,987,560&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmqEepOoFY76" title="Shares of common stock issuable upon exercise of warrants"&gt;9,397,879&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zIfMwJ4Xqds7" title="Total"&gt;14,099,209&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zgs6K3Hy0yV3" title="Total"&gt;12,025,049&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_za32erE5OrRg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2024 as part of the Loan and Security Agreement, see Note 9, the Company issued warrants to purchase $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zeUUkMmdhi28" title="Warrants to purchase shares"&gt;2,400,000&lt;/span&gt; worth of shares
of the Company&#x2019;s stock which have an exercise price equal to the lesser of (i) $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zoejlqdS0Pld" title="Warrants exercise price"&gt;4.75&lt;/span&gt; and (ii) the price per share of the Company&#x2019;s
net bona fide round of equity financing before September 30, 2024 (the &#x201c;2024 Loan Agreement Warrants&#x201d;). In connection with
the underwritten common stock offering consummated on May 7, 2024, pursuant to the terms of the 2024 Loan Agreement Warrants, the exercise
price was reduced to $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zsDGYMKom5zk" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share and the shares issuable was calculated at &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zMWEeVNWdeR1" title="Shares of common stock issuable upon exercise of warrants"&gt;589,681&lt;/span&gt; shares. On September 30, 2024, per the terms of
the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zf2998vCfSC1" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share and &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementWarrantsMember_zuuh8KDxTpAl" title="Shares of common stock issuable upon exercise of warrants"&gt;589,681&lt;/span&gt; shares, respectively.
The Company included these shares for the year ended December 31, 2024 as shares of common stock issuable upon exercise of warrants in
the table above and no shares for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000615"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000617">&lt;p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSul6Rq5xdpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zabuy2wRZd61" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Shares of common stock issuable upon exercise of stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zmWm1k1bSY37" title="Shares of common stock issuable upon exercise of stock options"&gt;176,587&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z96GWyhJCia9" title="Shares of common stock issuable upon exercise of stock options"&gt;179,001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Shares of common stock underlying restricted stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHNOxrGn4DHb" title="Shares of common stock underlying restricted stock"&gt;3,320,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zBQvJ3d3JXK3" title="Shares of common stock underlying restricted stock"&gt;2,448,169&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Shares of common stock issuable upon exercise of conversion feature of loan agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zrovK2zgkxX3" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"&gt;614,251&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LoanAgreementMember_zSOzvZv3c1R8" title="Shares of common stock issuable upon exercise of conversion feature of loan agreement"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Shares of common stock issuable upon exercise of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zttbklb0nqE9" title="Shares of common stock issuable upon exercise of warrants"&gt;9,987,560&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmqEepOoFY76" title="Shares of common stock issuable upon exercise of warrants"&gt;9,397,879&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zIfMwJ4Xqds7" title="Total"&gt;14,099,209&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zgs6K3Hy0yV3" title="Total"&gt;12,025,049&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000619"
      unitRef="Shares">176587</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000621"
      unitRef="Shares">179001</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000623"
      unitRef="Shares">3320811</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000625"
      unitRef="Shares">2448169</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">614251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000631"
      unitRef="Shares">9987560</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">9397879</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">14099209</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000637"
      unitRef="Shares">12025049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-01-31_custom_LoanAndSecurityAgreementMember"
      decimals="0"
      id="Fact000639"
      unitRef="USD">2400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-31_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact000641"
      unitRef="USDPShares">4.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementWarrantsMember"
      decimals="INF"
      id="Fact000643"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementWarrantsMember"
      decimals="INF"
      id="Fact000645"
      unitRef="Shares">589681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-30_custom_TwentyTwentyFourLoanAgreementWarrantsMember"
      decimals="INF"
      id="Fact000647"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-09-30_custom_TwentyTwentyFourLoanAgreementWarrantsMember"
      decimals="INF"
      id="Fact000649"
      unitRef="Shares">589681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000651">&lt;p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zwfEFjAJz5n1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_ztD0jaU13w4f"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation expense in accordance with ASC 718, &lt;i&gt;Stock Based Compensation&lt;/i&gt;. The Company measures
the cost of the employee/director/consultant services received in exchange for an award of equity instruments based on the grant date
fair value for the employees and directors and vesting date fair value for consultants of the award. The Company uses the Black-Scholes
option pricing model to determine the fair value of options on the grant date which includes assumptions for expected volatility, risk-free
interest rate, dividend yield and estimated expected term. The Company uses the closing price of its common stock as quoted on the Nasdaq
to determine the fair value of restricted stock. The Company accounts for forfeitures as they occur, which may result in the reversal
of compensation costs in subsequent periods as the forfeitures arise. The Company estimates the expected term using the &#x201c;simplified&#x201d;
method, as outlined in SEC Staff Accounting Bulletin No. 107, &#x201c;Share-Based Payment.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <ABEO:DerivativeLiabiltyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000653">&lt;p id="xdx_84E_ecustom--DerivativeLiabiltyPolicyTextBlock_z6N5adY9gzV4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zYnJzhu0QFWj"&gt;Derivative
Liability&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the fair value of the conversion right embedded within the Loan and Security Agreement in accordance with the guidance
in ASC 815, which requires the Company to bifurcate and separately account for the conversion feature as an embedded derivative contained
in the Company&#x2019;s Loan and Security Agreement. Accordingly, the Company accounts for the conversion feature as a derivative liability
in the consolidated balance sheet. Derivatives are measured at their fair value on the balance sheet. In determining the appropriate
fair value, the Company uses a Monte Carlo simulation model, which incorporated assumptions and estimates to value the derivatives. The
derivative liability is remeasured at each reporting period with the change in fair value recorded to change in fair value of warrant
and derivative liabilities in the consolidated statement of operations until the derivative is exercised, expired, reclassified, or otherwise
settled. At September 30, 2024, the conversion feature no longer met the criteria of a derivative liability, and the derivative liability
was reclassified to equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ABEO:DerivativeLiabiltyPolicyTextBlock>
    <ABEO:WarrantsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000655">&lt;p id="xdx_842_ecustom--WarrantsPolicyTextBlock_zoQGfsgsfiHj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zHFumLbJliQ9"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 7, 2024, the Company issued pre-funded warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zMVnB4QVGsG7" title="Warrants to purchase shares"&gt;6,142,656&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240507__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zlA8quO4olP8" title="Warrants exercise price"&gt;4.0699&lt;/span&gt; per
share (&#x201c;2024 Pre-Funded Warrants&#x201d;). The prefunded warrants are classified as equity in accordance with ASC 815, &lt;i&gt;Derivatives
and Hedging&lt;/i&gt;, given the prefunded warrants are indexed to the Company&#x2019;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#x2019;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On June 24, 2024 and December 2, 2024, &lt;span id="xdx_90D_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zFGwr8FAY0Ek" title="Exercise of warrants"&gt;700,000&lt;/span&gt; and &lt;span id="xdx_90C_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20241202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zyLHJ2IPrvLd" title="Exercise of warrants"&gt;1,228,511&lt;/span&gt;, respectively of the
2024 Pre-Funded Warrants were exercised, leaving &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2024Member_zAw1cDtUxtqg" title="Exercise of warrants"&gt;4,214,125&lt;/span&gt; of 2024 Pre-Funded Warrants outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 8, 2024, the Company issued warrants to purchase up to $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zQYCyZpIteB5" title="Warrants to purchase shares"&gt;2,400,000&lt;/span&gt; worth of shares of the Company&#x2019;s common stock. On January
8, 2024, the January Warrants did not include an explicit share limit and the number of shares issuable under the warrant agreements
were variable based on the exercise price and therefore the warrants were liability classified based on a Black-Scholes valuation in
accordance with ASC 815 and were recorded at the closing date fair value of $&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_z60DybBTAuGk" title="Fair value of warrants"&gt;0.2&lt;/span&gt; million which was based on a Black-Scholes option pricing
model. The warrants are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes
in the fair value between reporting periods recorded in the consolidated statements of operations and comprehensive loss. On September
30, 2024, per the terms of the 2024 Loan Agreement Warrants, the exercise price and the number of shares became set at $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zjH43fPgA0Kc" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share
and &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--PlanNameAxis__custom--LoanAgreementWarrants2024Member_zoa6IG21xxc3" title="Warrants to purchase shares"&gt;589,681&lt;/span&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 6, 2023, the Company issued pre-funded warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_z49HJKFza3Mh" title="Warrants to purchase shares"&gt;2,919,140&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240706__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zJMeVqFRqfQ8" title="Warrants exercise price"&gt;4.0299&lt;/span&gt;
per share (&#x201c;2023 Pre-Funded Warrants&#x201d;. The prefunded warrants are classified as equity in accordance with ASC 815, &lt;i&gt;Derivatives
and Hedging&lt;/i&gt;, given the prefunded warrants are indexed to the Company&#x2019;s own shares of common stock and meet the requirements
to be classified in equity. The prefunded warrants were recorded at their relative fair value at issuance in the stockholders&#x2019;
equity section of the consolidated balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per
share calculation given their nominal exercise price. On May 9, 2024, &lt;span id="xdx_903_ecustom--NumberOfWarrantsOrRightsExercised_iI_c20240509__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zc9lnxMnlpF2" title="Exercise of warrants"&gt;300,000&lt;/span&gt; of the 2023 Pre-Funded Warrants were exercised, leaving
&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--PreFundedWarrants2023Member_zwDD2RDpicle" title="Exercise of warrants"&gt;2,619,140&lt;/span&gt; 2023 Pre-Funded Warrants outstanding as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 3, 2022, the Company issued warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221103_zXGfklcxIXq4" title="Warrants to purchase shares"&gt;7,609,879&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221103_zauKxlMXp0P6" title="Exercise price"&gt;4.75&lt;/span&gt; per share,
subject to customary adjustments thereunder. On December 17, 2021, the Company issued warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211217_zCFgs9L0UKG3" title="Warrants to purchase shares"&gt;1,788,000&lt;/span&gt; shares of common
stock, with an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211217_z0EzyAiq2LFl" title="Exercise price"&gt;9.75&lt;/span&gt; per share, subject to customary adjustments thereunder. The warrants issued in 2022 and 2021 were
determined to be freestanding instruments as they are legally detachable and separately exercisable from each other and from the common
stock issued. The common stock warrants are accounted for as liabilities in the consolidated balance sheets at their estimated fair value
because they are not indexed to the Company&#x2019;s own stock. The warrants are revalued on each subsequent balance sheet date until
such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded in the consolidated statements
of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ABEO:WarrantsPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-07_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member"
      decimals="INF"
      id="Fact000657"
      unitRef="Shares">6142656</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-07_custom_PreFundedWarrants2024Member"
      decimals="INF"
      id="Fact000659"
      unitRef="USDPShares">4.0699</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ABEO:NumberOfWarrantsOrRightsExercised
      contextRef="AsOf2024-06-24_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member"
      decimals="INF"
      id="Fact000661"
      unitRef="Shares">700000</ABEO:NumberOfWarrantsOrRightsExercised>
    <ABEO:NumberOfWarrantsOrRightsExercised
      contextRef="AsOf2024-12-02_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member"
      decimals="INF"
      id="Fact000663"
      unitRef="Shares">1228511</ABEO:NumberOfWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_PreFundedWarrants2024Member"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">4214125</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-08_us-gaap_CommonStockMember_custom_LoanAgreementWarrants2024Member"
      decimals="INF"
      id="Fact000667"
      unitRef="Shares">2400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-082024-01-08_us-gaap_CommonStockMember_custom_LoanAgreementWarrants2024Member"
      decimals="-5"
      id="Fact000669"
      unitRef="USD">200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-30_custom_LoanAgreementWarrants2024Member"
      decimals="INF"
      id="Fact000671"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-09-30_custom_LoanAgreementWarrants2024Member"
      decimals="INF"
      id="Fact000673"
      unitRef="Shares">589681</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-07-06_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member"
      decimals="INF"
      id="Fact000675"
      unitRef="Shares">2919140</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-07-06_custom_PreFundedWarrants2023Member"
      decimals="INF"
      id="Fact000677"
      unitRef="USDPShares">4.0299</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ABEO:NumberOfWarrantsOrRightsExercised
      contextRef="AsOf2024-05-09_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member"
      decimals="INF"
      id="Fact000679"
      unitRef="Shares">300000</ABEO:NumberOfWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_PreFundedWarrants2023Member"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">2619140</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-11-03"
      decimals="INF"
      id="Fact000683"
      unitRef="Shares">7609879</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-11-03"
      decimals="INF"
      id="Fact000685"
      unitRef="USDPShares">4.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-17"
      decimals="INF"
      id="Fact000687"
      unitRef="Shares">1788000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-17"
      decimals="INF"
      id="Fact000689"
      unitRef="USDPShares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000691">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRa96MeMTpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zbFG3tIfIBL1"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standard Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07,
&#x201c;Segment Reporting (Topic 280): &lt;i&gt;Improvements to Reportable Segment Disclosures&lt;/i&gt;&#x201d; (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07
requires additional disclosures for segment reporting, including disclosure of the title and position of the Chief Operating Decision
Maker and requires a public entity that has a single reportable segment to provide all the disclosures required by the amendments in
ASU 2023-07, and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal periods beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 effective for its
Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent interim periods. Since ASU 2023-07 addresses only disclosures,
the adoption of ASU 2023-07 did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <ABEO:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000693">&lt;p id="xdx_843_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zPHaeJkS5ZBb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zGcXIvinM2ze"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): &lt;i&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;. The amendments in ASU 2024-03 address investor requests for more
detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories
of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating this guidance to determine the impact it may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): &lt;i&gt;Improvements to Income Tax Disclosures&lt;/i&gt;. ASU 2023-09 is intended
to enhance the transparency and decision usefulness of income tax information through improvements to income tax disclosures primarily
related to the rate reconciliation and income taxes paid information. The standard is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The requirements of this ASU are disclosure related and will not have an impact
on the Company&#x2019;s financial condition, results of operations, or cash flows. The Company is currently evaluating the impact of adopting
this ASU on its income tax disclosures.&lt;/span&gt;&lt;/p&gt;

</ABEO:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000695">&lt;p id="xdx_806_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zGObbkJx31vh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_821_zhUnedacw0M3"&gt;SHORT-TERM INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zwNNuCZofCsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the short-term investments (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zMj2EW0vkLLc" style="display: none"&gt;SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross Unrealized Gain&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross Unrealized Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Available-for-sale, short-term investments:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zRlOOSqfwPgd" style="width: 12%; text-align: right" title="Amortized cost"&gt;23,990&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLbc29LuSFCh" style="width: 12%; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_ztnCRWa2fUK2" style="width: 12%; text-align: right" title="Gross Unrealized Loss"&gt;(22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zuHhOyXkVYag" style="width: 12%; text-align: right" title="Fair Value"&gt;23,968&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;U.S. federal agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zlu9Qo9DHkw5" style="text-align: right" title="Amortized cost"&gt;40,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zqmu3Cv8iaH6" style="text-align: right" title="Gross Unrealized Gain"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zjRupTkeAZP3" style="text-align: right" title="Gross Unrealized Loss"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zmx6l6NAbQC8" style="text-align: right" title="Fair Value"&gt;40,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zf7NvHz2a7ql" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized cost"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z5vVFpxiMux4" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gain"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z083lbHIR0r2" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Loss"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0719"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zGliwiQPj297" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value"&gt;10,020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total available-for-sale, short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zmmdnYd2SZZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized cost"&gt;74,355&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zyLr3YVS25Ob" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gain"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zfmFTJPwYvuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Loss"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zFWt8v2nZ742" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value"&gt;74,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross Unrealized Gain&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross Unrealized Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Available-for-sale, short-term investments:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zXcaNzGOo624" style="width: 12%; text-align: right" title="Amortized cost"&gt;8,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgT8qB6kIb34" style="width: 12%; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zjiTfCXntg3g" style="width: 12%; text-align: right" title="Gross Unrealized Loss"&gt;(13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zROimDBYKWVb" style="width: 12%; text-align: right" title="Fair Value"&gt;8,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;U.S. federal agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_z7CBoHFwFu7d" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized cost"&gt;29,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zzOqtHoBUgy" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0741"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zYUjnYLo9vH" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Loss"&gt;(53&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zyzsGl2pa3S2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value"&gt;29,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total available-for-sale, short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zGdqgrqcp1B" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized cost"&gt;37,819&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zx4c9m33Eq87" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0749"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zsvhUjgGGRw" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Loss"&gt;(66&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zt4sJkdsAiT3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value"&gt;37,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zcIEF0M6ilba" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the available-for-sale securities classified as short-term investments mature in one year or less. The Company
carries its available-for-sale securities at fair value in the consolidated balance sheets. Unrealized losses on available-for-sale securities
as of December 31, 2024, were not significant and were primarily due to changes in interest rates, including market credit spreads, and
not due to increased credit risks associated with specific securities. None of the short-term investments have been in a continuous unrealized
loss position for more than 12 months. Accordingly, no other-than-temporary impairment was recorded for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_906_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20240101__20241231_zthi3VgtNzx4" title="Available-for-sale securities realized gain loss"&gt;&lt;span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20230101__20231231_zgEDMqpGReec" title="Available-for-sale securities realized gain loss"&gt;no&lt;/span&gt;&lt;/span&gt; significant realized gains or losses recognized on the sale or maturity of available-for-sale investments during the years ended
December 31, 2024 or 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000697">&lt;p id="xdx_897_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zwNNuCZofCsh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the short-term investments (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zMj2EW0vkLLc" style="display: none"&gt;SCHEDULE OF AVAILABLE FOR SALE SHORT-TERM INVESTMENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross Unrealized Gain&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross Unrealized Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Available-for-sale, short-term investments:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zRlOOSqfwPgd" style="width: 12%; text-align: right" title="Amortized cost"&gt;23,990&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zLbc29LuSFCh" style="width: 12%; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_ztnCRWa2fUK2" style="width: 12%; text-align: right" title="Gross Unrealized Loss"&gt;(22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zuHhOyXkVYag" style="width: 12%; text-align: right" title="Fair Value"&gt;23,968&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;U.S. federal agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zlu9Qo9DHkw5" style="text-align: right" title="Amortized cost"&gt;40,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zqmu3Cv8iaH6" style="text-align: right" title="Gross Unrealized Gain"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zjRupTkeAZP3" style="text-align: right" title="Gross Unrealized Loss"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zmx6l6NAbQC8" style="text-align: right" title="Fair Value"&gt;40,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zf7NvHz2a7ql" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized cost"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z5vVFpxiMux4" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gain"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_z083lbHIR0r2" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Loss"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0719"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CertificatesOfDepositMember_zGliwiQPj297" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value"&gt;10,020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total available-for-sale, short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zmmdnYd2SZZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized cost"&gt;74,355&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zyLr3YVS25Ob" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gain"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zfmFTJPwYvuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Loss"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zFWt8v2nZ742" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value"&gt;74,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross Unrealized Gain&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross Unrealized Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Available-for-sale, short-term investments:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zXcaNzGOo624" style="width: 12%; text-align: right" title="Amortized cost"&gt;8,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgT8qB6kIb34" style="width: 12%; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zjiTfCXntg3g" style="width: 12%; text-align: right" title="Gross Unrealized Loss"&gt;(13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zROimDBYKWVb" style="width: 12%; text-align: right" title="Fair Value"&gt;8,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;U.S. federal agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_z7CBoHFwFu7d" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized cost"&gt;29,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zzOqtHoBUgy" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0741"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zYUjnYLo9vH" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Loss"&gt;(53&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zyzsGl2pa3S2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value"&gt;29,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total available-for-sale, short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zGdqgrqcp1B" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized cost"&gt;37,819&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zx4c9m33Eq87" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0749"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zsvhUjgGGRw" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Loss"&gt;(66&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zt4sJkdsAiT3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value"&gt;37,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000699"
      unitRef="USD">23990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000703"
      unitRef="USD">22000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000705"
      unitRef="USD">23968000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000707"
      unitRef="USD">40365000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2024-01-012024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000709"
      unitRef="USD">10000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000713"
      unitRef="USD">40375000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-12-31_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact000715"
      unitRef="USD">10000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2024-01-012024-12-31_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact000717"
      unitRef="USD">20000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-12-31_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact000721"
      unitRef="USD">10020000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000723"
      unitRef="USD">74355000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000725"
      unitRef="USD">30000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000727"
      unitRef="USD">22000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000729"
      unitRef="USD">74363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000731"
      unitRef="USD">8406000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000735"
      unitRef="USD">13000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000737"
      unitRef="USD">8393000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000739"
      unitRef="USD">29413000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000743"
      unitRef="USD">53000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2023-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000745"
      unitRef="USD">29360000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">37819000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000751"
      unitRef="USD">66000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000753"
      unitRef="USD">37753000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000757"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000759">&lt;p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zOqRscL1t5ma" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_82A_zCd5veDxCTja"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_z3zpII5mkwEk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost and depreciated or amortized using the straight-line method based on useful lives as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zdJsbegO5u6g" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Useful
    lives (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zVk9x1UGLBhi" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zKDdVIgVTAQh" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful lives (years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 35%; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zcMuPkhN31Bj" title="Useful lives (years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_z3xNLAKXuDN2" style="width: 10%; text-align: right"&gt;8,868&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zRwQhlueoQT3" style="width: 10%; text-align: right"&gt;6,935&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture, software and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z9EQjlFyEREl" title="Useful lives (years)"&gt;3&lt;/span&gt; to &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zzMa4GmEDpi8" title="Useful lives (years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_zOWoiR7cR2Ll" style="text-align: right"&gt;1,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_z7xhfJLN8Lsb" style="text-align: right"&gt;986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9ss9QtDYD28" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;Shorter of remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVWATQYDPzn8" style="text-align: right"&gt;8,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9E0AHx7P5G5" style="text-align: right"&gt;8,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Construction-in-progress&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zHCVSHfZ7Wr1" style="border-bottom: Black 1pt solid; text-align: right"&gt;624&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z23Y7teNExGb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maCzvcX_zktQhF5p3132" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msCzvcX_zUCEnoMEnzw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,980&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,991&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtCzvcX_z78B58J3xhb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,430&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zeoVlOzy9Bhf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
and amortization on property and equipment was $&lt;span id="xdx_90E_eus-gaap--DepreciationAndAmortization_pn5n6_c20240101__20241231_zxj8N1R0cRw6" title="Depreciation expense"&gt;2.0&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--DepreciationAndAmortization_pn5n6_c20230101__20231231_z2vXRwMHBT49" title="Depreciation expense"&gt;2.3&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively.
The Company incurred a gain on disposal of equipment of $&lt;span id="xdx_909_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_c20240101__20241231_zNXYFIZne613" title="Gain (loss) on disposal of equipment"&gt;2,000&lt;/span&gt; and a loss on disposal of $&lt;span id="xdx_90D_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn3d_di_c20230101__20231231_zjFkFDlMT9Ke" title="Gain (loss) on disposal of equipment"&gt;47,000&lt;/span&gt; during the years ended December 31,
2024 and 2023, respectively, which is reflected in other income in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000761">&lt;p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_z3zpII5mkwEk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost and depreciated or amortized using the straight-line method based on useful lives as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zdJsbegO5u6g" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Useful
    lives (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zVk9x1UGLBhi" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zKDdVIgVTAQh" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful lives (years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 35%; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zcMuPkhN31Bj" title="Useful lives (years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_z3xNLAKXuDN2" style="width: 10%; text-align: right"&gt;8,868&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zRwQhlueoQT3" style="width: 10%; text-align: right"&gt;6,935&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture, software and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z9EQjlFyEREl" title="Useful lives (years)"&gt;3&lt;/span&gt; to &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zzMa4GmEDpi8" title="Useful lives (years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_zOWoiR7cR2Ll" style="text-align: right"&gt;1,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureSoftwareAndOfficeEquipmentMember_z7xhfJLN8Lsb" style="text-align: right"&gt;986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9ss9QtDYD28" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;Shorter of remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVWATQYDPzn8" style="text-align: right"&gt;8,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9E0AHx7P5G5" style="text-align: right"&gt;8,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Construction-in-progress&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zHCVSHfZ7Wr1" style="border-bottom: Black 1pt solid; text-align: right"&gt;624&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z23Y7teNExGb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maCzvcX_zktQhF5p3132" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msCzvcX_zUCEnoMEnzw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,980&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,991&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtCzvcX_z78B58J3xhb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,430&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_LaboratoryEquipmentMember"
      id="Fact000763">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_LaboratoryEquipmentMember"
      decimals="-3"
      id="Fact000764"
      unitRef="USD">8868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_LaboratoryEquipmentMember"
      decimals="-3"
      id="Fact000765"
      unitRef="USD">6935000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember_srt_MinimumMember"
      id="Fact000767">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember_srt_MaximumMember"
      id="Fact000769">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember"
      decimals="-3"
      id="Fact000770"
      unitRef="USD">1113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_FurnitureSoftwareAndOfficeEquipmentMember"
      decimals="-3"
      id="Fact000771"
      unitRef="USD">986000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact000773"
      unitRef="USD">8805000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact000774"
      unitRef="USD">8603000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="Fact000775"
      unitRef="USD">624000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000778"
      unitRef="USD">19410000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000779"
      unitRef="USD">16524000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000781"
      unitRef="USD">14980000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000782"
      unitRef="USD">12991000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000784"
      unitRef="USD">4430000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000785"
      unitRef="USD">3533000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000787"
      unitRef="USD">2000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000789"
      unitRef="USD">2300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000791"
      unitRef="USD">2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000793"
      unitRef="USD">-47000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000795">&lt;p id="xdx_801_eus-gaap--FairValueDisclosuresTextBlock_zfRPP4kX3Yxi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_825_zA7nKOKVqx8j"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates the fair value of the Company&#x2019;s assets and liabilities that qualify as financial instruments and includes additional
information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial
instruments. The estimated fair value of other receivables, prepaid expenses and other current assets, other assets, accounts payable,
accrued expenses, and payables to licensor approximate their carrying amounts due to the relatively short maturity of these instruments.
The estimated fair value of the Loan Agreement as of December 31, 2024, was $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241231_zJ8gJMnukw45" title="Estimated fair value of loan agreement"&gt;24.7&lt;/span&gt; million. Both observable and unobservable inputs were
used to determine the fair value of long-term debt, which was classified within the Level 3 category.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement
date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used
to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active
    markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
    and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use
    significant unobservable inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually)
into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement
date in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zipXxzDqIJZ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of financial assets measured at fair value on a recurring and non-recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zb8vLDZeZlh9" style="display: none"&gt;SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value at&lt;br/&gt;
 December 31,&lt;br/&gt;
 2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Recurring Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; width: 36%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zr4qQKTfUFxh" style="width: 12%; text-align: right" title="Cash equivalents fair value"&gt;17,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoU7BWvsLvdj" style="width: 12%; text-align: right" title="Cash equivalents fair value"&gt;17,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoe8909E2723" style="width: 12%; text-align: right" title="Cash equivalents fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zf0zgOyrWeZg" style="width: 12%; text-align: right" title="Cash equivalents fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Money market deposit account&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zQHAjJEDYsif" style="text-align: right" title="Cash equivalents fair value"&gt;5,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zXMBELUrecei" style="text-align: right" title="Cash equivalents fair value"&gt;5,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zKQvGmeek3Ci" style="text-align: right" title="Cash equivalents fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_z13aXFb8YUU3" style="text-align: right" title="Cash equivalents fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0815"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z9rkQS1WfENd" style="text-align: right" title="Short-term investments fair value"&gt;23,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z28ai9lBLzpg" style="text-align: right" title="Short-term investments fair value"&gt;23,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zsPxZ8lc6gYa" style="text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zSVBi1CQsure" style="text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;U.S. federal agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zTREwELdc2X4" style="text-align: right" title="Short-term investments fair value"&gt;40,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zxaUO2jH9d0g" style="text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zdFB5KWMuU4i" style="text-align: right" title="Short-term investments fair value"&gt;40,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zRbgQjl5fUg6" style="text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zubR8RtOnT06" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"&gt;10,020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zsuCLigAJfzj" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0835"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zjbWgTF9Twx5" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"&gt;10,020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zdxoBDGubLc" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zA3Uzn1yrPff" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"&gt;97,099&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkAgvzzcD9X9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"&gt;46,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGlEpab97I9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"&gt;50,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQylC3rqse7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_z0DNPX8IHBii" style="border-bottom: Black 1pt solid; text-align: right"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zufP1eiWhOH5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zcAP8OhzYiVj" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zlnzwh1yztLe" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzbS8g42I3T8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zY6FNtSidbc4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGCujSBBfiNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC4R6ZeMhQog" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value at&lt;br/&gt; December 31,&lt;br/&gt;

    2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Recurring Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; width: 36%"&gt;Money market fund&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z5MGhwssVxC1" style="width: 12%; text-align: right"&gt;1,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zcheNgrtHx4g" style="width: 12%; text-align: right"&gt;1,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zBjDh39isri" style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ziutopJ1uSPa" style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zGjt5pcE5o97" style="text-align: right"&gt;8,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zs1pZH54yzXk" style="text-align: right"&gt;8,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zgnDZ6HrS7Te" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zqH9RDjyWiy2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;U.S. federal agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zeImKI3jS6Vd" style="border-bottom: Black 1pt solid; text-align: right"&gt;29,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zvYZOOLA1Mx3" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zpsy8MZtA2Mj" style="border-bottom: Black 1pt solid; text-align: right"&gt;29,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zuBwpnkmg5vi" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0873"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRfh7q4IQ7sk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;38,787&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQDEH1VRFQEd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGYYJkQTK9K2" style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,360&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWyylU5yoqgi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Payable to licensor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_z0wHJNRP9JZ" style="text-align: right"&gt;4,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zyn6DeUyfWj7" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0879"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_ztz5ds9e83Z2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zYVb9hclTaF4" style="text-align: right"&gt;4,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zZ29UGiWdUQ5" style="border-bottom: Black 1pt solid; text-align: right"&gt;31,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zJQBGntILD9b" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0883"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zj7a1Qc104kg" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zVjrMjFFAtb6" style="border-bottom: Black 1pt solid; text-align: right"&gt;31,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT8eW20JRiN3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJlwZzUmA6cg" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0887"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwEYU8pbUZQ3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUHK8JzoUS7a" style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z8bJis2UhRRk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrant
Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_zLtp3yxAShJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company had the following outstanding warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zTEGzuH7ylNc" style="display: none"&gt;SCHEDULE OF OUTSTANDING WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zVGrSMiVrbOl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z30RTI2vUCn9" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zI8eLCm3Xrsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Warrants issued as part of the 2021 public offering, expiration date &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zXq2Wwadqni6" title="Warrants, expiration date"&gt;December 2026&lt;/span&gt;, exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zfjX8HJRQEig" title="Warrants, exercise price"&gt;9.75&lt;/span&gt; per share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,788,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,788,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zf3tzd0ffCYh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants issued as part of the 2022 Private Placement Offering, expiration date &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zSWZlag3Xbi9" title="Warrants, expiration date"&gt;November 2027&lt;/span&gt;, exercise price $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_z475wsbrTNUa" title="Warrants, exercise price"&gt;4.75&lt;/span&gt; per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,609,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,609,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zgwOkqHcJMw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants issued as part of the 2024 Loan Agreement, expiration date &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zdoapL79LLR7" title="Warrants, expiration date"&gt;January 2029&lt;/span&gt;, exercise price $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zJ5BPgaz46Vh" title="Warrants, exercise price"&gt;4.07&lt;/span&gt; per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;589,681&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0908"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zYoS9AsvVNr6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,609,879&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,609,879&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_z74iCmQvhRId" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common stock warrants related to the 2021 Public Offering and the 2022 Private Placement are not indexed to the Company&#x2019;s own stock
and therefore have been classified as liabilities at their estimated fair value. The common stock warrants issued in connection with
the Loan Agreement issuance were determined to be liability classified under ASC 815 as the common stock warrants were not considered
indexed to the Company&#x2019;s stock. Changes in the estimated fair value of the warrant liabilities is recorded as changes in fair value
of warrant liabilities in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2024, as part of the Loan and Security Agreement, see Note 9, the Company issued warrants to purchase $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zz8pyafuZUOk" title="Warrants to purchase shares"&gt;2,400,000&lt;/span&gt; worth of shares
of the Company&#x2019;s stock which have an exercise price equal to the lesser of (i) $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zBNO2XSoqBud" title="Warrants exercise price"&gt;4.75&lt;/span&gt; and (ii) the price per share of the Company&#x2019;s
next bona fide round of equity financing before September 30, 2024 (the &#x201c;2024 Loan Agreement Warrants&#x201d;). In connection with
the underwritten common stock offering consummated on May 7, 2024, pursuant to the terms of the 2024 Loan Agreement Warrants, the exercise
price was reduced to $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementMember_zQqDbp7tTJ5f" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share and the shares issuable was calculated at &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourLoanAgreementMember_z7DJjC0HyD93" title="Shares of common stock issuable upon exercise of warrants"&gt;589,681&lt;/span&gt; shares. On September 30, 2024, per the terms of
the 2023 Loan Agreement Warrants, the exercise price and the number of shares became set at $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyThreeLoanAgreementMember_zEJ18XkUsCL" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share and &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyThreeLoanAgreementMember_zNVwEminFSme" title="Shares of common stock issuable upon exercise of warrants"&gt;589,681&lt;/span&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfActivityWarrantyLiabilityTableTextBlock_zKvlDGvHSJrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the activity on the warrant liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zZfNqip5VEV2" style="display: none"&gt;SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zAbCkqAeriP3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zk9vNzGrMyFl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WarrantLiabilities_iS_pn3n3_zkLpCfSAfuEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Beginning warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;31,352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;19,657&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FairValueAdjustmentOfWarrantsIssued_pn3n3_zax4nmVrFkja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Fair value of warrants issued in connection with the Loan Agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0935"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--GainLossRecognizedInEarningsFromChangeInFairValue_iN_pn3n3_di_zb74aMD7CPha" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Loss recognized in earnings from change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,695&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--WarrantLiabilities_iE_pn3n3_z7QIL8mstCR5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zFzpP8LHoEG5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liabilities are valued using significant inputs not observable in the market. Accordingly, the warrant liability is measured
at fair value on a recurring basis using unobservable inputs and are classified as Level 3 inputs within the fair value hierarchy. Fair
value measurements categorized within Level 3 are sensitive to changes in the assumptions or methodology used to determine fair value
and such changes could result in a significant increase or decrease in the fair value. The Company&#x2019;s valuation of the common stock
warrants utilized the Black-Scholes option-pricing model, which incorporated assumptions and estimates to value the common stock warrants.
The Company assessed these assumptions and estimates at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z29rlvcuTmU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table outlines the key inputs for the Black-Scholes option-pricing model:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zzfRD4nJtovk" style="display: none"&gt;SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: center"&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z7AlKWJUrUw5"&gt;5.57&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: center"&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDiCi34HRqae"&gt;5.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zcVhk02hsKdl" title="Expected term (years)"&gt;1.96&lt;/span&gt;
&#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zEa5d86fCkKc" title="Expected term (years)"&gt;4.02&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zMC9dmNs2Fna" title="Expected term (years)"&gt;2.96&lt;/span&gt;
&#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zS3QwkJb5q1d" title="Expected term (years)"&gt;3.84&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zwxA83DjHxne" title="Warrants measurement input"&gt;4.16&lt;/span&gt;% &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zKrkBTFhT4Xh" title="Warrants measurement input"&gt;4.24&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRAegRZo0w9h" title="Warrants measurement input"&gt;3.84&lt;/span&gt;% &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zgensBV8qG76" title="Warrants measurement input"&gt;3.92&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zhl1fCHSRzK1" title="Warrants measurement input"&gt;92.64&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoraCYRSkFh4" title="Warrants measurement input"&gt;100.00&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcsgRdfr7tOh" title="Warrants measurement input"&gt;100.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmv4kcxZolB" title="Warrants measurement input"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGQhwfkSThG4" title="Warrants measurement input"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zdsWkbpAnAxj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative
Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Conversion Right embedded within the Loan Agreement (see Note 9 below) required bifurcation as certain adjustments to the conversion
price were not indexed to the Company&#x2019;s own stock and therefore the Conversion Right was recorded as a derivative liability. The
derivative liability is remeasured at each reporting period with the change in fair value recorded to changes in fair value of warrants
and derivative liabilities in the condensed consolidated statement of operations until the derivative is exercised, expired, reclassified,
or otherwise settled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 30, 2024, pursuant to the Loan Agreement, the conversion price was fixed at $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zgBp5ZbjjBYf" title="Conversion price"&gt;4.88&lt;/span&gt; and is considered indexed to the Company&#x2019;s
own stock. At September 30, 2024, the Conversion Right no longer met the criteria of a derivative liability, and the derivative liability
was reclassified to equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zpMU7P2RYzP5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the activity on the derivative liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8B9_z7J5r0VD8j8d" style="display: none"&gt;SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zcWsM91NpHgk" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zSJEn2Jm4WQ6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_zgKQWzylEaC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Beginning derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--FairValueOfDerivativesIssued_zgOuKkKYcNna" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Fair value of derivatives issued in connection with Loan Agreement&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;822&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLossOnDerivative_zfFbfwKv7rXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span id="xdx_903_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20240101__20241231_z5JWqb45Gh44" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20230101__20231231_zun9QKFotl4f" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0986"&gt;Loss recognized in earnings from change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_iN_zOvJ03xsAm81" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reclassification of derivative liability in connection with the Loan Agreement&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,135&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_zHXFxmIpvlzf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0991"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zPCBaxmGtRZj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000797"
      unitRef="USD">24700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000799">&lt;p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zipXxzDqIJZ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of financial assets measured at fair value on a recurring and non-recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zb8vLDZeZlh9" style="display: none"&gt;SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value at&lt;br/&gt;
 December 31,&lt;br/&gt;
 2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Recurring Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; width: 36%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zr4qQKTfUFxh" style="width: 12%; text-align: right" title="Cash equivalents fair value"&gt;17,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoU7BWvsLvdj" style="width: 12%; text-align: right" title="Cash equivalents fair value"&gt;17,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoe8909E2723" style="width: 12%; text-align: right" title="Cash equivalents fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zf0zgOyrWeZg" style="width: 12%; text-align: right" title="Cash equivalents fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Money market deposit account&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zQHAjJEDYsif" style="text-align: right" title="Cash equivalents fair value"&gt;5,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zXMBELUrecei" style="text-align: right" title="Cash equivalents fair value"&gt;5,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_zKQvGmeek3Ci" style="text-align: right" title="Cash equivalents fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketDepositAccountMember_z13aXFb8YUU3" style="text-align: right" title="Cash equivalents fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0815"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z9rkQS1WfENd" style="text-align: right" title="Short-term investments fair value"&gt;23,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_z28ai9lBLzpg" style="text-align: right" title="Short-term investments fair value"&gt;23,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zsPxZ8lc6gYa" style="text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zSVBi1CQsure" style="text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;U.S. federal agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zTREwELdc2X4" style="text-align: right" title="Short-term investments fair value"&gt;40,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zxaUO2jH9d0g" style="text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zdFB5KWMuU4i" style="text-align: right" title="Short-term investments fair value"&gt;40,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zRbgQjl5fUg6" style="text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zubR8RtOnT06" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"&gt;10,020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zsuCLigAJfzj" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0835"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zjbWgTF9Twx5" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"&gt;10,020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--CertificatesOfDepositMember_zdxoBDGubLc" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zA3Uzn1yrPff" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"&gt;97,099&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkAgvzzcD9X9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"&gt;46,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGlEpab97I9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"&gt;50,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQylC3rqse7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_z0DNPX8IHBii" style="border-bottom: Black 1pt solid; text-align: right"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zufP1eiWhOH5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zcAP8OhzYiVj" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zlnzwh1yztLe" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, liabilities"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzbS8g42I3T8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zY6FNtSidbc4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGCujSBBfiNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC4R6ZeMhQog" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value at&lt;br/&gt; December 31,&lt;br/&gt;

    2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Recurring Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; width: 36%"&gt;Money market fund&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z5MGhwssVxC1" style="width: 12%; text-align: right"&gt;1,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zcheNgrtHx4g" style="width: 12%; text-align: right"&gt;1,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zBjDh39isri" style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ziutopJ1uSPa" style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zGjt5pcE5o97" style="text-align: right"&gt;8,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zs1pZH54yzXk" style="text-align: right"&gt;8,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zgnDZ6HrS7Te" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zqH9RDjyWiy2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;U.S. federal agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zeImKI3jS6Vd" style="border-bottom: Black 1pt solid; text-align: right"&gt;29,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zvYZOOLA1Mx3" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zpsy8MZtA2Mj" style="border-bottom: Black 1pt solid; text-align: right"&gt;29,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zuBwpnkmg5vi" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0873"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRfh7q4IQ7sk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;38,787&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQDEH1VRFQEd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGYYJkQTK9K2" style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,360&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWyylU5yoqgi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Payable to licensor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_z0wHJNRP9JZ" style="text-align: right"&gt;4,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zyn6DeUyfWj7" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0879"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_ztz5ds9e83Z2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--PayableToLicensorMember_zYVb9hclTaF4" style="text-align: right"&gt;4,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zZ29UGiWdUQ5" style="border-bottom: Black 1pt solid; text-align: right"&gt;31,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zJQBGntILD9b" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0883"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zj7a1Qc104kg" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--WarrantLiabilitiesMember_zVjrMjFFAtb6" style="border-bottom: Black 1pt solid; text-align: right"&gt;31,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT8eW20JRiN3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJlwZzUmA6cg" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0887"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwEYU8pbUZQ3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUHK8JzoUS7a" style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact000801"
      unitRef="USD">17627000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact000803"
      unitRef="USD">17627000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember"
      decimals="-3"
      id="Fact000809"
      unitRef="USD">5109000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_MoneyMarketDepositAccountMember"
      decimals="-3"
      id="Fact000811"
      unitRef="USD">5109000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000817"
      unitRef="USD">23968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000819"
      unitRef="USD">23968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000825"
      unitRef="USD">40375000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">40375000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact000833"
      unitRef="USD">10020000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact000837"
      unitRef="USD">10020000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000841"
      unitRef="USD">97099000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000843"
      unitRef="USD">46704000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000845"
      unitRef="USD">50395000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember"
      decimals="-3"
      id="Fact000848"
      unitRef="USD">32014000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember"
      decimals="-3"
      id="Fact000854"
      unitRef="USD">32014000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000855"
      unitRef="USD">32014000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000861"
      unitRef="USD">32014000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact000862"
      unitRef="USD">1034000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact000863"
      unitRef="USD">1034000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000866"
      unitRef="USD">8393000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000867"
      unitRef="USD">8393000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000870"
      unitRef="USD">29360000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="Fact000872"
      unitRef="USD">29360000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000874"
      unitRef="USD">38787000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000875"
      unitRef="USD">9427000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000876"
      unitRef="USD">29360000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember"
      decimals="-3"
      id="Fact000878"
      unitRef="USD">4580000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PayableToLicensorMember"
      decimals="-3"
      id="Fact000881"
      unitRef="USD">4580000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">31352000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilitiesMember"
      decimals="-3"
      id="Fact000885"
      unitRef="USD">31352000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">35932000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000889"
      unitRef="USD">35932000</us-gaap:LiabilitiesFairValueDisclosure>
    <ABEO:ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000891">&lt;p id="xdx_897_ecustom--ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock_zLtp3yxAShJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company had the following outstanding warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zTEGzuH7ylNc" style="display: none"&gt;SCHEDULE OF OUTSTANDING WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zVGrSMiVrbOl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z30RTI2vUCn9" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zI8eLCm3Xrsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Warrants issued as part of the 2021 public offering, expiration date &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zXq2Wwadqni6" title="Warrants, expiration date"&gt;December 2026&lt;/span&gt;, exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zfjX8HJRQEig" title="Warrants, exercise price"&gt;9.75&lt;/span&gt; per share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,788,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,788,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zf3tzd0ffCYh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants issued as part of the 2022 Private Placement Offering, expiration date &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zSWZlag3Xbi9" title="Warrants, expiration date"&gt;November 2027&lt;/span&gt;, exercise price $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_z475wsbrTNUa" title="Warrants, exercise price"&gt;4.75&lt;/span&gt; per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,609,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,609,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zgwOkqHcJMw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants issued as part of the 2024 Loan Agreement, expiration date &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zdoapL79LLR7" title="Warrants, expiration date"&gt;January 2029&lt;/span&gt;, exercise price $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgTElBQklMSVRJRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourLoanAgreementMember_zJ5BPgaz46Vh" title="Warrants, exercise price"&gt;4.07&lt;/span&gt; per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;589,681&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0908"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyTwoPrivatePlacementOfferingMember_zYoS9AsvVNr6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,609,879&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,609,879&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ABEO:ScheduleOfOutstandingWarrantLiabilitiesTableTextBlock>
    <ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable
      contextRef="From2024-01-012024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember"
      id="Fact000896">December 2026</ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember"
      decimals="INF"
      id="Fact000898"
      unitRef="USDPShares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember"
      decimals="INF"
      id="Fact000893"
      unitRef="Shares">1788000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember"
      decimals="INF"
      id="Fact000894"
      unitRef="Shares">1788000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable
      contextRef="From2024-01-012024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember"
      id="Fact000903">November 2027</ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember"
      decimals="INF"
      id="Fact000905"
      unitRef="USDPShares">4.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">7609879</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember"
      decimals="INF"
      id="Fact000901"
      unitRef="Shares">7609879</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable
      contextRef="From2024-01-012024-12-31_custom_TwentyTwentyFourLoanAgreementMember"
      id="Fact000910">January 2029</ABEO:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_TwentyTwentyFourLoanAgreementMember"
      decimals="INF"
      id="Fact000912"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwentyTwentyFourLoanAgreementMember"
      decimals="INF"
      id="Fact000907"
      unitRef="Shares">589681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember"
      decimals="INF"
      id="Fact000914"
      unitRef="Shares">7609879</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_TwentyTwentyTwoPrivatePlacementOfferingMember"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">7609879</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-01-31_custom_LoanAndSecurityAgreementMember"
      decimals="0"
      id="Fact000917"
      unitRef="USD">2400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-31_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact000919"
      unitRef="USDPShares">4.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementMember"
      decimals="INF"
      id="Fact000921"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-05-07_custom_TwentyTwentyFourLoanAgreementMember"
      decimals="INF"
      id="Fact000923"
      unitRef="Shares">589681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-30_custom_TwentyTwentyThreeLoanAgreementMember"
      decimals="INF"
      id="Fact000925"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-09-30_custom_TwentyTwentyThreeLoanAgreementMember"
      decimals="INF"
      id="Fact000927"
      unitRef="Shares">589681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ABEO:ScheduleOfActivityWarrantyLiabilityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000929">&lt;p id="xdx_89D_ecustom--ScheduleOfActivityWarrantyLiabilityTableTextBlock_zKvlDGvHSJrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the activity on the warrant liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zZfNqip5VEV2" style="display: none"&gt;SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zAbCkqAeriP3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zk9vNzGrMyFl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WarrantLiabilities_iS_pn3n3_zkLpCfSAfuEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Beginning warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;31,352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;19,657&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FairValueAdjustmentOfWarrantsIssued_pn3n3_zax4nmVrFkja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Fair value of warrants issued in connection with the Loan Agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0935"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--GainLossRecognizedInEarningsFromChangeInFairValue_iN_pn3n3_di_zb74aMD7CPha" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Loss recognized in earnings from change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,695&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--WarrantLiabilities_iE_pn3n3_z7QIL8mstCR5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ABEO:ScheduleOfActivityWarrantyLiabilityTableTextBlock>
    <ABEO:WarrantLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000931"
      unitRef="USD">31352000</ABEO:WarrantLiabilities>
    <ABEO:WarrantLiabilities
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000932"
      unitRef="USD">19657000</ABEO:WarrantLiabilities>
    <ABEO:FairValueAdjustmentOfWarrantsIssued
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000934"
      unitRef="USD">220000</ABEO:FairValueAdjustmentOfWarrantsIssued>
    <ABEO:GainLossRecognizedInEarningsFromChangeInFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000937"
      unitRef="USD">-442000</ABEO:GainLossRecognizedInEarningsFromChangeInFairValue>
    <ABEO:GainLossRecognizedInEarningsFromChangeInFairValue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000938"
      unitRef="USD">-11695000</ABEO:GainLossRecognizedInEarningsFromChangeInFairValue>
    <ABEO:WarrantLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000940"
      unitRef="USD">32014000</ABEO:WarrantLiabilities>
    <ABEO:WarrantLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000941"
      unitRef="USD">31352000</ABEO:WarrantLiabilities>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000943">&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z29rlvcuTmU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table outlines the key inputs for the Black-Scholes option-pricing model:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zzfRD4nJtovk" style="display: none"&gt;SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: center"&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z7AlKWJUrUw5"&gt;5.57&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: center"&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDiCi34HRqae"&gt;5.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zcVhk02hsKdl" title="Expected term (years)"&gt;1.96&lt;/span&gt;
&#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zEa5d86fCkKc" title="Expected term (years)"&gt;4.02&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zMC9dmNs2Fna" title="Expected term (years)"&gt;2.96&lt;/span&gt;
&#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zS3QwkJb5q1d" title="Expected term (years)"&gt;3.84&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zwxA83DjHxne" title="Warrants measurement input"&gt;4.16&lt;/span&gt;% &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zKrkBTFhT4Xh" title="Warrants measurement input"&gt;4.24&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRAegRZo0w9h" title="Warrants measurement input"&gt;3.84&lt;/span&gt;% &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zgensBV8qG76" title="Warrants measurement input"&gt;3.92&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zhl1fCHSRzK1" title="Warrants measurement input"&gt;92.64&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoraCYRSkFh4" title="Warrants measurement input"&gt;100.00&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcsgRdfr7tOh" title="Warrants measurement input"&gt;100.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmv4kcxZolB" title="Warrants measurement input"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFIEZBSVIgVkFMVUUgT0YgV0FSUkFOVFMgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGQhwfkSThG4" title="Warrants measurement input"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact000944"
      unitRef="USDPShares">5.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact000945"
      unitRef="USDPShares">5.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember"
      id="Fact000947">P1Y11M15D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember"
      id="Fact000949">P4Y7D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember"
      id="Fact000951">P2Y11M15D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember"
      id="Fact000953">P3Y10M2D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000955"
      unitRef="Pure">4.16</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Pure">4.24</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000959"
      unitRef="Pure">3.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000961"
      unitRef="Pure">3.92</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000963"
      unitRef="Pure">92.64</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000965"
      unitRef="Pure">100.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000967"
      unitRef="Pure">100.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact000969"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact000971"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-09-30_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact000973"
      unitRef="USDPShares">4.88</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000975">&lt;p id="xdx_89A_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zpMU7P2RYzP5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the activity on the derivative liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8B9_z7J5r0VD8j8d" style="display: none"&gt;SCHEDULE OF ACTIVITY OF DERIVATIVE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zcWsM91NpHgk" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zSJEn2Jm4WQ6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_zgKQWzylEaC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Beginning derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--FairValueOfDerivativesIssued_zgOuKkKYcNna" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Fair value of derivatives issued in connection with Loan Agreement&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;822&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLossOnDerivative_zfFbfwKv7rXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span id="xdx_903_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20240101__20241231_z5JWqb45Gh44" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"&gt;&lt;span id="xdx_90B_eus-gaap--DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20230101__20231231_zun9QKFotl4f" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23FairValueAdjustmentOfWarrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0986"&gt;Loss recognized in earnings from change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement_iN_zOvJ03xsAm81" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reclassification of derivative liability in connection with the Loan Agreement&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,135&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_zHXFxmIpvlzf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0991"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <ABEO:FairValueOfDerivativesIssued
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000980"
      unitRef="USD">822000</ABEO:FairValueOfDerivativesIssued>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000983"
      unitRef="USD">313000</us-gaap:DerivativeLossOnDerivative>
    <ABEO:ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000988"
      unitRef="USD">-1135000</ABEO:ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement>
    <us-gaap:LossContingencyDisclosures contextRef="From2024-01-01to2024-12-31" id="Fact000994">&lt;p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zZSAZaApmfzj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_82F_zfFw9jdS1Jfi"&gt;SETTLEMENT LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 12, 2021, the Company entered into a settlement agreement (&#x201c;Settlement Agreement&#x201d;) with the Company&#x2019;s prior
licensor REGENXBIO Inc. (&#x201c;REGENXBIO&#x201d;) to resolve all existing disputes between the parties. In accordance with the Settlement
Agreement, the Company agreed to pay REGENXBIO a total of $&lt;span id="xdx_905_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zEwu1gvduwK8" title="Settlement liabilities, current"&gt;30.0&lt;/span&gt; million, payable as follows: &lt;span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zz8ou7zWJNTi" title="Loss contingency settlement agreement terms"&gt;(1) $20.0 million paid in November 2021
after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement
(paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement
or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement (paid in November 2024).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded the payable due to REGENXBIO in the consolidated balance sheet based on the present value of the remaining payments
due to REGENXBIO under the Settlement Agreement using an effective interest rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_znVsSSoGPVrj"&gt;9.6&lt;/span&gt;%. The Company paid all amounts due in November
2024 and therefore there were no amounts outstanding as of December 31, 2024. The present value of the amount due as of December 31,
2023 was $&lt;span id="xdx_906_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_z41pAKc5Haq8"&gt;4.6&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LossContingencyDisclosures>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_custom_REGENXBIOMember"
      decimals="-5"
      id="Fact000996"
      unitRef="USD">30000000.0</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:LossContingencySettlementAgreementTerms
      contextRef="From2021-11-112021-11-12_custom_REGENXBIOMember"
      id="Fact000998">(1) $20.0 million paid in November 2021
after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement
(paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement
or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement (paid in November 2024).</us-gaap:LossContingencySettlementAgreementTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31_custom_REGENXBIOMember"
      decimals="INF"
      id="Fact000999"
      unitRef="Pure">0.096</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-12-31_custom_REGENXBIOMember"
      decimals="-5"
      id="Fact001000"
      unitRef="USD">4600000</us-gaap:LongTermDebt>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001002">&lt;p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zCF2pdtOPzbi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_82E_z8swC3D3KsM6"&gt;ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0klTybGiMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the components of accrued expenses (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zhHL2yHiwIrf" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zgf4LoVT2Kc3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zvLG8hnRct3b" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz9Ql_zyVyMa7TPaHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued employee compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCz9Ql_ze73B163aD3c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued contracted services and other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,941&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,297&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz9Ql_zPeVdkGjBeY3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_z5zrktVjewKc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001004">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zE0klTybGiMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the components of accrued expenses (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zhHL2yHiwIrf" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zgf4LoVT2Kc3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zvLG8hnRct3b" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCz9Ql_zyVyMa7TPaHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued employee compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCz9Ql_ze73B163aD3c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued contracted services and other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,941&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,297&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz9Ql_zPeVdkGjBeY3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001006"
      unitRef="USD">4392000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001007"
      unitRef="USD">3688000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001009"
      unitRef="USD">1941000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001010"
      unitRef="USD">2297000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001012"
      unitRef="USD">6333000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001013"
      unitRef="USD">5985000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001015">&lt;p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zujyXqb0Dln3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_822_zWlQ7cfA1YGa"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases space under operating leases for administrative, manufacturing and laboratory facilities in Cleveland, Ohio. The Company
also leases office space in New York, New York, that the Company sublets. The Company also leases certain office equipment under operating
leases, which have a non-cancelable lease term of less than one year and the Company has elected the practical expedient to exclude these
short-term leases from the Company&#x2019;s right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2024, the Company signed a lease for &lt;span id="xdx_900_eus-gaap--AreaOfLand_iI_usqft_c20241231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zCwLK6jtSFIc" title="Lease cost"&gt;16,566&lt;/span&gt; square feet of office space at 6700 Euclid Avenue, Cleveland, Ohio. Pursuant to the lease
agreement, the lease term commences on January 1, 2025 with an initial term through December 30, 2030. Annual lease payments during the
term of the lease are approximately $&lt;span id="xdx_90F_eus-gaap--OperatingLeasePaymentsUse_pn5n6_c20240101__20241231_za46fa05eibg" title="Annual lease payments"&gt;0.3&lt;/span&gt; million. The total lease payments over the duration of the lease term are approximately $&lt;span id="xdx_90E_eus-gaap--OperatingLeasePayments_pn5n6_c20240101__20241231_zPtGr1jSwOWd" title="Total lease payments"&gt;1.5&lt;/span&gt;
million. The additional space at the 6700 Euclid Avenue facility will allow the Company to convert office space at the 6555 Carnegie
Avenue facility into additional manufacturing space to increase pz-cel manufacturing capacity. As the lease does not commence and the
Company does not have access to the leased space until January 1, 2025, the impact of this lease agreement is not reflected in the consolidated
financial statements of the Company as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2023, the Company terminated one of its operating leases for office space. The termination resulted in a gain of $&lt;span id="xdx_905_eus-gaap--GainLossOnTerminationOfLease_pn5n6_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceOneMember_zJBI1L0xa0Y8" title="Gain (loss) on termination of lease"&gt;1.1&lt;/span&gt; million representing
the difference between the carry value of the right-of-use assets and the related lease liabilities. This gain was recorded in the year
ended December 31, 2023, and is included in gain on operating lease right-of-use assets in the consolidated statement of operations and
comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2023, the Company modified one of its operating leases for office space to add up to &lt;span id="xdx_906_eus-gaap--AreaOfLand_iI_usqft_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zvtL4x96Rfjf" title="Area of land"&gt;14,032&lt;/span&gt; square feet to the Company&#x2019;s existing
facility in Cleveland, Ohio. The lease modification resulted in the recognition of $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zPpxYS5Tdx5k" title="Right-of-use assets"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_pn5n6_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_z5J77HKxd5d1" title="Lease liabilities"&gt;0.4&lt;/span&gt;&lt;/span&gt; million of additional right-of-use assets and
related lease liabilities in the Company&#x2019;s consolidated balance sheet during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2022 and 2023, the Company entered into two sublease agreements with unrelated third parties to occupy the Company&#x2019;s administrative
offices in New York, New York. The Company expects to receive $&lt;span id="xdx_90D_eus-gaap--SubleaseIncome_pn5n6_c20240101__20241231__us-gaap--AwardDateAxis__custom--SeptemberTwoThouandTwentyFiveMember_znBZUuU9JCN1" title="Sublease income"&gt;0.5&lt;/span&gt; million in future sublease income through September 2025 from the
two subleases noted above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zHqncXgOgfI8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the Company&#x2019;s operating lease liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zSXKYa6qpv1a" style="display: none"&gt;SUMMARY OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zywhxeVoY6Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_zExrjeakqDU7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzJ5e_zzftb7jKYr4i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Current operating lease liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzJ5e_z3ptF5BnuDR1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Non-current operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,262&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,402&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzJ5e_zbEYM6NwI84k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z1NMcCerDdFb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
costs and rent are reflected in general and administrative expenses and research and development expenses in the consolidated statements
of operations and comprehensive loss, as determined by the underlying activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zLO5vmxyZoff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the components of lease costs and rent (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zAqOuKsMyG1i" style="display: none"&gt;SCHEDULE OF COMPONENTS OF LEASE COST&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zPbyK4BgezUg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zEe20696qzHk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_maLCzRlC_zexGgZSlOph4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--VariableLeaseCost_pn3n3_maLCzRlC_zOknanic4gh8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzRlC_zWFA1AtjKpJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Short-term lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;49&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;63&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LeaseCost_iT_pn3n3_mtLCzRlC_zTZu4St3ZdOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,717&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,810&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zFPLPbLDV1p" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
paid for amounts included in the measurement of operating lease liabilities was $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseExpense_pn5n6_c20240101__20241231_zL5ZIrdbJvbj" title="Operating lease liabilities"&gt;1.3&lt;/span&gt; million and $&lt;span id="xdx_905_eus-gaap--OperatingLeaseExpense_pn5n6_c20230101__20231231_zeWin1E1j6S2" title="Operating lease liabilities"&gt;1.2 &lt;/span&gt;million for the years ended December
31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgxclDHvdVR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments and obligations, which do not include short-term leases, related to the Company&#x2019;s operating lease liabilities
as of December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zZoR7xzYjpv7" style="display: none"&gt;SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Future minimum lease payments and obligations&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zhpptrbDid29" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0kQ_zumIRufpw2E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;853&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0kQ_ztQolLdnqQ2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPz0kQ_zklCTUsrdfl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;807&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPz0kQ_zHitQCfr4kd9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPz0kQ_zfwSYH0S5kUb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPz0kQ_ziwWsTMaOfIg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;834&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0kQ_zJifI0OSsI41" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,967&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zea4xJ417NWc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;882&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zki4bC6ZxUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zTmBF6APUW41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average remaining term of the Company&#x2019;s operating leases was &lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20241231_z9H7wjg1Xgw7" title="Weighted average remaining term"&gt;60&lt;/span&gt; months and the weighted-average discount rate used to
measure the present value of the Company&#x2019;s operating lease liabilities was &lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_z3pMWvZrE9Pb" title="Weighted average discount rate"&gt;7.0&lt;/span&gt;% as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company received $&lt;span id="xdx_907_eus-gaap--SubleaseIncome_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SubLeaseAgreementMember_zjQLwXKxKgbl" title="Sublease income"&gt;0.6&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--SubleaseIncome_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SubLeaseAgreementMember_zhbWC7MpIEbc" title="Sublease income"&gt;0.5&lt;/span&gt; million during the years ended December 31, 2024 and 2023, respectively, of sublease income which
is recorded in other income on the consolidated statements of operations and comprehensive loss. Future cash receipts from the Company&#x2019;s
sublease agreements as of December 31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_zwqVEJqs2Nh3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zKmqxz9XUW8b" style="display: none"&gt;SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zjtUtumCZmt9" style="font-weight: bold; text-align: center"&gt;Operating&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Future cash receipts&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Subleases&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_iI_pn3n3_maFCRFOzUBz_zkr9S0A8Ga6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left; padding-bottom: 1pt"&gt;2025&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;485&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--FutureCashReceiptsFromOperatingSublease_iTI_pn3n3_mtFCRFOzUBz_zE0u317Rznzh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total future cash receipts&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zF1ZDeYLOXTi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2024-12-31_custom_LeaseAgreementMember"
      decimals="INF"
      id="Fact001017"
      unitRef="sqft">16566</us-gaap:AreaOfLand>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001019"
      unitRef="USD">300000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001021"
      unitRef="USD">1500000</us-gaap:OperatingLeasePayments>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="From2023-01-012023-12-31_custom_OfficeSpaceOneMember"
      decimals="-5"
      id="Fact001023"
      unitRef="USD">1100000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:AreaOfLand
      contextRef="AsOf2023-12-31_custom_OfficeSpaceTwoMember"
      decimals="INF"
      id="Fact001025"
      unitRef="sqft">14032</us-gaap:AreaOfLand>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31_custom_OfficeSpaceTwoMember"
      decimals="-5"
      id="Fact001027"
      unitRef="USD">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31_custom_OfficeSpaceTwoMember"
      decimals="-5"
      id="Fact001029"
      unitRef="USD">400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubleaseIncome
      contextRef="From2024-01-012024-12-31_custom_SeptemberTwoThouandTwentyFiveMember"
      decimals="-5"
      id="Fact001031"
      unitRef="USD">500000</us-gaap:SubleaseIncome>
    <ABEO:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001033">&lt;p id="xdx_896_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zHqncXgOgfI8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the Company&#x2019;s operating lease liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zSXKYa6qpv1a" style="display: none"&gt;SUMMARY OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zywhxeVoY6Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_zExrjeakqDU7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzJ5e_zzftb7jKYr4i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Current operating lease liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzJ5e_z3ptF5BnuDR1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Non-current operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,262&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,402&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzJ5e_zbEYM6NwI84k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ABEO:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001035"
      unitRef="USD">823000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001036"
      unitRef="USD">998000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001038"
      unitRef="USD">3262000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001039"
      unitRef="USD">4402000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001041"
      unitRef="USD">4085000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001042"
      unitRef="USD">5400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001044">&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zLO5vmxyZoff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the components of lease costs and rent (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zAqOuKsMyG1i" style="display: none"&gt;SCHEDULE OF COMPONENTS OF LEASE COST&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zPbyK4BgezUg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zEe20696qzHk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_maLCzRlC_zexGgZSlOph4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--VariableLeaseCost_pn3n3_maLCzRlC_zOknanic4gh8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzRlC_zWFA1AtjKpJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Short-term lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;49&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;63&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LeaseCost_iT_pn3n3_mtLCzRlC_zTZu4St3ZdOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,717&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,810&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001046"
      unitRef="USD">1288000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001047"
      unitRef="USD">1389000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001049"
      unitRef="USD">380000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001050"
      unitRef="USD">358000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001052"
      unitRef="USD">49000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001053"
      unitRef="USD">63000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001055"
      unitRef="USD">1717000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001056"
      unitRef="USD">1810000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001058"
      unitRef="USD">1300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001060"
      unitRef="USD">1200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001062">&lt;p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zgxclDHvdVR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments and obligations, which do not include short-term leases, related to the Company&#x2019;s operating lease liabilities
as of December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zZoR7xzYjpv7" style="display: none"&gt;SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Future minimum lease payments and obligations&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zhpptrbDid29" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0kQ_zumIRufpw2E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;853&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0kQ_ztQolLdnqQ2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPz0kQ_zklCTUsrdfl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;807&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPz0kQ_zHitQCfr4kd9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPz0kQ_zfwSYH0S5kUb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPz0kQ_ziwWsTMaOfIg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;834&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0kQ_zJifI0OSsI41" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,967&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zea4xJ417NWc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;882&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zki4bC6ZxUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001064"
      unitRef="USD">853000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001066"
      unitRef="USD">791000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001068"
      unitRef="USD">807000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001070"
      unitRef="USD">823000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001072"
      unitRef="USD">859000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001074"
      unitRef="USD">834000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001076"
      unitRef="USD">4967000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001078"
      unitRef="USD">882000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001080"
      unitRef="USD">4085000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact001082">P60M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001084"
      unitRef="Pure">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:SubleaseIncome
      contextRef="From2024-01-012024-12-31_custom_SubLeaseAgreementMember"
      decimals="-5"
      id="Fact001086"
      unitRef="USD">600000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="From2023-01-012023-12-31_custom_SubLeaseAgreementMember"
      decimals="-5"
      id="Fact001088"
      unitRef="USD">500000</us-gaap:SubleaseIncome>
    <ABEO:ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001090">&lt;p id="xdx_892_ecustom--ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock_zwqVEJqs2Nh3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zKmqxz9XUW8b" style="display: none"&gt;SCHEDULE OF FUTURE CASH RECEIPTS FROM OPERATING SUBLEASE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zjtUtumCZmt9" style="font-weight: bold; text-align: center"&gt;Operating&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Future cash receipts&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Subleases&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths_iI_pn3n3_maFCRFOzUBz_zkr9S0A8Ga6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left; padding-bottom: 1pt"&gt;2025&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;485&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--FutureCashReceiptsFromOperatingSublease_iTI_pn3n3_mtFCRFOzUBz_zE0u317Rznzh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total future cash receipts&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ABEO:ScheduleOfFutureCashReceiptsFromOperatingSubleaseTableTextBlock>
    <ABEO:FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001092"
      unitRef="USD">485000</ABEO:FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths>
    <ABEO:FutureCashReceiptsFromOperatingSublease
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001094"
      unitRef="USD">485000</ABEO:FutureCashReceiptsFromOperatingSublease>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001096">&lt;p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zCrJ4FSNwwmj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_82D_zlAaFcgYdmoh"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zyxxvjuPhWjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the Company&#x2019;s debt, net of debt issuance costs and discounts (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zqffGlfH4Sgl" style="display: none"&gt;SCHEDULE
OF DEBT AND NET OF DEBT ISSUANCE COSTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zoYDkBwaIEwi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zbywQZHxVMrc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_maLTDzr8F_zP3IwhDVIyIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Loan Agreement Principal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AccretedFinalPaymentFee_iI_pn3n3_maLTDzr8F_zjXiZ8Qtzehg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accreted final payment fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1104"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTDzr8F_zre8cPV9mPbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Unamortized debt issuance costs and discounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,391&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzr8F_mtLTDNzuex_zf2GAldghadl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total long-term debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1110"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebtCurrent_iI_pn3n3_maLTDNzuex_z0qFJMsDr0Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,926&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_maLTDNzuex_zXEECTBoo7Sd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Long-term debt, net of current maturities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,037&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zIwKylnKLWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loan
and Security Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 8, 2024 (the &#x201c;Closing Date&#x201d;), the Company entered into a Loan and Security Agreement, as supplemented by a Supplement,
dated as of January 8, 2024 (collectively, the &#x201c;Loan Agreement&#x201d;) with Avenue Venture Opportunities Fund, L.P., a Delaware
limited partnership, as administrative agent and collateral agent (&#x201c;Avenue&#x201d; and the &#x201c;Agent&#x201d;) and Avenue Venture
Opportunities Fund II, L.P., a Delaware limited partnership (&#x201c;Avenue 2&#x201d; and, together with Avenue, the &#x201c;Lenders&#x201d;).
The Loan Agreement provides for senior secured term loans (the &#x201c;Loans&#x201d;) in an aggregate principal amount up to $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zqppfvuO7xT7" title="Aggregate principal amount"&gt;50&lt;/span&gt; million,
with (i) a committed tranche of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember_zYpwadigIBb8" title="Aggregate principal amount"&gt;20&lt;/span&gt; million advanced on the Closing Date (&#x201c;Tranche 1&#x201d;), (ii) a committed tranche of up to
$&lt;span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheTwoMember_zWyRo3ErNvL3" title="Aggregate principal amount"&gt;10&lt;/span&gt; million which may be advanced upon the request of the Company between June 30, 2024 and September 30, 2024, subject to the Company
obtaining FDA approval of pz-cel in recessive dystrophic epidermolysis bullosa, with the issuance of a Priority Review Voucher (&#x201c;Tranche
2&#x201d;), and (iii) a discretionary tranche of up to $&lt;span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--DiscretionaryTrancheMember_zlkrfmmzjFe6" title="Aggregate principal amount"&gt;20&lt;/span&gt; million which may be advanced between March 31, 2025 and March 31, 2026 (the
&#x201c;Discretionary Tranche&#x201d;) provided at the discretion of the Lenders. The Loans are due and payable on July 1, 2027 (the &#x201c;Maturity
Date&#x201d;). As of December 31, 2024, the Tranche 2 is no longer available as the Company did not meet the Tranche 2 criteria.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
loan principal is repayable in equal monthly installments beginning on May 1, 2025. The Loans bear interest at a rate per annum (subject
to increase during an event of default) equal to the greater of (i) the prime rate, as published by the Wall Street Journal from time
to time, plus &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250501__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__srt--RangeAxis__srt--MinimumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zatbGoC3Xkj5" title="Prime rate percentage"&gt;5.00&lt;/span&gt;% and (ii) &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250501__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zn7RFH12AA3f" title="Prime rate percentage"&gt;13.50&lt;/span&gt;%. The stated interest rate and effective interest rate as of December 31, 2024 was &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z7gSZs89oRql" title="Stated interest rate"&gt;13.50&lt;/span&gt;% and &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zJ8Lau6PXYKf" title="Effective interest rate"&gt;22.09&lt;/span&gt;%,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may, subject to certain parameters, voluntarily prepay the Loans, in whole, at any time. If prepayment occurs on or before the
one-year anniversary of the Closing Date, &lt;span id="xdx_900_eus-gaap--PropertyManagementFeePercentFeeDescription_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zMsKEvCer466" title="Percentage fee, description"&gt;the Company is required to pay a prepayment fee equal to 3.00% of the principal amount of the
Loans prepaid; if prepayment occurs after the one-year anniversary of the Closing Date and on or before the two-year anniversary of the
Closing Date, the Company is required to pay a fee equal to 2.00% of the principal amount of the Loans&#x37e; if prepayment occurs after
the two-year anniversary of the Closing Date, the Company is required to pay a fee equal to 1.00% of the principal amount of the Loans.
A final payment fee of 5.00% of the principal amount of the funded Tranche 1, Tranche 2 Loans and Discretionary Tranche Loans is also
due upon the Maturity Date or any earlier date of prepayment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s obligations under the Loan Agreement are secured by a pledge of substantially all of the Company&#x2019;s assets. Pursuant
to the Loan Agreement, the Company is subject to a financial covenant requiring the Company to maintain at all times $&lt;span id="xdx_90B_eus-gaap--InvestmentsAndCash_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z7I5JaLR6y6c" title="Unrestricted cash"&gt;5&lt;/span&gt; million in unrestricted
cash. The Loan Agreement also contains affirmative and negative covenants customary for financings of this type that, among other things,
limit the ability of the Company and its subsidiaries to (i) incur additional debt, guarantees or liens&#x37e; (ii) pay dividends&#x37e;
(iii) enter into certain change of control transactions&#x37e; (iv) sell, transfer, lease, license, or otherwise dispose of certain assets&#x37e;
(v) make certain investments or loans&#x37e; and (vi) engage in certain transactions with related persons, in each case, subject to certain
exceptions. The Loan Agreement also includes events of default customary for financings of this type, in certain cases subject to customary
periods to cure, following which the Agent may accelerate all amounts outstanding under the Loans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Supplement to the Loan and Security Agreement, Avenue also has the right to convert up to $&lt;span id="xdx_901_eus-gaap--PrincipalAmountOutstandingOnLoansManagedAndSecuritized_iI_pn6n6_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z9yWtGaIpDGh" title="Outstanding principal amount of loan"&gt;3&lt;/span&gt; million of the outstanding principal
of the Loans into shares of Company common stock (the &#x201c;Conversion Right&#x201d;) at a price per share equal to 120% of the exercise
price of the Warrants (further discussed below) at any time while the Loans are outstanding, subject to certain terms and conditions,
including ownership limitations. The Conversion Right required bifurcation as certain adjustments to the conversion price were not indexed
to the Company&#x2019;s own stock and therefore the Conversion Right was recorded as a derivative liability. On January 8, 2024, the Conversion
Right was recorded at the closing date fair value of $&lt;span id="xdx_90A_ecustom--FairValueOfConversionRight_pn5n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zR8WcZwyW0Tl" title="Fair value of conversion right"&gt;0.8&lt;/span&gt; million which was based on a Monte Carlo simulation model. The derivative liability
is remeasured at each reporting period with the change in fair value recorded to change in fair value of warrants and derivative liabilities
in the condensed consolidated statement of operations until the derivative is exercised, expired, reclassified, or otherwise settled.
On September 30, 2024, pursuant to the Loan Agreement, the conversion price was fixed at $&lt;span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zezejV664V1a" title="Conversion Price"&gt;4.88&lt;/span&gt; and is considered indexed to the Company&#x2019;s
own stock. At September 30, 2024, the Conversion Right no longer met the criteria of a derivative liability and the derivative liability
of $&lt;span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240930__20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z3xJlAyrWfof" title="DerivativeLiabilities"&gt;1.1&lt;/span&gt; million was reclassified to equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, subject to applicable law and specified provisions set forth in the Supplement to the Loan and Security Agreement and solely
to the extent permitted under applicable stock exchange rules without requiring stockholder approval, the Lenders may participate in
certain equity financing transactions of the Company in an aggregate amount of up to $&lt;span id="xdx_901_eus-gaap--DebtInstrumentIssuedPrincipal_pn6n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zbWhotfeXAD5" title="Aggregate transaction amount"&gt;1&lt;/span&gt; million on the same terms, conditions and pricing
offered by the Company to other investors participating in such financing transactions (such right, the &#x201c;Participation Right&#x201d;).
&lt;span id="xdx_902_ecustom--ParticipationRightDescription_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zbbR5F4TEkg6" title="Participation right description"&gt;The Participation Right automatically terminates upon the earliest of (i) July 1, 2027, (ii) such time that the Lenders have purchased
$1 million of the Company&#x2019;s equity securities in the aggregate pursuant to the Participation Right, and (iii) the repayment in
full of all of the obligations under the Loan Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date and pursuant to the funding of Tranche 1 of the Loan Agreement, the Company issued to each of Avenue and Avenue 2 (collectively,
the &#x201c;Warrant Holders&#x201d;) warrants to purchase up to $&lt;span id="xdx_90F_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueMember_zvWhcCBUEKW2" title="Warrants purchase amount"&gt;480,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--VestingAxis__custom--TrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueTwoMember_zRHkPHHoHMz1" title="Warrants purchase amount"&gt;1,920,000&lt;/span&gt; of Company common stock, respectively which is
more fully described in Note 10 below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z3D0xIpWowBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
future payment obligations of the principal are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z5c7uFcASU82" style="display: none"&gt;SCHEDULE
OF FUTURE PAYMENT OBLIGATIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20241231_zx7SiEVbuXuh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzeHi_z2frBGi0rYNc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,926&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzeHi_znqqtiYjHVsi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzeHi_zzIIExoKjtm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzeHi_zSiEbNNpn9qg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total principal&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zXCTZC60DKdh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001098">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zyxxvjuPhWjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the Company&#x2019;s debt, net of debt issuance costs and discounts (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zqffGlfH4Sgl" style="display: none"&gt;SCHEDULE
OF DEBT AND NET OF DEBT ISSUANCE COSTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zoYDkBwaIEwi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zbywQZHxVMrc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_maLTDzr8F_zP3IwhDVIyIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Loan Agreement Principal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AccretedFinalPaymentFee_iI_pn3n3_maLTDzr8F_zjXiZ8Qtzehg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accreted final payment fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1104"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTDzr8F_zre8cPV9mPbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Unamortized debt issuance costs and discounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,391&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzr8F_mtLTDNzuex_zf2GAldghadl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total long-term debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1110"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebtCurrent_iI_pn3n3_maLTDNzuex_z0qFJMsDr0Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,926&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_maLTDNzuex_zXEECTBoo7Sd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Long-term debt, net of current maturities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,037&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001100"
      unitRef="USD">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <ABEO:AccretedFinalPaymentFee
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001103"
      unitRef="USD">354000</ABEO:AccretedFinalPaymentFee>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001106"
      unitRef="USD">1391000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001109"
      unitRef="USD">18963000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001112"
      unitRef="USD">5926000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001115"
      unitRef="USD">13037000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember"
      decimals="-6"
      id="Fact001118"
      unitRef="USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember"
      decimals="-6"
      id="Fact001120"
      unitRef="USD">20000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheTwoMember"
      decimals="-6"
      id="Fact001122"
      unitRef="USD">10000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_DiscretionaryTrancheMember"
      decimals="-6"
      id="Fact001124"
      unitRef="USD">20000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-05-01_custom_LoanAndSecurityAgreementMember_srt_MinimumMember_srt_ScenarioForecastMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Pure">0.0500</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-05-01_custom_LoanAndSecurityAgreementMember_srt_MaximumMember_srt_ScenarioForecastMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Pure">0.1350</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001130"
      unitRef="Pure">0.1350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-12-31_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001132"
      unitRef="Pure">0.2209</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:PropertyManagementFeePercentFeeDescription
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember"
      id="Fact001134">the Company is required to pay a prepayment fee equal to 3.00% of the principal amount of the
Loans prepaid; if prepayment occurs after the one-year anniversary of the Closing Date and on or before the two-year anniversary of the
Closing Date, the Company is required to pay a fee equal to 2.00% of the principal amount of the Loans&#x37e; if prepayment occurs after
the two-year anniversary of the Closing Date, the Company is required to pay a fee equal to 1.00% of the principal amount of the Loans.
A final payment fee of 5.00% of the principal amount of the funded Tranche 1, Tranche 2 Loans and Discretionary Tranche Loans is also
due upon the Maturity Date or any earlier date of prepayment.</us-gaap:PropertyManagementFeePercentFeeDescription>
    <us-gaap:InvestmentsAndCash
      contextRef="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember"
      decimals="-6"
      id="Fact001136"
      unitRef="USD">5000000</us-gaap:InvestmentsAndCash>
    <us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized
      contextRef="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember"
      decimals="-6"
      id="Fact001138"
      unitRef="USD">3000000</us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized>
    <ABEO:FairValueOfConversionRight
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember"
      decimals="-5"
      id="Fact001140"
      unitRef="USD">800000</ABEO:FairValueOfConversionRight>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-09-30_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001142"
      unitRef="USDPShares">4.88</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-09-302024-09-30_custom_LoanAndSecurityAgreementMember"
      decimals="-5"
      id="Fact001144"
      unitRef="USD">1100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember"
      decimals="-6"
      id="Fact001146"
      unitRef="USD">1000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <ABEO:ParticipationRightDescription
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember"
      id="Fact001148">The Participation Right automatically terminates upon the earliest of (i) July 1, 2027, (ii) such time that the Lenders have purchased
$1 million of the Company&#x2019;s equity securities in the aggregate pursuant to the Participation Right, and (iii) the repayment in
full of all of the obligations under the Loan Agreement.</ABEO:ParticipationRightDescription>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember_us-gaap_WarrantMember_custom_AvenueMember"
      decimals="0"
      id="Fact001150"
      unitRef="USD">480000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_custom_TrancheOneMember_us-gaap_WarrantMember_custom_AvenueTwoMember"
      decimals="0"
      id="Fact001152"
      unitRef="USD">1920000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001154">&lt;p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z3D0xIpWowBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
future payment obligations of the principal are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z5c7uFcASU82" style="display: none"&gt;SCHEDULE
OF FUTURE PAYMENT OBLIGATIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20241231_zx7SiEVbuXuh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzeHi_z2frBGi0rYNc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,926&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzeHi_znqqtiYjHVsi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzeHi_zzIIExoKjtm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzeHi_zSiEbNNpn9qg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total principal&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001156"
      unitRef="USD">5926000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001158"
      unitRef="USD">8889000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001160"
      unitRef="USD">5185000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001162"
      unitRef="USD">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001164">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zCVPMtLTbta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_82A_zlJlVAVUbTyd"&gt;EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate number of authorized shares of the Company&#x2019;s preferred stock is &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zqGTzgMupP1j" title="Preferred stock shares authorized"&gt;2,000,000&lt;/span&gt; shares with a par value of one cent ($&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_z1EfIEquYOj6" title="Preferred stock par value"&gt;0.01&lt;/span&gt;).
There is &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_zVZ1MdJYcLWk" title="Preferred stock shares outstanding"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zNo35nZLxPWe" title="Preferred stock shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; preferred stock outstanding as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock and Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Public
Offerings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 21, 2021, the Company closed an underwritten public offering of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211220__20211221_zjw7Yp9fdStg" title="Stock issued at public offerings"&gt;1,788,000&lt;/span&gt; shares of common stock at a public offering price
of $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20211221_zwvluIKHsDM4" title="Public offering price"&gt;9.75&lt;/span&gt; per share and stock purchase warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211221_z3M37BwmFEpl" title="Warrants issued to purchase of common stock"&gt;1,788,000&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211221_zkcdddGKi18a" title="Exercise price"&gt;9.75&lt;/span&gt;. The net proceeds
to the Company were $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20211220__20211221_zWAxVjCnQQz7" title="Proceeds from public offering"&gt;16.0&lt;/span&gt; million, after deducting $&lt;span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20211220__20211221_zCAUpgS3UTJf" title="Payments of underwriting discounts and comissions"&gt;1.5&lt;/span&gt; million of underwriting discounts and commissions and offering expenses payable
by the Company. The net proceeds were allocated to the warrant liability as noted below with the remainder of $&lt;span id="xdx_901_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_pn5n6_c20211221_zjwrYIPQvTAe" title="Additional paid-in capital"&gt;7.0&lt;/span&gt; million recorded in
common stock and additional paid-in capital. In the event of certain fundamental transactions involving the Company, the holders of the
stock purchase warrants may require the Company to make a payment based on a Black-Scholes valuation, using specific inputs that are
not considered indexed to the Company&#x2019;s stock in accordance with ASC 815, &lt;i&gt;Derivatives and Hed&lt;/i&gt;ging (&#x201c;ASC 815&#x201d;).
Therefore, the Company accounted for the stock purchase warrants as liabilities, which were recorded at the closing date fair value of
$&lt;span id="xdx_905_ecustom--FairValueWarrantLiabilities_iI_pn5n6_c20211221_zVYP1L1dRUJ4" title="Warrant liabilities"&gt;9.0&lt;/span&gt; million which was based on a Black-Scholes option pricing model. The remainder of the proceeds were allocated to common stock issued
and recorded as a component of equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there were &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_z8s0KDpPVvMf" title="Warrants outstanding"&gt;1,788,000&lt;/span&gt; stock purchase warrants outstanding related to this public offering. These stock purchase
warrants expire on &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyOnePublicOfferingWarrantsMember_zukbOeXQH48g" title="Warrants maturity date"&gt;December 21, 2026&lt;/span&gt;. During such time as each warrant is outstanding, the holder of the warrant is entitled to participate
in any dividends or other distribution of assets to holders of shares of common stock. There was no warrant activity during the year
ended December 31, 2024 and 2023, other than the change in fair value of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 7, 2024, the Company sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRE2lSf75jQ8" title="Shares issued"&gt;12,285,056&lt;/span&gt; shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zke0RyAPzJx7" title="Warrants exercised"&gt;6,142,656&lt;/span&gt;
shares of its common stock (the &#x201c;2024 Pre-Funded Warrants&#x201d;), for an aggregate purchase price of $&lt;span id="xdx_90B_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zIcRx29qLss9" title="Purchase price of common stock"&gt;75.0&lt;/span&gt; million gross, or $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240507__20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_z3kYUcC4eht" title="Shares issuance costs"&gt;70.2&lt;/span&gt;
million net of related costs. The offering price for each share of common stock was $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjR3yBKwgaVi" title="Offering price"&gt;4.07&lt;/span&gt;, and the offering price for the 2024 Pre-Funded
Warrants was $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zeptkaw6Prn4" title="Offering price"&gt;4.0699&lt;/span&gt;, which represents the per share offering price for the Company&#x2019;s common stock less a $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zV8rGhpMo7q" title="Exercise price"&gt;0.0001 &lt;/span&gt;per share exercise
price for each 2024 Pre-Funded Warrant. The 2024 Pre-Funded Warrants are immediately exercisable at a nominal exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240507__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_ziZ0KaaK36td" title="Exercise price"&gt;0.0001&lt;/span&gt;
per share and may be exercised at any time until the pre-funded warrants are exercised in full. On June 24, 2024, &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240624__20240624__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zaFiM6mfNPP5" title="Warrants exercised"&gt;700,000&lt;/span&gt; of the 2024
Pre-Funded Warrants were exercised and on December 2, 2024 &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241202__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zINMLwQIJzpc" title="Warrants outstanding"&gt;1,228,531&lt;/span&gt; of the 2024 Pre-Funded Warrants were exercised, leaving &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourPreFundedWarrantsMember_zw9yyqqZxMQl" title="Warrants outstanding"&gt;4,214,125&lt;/span&gt;
2024 Pre-Funded Warrants outstanding as of December 31, 2024. The 2024 Pre-Funded Warrants are classified as equity in accordance with
ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, given the prefunded warrants are indexed to the Company&#x2019;s own shares of common stock and
meet the requirements to be classified in equity. The 2024 Pre-Funded warrants were recorded at their relative fair value at issuance
in the stockholders&#x2019; equity section of the consolidated balance sheet and the 2024 Pre-Funded Warrants are considered outstanding
shares in the basic and diluted earnings per share calculation for year ended December 31, 2024 given their nominal exercise price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Open
Market Sale Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 17, 2018, the Company entered into an open market sale agreement (as amended, the &#x201c;ATM Agreement&#x201d;) with Jefferies
LLC (&#x201c;Jefferies&#x201d;) pursuant to which, the Company may sell from time to time, through Jefferies, shares of its common stock
for an aggregate sales price of up to $&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20180816__20180817__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zam0q7cpvpj5" title="Aggregate sale price"&gt;75.0&lt;/span&gt; million. Any sales of shares pursuant to this agreement are made under the Company&#x2019;s
effective &#x201c;shelf&#x201d; registration statement on Form S-3 that is on file with and has been declared effective by the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company sold &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zsMBx08QVUfe" title="Company sold shares of its common stock"&gt;2,825,954&lt;/span&gt; and &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zGpGLkm34eBh" title="Company sold shares of its common stock"&gt;3,659,882&lt;/span&gt; shares of its common stock under the ATM Agreement during the years ended December 31, 2024 and
2023, respectively, resulting in net proceeds of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zSCuJIGfyE5c" title="Net proceeds"&gt;15.5&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementsMember__dei--LegalEntityAxis__custom--JefferiesLlcMember_zAgC0z4vuAGg" title="Sale of stock value"&gt;14.4&lt;/span&gt; million during the years ended December 31, 2024 and 2023, respectively.
Subsequent to December 31, 2024 and through March 1, 2025, the Company sold &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zIlbPWTNkb4k" title="Shares issued"&gt;915,925&lt;/span&gt; shares of its common stock under the ATM Agreement resulting
in $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zPU6sDrmxWZi" title="value issued"&gt;4.8&lt;/span&gt; million in net proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Private
Placement Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 3, 2022, the Company sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zZ3TywXhELhf" title="Shares issued"&gt;7,065,946&lt;/span&gt; shares of its common stock, and in lieu of shares of common stock, pre-funded warrants exercisable
for &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zPmlZaJSfoNk" title="Warrants exercised"&gt;543,933&lt;/span&gt; shares of common stock and accompanying warrants to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z7kOqsTnGKbh" title="Warrants purchase, shares"&gt;7,609,879&lt;/span&gt; shares of its common stock to a group of new and existing
institutional investors in a private placement. The offering price for each share of common stock and accompanying warrant was $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockAndAccompanyingWarrantMember_zGpIDJRFyF0j" title="Offering price"&gt;4.60&lt;/span&gt;,
and the offering price for each pre-funded warrant and accompanying warrant was $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantAndAccompanyingWarrantMember_zfqCXs7rhonh" title="Offering price"&gt;4.59&lt;/span&gt;, which equaled the offering price per share of
the common stock and accompanying warrant, less the $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zAHTjz4dh2Me" title="Offering price"&gt;0.01&lt;/span&gt; per share exercise price of each pre-funded warrant. Each accompanying warrant
represents the right to purchase one share of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_z9sEpZUOlgw3" title="Exercise price"&gt;4.75&lt;/span&gt; per share of common stock.
The pre-funded warrants were exercised in December 2022 and converted to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20221201__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zzXuOgDdkkG9" title="Warrants exercised"&gt;543,933&lt;/span&gt; shares of commons stock. Total shares sold and converted
during the year ended December 31, 2022 were &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z5vPksdnpo3c" title="Sale of stock"&gt;7,609,879&lt;/span&gt; for an aggregate purchase price of $&lt;span id="xdx_901_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zBYNNhBHJaC9" title="Purchase price of common stock"&gt;35.0 &lt;/span&gt;million gross, or $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zjidxjHA91Uh" title="Proceeds from issuance of common stock"&gt;32.6&lt;/span&gt; million net of
related costs of $&lt;span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zZaMF9BVLCR6" title="Stock issuance costs"&gt;1.5&lt;/span&gt; million which was expensed to general and administrative expenses and $&lt;span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pn5n6_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zaCQU5YOeAb4" title="Additional paid in capital stock reduction"&gt;0.9 &lt;/span&gt;million which was recorded as a reduction
to additional paid-in-capital. The net proceeds were allocated to the warrant liability as noted below with the remainder of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_z9RbapXKbp89" title="Proceeds from warrant liability'"&gt;12.9&lt;/span&gt; million
and $&lt;span id="xdx_900_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_pn5n6_c20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_ztSBdSUrKxTk" title="Additional paid-in capital"&gt;0.1&lt;/span&gt; million recorded in additional paid-in capital and common stock, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the event of certain fundamental transactions involving the Company, the holders of the stock purchase warrants may require the Company
to make a payment based on a Black-Scholes valuation, using specific inputs that are not considered indexed to the Company&#x2019;s stock
in accordance with ASC 815. Therefore, the Company is accounting for the stock purchase warrants as liabilities. On November 3, 2022,
the stock purchase warrants were recorded at the closing date fair value of $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20221102__20221103__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zmZ2nvQWucP6" title="Fair value of warrants"&gt;22.0&lt;/span&gt; million which was based on a Black-Scholes option pricing
model. The remainder of the proceeds were allocated to common stock issued and recorded as a component of equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there were &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementOfferingsMember_zpEztix7VBx" title="Warrant outstanding"&gt;7,609,879&lt;/span&gt; warrants outstanding related to this private placement offering. The warrants expire on November
3, 2027. During such time as each warrant is outstanding, the holder of the warrant is entitled to participate in any dividends or other
distribution of assets to holders of shares of common stock. There was no warrant activity during the year ended December 31, 2024 and
2023, other than the change in fair value of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Direct
Placement Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 6, 2023, the Company sold &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwOMkhcsXxrk" title="Shares issued"&gt;3,284,407&lt;/span&gt; shares of its common stock, and in lieu of shares of common stock, pre-funded warrants exercisable
for &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_z5pniHJteYWa" title="Warrants exercised"&gt;2,919,140&lt;/span&gt; shares of common stock (the &#x201c;2023 Pre-Funded Warrants&#x201d;), to a group of existing institutional investors for
an aggregate purchase price of $&lt;span id="xdx_907_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zycai40UA0Ch" title="Purchase price of common stock"&gt;25.0&lt;/span&gt; million gross, or $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230706__20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zhYYni0HVDo" title="Shares issuance costs"&gt;23.0&lt;/span&gt; million net of related costs. The offering price for each share of common
stock was $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD2JW35X3VNj" title="Offering price"&gt;4.03&lt;/span&gt;, and the offering price for the 2023 Pre-Funded Warrants was $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zIBxzy2TpIa9" title="Offering price"&gt;4.0299&lt;/span&gt;, which represents the per share offering price for
the Company&#x2019;s common stock less a $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zr1ChDX8xH7a" title="Exercise price"&gt;0.0001 &lt;/span&gt;per share exercise price for each such 2023 Pre-Funded Warrant. The 2023 Pre-Funded Warrants
are immediately exercisable at a nominal exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230706__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_znEqPkaogfaf" title="Exercise price"&gt;0.0001&lt;/span&gt; per share, may be exercised at any time and do not have an expiration
date. On May 9, 2024, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240509__20240509__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zbRS7ESYk3xk" title="Warrants exercised"&gt;300,000&lt;/span&gt; of the 2023 Pre-Funded Warrants were exercised, leaving &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePreFundedWarrantsMember_zXiAfdIQ7qTd" title="Warrants outstanding"&gt;2,619,140&lt;/span&gt; 2023 Pre-Funded Warrants outstanding
as of December 31, 2024. The 2023 Pre-Funded Warrants are classified as equity in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;,
given the 2023 Pre-Funded Warrants are indexed to the Company&#x2019;s own shares of common stock and meet the requirements to be classified
in equity. The 2023 Pre-Funded Warrants were recorded at their relative fair value at issuance in the stockholders&#x2019; equity section
of the consolidated balance sheet and the 2023 Pre-Funded Warrants are considered outstanding shares in the basic and diluted earnings
per share calculation for the year ended December 31, 2024 given their nominal exercise price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Warrants related to the Loan and Security Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 8, 2024, in connection with entering into the Loan and Security Agreement, the Company issued to each of Avenue and Avenue 2
(collectively, the &#x201c;Warrant Holders&#x201d;) warrants to purchase up to $&lt;span id="xdx_902_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueMember_ztveWeRlMpr3" title="Warrants purchase amount"&gt;480,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--PaymentsForRepurchaseOfWarrants_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AvenueTwoMember_z5A8pnbCdpx" title="Warrants purchase amount"&gt;1,920,000&lt;/span&gt; worth of shares, respectively, of
Company common stock (collectively, the &#x201c;January Warrants&#x201d;). The Warrants expire on January 8, 2029 (the &#x201c;Expiration
Date&#x201d;) and upon issuance, had an exercise price per share equal to the lesser of (i) $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zLu9wM0xfHse" title="Warrants exercise price"&gt;4.75&lt;/span&gt; and (ii) the price per share of the
Company&#x2019;s next bona fide round of equity financing before September 30, 2024 in which the Company sells or issues shares of its
common stock, excluding certain excluded issuances as defined in the Supplement. In connection with the underwritten common stock offering
consummated on May 7, 2024, and pursuant to the term of the January Warrants, the exercise price of the January Warrants was reduced
to $&lt;span id="xdx_903_eus-gaap--WarrantExercisePriceDecrease_c20240507__20240507__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9M1Zhf7xe9" title="Exercise price per share"&gt;4.07&lt;/span&gt; per share for &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240507__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zi1B1wWPj0Rk" title="Shares of common stock issuable upon exercise of warrants"&gt;589,681&lt;/span&gt; shares. In addition, upon a change of control where the per share price of the Company common stock is
less than or equal to two times that of the exercise price, the Warrant Holders would be entitled to receive the shares of common stock
underlying the January Warrants without payment of the exercise price. On January 8, 2024, the January Warrants did not include an explicit
share limit and the number of shares issuable under the warrant agreements were variable based on the exercise price and therefore the
January Warrants were liability classified based on a Black-Scholes valuation in accordance with ASC 815 and were recorded at the closing
date fair value of $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240108__20240108__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zrjfEBpqJOO6" title="Fair value of warrants"&gt;0.2&lt;/span&gt; million which was based on a Black-Scholes option pricing model. On September 30, 2024, per the terms of the
January Warrants, the exercise price and the number of shares issuable became set at $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zJS4gA1xs99i" title="Warrants exercise price"&gt;4.07&lt;/span&gt; per share and &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zmQOMlAwFG8g" title="Shares of common stock issuable upon exercise of warrants"&gt;589,681&lt;/span&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Warrant Holders may exercise the January Warrants at any time, or from time to time up to and including the Expiration Date, by making
a cash payment equal to the exercise price multiplied by the quantity of shares. The Warrant Holders may also exercise the January Warrants
on a cashless basis by receiving a net number of shares calculated pursuant to the formula set forth in the January Warrants. The January
Warrants are subject to anti-dilution adjustments for stock dividends, stock splits, and reverse stock splits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001168"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001172"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-12-202021-12-21"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">1788000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-12-21"
      decimals="INF"
      id="Fact001176"
      unitRef="USDPShares">9.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-21"
      decimals="INF"
      id="Fact001178"
      unitRef="Shares">1788000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-21"
      decimals="INF"
      id="Fact001180"
      unitRef="USDPShares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-12-202021-12-21"
      decimals="-5"
      id="Fact001182"
      unitRef="USD">16000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-12-202021-12-21"
      decimals="-5"
      id="Fact001184"
      unitRef="USD">1500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2021-12-21"
      decimals="-5"
      id="Fact001186"
      unitRef="USD">7000000.0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <ABEO:FairValueWarrantLiabilities
      contextRef="AsOf2021-12-21"
      decimals="-5"
      id="Fact001188"
      unitRef="USD">9000000.0</ABEO:FairValueWarrantLiabilities>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember"
      decimals="INF"
      id="Fact001190"
      unitRef="Shares">1788000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_TwentyTwentyOnePublicOfferingWarrantsMember"
      id="Fact001192">2026-12-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-05-072024-05-07_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001194"
      unitRef="Shares">12285056</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-05-072024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001196"
      unitRef="Shares">6142656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ABEO:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2024-05-072024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="-5"
      id="Fact001198"
      unitRef="USD">75000000.0</ABEO:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-05-072024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="-5"
      id="Fact001200"
      unitRef="USD">70200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-05-07_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001202"
      unitRef="USDPShares">4.07</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001204"
      unitRef="USDPShares">4.0699</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001206"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-07_us-gaap_CommonStockMember_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001208"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-06-242024-06-24_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001210"
      unitRef="Shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-02_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001212"
      unitRef="Shares">1228531</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Shares">4214125</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2018-08-162018-08-17_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember"
      decimals="-5"
      id="Fact001216"
      unitRef="USD">75000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember"
      decimals="INF"
      id="Fact001218"
      unitRef="Shares">2825954</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-01-012023-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember"
      decimals="INF"
      id="Fact001220"
      unitRef="Shares">3659882</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-01-012024-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember"
      decimals="-5"
      id="Fact001222"
      unitRef="USD">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-01-012023-12-31_custom_OpenMarketSaleAgreementsMember_custom_JefferiesLlcMember"
      decimals="-5"
      id="Fact001224"
      unitRef="USD">14400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember"
      decimals="INF"
      id="Fact001226"
      unitRef="Shares">915925</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember"
      decimals="-5"
      id="Fact001228"
      unitRef="USD">4800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember"
      decimals="INF"
      id="Fact001230"
      unitRef="Shares">7065946</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001232"
      unitRef="Shares">543933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001234"
      unitRef="Shares">7609879</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_CommonStockAndAccompanyingWarrantMember"
      decimals="INF"
      id="Fact001236"
      unitRef="USDPShares">4.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantAndAccompanyingWarrantMember"
      decimals="INF"
      id="Fact001238"
      unitRef="USDPShares">4.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001240"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember"
      decimals="INF"
      id="Fact001242"
      unitRef="USDPShares">4.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-12-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001244"
      unitRef="Shares">543933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="INF"
      id="Fact001246"
      unitRef="Shares">7609879</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <ABEO:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="-5"
      id="Fact001248"
      unitRef="USD">35000000.0</ABEO:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="-5"
      id="Fact001250"
      unitRef="USD">32600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_PreFundedWarrantMember"
      decimals="-5"
      id="Fact001252"
      unitRef="USD">1500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="-5"
      id="Fact001254"
      unitRef="USD">900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="-5"
      id="Fact001256"
      unitRef="USD">12900000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2022-11-03_custom_PrivatePlacementOfferingsMember_custom_PreFundedWarrantMember"
      decimals="-5"
      id="Fact001258"
      unitRef="USD">100000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-11-022022-11-03_custom_PrivatePlacementOfferingsMember"
      decimals="-5"
      id="Fact001260"
      unitRef="USD">22000000.0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_PrivatePlacementOfferingsMember"
      decimals="0"
      id="Fact001262"
      unitRef="USD">7609879</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-062023-07-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001264"
      unitRef="Shares">3284407</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-07-062023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember"
      decimals="INF"
      id="Fact001266"
      unitRef="Shares">2919140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ABEO:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-062023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember"
      decimals="-5"
      id="Fact001268"
      unitRef="USD">25000000.0</ABEO:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-062023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember"
      decimals="-5"
      id="Fact001270"
      unitRef="USD">23000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharePrice
      contextRef="AsOf2023-07-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001272"
      unitRef="USDPShares">4.03</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember"
      decimals="INF"
      id="Fact001274"
      unitRef="USDPShares">4.0299</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember"
      decimals="INF"
      id="Fact001276"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-06_us-gaap_CommonStockMember_custom_TwoThousandTwentyThreePreFundedWarrantsMember"
      decimals="INF"
      id="Fact001278"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-05-092024-05-09_custom_TwoThousandTwentyThreePreFundedWarrantsMember"
      decimals="INF"
      id="Fact001280"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePreFundedWarrantsMember"
      decimals="INF"
      id="Fact001282"
      unitRef="Shares">2619140</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember_custom_AvenueMember"
      decimals="0"
      id="Fact001284"
      unitRef="USD">480000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember_custom_AvenueTwoMember"
      decimals="0"
      id="Fact001286"
      unitRef="USD">1920000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-08_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001288"
      unitRef="USDPShares">4.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2024-05-072024-05-07_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001290"
      unitRef="USDPShares">4.07</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-05-07_custom_LoanAndSecurityAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001292"
      unitRef="Shares">589681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-082024-01-08_custom_LoanAndSecurityAgreementMember"
      decimals="-5"
      id="Fact001294"
      unitRef="USD">200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-30_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001296"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-09-30_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001298"
      unitRef="Shares">589681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001300">&lt;p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zQKqSSQ65Qxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_82D_zdyuTsPb3Ud4"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company previously granted stock options under its 2005 Equity Incentive Plan (the &#x201c;2005 Incentive Plan&#x201d;), under which no
further grants can be made. In addition, prior to May 17, 2023, the Company had previously granted stock options and stock awards under
the Abeona Therapeutics Inc. 2015 Equity Incentive Plan (the &#x201c;2015 Incentive Plan&#x201d;). As of May 17, 2023, no further grants
can be made under the 2015 Incentive Plan. The Company now grants stock options and stock awards under the Abeona Therapeutics Inc. 2023
Equity Incentive Plan (the &#x201c;2023 Incentive Plan&#x201d;) which was approved by stockholders on May 17, 2023. On April 24, 2024,
stockholders approved an amendment to the 2023 Incentive Plan to increase the shares authorized for issuance from &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240424__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zMJc4DjCKfWd" title="Increase in shares authorized"&gt;1,700,000&lt;/span&gt; shares to
&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240424__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zlKFIPwmfQi8" title="Increase in shares authorized"&gt;3,200,000&lt;/span&gt; shares. On December 20, 2024, stockholders approved an additional increase in the shares authorized for issuance under the
2023 Incentive Plan from &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241220__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_z4tCmGvXUzob" title="Increase in shares authorized"&gt;3,200,000&lt;/span&gt; shares to &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241220__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zotA7lpId0x7" title="Increase in shares authorized"&gt;8,400,000&lt;/span&gt; shares. As of December 31, 2024, there were &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--InducementPlanMember_zn9XnyWOURwc" title="Shares available for grant"&gt;5,251,251&lt;/span&gt; shares available to be granted
under the 2023 Incentive Plan. In addition, in 2023, the Company&#x2019;s board of directors approved various restricted stock awards
granted to certain new hires as inducement grants. On October 10, 2023, the Company&#x2019;s board of directors approved the Abeona Therapeutics
Inc. 2023 Employment Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;). As of December 31, 2024, there were &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231_z1wEqKL4jcw3" title="Shares available for grant"&gt;584,700&lt;/span&gt;
shares available to be granted under the Inducement Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zhx79hHirrGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes stock-based compensation (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zaDyHTSQSI86" style="display: none"&gt;SCHEDULE
OF STOCK BASED COMPENSATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_z9CUCC6VF1n4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zduZHkbXbUi3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTN8oypPqUAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,561&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zq3XjoK6NBM8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,067&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,683&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_ztXtTAzvfhI5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,628&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,768&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_ziBa1OzRCu49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock
Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of each option award on the date of grant using the Black-Scholes option-pricing model. The Company
then recognize the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over
the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility &#x2013; the Company estimates the volatility of the share price at the date of grant using a &#x201c;look-back&#x201d; period
    which coincides with the expected term, defined below. The Company believes using a &#x201c;look-back&#x201d; period which coincides
    with the expected term is the most appropriate measure for determining expected volatility.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &#x2013; the Company estimates the expected term using the &#x201c;simplified&#x201d; method, as outlined in SEC Staff Accounting
    Bulletin No. 107, &#x201c;Share-Based Payment.&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate &#x2013; the Company estimates the risk-free interest rate using the U.S. Treasury yield curve for periods equal to
    the expected term of the options in effect at the time of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends
    &#x2013; the Company uses an expected dividend yield of zero because the Company has not declared nor paid a cash dividend, nor are
    there any plans to declare a dividend.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not grant any stock options in the year ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures
arise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3xd7BT9pwj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes stock option activity during the year ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z1irdfs6brwl" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
 Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt;
 Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt;
 Remaining&lt;br/&gt;
 Contractual&lt;br/&gt;
 Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt;
 Intrinsic Value &lt;br/&gt; (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zs5KKlP8Tlxh" style="width: 11%; text-align: right" title="Number of options, Outstanding balance"&gt;240,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zxhjQjuzF3wi" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding balance"&gt;37.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zoOgPUiMgYW3" title="Weighted average remaining contractual term (years), outstanding"&gt;6.42&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231_zhOuHtWkkTOh" style="width: 11%; text-align: right" title="Aggregate intrinsic value, Outstanding balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zC8vXntWN1Vb" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1335"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zTv7A8olJ1Q8" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1337"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zNZYO1nmE9i7" style="text-align: right" title="Number of options, cancelled/forfeited"&gt;(61,769&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z2OVPZwNT3Ib" style="text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;32.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zBjYOSihAHQa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zsrxxzBv3Dkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zd8UBkJQtjkk" style="text-align: right" title="Number of options, outstanding balance"&gt;179,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zcQMxsCSTkuf" style="text-align: right" title="Weighted average exercise price, outstanding balance"&gt;38.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zCGEpC2NUIj6" title="Weighted average remaining contractual term (years), outstanding"&gt;6.83&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231_zeAxJOPu9b04" style="text-align: right" title="Aggregate intrinsic value, outstanding balance"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_z7avEf4FPrid" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1355"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zihb5WU6BZde" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zoZOpr5tj9ia" style="text-align: right" title="Number of options, cancelled/forfeited"&gt;(2,414&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zpNtFtsI3sn9" style="text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;33.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_znEJE6XmoK2l" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1363"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zVTyqDs62Whh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zhWm5QnWfZD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding balance"&gt;176,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zCh0HJ8zLHDi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding balance"&gt;38.64&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziyX67aZ0Yv1" title="Weighted average remaining contractual term (years), outstanding"&gt;5.83&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231_z12PkmH0nqA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding balance"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zzr2mTlb8GN3" style="text-align: right" title="Number of options, exercisable"&gt;163,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z8WlgNDZrIw5" style="text-align: right" title="Weighted average exercise price, exercisable"&gt;39.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zmo7SlZz8WLl" title="Weighted average remaining contractual term (years), exercisable"&gt;5.77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231_zuPlORunFxj6" style="text-align: right" title="Aggregate intrinsic value, exercisable"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231_z1yXwzJVUUFg" style="text-align: right" title="Number of options, unvested"&gt;13,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231_zDmPxnahLmei" style="text-align: right" title="Weighted average exercise price, unvested"&gt;33.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zq0oV7D3YJre" title="Weighted average remaining contractual term (years), unvested"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iI_pn3n3_c20241231_zYDYjRIXaGnc" style="text-align: right" title="Aggregate intrinsic value, unvested"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z47dxooNsrNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair
value of the Company&#x2019;s common stock for those options that had exercise prices lower than the fair value of the Company&#x2019;s
common stock. As of December 31, 2024, the total compensation cost related to non-vested option awards not yet recognized was $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyKb220Q7DGk" title="Compensation cost related to non-vested options not recognized"&gt;0.3&lt;/span&gt; million
with a weighted average remaining vesting period of &lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDvC6KsTGWb9" title="Weighted average period total compensation costs related to non-vested options"&gt;0.5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_z7HjMJozkk1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there are no options outstanding under the 2005 Incentive Plan. Further information regarding options outstanding
under the 2015 Incentive Plan as of December 31, 2024 is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_zSeaet6NdvZd" style="display: none"&gt;SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Range of &lt;br/&gt;
Exercise Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
 Options&lt;br/&gt;
 Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Remaining&lt;br/&gt;
 Life In&lt;br/&gt;
 Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
 Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
 Options&lt;br/&gt;
 Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Remaining&lt;br/&gt;
 Life in&lt;br/&gt;
 Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
 Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zC3Ncovv0UH5" style="width: 9%; text-align: right" title="Range of exercise price, lower limit"&gt;4.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziZq3iXSNOGe" style="width: 9%; text-align: right" title="Range of exercise price, upper limit"&gt;22.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zM5URYCJVBzk" style="width: 9%; text-align: right" title="Number of options outstanding"&gt;20,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMvFZa0EqPoj" title="Weighted-average remaining life in years"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zfo3vcC2SwY8" style="width: 9%; text-align: right" title="Weighted-average exercise price"&gt;16.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zgLIwrVEzBFi" style="width: 9%; text-align: right" title="Number of options exercisable"&gt;15,154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zW0FR4cf1qM" title="Weighted-average remaining life in years, exercisable"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zl9EygmFbHVg" style="width: 8%; text-align: right" title="Weighted-average exercise price, exercisable"&gt;17.16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOPNC5y7xldc" style="text-align: right" title="Range of exercise price, lower limit"&gt;25.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zLBO8t9Y5Oq6" style="text-align: right" title="Range of exercise price, upper limit"&gt;47.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4Q8iB0tETZg" style="text-align: right" title="Number of options outstanding"&gt;104,279&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zudchz5beXQl" title="Weighted-average remaining life in years"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8s82GKavb05" style="text-align: right" title="Weighted-average exercise price"&gt;33.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNAFz0O5ADF8" style="text-align: right" title="Number of options exercisable"&gt;99,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zd4kfk2GTaUj" title="Weighted-average remaining life in years, exercisable"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKR6wohT8Uec" style="text-align: right" title="Weighted-average exercise price, exercisable"&gt;33.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zwoZNAivC8cb" style="text-align: right" title="Range of exercise price, lower limit"&gt;54.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztHtG4xg92H1" style="text-align: right" title="Range of exercise price, upper limit"&gt;58.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVTgnJbAWxn4" style="text-align: right" title="Number of options outstanding"&gt;52,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1swoirEi3ck" title="Weighted-average remaining life in years"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zgIQ5jY4dwg7" style="text-align: right" title="Weighted-average exercise price"&gt;56.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzgl7yQYfE4b" style="text-align: right" title="Number of options exercisable"&gt;48,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z8yLbTdpJYV5" title="Weighted-average remaining life in years, exercisable"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVxSOjWG9AKj" style="text-align: right" title="Weighted-average exercise price, exercisable"&gt;56.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWLspd65hyJ6" style="padding-bottom: 1pt; text-align: right" title="Range of exercise price, lower limit"&gt;164.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zeHg76yuS3O5" style="padding-bottom: 1pt; text-align: right" title="Range of exercise price, upper limit"&gt;183.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zQUYP1Cg4WRf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options outstanding"&gt;200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zj2SBTcyV6x8" title="Weighted-average remaining life in years"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z8a1QitP9HA1" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price"&gt;164.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBQTkGNTfDE8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options exercisable"&gt;200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z6mwY42PJ2Xk" title="Weighted-average remaining life in years, exercisable"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4AQfqqqQdm" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price, exercisable"&gt;164.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zjJHzyr57zfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding"&gt;176,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zBC76UVisnV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable"&gt;163,386&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zL79QiLuZ3Y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restricted
Stock:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zg2zn1toFKU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes restricted stock award activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zMgQXNlT6Ys9" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
Awards&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average&lt;br/&gt;
 Grant Date Fair&lt;br/&gt;
 Value Per Unit&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCtzlseGmGe5" style="width: 16%; text-align: right" title="Restricted common stock awards, balance"&gt;816,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBFXcfp2FdUb" style="width: 16%; text-align: right" title="Weighted-average grant date fair value, balance"&gt;5.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHBunrTltDJa" style="text-align: right" title="Restricted common stock awards, granted"&gt;1,958,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB9nVUIef3i7" style="text-align: right" title="Weighted-average grant date fair value, granted"&gt;3.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaOPRmWEPmNj" style="text-align: right" title="Restricted common stock awards, cancelled/forfeited"&gt;(56,398&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkhEq2bGMIUe" style="text-align: right" title="Weighted-average grant date fair value, cancelled/forfeited"&gt;4.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1G3Cm4a5qHk" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted common stock awards, vested"&gt;(270,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVybEXlOJfMi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value, vested"&gt;5.59&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zS5Ax97waVh4" style="text-align: right" title="Restricted common stock awards, balance"&gt;2,448,169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwNwtQmU6Qdb" style="text-align: right" title="Weighted-average grant date fair value, balance"&gt;4.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znUFmjRYMMdj" style="text-align: right" title="Restricted common stock awards, granted"&gt;2,065,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUkA9hlrNXFi" style="text-align: right" title="Weighted-average grant date fair value, granted"&gt;4.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXkymYkPuR88" style="text-align: right" title="Restricted common stock awards, cancelled/forfeited"&gt;(183,114&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfGvEA8kitBi" style="text-align: right" title="Weighted-average grant date fair value, cancelled/forfeited"&gt;3.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyDyzKnZEExc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted common stock awards, vested"&gt;(1,009,298&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdWv19Qb9lyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value, vested"&gt;4.64&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSyyCfIAHalb" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted common stock awards, balance"&gt;3,320,811&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zogNe2X9uHL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant date fair value, balance"&gt;4.60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zMLvF2ap3Y43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there was $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20240101__20241231_zPIIpnu6hJm6" title="Compensation cost related to restricted common stock not recognized"&gt;11.9&lt;/span&gt; million of total unrecognized compensation expense related to unvested restricted stock awards,
which is expected to be recognized over a weighted average vesting period of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231_zPozE0gtYUJk" title="Weighted average compensation costs related to restricted common stock"&gt;2.1&lt;/span&gt; years. The total fair value of restricted stock awards
that vested was $&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_pn5n6_c20240101__20241231_z4T9EzPSTshl" title="Fair value of restricted stock awards that vested"&gt;4.7&lt;/span&gt; million and $&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue_pn5n6_c20230101__20231231_zaInAj1um6Sf" title="Fair value of restricted stock awards that vested"&gt;1.5&lt;/span&gt; million during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-04-24_srt_MinimumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001302"
      unitRef="Shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-04-24_srt_MaximumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001304"
      unitRef="Shares">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-12-20_srt_MinimumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001306"
      unitRef="Shares">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-12-20_srt_MaximumMember_custom_TwoThousandTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001308"
      unitRef="Shares">8400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_InducementPlanMember"
      decimals="INF"
      id="Fact001310"
      unitRef="Shares">5251251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001312"
      unitRef="Shares">584700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001314">&lt;p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zhx79hHirrGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes stock-based compensation (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zaDyHTSQSI86" style="display: none"&gt;SCHEDULE
OF STOCK BASED COMPENSATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_z9CUCC6VF1n4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zduZHkbXbUi3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTN8oypPqUAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,561&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zq3XjoK6NBM8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,067&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,683&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_ztXtTAzvfhI5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,628&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,768&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001316"
      unitRef="USD">1561000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001317"
      unitRef="USD">1085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001319"
      unitRef="USD">5067000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001320"
      unitRef="USD">3683000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001322"
      unitRef="USD">6628000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001323"
      unitRef="USD">4768000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001325">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3xd7BT9pwj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes stock option activity during the year ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z1irdfs6brwl" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
 Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt;
 Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt;
 Remaining&lt;br/&gt;
 Contractual&lt;br/&gt;
 Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt;
 Intrinsic Value &lt;br/&gt; (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zs5KKlP8Tlxh" style="width: 11%; text-align: right" title="Number of options, Outstanding balance"&gt;240,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zxhjQjuzF3wi" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding balance"&gt;37.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zoOgPUiMgYW3" title="Weighted average remaining contractual term (years), outstanding"&gt;6.42&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231_zhOuHtWkkTOh" style="width: 11%; text-align: right" title="Aggregate intrinsic value, Outstanding balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zC8vXntWN1Vb" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1335"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zTv7A8olJ1Q8" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1337"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zNZYO1nmE9i7" style="text-align: right" title="Number of options, cancelled/forfeited"&gt;(61,769&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z2OVPZwNT3Ib" style="text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;32.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zBjYOSihAHQa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zsrxxzBv3Dkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zd8UBkJQtjkk" style="text-align: right" title="Number of options, outstanding balance"&gt;179,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zcQMxsCSTkuf" style="text-align: right" title="Weighted average exercise price, outstanding balance"&gt;38.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zCGEpC2NUIj6" title="Weighted average remaining contractual term (years), outstanding"&gt;6.83&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231_zeAxJOPu9b04" style="text-align: right" title="Aggregate intrinsic value, outstanding balance"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_z7avEf4FPrid" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1355"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zihb5WU6BZde" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zoZOpr5tj9ia" style="text-align: right" title="Number of options, cancelled/forfeited"&gt;(2,414&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zpNtFtsI3sn9" style="text-align: right" title="Weighted average exercise price, cancelled/forfeited"&gt;33.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_znEJE6XmoK2l" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1363"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zVTyqDs62Whh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zhWm5QnWfZD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding balance"&gt;176,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zCh0HJ8zLHDi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding balance"&gt;38.64&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_ziyX67aZ0Yv1" title="Weighted average remaining contractual term (years), outstanding"&gt;5.83&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231_z12PkmH0nqA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding balance"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zzr2mTlb8GN3" style="text-align: right" title="Number of options, exercisable"&gt;163,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z8WlgNDZrIw5" style="text-align: right" title="Weighted average exercise price, exercisable"&gt;39.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zmo7SlZz8WLl" title="Weighted average remaining contractual term (years), exercisable"&gt;5.77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231_zuPlORunFxj6" style="text-align: right" title="Aggregate intrinsic value, exercisable"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231_z1yXwzJVUUFg" style="text-align: right" title="Number of options, unvested"&gt;13,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231_zDmPxnahLmei" style="text-align: right" title="Weighted average exercise price, unvested"&gt;33.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zq0oV7D3YJre" title="Weighted average remaining contractual term (years), unvested"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iI_pn3n3_c20241231_zYDYjRIXaGnc" style="text-align: right" title="Aggregate intrinsic value, unvested"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001327"
      unitRef="Shares">240770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001329"
      unitRef="USDPShares">37.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31" id="Fact001331">P6Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001339"
      unitRef="Shares">61769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001341"
      unitRef="USDPShares">32.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001347"
      unitRef="Shares">179001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001349"
      unitRef="USDPShares">38.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact001351">P6Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001353"
      unitRef="USD">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001359"
      unitRef="Shares">2414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001361"
      unitRef="USDPShares">33.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001367"
      unitRef="Shares">176587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001369"
      unitRef="USDPShares">38.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact001371">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001373"
      unitRef="USD">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001375"
      unitRef="Shares">163386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001377"
      unitRef="USDPShares">39.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact001379">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001381"
      unitRef="USD">4000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001383"
      unitRef="Shares">13201</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001385"
      unitRef="USDPShares">33.29</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ABEO:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact001387">P6Y7M24D</ABEO:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1>
    <ABEO:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001389"
      unitRef="USD">2000</ABEO:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001391"
      unitRef="USD">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember31393828"
      id="Fact001393">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember"
      id="Fact001395">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_z7HjMJozkk1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there are no options outstanding under the 2005 Incentive Plan. Further information regarding options outstanding
under the 2015 Incentive Plan as of December 31, 2024 is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_zSeaet6NdvZd" style="display: none"&gt;SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Range of &lt;br/&gt;
Exercise Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
 Options&lt;br/&gt;
 Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Remaining&lt;br/&gt;
 Life In&lt;br/&gt;
 Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
 Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
 Options&lt;br/&gt;
 Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Remaining&lt;br/&gt;
 Life in&lt;br/&gt;
 Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
 Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zC3Ncovv0UH5" style="width: 9%; text-align: right" title="Range of exercise price, lower limit"&gt;4.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziZq3iXSNOGe" style="width: 9%; text-align: right" title="Range of exercise price, upper limit"&gt;22.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zM5URYCJVBzk" style="width: 9%; text-align: right" title="Number of options outstanding"&gt;20,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMvFZa0EqPoj" title="Weighted-average remaining life in years"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zfo3vcC2SwY8" style="width: 9%; text-align: right" title="Weighted-average exercise price"&gt;16.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zgLIwrVEzBFi" style="width: 9%; text-align: right" title="Number of options exercisable"&gt;15,154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zW0FR4cf1qM" title="Weighted-average remaining life in years, exercisable"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zl9EygmFbHVg" style="width: 8%; text-align: right" title="Weighted-average exercise price, exercisable"&gt;17.16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOPNC5y7xldc" style="text-align: right" title="Range of exercise price, lower limit"&gt;25.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zLBO8t9Y5Oq6" style="text-align: right" title="Range of exercise price, upper limit"&gt;47.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4Q8iB0tETZg" style="text-align: right" title="Number of options outstanding"&gt;104,279&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zudchz5beXQl" title="Weighted-average remaining life in years"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8s82GKavb05" style="text-align: right" title="Weighted-average exercise price"&gt;33.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNAFz0O5ADF8" style="text-align: right" title="Number of options exercisable"&gt;99,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zd4kfk2GTaUj" title="Weighted-average remaining life in years, exercisable"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKR6wohT8Uec" style="text-align: right" title="Weighted-average exercise price, exercisable"&gt;33.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zwoZNAivC8cb" style="text-align: right" title="Range of exercise price, lower limit"&gt;54.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztHtG4xg92H1" style="text-align: right" title="Range of exercise price, upper limit"&gt;58.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVTgnJbAWxn4" style="text-align: right" title="Number of options outstanding"&gt;52,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1swoirEi3ck" title="Weighted-average remaining life in years"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zgIQ5jY4dwg7" style="text-align: right" title="Weighted-average exercise price"&gt;56.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzgl7yQYfE4b" style="text-align: right" title="Number of options exercisable"&gt;48,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z8yLbTdpJYV5" title="Weighted-average remaining life in years, exercisable"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zVxSOjWG9AKj" style="text-align: right" title="Weighted-average exercise price, exercisable"&gt;56.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWLspd65hyJ6" style="padding-bottom: 1pt; text-align: right" title="Range of exercise price, lower limit"&gt;164.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zeHg76yuS3O5" style="padding-bottom: 1pt; text-align: right" title="Range of exercise price, upper limit"&gt;183.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zQUYP1Cg4WRf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options outstanding"&gt;200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zj2SBTcyV6x8" title="Weighted-average remaining life in years"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z8a1QitP9HA1" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price"&gt;164.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBQTkGNTfDE8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options exercisable"&gt;200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z6mwY42PJ2Xk" title="Weighted-average remaining life in years, exercisable"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4AQfqqqQdm" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price, exercisable"&gt;164.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zjJHzyr57zfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding"&gt;176,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityIncentivePlanMember_zBC76UVisnV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable"&gt;163,386&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001397"
      unitRef="USDPShares">4.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001399"
      unitRef="USDPShares">22.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001401"
      unitRef="Shares">20088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember"
      id="Fact001403">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001405"
      unitRef="USDPShares">16.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001407"
      unitRef="Shares">15154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember"
      id="Fact001409">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001411"
      unitRef="USDPShares">17.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001413"
      unitRef="USDPShares">25.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001415"
      unitRef="USDPShares">47.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001417"
      unitRef="Shares">104279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember"
      id="Fact001419">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001421"
      unitRef="USDPShares">33.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001423"
      unitRef="Shares">99263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember"
      id="Fact001425">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001427"
      unitRef="USDPShares">33.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001429"
      unitRef="USDPShares">54.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001431"
      unitRef="USDPShares">58.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001433"
      unitRef="Shares">52020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember"
      id="Fact001435">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001437"
      unitRef="USDPShares">56.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001439"
      unitRef="Shares">48769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember"
      id="Fact001441">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001443"
      unitRef="USDPShares">56.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001445"
      unitRef="USDPShares">164.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001447"
      unitRef="USDPShares">183.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001449"
      unitRef="Shares">200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember"
      id="Fact001451">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001453"
      unitRef="USDPShares">164.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember"
      id="Fact001457">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001459"
      unitRef="USDPShares">164.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001461"
      unitRef="Shares">176587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001463"
      unitRef="Shares">163386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001465">&lt;p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zg2zn1toFKU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes restricted stock award activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zMgQXNlT6Ys9" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK AWARD ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
Awards&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average&lt;br/&gt;
 Grant Date Fair&lt;br/&gt;
 Value Per Unit&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCtzlseGmGe5" style="width: 16%; text-align: right" title="Restricted common stock awards, balance"&gt;816,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBFXcfp2FdUb" style="width: 16%; text-align: right" title="Weighted-average grant date fair value, balance"&gt;5.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHBunrTltDJa" style="text-align: right" title="Restricted common stock awards, granted"&gt;1,958,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB9nVUIef3i7" style="text-align: right" title="Weighted-average grant date fair value, granted"&gt;3.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaOPRmWEPmNj" style="text-align: right" title="Restricted common stock awards, cancelled/forfeited"&gt;(56,398&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkhEq2bGMIUe" style="text-align: right" title="Weighted-average grant date fair value, cancelled/forfeited"&gt;4.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1G3Cm4a5qHk" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted common stock awards, vested"&gt;(270,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVybEXlOJfMi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value, vested"&gt;5.59&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zS5Ax97waVh4" style="text-align: right" title="Restricted common stock awards, balance"&gt;2,448,169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwNwtQmU6Qdb" style="text-align: right" title="Weighted-average grant date fair value, balance"&gt;4.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znUFmjRYMMdj" style="text-align: right" title="Restricted common stock awards, granted"&gt;2,065,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUkA9hlrNXFi" style="text-align: right" title="Weighted-average grant date fair value, granted"&gt;4.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXkymYkPuR88" style="text-align: right" title="Restricted common stock awards, cancelled/forfeited"&gt;(183,114&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfGvEA8kitBi" style="text-align: right" title="Weighted-average grant date fair value, cancelled/forfeited"&gt;3.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyDyzKnZEExc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted common stock awards, vested"&gt;(1,009,298&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdWv19Qb9lyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value, vested"&gt;4.64&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSyyCfIAHalb" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted common stock awards, balance"&gt;3,320,811&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zogNe2X9uHL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant date fair value, balance"&gt;4.60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001467"
      unitRef="Shares">816958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001469"
      unitRef="USDPShares">5.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">1958159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468"
      decimals="INF"
      id="Fact001473"
      unitRef="USDPShares">3.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468"
      decimals="INF"
      id="Fact001475"
      unitRef="Shares">56398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468"
      decimals="INF"
      id="Fact001477"
      unitRef="USDPShares">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468"
      decimals="INF"
      id="Fact001479"
      unitRef="Shares">270550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember31394468"
      decimals="INF"
      id="Fact001481"
      unitRef="USDPShares">5.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001483"
      unitRef="Shares">2448169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001485"
      unitRef="USDPShares">4.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484"
      decimals="INF"
      id="Fact001487"
      unitRef="Shares">2065054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484"
      decimals="INF"
      id="Fact001489"
      unitRef="USDPShares">4.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484"
      decimals="INF"
      id="Fact001491"
      unitRef="Shares">183114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484"
      decimals="INF"
      id="Fact001493"
      unitRef="USDPShares">3.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484"
      decimals="INF"
      id="Fact001495"
      unitRef="Shares">1009298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember31394484"
      decimals="INF"
      id="Fact001497"
      unitRef="USDPShares">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001499"
      unitRef="Shares">3320811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001501"
      unitRef="USDPShares">4.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001503"
      unitRef="USD">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2024-01-01to2024-12-31" id="Fact001505">P2Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <ABEO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001507"
      unitRef="USD">4700000</ABEO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue>
    <ABEO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001509"
      unitRef="USD">1500000</ABEO:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001511">&lt;p id="xdx_80E_eus-gaap--CollaborativeArrangementDisclosureTextBlock_zSj3kL8WKD5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_828_z67un7fKoIbg"&gt;LICENSE/SUPPLIER AGREEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
Agreement Relating to Recessive Dystrophic Epidermolysis Bullosa (RDEB)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2016, the Company entered into two licensing agreements between the Company and The Board of Trustees of Leland Stanford Junior University
(&#x201c;Stanford&#x201d;) to develop EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)) and EB-201 (AAV DJ COL7A1) and
to license the invention &#x201c;Gene Therapy for Recessive Dystrophic EB using Genetically Corrected Autologous Keratinocytes&#x201d;.
Under the terms of the licensing agreements, the Company paid an upfront of licensing fees in cash and is subject to annual license maintenance
fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments, and royalty
payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, the Company is subject to remaining
milestone payments totaling approximately $&lt;span id="xdx_908_ecustom--RemainingMilestonePaymentsDue_iI_pn5n6_c20241231__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--LicenseAgreementMember_zX7Xtarg6rMa" title="Remaining milestone payments due"&gt;0.2&lt;/span&gt; million which is due upon FDA approval of pz-cel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
Agreement Relating to Novel AAV Capsids (&#x201c;AIM&#x2122; capsids&#x201d;)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2016, the Company licensed an international patent family from The University of North Carolina at Chapel Hill (&#x201c;UNC&#x201d;) covering
novel AAV capsids (&#x201c;AIM&#x2122; capsids&#x201d;) that may potentially be used to deliver a wide variety of therapeutic transgenes
to human cells to treat genetic diseases. Under the terms of the licensing agreements, the Company paid an upfront licensing fees in
cash and is subject to on-going patent expenses incurred in relation to the patents licensed under this agreement and annual license
maintenance fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments,
and royalty payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty
payments under this agreement have been made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
Agreement Relating to CLN1 Disease&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2016, the Company licensed from UNC rights to two patent families directed to treating CLN1 disease (also known as infantile Batten disease).
Under the terms of the licensing agreements, the Company paid an upfront of licensing fees in cash and is subject to on-going patent
expenses incurred in relation to the patents licensed under this agreement and annual license maintenance fees. In addition, the Company
is subject to the achievement of certain milestones, regulatory approval milestone payments, and royalty payments in the low single digits
on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty payments under this agreement have been
made. The Company subsequently sublicensed the license to Taysha Gene Therapies (&#x201c;Taysha&#x201d;), see detail of the sublicense
agreement below. As part of the agreement with UNC, the Company is obligated to pay to UNC a percentage of any sublicense revenue that
the Company receives under the agreement. The Company recognizes any payments under this agreement as royalties in the consolidated statement
of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
Agreement Relating to Rett Syndrome&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2019, the Company licensed rights to one patent family from UNC and two patent families from The University Court of the University of
Edinburgh (&#x201c;U. Edinburgh&#x201d;) and The University Court of the University of Glasgow (&#x201c;U. Glasgow&#x201d;) relating to gene
therapy for the treatment of Rett Syndrome. Under the terms of the licensing agreements, the Company paid an upfront of licensing fees
in cash and is subject to on-going patent expenses incurred in relation to the patents licensed under this agreement and annual license
maintenance fees. In addition, the Company is subject to the achievement of certain milestones, regulatory approval milestone payments,
and royalty payments in the low single digits on annual net sales of the licensed product. As of December 31, 2024, no milestone or royalty
payments under this agreement have been made. The Company subsequently sublicensed the license to Taysha, see detail of the sublicense
agreement below. As part of the agreement with UNC, the Company is obligated to pay to UNC and U. Edinburgh a percentage of any sublicense
revenue that the Company receives under the agreement. The Company recognizes any payments under this agreement as royalties in the consolidated
statement of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Sublicense
and Inventory Purchase Agreements Relating to CLN1 Disease&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the Company entered into sublicense and inventory purchase agreements with Taysha relating to a potential gene therapy for
CLN1 disease. Under the sublicense agreement, Taysha received worldwide exclusive rights to intellectual property and know-how relating
to the research, development, and manufacture of the potential gene therapy, which the Company had referred to as ABO-202. Under the
inventory purchase agreement, the Company sold to Taysha certain inventory and other items related to ABO-202. The Company assessed the
nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated whether such
functionality can be retained without ongoing activities by the Company and determined that the license has significant stand-alone functionality.
Furthermore, the Company has no ongoing activities associated with the license to support or maintain the license&#x2019;s utility. Based
on this, the Company determined that the pattern of transfer of control of the license to Taysha was at a point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price of the contract includes (i) $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20200801__20200831__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zkVPL359Mhxj" title="Fixed consideration"&gt;7.0 &lt;/span&gt;million of fixed consideration, (ii) up to $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zPXJmd0lJJyg" title="Variable consideration"&gt;26.0&lt;/span&gt; million of variable consideration
in the form of event-based milestone payments, (iii) up to $&lt;span id="xdx_904_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--SalesBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zJ52FYet98rh" title="Variable consideration"&gt;30.0&lt;/span&gt; million of variable consideration in the form of sales-based milestone
payments, and (iv) high single-digit royalty-based payments based on net sales. The Company is obligated to pay a portion of milestone
payments and royalties on net sales received from Taysha to the UNC.. The event-based milestone payments are based on certain development
and regulatory events occurring. At inception, the Company evaluated whether the milestone conditions had been achieved and if it was
probable that a significant cumulative revenue reversal would not occur before recognizing the associated revenue and determined that
these milestone payments were not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, and
were not considered probable of being achieved until those approvals were received. Accordingly, at inception, the Company fully constrained
the $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20200801__20200831__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember_zMChVZ2nusy" title="Variable consideration"&gt;26.0&lt;/span&gt; million of event-based milestone payments until such time that it is probable that significant cumulative revenue reversal
would not occur. The sales-based milestone payments and other royalty-based payments are based on a level of sales for which the license
is deemed to be the predominant item to which the royalties relate. The Company will recognize revenue for these payments at the later
of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has
been satisfied or partially satisfied. To date, the Company has not recognized any sales-based or royalty revenue resulting from this
licensing arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
this arrangement, the Company has &lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_do_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z60TZGf1NiHe" title="Revenue recognized"&gt;&lt;span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_do_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zipUDwAScJF6" title="Revenue recognized"&gt;no&lt;/span&gt;&lt;/span&gt;t recognized any revenue during the years ended December 31, 2024 and 2023, respectively based on
event-based-milestone payments. The Company has &lt;span id="xdx_907_eus-gaap--ContractWithCustomerAssetNet_iI_pn5n6_do_c20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zcKsOiSdq4xh" title="Contract assets"&gt;&lt;span id="xdx_908_eus-gaap--ContractWithCustomerAssetNet_iI_pn5n6_do_c20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAndInventoryPurchaseAgreementsMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zkrYUICKN45e" title="Contract assets"&gt;no&lt;/span&gt;&lt;/span&gt; contract assets or liabilities as of December 31, 2024 and 2023 as a result of this
transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Sublicense
Agreement Relating to Rett Syndrome&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the Company entered into a sublicense agreement with &lt;span style="background-color: white"&gt;Taysha &lt;/span&gt;for a gene therapy
for Rett syndrome, including intellectual property related to MECP2 gene constructs and regulation of their expression. The agreement
grants Taysha worldwide exclusive rights to intellectual property developed by scientists at UNC, U. Edinburgh and the Company, and the
Company&#x2019;s know-how relating to the research, development, and manufacture of the gene therapy for Rett syndrome and MECP2 gene
constructs and regulation of their expression.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assessed the nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated
whether such functionality can be retained without ongoing activities by the Company and determined that the license has significant
stand-alone functionality. Furthermore, the Company has no ongoing activities associated with the license to support or maintain the
license&#x2019;s utility. Based on this, the Company determined that the pattern of transfer of control of the license to Taysha was at
a point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction price of the contract includes (i) $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20201001__20201031__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_z49vKtRYCyJl" title="Fixed consideration"&gt;3.0&lt;/span&gt;
million of fixed consideration, (ii) up to $&lt;span id="xdx_900_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zyUD8WqiTW22" title="Variable consideration"&gt;26.5&lt;/span&gt;
million of variable consideration in the form of event-based milestone payments, (iii) up to $&lt;span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--SalesBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zo0tnsOWolc9" title="Variable consideration"&gt;30.0&lt;/span&gt;
million of variable consideration in the form of sales-based milestone payments, and (iv) high single-digit royalty-based payments
based on net sales. The Company is obligated to pay a portion of milestone payments and royalties on net sales received from Taysha
to the UNC and U. Edinburgh. The event-based milestone payments are based on certain development and regulatory events occurring.
The Company evaluated whether the milestone conditions have been achieved and if it is probable that a significant cumulative
revenue reversal would not occur before recognizing the associated revenue. The Company determined that these milestone payments are
not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, and are not considered
probable of being achieved until those approvals are received. Accordingly, the Company has fully constrained the $&lt;span id="xdx_90E_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn5n6_c20201001__20201031__srt--ProductOrServiceAxis__custom--EventBasedMilestonePaymentsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember_zkbFYFeAtvN5" title="Variable consideration"&gt;26.5&lt;/span&gt;
million in event-based milestone payments until such time that it is probable that a significant cumulative revenue reversal would
not occur. The sales-based milestone payments and other royalty-based payments are based on a level of sales for which the license
is deemed to be the predominant item to which the royalties relate. The Company will recognize revenue for these payments at the
later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been
allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales-based or royalty revenue
resulting from this licensing arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
this arrangement, the Company recognized &lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_dxL_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zcSroRFpu2n1" title="Revenue recognized::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1539"&gt;nil&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementRelatingToRettSyndromeMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zzEPyP49vWs6" title="Revenue recognized"&gt;3.5&lt;/span&gt; million in revenue during the years ended December 31, 2024 and 2023. The revenue
recognized was related to clinical milestones achieved by our sublicensor as per the sublicense agreement noted above. As of December
31, 2024 and 2023, the Company does not have any contract assets or contract liabilities as a result of this transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ultragenyx
License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 16, 2022, the Company and Ultragenyx Pharmaceutical Inc. (&#x201c;Ultragenyx&#x201d;) entered into an exclusive license agreement (the
&#x201c;License Agreement&#x201d;) for AAV gene therapy, ABO-102, for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the
License Agreement, Ultragenyx assumed responsibility for the ABO-102 program from the Company, with the exclusive right to develop, manufacture,
and commercialize ABO-102 worldwide. Also pursuant to the License Agreement, following regulatory approval, the Company is eligible to
receive tiered royalties from mid-single-digit up to 10% on net sales and up to $&lt;span id="xdx_90A_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20220515__20220516__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--LicenseAgreementTermsMember__srt--RangeAxis__srt--MaximumMember_zuIE9Lgjx83g" title="Milestone payments"&gt;30.0&lt;/span&gt; million in commercial milestone payments. Both
forms of consideration comprise the transaction price to which the Company expects to be entitled in exchange for transferring the related
intellectual property and certain, contractually-specified, transition services to Ultragenyx. The sales-based royalty and milestone
payments are subject to the royalty recognition constraint. As such, these fees are not recognized as revenue until the later of: (a)
the occurrence of the subsequent sale, and (b) the performance obligation to which they relate has been satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
pursuant to the License Agreement, Ultragenyx will reimburse the Company for certain development and transition costs actually incurred
by the Company. These costs are passed through to Ultragenyx without mark-up. The Company has determined that these costs are not incurred
for the purpose of satisfying any performance obligation under the License Agreement. Accordingly, the reimbursement of these costs is
recognized as a reduction of research and development costs. As of December 31, 2024 and 2023, the Company does not have any contract
assets or contract liabilities as a result of this transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ABEO:RemainingMilestonePaymentsDue
      contextRef="AsOf2024-12-31_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact001513"
      unitRef="USD">200000</ABEO:RemainingMilestonePaymentsDue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2020-08-012020-08-31_custom_SublicenseAndInventoryPurchaseAgreementsMember"
      decimals="-5"
      id="Fact001515"
      unitRef="USD">7000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="From2020-08-012020-08-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember"
      decimals="-5"
      id="Fact001517"
      unitRef="USD">26000000.0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="From2020-08-012020-08-31_custom_SalesBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember"
      decimals="-5"
      id="Fact001519"
      unitRef="USD">30000000.0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="From2020-08-012020-08-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAndInventoryPurchaseAgreementsMember"
      decimals="-5"
      id="Fact001521"
      unitRef="USD">26000000.0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember"
      decimals="-5"
      id="Fact001523"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember"
      decimals="-5"
      id="Fact001525"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="AsOf2024-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember"
      decimals="-5"
      id="Fact001527"
      unitRef="USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="AsOf2023-12-31_custom_SublicenseAndInventoryPurchaseAgreementsMember_us-gaap_LicenseMember"
      decimals="-5"
      id="Fact001529"
      unitRef="USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2020-10-012020-10-31_custom_SublicenseAgreementRelatingToRettSyndromeMember"
      decimals="-5"
      id="Fact001531"
      unitRef="USD">3000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="From2020-10-012020-10-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember"
      decimals="-5"
      id="Fact001533"
      unitRef="USD">26500000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="From2020-10-012020-10-31_custom_SalesBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember"
      decimals="-5"
      id="Fact001535"
      unitRef="USD">30000000.0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="From2020-10-012020-10-31_custom_EventBasedMilestonePaymentsMember_srt_MaximumMember_custom_SublicenseAgreementRelatingToRettSyndromeMember"
      decimals="-5"
      id="Fact001537"
      unitRef="USD">26500000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_SublicenseAgreementRelatingToRettSyndromeMember_us-gaap_LicenseMember"
      decimals="-5"
      id="Fact001541"
      unitRef="USD">3500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="From2022-05-152022-05-16_us-gaap_LicenseAgreementTermsMember_srt_MaximumMember"
      decimals="-5"
      id="Fact001543"
      unitRef="USD">30000000.0</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001545">&lt;p id="xdx_809_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z8HCPp7xlJGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2013; &lt;span id="xdx_828_zXq3gw5kLddg"&gt;401(k) PLAN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a tax-qualified employee savings and retirement plan (the &#x201c;401(k) Plan&#x201d;) covering all the Company&#x2019;s
employees in the United States. Pursuant to the 401(k) Plan, employees may elect to reduce their current compensation by up to the
statutorily prescribed annual limit ($&lt;span id="xdx_903_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20240101__20241231_zd6p6QprhXIl" title="Maximum annual contribution per employee under 401(k) plan"&gt;23,000&lt;/span&gt;
in 2024 and $&lt;span id="xdx_90A_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20230101__20231231_zpjC064qTKp4" title="Maximum annual contribution per employee under 401(k) plan"&gt;22,500&lt;/span&gt;
in 2023 for employees who are under age 50 and $&lt;span id="xdx_903_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20240101__20241231__us-gaap--RetirementPlanTypeAxis__custom--UnderAgeFifftyMember_zftxr22wjCmc"&gt;30,500&lt;/span&gt;
in 2024 and $&lt;span id="xdx_908_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_pp0p0_c20230101__20231231__us-gaap--RetirementPlanTypeAxis__custom--UnderAgeFifftyMember_zDx120x1SJ9k"&gt;30,000&lt;/span&gt; in 2023 for employees who are age 50 and older) and to have the amount of such reduction contributed to the
401(k) Plan. The 401(k) Plan is intended to qualify under Section 401 of the Internal Revenue Code so that contributions by
employees or by us to the 401(k) Plan, and income earned on 401(k) Plan contributions, are not taxable to employees until withdrawn
from the 401(k) Plan, and so that contributions by us, if any, will be deductible by us when made. At the direction of each
participant, the Company invests the assets of the 401(k) Plan in any of over &lt;span id="xdx_902_ecustom--NumberOfInvestmentOptions_pp0p0_uInteger_c20240101__20241231_zR4Aql5j2Eq4" title="Number of investment options"&gt;50&lt;/span&gt;
investment options. Company contributions under the 401(k) Plan were $&lt;span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20240101__20241231_zKDBx9Ox0a0h" title="Company contributions under 401 (k) Plan"&gt;0.5&lt;/span&gt;
million and $&lt;span id="xdx_909_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20230101__20231231_z42yyUZWvjD8" title="Company contributions under 401 (k) Plan"&gt;0.3&lt;/span&gt;
million for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001547"
      unitRef="USD">23000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001549"
      unitRef="USD">22500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="From2024-01-012024-12-31_custom_UnderAgeFifftyMember"
      decimals="0"
      id="Fact001550"
      unitRef="USD">30500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="From2023-01-012023-12-31_custom_UnderAgeFifftyMember"
      decimals="0"
      id="Fact001551"
      unitRef="USD">30000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <ABEO:NumberOfInvestmentOptions
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001553"
      unitRef="Integer">50</ABEO:NumberOfInvestmentOptions>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001555"
      unitRef="USD">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001557"
      unitRef="USD">300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001559">&lt;p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_z5haTvmOyjp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 &#x2013; &lt;span id="xdx_82A_zxq5iVVvU7vf"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zIT3yL4xvrif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense differs from the statutory amounts for each of the following years (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_z1W4eLi6yH3d" style="display: none"&gt;SCHEDULE
OF INCOME TAX EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zJrc5w5X32a5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_z1Lv5Z1LexAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBz0L9_zOi1p7PEgYla" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Income taxes at U.S. statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(13,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(11,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBz0L9_znwLYfLORRV" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State tax, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(679&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(242&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_iN_pn3n3_di_msITEBz0L9_zqbiZBf7ZUUc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Research and development credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,535&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,137&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_pn3n3_maITEBz0L9_zStgbwMgLEj8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred true ups&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,032&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1573"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBz0L9_z5VSxE5GRaok" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,418&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_pn3n3_maITEBz0L9_zuCOYqaUcNqe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Change in fair value of warrant liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_pn3n3_maITEBz0L9_zRVRCh5Pe861" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expired tax losses and credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maITEBz0L9_zT3AeU3O6XRl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(127&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBz0L9_zvM9t0sKr9v9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1587"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1588"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zvcIHMyzQjol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVO5kdlAUC96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
taxes are provided for the temporary differences between the financial reporting bases and the tax bases of the Company&#x2019;s assets
and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zhZZThYB4F77" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zlq4G6heDt6f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zoIEbYn8wVP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzzCb_zwhThLZPbTJ8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;88,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;78,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzzCb_zDyX3qoqWaKa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;General business credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_maDTAGzzCb_zvT88LMPKyt2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,780&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,780&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_iI_pn3n3_maDTAGzzCb_zE9MlxSq7I1f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Property, equipment and goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzzCb_zSAaX1cUYVD8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzzCb_z8KLfhLjrT97" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;661&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzzCb_zdMa7KV4X4M8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzzCb_z7UzmmDfG9qe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,843&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzzCb_zdaC636szIkg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;83&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzzCb_maDTALNzbeO_zK01rSVLRfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzbeO_zUXoTu7W4fbl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(114,406&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(108,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzbeO_zeKO9OwMaNW6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zwcBSgtJp9v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company identified adjustments related primarily to the recognition of deferred tax assets for stock-based
compensation. As a result, the Company has written off $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn5n6_c20241231_zEuoaTZsKFVh" title="Deferred tax assets"&gt;8.0&lt;/span&gt; million of deferred tax assets in the current period, with a corresponding
adjustment to the valuation allowance. There was no impact to total tax expense in the prior periods or current period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
operating Loss and Other Carryforwards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_z35pTDxJZTna" title="Operating loss carryforward"&gt;416.1&lt;/span&gt; million of U.S. federal net operating loss carryforwards and $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_zqJuUBa6t2I2" title="General business credit carryforwards"&gt;6.0&lt;/span&gt; million of general business
credit carryforwards. These carryforwards expire as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zJBwSyeSkln9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BE_zHBZp0r9iRDf" style="display: none"&gt;SUMMARY
OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net operating &lt;br/&gt;
loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;General &lt;br/&gt;
business credit&lt;br/&gt;
 carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zcPE0tjSieda" style="width: 16%; text-align: right" title="Net operating loss carryforwards"&gt;2,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zRqZRuEPytQ5" style="width: 16%; text-align: right" title="General business credit carryforwards"&gt;182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_z49VMgrFdvK5" style="text-align: right" title="Net operating loss carryforwards"&gt;7,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_zKHZRAT2I9d3" style="text-align: right" title="General business credit carryforwards"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_zHwFyUwFiuN" style="text-align: right" title="Net operating loss carryforwards"&gt;9,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_z7gbOPeerZq4" style="text-align: right" title="General business credit carryforwards"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zB8s5xT6fb3l" style="text-align: right" title="Net operating loss carryforwards"&gt;6,886&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zKZTJqdh8Df6" style="text-align: right" title="General business credit carryforwards"&gt;141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zSSM4hZ2Rmr4" style="text-align: right" title="Net operating loss carryforwards"&gt;7,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zxEdWHMLRcqi" style="text-align: right" title="General business credit carryforwards"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zsocbJx5H9H5" style="border-bottom: Black 1pt solid; text-align: right" title="Net operating loss carryforwards"&gt;65,644&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zb3Dp0hxB5Qi" style="border-bottom: Black 1pt solid; text-align: right" title="General business credit carryforwards"&gt;5,429&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231_zC3pZOilpAO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net operating loss carryforwards"&gt;99,945&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231_zStrXx0clpu2" style="border-bottom: Black 2.5pt double; text-align: right" title="General business credit carryforwards"&gt;6,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z9nEDbVxWy58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 22, 2017, the &#x201c;Tax Cuts and Jobs Act&#x201d; was signed into law. The tax reform has the following effects on the Company:
(1) permanently reduces the maximum corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017,
(2) allows temporary 100% expensing for certain business assets and property placed in service after September 27, 2018 and before January
1, 2023, (3) disallows NOL carrybacks but allows for the indefinite carryforward of those NOLs which applies to losses arising in tax
years beginning after December 31, 2018 and, (4) limits NOL deductions for each year equal to the lesser of the available carryover or
80% of a taxpayer&#x2019;s pre-NOL deduction taxable income. This applies to losses arising in tax years ending on or after December 31,
2017. As of December 31, 2024 and 2023, the Company has concluded that it is more likely than not that the Company will not realize the
benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within
a three-year period results in an annual limitation on the Company&#x2019;s ability to utilize its NOL carryforwards created during the
tax periods prior to the change in ownership. The Company has not completed an ownership change analysis pursuant to Section 382. Because
the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and
state income tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had $&lt;span id="xdx_903_ecustom--NetOperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember_zguj8oiCBdI5" title="Net operating loss carryforwards"&gt;316.2&lt;/span&gt; million of U.S. federal net operating loss carryforwards that do not expire and can be carried
forward indefinitely. Such net operating loss carryforwards can only be used to offset &lt;span id="xdx_90D_ecustom--OperatingLossCarryforwardsTaxablePercentage_iI_pid_dp_uPure_c20241231_zixbpQwouUTj" title="Operating loss taxable percentage"&gt;80&lt;/span&gt;% of taxable income in any given tax year. The
Company also has $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zQozZIDXFLKl" title="State net operating loss carryforwards"&gt;13.3&lt;/span&gt; million of state net operating loss carryforwards in varying amounts depending on the different state tax laws.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company acquired MacroChem Corporation on March 25, 2009, and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both of these corporations
were loss-making entities at the time of acquisition. As a result, the net operating losses related to those acquisitions may be subject
to annual limitations. The Company has not performed a study to determine whether or not there is such a limitation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Valuation
Allowance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024 and 2023, the Company maintained a full valuation allowance on its deferred tax assets based on a history of cumulative
losses. The Company will not record income tax benefits in the financial statements until it is determined that it is more likely than
not that the Company will generate sufficient taxable income to realize the deferred income tax assets. In 2024, the valuation allowance
increased by approximately $&lt;span id="xdx_905_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zQt6YXJstBuc" title="Valuation allowance"&gt;5.4&lt;/span&gt; million. In 2023, the valuation allowance increased by approximately $&lt;span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_zrLv5TRNMZ63" title="Valuation allowance"&gt;8.7&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrecognized
Tax Benefits&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024 and 2023, the Company had no reserves for unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and its subsidiaries are subject to taxation in the United States. The Company is subject to U.S. federal and state examinations
for 2020 and forward, and 2019 and forward, respectively. However, net operating losses are subject to audit in any tax year in which
those losses are utilized, notwithstanding the year of origin.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001561">&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zIT3yL4xvrif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense differs from the statutory amounts for each of the following years (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_z1W4eLi6yH3d" style="display: none"&gt;SCHEDULE
OF INCOME TAX EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zJrc5w5X32a5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_z1Lv5Z1LexAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBz0L9_zOi1p7PEgYla" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Income taxes at U.S. statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(13,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(11,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBz0L9_znwLYfLORRV" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State tax, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(679&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(242&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit_iN_pn3n3_di_msITEBz0L9_zqbiZBf7ZUUc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Research and development credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,535&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,137&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps_pn3n3_maITEBz0L9_zStgbwMgLEj8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred true ups&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,032&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1573"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBz0L9_z5VSxE5GRaok" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,418&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities_pn3n3_maITEBz0L9_zuCOYqaUcNqe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Change in fair value of warrant liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate_pn3n3_maITEBz0L9_zRVRCh5Pe861" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expired tax losses and credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maITEBz0L9_zT3AeU3O6XRl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(127&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBz0L9_zvM9t0sKr9v9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1587"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1588"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001563"
      unitRef="USD">-13384000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001564"
      unitRef="USD">-11379000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001566"
      unitRef="USD">-679000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001567"
      unitRef="USD">-242000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <ABEO:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001569"
      unitRef="USD">1535000</ABEO:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit>
    <ABEO:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001570"
      unitRef="USD">1137000</ABEO:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredit>
    <ABEO:IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001572"
      unitRef="USD">8032000</ABEO:IncomeTaxReconciliationChangeInDeferredTaxAssetsTrueUps>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001575"
      unitRef="USD">5418000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001576"
      unitRef="USD">8687000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001578"
      unitRef="USD">159000</ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities>
    <ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001579"
      unitRef="USD">2456000</ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitChangesOfWarrantLiabilities>
    <ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001581"
      unitRef="USD">2116000</ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate>
    <ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001582"
      unitRef="USD">1503000</ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpiredTaxLossedAndCreditTaxRate>
    <ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001584"
      unitRef="USD">-127000</ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences>
    <ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001585"
      unitRef="USD">112000</ABEO:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001590">&lt;p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVO5kdlAUC96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
taxes are provided for the temporary differences between the financial reporting bases and the tax bases of the Company&#x2019;s assets
and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zhZZThYB4F77" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zlq4G6heDt6f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zoIEbYn8wVP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzzCb_zwhThLZPbTJ8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;88,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;78,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzzCb_zDyX3qoqWaKa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;General business credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_maDTAGzzCb_zvT88LMPKyt2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,780&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,780&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill_iI_pn3n3_maDTAGzzCb_zE9MlxSq7I1f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Property, equipment and goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzzCb_zSAaX1cUYVD8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzzCb_z8KLfhLjrT97" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;661&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzzCb_zdMa7KV4X4M8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzzCb_z7UzmmDfG9qe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,843&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzzCb_zdaC636szIkg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;83&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzzCb_maDTALNzbeO_zK01rSVLRfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzbeO_zUXoTu7W4fbl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(114,406&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(108,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzbeO_zeKO9OwMaNW6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1625"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001592"
      unitRef="USD">88059000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001593"
      unitRef="USD">78698000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001595"
      unitRef="USD">6000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001596"
      unitRef="USD">4752000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001598"
      unitRef="USD">2780000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001599"
      unitRef="USD">2780000</us-gaap:DeferredTaxAssetsStateTaxes>
    <ABEO:DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001601"
      unitRef="USD">1002000</ABEO:DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill>
    <ABEO:DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001602"
      unitRef="USD">887000</ABEO:DeferredTaxAssetsPropertyPlantAndEquipmentsAndGoodwill>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001604"
      unitRef="USD">2463000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001605"
      unitRef="USD">11983000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001607"
      unitRef="USD">661000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001608"
      unitRef="USD">615000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001610"
      unitRef="USD">107000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001611"
      unitRef="USD">347000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001613"
      unitRef="USD">13264000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001614"
      unitRef="USD">8843000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001616"
      unitRef="USD">70000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001617"
      unitRef="USD">83000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001619"
      unitRef="USD">114406000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001620"
      unitRef="USD">108988000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001622"
      unitRef="USD">114406000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001623"
      unitRef="USD">108988000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001628"
      unitRef="USD">8000000.0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="-5"
      id="Fact001630"
      unitRef="USD">416100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="-5"
      id="Fact001632"
      unitRef="USD">6000000.0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001634">&lt;p id="xdx_89D_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zJBwSyeSkln9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BE_zHBZp0r9iRDf" style="display: none"&gt;SUMMARY
OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net operating &lt;br/&gt;
loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;General &lt;br/&gt;
business credit&lt;br/&gt;
 carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zcPE0tjSieda" style="width: 16%; text-align: right" title="Net operating loss carryforwards"&gt;2,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyFiveMember_zRqZRuEPytQ5" style="width: 16%; text-align: right" title="General business credit carryforwards"&gt;182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_z49VMgrFdvK5" style="text-align: right" title="Net operating loss carryforwards"&gt;7,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySixMember_zKHZRAT2I9d3" style="text-align: right" title="General business credit carryforwards"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_zHwFyUwFiuN" style="text-align: right" title="Net operating loss carryforwards"&gt;9,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentySevenMember_z7gbOPeerZq4" style="text-align: right" title="General business credit carryforwards"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zB8s5xT6fb3l" style="text-align: right" title="Net operating loss carryforwards"&gt;6,886&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyEightMember_zKZTJqdh8Df6" style="text-align: right" title="General business credit carryforwards"&gt;141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zSSM4hZ2Rmr4" style="text-align: right" title="Net operating loss carryforwards"&gt;7,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--TaxYearTwoThousandTwentyNineMember_zxEdWHMLRcqi" style="text-align: right" title="General business credit carryforwards"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zsocbJx5H9H5" style="border-bottom: Black 1pt solid; text-align: right" title="Net operating loss carryforwards"&gt;65,644&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231__us-gaap--TaxPeriodAxis__custom--ThereafterMember_zb3Dp0hxB5Qi" style="border-bottom: Black 1pt solid; text-align: right" title="General business credit carryforwards"&gt;5,429&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231_zC3pZOilpAO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net operating loss carryforwards"&gt;99,945&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_c20241231_zStrXx0clpu2" style="border-bottom: Black 2.5pt double; text-align: right" title="General business credit carryforwards"&gt;6,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyFiveMember"
      decimals="-3"
      id="Fact001636"
      unitRef="USD">2370000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyFiveMember"
      decimals="-3"
      id="Fact001638"
      unitRef="USD">182000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySixMember"
      decimals="-3"
      id="Fact001640"
      unitRef="USD">7160000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySixMember"
      decimals="-3"
      id="Fact001642"
      unitRef="USD">72000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySevenMember"
      decimals="-3"
      id="Fact001644"
      unitRef="USD">9977000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentySevenMember"
      decimals="-3"
      id="Fact001646"
      unitRef="USD">93000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyEightMember"
      decimals="-3"
      id="Fact001648"
      unitRef="USD">6886000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyEightMember"
      decimals="-3"
      id="Fact001650"
      unitRef="USD">141000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyNineMember"
      decimals="-3"
      id="Fact001652"
      unitRef="USD">7908000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31_custom_TaxYearTwoThousandTwentyNineMember"
      decimals="-3"
      id="Fact001654"
      unitRef="USD">83000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_ThereafterMember"
      decimals="-3"
      id="Fact001656"
      unitRef="USD">65644000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31_custom_ThereafterMember"
      decimals="-3"
      id="Fact001658"
      unitRef="USD">5429000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001660"
      unitRef="USD">99945000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001662"
      unitRef="USD">6000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <ABEO:NetOperatingLossCarryforwards
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="-5"
      id="Fact001664"
      unitRef="USD">316200000</ABEO:NetOperatingLossCarryforwards>
    <ABEO:OperatingLossCarryforwardsTaxablePercentage
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001666"
      unitRef="Pure">0.80</ABEO:OperatingLossCarryforwardsTaxablePercentage>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001668"
      unitRef="USD">13300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001670"
      unitRef="USD">5400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001672"
      unitRef="USD">8700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001674">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkwXhYTV9jc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 &#x2013; &lt;span id="xdx_828_zN5Pn6M3vGIb"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes a liability for a contingency when it is probable that liability has been incurred and when the amount of loss can
be reasonably estimated. When a range of probable loss can be estimated, the Company accrues the most likely amount of such loss, and
if such amount is not determinable, then the Company accrues the minimum of the range of probable loss. As of December 31, 2024 and 2023,
there was no litigation against the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001676">&lt;p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zGaXqgV0FYLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
16 &#x2013; &lt;span id="xdx_82C_zqktnkCmqim3"&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), or decision making group, in deciding how to allocate resources in assessing performance. The Company is a
clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases and has one reportable segment.
The Company&#x2019;s CODM is the chief executive officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting policies of the clinical-stage biopharmaceutical segment are the same as those described in the summary of significant accounting
policies. The CODM assesses performance for the clinical-stage biopharmaceutical segment based on net loss, which is reported on the
consolidated statements of operations and comprehensive loss as consolidated net loss. The measure of segment assets is reported on the
consolidated balance sheet as total consolidated assets. Expenditures for additions to long-lived assets, which include purchases of
property and equipment, are included in total consolidated assets reviewed by the chief operating decision maker and are reported on
the consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating
losses while it seeks regulatory approval for pz-cel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
such, the CODM uses cash forecast models in deciding how to invest into the clinical-stage biopharmaceutical segment. Such cash forecast
models are reviewed to make decisions about allocating resources and assessing the entity-wide operating results and performance. Net
loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used to make decisions about allocating
resources, assessing the performance of the segment and in establishing management&#x2019;s compensation, along with cash forecast models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_ztJoAx3m1Wsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zdSjXWpHlcab"&gt;&#160;SCHEDULE
OF SIGNIFICANT EXPENSE CATEGORIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231_zM6ttbo2Nyn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zL3Gwowwcknk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_ziFvzS9qLimj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;License and other revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1680"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zRbz8EoaOmhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5LxCVkvrq4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Salaries &amp;amp; related costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkJXMBLsopTd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Non-cash stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,561&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0A7ZZ6YUKtf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other research and development costs &lt;span id="xdx_F40_zLi6GOQFH6dj"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,454&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,632&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_zDWbyShBkcu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,360&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zgDi1AOLtp46" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBqLHIsuFbff" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Salaries &amp;amp; related costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRio3dbbGYQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Non-cash stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrecommercialPreparationCosts_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGJKmg7reyNj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Pre-commercial preparation costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPexKxOBGZWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other general and administrative costs &lt;span id="xdx_F4D_zM7CZfeEvSul"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,237&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,156&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_z1mlRoUsChqc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total general and administrative costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;29,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;19,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--OtherSegments_zUDbASdMShak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other segment items &lt;span id="xdx_F42_z9oKAR73if38"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(477&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,593&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_zHsPrjrprioa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(63,734&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(54,188&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F02_zOCHrx46Bl7h"&gt;(a)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F17_z9sNosGHbGU8"&gt;Other
    research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial
    costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and
    manufacturing facilities, and consultant-related expenses.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F06_zFw2pWHJlIQd"&gt;(b)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F19_zDoiH2kSjjxe"&gt;Other
    general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional
    fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F01_zdB334Pd12I2"&gt;(c)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F16_zev26bldGfJg"&gt;Other
    segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and
    other income.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_z9utyDtdnWZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001678">&lt;p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_ztJoAx3m1Wsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zdSjXWpHlcab"&gt;&#160;SCHEDULE
OF SIGNIFICANT EXPENSE CATEGORIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231_zM6ttbo2Nyn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zL3Gwowwcknk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_ziFvzS9qLimj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;License and other revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1680"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zRbz8EoaOmhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5LxCVkvrq4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Salaries &amp;amp; related costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkJXMBLsopTd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Non-cash stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,561&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0A7ZZ6YUKtf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other research and development costs &lt;span id="xdx_F40_zLi6GOQFH6dj"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,454&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,632&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_zDWbyShBkcu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,360&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zgDi1AOLtp46" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--SalariesAndWages_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBqLHIsuFbff" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Salaries &amp;amp; related costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRio3dbbGYQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Non-cash stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,067&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrecommercialPreparationCosts_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGJKmg7reyNj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Pre-commercial preparation costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPexKxOBGZWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other general and administrative costs &lt;span id="xdx_F4D_zM7CZfeEvSul"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,237&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,156&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_z1mlRoUsChqc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total general and administrative costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;29,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;19,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--OtherSegments_zUDbASdMShak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other segment items &lt;span id="xdx_F42_z9oKAR73if38"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(477&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,593&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_zHsPrjrprioa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(63,734&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(54,188&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F02_zOCHrx46Bl7h"&gt;(a)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F17_z9sNosGHbGU8"&gt;Other
    research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial
    costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and
    manufacturing facilities, and consultant-related expenses.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F06_zFw2pWHJlIQd"&gt;(b)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F19_zDoiH2kSjjxe"&gt;Other
    general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional
    fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F01_zdB334Pd12I2"&gt;(c)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F16_zev26bldGfJg"&gt;Other
    segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and
    other income.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001681"
      unitRef="USD">3500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001686"
      unitRef="USD">15345000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001687"
      unitRef="USD">11373000</us-gaap:SalariesAndWages>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001689"
      unitRef="USD">1561000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001690"
      unitRef="USD">1086000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001692"
      unitRef="USD">17454000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001693"
      unitRef="USD">18632000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001695"
      unitRef="USD">34360000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001696"
      unitRef="USD">31091000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001701"
      unitRef="USD">10729000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001702"
      unitRef="USD">6942000</us-gaap:SalariesAndWages>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001704"
      unitRef="USD">5067000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001705"
      unitRef="USD">3682000</us-gaap:ShareBasedCompensation>
    <ABEO:PrecommercialPreparationCosts
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001707"
      unitRef="USD">4818000</ABEO:PrecommercialPreparationCosts>
    <ABEO:PrecommercialPreparationCosts
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001708"
      unitRef="USD">1224000</ABEO:PrecommercialPreparationCosts>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001710"
      unitRef="USD">9237000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001711"
      unitRef="USD">7156000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001713"
      unitRef="USD">29851000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001714"
      unitRef="USD">19004000</us-gaap:GeneralAndAdministrativeExpense>
    <ABEO:OtherSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001716"
      unitRef="USD">-477000</ABEO:OtherSegments>
    <ABEO:OtherSegments
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001717"
      unitRef="USD">7593000</ABEO:OtherSegments>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001719"
      unitRef="USD">-63734000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001720"
      unitRef="USD">-54188000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001725">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_z4L1BvoyZTBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
17 &#x2013; &lt;span id="xdx_822_z3VIkUloOUk7"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January of 2025, the compensation committee of the board of directors granted various employees and directors restricted stock awards,
under which the holders have the right to receive an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIfnj1oZVdY8" title="Restricted stock awards, issued"&gt;1,956,280&lt;/span&gt; shares of the Company&#x2019;s common stock. Total stock compensation
estimated for these awards at the time of grant was $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXM3UcJ1wcZg" title="Estimated total stock compensation"&gt;10.3&lt;/span&gt; million, with $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__custom--ThreeEqualAnnualInstallmentsMember_zW2bl9QIEV9k" title="Estimated total stock compensation"&gt;8.7&lt;/span&gt; million vesting in three equal annual installments and $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250131__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__custom--OneAnnualInstallmentsMember_zhCZJoRJ6SPi" title="Estimated total stock compensation"&gt;1.6&lt;/span&gt;
million vesting in one annual installment. Pursuant to the terms of the awards, the shares not vested are forfeited upon separation from
the Company.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-01-012025-01-31_us-gaap_CommonStockMember_srt_DirectorMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001727"
      unitRef="Shares">1956280</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001729"
      unitRef="USD">10300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember_custom_ThreeEqualAnnualInstallmentsMember"
      decimals="-5"
      id="Fact001731"
      unitRef="USD">8700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-01-31_srt_DirectorMember_us-gaap_SubsequentEventMember_custom_OneAnnualInstallmentsMember"
      decimals="-5"
      id="Fact001733"
      unitRef="USD">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001692"
          xlink:label="Fact001692"
          xlink:type="locator"/>
        <link:footnote id="Footnote001721" xlink:label="Footnote001721" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other
    research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial
    costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and
    manufacturing facilities, and consultant-related expenses.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001692"
          xlink:to="Footnote001721"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001693"
          xlink:label="Fact001693"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001693"
          xlink:to="Footnote001721"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001710"
          xlink:label="Fact001710"
          xlink:type="locator"/>
        <link:footnote id="Footnote001722" xlink:label="Footnote001722" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other
    general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional
    fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001710"
          xlink:to="Footnote001722"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001711"
          xlink:label="Fact001711"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001711"
          xlink:to="Footnote001722"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001716"
          xlink:label="Fact001716"
          xlink:type="locator"/>
        <link:footnote id="Footnote001723" xlink:label="Footnote001723" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other
    segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and
    other income.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001716"
          xlink:to="Footnote001723"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001717"
          xlink:label="Fact001717"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001717"
          xlink:to="Footnote001723"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
